0001124140-24-000012.txt : 20240221 0001124140-24-000012.hdr.sgml : 20240221 20240221170528 ACCESSION NUMBER: 0001124140-24-000012 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 133 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EXACT SCIENCES CORP CENTRAL INDEX KEY: 0001124140 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 204782291 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35092 FILM NUMBER: 24660807 BUSINESS ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 BUSINESS PHONE: 608-284-5700 MAIL ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 FORMER COMPANY: FORMER CONFORMED NAME: EXACT CORP DATE OF NAME CHANGE: 20000919 10-K 1 exas-20231231.htm 10-K exas-20231231
0001124140FALSE2023FYP3YP3Yhttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherOperatingIncomeExpenseNet00011241402023-01-012023-12-3100011241402023-06-30iso4217:USD00011241402024-02-21xbrli:shares00011241402023-12-3100011241402022-12-31iso4217:USDxbrli:shares00011241402022-01-012022-12-3100011241402021-01-012021-12-310001124140us-gaap:CommonStockMember2020-12-310001124140us-gaap:AdditionalPaidInCapitalMember2020-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001124140us-gaap:RetainedEarningsMember2020-12-3100011241402020-12-310001124140us-gaap:CommonStockMember2021-01-012021-12-310001124140us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001124140us-gaap:RetainedEarningsMember2021-01-012021-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001124140us-gaap:CommonStockMember2021-12-310001124140us-gaap:AdditionalPaidInCapitalMember2021-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001124140us-gaap:RetainedEarningsMember2021-12-3100011241402021-12-310001124140us-gaap:CommonStockMember2022-01-012022-12-310001124140us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001124140us-gaap:RetainedEarningsMember2022-01-012022-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001124140us-gaap:CommonStockMember2022-12-310001124140us-gaap:AdditionalPaidInCapitalMember2022-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001124140us-gaap:RetainedEarningsMember2022-12-310001124140us-gaap:CommonStockMember2023-01-012023-12-310001124140us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001124140us-gaap:RetainedEarningsMember2023-01-012023-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001124140us-gaap:CommonStockMember2023-12-310001124140us-gaap:AdditionalPaidInCapitalMember2023-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001124140us-gaap:RetainedEarningsMember2023-12-310001124140us-gaap:ConvertibleNotesPayableMember2023-01-012023-12-310001124140us-gaap:ConvertibleNotesPayableMember2022-01-012022-12-310001124140us-gaap:ConvertibleNotesPayableMember2021-01-012021-12-310001124140us-gaap:RestrictedStockMember2023-01-012023-12-310001124140us-gaap:RestrictedStockMember2022-01-012022-12-310001124140us-gaap:RestrictedStockMember2021-01-012021-12-310001124140us-gaap:PerformanceSharesMember2023-01-012023-12-310001124140us-gaap:PerformanceSharesMember2022-01-012022-12-310001124140us-gaap:PerformanceSharesMember2021-01-012021-12-310001124140exas:EmployeeAndNonEmployeesStockOptionMember2023-01-012023-12-310001124140exas:EmployeeAndNonEmployeesStockOptionMember2022-01-012022-12-310001124140exas:EmployeeAndNonEmployeesStockOptionMember2021-01-012021-12-310001124140exas:SharesIssuedUponAcquisitionMember2023-01-012023-12-310001124140exas:SharesIssuedUponAcquisitionMember2022-01-012022-12-310001124140exas:SharesIssuedUponAcquisitionMember2021-01-012021-12-310001124140srt:MinimumMember2023-12-310001124140srt:MaximumMember2023-12-310001124140us-gaap:RevenueFromContractWithCustomerMemberexas:MedicareMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-31xbrli:pure0001124140us-gaap:RevenueFromContractWithCustomerMemberexas:MedicareMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001124140us-gaap:RevenueFromContractWithCustomerMemberexas:MedicareMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001124140us-gaap:AccountsReceivableMemberexas:MedicareMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001124140us-gaap:AccountsReceivableMemberexas:MedicareMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001124140us-gaap:AccountsReceivableMemberexas:MedicareMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001124140us-gaap:RevenueFromContractWithCustomerMemberexas:UnitedHealthCareMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001124140us-gaap:RevenueFromContractWithCustomerMemberexas:UnitedHealthCareMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001124140us-gaap:RevenueFromContractWithCustomerMemberexas:UnitedHealthCareMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001124140exas:UnitedHealthCareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001124140exas:UnitedHealthCareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001124140exas:UnitedHealthCareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001124140us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberexas:StateOfWisconsinMember2023-01-012023-12-310001124140us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberexas:StateOfWisconsinMember2022-01-012022-12-310001124140us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberexas:StateOfWisconsinMember2021-01-012021-12-310001124140us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberexas:StateOfWisconsinMember2023-01-012023-12-310001124140us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberexas:StateOfWisconsinMember2022-01-012022-12-310001124140us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberexas:StateOfWisconsinMember2021-01-012021-12-310001124140us-gaap:ProductMemberexas:ScreeningMember2023-01-012023-12-310001124140us-gaap:ProductMemberexas:ScreeningMember2022-01-012022-12-310001124140us-gaap:ProductMemberexas:ScreeningMember2021-01-012021-12-310001124140exas:ScreeningMemberus-gaap:ServiceMember2023-01-012023-12-310001124140exas:ScreeningMemberus-gaap:ServiceMember2022-01-012022-12-310001124140exas:ScreeningMemberus-gaap:ServiceMember2021-01-012021-12-310001124140us-gaap:ProductAndServiceOtherMemberexas:ScreeningMember2023-01-012023-12-310001124140us-gaap:ProductAndServiceOtherMemberexas:ScreeningMember2022-01-012022-12-310001124140us-gaap:ProductAndServiceOtherMemberexas:ScreeningMember2021-01-012021-12-310001124140exas:ScreeningMember2023-01-012023-12-310001124140exas:ScreeningMember2022-01-012022-12-310001124140exas:ScreeningMember2021-01-012021-12-310001124140exas:PrecisionOncologyMemberus-gaap:ProductMember2023-01-012023-12-310001124140exas:PrecisionOncologyMemberus-gaap:ProductMember2022-01-012022-12-310001124140exas:PrecisionOncologyMemberus-gaap:ProductMember2021-01-012021-12-310001124140exas:PrecisionOncologyMemberus-gaap:ServiceMember2023-01-012023-12-310001124140exas:PrecisionOncologyMemberus-gaap:ServiceMember2022-01-012022-12-310001124140exas:PrecisionOncologyMemberus-gaap:ServiceMember2021-01-012021-12-310001124140exas:PrecisionOncologyMemberexas:InternationalSalesMember2023-01-012023-12-310001124140exas:PrecisionOncologyMemberexas:InternationalSalesMember2022-01-012022-12-310001124140exas:PrecisionOncologyMemberexas:InternationalSalesMember2021-01-012021-12-310001124140exas:PrecisionOncologyMemberus-gaap:ProductAndServiceOtherMember2023-01-012023-12-310001124140exas:PrecisionOncologyMemberus-gaap:ProductAndServiceOtherMember2022-01-012022-12-310001124140exas:PrecisionOncologyMemberus-gaap:ProductAndServiceOtherMember2021-01-012021-12-310001124140exas:PrecisionOncologyMember2023-01-012023-12-310001124140exas:PrecisionOncologyMember2022-01-012022-12-310001124140exas:PrecisionOncologyMember2021-01-012021-12-310001124140exas:COVID19TestingMember2023-01-012023-12-310001124140exas:COVID19TestingMember2022-01-012022-12-310001124140exas:COVID19TestingMember2021-01-012021-12-310001124140exas:VariablePriceContractMember2023-01-012023-12-310001124140exas:VariablePriceContractMember2022-01-012022-12-310001124140exas:VariablePriceContractMember2021-01-012021-12-310001124140exas:CashAndMoneyMarketMember2023-12-310001124140exas:CashAndMoneyMarketMember2022-12-310001124140us-gaap:CashEquivalentsMember2023-12-310001124140us-gaap:CashEquivalentsMember2022-12-310001124140us-gaap:ShortTermInvestmentsMember2023-12-310001124140us-gaap:ShortTermInvestmentsMember2022-12-310001124140us-gaap:CommercialPaperMemberus-gaap:CashEquivalentsMember2023-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:CashEquivalentsMember2023-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310001124140us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310001124140us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2023-12-310001124140us-gaap:CommercialPaperMemberus-gaap:CashEquivalentsMember2022-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:CashEquivalentsMember2022-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-12-310001124140us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2022-12-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-12-310001124140us-gaap:LandMember2023-12-310001124140us-gaap:LandMember2022-12-310001124140exas:BuildingsAndLeaseholdImprovementsMember2023-12-310001124140exas:BuildingsAndLeaseholdImprovementsMember2022-12-310001124140us-gaap:LandImprovementsMember2023-12-310001124140us-gaap:LandImprovementsMember2022-12-310001124140us-gaap:BuildingMembersrt:MinimumMember2023-12-310001124140us-gaap:BuildingMembersrt:MaximumMember2023-12-310001124140us-gaap:BuildingMember2023-12-310001124140us-gaap:BuildingMember2022-12-310001124140exas:OfficeEquipmentAndComputerSoftwareMember2023-12-310001124140exas:OfficeEquipmentAndComputerSoftwareMember2022-12-310001124140srt:MinimumMemberus-gaap:EquipmentMember2023-12-310001124140srt:MaximumMemberus-gaap:EquipmentMember2023-12-310001124140us-gaap:EquipmentMember2023-12-310001124140us-gaap:EquipmentMember2022-12-310001124140us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2023-12-310001124140us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2023-12-310001124140us-gaap:FurnitureAndFixturesMember2023-12-310001124140us-gaap:FurnitureAndFixturesMember2022-12-310001124140us-gaap:AssetUnderConstructionMember2023-12-310001124140us-gaap:AssetUnderConstructionMember2022-12-310001124140us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310001124140us-gaap:LeaseholdImprovementsMember2023-12-310001124140us-gaap:BuildingImprovementsMember2023-12-310001124140us-gaap:TradeNamesMember2023-12-310001124140us-gaap:CustomerRelationshipsMember2023-12-310001124140us-gaap:PatentsMember2023-12-310001124140us-gaap:DevelopedTechnologyRightsMember2023-12-310001124140us-gaap:TradeNamesMember2022-12-310001124140us-gaap:CustomerRelationshipsMember2022-12-310001124140us-gaap:PatentsMember2022-12-310001124140us-gaap:DevelopedTechnologyRightsMember2022-12-310001124140exas:ThriveEarlierDetectionCorporationMember2021-01-050001124140us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberexas:OncotypeDXGenomicProstateScoreTestMember2022-08-020001124140us-gaap:ServiceAgreementsMember2022-07-012022-09-300001124140us-gaap:InProcessResearchAndDevelopmentMember2021-07-012021-09-300001124140us-gaap:DevelopedTechnologyRightsMember2022-04-012022-06-300001124140exas:OmicEraMember2022-01-012022-12-310001124140exas:PreventionGeneticsLLCMember2022-01-012022-12-310001124140exas:ResolutionBioscienceMember2023-01-012023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberexas:RestrictedCashMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberexas:RestrictedCashMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberexas:RestrictedCashMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberexas:RestrictedCashMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001124140us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberexas:RestrictedCashMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberexas:RestrictedCashMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberexas:RestrictedCashMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberexas:RestrictedCashMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140exas:MDxHealthMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ThriveAshionAndOmicEraMember2023-12-310001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ThriveAshionAndOmicEraMember2022-12-310001124140srt:WeightedAverageMemberexas:MeasurementInputProbabilityOfSuccessMemberexas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember2023-12-310001124140srt:WeightedAverageMemberexas:MeasurementInputProbabilityOfSuccessMemberexas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember2022-12-310001124140srt:WeightedAverageMemberexas:MeasurementInputPresentValueFactorMemberexas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember2023-12-310001124140srt:WeightedAverageMemberexas:MeasurementInputPresentValueFactorMemberexas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember2022-12-310001124140exas:VentureCapitalInvestmentFundMember2023-01-012023-12-310001124140exas:VentureCapitalInvestmentFundMember2023-12-310001124140exas:VentureCapitalInvestmentFundMember2022-12-310001124140us-gaap:ForeignExchangeForwardMember2023-12-310001124140us-gaap:ForeignExchangeForwardMember2022-12-310001124140exas:SecuritizedReceivablesMember2022-06-290001124140exas:SecuritizedReceivablesMembersrt:MinimumMember2022-06-290001124140exas:SecuritizedReceivablesMember2023-12-310001124140exas:SecuritizedReceivablesMember2022-12-310001124140us-gaap:RevolvingCreditFacilityMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2021-11-300001124140us-gaap:RevolvingCreditFacilityMemberexas:RevolvingLoanAgreementMemberexas:DailyBloombergShortTermBankYieldIndexRateMemberus-gaap:LineOfCreditMember2021-11-012021-11-300001124140us-gaap:LetterOfCreditMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2021-01-012021-12-310001124140us-gaap:LetterOfCreditMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2023-01-012023-12-310001124140us-gaap:RevolvingCreditFacilityMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2023-12-310001124140us-gaap:RevolvingCreditFacilityMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2022-12-310001124140us-gaap:ConstructionLoansMember2019-12-310001124140exas:OneMonthLondonInterbankOfferRateMemberus-gaap:ConstructionLoansMember2022-01-012022-12-310001124140exas:ConvertibleNotesPayable2030Member2023-12-310001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2030Member2023-12-310001124140exas:ConvertibleNotesPayable2028Member2023-12-310001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2028Member2023-12-310001124140exas:ConvertibleNotesPayable2027Member2023-12-310001124140exas:ConvertibleNotesPayable2027Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2023-12-310001124140exas:ConvertibleNotesPayable2025Member2023-12-310001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2025Member2023-12-310001124140exas:ConvertibleNotesPayable2028Member2022-12-310001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2028Member2022-12-310001124140exas:ConvertibleNotesPayable2027Member2022-12-310001124140exas:ConvertibleNotesPayable2027Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-12-310001124140exas:ConvertibleNotesPayable2025Member2022-12-310001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberexas:ConvertibleNotesPayable2025Member2022-12-310001124140exas:ConvertibleNotesPayable2025Member2018-01-310001124140exas:ConvertibleNotesPayable2025Member2018-01-012018-01-310001124140exas:ConvertibleNotesPayable2025Member2018-06-300001124140exas:ConvertibleNotesPayable2025Member2018-06-012018-06-300001124140exas:ConvertibleNotesPayable2027Member2019-03-310001124140exas:ConvertibleNotesPayable2027Member2019-03-012019-03-310001124140exas:ConvertibleNotesPayable2027Memberexas:ConvertibleNotesPayable2025Member2019-03-012019-03-310001124140exas:ConvertibleNotesPayable2025Member2019-03-012019-03-310001124140exas:ConvertibleNotesPayable2028Member2020-02-290001124140exas:ConvertibleNotesPayable2028Member2020-02-012020-02-290001124140exas:ConvertibleNotesPayable2025Member2020-02-012020-02-2900011241402020-02-012020-02-290001124140exas:ConvertibleNotesPayable2030Member2023-03-010001124140exas:ConvertibleNotesPayable2027Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2028Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2030Member2023-03-012023-03-3100011241402023-03-012023-03-310001124140exas:ConvertibleNotesPayable2030Memberexas:ConvertibleNotesPayable2025Member2023-03-060001124140exas:ConvertibleNotesPayable2025Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2025Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2025Member2023-01-012023-12-310001124140exas:ConvertibleNotesPayable2027Member2023-01-012023-12-310001124140exas:ConvertibleNotesPayable2028Member2023-01-012023-12-310001124140exas:ConvertibleNotesPayable2030Member2023-01-012023-12-310001124140exas:ConvertibleNotesPayable2030Member2022-01-012022-12-310001124140exas:ConvertibleNotesPayable2030Member2021-01-012021-12-310001124140exas:ConvertibleNotesPayable2028Member2022-01-012022-12-310001124140exas:ConvertibleNotesPayable2028Member2021-01-012021-12-310001124140exas:ConvertibleNotesPayable2027Member2022-01-012022-12-310001124140exas:ConvertibleNotesPayable2027Member2021-01-012021-12-310001124140exas:ConvertibleNotesPayable2025Member2022-01-012022-12-310001124140exas:ConvertibleNotesPayable2025Member2021-01-012021-12-310001124140exas:SalesMilestoneRangeThreeMemberus-gaap:LicensingAgreementsMemberexas:MAYOFoundationMember2017-10-310001124140us-gaap:LicensingAgreementsMemberexas:MAYOFoundationMember2023-01-012023-12-310001124140exas:ThriveEarlierDetectionCorporationMemberus-gaap:LicensingAgreementsMember2021-01-050001124140exas:TARDISTechnologyMember2021-01-112021-01-110001124140exas:TARDISTechnologyMember2021-01-110001124140exas:TheBroadInstituteLLCMemberexas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMemberus-gaap:LicensingAgreementsMember2023-06-300001124140exas:TheBroadInstituteLLCMemberexas:SalesMilestoneRangeOneMemberus-gaap:LicensingAgreementsMember2023-06-302023-06-300001124140us-gaap:LicensingAgreementsMemberexas:WatchmakerGenomicsIncMember2023-07-310001124140exas:PfizerIncMemberus-gaap:ManufacturedProductOtherMember2021-11-300001124140exas:PfizerIncMemberus-gaap:ManufacturedProductOtherMember2022-01-012022-12-310001124140exas:PfizerIncMemberus-gaap:ManufacturedProductOtherMember2021-01-012021-12-310001124140exas:OmicEraMember2022-05-012022-05-310001124140exas:OmicEraMember2022-05-010001124140exas:PreventionGeneticsLLCMember2021-12-012021-12-310001124140exas:PreventionGeneticsLLCMember2021-12-310001124140exas:AshionAnalyticsMember2021-04-012021-04-300001124140exas:AshionAnalyticsMember2021-04-300001124140exas:ThriveEarlierDetectionCorporationMember2021-01-012021-01-310001124140exas:ThriveEarlierDetectionCorporationMember2021-01-310001124140exas:TARDISTechnologyMember2021-01-112021-01-110001124140exas:TARDISTechnologyMember2021-01-110001124140us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310001124140us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-12-310001124140us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-12-310001124140us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-12-310001124140exas:OmnibusLongTermIncentivePlan2019Member2023-01-012023-12-310001124140exas:OmnibusLongTermIncentivePlan2019Memberexas:EmployeeAndNonEmployeesStockOptionMember2023-01-012023-12-310001124140exas:OmnibusLongTermIncentivePlan2019Membersrt:MinimumMember2023-01-012023-12-310001124140srt:MaximumMemberexas:OmnibusLongTermIncentivePlan2019Member2023-01-012023-12-310001124140exas:OmnibusLongTermIncentivePlan2019Memberexas:EmployeeAndNonEmployeesStockOptionMember2023-12-310001124140us-gaap:RestrictedStockMemberexas:OmnibusLongTermIncentivePlan2019Member2023-12-310001124140exas:OmnibusLongTermIncentivePlan2019Member2022-06-092022-06-090001124140exas:OmnibusLongTermIncentivePlan2019Member2023-06-082023-06-080001124140exas:OmnibusLongTermIncentivePlan2019Member2023-12-310001124140exas:OmnibusLongTermIncentivePlan2010Member2023-01-012023-12-310001124140exas:OmnibusLongTermIncentivePlan2010Memberexas:EmployeeAndNonEmployeesStockOptionMember2023-01-012023-12-310001124140exas:OmnibusLongTermIncentivePlan2010Membersrt:MinimumMember2023-01-012023-12-310001124140srt:MaximumMemberexas:OmnibusLongTermIncentivePlan2010Member2023-01-012023-12-310001124140exas:OmnibusLongTermIncentivePlan2010Memberexas:EmployeeAndNonEmployeesStockOptionMember2023-12-310001124140us-gaap:RestrictedStockMemberexas:OmnibusLongTermIncentivePlan2010Member2023-12-310001124140exas:OmnibusLongTermIncentivePlan2010Member2023-12-310001124140exas:EmployeeStockPurchasePlan2010Member2014-07-242014-07-240001124140exas:EmployeeStockPurchasePlan2010Member2016-07-282016-07-280001124140exas:EmployeeStockPurchasePlan2010Member2022-06-092022-06-090001124140exas:EmployeeStockPurchasePlan2010Member2023-12-310001124140exas:EmployeeStockPurchasePlan2010Membersrt:MinimumMember2023-01-012023-12-31exas:item0001124140exas:EmployeeStockPurchasePlan2010Membersrt:MaximumMember2023-01-012023-12-310001124140exas:EmployeeStockPurchasePlan2010Member2023-01-012023-12-310001124140exas:EmployeeStockPurchasePlan2010Member2023-12-312023-12-310001124140us-gaap:CostOfSalesMember2023-01-012023-12-310001124140us-gaap:CostOfSalesMember2022-01-012022-12-310001124140us-gaap:CostOfSalesMember2021-01-012021-12-310001124140us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001124140us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001124140us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001124140us-gaap:SellingAndMarketingExpenseMember2023-01-012023-12-310001124140us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-310001124140us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001124140us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-310001124140us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001124140us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001124140exas:ThriveEarlierDetectionCorporationMemberexas:EmployeeAndNonEmployeesStockOptionMember2021-01-012021-12-310001124140exas:ThriveEarlierDetectionCorporationMemberexas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2021-01-012021-12-310001124140exas:ThriveEarlierDetectionCorporationMember2021-01-012021-12-310001124140us-gaap:GeneralAndAdministrativeExpenseMemberexas:ThriveEarlierDetectionCorporationMember2021-01-012021-12-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2022-12-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2023-01-012023-12-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2023-12-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2022-01-012022-12-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2021-01-012021-12-310001124140us-gaap:PerformanceSharesMember2022-12-310001124140us-gaap:PerformanceSharesMember2023-01-012023-12-310001124140us-gaap:PerformanceSharesMember2023-12-310001124140us-gaap:PerformanceSharesMember2022-01-012022-12-310001124140us-gaap:PerformanceSharesMember2021-01-012021-12-310001124140exas:EmployeeStockPurchasePlan2010Memberus-gaap:EmployeeStockMember2023-01-012023-12-310001124140exas:EmployeeStockPurchasePlan2010Memberus-gaap:EmployeeStockMember2022-01-012022-12-310001124140exas:EmployeeStockPurchasePlan2010Memberus-gaap:EmployeeStockMember2021-01-012021-12-310001124140exas:OfferingPeriodEndDateOneMemberexas:EmployeeStockPurchasePlan2010Member2023-04-302023-04-300001124140exas:OfferingPeriodEndDateTwoMemberexas:EmployeeStockPurchasePlan2010Member2023-11-012023-11-010001124140us-gaap:EmployeeStockMember2023-01-012023-12-310001124140us-gaap:EmployeeStockMember2022-01-012022-12-310001124140us-gaap:EmployeeStockMember2021-01-012021-12-310001124140us-gaap:EmployeeStockMembersrt:MinimumMember2022-01-012022-12-310001124140us-gaap:EmployeeStockMembersrt:MaximumMember2022-01-012022-12-310001124140us-gaap:EmployeeStockMembersrt:MinimumMember2021-01-012021-12-310001124140us-gaap:EmployeeStockMembersrt:MaximumMember2021-01-012021-12-310001124140exas:EmployeeStockPurchasePlan2019Member2023-12-310001124140us-gaap:AccountingStandardsUpdate201602Member2021-01-012021-12-310001124140exas:DOSRuleInvestigationMember2023-09-302023-09-300001124140exas:DOSRuleInvestigationMember2023-01-012023-12-310001124140exas:DOSRuleInvestigationMember2021-01-012021-12-310001124140exas:QuiTamSuitMember2023-10-312023-10-310001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2021-12-012021-12-310001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2021-12-31exas:position0001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2023-01-012023-12-310001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2023-12-310001124140us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberexas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2023-12-310001124140us-gaap:OtherNoncurrentAssetsMemberexas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2023-12-310001124140exas:ResolutionBioscienceMember2023-09-122023-09-120001124140exas:ResolutionBioscienceMember2023-09-120001124140us-gaap:DevelopedTechnologyRightsMemberexas:ResolutionBioscienceMember2023-09-120001124140exas:OmicEraMember2022-05-022022-05-020001124140exas:OmicEraDiagnosticsAcquisitionMember2022-05-012022-05-310001124140exas:OmicEraMember2022-05-020001124140exas:PreventionGeneticsLLCMember2021-12-312021-12-31exas:test0001124140exas:PreventionGeneticsLLCMemberexas:BusinessAcquisitionPaymentTrancheOneMember2021-12-312021-12-310001124140exas:PreventionGeneticsLLCMember2022-12-310001124140exas:AshionAnalyticsMember2021-04-142021-04-140001124140exas:AshionAnalyticsMember2021-04-140001124140exas:AshionAnalyticsMemberexas:CommercialLaunchMilestoneMember2021-04-140001124140exas:MRDProductRevenueMilestoneMemberexas:AshionAnalyticsMember2021-04-140001124140exas:ThriveEarlierDetectionCorporationMember2021-01-052021-01-050001124140us-gaap:GeneralAndAdministrativeExpenseMemberexas:ThriveEarlierDetectionCorporationMember2021-01-052021-01-050001124140exas:FDAApprovalMemberexas:ThriveEarlierDetectionCorporationMember2021-01-050001124140exas:ThriveEarlierDetectionCorporationMemberexas:CenterForMedicareAndMedicaidServicesCMSCoverageMember2021-01-050001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ThriveEarlierDetectionCorporationMember2021-01-050001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ThriveEarlierDetectionCorporationMemberexas:AllocatedToConsiderationTransferredMember2021-01-050001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ThriveEarlierDetectionCorporationMemberexas:AllocatedToPreviousOwnershipInterestMember2021-01-050001124140exas:AllocatedToCompensationMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ThriveEarlierDetectionCorporationMember2021-01-050001124140exas:ThriveEarlierDetectionCorporationMemberexas:CompensationExpenseMember2021-01-050001124140us-gaap:GeneralAndAdministrativeExpenseMemberexas:ThriveEarlierDetectionCorporationMember2021-01-012021-03-310001124140us-gaap:EmployeeStockOptionMemberexas:ThriveEarlierDetectionCorporationMember2021-01-052021-01-050001124140us-gaap:EmployeeStockOptionMemberexas:ThriveEarlierDetectionCorporationMembersrt:MinimumMember2021-01-052021-01-050001124140us-gaap:EmployeeStockOptionMemberexas:ThriveEarlierDetectionCorporationMembersrt:MaximumMember2021-01-052021-01-050001124140exas:ThriveEarlierDetectionCorporationMember2021-01-050001124140exas:ThriveEarlierDetectionCorporationMemberus-gaap:InvestmentIncomeMember2021-01-012021-03-310001124140exas:ThriveEarlierDetectionCorporationMember2021-01-062021-12-310001124140exas:ThriveEarlierDetectionCorporationMember2020-01-012020-12-310001124140exas:EmployeesWithQualifyingTerminationEventsMemberexas:ThriveEarlierDetectionCorporationMember2021-01-012021-03-310001124140exas:ThriveEarlierDetectionCorporationMember2021-01-012021-03-310001124140exas:ThriveEarlierDetectionCorporationMember2021-01-012021-03-310001124140exas:ThriveEarlierDetectionCorporationMember2021-01-012021-12-310001124140exas:PFSGenomicsMember2021-05-030001124140exas:PFSGenomicsMember2021-06-230001124140exas:PFSGenomicsMember2021-06-232021-06-230001124140us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberexas:OncotypeDXGenomicProstateScoreTestMember2022-08-022022-08-0200011241402022-08-020001124140us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberexas:OncotypeDXGenomicProstateScoreTestMember2022-01-012022-12-3100011241402022-08-022022-08-020001124140us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberexas:OncotypeDXGenomicProstateScoreTestMember2023-01-012023-12-310001124140us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberexas:OncotypeDXGenomicProstateScoreTestMember2023-08-230001124140country:US2023-01-012023-12-310001124140country:US2022-01-012022-12-310001124140country:US2021-01-012021-12-310001124140us-gaap:NonUsMember2023-01-012023-12-310001124140us-gaap:NonUsMember2022-01-012022-12-310001124140us-gaap:NonUsMember2021-01-012021-12-310001124140us-gaap:DomesticCountryMember2023-12-310001124140us-gaap:StateAndLocalJurisdictionMember2023-12-310001124140us-gaap:ForeignCountryMember2023-12-310001124140us-gaap:DomesticCountryMemberus-gaap:ResearchMember2023-12-310001124140us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2023-12-310001124140us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMemberstpr:CA2023-12-310001124140us-gaap:DomesticCountryMember2023-01-012023-12-310001124140us-gaap:DomesticCountryMember2022-01-012022-12-310001124140us-gaap:DomesticCountryMember2021-01-012021-12-310001124140us-gaap:StateAndLocalJurisdictionMember2023-01-012023-12-310001124140us-gaap:StateAndLocalJurisdictionMember2022-01-012022-12-310001124140us-gaap:StateAndLocalJurisdictionMember2021-01-012021-12-310001124140us-gaap:ForeignCountryMember2023-01-012023-12-310001124140us-gaap:ForeignCountryMember2022-01-012022-12-310001124140us-gaap:ForeignCountryMember2021-01-012021-12-310001124140us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310001124140us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310001124140us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-12-310001124140us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-01-012023-12-310001124140us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-01-012022-12-310001124140us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-01-012021-12-310001124140us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-12-310001124140us-gaap:ValuationAllowanceOfDeferredTaxAssetsMemberexas:GenomicHealthIncMember2021-01-012021-12-310001124140exas:ThriveEarlierDetectionCorporationMemberus-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-01-012023-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________________
FORM 10-K
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended: December 31, 2023
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 001-35092
_____________________________________________________________________________
EXACT SCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
5505 Endeavor Lane, Madison, Wisconsin
(Address of principal executive offices)
02-0478229
(IRS Employer
Identification No.)
53719
(Zip Code)
Registrant’s telephone number, including area code: (608) 284‑5700
Securities registered pursuant to Section 12(b) of the Act:
Common Stock, $0.01 Par ValueEXAS
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x  No ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨  No x
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x  No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b‑2 of the Exchange Act. (Check one):
Large accelerated filerxAccelerated filer¨Non‑accelerated filer¨Smaller reporting company☐Emerging growth company☐
(Do not check if a smaller reporting company)
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. x
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ¨
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b‑2 of the Act). Yes ☐  No x
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, as of the last business day of the Registrant’s most recently completed second fiscal quarter was approximately $16,796,351,138 (based on the closing price of the Registrant’s Common Stock on June 30, 2023 of $93.90 per share).
The number of shares outstanding of the Registrant’s $0.01 par value Common Stock as of February 20, 2024 was 181,530,967.
DOCUMENT INCORPORATED BY REFERENCE
The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended December 31, 2023. Portions of such proxy statement are incorporated by reference into Part III of this Form 10‑K.


EXACT SCIENCES CORPORATION
ANNUAL REPORT ON FORM 10‑K
YEAR ENDED DECEMBER 31, 2023
TABLE OF CONTENTS
Page No.

2
PART I
This Annual Report on Form 10‑K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this Annual Report on Form 10‑K regarding our strategies, prospects, expectations, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; our reliance upon certain suppliers, including suppliers that are the sole source of certain supplies and products used in our tests and operations; approval and maintenance of adequate reimbursement rates for our products and services within and outside of the U.S.; the amount and nature of competition for our products and services; the effects of any judicial, executive or legislative action affecting us or the healthcare system; recommendations, guidelines and quality metrics issued by various organizations regarding cancer screening or our products and services; our ability to successfully develop and commercialize new products and services and assess potential market opportunities; our ability to effectively enter into and utilize strategic partnerships and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; our ability to protect and enforce our intellectual property; the results of our validation studies and clinical trials, including the risks that the results of future studies and trials may differ materially from the results of previously completed studies and trials; our ability to manage an international business and our expectations regarding our international expansion and opportunities; our ability to raise the capital necessary to support our operations or meet our payment obligations under our indebtedness; the potential effects of changing macroeconomic conditions, including the effects of inflation, interest rate and foreign currency exchange rate fluctuations, and geopolitical conflict; the possibility that the anticipated benefits from our business acquisitions will not be realized in full or at all or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of acquired businesses’ operations or the divestiture of business operations will be greater than expected and the possibility that integration or divestiture efforts will disrupt our business and strain management time and resources; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; and our ability to retain and hire key personnel. The risks included above are not exhaustive. Other important risks and uncertainties are described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections in this Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. You are further cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
3


Item 1. Business
Overview
Exact Sciences Corporation (together with its subsidiaries, “Exact,” “we,” “us,” “our” or the “Company”) is a leading, global, advanced cancer diagnostics company. We have developed some of the most impactful tests in cancer screening and diagnostics, and are currently working to develop additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.
Our mission at Exact Sciences is to eradicate cancer and the suffering it causes by preventing it, detecting it earlier, and guiding personalized treatment. Our revenues are primarily generated by our laboratory testing services from our Cologuard® colorectal cancer screening test and our Oncotype DX® cancer diagnostic tests and services.
During 2023, we achieved many milestones, including:
•delivering more than 4 million tests to patients, including a record number of Cologuard and Oncotype DX results,
•growing revenues to $2.50 billion for the year ended December 31, 2023, an increase of 20% compared to the year ended December 31, 2022,
•accelerating our path to profitability through prioritization efforts, leading to improved financial results including positive cash provided by operating activities of $156.1 million for the year ended December 31, 2023, an improvement of $379.7 million compared to the year ended December 31, 2022,
•increasing the percentage of healthcare professionals who offer our Cologuard test as a front-line screening test,
•elevating our Cologuard test brand awareness with consumers to 89%, an all-time high,
•expanding the impact of our Oncotype DX Breast Recurrence Score® test by launching in Japan on a reimbursed basis,
•acquiring Resolution Bioscience, Inc. (“Resolution Bioscience”) to complement our solid tumor therapy selection capabilities with a high-quality liquid therapy selection platform,
•releasing positive results from our pivotal BLUE-C study to support our next generation Cologuard test and submitting these results for U.S. Food and Drug Administration (“FDA”) approval,
•making great progress toward the development of OncodetectTM, our molecular residual disease and recurrence monitoring (“MRD”) test, and
•advancing our multi-cancer early detection (“MCED”) program.
Our Products and Services
With a leading portfolio of products for earlier cancer detection and treatment guidance, we provide patients with earlier, smarter answers. Our current products and services focus on screening and precision oncology tests.
Our Screening Tests
Cologuard Test
Our flagship screening product, the Cologuard test, is a patient-friendly, non-invasive, stool-based DNA (“sDNA”) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Eleven biomarkers are targeted that have been shown to be strongly associated with colorectal cancer and pre-cancer. Methylation, mutation, and hemoglobin results are combined in the laboratory analysis through a proprietary algorithm to provide a single positive or negative reportable result.
We believe the large, underserved population of unscreened and inadequately screened patients represents a significant opportunity for our Cologuard test. It is widely accepted that colorectal cancer is among the most preventable, yet least prevented cancers. Colorectal cancer can take up to 10-15 years to progress from a pre-cancerous lesion to metastatic cancer and death. Patients who are diagnosed early in the progression of the disease — with pre-cancerous lesions or early-stage cancer — are more likely to have a complete recovery and to be treated less expensively. Colorectal cancer is the second leading cause of cancer deaths in the United States (“U.S.”) and the leading cause of cancer deaths in the U.S. among non-smokers. Each year in the U.S. there are approximately 153,000 new cases of colorectal cancer and approximately 53,000 deaths.
4
Upon approval by the FDA in August 2014, our Cologuard test became the first and only FDA-approved sDNA non-invasive colorectal cancer screening test. In September 2019, the FDA expanded its indication to include average-risk individuals ages 45-49. Our Cologuard test is now indicated for average risk adults 45 years of age and older.
Our peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening,” published in the New England Journal of Medicine in April 2014, highlighted the performance of the Cologuard test in its 10,000 patient Deep-C clinical trial:
•Cancer Sensitivity: 92%
•Stage I and II Cancer Sensitivity: 94%
•High-Grade Dysplasia Sensitivity: 69%
•Specificity: 87%
We believe the competitive advantages of sDNA screening provide a significant market opportunity. There are nearly 110 million Americans between the ages of 45 and 85 who are at average risk for colorectal cancer. At a three-year screening interval and an average revenue per test of approximately $500, this represents a potential $18 billion market for our Cologuard test.
More than 55% of Americans between the ages of 45 and 85 who are at average risk for colorectal cancer are not up-to-date with screening according to the American Cancer Society’s (“ACS”) colorectal cancer screening guidelines. We believe our Cologuard test helps more people get screened for colorectal cancer. Internal studies have shown that approximately 40% of surveyed Cologuard users were previously unscreened for colorectal cancer.
Our Cologuard test is included in key guidelines and quality measures that many healthcare providers rely on when making screening recommendations.
•In its updated guidelines released in May 2021, the U.S. Preventive Services Task Force (“USPSTF”) gave an “A” grade to colorectal cancer screening starting at age 50 and continuing until age 75 and a “B” grade to colorectal cancer screening for ages 45 to 49. The updated guidelines include our Cologuard test (referred to in their statement as sDNA-FIT) as a recommended screening method for all average-risk patients in the 45-75 age group.
•The ACS has specifically included our Cologuard test as a recommended colorectal cancer screening test in average-risk, asymptomatic individuals. The ACS recommends colorectal cancer screening beginning at age 45 for people at average risk of colorectal cancer.
•The National Comprehensive Cancer Network (“NCCN”) includes sDNA screening at a once-every-three-years interval in its Colorectal Cancer Screening Guidelines.
•The National Committee for Quality Assurance (“NCQA”) includes sDNA testing on a three-year interval as one of the methods permitted for colorectal cancer screening in its most recent Healthcare Effectiveness Data and Information Set (“HEDIS”) quality measures.
•The Centers for Medicare & Medicaid Services (“CMS”) includes our Cologuard test in its most recent Medicare Advantage Star Ratings program.
Clinical Genetic Testing
We provide more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline, whole exome (“PGxome®”), and whole genome (“PGnome®”) sequencing tests.
Our hereditary cancer test, RiskguardTM, helps people understand their inherited risk of cancer, arming them with critical information to make better treatment decisions.
Our Precision Oncology Tests
Our precision oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. We enable patients to take a more active role in their cancer care and make it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations.
5
Oncotype DX Breast Recurrence Score Test
Our Oncotype DX Breast Recurrence Score test has been demonstrated to identify patients who are most likely to benefit from chemotherapy as well as those who may receive no clinical benefit from chemotherapy.
Among women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death. In 2024, nearly 311,000 women are expected to be diagnosed with invasive breast cancer in the U.S. according to ACS, and nearly 56,000 women are expected to be diagnosed with non-invasive (in situ) breast cancer. Worldwide, it is estimated that there are approximately 2.3 million newly diagnosed cases of breast cancer each year.
The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue to provide personalized information for tailoring treatment based on the biology of the patient’s individual disease. The test is supported by multiple rigorous clinical validation studies, including the landmark TAILORx and RxPONDER studies, confirming the test’s ability to predict the likelihood of chemotherapy benefit as well as the chance of cancer recurrence in certain common types of early-stage breast cancer.
As the only test proven to predict both the likelihood of chemotherapy benefit and cancer recurrence, the Oncotype DX Breast Recurrence Score test is globally recognized as standard of care and included in all major breast cancer treatment guidelines.
Oncotype DX Breast DCIS Score® Test
Our Oncotype DX Breast DCIS Score test provides ductal carcinoma in situ (“DCIS”) patients an individualized prediction of the 10-year risk of local recurrence (DCIS or invasive carcinoma), represented by a DCIS Score® result. This test helps guide treatment decision-making in women with DCIS treated by local excision, with or without tamoxifen. Development of our Oncotype DX Breast DCIS Score test was based on published results for the Oncotype DX Breast Recurrence Score test that showed similarity in the expression profiles of genes between DCIS and invasive breast cancer when both are present within the same patient tumor.
Oncotype DX Colon Recurrence Score® Test
In patients with stage II and stage III colon cancer, the decision to treat with chemotherapy following surgery is based on an assessment of the likelihood of cancer recurrence and, as a result, it is critical for clinicians to accurately assess a patient’s risk of recurrence. Our Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. By evaluating specific genes within a patient’s colon tumor, the test can determine the likelihood that the cancer cells will spread and cause the disease to return after surgery. Based on this information, healthcare providers and patients can make more informed treatment decisions. The Oncotype DX Colon Recurrence Score test is supported by three rigorous clinical validation studies confirming the test’s ability to provide additional and independent value beyond the currently used measures for determining colon cancer recurrence risk.
OncoExTra™ Test
In April 2021, we began performing and selling the OncoExTra test, previously known as GEM ExTra, as a result of our acquisition of Ashion Analytics, LLC (“Ashion”). The OncoExTra test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today.
COVID-19 Testing Business
We discontinued our COVID-19 testing operations in the second quarter of 2023. From March 2020 through June 2023, we partnered with various customers, including the State of Wisconsin Department of Health Services, to administer testing. Customers were responsible for employing trained personnel to collect specimens. Specimens were sent to our laboratory in Madison, Wisconsin, where we ran the assay in our laboratories and provided test results to ordering providers.
6
Pipeline Research and Development
Our research and development efforts are focused on developing new products and enhancing existing products to address unmet cancer needs and expand the clinical utility and addressable patient populations for our existing tests. We are focused on enhancing our Cologuard test’s performance characteristics and developing blood and other liquid-based (“liquid biopsy”) tests. These development efforts may lead to a variety of new products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and patient monitoring.
Through our collaboration with the Mayo Foundation for Medical Education and Research (“Mayo”), we have successfully performed validation studies involving multiple types of cancer using tissue, blood, and other sample types. In September 2020, Mayo agreed to make available certain personnel to provide us research and development assistance through January 2025. Through recent business development activities, we have also acquired exclusive access to technologies developed by The Johns Hopkins University (“JHU”), Broad Institute, Inc. (“Broad Institute”), Oxford University, and the Ludwig Institute for Cancer Research.
We are focusing our research and development efforts on three main areas:
•Colorectal Cancer Screening. We are seeking to improve our Cologuard test’s performance characteristics, focusing on reducing the false positive rate of the test. In June 2023, we and Mayo presented data from the prospective BLUE-C study, the FDA registrational trial for our next-generation Cologuard test, showing overall sensitivity of 94% for colorectal cancer at specificity of 91%. We submitted our next-generation Cologuard test for FDA approval in December 2023. We are also working to develop a blood-based screening test for colorectal cancer as a second-line option for people who haven’t been screened with more accurate methods.
•MCED Test Development. We are seeking to develop a MCED test, which will be branded as CancerguardTM to help detect many different types of cancer from a single blood draw. In September 2022, we presented data at the European Society for Medical Oncology (“ESMO”) Congress from a biomarker validation study, which demonstrated the ability to detect cancer signals from 15 organ sites with a mean sensitivity of 61% and mean specificity of 98.2%. The multi-biomarker approach detected stage I and stage II cancers with a combined sensitivity of 38.7%. In June 2023, we announced a collaboration with Baylor Scott & White to utilize our Cancerguard test within a subset of their clinics to generate real-world experience and evidence of our MCED approach. A larger case-control study is underway to further validate the results shared at ESMO and to determine the final design of the Cancerguard test. In the future, we plan to begin recruiting patients for the FDA registrational Study of All comeRs (“SOAR”) trial, which we expect to be the largest prospective, interventional MCED trial ever conducted in the U.S.
•MRD Test Development. We plan to offer our Oncodetect test, a tumor-informed MRD test to help detect small amounts of tumor DNA that may remain in patients’ blood after they have undergone initial cancer treatment. This test will help patients and oncologists understand the success of initial treatment, guide further treatment, and monitor for cancer recurrence. Our goal is to support all patients in MRD and recurrence monitoring, whether there is access to tumor tissue to inform patient-specific biomarker targets or no access to tissue and a predefined biomarker panel is used. We recently completed analytical validation of our tumor informed platform utilizing colorectal cancer samples and are currently conducting a clinical validation study for Medicare submission. In June 2023, we entered into a sponsored research agreement and exclusive license agreement with Broad Institute to utilize their Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (“MAESTRO”) diagnostic testing technology to further our ability to develop and launch impactful MRD tests.
Research and development, which includes our clinical study programs, accounts for a material portion of our operating expenses. As we seek to enhance our product portfolio and advance our pipeline, we expect that our research and development expenditures will continue to be a significant portion of our operating expenditures.
Commercial Operations
We have one core commercial function with specific teams focused on screening, precision oncology, and international markets.
Cologuard Test Commercial Operations
We promote our Cologuard test through a region and market-based model comprised of our health systems, primary care, market development, and inside sales team members.
7
Our sales team actively engages with healthcare providers and their staff to emphasize the need for colorectal cancer screening, educate them on the value of our Cologuard test, and facilitate their ability to order the test. We focus on specific healthcare providers based on a combination of Cologuard order history and ordering potential data. We also focus on healthcare provider groups and larger regional and national health systems.
A critical part of the value proposition of our Cologuard test is its adherence program, which involves active engagement with patients and providers by our adherence team. This customer-oriented support activity is focused on encouraging and helping patients complete Cologuard tests that have been ordered for them by their providers. We undertake a variety of activities to promote patient adherence including letters, text messages, online chat, emails, and phone calls.
We have undertaken a significant public relations effort to engage patients in the U.S., and launched demographically-targeted, direct-to-patient advertising campaigns in digital, social, print, and other channels. We promote our Cologuard test through a national television advertising campaign, with a majority of placements in national cable and syndicated programming widely viewed by our target patient demographic. During 2023, we continued to deepen our investment in virtual resources, strengthened our digital and television media channels, and explored innovative campaigns to reach 45-49 year old patients.
Precision Oncology Commercial Operations
We promote our precision oncology tests through our Precision Oncology sales force. Our commercial infrastructure, including our sales force, managed care group, and patient support network, is critical to the success of our precision oncology products. In our domestic sales, marketing and reimbursement efforts, we interact directly with medical, radiation, and surgical oncologists, pathologists, and payers. We employ a direct sales approach that targets oncologists and cancer surgeons, and utilizes medical education and scientific liaisons who target key opinion leaders. We also plan to continue conducting clinical studies with the objective of having results published in peer-reviewed journals. We believe the combination of these approaches is our best means to increase patient and healthcare provider awareness of our precision oncology products and services and the number of favorable reimbursement coverage decisions by third-party payers.
International Commercial Operations
We commercialize or plan to commercialize our Oncotype® tests outside the United States through employees in Canada, Japan, and a number of European countries, as well as through exclusive distribution agreements. We have provided our Oncotype tests in approximately 120 countries. We do not offer our Cologuard test outside of the U.S. We are exploring opportunities to make available outside of the U.S. our Cologuard test and other current and future products.
Inclusion of our products in guidelines and quality measures will be critical to our international success. The Oncotype DX breast cancer test is recognized in international guidelines issued by the St. Gallen International Breast Cancer Expert Panel and European Society for Medical Oncology. Our Oncotype DX breast cancer test has been recommended to guide certain patients’ chemotherapy treatment decisions by the National Institute for Health and Care Excellence in England, the Gynecologic Oncology Working Group in Germany, and the Japan Breast Cancer Society. Our Oncotype DX breast cancer test is reimbursed for certain patients in the public health systems in more than ten countries.
We are exploring opportunities to establish local laboratories in certain locations outside of the U.S. and established local testing capacity in Germany beginning in late 2021. Certain countries have severe restrictions on reimbursing tests performed abroad or exporting tissue samples or patient health data. These restrictions limit our ability to offer our tests in those countries without local laboratories or a method of test delivery that does not require samples to be transported to our U.S. laboratory.
Reimbursement for our Tests
Reimbursement for our Cologuard Test
Our Cologuard test has broad reimbursement coverage from Medicare and commercial payers. Updated USPSTF colorectal cancer screening guidelines became final in May 2021 and after a transition period, mandate coverage of our Cologuard test beginning at age 45 for ACA covered health plans. Medicare Part B covers our Cologuard test once every three years for beneficiaries who are age 45 to 85, asymptomatic and at average risk for developing colorectal cancer.
8
The following laws and regulations establish coverage requirements relevant to our Cologuard test.
•Section 2713 of the Patient Protection and Affordable Care Act (“ACA”) mandates that certain health insurers cover, without imposing any patient cost-sharing, evidence-based items or services that have in effect a rating of “A” or “B” in the current recommendations of USPSTF (“ACA Mandate”), which includes follow-up colonoscopy after a positive non-invasive stool-based screening test be covered without cost sharing.
•Federal regulations require that Medicare Advantage plans cover “A” or “B” rated preventive services without patient cost-sharing, and CMS has issued a notice affirming that Medicare Advantage plans must include coverage of our Cologuard test every three years without patient cost-sharing including coverage of a follow-up colonoscopy after a positive non-invasive stool-based screening test effective January 1, 2023. Additional Part B cost sharing for procedures performed in addition to follow-on colonoscopy (e.g. polyp removal or pathology) will be phased out by 2030.
•We believe the laws of approximately 30 states currently mandate coverage of our Cologuard test by certain health insurance plans.
Most commercial payers have issued positive coverage decisions for our Cologuard test, and we continue to negotiate contracts with payers to include our Cologuard test as an in-network service. In-network agreements with payers have varying terms and conditions, including reimbursement rate, term, and termination. Other payers may perform post-payment reviews or audits, which may lead to payment recoupments.
State Medicaid agencies generally assign a reimbursement rate for our Cologuard test equal to or less than the prevailing Medicare rate, often determined by state law as a percentage of the Medicare reimbursement rate.
Reimbursement for our Precision Oncology Tests
We depend on government insurance plans, managed care organizations, and commercial insurance plans for reimbursement of our precision oncology tests.
Medicare coverage for our precision oncology tests is currently subject to the discretion of the local Medicare Administrative Contractors (“MAC”). Palmetto, the MAC that establishes the coverage and coding policies for most of our tests under Medicare, developed the Molecular Diagnostic Services Program (“MolDx”), to identify and establish Medicare coverage for molecular diagnostic tests that fall within the scope of its Molecular Diagnostic Test local coverage decision (“LCD”). To obtain coverage under the MolDx program, developers of molecular diagnostic tests must submit a detailed dossier of analytical and clinical data to substantiate that a test meets Medicare’s requirements for coverage. We have received positive coverage decisions under the MolDx program for our breast, colon, Riskguard, and OncoExTra tests.
Reimbursement of our precision oncology tests by third-party payers is essential to our commercial success. Where there is a payer policy, contract or agreement in place, we bill the third-party payer, the hospital or referring laboratory and/or the patient (for deductibles and coinsurance or co-payments, where applicable) in accordance with established policy, contract or agreement terms. Some payers may apply various medical management requirements, including a requirement that they give prior authorization for an precision oncology test before they are willing to pay for it. Where there is no payer policy in place, we pursue third-party reimbursement on behalf of each patient on a case-by-case basis. Our efforts on behalf of these patients involve a substantial amount of time and expense, and bills may not be paid for many months, if at all. Furthermore, if a third-party payer denies coverage after final appeal, it may take a substantial amount of time to collect from the patient, if we are able to collect at all.
State Medicaid agencies generally assign a reimbursement rate for our precision oncology tests equal to or less than the prevailing Medicare rate, often determined by state law as a percentage of the Medicare reimbursement rate.
International Reimbursement
In many countries, public healthcare systems are primarily responsible for financing and establishing reimbursement for diagnostic tests. The majority of our international precision oncology revenues come from reimbursement (directly or indirectly), payments from our distributors, and patient self-pay. We have obtained coverage or other public financing for our breast cancer test outside of the U.S., including coverage for certain patients in Canada, France, Germany, Ireland, Israel, Italy, Japan, the Netherlands, Saudi Arabia, Spain, Sweden, Switzerland, and the United Kingdom (“U.K.”).
9
We expect that our international sales will be heavily dependent on the availability of reimbursement, and broadening coverage and reimbursement for our precision oncology tests and other tests outside of the United States will take years.
Reimbursement for Future Products
Successful commercialization of our newly developed products will also depend on our ability to obtain and maintain reimbursement at adequate reimbursement rates from government insurance plans, managed care organizations, commercial insurance plans, and public healthcare systems outside the U.S. for such products.
Our Clinical Laboratory and Manufacturing Facilities
We process our Cologuard test at two state of the art, high throughput clinical laboratories in Madison, Wisconsin that are certified pursuant to federal Clinical Laboratory Improvement Amendments (“CLIA”) and accredited by College of American Pathologist (“CAP”). Our total lab capacity at both facilities is approximately seven million Cologuard tests per year, with the opportunity to add additional capacity, if needed.
We currently manufacture our Cologuard test at two facilities in Madison, Wisconsin. We are committed to manufacturing and providing medical devices and related products that meet customer expectations and applicable regulatory requirements. We adhere to manufacturing and safety standards required by federal, state, and local laws and regulations and operate our manufacturing facilities under a quality management system. We purchase certain components for our Cologuard test from third-party suppliers and manufacturers.
Beginning in March 2020, we allocated space at our clinical laboratories in Madison, Wisconsin to process our COVID-19 tests. Throughout 2020 and 2021, we manufactured and assembled our COVID-19 test kits at our manufacturing facilities in Madison, Wisconsin. From 2022 through June 2023, we continued to manufacture COVID-19 reagents out of our manufacturing facilities, and provided all the components for the test kits to a third-party vendor for assembly. We discontinued our COVID-19 testing in the second quarter of 2023.
A majority of our internally developed Oncotype tests for domestic and international patients are currently processed in our CLIA-certified and CAP-accredited clinical reference laboratory facilities in Redwood City, California. Beginning in 2022, Oncotype DX breast cancer tests for German patients have been processed in our newly constructed facility in Trier, Germany, a portion of which is operated by a third-party partner. Our OncoExTra tests, along with tests completed under certain of our reference lab agreements, are processed in our CLIA-certified and CAP-accredited clinical reference laboratory facilities in Phoenix, Arizona. Our liquid therapy selection tests, which were acquired as part of our acquisition of Resolution Bioscience, are currently processed in our CLIA-certified and CAP-accredited clinical reference laboratory facility in Kirkland, Washington.
As part of the acquisition of PreventionGenetics, LLC (“PreventionGenetics”) in December 2021, we acquired a CLIA-certified and CAP-accredited DNA testing laboratory in Marshfield, Wisconsin. PreventionGenetics’ laboratory provides more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline whole exome and whole genome sequencing tests in addition to our hereditary cancer test, Riskguard.
We believe that we currently have sufficient capacity to process all of our tests. We are in the process of expanding our existing facilities to prepare for the expected future growth in our operations.
Competition
We operate in a rapidly evolving and highly competitive industry. There are a number of private and public companies that offer products or have announced that they are developing products that compete with ours. Certain of these companies have or may be acquired by, or enter into commercial partnerships with, larger companies with greater expertise or resources, which may increase their ability to offer or develop products that compete with ours.
10
Some of our current and potential competitors may have significant competitive advantage over us, which may make them more attractive to hospitals, clinics, group purchasing organizations and physicians, including:
•technology breakthroughs that we do not have access to;
•entrenched leaders in new areas that we are entering; and
•alternative distribution models that customers prefer.
The U.S. market for colorectal cancer screening is large, consisting of nearly 110 million eligible individuals between the ages of 45 and 85, and has attracted numerous competitors. Our Cologuard test faces competition from procedure-based detection technologies such as colonoscopy, flexible sigmoidoscopy, “virtual” colonoscopy—a radiological imaging approach that visualizes the inside of the bowel by CT scan (spiral computerized axial tomography)—as well as other common screening tests, such as the fecal occult blood test (“FOBT”) and the fecal immunochemical test (“FIT”). Other screening technologies include liquid biopsy tests, such as Epi proColon, which was approved by the FDA in April 2016, pill-based imaging solutions like PillCam COLON, which was cleared by the FDA in February 2014, and C-Scan, which obtained a CE Mark in early 2019. As noted below, a number of companies are developing liquid biopsy tests for colorectal cancer screening, as well as other applications.
We also are aware of at least three companies, Geneoscopy, Mainz Biomed, and Prescient Metabiomics, that are seeking to develop or have developed stool-based colorectal cancer tests in the United States. Geneoscopy conducted a prospective colorectal cancer screening clinical trial for its stool-based colorectal cancer screening test and reported pivotal trial results in October 2023. Geneoscopy filed for FDA approval in January 2023. Our competitors may also be developing additional methods of detecting colorectal cancer and pre-cancer that have not yet been announced.
We believe that our Cologuard test, the first and only sDNA-based non-invasive colorectal cancer screening test on the market today, compares favorably to other available products and services. All other colorectal cancer detection methods in use today are constrained by some combination of poor sensitivity, poor adherence, or high cost. For example, colonoscopy requires advanced dietary restrictions and bowel cleansing, potential time away from work, someone to drive the patient home from the procedure and can also be uncomfortable, time-consuming, hazardous, and expensive. One study showed that 7 out of 10 people age 50 and older who were told they should get a colonoscopy did not do so primarily due to fear. Fecal blood testing, including FIT testing, suffers from poor sensitivity, with only a 74% detection rate for cancer and 24% detection rate for pre-cancer. Additionally, FIT testing suffers from low adherence over time. One study published in the American Journal of Managed Care demonstrated that only 3 out of every 1,000 patients studied adhered to fecal test screening guidelines during a continuous 10-year observation period. There are currently no blood-based DNA tests approved by the FDA and included in USPSTF guidelines, primarily because of their inherent disadvantage of relatively low sensitivity. The only blood-based DNA test with FDA approval is Epigenomics AG Epi proColon test, which has an overall cancer sensitivity rate of 68%, and only 59% for early-stage cancer. In February 2023, Epigenomics AG announced that it would stop the sale of Epi proColon and recall the product.
Our precision oncology products compete against a number of companies that offer products or have conducted research to profile genes and gene expression in breast and colon cancer such as Agendia Inc., Veracyte, Inc., Myriad Genetics, Inc., and Hologic, Inc. Historically, our principal competition for our precision oncology tests has also come from existing diagnostic methods used by pathologists and oncologists which can be difficult to compete with or supplement. Other potential competitors include companies that develop diagnostic tests such as Roche Diagnostics, a division of Roche Holding, Ltd, and Siemens AG, as well as other companies and academic and research institutions.
We believe that our precision oncology tests compete primarily on the basis of the value of the information they provide, the clinical validation of their utility, their level of adoption and reimbursement coverage, and their inclusion in clinical practice guidelines. They are also supported by our ability to commercialize products through our clinical development platform, our collaborations with clinical study groups, the quality of our clinical laboratory, and the level of customer service we provide. While we believe that our precision oncology tests compete favorably with respect to these factors, to continue to do so we must innovate and adopt advanced technology, successfully market, sell and enhance our tests, obtain peer-reviewed publications of our clinical studies in a timely manner, continue to obtain positive reimbursement determinations, continue to expand in countries outside of the U.S., continue to develop our technological and clinical operations, encourage healthcare provider participation in Medicare-required information collection efforts, and successfully expand our reach into additional product markets, including through collaborations with third parties.
11
In addition to our on-market products, we intend to offer additional liquid biopsy solutions, including tests that screen for colorectal cancer, screen for multiple types of cancers in a single test, provide prognostic information, guide therapy selection, and measure molecular residual disease and cancer recurrence.
We are aware of a large number of companies including Guardant Health, Inc. (“Guardant”), Freenome Inc. (“Freenome”), GRAIL, Inc., and Natera Inc. (“Natera”) that have developed, or are developing, liquid biopsy tests for the detection of cancer. These tests could represent significant competition for our current tests and other tests we are currently developing or may develop in the future. Guardant and Freenome are conducting prospective colorectal cancer screening clinical trials for their liquid biopsy tests. Guardant reported pivotal trial results in May 2023, and Freenome is expected to report pivotal trial results in 2024. Guardant made its blood-based colorectal cancer screening test, Shield, available as a laboratory developed test beginning in May 2022 and filed for FDA approval in March 2023.
Guardant and Natera have also developed, and are conducting prospective clinical trials to generate evidence in support of, MRD tests that could represent significant competition for the MRD tests we are currently developing or may develop in the future. Guardant made its MRD test, Reveal, available as a laboratory developed test beginning in February 2021 and has obtained limited commercial coverage and Medicare coverage for the test for certain stages of colorectal cancer in the adjuvant setting. Natera made its MRD test, Signatera, available as a laboratory developed test beginning in 2019 and has obtained limited commercial and Medicare reimbursement for the test across multiple clinical indications, including certain stages of colorectal cancer and breast cancer.
The hereditary cancer testing market is becoming increasingly competitive, and we expect this competition to intensify in the future. We face competition from a variety of sources, including Ambry Genetics, a subsidiary of Konica Minolta Inc.; Myriad Genetics, Inc.; Invitae; Natera; Color Health, Inc.; and Sema4 Genomics; a few large, established general testing companies such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated; and clinical laboratories in an academic or healthcare provider setting that perform clinical genetic testing on behalf of their affiliated institutions.
Competitors may develop their own versions of our tests in countries where we did not apply for patents, where our patents have not issued or where our intellectual property rights are not recognized and compete with us in those countries, including encouraging healthcare providers or patients to use their tests in other countries. We are aware of companies in China that offer or intend to offer tests similar to ours. Competitors also may be able to design around our intellectual property.
We may be unable to compete effectively against our competitors either because their products and services are superior or because they are more effective in developing or commercializing competing products and services. Furthermore, even if we do develop new marketable products or services, our current and future competitors may develop products and services that are more clinically or commercially attractive than ours, and they may bring those products and services to market earlier or more effectively than us. If we are unable to compete successfully against current or future competitors, we may be unable to increase market acceptance for and sales of our tests, which could prevent us from increasing or sustaining our revenues or achieving sustained profitability and could cause the market price of our common stock to decline.
Seasonality
We are continuing to learn how seasonal factors may affect our business. Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors, such as the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers, climate and weather conditions in our markets, seasonal conditions that may affect medical practices and patient and provider activity, including influenza outbreaks that may reduce the percentage of patients that can be seen or decrease patient’s willingness to visit medical practices, and other factors relating to the timing of patient deductibles and co-insurance limits.
12
Regulation
Certain of our activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act (“FDCA”) and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing, distribution, and export of diagnostic products. Our clinical laboratory facilities are subject to oversight by CMS pursuant to CLIA, as well as agencies in various states, including New York. We are subject to many other federal, state and foreign laws, including anti-fraud and abuse, anti-kickback and patient privacy. Failure to comply with applicable requirements can lead to significant sanctions, including interruption of our operations, withdrawal of products from the market, recalls, payment denials, refunds and recoupments, refusal to authorize government contracts, product seizures, exclusion from participation in federal and state healthcare programs, civil money penalties, injunctions, and criminal prosecution. For more information, see “Item 1A. Risk Factors — Risks Relating to Governmental Regulation and Reimbursement.”
U.S. Food and Drug Administration
Unless otherwise exempted or subject to enforcement discretion, medical devices, which include screening and diagnostic tests, must receive either FDA or regulatory approval or clearance before being marketed in the United States. Our Cologuard test is regulated by the FDA as a Class III medical device. The FDA granted premarket approval (“PMA”) for our Cologuard test in August 2014. The regulations governing our Cologuard test’s approval place substantial restrictions on how our Cologuard test is marketed and sold, specifically, by prescription only. In addition, as a condition of our FDA approval, we were required to conduct a post-approval study. The post-approval study concluded in 2020 and final results were submitted to the FDA in late 2020. The FDA notified us in 2023 that our study report fully satisfied our post-approval study requirement and requested that we update the Cologuard labeling, via a PMA supplement to, include the new study information. We have submitted the requested supplement and it is currently under FDA review.
Additionally, manufacturers of medical devices must comply with various regulatory requirements under the FDCA and regulations thereunder, including, but not limited to, quality system regulations, unless they are exempt, facility registration, product listing, labeling requirements, and certain post-market surveillance requirements. Entities that fail to comply with FDA requirements can be liable for criminal or civil penalties, such as recalls, detentions, orders to cease manufacturing, and restrictions on labeling and promotion, among other potential sanctions. In 2017, we recalled one of the components of our Cologuard test kit and circumstances may arise that cause us to recall other products or components used in connection with our Cologuard test.
Certain of our products in development or additional diagnostic products and services that we seek to develop may be regulated by the FDA as medical devices and require FDA approval or clearance. The regulatory review and approval process for medical devices can be costly, timely, and uncertain. This process may involve, among other things, successfully completing clinical trials and submitting a premarket clearance notice or filing a premarket approval application with the FDA.
Laboratory Developed Tests (“LDTs”)
Our Oncotype tests, OncoExTra test, and certain other tests we offer are regulated as LDTs, and we may seek to commercialize certain of our products in development as LDTs. LDTs are clinical laboratory tests that are developed and validated by a laboratory for its own use. The FDA historically has taken the position that it has the authority to regulate such tests as medical devices under the FDCA but has for the most part exercised enforcement discretion and has not required clearance or approval of LDTs prior to marketing.
At various times since 2006, the FDA has issued documents outlining its intent to require varying levels of FDA oversight of many LDTs, including our tests. In October 2023, the FDA published a proposed rule that, if finalized, would regulate LDTs as medical devices under the FDCA. The comment period for the FDA’s proposed rule closed in December 2023 and the FDA has indicated its desire to issue a final rule on LDTs in April 2024 or shortly thereafter. Even if the FDA does not finalize its proposed rule, the U.S. Congress may enact statutory changes that could alter or eliminate the FDA’s current LDT enforcement policy. It is therefore unclear at this time what form that final regulation may take, or if the FDA will finalize the regulation at all. It is also unclear what additional obligations might be placed on us as we continue to offer LDTs in light of the FDA's renewed interest in greater oversight into this class of tests. Action by the FDA to phase out its current policy of enforcement discretion over LDTs may materially impact our development and commercialization of LDTs, including our Oncotype tests.
13
Laboratory Certification, Accreditation, and Licensing
We are also subject to U.S. and state laws and regulations regarding the operation of clinical laboratories. CLIA requirements and laws of certain states impose certification requirements for clinical laboratories, and establish standards for quality assurance and quality control, among other things. CLIA provides that a state may adopt different or more stringent regulations than federal law and permits states to apply for exemption from CLIA if the state’s laboratory laws are equivalent to or more stringent than CLIA. For example, the State of New York's clinical laboratory regulations, which have received an exemption from CLIA, contain provisions that are in certain respects more stringent than federal law. Therefore, as long as New York maintains a licensure program that is CLIA-exempt, we will need to comply with New York's clinical laboratory regulations in order to offer our clinical laboratory products and services in New York.
We have current certificates to perform clinical laboratory testing. Clinical laboratories are subject to inspection by regulators and to sanctions for failing to comply with applicable requirements. Sanctions available under CLIA and certain state laws include prohibiting a laboratory from running tests, requiring a laboratory to implement a corrective plan, and imposing civil monetary penalties.
HIPAA and Other Privacy Laws
The Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (“HIPAA”) established comprehensive protection for the privacy and security of health information. The HIPAA standards apply to three types of organizations, or “Covered Entities”: health plans, healthcare clearinghouses, and healthcare providers that conduct certain healthcare transactions electronically. Covered Entities and their business associates must have in place administrative, physical, and technical standards to guard against the misuse of individually identifiable health information. We perform activities that may implicate HIPAA, such as providing clinical laboratory testing services and entering into specific kinds of relationships with Covered Entities and business associates of Covered Entities. Penalties for violations of HIPAA include civil money and criminal penalties.
Our activities must also comply with other applicable privacy laws, which impose restrictions on the access, use and disclosure of personal information. More state and international privacy laws are being adopted. Many state laws are not preempted by HIPAA because they are more stringent or are broader in scope than HIPAA including the California Consumer Privacy Act of 2018 (“CCPA”), including expansions and amendments to CCPA pursuant to the California Privacy Rights Act which became operative on January 1, 2023. CCPA protects personal information other than health information covered by HIPAA and allows certain data access and erasure rights to California consumers as well as rights to limit use and disclosure of sensitive personal information. Other similar state laws have been enacted. Further, we are required to comply with international, national, and provincial personal data protection laws and regulations, including the European Union's (“E.U.”) General Data Protection Regulation (“GDPR”) and Japan's Act on the Protection of Personal Information (“APPI”). The GDPR and other national or provincial laws provide a prescriptive, detailed regulation that provides extensive powers to public authorities to sanction and stop use of personal data. The GDPR and national or provincial laws outside of Europe such as APPI have and will continue to require significant effort and expense to ensure compliance. All of these laws may impact our business and may change periodically, which could adversely affect our business operations.
Federal and State Billing and Fraud and Abuse Laws
Anti-fraud Laws/Overpayments. We are subject to numerous federal and state anti-fraud and abuse laws, including the Federal False Claims Act. Many of these anti-fraud laws are broad in scope, and neither the courts nor government agencies have extensively interpreted these laws. Prohibitions under some of these laws include:
•the submission of false claims or false information to government programs,
•the retention of any overpayments by governmental payers,
•deceptive or fraudulent conduct,
•excessive or unnecessary services or services at excessive prices, and
•defrauding private sector health insurers.
Numerous federal and state agencies enforce the anti-fraud and abuse laws. In addition, private insurers may also bring private actions. In some circumstances, private whistleblowers are authorized to bring fraud suits on behalf of the government against providers and are entitled to receive a portion of any final recovery.
14
In addition, amendments to the False Claims Act impose severe penalties for the knowing and improper retention of overpayments collected from governmental payers. Within 60 days of identifying and quantifying an overpayment, a provider is required to notify CMS or the Medicare contractor of the overpayment and the reason for it and return the overpayment. These amendments could subject our procedures for identifying and processing payments to greater scrutiny. Overpayments may occur from time to time in the healthcare industry without any fraudulent intent. For example, overpayments may result from mistakes in reimbursement claim forms or from improper processing by governmental payers. We maintain protocols intended to identify any overpayments. From time to time we have identified overpayments and made refunds to government payers.
To avoid liability, we must carefully and accurately code claims for reimbursement, proactively monitor the accuracy and appropriateness of Medicare claims and payments received, diligently investigate any credible information indicating that we may have received an overpayment, and promptly return any overpayments.
Federal and State “Self-Referral” and “Anti-Kickback” Restrictions
Anti-Kickback Statute. The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs, unless an exception applies. The term “remuneration” is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payment, ownership interests and providing anything at less than its fair market value. Sanctions for violations of the federal Anti-Kickback Statute may include imprisonment and other criminal penalties, civil monetary penalties, and exclusion from participation in federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs, and do not contain identical safe harbors.
In addition, the Eliminating Kickbacks in Recovery Act of 2018 (“EKRA”) imposes criminal penalties for knowing or willful payment or offer, or solicitation or receipt, of any remuneration, whether directly or indirectly, overtly or covertly, in cash or in kind, in exchange for the referral or inducement of laboratory testing (among other healthcare services) unless a specific exception applies. Although it appears that EKRA was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written and could apply to laboratory services covered under public or private payer arrangements.
Self-Referral Law. The federal “self-referral” law, commonly referred to as the “Stark” law, provides that healthcare providers who, personally or through a family member, have ownership interests in or compensation arrangements with a laboratory are prohibited from making a referral to that laboratory for laboratory tests reimbursable by Medicare, and also prohibits laboratories from submitting a claim for Medicare payments for laboratory tests referred by healthcare providers who, personally or through a family member, have ownership interests in or compensation arrangements with the testing laboratory. The Stark law contains a number of specific exceptions which, if met, permit healthcare providers who have ownership or compensation arrangements with a testing laboratory to make referrals to that laboratory and permit the laboratory to submit claims for Medicare payments for laboratory tests performed pursuant to such referrals. We are subject to comparable state laws, some of which apply to all payers regardless of source of payment, and do not contain identical exceptions to the Stark law.
Sunshine Act
In 2010, Congress enacted a statute commonly known as the Sunshine Act, which aims to promote transparency. The Sunshine Act requires manufacturers of drugs, devices, biologicals, and medical supplies covered by Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to CMS any payments or other transfers of value made to healthcare providers and teaching hospitals, unless an exception applies. Manufacturers must also disclose to CMS any healthcare provider ownership or investment interests. Some states have similar transparency laws.
15
International
When marketing our tests outside of the U.S., we are subject to other countries' regulatory requirements governing human clinical testing, export of tissue, marketing approval for our products, and performance and reporting of tests in each market. These requirements vary by jurisdiction, differ from those in the U.S., and may require us to perform additional pre-clinical or clinical testing. For example, the E.U. has amended its existing regulatory framework for in vitro diagnostics by introducing the Regulation 2017/746 (EU) (“EU IVDR”), which amends the existing framework and imposes stricter requirements for the development, marketing and sale of in vitro diagnostics such as our Oncotype DX Breast Recurrence Score test in the E.U. These new regulations are more stringent in a variety of areas, including clinical requirements, traceability, quality systems and post-market surveillance activities. The EU IVDR became effective starting in May 2022. As our Oncotype DX Breast Recurrence Score test has a pre-existing certification from our notified body, we had until May 2026 to meet certain of the new, more stringent regulatory requirements of EU IVDR with respect to our Oncotype DX Breast Recurrence Score test, including obtaining a new positive conformity assessment from our notified body. We received a CE marking on our Oncotype DX Breast Recurrence Score test in December 2023, certifying that we are in compliance with the new EU IVDR regulatory requirements. Complying with the requirements of these regulations has required us to, and may continue to require us to, incur significant expenditures. Failure to meet these requirements could adversely impact our business in the E.U. and other regions that tie their product registrations to the E.U. requirements. Additionally, in many countries outside of the U.S., coverage, pricing, and reimbursement approvals are also required in order for our tests to be made available to patients in substantial volume.
Many countries in which we offer our tests have anti-inducement laws or regulations prohibiting providers, as well as medical and in vitro diagnostic device manufacturers, from offering, paying, soliciting, or receiving remuneration, directly or indirectly, or providing a benefit to a healthcare professional in order to induce business, or may require declaration of any benefits provided to healthcare professionals. In situations involving healthcare providers employed by public or state-funded institutions or national healthcare services, violation of the local anti-corruption or anti-gift laws may also constitute a violation of the U.S. Foreign Corrupt Practices Act (“FCPA”).
The FCPA prohibits any U.S. individual, business entity, or employee of a U.S. business entity from offering or providing, directly or through a third party, including the distributors we rely on in certain markets, anything of value to a foreign government official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the Securities and Exchange Commission (“SEC”) to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We are also required to maintain accurate information and control over sales and distributors’ activities that may fall within the purview of the FCPA, its books and records provisions, and its anti-bribery provisions.
Other Laws
Occupational Safety and Health. In addition to its comprehensive regulation of health and safety in the workplace in general, the Occupational Safety and Health Administration has established extensive requirements aimed specifically at laboratories and other healthcare-related facilities. In addition, because our operations require employees to use certain hazardous chemicals, we also must comply with regulations on hazard communication and hazardous chemicals in laboratories. These regulations require us, among other things, to develop written programs and plans, which must address methods for preventing and mitigating employee exposure, the use of personal protective equipment, and training.
Specimen Transportation. Our commercialization activities subject us to regulations of the Department of Transportation, the U.S. Postal Service, and the Centers for Disease Control and Prevention that apply to the surface and air transportation, as well as importation, of clinical laboratory specimens.
Environmental. The cost of compliance with federal, state, and local provisions related to the protection of the environment has had no material effect on our business. There were no material capital expenditures for environmental control facilities in the year ended December 31, 2023, and there are no material expenditures planned for such purposes for the year ended December 31, 2024.
16
Intellectual Property
We rely on a combination of patents, patent applications, copyrights and trademarks, as well as contracts, such as confidentiality, material data transfer, and license and invention assignment agreements to protect our intellectual property rights. We also rely upon trade secret laws to protect unpatented know-how and continuing technological innovation.
We have intellectual property rights pertaining to sample type, sample preparation, sample preservation, biomarkers, gene expression and sequencing technology, and related methods and formulations.
Our success depends upon our ability to protect our technologies through patent coverage and, where necessary, defend and enforce our patents in administrative proceedings and litigation. As of December 31, 2023, we had 208 issued patents in the U.S. and 878 issued patents outside of the U.S., which includes validated patents issued by the European Patent Office in key E.U. countries, covering genes and methods that are components of the Cologuard test, Oncoguard® Liver test, Oncotype DX tests, pipeline technologies or research methods, and platform technologies. Our issued U.S. patents expire at various times between 2024 and 2043. In addition, we have pending patent applications in the U.S. and in other countries, including provisional and non-provisional filings. Some of these U.S. patent applications also have corresponding pending or granted applications under the Patent Cooperation Treaty in Canada, Europe, Japan, Australia, and other jurisdictions. We solely own, jointly own, or exclusively license these patents and patent applications. In certain cases where joint ownership positions were created, we have negotiated contractual provisions providing us with the opportunity to acquire exclusive rights under the patents and patent applications. Under some patents and patent applications, we have elected to allow exclusive options to lapse without exercising the option. The joint ownership agreements generally are in the form of material data transfer agreements that were executed at the onset of our collaborations with third parties.
License Agreements
We license certain technologies that are, or may be, incorporated into our technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require us to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees.
Mayo Foundation for Medical Education and Research
In June 2009, we entered into an exclusive, worldwide license agreement with Mayo Foundation for Medical Education and Research, under which Mayo granted us an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance, or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease, or condition. Our license agreement with Mayo was most recently amended and restated in September 2020. 
The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing, and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the E.U., China, Japan, and Korea. Under the license agreement, we assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and are obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property.
Pursuant to our license agreement with Mayo, we are required to pay Mayo a low-single-digit royalty on net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement.
We are also required to pay Mayo up to $3.0 million in sales-based milestone payments upon cumulative net sales of each product using the licensed Mayo intellectual property reaching specified levels.
17
The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2043 (or later, if certain licensed patent applications are issued). However, if we are still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date we stop using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if we sue Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement.
In addition to granting us a license to the covered Mayo intellectual property, Mayo provides us with product development research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025.
Johns Hopkins University
Through the acquisition of Thrive Earlier Detection Corporation (“Thrive”), we acquired a worldwide exclusive license agreement with JHU for use of several JHU patents and licensed know-how. We are seeking to utilize the JHU licensed technology to develop and commercialize a blood-based MCED test. The agreement terms would require us to pay single-digit sales-based royalties and up to $45.0 million in sales-based milestone payments if net sales of a licensed product using JHU proprietary data reach specified levels.
In addition to granting us a license to the covered JHU intellectual property, JHU provides us with research and development assistance pursuant to other collaboration arrangements.
Human Capital
Our vision to provide the clarity to take life-changing action earlier drives us to find ambitious, dynamic individuals who thrive in a team-based environment. To facilitate talent attraction and retention, we strive to make Exact Sciences a diverse and inclusive workplace, with opportunities for our employees to grow and develop in their careers, supported by strong compensation, benefits, and health and wellness programs.
At December 31, 2023, we had approximately 6,600 full-time, part-time and temporary employees, 6,500 of which were full-time employees. More than 95% of our employees are located in the United States and none of our employees are represented by a labor union. During fiscal year 2023, our voluntary turnover rate was approximately 8%, below the healthcare industry benchmark, which is comprised of certain of our key competitors (Aon, 2023 Salary Increase and Turnover Study — Second Edition, June 2023).
Diversity and Inclusion
We believe diversity in thought, experience, perspective, and background within our team is necessary to support our core value of innovation. We are firmly committed to providing equitable opportunity in all aspects of employment and will not discriminate in any employment decision because of a person’s race, color, sex, religion, national origin, age, disability, sexual orientation, marital status, gender identity, genetic information, veteran status, or any other basis prohibited by applicable law. In order to increase the pool of diverse candidates for open positions, we partner with community resource groups and participate in diversity-focused career recruiting efforts.
Our talent strategy and inclusion team, led by our Executive VP of Human Resources, is responsible for developing and implementing our inclusion and diversity programs. The Human Capital Committee of our Board of Directors oversees and monitors our policies and strategies relating to culture, talent, and human capital management, including diversity, equity, and inclusion. We track and monitor workforce diversity data to ensure we are fulfilling our diversity and inclusion aspiration – to be known as a great place to work for all. Thanks, in part, to our compelling mission, competitive benefits and the positive results of our diversity and inclusion program, women make up approximately 54% of total employees (full-time and part-time), and 49% of management positions. Our eleven-member Board of Directors includes four female members to support diversity of opinion and perspective at the board level. In addition, we have been awarded with a Great Place to Work Certification® in 2023, Forbes' Best-in-State Employer in 2023, and Wisconsin State Journal Top Workplaces in 2023.
18
Compensation and Benefits
Attracting the best talent starts with offering industry-leading compensation and benefits. We want our compensation and benefits to give our employees a sense of ownership in our company, and pride and determination to achieve our mission. To help our eligible employees achieve financial well-being and share in the success they create, we offer competitive base pay, a company-sponsored 401(k) plan with employer matching, retirement planning resources, employee stock purchase plan opportunities, stock awards upon hire and annually thereafter, and annual cash bonus programs. To help our eligible employees get and stay healthy, we offer our employees generous health benefits, including among others, medical, dental, and vision care coverage for employees and their dependents; family formation benefits (such as adoption assistance, (in)fertility treatments, etc.), life, disability, and accident insurance and critical illness benefits; health care and dependent care flexible spending account programs and employer contributions to health savings accounts (for specific medical plans). To enable our eligible employees to take the time they need to re-energize and focus on what matters most, we offer a parental leave program and ample time away benefits (vacation, sick, holidays, volunteer time, voting time, other leaves). To foster a culture of care and compassion, we offer eligible employees an employee assistance program with employer-paid counseling coverage for employee and household members, charitable donation matches, commuter benefits, wellness programs, including fitness and mental health/well-being, and more.
Training and Development
We invest significant resources to develop the talent needed to achieve long-term success. We have implemented a comprehensive employee training program that applies to all employees, including full-time, part-time, and temporary employees. Senior leadership, in conjunction with Human Resources, is responsible for ensuring that all staff, including contractors and consultants, have the appropriate education, training, competency, and credentials.
We create opportunities for personal growth, professional growth, and career mobility for all employees. From facilitated workshops and podcasts to eLearning modules, individual development plans, mentoring and coaching, we have invested in developmental capabilities to meet our employees at any stage of their career and help them grow. We have a variety of tools to facilitate developmental feedback. We maintain a mentoring program aimed to support the growth and development journey of employees, increase talent retention, enhance our inclusive culture, and increase partnership and collaboration across the business. We also host an annual leadership summit, bringing leaders across the Company together for two and a half days of dedicated development and enrichment activities. Thanks, in large part, to our training and development investments, in 2023 we were able to fill 38% of our open positions with internal candidates.
Financial Information
See our consolidated financial statements included elsewhere in this Form 10-K and accompanying notes to the consolidated financial statements.
Available Information
We were incorporated in the State of Delaware on February 10, 1995. Our corporate headquarters are located at 5505 Endeavor Lane, Madison, Wisconsin 53719. Our telephone number is 608-284-5700. Our Internet website address is www.exactsciences.com. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8‑K, including exhibits, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are available free of charge through the investor relations page of our Internet website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our Internet website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report on Form 10-K.
Item 1A. Risk Factors
We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. This discussion highlights some of the risks that may affect future operating results. These are the risks and uncertainties we believe are most important for you to consider. We cannot be certain that we will successfully address these risks. If we are unable to address these risks, our business may not grow, our stock price may suffer, and we may be unable to stay in business. Additional risks and uncertainties not presently known to us, which we currently deem immaterial or which are similar to those faced by other companies in our industry or business in general, may also impair our business operations.
19
Risk Factors Summary
The following is a summary of the principal risks that could adversely affect our business, operations and financial results.
Risks Related to our Business and Business Strategy
•We may never become profitable or sustain profitability.
•We may need additional capital to execute our strategic plan.
•Our success depends heavily on our Cologuard and Precision Oncology tests and the successful commercialization of our tests in development.
•Our operating results could be subject to significant fluctuation, which could increase the volatility of our stock price and cause losses to our shareholders.
•We face intense competition from other companies and may not be able to compete successfully.
•If any of our facilities or our laboratory equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business could be materially harmed.
•We heavily rely upon certain suppliers, including suppliers that are the sole source of certain supplies and products used in our tests and business operations. The loss or interruption of supply from our suppliers could have a disruptive effect on our business.
•Failure in our information technology, storage systems, or our clinical laboratory equipment could significantly disrupt our operations and our research and development efforts.
•If the courier delivery services we use in connection with our tests are disrupted or become significantly more expensive, customer satisfaction and our business could be negatively impacted.
•The success of our business substantially depends on the efforts of our senior management team and qualified personnel and our ability to foster and maintain an inclusive and collaborative corporate culture.
•Our business and reputation will suffer if we are unable to establish and comply with stringent quality standards to assure that the highest level of quality is observed in the performance of our tests.
•Our inability to manage growth could harm our business.
•We may engage in acquisitions or divestitures that are not successful and which could disrupt our business and reduce our financial resources and shareholder value.
•International expansion of our business exposes us to business, regulatory, labor, political, operational, financial, compliance, payment collection, and economic risks associated with doing business outside of the U.S.
•Our business may be adversely affected by global macroeconomic conditions and volatility in the capital markets.
•Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, adverse effects on our business and financial results.
•Ethical, legal and social concerns related to the use of genetic information could reduce demand for our genetic tests.
•Climate change, or legal or regulatory measures to address climate change or other corporate social responsibility and sustainability matters, could adversely affect our business, financial condition and results of operations.
•The use of Artificial Intelligence presents new risks and challenges to our business.
•We may be a party to litigation in the normal course of business or otherwise, which could affect our business and financial position.
Risks Relating to Governmental Regulation and Reimbursement
•We face uncertainty related to healthcare reform, pricing, coverage, and reimbursement.
•If payers, including managed care organizations, do not approve and maintain reimbursement for our tests at adequate reimbursement rates, our commercial success could be compromised.
•If we are unable to obtain or maintain reimbursement at adequate reimbursement rates for our Oncotype DX tests outside of the U.S., our ability to expand internationally will be compromised.
•Failure to comply with federal, state and foreign laboratory licensing and related requirements could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.
•Our products could be subject to recall.
•Delays in receipt of, or failure to obtain, required FDA clearances or approvals for our products in development, or improvements to or expanded indications for our current offerings, could materially delay or prevent us from commercializing or otherwise adversely impact future product commercialization.
20
•The FDA may change its position with respect to its regulation of the laboratory developed tests we offer or may seek to offer in the future, causing us to incur substantial costs and time delays and decreased demand for or reimbursement of our tests.
•We are subject to numerous U.S. and foreign laws and governmental regulations, and any governmental enforcement action may materially affect our financial condition and business operations.
•Our business is subject to various complex laws and regulations applicable to providers of clinical diagnostics and services.
•Due to billing complexities in the diagnostic and laboratory service industry, we may have difficulties receiving timely payment for the tests we perform, and may face write-offs, disputes with payers and patients, and long collection cycles.
•Some of our activities may subject us to risks under federal, state, and foreign laws prohibiting “kickbacks” and false or fraudulent claims as well as the Foreign Corrupt Practices Act and similar anti-bribery laws.
•Failure to comply with privacy, security, and consumer protection laws and regulations could result in fines, penalties and damage to our reputation and have a material adverse effect on our business.
•Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
•We expect to rely on third parties to conduct any future studies of our technologies that may be required by the FDA or other U.S. or foreign regulatory bodies, and those third parties may not perform satisfactorily.
•Changes in tax laws or regulations or exposure to tax liabilities could adversely affect our financial condition and results of operations.
Risks Relating to Product Development, Commercialization and Sales of our Products
•The success of our Cologuard test, our Precision Oncology tests, and any other screening or diagnostic product or service we may offer or develop will depend on the degree of market acceptance by healthcare providers, patients, healthcare payers, and others in the medical community.
•Recommendations, guidelines, and quality metrics issued by various organizations may significantly affect payers’ willingness to cover, and healthcare providers’ willingness to prescribe or order, our products.
•We expect to continue to make significant investments in our research and development efforts, which may not be successful.
•Our dependence on distributors for sales in many markets outside of the U.S. could limit or prevent us from selling our tests in those markets and impact our revenue.
Risks Relating to our Intellectual Property
•We rely on strategic collaborative and licensing arrangements with third parties to develop critical intellectual property. We may not be able to successfully establish and maintain such intellectual property.
•We may be subject to substantial costs and liability, or be prevented from using technologies incorporated in our tests as a result of litigation or other proceedings relating to patent or other intellectual property rights.
•If we are unable to protect or enforce our intellectual property effectively, we may be unable to prevent third parties from using our intellectual property, which would impair any competitive advantage we may otherwise have.
•If patent regulations or standards are modified, such changes could have a negative impact on our business.
Risks Relating to our Securities
•If we fail to maintain an effective system of internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and our stock price may be adversely impacted.
•Our stock price has fluctuated widely and is likely to continue to be volatile.
•Our balance sheet includes significant amounts of goodwill and intangible assets. The impairment of a significant portion of these assets would negatively affect our results of operations.
•Our significant indebtedness could adversely affect our business, financial condition, and results of operations and our ability to meet our payment obligations under such indebtedness and limit our ability to raise additional capital to fund our operations.
21
Risks Related to our Business and Business Strategy
We may never become profitable or sustain profitability.
We have incurred losses since we were formed. From our date of inception on February 10, 1995 through December 31, 2023, we have accumulated a total deficit of approximately $3.47 billion. Our net loss was $204.1 million, $623.5 million and $595.6 million for the years ended December 31, 2023, December 31, 2022 and December 31, 2021, respectively. We expect to continue investing significantly toward development and commercialization of our colorectal cancer screening technology, our precision oncology tests, our MCED and MRD tests, and other products and services. Although our net losses have diminished considerably over the last several years, if our revenue does not continue to grow faster than our cost of sales and operating expenses, we will not become profitable. We cannot be certain that the revenue from the sale of any products or services based on our technologies will be sufficient to make us profitable.
We may need additional capital to execute our strategic plan.
Although we believe that we have sufficient capital to fund our operations for at least the next 12 months, we may require additional capital to fully fund our current strategic plan, which includes continuing to scale our Cologuard and precision oncology tests and developing a pipeline of future products and services. Additional financing may not be available in amounts or on terms satisfactory to us or at all. Our success in raising additional capital may be significantly affected by general market conditions, the market price of our common stock, our financial condition and existing indebtedness, uncertainty about the future commercial success of our current products and services, the development and commercial success of future products or services, regulatory developments, the status and scope of our intellectual property, any ongoing litigation, our compliance with applicable laws and regulations and other factors. If we raise additional funds through the sale of equity, convertible debt or other equity-linked securities, our shareholders’ ownership will be diluted, and the market price of our common stock could be depressed. We may issue securities that have rights, preferences and privileges senior to our common stock. If we raise additional funds through collaborations, licensing arrangements or other structured financing transactions, we may relinquish rights to our technologies, products or services, grant security interests in our assets or grant licenses to third parties on terms that are unfavorable to us.
Our success depends heavily on our Cologuard and Precision Oncology tests and the successful commercialization of our tests in development.
Our ability to generate revenues depends very substantially on the commercial success of our Cologuard and precision oncology tests. Additionally, we are devoting significant resources to developing new tests in colorectal cancer screening, MRD, MCED, and other areas of cancer diagnostics. There can be no assurance that we will be able to continue to grow sales of our Cologuard and precision oncology tests or that we will develop or commercialize any other products or services that will generate significant revenue. The knowledge and experience we have gained commercializing our Cologuard and precision oncology tests may not translate into successful commercialization efforts with respect to new and different products. The commercial success of our tests, our successful commercialization of any new products and our ability to generate revenues will depend on a variety of factors, including the following:
•acceptance in the medical community;
•inclusion in healthcare guidelines and recommendations, such as those developed by ACS, USPSTF, American Society of Clinical Oncology, and NCCN, and similar guidelines and recommendations outside the U.S.;
•inclusion in quality measures, including the HEDIS measures and the CMS Medicare Advantage Star Ratings;
•recommendations and studies that may be published by government agencies, companies, professional organizations, academic or medical journals or other key opinion leaders;
•patient acceptance and demand;
•patient compliance with orders for our tests by healthcare providers, and patient adherence to recommendations regarding periodic re-testing;
•successful new screening initiatives, including gap closure programs through which we partner with health systems and payers to deliver Cologuard test kits to their patients or members who are due for colorectal cancer screening under applicable guidelines;
•effective marketing and educational programs, including successful direct-to-patient marketing such as television advertising and social media;
•the number of patients screened for colorectal cancer, as well as the number of patients who use our Cologuard test for that purpose; 
22
•the number of women diagnosed with breast cancer;
•sufficient coverage and reimbursement by payers;
•the existence of federal or state laws that mandate coverage for colorectal cancer and other types of screening, the extent to which those laws mandate coverage of our tests and the enforcement of those laws; 
•the amount and nature of competition from other products and procedures; 
•maintaining regulatory approvals to legally market;
•the ease of use of our ordering process for healthcare providers;
•maintaining and defending patent protection for the intellectual property relevant to our products and services; and 
•our ability to establish and maintain adequate commercial manufacturing, distribution, sales and CLIA laboratory testing capabilities.
If we are unable to continue growing sales of our Cologuard and precision oncology tests, we are delayed or limited in doing so, or we are unable to successfully commercialize our tests in development or other new products, our business prospects, financial condition and results of operations would be adversely affected.
Our operating results could be subject to significant fluctuation, which could increase the volatility of our stock price and cause losses to our shareholders.
Our revenues and results of operations have historically, and may in the future, fluctuate significantly, depending on a variety of factors, including the following:
•our success in marketing and selling, and changes in demand for, our Cologuard and precision oncology tests, and the level of reimbursement and collection obtained for such tests;
•seasonal variations or non-seasonal events or circumstances affecting healthcare provider recommendations for our tests and patient compliance with healthcare provider recommendations, including without limitation, holidays, weather events, and circumstances such as the outbreak of influenza that may limit patient access to medical practices or institutions for diagnostic tests and preventive services;
•our success in collecting payments from third-party and other payers, patients and collaborative partners, variation in the timing of these payments and recognition of these payments as revenues;
•the pricing of our tests, including potential changes in CMS or other reimbursement rates;
•circumstances affecting our ability to provide our tests, including weather events, supply shortages, or regulatory or other circumstances that adversely affect our ability to manufacture our tests or process tests in our clinical laboratories;
•fluctuations in the amount and timing of our selling and marketing costs and our ability to manage costs and expenses and effectively implement our business; and
•our research and development activities, including the timing, size, complexity, and cost of clinical studies.
If our revenues or operating results fall below the expectations of investors or public market analysts, the trading price of our common stock could decline substantially.
We face intense competition from other companies and may not be able to compete successfully.
We operate in a rapidly evolving and highly competitive industry. There are a number of private and public companies that offer products, or have announced that they are developing products that compete with ours.
Some of our current and potential competitors may have significant competitive advantages over us, which may make them more attractive to hospitals, clinics, group purchasing organizations and physicians. See “Item 1. Business — Competition” in this Annual Report on Form 10-K for additional information regarding our competitors and the effects of competition on our business.
We may be unable to compete effectively against our competitors either because their products and services are superior or because they are more effective in developing or commercializing competing products and services. Furthermore, even if we do develop new marketable products or services, our current and future competitors may develop products and services that are more clinically or commercially attractive than ours, and they may bring those products and services to market earlier or more effectively than us. If we are unable to compete successfully against current or future competitors, we may be unable to increase market acceptance for, and sales of, our tests, which could prevent us from increasing or sustaining our revenues or achieving sustained profitability and could cause the market price of our common stock to decline.
23
If any of our facilities or our laboratory equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business could be materially harmed.
Our manufacturing, testing and laboratory facilities are located in Madison and Marshfield, Wisconsin, Redwood City, California, Kirkland, Washington, Phoenix, Arizona, and Trier, Germany, and our headquarters are also located in Madison, Wisconsin. If our present, or any future facilities, were to be damaged, destroyed or otherwise unable to operate, whether due to fire, floods, storms, tornadoes, earthquakes, other inclement weather events or natural disasters, employee malfeasance, terrorist acts, power outages, or otherwise, it may render it difficult or impossible for us to perform our tests for some period of time, and our business could be severely disrupted. Our facilities and the equipment we use to perform our tests would be costly to replace and could require substantial lead time to repair or replace. The inability to perform our tests or the backlog of tests that could develop if any of our facilities become inoperable for even a short period of time may result in the loss of customers or harm our reputation, and we may be unable to regain those customers or rebuild our reputation in the future. Although we possess insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all.
If our testing facilities become inoperable for any reason, we may not be able to transfer any or all testing to our other facilities and would need to rely on a third party to perform certain of these tests. We could use only another facility with established state licensure and CLIA accreditation, and for tests provided internationally, ISO 15189 accreditation, under the scope of which Oncotype tests could be performed following validation and other required procedures. We cannot assure you that we would be able to find an appropriately certified facility willing to comply with the required procedures, that this laboratory would be willing to perform the tests for us on commercially reasonable terms, or that it would be able to meet our quality or regulatory standards. Alternatively, establishing a redundant facility for certain of our testing would require considerable time and money to secure adequate space, construct the facility, recruit and train employees, and establish the additional operational and administrative infrastructure necessary to support this facility. We also may not be able, or it may take considerable time, to replicate our testing processes or results in a new facility. Additionally, any such new facility would be subject to certification under CLIA and licensing by several states, including California and New York, which could take a significant amount of time and result in delays in our ability to resume operations.
We heavily rely upon certain suppliers, including suppliers that are the sole source of certain supplies and products used in our tests and business operations. The loss or interruption of supply from our suppliers could have a disruptive effect on our business.
We purchase certain supplies and products from third-party suppliers. In some cases, due to the unique attributes of certain products that are incorporated into our tests or otherwise used in our operations, we maintain either a single-source supplier relationship or a very limited set of supplier relationships. Certain of our third-party suppliers possess exclusive intellectual property or otherwise may be the only party with the rights or expertise to provide us critical supplies and/or products. These third parties are independent entities subject to their own unique operational, regulatory compliance, and financial risks that are outside our control. These third parties may not be willing to enter or renew long-term supply arrangements with us or continue to supply us at all. Additionally, they may not perform their obligations in a timely and cost-effective manner, and they may be unwilling or unable to increase production capacity commensurate with demand for our tests or future products or services. Our relationships with suppliers may also be negatively affected by general supply chain material shortages worldwide, as suppliers struggle to keep pace with demand and manage their own supply chains.
We may become dependent on additional single- or limited-source suppliers, or become increasingly dependent on existing suppliers, as we expand and develop our product and service pipeline. For example, our OncoExTra test is currently only validated to be performed on Illumina’s sequencing platform, and we are not aware of any other platform that we could use in the near future as a commercially viable alternative. Further, Illumina may be the only commercially viable supplier of certain equipment and reagents necessary for some of our current tests and future tests we may develop, including MCED and MRD tests. Since August 2021, Illumina has owned GRAIL, which is commercializing a MCED test against which certain of our planned tests would compete. Illumina’s ownership of GRAIL could incentivize Illumina to offer its sequencing products in a manner that advantages GRAIL over us and other competitors, including the potential that Illumina may be unwilling or unable to supply, or commit to supplying, us with sequencing equipment and reagents on commercially acceptable terms, or at all. Illumina has made an irrevocable standing offer to supply any customer with its sequencing products, which we have accepted. However, that offer may not provide pricing or other terms necessary for us or others to successfully compete against GRAIL, including outside of the U.S. On December 17, 2023, Illumina publicly announced its intention to divest GRAIL by the end of the second quarter of 2024, after various regulatory decisions in the U.S. and E.U. questioned whether Illumina’s ownership of GRAIL was consistent with antitrust laws. The timing and terms of such divestiture are uncertain and, even if it occurs as
24
announced, it may not mitigate the risks associated with our use of Illumina’s products. Although we expect to continue our efforts to validate alternative sequencing platforms on which we could run our OncoExTra tests or other future tests in a commercially viable manner, we may expend considerable time and efforts, endure delays to our test development and commercialization timelines, and be ultimately unsuccessful in our efforts to validate alternatives. Even if we validate an alternative sequencing platform, we may become substantially dependent on the supplier of that platform.
Similarly, as an additional example, we rely on Hamilton Company (“Hamilton”) to provide us laboratory equipment and related supplies (such as racking and pipette tips) necessary to perform certain critical steps in our clinical laboratory tests, including our Cologuard and precision oncology tests. Although other companies may offer viable alternative platforms, we have invested significant capital, time and expertise to procure Hamilton machines and to optimize their use in our tests. We have a long-term supply agreement with Hamilton, which requires our exclusive use of certain Hamilton consumables and components with our Hamilton laboratory equipment. However, it is possible that Hamilton could become unable or unwilling to continue providing us with equipment and supplies on commercially acceptable terms, if at all. If our access to certain Hamilton consumables and components became impacted, we may need to completely replace the Hamilton platform. Validating alternative vendors’ offerings could be expensive, time-consuming, and unsuccessful. Further, because our Cologuard test is regulated by the FDA, we may also need FDA clearance or approval to replace certain Hamilton equipment and supplies with another vendor’s offerings. FDA approval or clearance may entail extensive new clinical and material costs and delays and may be ultimately unsuccessful.
The loss of a critical supplier, the failure to perform by a critical supplier, the deterioration of our relationship with a critical supplier or any unilateral modification to the contractual terms under which we are supplied certain supplies and/or products could have a disruptive effect on our business, and could adversely affect our results of operations for an extended period of time, particularly if we are required to validate an alternative supplier.
Failure in our information technology, storage systems, or our clinical laboratory equipment could significantly disrupt our operations and our research and development efforts.
Our ability to execute our business strategy depends, in part, on the continued and uninterrupted performance of our information technology (“IT”) systems, which support our operations, including at our clinical laboratories, and our research and development efforts. We depend on our IT systems to receive and process test orders, securely store patient health records and deliver the results of our tests. The integrity and protection of our own data, and that of our customers and employees, is critical to our business. IT systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts from criminal hackers, hacktivists, state-sponsored intrusions, industrial espionage and employee malfeasance, breaches due to employee error and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses, and similar disruptive problems. Cyber-attacks are becoming more sophisticated and frequent, and in some cases have caused significant harm at other companies. While we devote significant resources to protect the security of our IT systems, including the personal data and other information that we receive and store, there can be no assurance that any security measures will be effective against current or future security threats. We have experienced and expect to continue to experience attempted cyber-attacks of our IT systems and networks. To date, none of these attempted cyber-attacks has had a material effect on our operations or financial condition. However, any such breach or interruption could compromise our networks and the information stored therein could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our IT systems, unauthorized access, loss or disclosure could also disrupt our operations, including our ability to:
•process tests, provide test results, bill payers or patients;
•process claims and appeals;
•provide customer assistance services;
•conduct research and development activities;
•collect, process and prepare company financial information;
•provide information about our tests and other patient and healthcare provider education and outreach efforts through our website; and
•manage the administrative aspects of our business.
25
Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act of 1996, similar U.S. state data protection regulations, the GDPR, and other regulations, the breach of which could result in significant penalties and damage to our reputation. In addition, disruptions to our business occurring as a result of system updates and enhancements, such as our efforts to move our precision oncology tests to our technology and services platform, could have a material adverse effect on our financial condition and operating results. There can be no assurance that our process of improving existing systems, developing new systems to support our expanding operations, protecting confidential patient information, and improving service levels will not be delayed or will not give rise to additional systems issues in the future. Although we carry insurance for this purpose, failure to adequately protect and maintain the integrity of our information systems and data, including as a result of a security breach, may result in significant losses that exceed our insurance coverage limits and have a material adverse effect on our financial position, results of operations and cash flows.
We rely on courier delivery services to transport Cologuard collection kits to patients and samples for all of our tests back to laboratory facilities for analysis. If these delivery services are disrupted or become significantly more expensive, customer satisfaction and our business could be negatively impacted.
In most cases, we ship Cologuard collection kits to patients, and patients ship samples to our Madison, Wisconsin laboratory facilities for analysis by air and ground express courier delivery service. Additionally, medical providers typically ship samples for Oncotype testing to our laboratory facilities via air and ground express courier delivery service. Disruptions in delivery service, whether due to bad weather, natural disaster, labor disruptions, terrorist acts or threats, or for other reasons, can adversely affect customer satisfaction, specimen quality and our ability to provide our services on a timely basis. If the courier delivery services that transport Cologuard collection kits or other test samples institute significant price increases, our profitability would be negatively affected and we may need to identify alternative delivery methods, if possible, modify our service model, or attempt to raise our pricing, which may not be possible with regard to Medicare claims or commercially practicable with regard to commercial claims.
The success of our business substantially depends on the efforts of our senior management team and our qualified personnel and our ability to foster and maintain an inclusive and collaborative corporate culture.
Our success depends largely on the skills, experience, and performance of our senior management team, and of the highly skilled personnel supporting our research and development programs, commercial laboratory operations, sales efforts and information technology infrastructure. The loss of the service of any member of our senior management could significantly delay or prevent the achievement of our corporate strategies and initiatives, or adversely impact our ability to develop key relationships and commercialize our products and services. Also, facilitating seamless leadership transitions for key positions is a critical factor in sustaining the success of our organization. If our succession planning efforts are not effective, it could adversely impact our business. We face intense competition for certain highly technical or scientific personnel and experienced salespeople among life science and technology businesses. We also compete with universities and public and private research institutions for highly qualified scientific personnel. In addition, as our sales efforts grow in size and complexity, we may not be able to successfully manage our dispersed or inside sales forces or our sales force may not be effective. Because of the competition for their services, we may be unable to hire, partner with or retain additional qualified sales representatives or marketing or medical affairs personnel, either as our employees or independent contractors or through independent sales or other third-party organizations. Market competition for commercial, marketing and medical affairs talent is significant, and we may not be able to hire or retain such talent on commercially reasonable terms, if at all.
All of our employees in the U.S. are at will, which means that either we or the employee may terminate their employment at any time. If we fail to attract and retain necessary personnel or effectively manage leadership changes among key positions in our organization, our business and operating results could be harmed. In addition, recruiting and retaining talented and diverse personnel and fostering an inclusive culture focused on collaboration and partnership across the business are critical to our success. As we grow, we may face challenges in attracting and retaining qualified personnel with diverse backgrounds, experiences and skill sets, which could harm our ability to execute our business strategy.
26
Our business and reputation will suffer if we are unable to establish and comply with stringent quality standards to assure that the highest level of quality is observed in the performance of our tests.
Inherent risks are involved in providing and marketing our tests, including our Cologuard test and our precision oncology tests, and related services. Patients and healthcare providers rely on us to provide accurate clinical and diagnostic information that may be used to make critical healthcare decisions. As such, users of our tests may have a greater sensitivity to errors than users of some other types of products and services.
We must maintain top service standards and FDA-mandated and other quality controls. Past or future performance or accuracy defects, incomplete or improper process controls, excessively slow turnaround times, unanticipated uses of our tests or mishandling of samples or test results (whether by us, patients, healthcare providers, courier delivery services, or others) can lead to adverse outcomes for patients and interruptions to our services. These events could lead to voluntary or legally mandated safety alerts relating to our tests or our laboratory facilities and could result in the removal of our products and services from the market or the suspension of our laboratories' operations. Insufficient quality controls and any resulting negative outcomes could result in significant costs and litigation, as well as negative publicity that could reduce demand for our tests and payers’ willingness to cover our tests. Even if we maintain adequate controls and procedures, damaging and costly errors may occur.
Our inability to manage growth could harm our business.
In connection with the commercialization of our tests, we have added, and expect to continue adding, personnel to certain areas of our business, including laboratory operations, quality assurance, and compliance. Our number of full-time employees has increased from 4,800 as of December 31, 2020 to 6,500, as of December 31, 2023. As we continue to build our commercialization, marketing, and sales efforts and expand research and development activities for current and new products and services, the scope and complexity of our operations is increasing significantly. In addition, our acquisitions have contributed to the increasing complexity of operations, requiring significant changes to our corporate operations as we integrate other companies and their personnel to our systems. This growth has also increased our operating expenses and capital requirements, and we expect that they will continue to increase significantly. Our ability to manage our growth effectively requires us to expend funds to improve our operational, financial and management controls, reporting systems and procedures. As we expand the commercialization of our current tests and move towards commercializing new tests, we will also need to effectively manage our growing manufacturing, laboratory operations, and sales and marketing needs. We are continuing to explore the need to add new facilities to support anticipated demand for our current and future tests. We face various risks in managing these expansion efforts, including financing, construction delays, budget management, quality control, design efficiency, and transition execution. If we are unable to manage our anticipated growth effectively, our business could be harmed.
We may engage in acquisitions or divestitures that are not successful and which could disrupt our business and reduce our financial resources and shareholder value.
We undertake acquisition activities from time to time. For example, in September 2023, we acquired Resolution Bioscience, Inc. Certain risks may exist as a result of these and other acquisition activities, including, among others:
•potential unknown liabilities and unforeseen increased expenses, delays, or unfavorable conditions in connection with the integration of the acquired businesses into our business;
•diversion of management’s attention and company resources from our existing operations of our business;
•the issuance of dilutive securities, assumption or incurrence of additional debt obligations or expenses, or use of substantial portions of our cash in acquisitions;
•difficulties in successful integration of the operations and information technology systems of acquired businesses into our business;
•the potential loss of key employees, customers and strategic partners of ours and of acquired businesses;
•the inability to realize the anticipated benefits of the acquisitions or do so within the anticipated timeframe;
•negative impacts on our near-term financial results after an acquisition or on our future financial results if we do not effectively manage our expanded operations; and
•the market price of our common stock may decline as a result of the acquisitions.
27
In the future, we may enter into transactions to acquire other businesses, products, services, or technologies, which may ultimately be unsuccessful. If we do identify suitable acquisition targets, we may not be able to make such acquisitions on favorable terms or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by investors, healthcare providers, patients, and others. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.
We may also pursue strategic divestitures that may prove distracting, unprofitable, or otherwise unsuccessful. For example, in August 2022 we completed a divestiture of assets related to our Oncotype DX Genomic Prostate Score test (“GPS test”) to MDxHealth SA (“MDxHealth”). A successful divestiture depends on various factors, including our ability to effectively transfer liabilities, contracts, facilities and employees to the buyer, identify and separate the personnel, contracts, and assets, including intellectual property, to be divested from the portion of the business and assets that we wish to keep, and reduce fixed costs previously associated with the divested assets or business. In exiting a business, we may still retain liabilities associated with that business and other indemnification obligations. We may also need to provide transition services to the buyer for an extended period of time following the closing, which may cause us to incur unanticipated costs and distraction. With respect to any divestiture, we may encounter difficulty finding potential buyers or other divestiture options on favorable terms. We may agree to milestone or earnout-based consideration, the achievement of which will be outside our control, and which we may ultimately never receive. Any divestiture could affect our profitability as a result of the gains or losses on such sale of a business or service, the loss of the operating income resulting from such sale or the costs or liabilities that are not assumed by the acquirer (i.e., stranded costs) that may negatively impact profitability subsequent to any divestiture. We may also be required to recognize impairment charges as a result of a divestiture.
International expansion of our business exposes us to business, regulatory, labor, political, operational, financial, liability, compliance, payment collection, and economic risks associated with doing business outside of the U.S.
While we do not offer our Cologuard test outside of the U.S., we currently commercialize or plan to commercialize our Oncotype DX tests through employees in Canada, Japan, and a number of European countries, as well as through exclusive distribution agreements. We have provided our Oncotype tests in approximately 120 countries. Our business strategy incorporates continued international expansion, which includes growing our direct sales and healthcare provider outreach and education capabilities outside of the U.S. and developing our relationships with payers and distributors in foreign markets. Doing business internationally involves a number of risks, including:
•difficulties in complying with multiple, conflicting, and changing laws and regulations, such as tax laws, export and import restrictions, employment laws, privacy and data protection laws, regulatory requirements and other governmental approvals, permits and licenses, including the changing regulation in Europe with regard to medical device and in vitro diagnostic regulations;
•significant competition from local and regional product offerings and the fact that products designed for U.S. markets may not be preferred by foreign authorities, payers, medical providers and patients;
•restrictions or prohibitions of transmitting personal data, including patient data, from foreign jurisdictions to our centralized laboratories in the U.S.;
•difficulties in staffing and managing foreign operations;
•difficulties in managing distributor relationships;
•complexities associated with managing multiple payer reimbursement regimes, public payers, or patient self-pay systems;
•logistics and regulations associated with shipping tissue samples, performing tests locally or complying with local regulations concerning the analysis of tissue, including infrastructure conditions and transportation delays;
•limits in our ability to access or penetrate international markets if we are not able to process tests locally;
•lack of intellectual property protection in certain markets;
•financial risks, such as longer payment cycles, difficulty collecting accounts receivable, lower margins resulting from smaller scale foreign operations, the impact of local and regional financial crises on demand and payment for our tests, and exposure to foreign currency exchange rate fluctuations;
•natural disasters, political and economic instability, including wars, strikes, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;
•staffing difficulties, funding restrictions, and other difficulties facing medical institutions and payers;
28
•regulatory and compliance risks that relate to maintaining accurate information and control over the activities of our sales force and distributors that may fall within the purview of the FCPA, its books and records provisions or its anti-bribery provisions, or similar anti-bribery or anti-corruption laws or regulations, such as the U.K. Anti-bribery Act and the U.K. Criminal Finances Act; and
•complexity of compliance with local standard contractual requirements to access public customers and payers.
Any of these factors could significantly harm our current international operations or future international expansion and, consequently, our financial condition and results of operations.
Our business may be adversely affected by global macroeconomic conditions and volatility in the capital markets.
The growth of our business is, and will continue to be, affected by changes in the overall global economy. Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, high interest rates, foreign currency exchange rates, weakness in general economic conditions and threatened or actual recessions, including those resulting from the current and future conditions in the global financial markets, and budgeting constraints of governmental entities. Cost inflation, including increases in raw material prices, labor rates, and transportation costs, may continue to impact our profitability. Our ability to recover these cost increases through price increases is significantly limited by the process by which we are reimbursed for our products and services by government and private payers. In addition, disruptions in the U.S., Europe or other economies, including due to geopolitical conflict, could disrupt global markets, interrupt global supply chains, and have other potential inflationary or recessionary effects on the global economy.
The volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations. The high interest rate environment and reduced access to capital markets could also adversely affect the ability of our suppliers, distributors, licensors, collaborators, contract manufacturers and other commercial partners to remain effective business partners or to remain in business. The loss of a critical business partner, or a failure to perform by a critical business partner, could have a disruptive effect on our business and could adversely affect our results of operations.
Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, adverse effects on our business and financial results.
Pandemics or disease outbreaks, such as the COVID-19 pandemic, have created and may continue to create significant volatility, uncertainty and economic disruption in the markets in which we sell or plan to sell our current or future tests and in which we operate, and may negatively impact business and healthcare activity globally. For example, in response to the COVID-19 pandemic, governments around the world imposed measures designed to reduce the transmission of COVID-19, patients postponed visits to healthcare providers, certain healthcare providers temporarily closed their offices or restricted patient visits, healthcare provider employees became generally unavailable and there were disruptions in the operations of payers, suppliers and other third parties that are necessary for our tests to be administered. The extent to which fear of exposure to or actual effects of COVID-19, new variants, disease outbreak, epidemic or a similar widespread health concern impacts our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the speed and extent of geographic spread of the disease, the duration of the outbreak, travel restrictions, the efficacy of vaccination and treatment; impact on the U.S. and international healthcare systems, the U.S. economy and worldwide economy; the timing, scope and effectiveness of U.S. and international governmental response; and the impact on the health, well-being and productivity of our employees; and short- and long-term changes in the behaviors of medical professionals and patients resulting from any such pandemic, outbreak, epidemic or other health concern.
Ethical, legal and social concerns related to the use of genetic information could reduce demand for our genetic tests.
Genetic testing has raised ethical, legal and social issues regarding privacy rights and the appropriate uses of the resulting information. Governmental authorities could, for social or other purposes, limit or regulate the use of genetic information or genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Similarly, these concerns may lead patients to refuse to use, or clinicians to be reluctant to order, genetic tests even if permissible. These and other ethical, legal and social concerns may limit market acceptance of our genetic tests or reduce the potential markets for these tests, either of which could have an adverse effect on our business, financial condition or results of operations.
29
Climate change, or legal or regulatory measures to address climate change or other corporate social responsibility and sustainability matters, could adversely affect our business, financial condition and results of operations.
The effects of global climate change present risks to our business. Natural disasters, extreme weather and other conditions caused by or related to climate change could adversely impact our supply chain, the courier delivery services we use, the availability and cost of raw materials and components, energy supply, water, transportation, or other inputs necessary for the operation of our business. Climate change and natural disasters could also impact behaviors of medical providers or patients or result in physical damage to our facilities as well as those of our suppliers, health care providers and other business partners, all of which could negatively impact and disrupt our business and operations. Our facilities and our laboratory equipment would be costly to replace and could require substantial lead time to repair or replace. Although we believe we possess adequate insurance for the disruption of our business from causalities, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.
New or additional legal or regulatory requirements may be enacted to reduce greenhouse gas emissions, mitigate the effects of climate change on the environment or address other corporate social responsibility and sustainability matters. Any such new or additional legal or regulatory requirements may increase the costs associated with, or disrupt, the development, manufacturing and distribution of our tests or the performance of related services, which may adversely affect our business and financial results. In addition, any failure to adequately address stakeholder expectations with respect to corporate social responsibility and sustainability matters, including addressing climate change, may result in the loss of business, damage to our reputation, diluted market valuations, challenges in attracting and retaining talented employees and restrictions on certain aspects of our activities. Furthermore, our adoption of certain standards for our corporate social responsibility and sustainability efforts and related matters or mandated compliance to certain requirements could necessitate additional investments that could hinder our profitability.
The use of Artificial Intelligence presents new risks and challenges to our business.
Artificial Intelligence (“AI”) is increasingly being used across the global business landscape, including in the life sciences and healthcare industries. We have already employed certain AI technologies into our business to enhance our operations, products, technology, and services and expect our use of AI to increase as the technology rapidly evolves and improves. However, AI innovation presents risks and challenges that could impact our business. AI algorithms may be flawed. Datasets may be insufficient or contain biased information. Ineffective AI development and deployment practices by us or our commercial partners could result in violations of our confidentiality and privacy obligations or applicable laws and regulations, jeopardize our intellectual property rights, cause or contribute to unlawful discrimination, result in the misuse of personally identifiable information, including PHI, or give rise to significant cyber security risks, any of which could have a material adverse effect on our business, results of operations, and financial condition.
We may also face increased competition from other companies that are employing AI and related technologies, some of whom may develop more effective methods than we and any of our commercial partners have, which could have a material adverse effect on our business, results of operations, or financial condition. In addition, uncertainties regarding developing legal and regulatory requirements and standards may require significant resources to modify and maintain business practices to comply with U.S. and foreign laws concerning the use of AI and related technologies, the nature of which cannot be determined at this time.
We may be a party to litigation in the normal course of business or otherwise, which could affect our business and financial position.
From time to time, we are a party to or otherwise involved in legal proceedings, claims and government investigations and other legal matters, both inside and outside the U.S., arising in the ordinary course of our business or otherwise. We are currently involved in various legal proceedings and claims that have not yet been fully resolved, and additional claims may arise in the future. Legal proceedings in which we are currently involved include those proceedings described in Note 15 of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.
Additionally, the distribution, sale, use and results of our tests could lead to liability claims. Legal proceedings can be complex and take many months, or even years, to reach resolution, with the final outcome depending on a number of variables, some of which are not within our control. Litigation is subject to significant uncertainty and may be expensive, time-consuming, and disruptive to our operations. Although we will vigorously defend ourselves in such legal proceedings, their ultimate resolution and potential financial and other impacts on us are uncertain. For these and other reasons, we may choose to
30
settle legal proceedings and claims, regardless of their actual merit. If a legal proceeding is resolved against us, it could result in significant compensatory damages, and in certain circumstances punitive or trebled damages, disgorgement of revenue or profits, remedial corporate measures or injunctive relief imposed on us. If our existing insurance does not cover the amount or types of damages awarded, or if other resolution or actions taken as a result of a legal proceeding were to restrain our ability to operate, our financial position, results of operations or cash flows could be materially adversely affected. Any claim brought against us, with or without merit, could increase our liability insurance rates or prevent us from securing insurance coverage in the future. In addition, legal proceedings, and any adverse resolution thereof, can result in adverse publicity and damage to our reputation, which could adversely impact our business.
The amounts we record for legal contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. While we have accrued for certain potential legal liabilities, there is no guarantee that additional costs will not be incurred beyond the amounts accrued.
Risks Relating to Governmental Regulation and Reimbursement
We face uncertainty related to healthcare reform, pricing, coverage, and reimbursement.
We must navigate complex healthcare regulations, which control how we conduct our business and how we are paid. Existing legislation, and possible future legal and regulatory changes, including potential repeal or modification of the ACA, could materially change the structure and finances of the health insurance system and the methodology for reimbursing medical services, drugs and devices, including our current and future products and services. The ACA has also been the subject of various legal challenges and if the plaintiffs in any case challenging the ACA are ultimately successful insurance coverage for our tests could be materially and adversely affected. Any change in reimbursement policy could result in a change in patient cost-sharing, which could adversely affect a provider’s willingness to prescribe and patient’s willingness and ability to use our tests and any other product or service we may develop. Healthcare reforms, which may intend to reduce healthcare costs, may have the effect of discouraging third-party payers from covering certain kinds of medical products and services, particularly newly developed technologies, like those we have developed in the past or we may develop in the future. We cannot predict whether future healthcare reform initiatives will be implemented at the federal or state level or the effect any such future legislation or regulation will have on us. The taxes imposed by new legislation, cost reduction measures and the expansion in the government’s role in the U.S. healthcare industry may result in decreased profits to us, which may adversely affect our business, financial condition and results of operations.
The Protecting Access to Medicare Act of 2014 (“PAMA”) presents significant uncertainty for future CMS reimbursement rates. Because Medicare currently covers a significant number of our patients, any reduction in the CMS reimbursement rate for our tests would negatively affect our revenues and our business prospects. Under PAMA, CMS reimbursement rates for clinical diagnostic laboratory tests are updated every three years or annually for clinical laboratory tests that are considered “advanced diagnostic laboratory tests.” There can be no assurance under PAMA that adequate CMS reimbursement rates will continue to be assigned to our tests. Congress could modify or repeal PAMA in the future or CMS could modify regulations under PAMA, and any such action could have the effect of reducing the CMS reimbursement rate for our tests. Further, it is possible that Medicare or other federal payers that provide reimbursement for our tests may suspend, revoke or discontinue coverage at any time, may require co-payments from patients, or may reduce the reimbursement rates payable to us. Any such action could have a negative impact on our revenues.
Coverage of our Cologuard test and other screening or diagnostic products that we may develop may also depend, in whole or in part, on whether payers determine, or courts and/or legislative or regulatory authorities determine, coverage is required under applicable federal or state laws mandating coverage of certain cancer screening or diagnostic services. For example, while we believe the ACA Mandate requires most health insurers to cover our Cologuard test for most patients between the ages of 45 and 75 without patient cost-sharing, some health insurers have disagreed and determined not to cover our Cologuard test and others may take that position in the future. Further, states may decide to modify their laws, which may include repeal of those coverage mandates that we believe currently apply to our Cologuard test.
31
If payers, including managed care organizations, do not approve and maintain reimbursement for our tests at adequate reimbursement rates, our commercial success could be compromised.
Our commercial success depends, in large part, on the availability of reimbursement at adequate reimbursement rates for our current tests, including our flagship Cologuard and Oncotype tests and our products in development, from government insurance plans, managed care organizations and commercial insurance plans. Although we received a positive coverage decision and what we believe is an adequate reimbursement rate from CMS for our Cologuard test, it is also critical that other third-party payers approve and maintain reimbursement for our Cologuard test at adequate reimbursement rates. We also have received positive coverage determinations for our Oncotype DX breast cancer test for N-, ER+ patients from most third-party payers, but have less favorable coverage for our other Oncotype tests. Additionally, successful commercialization of our newly developed products will also depend on our ability to obtain and maintain reimbursement from government insurance plans, managed care organizations, and commercial insurance plans at adequate reimbursement rates. Healthcare providers may be reluctant to prescribe, and patients may be reluctant to complete, our tests if they are not confident that patients will be reimbursed for our tests.
Third-party payers, both in the U.S. and internationally, are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for healthcare products and services. As a result, there is uncertainty surrounding the future level of reimbursement, if any, for our current tests and any new tests we may develop. Reimbursement by a third-party payer may depend on a number of factors, including a payer’s determination that tests using our technologies are sufficiently sensitive and specific; not experimental or investigational; approved or recommended by the major guideline organizations; subject to applicable federal or state coverage mandates; reliable, safe and effective; medically necessary; appropriate for the specific patient; and cost-effective. Moreover, coverage determinations and reimbursement rates are subject to change, and we cannot guarantee that even if we initially achieve adequate coverage and reimbursement rates for our tests, they will continue to apply in the future or remain adequate as we face increases in operating costs, such as labor and supply costs that are subject to inflation, and government and commercial payers may cause us to accept lower prices.
Even where a third-party payer agrees to cover one of our tests, other factors may have a significant impact on the actual reimbursement we receive from that payer. For example, if we do not have a contract with a given payer, we may be deemed an “out-of-network” provider by that payer, which could result in the payer allocating a portion of the cost of the test to the patient, notwithstanding any applicable coverage mandate. We may be unsuccessful in our efforts to enter into, or maintain, a network contract with a given payer, and we expect that our network status with a given payer may change from time to time for a variety of reasons, many of which may be outside our control. To the extent one of our tests is out of network for a given payer, healthcare providers may be less likely to prescribe that test for their patients and their patients may be less likely to comply with those prescriptions that are written. Also, some payers may mandate prior authorization or other medical management practices that impose significant additional costs on us, may be difficult to comply with given our position as a laboratory that generally does not have direct access to patient medical records, may make healthcare providers less likely to prescribe our tests for their patients, and may make patients less likely to comply with healthcare provider orders for our tests, all or any of which may have an adverse effect on our revenues.
If we are unable to obtain or maintain reimbursement at adequate reimbursement rates for our Oncotype DX tests outside of the U.S., our ability to expand internationally will be compromised.
The majority of our international Oncotype DX breast and colon cancer test revenues come from payer reimbursement, including from public or government-controlled or regulated payers, payments from our distributors, and patient self-pay. Obtaining reimbursement from public payers outside of the U.S. generally involves complex requirements that we may be unable to satisfy.
Even if public or private reimbursement is obtained, it may be discontinued, cover competing tests, or the reimbursement may be limited to a subset of the eligible patient population or conditioned upon local performance of the tests or other requirements we may have difficulty satisfying.
Reimbursement levels outside of the U.S. may vary considerably from the domestic reimbursement amounts we receive. In addition, because we generally rely on distributors to obtain reimbursement for our tests in certain countries outside of the U.S., to the extent we do not have direct reimbursement arrangements with payers, we may not be able to retain reimbursement coverage in those countries if our agreement with a distributor is terminated or expires, if a distributor fails to pay us or if other events prevent payment.
32
Failure to comply with federal, state and foreign laboratory licensing and related requirements could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.
We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations establish specific standards with respect to personnel qualifications, facility administration, proficiency testing, quality control, quality assurance and inspections. Any testing subject to CLIA regulation must be performed in a CLIA certified laboratory. CLIA certification is also required in order for us to be eligible to bill state and federal healthcare programs, as well as commercial payers, for our tests. In addition, some states, including California and New York, require that we hold licenses or permits to test samples from patients in those states, even if our laboratory facilities are not located in those states, and as a result we are also required to maintain standards related to those states’ licensure requirements to conduct testing in our laboratories.
Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA certification and/or state licenses, imposition of a directed plan of action, on-site monitoring, civil monetary penalties, criminal sanctions, inability to receive reimbursement from Medicare, Medicaid and commercial payers, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing clinical laboratory licensure or our failure to renew our CLIA certification, a state or foreign license or accreditation, could have a material adverse effect on our business, financial condition and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.
We may also be subject to laboratory regulations in foreign jurisdictions as we seek to expand international utilization of our tests or as such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations such as restrictions on the transport of specimens necessary for us to perform our tests that may limit our ability to make our tests available outside of the U.S. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays.
Our products could be subject to recall.
Manufacturers of medical devices must comply with various regulatory requirements under the FDCA and regulations thereunder, including, but not limited to, quality system regulations, unless they are exempt, facility registration, product listing, labeling requirements, and certain post-market surveillance requirements. If we do not meet applicable regulatory or quality standards, our products may be subject to recall, and, under certain circumstances, we may be required to notify applicable regulatory authorities about a recall. In 2017, we recalled one of the components of our Cologuard test kit and circumstances may arise that cause us to recall other products or components used in connection with our Cologuard test. Any such recalls could have an adverse effect on our ability to provide the Cologuard test, which in turn would adversely affect our financial condition.
Delays in receipt of, or failure to obtain, required FDA clearances or approvals for our products in development, or improvements to or expanded indications for our current offerings, could materially delay or prevent us from commercializing or otherwise adversely impact future product commercialization.
Unless otherwise exempted or subject to enforcement discretion, medical devices, which include screening and diagnostic tests, must receive either FDA regulatory approval or clearance before being marketed in the U.S. Our Cologuard test is regulated by the FDA as a medical device and we may develop new tests that are deemed medical devices and require FDA clearance or approval. The FDA determines whether a medical device will require either regulatory approval or clearance based on statutory criteria that include the risk associated with the device and whether the device is similar to an existing, legally marketed product. The process to obtain either regulatory approval or clearance will likely be costly, time-consuming, and uncertain. The regulatory approval process is generally more challenging than the clearance process. Even if we design a product that we expect to be eligible for the regulatory clearance process, the FDA may require that the product undergo the regulatory approval process. There can be no assurance that the FDA will ever permit us to market any new product that we develop. Even if regulatory approval or clearance is granted, such approval may include significant limitations on indicated uses, which could materially and adversely affect the prospects of any new medical device.
33
FDA regulatory approval or clearance is also required for certain enhancements we may make to our Cologuard test or future FDA-approved or -cleared tests. For example, our next generation Cologuard test will require FDA approval before it can be marketed and we are in the process of seeking that approval. FDA approval or clearance may also be required to make changes to the processes, equipment, reagents, and other consumables used in connection with a test. The FDA’s approval pathway can be time-consuming and costly and there can be no assurance that the FDA will ultimately approve any premarket approval submitted by us in a timely manner or at all.
In addition, the FDA’s ability to review and clear or approve new products or changes to existing products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, prolonged government shutdowns or global health concerns may prevent or delay the FDA or other regulatory authorities from conducting, at all or in a timely manner, their regular inspections, reviews, or other regulatory activities (including pre-submission engagements). Any such delay in the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions could have a material adverse effect on our business.
Delays in receipt of, or failure to obtain, clearances or approvals could materially delay or prevent us from commercializing our products or result in substantial additional costs that could decrease our profitability. In addition, even if we receive FDA clearance or approval for a new or enhanced product, the FDA may condition, withdraw, or materially modify its clearance or approval.
The FDA may change its position with respect to its regulation of the laboratory developed tests we offer or may seek to offer in the future, causing us to incur substantial costs and time delays associated with meeting requirements for pre-market clearance or approval or we could experience decreased demand for or reimbursement of our tests.
Our Oncotype tests, OncoExTra test, and certain other tests we offer are regulated as LDTs and we may seek to commercialize certain of our products in development as LDTs. LDTs are clinical laboratory tests that are developed and validated by a laboratory for its own use. The FDA historically has taken the position that it has the authority to regulate such tests as medical devices under the FDC Act but has for the most part exercised enforcement discretion and has not required clearance, de novo classification, or approval of LDTs prior to marketing.
At various times since 2006, the FDA has issued documents outlining its intent to require varying levels of FDA oversight of many LDTs, including our tests. In October 2023, the FDA announced a proposed rule seeking to regulate LDTs as medical devices under the FDCA. The comment period for the FDA’s proposed rule closed in December 2023 and the FDA has indicated its desire to issue a final rule on LDTs in April 2024 or shortly thereafter. Even if FDA does not finalize its proposed rule, the U.S. Congress may enact statutory changes that could alter or eliminate FDA’s current LDT enforcement policy. It is therefore unclear at this time what form that final regulation may take, or if FDA will finalize the regulation at all. It is also unclear what additional obligations might be placed on us as we continue to offer LDTs in light of FDA's renewed interest in greater oversight into this class of tests and the potential for legislative changes. Action by the FDA or Congress to phase out the FDA’s current policy of enforcement discretion over LDTs may materially impact our development and commercialization of LDTs, including our Oncotype tests. If pre-market review is required for our current LDTs, the FDA could require that we stop selling our tests pending pre-market clearance or approval and our business could be negatively impacted in the U.S. until such review is completed and clearance or approval is obtained. The regulatory approval process may involve, among other things, successfully completing additional clinical studies and submitting a pre-market clearance notice or filing a pre-market approval application with the FDA. Such pre-market clinical testing could delay the commencement or completion of other clinical testing, significantly increase our test development costs, delay commercialization of any future LDTs, and interrupt sales of our current LDTs. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical studies may also ultimately lead to delay or denial of regulatory clearance or approval. If pre-market review is required by the FDA, there can be no assurance that our LDTs will be cleared or approved on a timely basis, if at all, nor can there be assurance that the labeling claims cleared or approved by the FDA will be consistent with our current claims or adequate to support continued adoption of and reimbursement for our LDTs.
If our Oncotype tests are allowed to remain on the market but there is uncertainty about the regulatory status of such tests, if they are labeled investigational by the FDA, or if labeling claims the FDA allows us to make are more limited than the claims we currently make, orders or reimbursement may decline.
34
We are subject to numerous U.S. and foreign laws and governmental regulations, and any governmental enforcement action may materially affect our financial condition and business operations.
We are subject to regulation in the U.S. by both the federal government and the states in which we conduct our business, as well as in other jurisdictions outside of the U.S., including:
•Federal, state, and local laws regarding the use, storage, handling and disposal of medical and hazardous waste, as well as regulations relating to the safety and health of laboratory employees;
•the Federal Anti-Kickback Statute and state anti-kickback prohibitions and EKRA;
•the Federal Physician Self-Referral Law, commonly known as the Stark Law, and the state equivalents;
•the HIPAA, the CCPA, including expansions and amendments pursuant to the California Privacy Rights Act, and other state privacy laws;
•Federal, state, and local consumer protection laws governing communications, including the Telephone Consumer Protection Act (“TCPA”) and the Controlling the Assault of Non-Solicited Pornography and Marketing Act (“CAN-SPAM Act”);
•the Medicare civil money penalty and exclusion requirements;
•the Federal False Claims Act civil and criminal penalties and state equivalents; and
•the FCPA, the United Kingdom Anti-Bribery Act, the GDPR and other national or provincial laws protecting personal information, the E.U. Medical Device and In Vitro Diagnostic Device Regulations, and national laws restricting industry interaction with healthcare professionals, all of which may or will apply to our international activities.
We have adopted policies and procedures designed to comply with these laws. In the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance is also subject to governmental review. The growth of our business and sales organization and our expansion outside of the U.S. may increase the potential of violating these laws or our internal policies and procedures. The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations.
The U.S. Attorney’s Offices have increased their scrutiny over the healthcare industry in recent years. The U.S. Congress, U.S. Department of Justice (“DOJ”), Office of Inspector General of the Department of Health and Human Services, and Department of Defense have all issued subpoenas and other requests for information to conduct investigations of, and commenced, civil and criminal litigation against healthcare companies related to financial arrangements with healthcare providers, regulatory compliance, product promotional practices, and documentation, coding and billing practices. In addition, the Federal False Claims Act and state equivalents have led to whistleblowers filing numerous qui tam civil lawsuits against healthcare companies, in part, because a whistleblower can receive a portion of any amount obtained by the government through such a lawsuit.
Governmental enforcement action or qui tam civil litigation against us may result in material costs and occupy significant management resources, even if we ultimately prevail. In addition, qui tam litigation or governmental enforcement action may result in substantial damages (including treble damages), fines, civil and criminal penalties, payment of attorney's fees or administrative remedies, including exclusion from government reimbursement programs and entry into corporate integrity agreements with governmental agencies, which could entail significant obligations and costs. As described further in Note 15 of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K, in September 2023, we entered into settlement agreements with the United States, acting through the U.S. DOJ, with respect to (1) a civil investigative demand initiated by the U.S. DOJ concerning Genomic Health, Inc.’s (“Genomic Health”) compliance with the Medicare Laboratory Date of Service billing regulations prior to our acquisition of Genomic Health in 2019 and (2) a qui tam lawsuit alleging violations of the Federal Anti-Kickback Statute and False Claims Act for offering gift cards to patients in exchange for returning the Cologuard screening test, for which Niles Rosen M.D., the petitioner in the qui tam lawsuit, was also a party to the settlement agreement. The settlement agreement between Genomic Health and the U.S. DOJ required us to pay $32.5 million, which was paid in September 2023 and the settlement agreement with the U.S. DOJ and Dr. Rosen required us to pay $13.8 million plus legal fees, which was paid in October 2023. Any such actions or litigation in the future could result in adverse penalties or outcomes that could materially and adversely affect our business, financial condition and results of operations.
35
Our business is subject to various complex laws and regulations applicable to providers of clinical diagnostic products and services.
As a provider of clinical diagnostic products and services, we and our partners are subject to extensive and frequently changing federal, state, local and foreign laws and regulations governing various aspects of our business. In particular, the clinical laboratory and healthcare industry is subject to significant governmental certification and licensing regulations, as well as federal, state and foreign laws regarding:
•test ordering and billing practices;
•marketing, sales and pricing practices;
•health information privacy and security, including HIPAA and comparable state and foreign laws;
•insurance, including foreign public reimbursement;
•anti-markup legislation; and
•consumer protection.
We are also required to comply with FDA regulations, including with respect to our labeling and promotion activities. In addition, advertising of our tests is subject to regulation by the Federal Trade Commission, or FTC, and advertising of laboratory services is regulated by certain state laws. Violation of any FDA requirement could result in enforcement actions, such as seizures, injunctions, civil penalties and criminal prosecutions, and violation of any FTC or state law requirement could result in injunctions and other associated remedies, all of which could have a material adverse effect on our business. Most states also have similar regulatory and enforcement authority for medical devices. Additionally, most foreign countries have authorities comparable to the FDA and processes for obtaining marketing approvals. In particular, the entry into application of the E.U.'s In Vitro Diagnostic Device Regulation will impose new requirements and create new compliance risks. Obtaining and maintaining these approvals, and complying with all laws and regulations, may subject us to similar risks and delays as those we could experience under FDA, FTC and state regulation. We incur various costs in complying and overseeing compliance with these laws and regulations. The growth of our business and sales organization, the acquisition of additional businesses or products and services and our expansion outside of the U.S. may increase the potential of violating these laws, regulations or our internal policies and procedures.
Healthcare policy has been a subject of extensive discussion in the executive and legislative branches of the federal and many state governments, and healthcare laws and regulations are subject to change. Development of the existing commercialization strategy for our tests and planned development of products in our pipeline has been based on existing healthcare policies. We cannot predict what additional changes, if any, will be proposed or adopted or the effect that such proposals or adoption may have on our business, financial condition and results of operations.
If we, or our partners, fail to comply with these laws and regulations, we could incur significant fines and penalties and our reputation and prospects could suffer. Additionally, any such partners could be forced to cease offering our products and services in certain jurisdictions, which could materially disrupt our business.
Due to billing complexities in the diagnostic and laboratory service industry, we may have difficulties receiving timely payment for the tests we perform, and may face write-offs, disputes with payers and patients, and long collection cycles.
Billing for diagnostic and laboratory services is a complex process. We bill many different payers including patients, private insurance companies, Medicare, Medicaid, and employer groups, all of which have different billing requirements. 
We are continuing to work with third-party payers to cover and reimburse our tests. If we are unsuccessful, we may not receive payment for the tests we perform for patients on a timely basis, if at all, and we may not be able to provide services for patients with certain healthcare plans. We may face patient dissatisfaction, complaints or lawsuits, including to the extent our tests are not fully covered by insurers and patients become responsible for all or part of the price of the test. As a result, patient demand for our tests could be adversely affected. To the extent patients express dissatisfaction with our billing practices to their healthcare providers, those healthcare providers may be less likely to prescribe our tests for other patients, and our business would be adversely affected.
36
Even if payers agree to cover our tests, our billing and collections process may be complicated by the following and other factors, which may be beyond our control:
•complex and disparate reimbursement rules and requirements;
•disputes among payers as to which payer is responsible for payment;
•disparity in coverage among various payers or among various healthcare plans offered by a single payer;
•payer medical management requirements, including prior authorization requirements;
•differing information and billing requirements among payers;
•failure by patients or healthcare providers to provide complete and correct billing information; and
•limitations and requirement for patient billing, including those related to deductibles, co-payments, and co-insurance originating from contracts with commercial payers.
For example, pursuant to certain CMS rules (the “Medicare Laboratory Date of Service billing regulation”), subject to certain exceptions issued by CMS, we cannot bill Medicare directly for some tests provided for Medicare beneficiaries in some situations involving certain hospital patients and instead must bill hospitals for such tests. In these circumstances, only the hospital may bill Medicare for such tests. These billing rules may lead to confusion regarding whether Medicare provides adequate reimbursement for our tests, and could discourage providers from ordering our tests for Medicare patients or even non-Medicare patients. In addition, changes in Medicare billing rules and processes could result in delays in receiving payments or receiving payments that are less than the original invoice. When hospitals disclaim responsibility for or delay payment of our bills for tests affected by the Medicare Laboratory Date of Service billing regulation, and when our collection efforts are unsuccessful, we may be forced to accept payments from hospitals that are less than the original invoice or we may be unable to collect from hospitals at all despite diligent efforts.
Similarly, when we have a contract with a commercial payer to cover our tests, we are not permitted to bill patients insured by that payer for amounts beyond deductibles, co-payments, and co-insurance as prescribed in the coverage agreement between the payer and the patients. Therefore, when such contracted payers do not pay us our full, contracted rate for a test, for example, for failure to satisfy prior-authorization or other payer medical management requirements, we may not be permitted to collect the balance from the patient and our business is adversely impacted.
In the past, failures to submit claims to insurers timely have required us to record downward adjustments to our revenue. Despite efforts to improve our billing systems and prevent recurrences of these failures, future failures to timely submit claims could result in further downward adjustments to revenue.
As a result of the above, we may face write-offs of doubtful accounts, disputes with payers and patients, and long collection cycles.
We also may face lawsuits by government or commercial payers if they believe they have overpaid us for our test services or as a result of other circumstances. For example, as described in Note 15 of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K, in September 2023, Genomic Health, entered into a settlement agreement with the United States, acting through the U.S. DOJ, to resolve a civil investigation concerning Genomic Health’s compliance with the Medicare Date of Service billing regulation prior to our acquisition of Genomic Health in 2019. This settlement agreement required us to pay $32.5 million, which was paid in October, 2023.
Some of our activities may subject us to risks under federal and state laws prohibiting “kickbacks” and false or fraudulent claims.
In addition to FDA marketing and promotion restrictions, several other types of state and federal healthcare fraud and abuse laws have been applied in recent years to restrict certain marketing practices in the healthcare product and service industry and to regulate billing practices and financial relationships with healthcare providers, hospitals and other healthcare providers. These laws include a federal law commonly known as the Medicare/Medicaid anti-kickback law, and several similar state laws, which prohibit payments intended to induce healthcare providers or others either to refer patients or to acquire or arrange for or recommend the acquisition of healthcare products or services. While the federal law applies only to referrals, products or services for which payment may be made by a federal healthcare program, state laws often apply regardless of whether federal funds may be involved. These laws constrain the sales, marketing and other promotional activities of manufacturers of medical devices and providers of laboratory services by limiting the kinds of financial arrangements, including sales programs, that may be used with hospitals, healthcare providers, laboratories and other potential purchasers or prescribers of medical devices and laboratory services. In addition, the Eliminating Kickbacks in Recovery Act of 2018
37
imposes criminal penalties for knowing or willful payment or offer, or solicitation or receipt, of any remuneration, whether directly or indirectly, overtly or covertly, in cash or in kind, in exchange for the referral or inducement of laboratory testing (among other healthcare services) unless a specific exception applies. Although it appears that EKRA was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written and can apply to laboratory services covered under public or private payer arrangements. EKRA permits the DOJ to issue regulations clarifying EKRA’s exceptions or adding additional exceptions, but it has not done so. As a result, there is no agency guidance and limited court precedent to indicate how, and to what extent, it will be applied and enforced. We cannot assure you that our relationships with healthcare providers, sales representatives, hospitals, customers, or any other party will not be subject to scrutiny or will survive regulatory challenge under EKRA. Other federal and state laws generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or are for items or services that were not provided as claimed.
Additionally, to avoid liability under federal false claims laws, we must carefully and accurately code claims for reimbursement, proactively monitor the accuracy and appropriateness of Medicare claims and payments received, diligently investigate any credible information indicating that we may have received an overpayment, and promptly return any overpayments. Medicare payments are subject to audit, including through the Comprehensive Error Rate Testing (“CERT”) program, and payments may be recouped by CMS if it is determined that they were improperly made. Currently, a significant percentage of our revenues are generated by payments from Medicare. The federal anti-kickback statute and certain false claims laws prescribe civil and criminal penalties (including fines) for noncompliance that can be substantial. While we continually strive to comply with these complex requirements, interpretations of the applicability of these laws to marketing and billing practices are constantly evolving and even an unsuccessful challenge could cause adverse publicity and be costly to respond to, and thus could harm our business and prospects. Our failure to comply with applicable laws could result in various adverse consequences that could have a material adverse effect upon our business, including the exclusion of our products and services from government programs and the imposition of civil or criminal sanctions.
Some of our activities may subject us to risks under the Foreign Corrupt Practices Act and similar anti-bribery laws in non-U.S. jurisdictions.
Many countries in which we or our distributors offer our tests have regulations prohibiting providers, as well as medical and in vitro diagnostic device manufacturers, from offering or providing a benefit to a healthcare professional in order to induce business. In situations involving healthcare providers employed by public or state-funded institutions or national healthcare services, violation of local anti-corruption or anti-gift laws may also constitute a violation of the FCPA.
The FCPA prohibits any U.S. individual, business entity or employee of a U.S. business entity from offering or providing, directly or through a third party, including the distributors we rely on in certain markets, anything of value to a foreign government official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. We are also required to maintain accurate information and control over sales and distributors’ activities that may fall within the purview of the FCPA, its books and records provisions and its anti-bribery provisions. Other countries, including the U.K. and other Organisation for Economic Co-operation and Development (“OECD”) Anti-Bribery Convention members, have similar extraterritorial anti-corruption laws.
Any violation of these laws, or allegations of such violations, by us or any of our commercial partners could disrupt our operations, involve significant management distraction, cause us to incur significant costs and expenses, including legal fees, and result in a material adverse effect on our business. We could also suffer severe penalties, including criminal and civil penalties, debarment from public procurement, disgorgement and other remedial measures.
Failure to comply with privacy, security, and consumer protection laws and regulations could result in fines, penalties and damage to our reputation and have a material adverse effect on our business.
We are subject to a number of foreign, federal and state laws and regulations protecting the use, disclosure, and confidentiality of certain patient health and personal information, including patient records, and restricting the use and disclosure of that protected information, including state breach notification laws, the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, the European Union’s General Data Protection Regulation, the U.K. Data Protection Act and the U.K. GDPR, and the California Consumer Privacy Act, among others.
38
HIPAA extensively regulates the use and disclosure of individually identifiable health information, known as “protected health information,” and require covered entities, including health plans and most health care providers, to implement administrative, physical and technical safeguards to protect the security of such information. Covered entities must report breaches of unsecured protected health information to affected individuals without unreasonable delay and notification must also be made to the U.S. Department of Health & Human Services, Office for Civil Rights (the “OCR”) and, in certain situations involving large breaches, to the media. Various U.S. state laws and regulations may also require us to notify affected individuals and state agencies in the event of a data breach involving individually identifiable information.
Violations of the HIPAA privacy and security regulations may result in criminal and civil penalties. The OCR enforces the regulations and performs compliance audits. In addition to enforcement by OCR, state attorneys general are authorized to bring civil actions seeking either injunction or damages in response to violations that threaten the privacy of state residents. We follow and maintain a HIPAA compliance program, which we believe complies with the HIPAA privacy and security regulations, but there can be no assurance that OCR or other regulators will agree. The HIPAA privacy regulations and security regulations have and will continue to impose significant costs on us in order to comply with these standards.
We also remain subject to state privacy-related laws, such as the CCPA, that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties.
We utilize our patient adherence program to communicate with patients who are existing or potential users of our products and services for various business purposes. These activities could subject us to laws, rules and regulations relating to communications with consumers, such as the CAN-SPAM Act and the TCPA. Despite our compliance efforts, we could face allegations that we have violated these laws, rules and regulations as we have in the past. Even if such allegations are without merit, we could face liability and harm to our reputation.
We are also subject to laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may be more onerous than corresponding U.S. laws, including in particular the laws of Europe.
For instance, the GDPR applies across the European Union and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for non-compliance. The GDPR also requires companies processing personal data of individuals residing in the European Union to comply with EU privacy and data protection rules, even if we do not have a physical presence in the European Union. Noncompliance could result in the imposition of fines, penalties, or orders to stop noncompliant activities.
These laws and regulations, in addition to similar laws and regulations being enacted by other states and counties, impose stringent cybersecurity standards and potentially significant non-compliance penalties, involve the expenditure of significant resources, the investment of significant resources and the investment of significant time and effort to comply. As these laws and regulations continue develop in the United States and internationally, we may be required to expend significant time and resources in order to update existing processes or implement additional mechanisms as necessary to ensure compliance with such cybersecurity laws.
39
Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to comply with the rules and regulations of the CMS, FDA, and other comparable foreign regulatory authorities; provide true, complete and accurate information to such regulatory authorities; comply with manufacturing and clinical laboratory standards; comply with healthcare fraud and abuse laws in the U.S. and similar foreign laws; or report financial information or data accurately or to disclose unauthorized activities to us. In particular, research, sales, marketing, education, and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices, as well as off-label product promotion. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of participant recruitment for clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We maintain a global compliance program, including a code of business conduct and ethics and processes and systems for reporting, reviewing and remediating allegations of potential non-compliance or other misconduct, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. Even if it is later determined after an action is instituted against us that we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions, and have to divert significant management resources from other matters.
We expect to rely on third parties to conduct any future studies of our technologies that may be required by the FDA or other U.S. or foreign regulatory bodies, and those third parties may not perform satisfactorily.
We expect to rely on third parties, such as contract research organizations, medical institutions and clinical investigators to conduct studies of our technologies that may be required by the FDA or other U.S. or foreign regulatory bodies. Our reliance on these third parties for clinical development activities will reduce our control over these activities. These third parties may not complete activities on schedule or conduct studies in accordance with regulatory requirements or our study design. Our reliance on these third parties will not relieve us of our requirement to prepare, and ensure our compliance with, various procedures required under good clinical practices, even though third-party contract research organizations may prepare and comply with their own, comparable procedures. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our studies may be extended, delayed, suspended or terminated, the study data may be invalidated, and we may not be able to obtain a required regulatory approval.
Changes in tax laws or regulations or exposure to tax liabilities could adversely affect our financial condition and results of operations.
We are subject to tax in multiple U.S. tax jurisdictions and in foreign tax jurisdictions as we continue to expand internationally. As we grow, the development of our tax strategies requires additional expertise and may impact how we conduct our business. Our future effective tax rates could be unfavorably affected by changes in, or interpretations of, tax rules and regulations in the jurisdictions in which we do business or by changes in the valuation of our deferred tax assets and liabilities. Furthermore, we provide for certain tax liabilities that involve significant judgment. We are subject to the examination of our tax returns by federal, state and foreign tax authorities, which could focus on our intercompany transfer pricing methodology as well as other matters. If our tax strategies are ineffective or we are not in compliance with domestic and international tax laws, our financial position, operating results and cash flows could be adversely affected.
40
Risks Relating to Product Development, Commercialization, and Sales of our Products
The success of our Cologuard test, our Precision Oncology tests, and any other screening or diagnostic product or service we offer or develop will depend on the degree of market acceptance by healthcare providers, patients, healthcare payers, and others in the medical community.
Our products and services may not gain market acceptance by healthcare providers, healthcare payers, and others in the medical community. The degree of market acceptance of our Cologuard test, our precision oncology tests, and other products and services that we offer will depend on a number of factors, including:
•demonstrated performance and utility;
•price;
•the availability and attractiveness of alternative tests;
•the willingness of healthcare providers to prescribe our products and services;
•the ease of use of our ordering process for healthcare providers; and
•adequate third-party coverage or reimbursement.
Our assumptions regarding the market opportunity for our products or services may not prove true. For example, we estimate the potential market opportunity for our Cologuard test assuming, among other things, the size of the screening population, the adoption rate in the screening population and a three-year screening interval. Although ACS guidelines and others recommend a three-year screening interval for our Cologuard test and CMS has determined that Medicare will cover the test at this interval, the label for our Cologuard test does not specify a three-year interval and healthcare providers, healthcare payers, the FDA, and other regulators and opinion leaders could recommend a different interval. Further, patients may not adhere to any recommended testing interval.
Recommendations, guidelines, and quality metrics issued by various organizations may significantly affect payers’ willingness to cover, and healthcare providers’ willingness to prescribe or order, our products.
Securing influential recommendations, inclusion in healthcare guidelines, and inclusion in quality measures are keys to our healthcare provider and payer engagement strategies. These guidelines, recommendations, and quality metrics may shape payers’ coverage decisions and healthcare providers’ cancer screening procedures.
The USPSTF, a panel of primary care providers and epidemiologists and other national experts funded by the U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality, makes influential recommendations on clinical preventive services. USPSTF updates its screening recommendations periodically, approximately every five to eight years. The USPSTF's most recent recommendation statement for colorectal cancer screening gave an “A” grade to colorectal cancer screening starting at age 50 and continuing until age 75 and gave a “B” grade to colorectal cancer screening for ages 45 to 49. Any update to the USPSTF recommendations that may have the effect of reducing screening, that does not include FIT-DNA in a favorable manner, or that adds new technologies could have a material adverse effect on our business.
Maintaining a high USPSTF recommendation for our Cologuard test may have certain potentially significant implications. For example, the ACA mandates that certain non-grandfathered health insurers cover evidence-based items or services that have in effect a rating of “A” or “B” in the current recommendations of USPSTF without imposing any patient cost-sharing. Similarly, federal regulations require that Medicare Advantage plans cover “A” or “B” graded preventive services without patient cost-sharing. Following the updated 2016 USPSTF recommendation statement, CMS issued an updated Evidence of Coverage notice for Medicare Advantage plans that affirms such plans must include coverage of our Cologuard test every three years without patient cost-sharing. While we believe the ACA Mandate requires certain health insurers to cover our Cologuard test for individuals between the ages of 45 and 75 without patient cost-sharing, some health insurers have disagreed. Enforcement of the ACA Mandate is difficult and depends on state, federal, or other third-party enforcement actions that we do not control. Further, a court or regulatory agency may agree with arguments that have been made, or that may in the future be made, by insurers and determine that the ACA Mandate does not require that they cover our Cologuard test or future tests we may develop or may otherwise interpret the ACA Mandate in a manner unfavorable to us. Also, Congress may modify or repeal all or part of the ACA, and any such modification or repeal may repeal or limit the ACA Mandate for preventive services. Additionally, the ACA has also been the subject of various legal challenges and, if the plaintiffs are successful in any such challenges, insurance coverage for our Cologuard test or future tests we develop could be materially and adversely affected. If for any of these reasons the ACA Mandate ceases to require coverage of our Cologuard test or future tests we may develop or we are otherwise unable to secure effective enforcement of such mandate, our business prospects may be adversely affected.
41
The healthcare industry in the U.S. has experienced a trend toward cost containment and value-based purchasing of healthcare services. Some government and private payers are adopting pay-for-performance programs that differentiate payments for healthcare services based on the achievement of documented quality metrics, cost efficiencies, or patient outcomes. Payers may look to quality measures such as the NCQA, HEDIS, and the CMS Medicare Advantage Star Ratings to assess quality of care. These measures are intended to provide incentives to service providers to deliver the same or better results while consuming fewer resources. Our Cologuard test has been included in NCQA's HEDIS measures since 2017 and in CMS's Medicare Advantage Star Ratings since 2018. If for some reason our Cologuard test was removed from or not included in HEDIS, the Star Ratings, or other quality metrics, payers may be less inclined to reimburse our Cologuard test at adequate levels, if at all, which could adversely impact our business. Additionally, if our Cologuard test was removed from or not included in HEDIS, the Star Ratings, or other quality metrics, healthcare providers may not earn quality credit for prescribing our Cologuard test and therefore may be less inclined to do so. If our Cologuard test fails to maintain its current position within any updated USPSTF colorectal cancer screening recommendations, our Cologuard test may, as a result, become excluded from the HEDIS measures and the Star Ratings.
We expect to continue to make significant investments in our research and development efforts, which may not be successful.
We expect to incur significant expenses on development efforts to improve our current products and develop a pipeline for future products and services, but such efforts may not be successful. Developing new or improved cancer tests is a speculative and risky endeavor. Candidate products and services that may initially show promise may fail to achieve the desired results in larger clinical studies or may not achieve acceptable levels of clinical accuracy. Results from early studies or trials are not necessarily predictive of future clinical study or trial results, and interim results of a trial are not necessarily indicative of final results. From time to time, we may publicly disclose then-available data from clinical studies before the studies are complete, and the results and related findings and conclusions may be subject to change following the final analysis of the data related to the particular study or trial. As a result, such data should be viewed with caution until the final data are available. Additionally, such data from clinical studies are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment and/or follow-up continues and more patient data become available. Significant adverse differences between initial or interim data and final data could significantly harm our reputation and business prospects.
Any cancer screening or diagnostic test we develop will need to demonstrate in clinical studies a high level of accuracy. Because cancer screening tests seek to identify relatively rare occurrences, if in a clinical study a candidate product or service fails to identify even a small number of cancer cases, the sensitivity rate may be materially and adversely affected and we may have to abandon the candidate product or service. Any cancer diagnostic test we develop will need to address an unmet medical need with accurate performance and utility.
We may need to explore a number of different biomarker combinations, alter our candidate products or platform technologies, and repeat clinical studies before we identify a potentially successful candidate. We may need to acquire, whether through purchase, license or otherwise, technologies owned by third parties, and we may not be able to acquire such technologies on commercially reasonable terms or at all. We also require human sample types, such as blood, tissue, and stool for our research and product development, which may not be available to us on a timely basis or commercially reasonable terms. Our inability to negotiate access to such clinical samples or the ability of other laboratories or our competitors to secure access to these samples before us could limit or delay our ability to research, develop and commercialize future products. Product development is expensive, may take years to complete, and can have uncertain outcomes. Failure can occur at any stage of development. If, after development, a candidate product or service appears successful, we may, depending on the nature of the product or service, still need to obtain FDA and other regulatory clearances or approvals before we can market it. There can be no guarantee that the FDA would clear or approve any future product or service we may develop. 
Even if the FDA and other regulatory authorities clear or approve a new product or service we develop, we would need to commit substantial resources to commercialize, sell and market it before it could be profitable, and the product or service may never be commercially viable. In developing a test, we must make numerous assumptions regarding the commercial viability of a test, including with respect to healthcare providers’ and patients’ interest in a test, payers’ willingness to pay for a test, our costs to perform a test, and availability and attractiveness of competing offerings. Frequently, we must make those assumptions many years before a test is ready for clinical use.
If we determine that any of our current or future development programs is unlikely to succeed, we may abandon it without any return on our investment into the program. We may need to raise significant additional capital to bring any new products or services to market, which may not be available on acceptable terms, if at all.
42
Our dependence on distributors for sales in many markets outside of the U.S. could limit or prevent us from selling our tests in those markets and impact our revenue.
As of December 31, 2023, we have entered into exclusive distribution agreements for the sale of our Oncotype tests with distributors covering dozens of countries. We may enter into other similar arrangements to distribute our tests in other countries in the future. We intend to continue growing our business internationally, and to do so we may need to attract additional distributors to expand the territories in which we sell our tests. Despite contractual obligations, distributors may not commit the necessary resources to market and sell our tests to the level of our expectations. If current or future distributors do not perform adequately, or we are unable to enter into or maintain arrangements with distributors to market our tests in particular geographic areas, we may not realize long-term international revenue growth. Additionally, local laws may make it very difficult or costly for us to terminate or replace distributors, and local public procurement law may complicate providing our centralized laboratory services through a distributor. Furthermore, our revenue from distributors could be negatively impacted as a result of changes in business cycles, business or economic conditions, coverage determinations, reimbursement rates, changes in foreign currency exchange rates that make our tests more expensive in our distributors’ local currencies, or other factors that could affect their ability to pay us for tests on a timely basis or at all.
Risks Relating to our Intellectual Property
We rely on strategic collaborative and licensing arrangements with third parties to develop critical intellectual property. We may not be able to successfully establish and maintain such intellectual property.
The development and commercialization of our products and services rely, directly or indirectly, upon strategic collaborations and licensing agreements with third parties. We have collaborative and licensing arrangements with Mayo Foundation for Medical Education and Research, under which Mayo provides us with certain exclusive and non-exclusive intellectual property rights and ongoing product development and research and development assistance. In addition, we have licensing agreements with other partners that provide us with intellectual property and other business rights crucial to our product development and commercialization. We have incorporated licensed technology into our Cologuard test and expect to continue relying on, and incorporating, licensed technology into our pipeline products. Our dependence on licensing, collaboration, and other similar agreements with third parties may subject us to a number of risks. There can be no assurance that any current contractual arrangements between us and third parties or between our strategic partners and other third parties will be continued on materially similar terms and will not be breached or terminated early. Any failure to obtain or retain the rights to necessary technologies on acceptable commercial terms could require us to re-configure our products and services, which could negatively impact their commercial sale or increase the associated costs, either of which could materially harm our business and adversely affect our future revenues and ability to achieve sustained profitability.
In addition, establishing new strategic collaborations and licensing arrangements is difficult and time-consuming. Discussions with potential collaborators or licensors may not lead to the establishment of collaborations on favorable terms, if at all. To the extent we agree to work exclusively with one collaborator in a given area, our opportunities to collaborate with other entities could be limited. Potential collaborators or licensors may reject collaborations with us based upon their assessment of our financial, regulatory, or intellectual property position or other factors. Even if we successfully establish new collaborations, these relationships may never result in the successful commercialization of any product or service. In addition, the success of the projects that require collaboration with third parties will be dependent on the continued success of such collaborators. There is no guarantee that our collaborators will continue to be successful and, as a result, we may expend considerable time and resources developing products or services that will not ultimately be commercialized.
We may be subject to substantial costs and liability or be prevented from using technologies incorporated in our screening or diagnostic tests as a result of litigation or other proceedings relating to patent or other intellectual property rights.
Third parties may assert infringement or other intellectual property claims against our licensors, our licensees, our suppliers, our strategic partners, or us. We pursue a patent strategy that we believe provides us with a competitive advantage in the non-invasive early detection of cancer and pre-cancer as well as in the guidance of cancer treatment decisions, and is designed to maximize our patent protection against third parties. We have filed patent applications that we believe cover the methods we have designed and use in our Cologuard test to detect colorectal cancer and pre-cancer, our Oncotype tests to provide prognosis and guide treatment decisions, and for pipeline cancer tests still in development. In order to protect or enforce our patent and other intellectual property rights, we may have to initiate actions against third parties. Any actions regarding patents could be costly and time consuming and divert the attention of our management and key personnel from our business. Additionally, such actions could result in challenges to the validity, enforceability, or applicability of our patents.
43
Because the U.S. Patent and Trademark Office (“USPTO”) maintains patent applications in secrecy until a patent application publishes or the patent is issued, we have no way of knowing if others may have filed patent applications covering technologies used by our partners or us. Additionally, there may be third-party patents, patent applications, and other intellectual property relevant to our technologies that may block or compete with our technologies. From time to time we have received correspondence from third parties alleging to hold intellectual property rights that could block our development or commercialization of products. While none of these inquiries to date have had any material effect on us, we may receive inquiries in the future that could have a material effect on our business. Even if third-party claims are without merit, defending a lawsuit may result in substantial expense to us and may divert the attention of management and key personnel. In addition, we cannot provide assurance that we would prevail in any such suits to the extent necessary to conduct our business according to our strategic plan or that the damages or other remedies, if any, awarded against us would not be substantial. Claims of intellectual property infringement may require that we, or our strategic partners, enter into royalty or license agreements with third parties that may only be available on unacceptable terms, if at all. These claims may also result in injunctions against the further development and commercial sale of services or products containing our technologies, which would have a material adverse effect on our business, financial condition, and results of operations.
If we are unable to protect or enforce our intellectual property effectively, we may be unable to prevent third parties from using our intellectual property, which would impair any competitive advantage we may otherwise have.
We rely on patent protection as well as a combination of trademark, copyright, and trade secret protection and other contractual restrictions to protect our proprietary technologies and other intellectual property rights, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property, which may not be entirely successful, if at all. Additionally, certain of our patents began to expire in 2018. This loss of intellectual property protection may permit third parties to use certain intellectual property assets previously exclusively reserved for our use.
We cannot assure you that any of our currently pending or future patent applications will result in issued patents, and we cannot predict how long it will take for any such patents to be issued. Further, we cannot assure you that other parties will not challenge any patents issued to us or that courts or regulatory agencies will hold our patents to be valid or enforceable. We have been in the past, and may be in the future, the subject of pre- or post- grant proceedings challenges at the USPTO or international patent offices to determine priority of invention or validity of a patent, which could result in substantial cost to us as well as a possible adverse decision as to the priority of invention or validity of the patent involved. An adverse decision in any such challenge may result in the loss of rights under a patent or patent application. We cannot guarantee that we will be successful in defending challenges made against our patents and patent applications. Any successful third-party challenge to our patents could result in co-ownership of such patents with the third party or the unenforceability or invalidity of such patents.
Even where we have valid patents, third parties may be able to successfully design their products and services around those patents, such that their products and services do not infringe our patents. We may face competition internationally in jurisdictions where we do not have intellectual property protection. Our business may be adversely affected to the extent third parties are able to develop or commercialize competing products and services that do not infringe our patents. We may also be adversely affected to the extent third parties develop or commercialize competing products or services in countries where we did not apply for patents, where our patents have not issued, or where our intellectual property rights are not recognized or are poorly enforced.
We depend on trademarks to establish a market identity for our company and our products and services. To maintain the value of our trademarks, we may have to file lawsuits against third parties to prevent them from using trademarks confusingly similar to or dilutive of our registered or unregistered trademarks. We also may not obtain registrations for our pending or future trademark applications, and might have to defend our registered trademarks and pending applications from challenges by third parties. Enforcing or defending our registered and unregistered trademarks might result in significant litigation costs and, if we are unsuccessful, might result in damages, including the inability to continue using certain trademarks.
If patent regulations or standards are modified, such changes could have a negative impact on our business.
From time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress, or the USPTO may change the standards of patentability and validity of patents within the cancer screening and diagnostics space, and any such changes could have a negative impact on our business.
44
There have been several cases involving “gene patents” and diagnostic claims that have been considered by the U.S. Supreme Court that have affected the legal concept of subject matter eligibility by seemingly narrowing the scope of the statute defining patentable inventions.
Additionally, in December 2014 and again in 2019, the USPTO published revised guidelines for patent examiners to apply when examining process claims that narrow the scope of patentable subject matter. While these guidelines may be subject to review and modification by the USPTO over time, we cannot assure you that our patent portfolio will not be negatively impacted by the decisions mentioned above, rulings in other cases, or changes in guidance or procedures issued by the USPTO.
Additional substantive changes to patent law, whether new or associated with the America Invents Act — which substantially revised the U.S. patent system — may affect our ability to obtain, enforce or defend our patents. Accordingly, it is not clear what, if any, impact these substantive changes will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries, and our ability to enforce or defend our issued patents, all of which could have a material adverse effect on our business.
Risks Relating to our Securities
If we fail to maintain an effective system of internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and our stock price may be adversely impacted.
As a public company, we are subject to the Sarbanes-Oxley Act of 2002 and the related rules and regulations promulgated by the SEC, which require us, among other things, to maintain effective disclosure controls and procedures and internal control over financial reporting. Maintaining effective disclosure controls and procedures and internal control over financial reporting is necessary for us to produce reliable financial statements and to prevent fraud. In addition, we are required to disclose publicly for each fiscal year the conclusion of our management as to the effectiveness of our internal control over financial reporting and to report any material weaknesses identified by management. The Sarbanes-Oxley Act also requires that our management report on internal control over financial reporting be attested to by our independent registered public accounting firm. Although we determined that our internal control over financial reporting was effective as of December 31, 2023, we must continue to monitor and assess our internal control over financial reporting. If we identify material weaknesses in our internal control over financial reporting or if we are unable to assert that our internal control over financial reporting is effective when required in the future, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected.
Our stock price has fluctuated widely and is likely to continue to be volatile.
The market price for our common stock, like the securities of many other companies in the life sciences industry, has been highly volatile and could continue to be volatile and subject to significant price and volume fluctuations in response to various factors, many of which are beyond our control. Such factors include those listed in this “Item 1A. Risk Factors” section as well as:
•comments by securities analysts regarding our business or prospects;
•our quarterly operating performance;
•our issuance of common stock or other securities;
•our inability to accurately forecast future performance;
•our inability to meet analysts’ expectations;
•announcements by us or our competitors, including strategic actions, management changes, and material transactions; and
•general financial, domestic, international, economic, and market conditions, including overall fluctuations in the U.S. equity and credit markets, which may be unrelated or disproportionate to the operating performance of particular companies.
In the past, companies whose securities have experienced periods of volatility in market price have been subjected to securities class action or derivative litigation. In this regard, sharp drops in the market price of our common stock, could expose us to claims and litigation alleging violations of the securities laws or other related claims. Such litigation could result in substantial expenses and diversion of management’s attention and corporate resources, which would seriously harm our business, financial condition, and results of operations.
45
Our balance sheet includes significant amounts of goodwill and intangible assets. The impairment of a significant portion of these assets would negatively affect our results of operations.
Our balance sheet includes goodwill and intangible assets that represent 66% of our total assets at December 31, 2023, which are primarily associated with our acquisitions. On at least an annual basis, we assess whether there have been impairments in the carrying value of goodwill. In addition, we review intangible assets for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. If the carrying value of the asset is determined to be impaired, then it is written down to fair value by a charge to operating earnings. An impairment of a significant portion of goodwill or intangible assets could have a material negative effect on our results of operations.
Our significant indebtedness could adversely affect our business, financial condition, and results of operations and our ability to meet our payment obligations under such indebtedness and limit our ability to raise additional capital to fund our operations.
We have a significant amount of indebtedness. As of December 31, 2023, we had total indebtedness of $2.39 billion, including $2.34 billion in aggregate principal and interest due under our convertible senior notes and $50.0 million in borrowings under our Securitization Facility. We also had $4.4 million of letters of credit issued under our Revolver. This level of debt could have significant consequences on our future operations, including:
•increasing our vulnerability to adverse economic and industry conditions;
•making it more difficult for us to meet our payment and other obligations;
•making it more difficult to obtain any necessary future financing for working capital, capital expenditures, debt service requirements, or other purposes;
•requiring the dedication of a substantial portion of any cash flow from operations to service our indebtedness, thereby reducing the amount of cash flow available for other purposes, including capital expenditures;
•placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital than we have; and
•limiting our flexibility in planning for, or reacting to, changes in our business and the markets in which we compete.
Any of the above-listed factors could have an adverse effect on our business, financial condition, and results of operations and our ability to meet our payment obligations under our indebtedness.
Our ability to meet our payment and other obligations under our indebtedness depends on our ability to generate significant cash flow in the future. This, to some extent, is subject to general economic, financial, competitive, legislative, and regulatory factors as well as other factors that are beyond our control. We cannot assure you that our business will generate cash flow from operations, or that future borrowings will be available to us, in an amount sufficient to enable us to meet our payment obligations under our indebtedness and to fund other liquidity needs. If we are not able to generate sufficient cash flow to service our debt obligations, we may need to refinance or restructure our debt, sell assets, reduce or delay capital investments, share-settling the convertible notes or seek to raise additional capital, any of which events could have an adverse effect on our business, financial condition, and results of operations or be highly dilutive to our shareholders.
Our credit facilities contain certain customary representations, warranties, affirmative covenants and negative covenants, events of default as well as termination events which would permit the lenders to terminate upon the occurrence of certain specified events, including, among others, failure to pay amounts when due, certain defaults on other material indebtedness, certain judgments, a change of control and bankruptcy and insolvency events. A breach of any covenant in our credit facilities or the agreements and indentures governing any other indebtedness that we may have outstanding from time to time would result in a default under that agreement or indenture after any applicable grace periods. A default, if not waived, could result in (i) acceleration of the debt outstanding under the agreement and (ii) a default with respect to, and an acceleration of the debt outstanding under, other debt agreements. If that occurs, we may not be able to make all of the required payments or borrow sufficient funds to refinance such debt. Even if new financing were available at that time, it may not be on terms that are acceptable to us or terms as favorable as our current agreements. If our debt is in default for any reason, our business, results of operations and financial condition could be materially and adversely affected.
Item 1B. Unresolved Staff Comments
None.
46
Item 1C. Cybersecurity
Governance
Our Board of Directors administers its cybersecurity risk oversight function directly through our Audit and Finance Committee (“AFC”). Our AFC has primary responsibility for overseeing our risk management practices, programs, policies, and procedures related to data privacy, data protection, and cybersecurity. The AFC reviews and evaluates the processes utilized by management to identify and assess the material internal and external risks that may affect the Company's business. Our AFC regularly discusses with management, Company legal counsel, and the internal audit department the Company's major risk exposures. This includes potential financial impact on the Company and the steps taken to monitor and control those risks. Reviews with management are done annually which includes a summary of legal and regulatory compliance matters and risk management activities, including a review of the Company's cybersecurity program. Additionally, our AFC oversees the process by which our Board of Directors is informed regarding the risks facing the Company and coordinates with the Company's legal counsel to ensure our Board of Directors receives regular risk assessment updates from management.
The Chief Information Security Officer (“CISO”) is responsible for identifying, assessing and managing the Company’s risks from cybersecurity threats. The CISO has been with the Company for two years and has over 30 years of experience in technology, including 15 years in cybersecurity, and has held the CISO position at prior companies before joining Exact Sciences. The CISO is supported by a cybersecurity team that is staffed with experts in strategy, governance, risk management, compliance, engineering and development, security operations, and incident management.
The CISO provides our AFC with quarterly updates about our cybersecurity program and material risks. This includes updates on cybersecurity practices, programs, and the status of projects designed to strengthen internal cybersecurity and data protection.
Risk Management and Strategy
Processes for identifying and assessing cybersecurity risks
The CISO, with the support of the cybersecurity team and the owners of information technology across the business, monitors current events and trends related to cybersecurity and assesses any potential impact on current systems and operations. There are several processes in place to monitor and review our systems, including third-party solutions, to identify potential risks. Third-party service providers are required to notify us in the event of a cybersecurity incident within their systems, and annual reviews are conducted on the Company’s critical third-party vendors. Cybersecurity risks, threats, and incidents, including those from third-party service providers, are tracked and regularly provided to the CISO. Beginning in 2024, the Cybersecurity Leadership Team, which includes the CISO and executives from all business functions across the organization, meet at least quarterly to review and discuss cybersecurity risks facing the Company.
Processes for managing cybersecurity risks
The cybersecurity team tracks risks and incidents related to cybersecurity until the risk is mitigated to an acceptable level or fully remediated. When risks are identified, the cybersecurity team oversees mitigation plans with the risk owner which are communicated to necessary teams and remediation steps are taken.
Processes for incorporating cybersecurity risks into the overall risk management process
Our process for identifying, assessing, and managing risks related to cybersecurity is incorporated into our Enterprise Risk Management (“ERM”) process. The Risk Management team meets at least annually with cybersecurity leadership to discuss cybersecurity related risks identified and the potential likelihood and severity of each risk. Through the ERM process, cybersecurity risks are presented to the executive leadership team, including the CEO and CFO, as well as reported to the AFC.
Currently, we are not aware of any risks from cybersecurity threats, or from previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect the Company.
47
Item 2. Properties
As of December 31, 2023, our material facilities are as follows:
LocationPrimary FunctionTotal Square Feet (approx.)Leased or Owned
Madison, WisconsinResearch and development, corporate, operations and clinical laboratory1,581,000 Leased/Owned
Redwood City, CaliforniaResearch and development, corporate, operations and clinical laboratory243,000 Leased
See Note 15 in the Notes to Consolidated Financial Statements included in Part II, Item 8, “Consolidated Financial Statements and Supplementary Data” for further discussion surrounding our leased facilities.
Item 3. Legal Proceedings
From time to time we are a party to various legal proceedings arising in the ordinary course of our business. Legal proceedings, including litigation, government investigations and enforcement actions could result in material costs, occupy significant management resources and entail civil and criminal penalties. The information called for by this item is incorporated by reference to the information in Note 15 of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.
Item 4. Mine Safety Disclosures
Not applicable.
48
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is currently listed on the NASDAQ Capital Market under the symbol “EXAS.”
As of February 20, 2024, there were 181,530,967 shares of our common stock outstanding held by approximately 179 holders of record.
We have never paid any cash dividends on our common stock and do not plan to pay any cash dividends in the foreseeable future.
See Note 14 in the Notes to Consolidated Financial Statements for further information on our stock-based compensation plans.
The following graph compares the cumulative total return on our common stock with the cumulative total return of the NASDAQ Composite Index and the NASDAQ Biotechnology Index for the five-year period ended December 31, 2023. The graph assumes that the value of the investment in our stock and in each index was $100 on December 31, 2018 and assumes that all dividends were reinvested.
940
_________________________________
*    $100 invested on December 31, 2018 in stock or index including reinvestment of dividends.
Unregistered Sales of Equity Securities
Not applicable.
Item 6. Reserved
49

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Objective
The purpose of this Management's Discussion and Analysis is to better allow our investors to understand and view our Company from management's perspective. We are providing an overview of our business and strategy including a discussion of our financial condition and results of operations. The following discussion of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. We have omitted discussion of 2021 results where it would be redundant to the discussion previously included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of our Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 21, 2023.
Overview
Exact Sciences Corporation is a leading, global, advanced cancer diagnostics company. We have developed some of the most impactful tests in cancer screening and diagnostics, and we are currently working to develop additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.
Acquisitions
On September 12, 2023, we completed the acquisition of all of the outstanding capital stock of Resolution Bioscience, Inc. from Agilent Technologies, Inc. Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions through a CLIA certified lab based in Kirkland, Washington. The acquisition provides us with a high-quality blood-based therapy selection platform, complementing our comprehensive, tissue-based OncoExTra test.
2024 Priorities
Our top priorities for 2024 are to (1) focus on our people and customers, (2) bring our portfolio to life, and (3) magnify our impact.
Focus on our People and Customers
We want to continue to provide an exceptional experience for our patients and team members. We plan to improve customer relations by delivering simple and smooth workflows, providing communication that is clear and easy to understand, and providing results that are fast and accurate. We will also strive to ensure that Exact Sciences remains a great place to work by taking care of our people.
Bring our Portfolio to Life
We will focus on advancing new tests in our highest priority programs including colorectal cancer screening, MRD, and MCED. We plan to continue investing in our clinical trials to enhance existing products and bring new products to patients and providers, including obtaining FDA approval and securing coverage for our next generation Cologuard test.
Magnify our Impact
We are committed to improving lives through testing more people with our laboratory testing services in 2024 including expanding screening access to underserved populations. By testing more people, we will continue to expand our business in a cost-efficient manner allowing us to generate sustainable profits and increase shareholder value. Generating sustained profits will put the company in a better position to continue investing in life-changing cancer diagnostics to help achieve our mission.
50
Recent Developments and Trends
We estimate there are up to 60 million Americans that are not up to date with their colon cancer screenings. The capacity for screening colonoscopies in the U.S. is relatively fixed because it is dependent on the number of gastroenterologists available to perform the procedures. Health systems and health care providers are motivated to increase screening rates because they are measured as part of the HEDIS and Medicare Stars quality measure systems. More health systems are recognizing the opportunity to partner with Exact Sciences to address their screening rates and related quality measures. We aim to partner with them to implement our Cologuard test as an essential part of their screening toolkit and embed it in their workflows. We continue to implement more electronic ordering interfaces connecting health systems to Exact Sciences. Our Cologuard test market share is increasing in larger health systems, helping us screen more Americans.
We have an opportunity to impact even more lives by increasing adoption of Oncotype DX internationally. In 2023, we secured reimbursement for Oncotype DX in Japan. Breast cancer is the most common cancer among Japanese women, with about 45,000 new diagnoses of early-stage HR+, HER2- breast cancer each year. With reimbursement in place, we estimate that more than 100 women a day could learn if their cancer is likely to recur, and potentially be spared of unnecessary chemotherapy.
Results of Operations
Revenue. Our Screening revenue primarily includes laboratory service revenue from our Cologuard and PreventionGenetics tests while our Precision Oncology revenue includes laboratory service revenue from global Oncotype DX and therapy selection tests.
(Amounts in millions)
20232022Change
Screening$1,864.7 $1,424.7 $440.0 
Precision Oncology629.1 601.5 27.6 
COVID-19 Testing6.0 58.1 (52.1)
Total$2,499.8 $2,084.3 $415.5 
The increase in Screening revenue was mainly due to an increase in the number of completed Cologuard tests. The increase in completed Cologuard tests for the year ended December 31, 2023 was due to improved sales team productivity, growth across all customer segments, more patients rescreening with our Cologuard test, and improvements in patient adherence. The increase in Precision Oncology revenue was mainly due to an increase in the number of completed Oncotype DX breast cancer tests, both domestically and internationally. The increase in completed Oncotype DX tests was partially offset by a decrease of $19.4 million in revenues from our divested GPS test. We discontinued COVID-19 testing in the second quarter of 2023 due to lower demand, which led to a decrease in COVID-19 testing revenue.
During the years ended December 31, 2023 and 2022, revenue recognized from changes in transaction price was $25.2 million and $20.3 million, respectively. The revenue recognized from changes in transaction price is a result of improvements made in our billing systems and processes, including international contracting and collections.
We expect continuing revenue growth for our Cologuard and Oncotype tests subject to seasonal variability. Our revenues are affected by the test volume of our products, patient adherence rates, payer mix, the levels of reimbursement, our order to cash operations, and payment patterns of payers and patients.
Cost of sales (exclusive of amortization of acquired intangible assets). The increase in cost of sales for the year ended December 31, 2023 was primarily due to an increase in production costs and personnel expenses, which was a result of an increase in completed Cologuard and Oncotype tests and the corresponding increase in headcount to support the increase in tests completed. Cost of sales as a percentage of revenue was 26% and 28% for the years ended December 31, 2023 and 2022, respectively. The decrease in cost of sales as a percentage of revenue was due to improved efficiency in logistical arrangements and personnel as a result of increased volumes. We expect that cost of sales will generally continue to increase in future periods as a result of an increase in our existing laboratory testing services and as we launch our pipeline products. We also expect to see a corresponding increase in personnel and support services associated with this growth.
51
(Amounts in millions)
20232022Change
Production costs$393.4 $329.5 $63.9 
Personnel expenses182.0 160.1 21.9 
Facility and support services54.4 63.6 (9.2)
Stock-based compensation20.8 19.2 1.6 
Other cost of sales expenses3.6 2.0 1.6 
Total cost of sales expense$654.2 $574.4 $79.8 
Research and development expenses. The increase in research and development expenses for the year ended December 31, 2023 was primarily due to an increase in personnel expenses and facility and support services. These increases were a result of an increase in headcount and other resources needed to support our ongoing clinical trials and other research and development efforts. Our direct research and development costs, which represent a significant portion of our research and development expenses, are primarily related to clinical trial expenses for our BLUE-C clinical study, as well as research related expenses for the development of our MCED and MRD tests. The decrease in direct research and development costs for the year ended December 31, 2023 was primarily due to a reduction in BLUE-C clinical trial related costs as enrollment completed in December 2022. This decrease was offset by an increase in costs related to our MCED and MRD research activities, which increased throughout 2023. We expect that research and development expenses will generally continue to increase in future periods as we continue investing in new tests and enhancing current products.
(Amounts in millions)
20232022Change
Personnel expenses$180.3 $143.3 $37.0 
Direct research and development expenses129.7 158.7 (29.0)
Facility and support services64.1 45.5 18.6 
Stock-based compensation41.2 33.8 7.4 
Professional fees7.2 3.9 3.3 
Other research and development expenses3.4 8.2 (4.8)
Total research and development expenses$425.9 $393.4 $32.5 
Sales and marketing expenses. The decrease in sales and marketing expenses for the year ended December 31, 2023 was primarily due to a decrease in direct marketing costs and professional fees, personnel expenses, and facility and support services. The decrease in direct marketing costs and professional fees was driven by decreases in advertising spend and costs incurred under our promotion agreement with Pfizer Inc., which ended in the third quarter of 2022. The decrease in personnel expenses was due to a realignment of the sales force, which reduced overlap and increased productivity. The decrease in facility and support services was due to fewer costs incurred on commercial related information technology projects. We anticipate sales and marketing expenses will generally increase in future periods while continuing to decrease as a percentage of revenue over time, driven by the growth of Cologuard and Oncotype testing services and the introduction to new tests.
(Amounts in millions)
20232022Change
Personnel expenses$412.9 $444.9 $(32.0)
Direct marketing costs183.7 237.5 (53.8)
Stock-based compensation65.6 62.6 3.0 
Professional and legal fees44.7 49.0 (4.3)
Facility and support services16.9 48.6 (31.7)
Other sales and marketing expenses3.3 3.4 (0.1)
Total sales and marketing expenses$727.1 $846.0 $(118.9)
52
General and administrative expenses. The increase in general and administrative expenses for the year ended December 31, 2023 was primarily due to an increase in professional and legal fees, facility and support services, and other general and administrative expenses. We reached settlements with counterparties related to the Medicare Date of Service Rule Investigation and the Federal Anti-Kickback Statute and False Claims Act qui tam lawsuit in 2023, resulting in an expense of $36.2 million included within professional and legal fees for the year ended December 31, 2023, as further described in Note 15 of our consolidated financial statements included in this Annual Report on Form 10-K. The increase in facility and support services was incurred to support the growth in our operations. The increase in other general and administrative expenses was primarily due to a $38.6 million decrease in the gain recorded on our outstanding contingent consideration liabilities as a result of change in fair value, as further described in Note 7 of our consolidated financial statements included in this Annual Report on Form 10-K. We expect general and administrative expenses will generally continue to increase in future periods to support the growth in our existing and pipeline products, but we expect it will decrease as a percentage of revenue over time as we leverage efficiencies in our personnel and information technology systems.
(Amounts in millions)
20232022Change
Personnel expenses$395.6 $390.8 $4.8 
Facility and support services182.2 136.7 45.5 
Professional and legal fees171.9 116.4 55.5 
Stock-based compensation103.7 91.2 12.5 
Other general and administrative39.8 2.2 37.6 
Total general and administrative expenses$893.2 $737.3 $155.9 
Amortization of acquired intangible assets. Amortization of acquired intangible assets decreased to $92.2 million for the year ended December 31, 2023 compared to $97.5 million for the year ended December 31, 2022. This decrease was primarily due to a decrease in amortization on the intangible asset that was disposed of with the sale of the GPS test in August 2022 and the intangible assets that were impaired during the year ended December 31, 2022. This was partially offset by amortization of the intangible assets acquired as part of our acquisition of OmicEra Diagnostics, GmbH in May 2022 and Resolution Bioscience in September 2023.
Impairment of long-lived assets. Impairment of long-lived assets decreased to $0.6 million for the year ended December 31, 2023 compared to $16.0 million for the year ended December 31, 2022. The impairment charges recorded during the year ended December 31, 2023 included impairments to building leases at certain of our domestic locations. The impairment charges recorded during the year ended December 31, 2022 included an impairment to the supply agreement intangible asset acquired as part of the acquisition of Genomic Health, an impairment of the acquired developed technology intangible asset acquired as part of the acquisition of Paradigm Diagnostics, Inc. (“Paradigm”), and building leases at certain of our domestic locations.
Other operating income (loss). Other operating income (loss) increased to a gain of $78.4 million for the year ended December 31, 2023 compared to a loss of $13.2 million for the year ended December 31, 2022. The $78.4 million gain recorded for the year ended December 31, 2023 primarily relates to a $73.3 million contingent consideration gain and $3.1 million in additional consideration received from MDxHealth as a result of an amendment to the asset purchase agreement in August 2023. The $13.2 million loss for the year ended December 31, 2022 represents the loss on the sale of our GPS test to MDxHealth. The sale of the GPS test is further discussed in Note 18 of our consolidated financial statements included in this Annual Report on Form 10-K.
Investment income (loss), net. Investment income (loss), net increased to net investment income of $32.7 million for the year ended December 31, 2023 compared to a net investment loss of $19.4 million for the year ended December 31, 2022. The net investment loss for the year ended December 31, 2023 was primarily due to gains recorded on our marketable securities and investments in privately held companies. The net investment loss for the year ended December 31, 2022 was primarily due to losses recorded on our investments in privately held companies and marketable securities.
53
Interest expense. Interest expense decreased to $19.4 million for the year ended December 31, 2023 compared to $19.6 million for the year ended December 31, 2022. Interest expense recorded from our outstanding convertible notes totaled $13.2 million, which was partially offset by a net gain on settlement of convertible notes of $10.3 million for the year ended December 31, 2023. Interest expense recorded from our outstanding convertible notes totaled $16.1 million for the year ended December 31, 2022. The convertible notes are further described in Note 10 of our consolidated financial statements included in this Annual Report on Form 10-K.
Income tax benefit (expense). Income tax expense was $2.4 million for the year ended December 31, 2023 compared to a benefit of $9.1 million for the year ended December 31, 2022. Income tax expense for the year ended December 31, 2023 was primarily related to current foreign and state tax expense. The income tax benefit recorded during the year ended December 31, 2022 was primarily related to the future limitations on and expiration of certain Federal and State deferred tax assets, offset by current foreign and state tax expense.
Liquidity and Capital Resources
Overview
We have incurred losses since our inception, and have historically financed our operations primarily through public offerings of our common stock and convertible debt and through revenue generated by the sale of our laboratory testing services. We expect our operating expenditures to continue to increase to support future growth of our laboratory testing services, as well as an increase in research and development and clinical trial costs to support the advancement of our pipeline products and bringing new tests to market. We expect that cash, cash equivalents and marketable securities on hand at December 31, 2023, along with cash flows generated through our operations, will be sufficient to fund our current operations for at least the next twelve months based on current operating plans.
We may raise additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. If we are unable to obtain sufficient additional funds to enable us to fund our business plans and strategic investments, our results of operations and financial condition could be materially adversely affected, and we may be required to delay the implementation of our plans or otherwise scale back our operations. There can be no certainty that we will ever be successful in generating sufficient cash flow from operations to achieve and maintain profitability and meet all of our obligations as they come due.
Cash, Cash Equivalents and Marketable Securities
As of December 31, 2023, we had approximately $605.4 million in unrestricted cash and cash equivalents and approximately $172.3 million in marketable securities.
The majority of our investments in marketable securities consist of fixed income investments, and all are deemed available-for-sale. The objectives of this portfolio are to provide liquidity and safety of principal while striving to achieve the highest rate of return. Our investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer.
Cash Flows
(Amounts In millions)
20232022
Net cash provided by (used in) operating activities
$156.1 $(223.6)
Net cash provided by investing activities
49.7 74.1 
Net cash provided by financing activities159.8 76.5 
Operating activities
The increase in cash provided by operating activities for the year ended December 31, 2023 compared to the year ended December 31, 2022 was primarily due to an increase in revenue, a decrease in operating expenses as a percentage of revenue, and timing of payments on our accounts payable and accrued expenses. The increase in revenue was primarily driven by an increase in the number of completed Cologuard and Oncotype tests. Operating expenses as a percentage of revenue decreased for the year ended December 31, 2023, primarily due to cost saving measures implemented in the second half of 2022.
54
Investing activities
The decrease in cash provided by investing activities for the year ended December 31, 2023 compared to the year ended December 31, 2022 was due to several factors. Cash provided by sales and maturities of marketable securities decreased by $89.9 million as we invested in more money market accounts due to changes in interest rates and macroeconomic conditions. The decrease was also attributable to a net cash outflow of $52.4 million from the acquisition of Resolution Bioscience in September 2023 compared to payments related to our business combinations of $14.7 million in 2022. The decrease in cash provided by investment activities was offset by a decrease of $90.3 million in purchases of property, plant and equipment due to completion of our clinical lab and warehouse expansions in 2022, and a decrease of $26.3 million in our spend in privately held companies. Additionally, we received $19.8 million in proceeds from maturities and sales of investments in privately held companies for the year ended December 31, 2023, compared to proceeds of $25.0 million from the sale of the GPS test for the year ended December 31, 2022.
Financing activities
The increase in cash provided by financing activities for the year ended December 31, 2023 compared to the year ended December 31, 2022 was primarily due to proceeds of $138.0 million from the issuance of convertible notes in the first quarter of 2023. Cash provided by financing activities for the year ended December 31, 2022 was primarily due to proceeds of $50.0 million from our accounts receivable securitization facility in the second quarter of 2022.
Material Cash Requirements
Convertible Notes
As of December 31, 2023, we had outstanding aggregate principal of $2.34 billion on our convertible notes with maturity dates of January 15, 2025 (the “2025 Notes”), March 15, 2027 (the “2027 Notes”), March 1, 2028 Notes (the “2028 Notes”), and March 1, 2030 (the “2030 Notes” and collectively, the “Notes”). The 2025 Notes have an outstanding principal balance of $249.2 million. The 2027 Notes have an outstanding principal balance of $563.8 million. The 2028 Notes have an outstanding principal balance of $949.0 million. The 2030 Notes have an outstanding principal balance of $573.0 million. The 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes accrue interest at a fixed rate of 1.0%, 0.375%, 0.375%, and 2.0% per year, respectively, which is payable in cash semi-annually in arrears each year until the maturity date. See Note 10 in the Notes to Consolidated Financial Statements for further information. Until the six-months immediately preceding the maturity date of the applicable series of Notes, each series of Notes is convertible only upon the occurrence of certain events and during certain periods. The Notes will be convertible into cash, shares of our common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of our common stock, at our election. It is our intent and policy to settle all conversions through a combination settlement.
Lease Commitments
We act as lessee in our lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles, and certain laboratory and office equipment, and finance leases for certain equipment and vehicles. As of December 31, 2023, we had minimum operating and finance lease payments of $239.7 million and $13.2 million, respectively. Of the outstanding operating lease obligations, $39.5 million matures in 2024, and the remaining $200.3 million will mature in periods subsequent to 2024. Of the outstanding finance lease obligations, $5.0 million matures in 2024, and the remaining $8.2 million will mature in periods subsequent to 2024. See Note 15 in the Notes to Consolidated Financial Statements for further information.
Contingent Consideration
Certain of our business combinations and asset acquisitions involve potential payment of future consideration that is contingent upon the achievement of certain regulatory and product revenue milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date for business combinations. A liability is recorded when achievement of a milestone becomes probable for asset acquisitions.
55
As a result of the acquisition of Thrive in January 2021, an additional $450.0 million would be payable in cash to Thrive’s former shareholders upon the achievement of two discrete events, FDA approval and CMS coverage, for $150.0 million, and $300.0 million, respectively, in relation to the development and commercialization of a blood-based, multi-cancer early detection test. The projected fiscal year of payment range is from 2028 to 2030. See Note 18 in the Notes to Consolidated Financial Statements for further information.
As a result of the acquisition of Ashion in April 2021, an additional $20.0 million would be payable in cash to Ashion's former shareholders upon the commercial launch, on or before the tenth anniversary of the acquisition of Ashion, of a test for MRD detection and/or treatment. The projected fiscal year of payment is 2025. An additional $30.0 million would be payable in cash to Ashion's former shareholders upon reaching cumulative revenues of $500.0 million from MRD products, on or before the fifth anniversary of the acquisition of Ashion. See Note 18 in the Notes to Consolidated Financial Statements for further information.
As a result of the acquisition of the proprietary Targeted Digital Sequencing (“TARDIS”) technology from The Translational Genomics Research Institute (“TGen”) in January 2021, an additional $45.0 million would be payable in cash to TGen upon the achievement of cumulative product revenue milestones related to MRD detection and/or treatment. Milestone payments of $10.0 million and $35.0 million would be payable upon achieving $100.0 million and $250.0 million, respectively, in cumulative revenue on or before December 31, 2030. See Note 18 in the Notes to Consolidated Financial Statements for further information.
License Agreements
We license certain technologies that are, or may be, incorporated into our technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require us to pay single-digit royalties and sales-based milestone payments based on net revenues received using the technologies and may require minimum royalty amounts or maintenance fees.
The timing and amounts of any such royalty or milestone payments is unknown due to the uncertain nature of product development and associated net revenues using these technologies. Refer to Note 11 and Note 18 in the Notes to Consolidated Financial Statements for further information.
Capital Expenditures
We expect to continue to invest in capital expenditures to support the growth of our existing products and our research and development activities. Our current projects include the build out of certain lab automation projects at our existing facilities in Madison, WI. These projects are expected to be completed in 2024 and beyond. We also have assets under construction related to leasehold and building improvements, laboratory equipment, and software projects. We expect to incur approximately $150.0 million in capital expenditures in 2024.
Sources of Cash
We have access to a revolving line-of-credit (the “Revolver”) of up to $150.0 million, which had its maturity date extended to November 2025 through an amended agreement in October 2022. The Revolver is collateralized by certain marketable securities which must continue to maintain a minimum market value of $150.0 million. PNC Bank, National Association has issued letters of credit totaling $4.4 million, which reduces the amount available for cash advances under the line of credit to $145.6 million. As of December 31, 2023, we had not drawn any funds under the Revolver. In addition to the Revolver, we have access to $150.0 million under an accounts receivable securitization facility (the “Securitization Facility”), which expires in June 2024 at which point we will need to repay the outstanding balance or refinance the Securitization Facility. Any refinancing is subject to market conditions and other factors, including evaluating other financing options available to us. The amount that we may borrow is determined based on the amount of qualifying accounts receivable at a given point in time. The Securitization Facility is collateralized by our accounts receivable. As of December 31, 2023, we had $50.0 million outstanding under the Securitization Facility, which is the minimum amount that we must borrow under the terms of the Securitization Facility. The Revolver and Securitization Facility are further described in Note 9 of our consolidated financial statements included in this Annual Report on Form 10-K.
56
We believe that our anticipated income from operations, cash and marketable securities on hand, and borrowing capacity under our Revolver and Securitization Facility will be adequate to meet our commitments for at least 12 months from the issuance of this Annual Report on Form 10-K. However, we may need to raise additional capital to fully fund our current business plan and meet all commitments discussed above. We continuously evaluate our liquidity and capital resources, including access to external capital, in light of current economic and market conditions and our operational performance.
As of December 31, 2023, we had no off-balance sheet arrangements.
Net Operating Loss Carryforwards
As of December 31, 2023, we had federal, state, and foreign net operating loss (“NOL”) carryforwards of approximately $402.9 million, $66.0 million, and $10.4 million, respectively. We also had federal and state research tax credit carryforwards of approximately $70.9 million and $33.0 million, respectively. The net operating loss and tax credit carryforwards will expire at various dates through 2041, if not utilized. The Internal Revenue Code and applicable state laws impose substantial restrictions on a corporation’s utilization of net operating loss and tax credit carryforwards if an ownership change is deemed to have occurred. Additionally, tax law limitations may result in our NOLs expiring before we have the ability to use them. The Tax Cuts and Jobs Act (H.R. 1) of 2017 limits the deduction for NOLs to 80% of current year taxable income and provides for an indefinite carryover period for federal NOLs. Both provisions are applicable for losses arising in tax years beginning after December 31, 2017. As of December 31, 2023, we had $278.5 million of NOLs incurred after December 31, 2017. For these reasons, even if we attain profitability, our ability to utilize our NOLs may be limited, potentially significantly so.
A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before we are able to realize their benefit, or that future deductibility is uncertain. In general, companies that have a history of operating losses are faced with a difficult burden of proof on their ability to generate sufficient future income in order to realize the benefit of the deferred tax assets. We have recorded a valuation against our deferred tax assets based on our history of losses and current uncertainty as to timing of future taxable income. Given the future limitations on and expiration of certain Federal and State deferred tax assets, the recording of a valuation allowance resulted in a deferred tax liability of approximately $17.3 million remaining as of December 31, 2023, which is included in other long-term liabilities on our consolidated balance sheet.
Critical Accounting Policies and Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that are believed to be appropriate under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
While our significant accounting policies are more fully described in Note 1 in the Notes to Consolidated Financial Statements, we believe that the following judgments are most critical to aid in fully understanding and evaluating our reported financial results.
Revenue Recognition. We recognize revenues when we release an approved patient test result to the ordering healthcare provider, in an amount that reflects the consideration we expect to collect in exchange for those services. The amount of revenue we recognize is based on the established billing rates less contractual and other adjustments, which yields the unconstrained amount that we expect to ultimately collect.
57
We determine the amount we expect to ultimately collect using historical collections, established reimbursement rates, and other adjustments. The expected amount is typically lower than, if applicable, the agreed-upon reimbursement amount due to several factors, such as the amount of any patient co-payments, out-of-network payers, the existence of secondary payers, and claim denials. The consideration derived from our contracts is fixed when we contract with a direct bill payer as our ability to collect is not contingent on the customer’s ability to collect through their downstream billing efforts. A change in the estimated transaction price derived by the aforementioned inputs would ultimately impact the amount of revenue recognized during the period. For the years ended December 31, 2023, 2022, and 2021, we've recognized an upward or downward adjustment to revenues from a change in transaction price representing approximately 1% of prior year revenues. A 1% change in our estimated transaction price for revenue recognized for the year ended December 31, 2023 would result in an adjustment to revenue of approximately $25.0 million in 2024.
In the case of some of our agreements, the right to bill and collect exists prior to the receipt of a specimen and release of a test result to the ordering healthcare provider, which results in deferred revenue. The deferred revenue balance is generally relieved upon the release of the applicable patient’s test result to the ordering healthcare provider or as of the date the customer has surpassed the window of time in which they are able to exercise their rights for testing services. We believe these points in time represent our fulfillment of our obligations to the customer.
The quality of our billing operations, most notably those activities that relate to obtaining the correct information in order to bill effectively for services provided, directly impacts the collectability of our receivables and revenue estimates. As such, we continually assess the state of our order to cash operations in order to identify areas of risk and opportunity that allow us to appropriately estimate receivables and revenue. Upon ultimate collection, the aggregate amount received from payers and patients where reimbursement was estimated is compared to previous collection estimates and, if necessary, the transaction price is adjusted. Finally, should we later determine the judgments underlying estimated collections change, our financial results could be negatively impacted in future quarters.
Tax Positions. We record a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
We compute our provision for income taxes based on the statutory tax rates and tax planning opportunities available to us in the various jurisdictions that we operate. Judgment is required in evaluating our tax positions and determining our annual tax provision.
We have incurred significant losses since our inception and due to the uncertainty of the amount and timing of future taxable income, it may be necessary to record an allowance to reduce the tax assets we have recognized.
Management has determined that a valuation allowance of $465.8 million and $419.4 million at December 31, 2023 and 2022, respectively is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact our effective tax rate.
Acquired Intangible Assets. We acquire finite-lived intangible assets through our business combinations and asset acquisitions, which primarily consist of developed technology. As of December 31, 2023, our developed technology intangible assets have a carrying value of $559.2 million. Key assumptions used to value developed technology under the income approach include projected revenue growth, projected gross margin and operating expenses, discount rate, tax rate, and obsolescence factor. We believe that the estimates applied are based on reasonable assumptions, but the estimates are inherently uncertain. As a result, the actual results may differ from the assumptions and judgments used to determine fair value of the assets acquired, which could result in material impairment charges in the future. Determining the useful life of the developed technology also requires judgment and actual useful life may differ.
Certain of our acquisitions include the acquisition of indefinite-lived in-process research and development (“IPR&D”). As a result of the acquisition of Thrive, we recorded an IPR&D asset of $1.25 billion. There are major risks and uncertainties associated with IPR&D due to the regulatory approvals needed, which rely on the success of clinical trials that demonstrate product effectiveness. Key assumptions used to calculate the fair value of the IPR&D asset included inputs such as projected revenues, projected gross margin and operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success. We believe that the estimates applied are based on reasonable assumptions, but the estimates are inherently uncertain. As a result, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and material IPR&D impairment charges may occur in future periods.
58
Contingent Consideration Liabilities. Business combinations may include contingent consideration to be paid based on the occurrence of future events, such as the achievement of certain development, regulatory and sales milestones. Contingent consideration is a financial liability recorded at fair value at the acquisition date. We remeasure the fair value of outstanding contingent consideration liabilities at each reporting period.
The estimate of fair value contains uncertainties as it involves judgement about the likelihood and timing of achieving milestones as well as the present-value factor. A change in the assumptions made for probability of success, projected fiscal year of payment, and present-value factor could have a material impact on the estimated fair value. Our contingent consideration liability is primarily due to our acquisition of Thrive, which resulted in a contingent consideration liability of $352.0 million. Due to changes in macroeconomic conditions and a delay in the projected fiscal year of payment for the regulatory and product development milestones associated with our acquisition of Thrive, the weighted average present-value factor decreased from 6.2% as of December 31, 2022 to 5.8% as of December 31, 2023, and the fair value of the contingent consideration liability was remeasured from $284.1 million as of December 31, 2022 to $270.1 million as of December 31, 2023. Further changes in the key assumptions made in determining the fair value of the contingent consideration liability recorded related to the acquisition of Thrive could impact the estimated fair value as follows:
AssumptionUnit of Measure ChangeFair Value Impact (In Thousands)
Probability of success5%$15,000 
Projected fiscal year of payment1 Year14,900 
Present-value factor
1%14,400 
Impairment of Indefinite-Lived Assets. We test indefinite-lived assets for impairment on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Based on the qualitative assessment, if it is determined that the fair value of indefinite-lived intangible assets is more likely than not to be less than its carrying amount, the fair value will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Determining whether impairment indicators exist and estimating the fair value of our indefinite-lived intangible assets if necessary for impairment testing requires significant judgment. We performed our annual goodwill assessment using a qualitative assessment and concluded there were no impairments. Qualitative factors considered in this assessment included industry and market conditions, overall financial performance, and other relevant events and factors. We also elected to bypass the qualitative assessment and performed a quantitative assessment for our annual IPR&D assessment and concluded that there were no impairments for the year ended December 31, 2023. Key assumptions used to calculate the fair value of the IPR&D asset for the quantitative assessment included inputs such as projected revenues, projected gross margin, projected operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success.
Impairment of Long-Lived Assets. We evaluate the fair value of long-lived assets, which include property, plant and equipment, leases, finite-lived intangible assets, and investments in privately held companies, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. The review of qualitative factors requires significant judgement. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. We recorded impairment charges totaling $0.6 million during the year ended December 31, 2023 related to building leases on certain of our domestic facilities We recorded impairment charges totaling $16.0 million during the year ended December 31, 2022 related to the supply agreement intangible asset acquired as part of the combination with Genomic Health, the developed technology intangible asset acquired as part of the acquisition of Paradigm, and building leases at certain of our domestic locations. We recorded an impairment charge of $20.2 million during the year ended December 31, 2021 related to the supply agreement intangible asset acquired as part of the combination with Genomic Health. We utilized the income approach to measure the fair value of the acquired developed technology intangible asset, supply agreement intangible asset, and building leases, which required management to make estimates including revenue projections, cash flow projections, and discount rates. We believe that the estimates applied are based on reasonable assumptions, but the estimates are inherently uncertain. As a result, the eventual realized value of the impaired asset may vary from its fair value.
59
Recent Accounting Pronouncements
See Note 1 in the Notes to Consolidated Financial Statements for the discussion of Recent Accounting Pronouncements.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Risk
Our exposure to market risk is principally confined to our cash, cash equivalents and marketable securities and our outstanding variable-rate debt. We invest our cash, cash equivalents, and marketable securities in securities of the U.S. governments and its agencies and in investment-grade, highly liquid investments consisting of commercial paper, bank certificates of deposit, and corporate bonds, which as of December 31, 2023 and December 31, 2022 were classified as available-for-sale. We place our cash, cash equivalents, restricted cash, and marketable securities with high-quality financial institutions, limit the amount of credit exposure to any one institution, and have established investment guidelines relative to diversification and maturities designed to maintain safety and liquidity.
Based on a hypothetical 100 basis point decrease in market interest rates, the potential losses in future earnings, fair value of risk-sensitive financial instruments, and cash flows are immaterial, although the actual effects may differ materially from the hypothetical analysis. While we believe our cash, cash equivalents, restricted cash, and marketable securities do not contain excessive risk, we cannot provide absolute assurance that, in the future, our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash, cash equivalents, restricted cash, and marketable securities at one or more financial institutions that are in excess of federally insured limits. Given the potential instability of financial institutions, we cannot provide assurance that we will not experience losses on these deposits. We do not utilize interest rate hedging agreements or other interest rate derivative instruments.
As of December 31, 2023, we had $50.0 million in outstanding variable rate debt. Based on a hypothetical 100 basis point increase in market interest rates, annual interest expense on variable rate debt as of December 31, 2023 would increase by approximately $0.5 million. If we were to draw down additional amounts under either our Revolving Loan or Securitization Facility, the impact of increases in prevailing market interest rates would be even greater. All of our other significant interest-bearing liabilities bear interest at fixed rates and therefore are not subject to fluctuations in market interest rates; however, because these interest rates are fixed, we may be paying a higher interest rate, relative to market, in the future if circumstances change.
Foreign Currency Risk
The functional currency for most of our international subsidiaries is the U.S. dollar, and as a result we are not subject to material gains and losses from foreign currency translation of the subsidiary financial statements. Substantially all of our revenues are recognized in U.S. dollars, although a small portion is denominated in foreign currency as we continue to expand into markets outside of the U.S. Certain expenses related to our international activities are payable in foreign currencies. As a result, factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets will affect our financial results.
We enter into forward contracts to mitigate the impact of adverse movements in foreign exchange rates related to the re-measurement of monetary assets and liabilities and hedge our foreign currency exchange rate exposure. As of December 31, 2023, we had open foreign currency forward contracts with notional amounts of $39.5 million. Although the impact of currency fluctuations on our financial results has been insignificant in the past, there can be no guarantee that the impact of currency fluctuations related to our international activities will not be material in the future.

60
Item 8. Consolidated Financial Statements and Supplementary Data
EXACT SCIENCES CORPORATION

61
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Exact Sciences Corporation
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Exact Sciences Corporation and its subsidiaries (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of operations, of comprehensive loss, of stockholders’ equity and of cash flows for each of the three years in the period ended December 31, 2023, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
62
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Valuation of Net Accounts Receivable - Variable Consideration
As described in Note 1 to the consolidated financial statements, the Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard and Oncotype tests. The Company’s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company’s transaction price is comprised of fixed and variable consideration and is allocated entirely to a single performance obligation defined as the point in time an approved patient test result is released to the ordering healthcare provider. Fixed consideration exists in arrangements where the Company has agreed to provide laboratory testing services to a customer for a specified rate and is expected to be collected in full at that rate. Variable consideration is primarily derived from payer and patient billing and can be impacted by several factors such as the amount of contractual adjustments, any patient co-payments, deductibles or patient adherence incentives, the existence of secondary payers, and claim denials. Management estimates the amount of variable consideration using the expected value method and is the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, management considers several factors, such as historical collections experience, current contractual and statutory requirements, customer mix, patient insurance eligibility and payer reimbursement contracts, and known or anticipated reimbursement trends not yet reflected in the data. The Company’s net accounts receivable as of December 31, 2023 was $203.6 million.
The principal considerations for our determination that performing procedures relating to the valuation of net accounts receivable - variable consideration is a critical audit matter are (i) the significant judgment by management due to the significant measurement uncertainty when developing the estimated amount of variable consideration; and (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating audit evidence obtained related to management’s estimate of the amount of variable consideration.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s estimate of the amount of variable consideration, including controls over management’s methodology and data used in developing the estimate. These procedures also included, among others (i) testing management’s process for developing the estimated amount of variable consideration; (ii) evaluating the appropriateness of the method used by management; (iii) testing the completeness and accuracy of the underlying historical collection data used in the method; (iv) testing, on a sample basis, the accuracy of revenue transactions and cash collections from the historical billing and collection data used in management’s method; and (v) performing a retrospective comparison of actual cash collected subsequent to year-end to evaluate the reasonableness of the prior year estimate of the amount of variable consideration.
In-Process Research and Development (IPR&D) Annual Impairment Assessment
As described in Notes 1 and 6 to the consolidated financial statements, the Company’s IPR&D intangible asset balance was $1,250 million as of December 31, 2023. Capitalized IPR&D projects are tested for impairment annually in the fourth quarter, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, and upon successful completion of the project. The Company performed a quantitative assessment as part of its annual IPR&D impairment analysis in the fourth quarter of 2023 under which it determined that the fair value exceeded the carrying value and no impairment loss was recorded. The value assigned to acquired IPR&D is determined using the multi-period excess earnings method approach, which utilizes significant unobservable inputs (Level 3 inputs) including projected revenues, projected gross margin, projected operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success.
63
The principal considerations for our determination that performing procedures relating to the IPR&D annual impairment assessment is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the IPR&D asset; (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management’s multi-period excess earnings method and significant assumptions related to projected revenues, projected gross margin, projected operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s IPR&D annual impairment assessment, including controls over the valuation of the IPR&D asset. These procedures also included, among others (i) testing management’s process for developing the fair value estimate of the IPR&D asset; (ii) evaluating the appropriateness of the multi-period excess earnings method used by management; (iii) testing the completeness and accuracy of the underlying data used in the multi-period excess earnings method; and (iv) evaluating the reasonableness of the significant assumptions used by management related to projected revenues, projected gross margin, projected operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success. Evaluating management’s assumptions related to projected revenues, projected gross margin, projected operating expenses, tax rate, and probability of commercial success involved considering (i) internal and external market and industry data, and (ii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the multi-period excess earnings method, and (ii) the reasonableness of the discount rate and obsolescence factor assumptions.
/s/ PricewaterhouseCoopers LLP
Chicago, Illinois
February 21, 2024

We have served as the Company’s auditor since 2020.



64
EXACT SCIENCES CORPORATION
Consolidated Balance Sheets
(Amounts in thousands, except share data)

December 31, 2023
December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents$605,378 $242,493 
Marketable securities172,266 389,564 
Accounts receivable, net203,623 158,043 
Inventory127,475 118,259 
Prepaid expenses and other current assets85,627 73,898 
Total current assets1,194,369 982,257 
Long-term assets:
Property, plant and equipment, net698,354 684,756 
Operating lease right-of-use assets143,708 167,003 
Goodwill2,367,120 2,346,040 
Intangible assets, net1,890,396 1,956,240 
Other long-term assets, net177,387 90,577 
Total assets$6,471,334 $6,226,873 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$78,816 $74,916 
Accrued liabilities341,683 299,216 
Operating lease liabilities, current portion29,379 28,366 
Debt, current portion50,000 — 
Other current liabilities14,823 10,249 
Total current liabilities514,701 412,747 
Long-term liabilities:
Convertible notes, net2,314,276 2,186,106 
Long-term debt, less current portion— 50,000 
Other long-term liabilities335,982 352,459 
Operating lease liabilities, less current portion161,070 182,399 
Total liabilities3,326,029 3,183,711 
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at December 31, 2023 and December 31, 2022
— — 
Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—181,364,180 and 177,925,631 shares at December 31, 2023 and December 31, 2022
1,815 1,780 
Additional paid-in capital6,611,237 6,311,644 
Accumulated other comprehensive income (loss)
1,428 (5,236)
Accumulated deficit(3,469,175)(3,265,026)
Total stockholders’ equity3,145,305 3,043,162 
Total liabilities and stockholders’ equity$6,471,334 $6,226,873 
The accompanying notes are an integral part of these consolidated financial statements.
65
EXACT SCIENCES CORPORATION
Consolidated Statements of Operations
(Amounts in thousands, except per share data)

Year Ended December 31,
202320222021
Revenue$2,499,766 $2,084,279 $1,767,087 
Operating expenses:
Cost of sales (exclusive of amortization of acquired intangible assets)654,248 574,394 458,757 
Research and development425,882 393,418 385,646 
Sales and marketing727,090 846,011 861,889 
General and administrative893,204 737,304 801,262 
Amortization of acquired intangible assets92,160 97,450 95,001 
Impairment of long-lived assets621 15,969 20,210 
Total operating expenses2,793,205 2,664,546 2,622,765 
Other operating income (loss)78,427 (13,244)— 
Loss from operations(215,012)(593,511)(855,678)
Other income (expense)
Investment income (loss), net32,713 (19,425)31,778 
Interest expense(19,447)(19,634)(18,606)
Total other income (expense)13,266 (39,059)13,172 
Net loss before tax(201,746)(632,570)(842,506)
Income tax benefit (expense)(2,403)9,064 246,881 
Net loss$(204,149)$(623,506)$(595,625)
Net loss per share—basic and diluted$(1.13)$(3.54)$(3.48)
Weighted average common shares outstanding—basic and diluted180,144 176,351 171,348 

The accompanying notes are an integral part of these consolidated financial statements.
66
EXACT SCIENCES CORPORATION
Consolidated Statements of Comprehensive Loss
(Amounts in thousands)

Year Ended December 31,
202320222021
Net loss$(204,149)$(623,506)$(595,625)
Other comprehensive loss, before tax:
Unrealized gain (loss) on available-for-sale investments5,343 (3,823)(2,162)
Foreign currency adjustment1,321 30 23 
Comprehensive loss, before tax(197,485)(627,299)(597,764)
Income tax benefit related to items of other comprehensive loss
— — 170 
Comprehensive loss, net of tax$(197,485)$(627,299)$(597,594)
The accompanying notes are an integral part of these consolidated financial statements.
67
EXACT SCIENCES CORPORATION
Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except share data)



Common StockAdditional
Paid In
Capital		Accumulated Other
Comprehensive
Income (Loss)		Accumulated
Deficit		Total
Stockholders’
Equity
Number of
Shares
$0.01
Par Value
Balance, January 1, 2021159,423,410 $1,595 $4,279,327 $526 $(2,045,895)$2,235,553 
Conversion of convertible notes, net of tax580 — 43 — — 43 
Exercise of common stock options1,295,104 13 14,424 — — 14,437 
Issuance of common stock to fund the Company’s 2020 401(k) match162,606 2 22,932 — — 22,934 
Compensation expense related to issuance of stock options and restricted stock awards1,879,169 19 334,004 — — 334,023 
Purchase of employee stock purchase plan shares331,769 3 23,067 — — 23,070 
Issuance of common stock for business combinations10,581,429 106 1,355,064 — — 1,355,170 
Net loss— — — — (595,625)(595,625)
Other comprehensive loss
— — — (1,969)— (1,969)
Balance, December 31, 2021173,674,067 $1,738 $6,028,861 $(1,443)$(2,641,520)$3,387,636 
Exercise of common stock options706,134 6 6,518 — — 6,524 
Issuance of common stock to fund the Company’s 2021 401(k) match391,129 4 29,198 — — 29,202 
Compensation expense related to issuance of stock options and restricted stock awards2,220,510 22 206,801 — — 206,823 
Purchase of employee stock purchase plan shares668,605 7 25,484 — — 25,491 
Issuance of common stock for business combinations265,186 3 14,789 — — 14,792 
Other— — (7)— — (7)
Net loss— — — — (623,506)(623,506)
Other comprehensive loss
— — — (3,793)— (3,793)
Balance, December 31, 2022177,925,631 $1,780 $6,311,644 $(5,236)$(3,265,026)$3,043,162 
Exercise of common stock options194,597 2 3,195 — — 3,197 
Issuance of common stock to fund the Company’s 2022 401(k) match517,550 5 35,095 — — 35,100 
Compensation expense related to issuance of stock options and restricted stock awards1,801,954 18 231,294 — — 231,312 
Purchase of employee stock purchase plan shares924,448 10 28,334 — — 28,344 
Replaced restricted stock awards for business combinations— — 1,675 — — 1,675 
Net loss— — — — (204,149)(204,149)
Other comprehensive income
— — — 6,664 — 6,664 
Balance, December 31, 2023181,364,180 $1,815 $6,611,237 $1,428 $(3,469,175)$3,145,305 
The accompanying notes are an integral part of these consolidated financial statements.
68
EXACT SCIENCES CORPORATION
Consolidated Statements of Cash Flows
(Amounts in thousands, except share data)
Year Ended December 31,
202320222021
Cash flows from operating activities:
Net loss$(204,149)$(623,506)$(595,625)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation114,448 100,108 85,345 
(Gain) loss on non-marketable and marketable equity investments
(4,098)21,774 (29,008)
Deferred tax benefit
(955)(11,901)(253,169)
Stock-based compensation231,312 206,823 253,063 
Post-combination expense for acceleration of unvested equity— — 80,960 
Gain on settlement of convertible notes
(10,324)— — 
Amortization of acquired intangible assets92,160 97,450 95,001 
Asset acquisition IPR&D expense500 — 85,337 
Loss on sale of asset— 13,244 — 
Impairment of long-lived assets621 15,969 20,210 
Gain on contingent consideration from sale of asset(73,300)— — 
Remeasurement of contingent consideration liabilities
(18,044)(56,617)6,360 
Non-cash lease expense27,891 28,639 25,825 
Other
399 10,835 12,356 
Changes in assets and liabilities, net of effects of acquisition:
Accounts receivable, net(43,416)61,088 25,150 
Inventory, net(7,690)(13,231)(9,221)
Operating lease liabilities(26,701)(20,646)(16,685)
Accounts payable and accrued liabilities82,750 (52,180)169,800 
Other assets
(11,618)(84)(24,672)
Other liabilities
6,333 (1,324)(33,263)
Net cash provided by (used in) operating activities156,119 (223,559)(102,236)
Cash flows from investing activities:
Purchases of marketable securities(139,854)(131,486)(1,164,050)
Maturities and sales of marketable securities
363,156 453,072 794,322 
Purchases of property, plant and equipment(124,190)(214,462)(135,766)
Proceeds from sale of asset— 25,000 — 
Maturities and sales of investments in privately held companies
19,794 — — 
Investments in privately held companies(16,564)(42,823)(18,044)
Business combination, net of cash acquired and issuance costs(52,413)(14,686)(499,730)
Asset acquisitions, net of cash acquired(500)— (58,073)
Other investing activities250 (549)(744)
Net cash provided by (used in) investing activities49,679 74,066 (1,082,085)
Cash flows from financing activities:
Proceeds from accounts receivable securitization facility— 50,000 — 
Proceeds from exercise of common stock options3,197 6,524 14,437 
Proceeds in connection with the Company's employee stock purchase plan28,344 25,491 23,070 
Payments on construction loan— — (23,749)
Proceeds from issuance of convertible notes137,976 — — 
Other financing activities(9,751)(5,530)(5,286)
Net cash provided by financing activities159,766 76,485 8,472 
Effects of exchange rate changes on cash and cash equivalents1,321 30 23 
Net increase (decrease) in cash, cash equivalents and restricted cash366,885 (72,978)(1,175,826)
Cash, cash equivalents and restricted cash at the beginning of period242,790 315,768 1,491,594 
Cash, cash equivalents and restricted cash at the end of period$609,675 $242,790 $315,768 
69
EXACT SCIENCES CORPORATION
Consolidated Statements of Cash Flows
(Amounts in thousands, except share data)
Year Ended December 31,
202320222021
Supplemental disclosure of non-cash investing and financing activities:
Property, plant and equipment acquired but not paid$18,505 $15,943 $33,177 
Business acquisition contingent consideration liability$— $4,600 $350,348 
Supplemental disclosure of cash flow information:
Interest paid$18,776 $11,519 $10,735 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$605,378 $242,493 $315,471 
Restricted cash — included in other long-term assets, net as of December 31, 2023 and 2021, and prepaid expenses and other current assets as of December 31, 2022
4,297 297 297 
Total cash, cash equivalents and restricted cash$609,675 $242,790 $315,768 
The accompanying notes are an integral part of these consolidated financial statements.
70
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements

(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business
Exact Sciences Corporation (together with its subsidiaries, “Exact” or the “Company”) was incorporated in February 1995. Exact is a leading, global advanced cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard® and Oncotype DX®. Exact is currently working to develop additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.
Basis of Presentation and Principles of Consolidation
The accompanying consolidated financial statements include the accounts of Exact Sciences Corporation and those of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.
Use of Estimates
The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company's financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, contingent consideration, and accounting for income taxes.
Cash and Cash Equivalents
The Company considers cash on hand, demand deposits in a bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents.
Marketable Securities
Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value. The unrealized gains and losses, net of tax, on the Company's debt securities are reported in other comprehensive income. Marketable equity securities are measured at fair value and the unrealized gains and losses, net of tax, are recognized in other income (expense) in the consolidated statements of operations. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method. Such amortization is included in investment income, net. Realized gains and losses and declines in value as a result of credit losses on available-for-sale securities are included in the consolidated statements of operations as investment income, net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in the consolidated statements of operations as investment income, net.
The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current.
The Company periodically evaluates its available-for-sale debt securities in unrealized loss positions to determine whether any impairment is a result of a credit loss or other factors. This evaluation includes, but is not limited to, significant quantitative and qualitative assessments and estimates regarding credit ratings, significance of a security’s loss position, adverse conditions specifically related to the security, and the payment structure of the security.
71
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Allowance for Doubtful Accounts
The Company estimates an allowance for doubtful accounts against accounts receivable using historical collection trends, aging of accounts, current and future implications surrounding the ability to collect such as economic conditions, and regulatory changes. The allowance for doubtful accounts is evaluated on a regular basis and adjusted when trends, significant events, or other substantive evidence such as an adverse change in a payer's ability to pay indicate that expected collections will be less than previously estimated. At December 31, 2023 and 2022, the allowance for doubtful accounts recorded was not significant to the Company's consolidated balance sheets. For the years ended December 31, 2023, 2022 and 2021, there was an insignificant amount of bad debt expense written off against the allowance and charged to operating expense.
Inventory
Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method (“FIFO”). The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale, no longer meets quality specifications, or has a cost basis in excess of its estimated realizable value and records a charge to cost of sales for such inventory as appropriate.
Direct and indirect manufacturing costs incurred during process validation with probable future economic benefit are capitalized. Validation costs incurred for other research and development activities, which are not permitted to be sold, are expensed to research and development in the Company’s consolidated statements of operations.
Property, Plant and Equipment
Property, plant and equipment are stated at cost and depreciated using the straight-line method over the assets’ estimated useful lives. Land is stated at cost and does not depreciate. Additions and improvements are capitalized, including direct and indirect costs incurred to validate equipment and bring to working conditions. Revalidation costs, including maintenance and repairs are expensed when incurred.
Software Development Costs
Costs related to internal use software, including hosted arrangements, are incurred in three stages: the preliminary project stage, the application development stage, and the post-implementation stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred during the application development stage that meet the criteria for capitalization are capitalized and amortized, when the software is ready for its intended use, using the straight‑line method over the estimated useful life of the software, or the duration of the hosting agreement.
Investments in Privately Held Companies
The Company determines whether its investments in privately held companies are debt or equity based on their characteristics. The Company also evaluates the investee to determine if the entity is a variable interest entity (“VIE”) and, if so, whether the Company is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required. If consolidation is not required and the Company does not have voting control of the entity, the investment is evaluated to determine if the equity method of accounting should be applied. The equity method applies to investments in common stock or in substance common stock where the Company exercises significant influence over the investee.
Investments in privately held companies determined to be equity securities without readily determinable fair values are accounted for under the measurement alternative method as permitted in Accounting Standards Codification (“ASC”) 321, Investments - Equity Securities. The Company adjusts the carrying value of its non-marketable equity securities for changes from observable transactions for identical or similar investments of the same issuer, less impairment. All gains and losses on non-marketable equity securities, realized and unrealized, are recognized in investment income, net in the consolidated statements of operations.
Investments in privately held companies determined to be debt securities are accounted for as available-for-sale or held-to-maturity securities unless the fair value option is elected.
72
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Derivative Financial Instruments
The Company hedges a portion of its foreign currency exposures related to outstanding monetary assets and liabilities using foreign currency forward contracts. The foreign currency forward contracts are included in prepaid expenses and other current assets or in accrued liabilities in the consolidated balance sheets, depending on the contracts’ net position. These contracts are not designated as hedges, and as a result, changes in their fair value are recorded in other income (expense) in the consolidated statements of operations.
Business Combinations and Asset Acquisitions
Business Combinations are accounted for under the acquisition method in accordance with ASC 805, Business Combinations. The acquisition method requires identifiable assets acquired and liabilities assumed and any non-controlling interest in the business acquired be recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. The amount by which the fair value of consideration transferred as the purchase price exceeds the net fair value of assets acquired and liabilities assumed is recorded as goodwill. Acquisitions that do not meet the definition of a business combination under ASC 805 are accounted for as asset acquisitions. Asset acquisitions are accounted for by allocating the cost of the acquisition to the individual assets acquired and liabilities assumed on a relative fair value basis. Goodwill is not recognized in an asset acquisition with any consideration in excess of net assets acquired allocated to acquired assets on a relative fair value basis. Transaction costs are expensed in a business combination and are considered a component of the cost of the acquisition in an asset acquisition.
Intangible Assets
Purchased intangible assets are recorded at fair value. The Company uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. The Company’s finite-lived intangible assets are being amortized on a straight-line basis over their estimated useful lives.
Patent costs are capitalized as incurred, only if the Company determines that there is some probable future economic benefit derived from the transaction. A capitalized patent is amortized over its estimated useful life, beginning when such patent is approved. Capitalized patent costs are expensed upon disapproval, upon a decision by the Company to no longer pursue the patent or when the related intellectual property is either sold or deemed to be no longer of value to the Company. The Company determined that all patent costs incurred during the years ended December 31, 2023, 2022 and 2021 should be expensed and not capitalized as the future economic benefit derived from the patent costs incurred cannot be determined.
Acquired In-process Research and Development (“IPR&D”)
Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The primary basis for determining technological feasibility of these projects is obtaining regulatory approval to market the underlying product. The amounts capitalized are accounted for as indefinite-lived intangible assets and are subject to impairment testing until completion or abandonment of the research and development efforts associated with the projects. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. The value assigned to acquired IPR&D is determined using the multi-period excess earnings method approach, which utilizes significant unobservable inputs (Level 3 inputs) including projected revenues, projected gross margin, projected operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success. There are often major risks and uncertainties associated with IPR&D projects as the Company is required to obtain regulatory approvals in order to market the resulting products. Such approvals require completing clinical trials that demonstrate the product's effectiveness. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods.
Capitalized IPR&D projects are tested for impairment annually in the fourth quarter, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, and upon successful completion of the project. The Company considers various factors for potential impairment, including the current legal and regulatory environment, current and future strategic initiatives and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors' products could result in partial or full impairment of the related intangible assets.
73
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Contingent Consideration Liabilities
Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain regulatory and product development milestones being achieved. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected probabilities of success, projected payment dates, present value-factors, and projected revenues (for revenue-based considerations). Changes in probabilities of success, present-value factors, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within general and administrative expenses on the Company’s consolidated statements of operations. Cash contingent consideration payments up to the acquisition date fair value of the contingent consideration liability are classified as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are classified as operating activities in the consolidated statements of cash flows.
Contingent Consideration Asset
The sale of the Company’s intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test (“GPS test”) resulted in the recognition of variable consideration in accordance with ASC 606. The Company estimates the amount of variable consideration that it is entitled to each quarter using the most likely amount method and considers whether there are any constraints on the consideration. If it is probable that a significant reversal of a gain would not occur, the Company will record a gain. To determine the classification of the consideration, the Company determines if the consideration is conditional on something other than the passage of time. Revenue-based contingent consideration that is conditional on something other than the passage of time, including future revenues from sales related to the GPS test, result in the variable consideration being classified as a contract asset. At the time the amount earned is determined, and passage of time is the only condition remaining, the contract asset is reclassified to a receivable.
Collateralized Debt Instruments
Debt instruments that are collateralized by security interests in financial assets held by the Company are accounted for as a secured borrowing and therefore: (i) the asset balances pledged as collateral are included within the applicable balance sheet line item and the borrowings are included within long-term debt in the consolidated balance sheet; (ii) interest expense is included within the consolidated statements of operations; and (iii) in the case of collateralized accounts receivable, receipts from customers related to the underlying accounts receivable are reflected as operating cash flows, and (iv) borrowings and repayments under the collateralized loans are reflected as financing cash flows within the consolidated statements of cash flows.
Goodwill
The Company evaluates goodwill for possible impairment at the reporting unit level on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting the Company's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value.
Impairment of Long-Lived Assets
The Company evaluates the fair value of long-lived assets, which include property, plant and equipment, leases, finite-lived intangible assets, and investments in privately held companies, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
74
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Net Loss Per Share
Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
December 31,
(In thousands)202320222021
Shares issuable upon conversion of convertible notes23,231 20,309 20,309 
Shares issuable upon the release of restricted stock awards6,273 5,255 4,321 
Shares issuable upon the release of performance share units1,598 968 878 
Shares issuable upon exercise of stock options1,286 1,518 2,284 
Shares issuable in connection with acquisitions— — 45 
32,388 28,050 27,837 
Accounting for Stock-Based Compensation
The Company requires all share-based payments to employees, including grants of employee stock options, restricted stock, restricted stock units, shares purchased under an employee stock purchase plan (if certain parameters are not met), and performance share units to be recognized in the financial statements based on their grant date fair values. The estimated fair value of these awards is recognized to expense using the straight-line method over the requisite service period, which is generally the vesting period. The Company will recognize expense on an accelerated basis for restricted stock units upon an employee's death, disability, or upon retirement eligibility, provided certain criteria are met. Forfeitures of any share-based awards are recognized as they occur.
The fair values and recognition of the Company’s share-based payment awards are determined as follows:
The fair value of each service-based option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions:
Expected Term—Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants.
Expected Volatility—Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards.
Risk-Free Interest Rate—The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term.
The fair value of service-based awards for each restricted stock unit award is determined on the date of grant using the closing stock price on that day.
The fair value of performance-based equity awards that do not include a market condition is determined on the date of grant using the closing stock price on that day. The fair value of performance-based equity awards that include a market condition is determined on the date of grant using a Monte Carlo valuation technique. The expense recognized each period is also dependent on the probability of what performance conditions will be met which is determined by management's evaluation of internal and external factors. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the goals and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance targets and operational milestones are not achieved, the award would not vest resulting in no stock-based compensation being recognized and any previously recognized stock-based compensation expense being reversed.
75
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Research and Development Costs
Research and development costs are expensed as incurred. These expenses include the costs of the Company's proprietary research and development efforts, as well as costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use. Acquired IPR&D assets that are acquired in an asset acquisition and which have no alternative future use are classified as an investing cash outflow in the consolidated statements of cash flows. Upfront and milestone payments due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred. Milestone payments due to third parties upon, or subsequent to, regulatory approval are capitalized and amortized into research and development costs over the shorter of the remaining license or product patent life, when there are no corresponding revenues related to the license or product. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received, rather than when the payment is made.
Advertising Costs
The Company expenses the costs of media advertising at the time the advertising takes place. The Company expensed approximately $137.9 million, $170.3 million, and $144.0 million of media advertising during the years ended December 31, 2023, 2022, and 2021, respectively, which is recorded in sales and marketing expenses on the Company’s consolidated statements of operations.
Fair Value Measurements
The Financial Accounting Standards Board (“FASB”) has issued authoritative guidance that requires fair value to be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under that standard, fair value measurements are separately disclosed by level within the fair value hierarchy. The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.
Leases
The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles, and certain laboratory and office equipment, and finance leases for certain equipment and vehicles.
The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (“ROU”) assets and lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations.
As the implicit interest rate is not readily determinable in most of the Company’s leases, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the United States (“U.S.”) Treasury rate and an indicative Moody's rating for operating leases or finance leases.
The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease for up to 10 years, and some of which include options to terminate the lease within 1 year. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest expense on the Company’s consolidated statements of operations.
76
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The Company accounts for leases acquired in business combinations by measuring the lease liability at the present value of the remaining lease payments as if the acquired lease were a new lease for the Company. This measurement includes recognition of a lease intangible for any below-market terms present in the leases acquired. The below-market lease intangible is included in the ROU asset on the consolidated balance sheets and are amortized over the remaining lease term. The Company has not acquired any leases with above-market terms.
The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.
Revenue Recognition
Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype®, PreventionGenetics, LLC (“PreventionGenetics”), and COVID-19 tests. The services are considered completed when the performance obligation is fulfilled, which is upon release of an approved patient test result to the healthcare provider. The Company follows ASC 606, Revenue from Contracts with Customers, to account for its laboratory service revenues.
Laboratory testing services
The Company’s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services (“CMS”) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, or in the context of certain lab service or reference agreements, the Company requires payment prior to the commencement of the Company's performance obligations.
The Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patient’s test result to the ordering healthcare provider. Or, in the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window. The Company elects the practical expedient to not disclose unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year.
The Company’s transaction price is comprised of fixed and variable consideration and is allocated entirely to a single performance obligation defined as the point in time an approved patient test result is released to the ordering healthcare provider. Fixed consideration exists in arrangements where the Company has agreed to provide laboratory testing services to a customer for a specified rate and is expected to be collected in full at that rate. Variable consideration is primarily derived from payer and patient billing and can be impacted by several factors such as the amount of contractual adjustments, any patient co-payments, deductibles or patient adherence incentives, the existence of secondary payers, and claim denials. Estimates of variable consideration are calculated using the expected value method and is the sum of probability-weighted amounts in a range of possible consideration amounts. Several factors are evaluated during this process, such as historical collections experience, current contractual and statutory requirements, customer mix, patient insurance eligibility and payer reimbursement contracts, and known or anticipated reimbursement trends not yet reflected in the data. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made.
77
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease in the estimate of the transaction price (i.e., an upward or downward revenue adjustment) in the period identified.
When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon completion of the performance obligations associated with the Company's tests, with recognition, generally occurring at the date of cash receipt.
Contract Balances
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets. Generally, billing occurs after the release of an approved patient test result to the healthcare provider, resulting in an account receivable. However, the Company sometimes receives advance payment from a patient or a direct bill payer before services are performed, resulting in deferred revenue. The deferred revenue recorded is recognized as revenue at the point in time an approved patient test result is released to the patient's healthcare provider. In the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window.
Practical Expedients
The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.
The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company’s consolidated statements of operations.
The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications (e.g. adherence reminder letters). These costs are expensed as incurred and recorded within general and administrative expenses in the Company’s consolidated statements of operations.
Cost of Sales
Cost of sales reflects the aggregate costs incurred in delivering the Company's products and services and includes material and service costs, personnel costs, including stock-based compensation expense, equipment and infrastructure expenses associated with laboratory testing services, shipping charges, and allocated overhead such as rent, information technology costs, equipment depreciation and utilities. Costs associated with the shipment of Cologuard test collection kits are recognized upon shipment, and costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test.
Foreign Currency Transactions
The functional currency for most of the Company’s international subsidiaries is the U.S. dollar. When the functional currency differs from the local currency, monetary assets and liabilities are remeasured at the current period-end exchange rate, while non-monetary assets and liabilities are remeasured at the historical rate. The gains and losses as a result of exchange rate adjustments of these subsidiaries are recognized in the consolidated statements of operations. Net foreign currency transaction gains or losses were not significant to the consolidated statements of operations for the periods presented.
For the Company’s international subsidiaries where the functional currency is other than the U.S. dollar, the financial statements are translated into the U.S. dollar, and the cumulative adjustments resulting from the translation into the U.S. dollar are included in the Company's consolidated balance sheet as a component of accumulated other comprehensive income (loss) (“AOCI”).
78
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Concentration of Credit Risk
Financial instruments that subject the Company to credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2023, the Company had cash and cash equivalents deposited in financial institutions in which the balances exceed the federal government agency insured limit of $250,000 by approximately $529.0 million. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.
Through December 31, 2023, the Company’s revenues have been primarily derived from the sale of Cologuard, Oncotype, and COVID-19 tests. The following is a breakdown of revenue and accounts receivable from major payers:
% Revenue for the years ended December 31,% Accounts Receivable at December 31,
Major Payer202320222021202320222021
Centers for Medicare and Medicaid Services17%14%20%10%14%11%
UnitedHealthcare12%12%11%10%9%8%
State of Wisconsin—%3%8%—%5%9%
Tax Positions
A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income, the Company has determined that a valuation allowance at December 31, 2023 and 2022 is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the Company's effective tax rate.
Guarantees and Indemnifications
The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a directors and officers insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2023 and 2022.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In July 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-03, Presentation of Financial Statement (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718). This update amends various Securities and Exchange Commission (“SEC”) paragraphs in the Accounting Standards Codification to reflect the issuance of SEC Staff Accounting Bulletin No. 120, among other things. The Company adopted this conforming guidance upon issuance during the third quarter of fiscal year 2023. There was no significant impact to the Company’s consolidated financial statements.
79
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Recently Issued Accounting Pronouncements Not Yet Adopted
In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.
(2) REVENUE
 The following table presents the Company’s revenues disaggregated by revenue source:
Year Ended December 31,
(In thousands)202320222021
Screening
Medicare Parts B & C$701,400 $545,458 $438,646 
Commercial992,244 743,238 569,944 
Other171,057 136,007 53,718 
Total Screening1,864,701 1,424,703 1,062,308 
Precision Oncology
Medicare Parts B & C$188,689 $197,327 $197,394 
Commercial181,318 177,518 180,177 
International153,277 117,738 109,913 
Other105,826 108,905 74,192 
Total Precision Oncology629,110 601,488 561,676 
COVID-19 Testing$5,955 $58,088 $143,103 
Total$2,499,766 $2,084,279 $1,767,087 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $25.2 million and $20.3 million for the years ended December 31, 2023 and 2022, respectively. The Company recorded a downward adjustment to revenue from a change in transaction price of $11.8 million for the year ended December 31, 2021.
80
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s consolidated balance sheets, was not significant as of December 31, 2023 and 2022.
Revenue recognized for the year ended December 31, 2023 and 2022, which was included in the deferred revenue balance at the beginning of the year was not significant.
(3) MARKETABLE SECURITIES
The following table sets forth the Company’s cash, cash equivalents, and marketable securities at December 31, 2023 and 2022:
December 31,
(In thousands)20232022
Cash and cash equivalents
Cash and money market$530,100 $178,168 
Cash equivalents75,278 64,325 
Total cash and cash equivalents605,378 242,493 
Marketable securities
Available-for-sale debt securities$168,425 $384,415 
Equity securities3,841 5,149 
Total marketable securities172,266 389,564 
Total cash, cash equivalents, and marketable securities$777,644 $632,057 
Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2023, consisted of the following:
(In thousands)Amortized Cost
Gains in AOCI (1)
Losses in AOCI (1)
Estimated Fair Value
Cash equivalents
Commercial paper$72,243 $— $— $72,243 
U.S. government agency securities3,035 — — 3,035 
Total cash equivalents75,278 — — 75,278 
Marketable securities
U.S. government agency securities$56,594 $166 $(44)$56,716 
Corporate bonds55,712 175 (59)55,828 
Asset backed securities35,081 65 (249)34,897 
Commercial paper
20,984 — — 20,984 
Total marketable securities168,371 406 (352)168,425 
Total available-for-sale debt securities$243,649 $406 $(352)$243,703 
_________________________________
(1)     There was no tax impact from the gains and losses in AOCI.
81
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2022, consisted of the following:
(In thousands)Amortized Cost
Gains in AOCI (1)
Losses in AOCI (1)
Estimated Fair Value
Cash equivalents
Commercial paper$63,021 $— $— $63,021 
U.S. government agency securities1,304 — — 1,304 
Total cash equivalents64,325 — — 64,325 
Marketable securities
U.S. government agency securities$228,012 $— $(2,789)$225,223 
Corporate bonds116,318 20 (1,667)114,671 
Asset backed securities45,374 2 (855)44,521 
Total marketable securities389,704 22 (5,311)384,415 
Total available-for-sale debt securities$454,029 $22 $(5,311)$448,740 
_________________________________
(1)     There was no tax impact from the gains and losses in AOCI.
The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at December 31, 2023:
Due one year or lessDue after one year through five years
(In thousands)CostFair ValueCostFair Value
Cash equivalents
Commercial paper$72,243 $72,243 $— $— 
U.S. government agency securities3,035 3,035 — — 
Total cash equivalents75,278 75,278 — — 
Marketable securities
Corporate bonds$33,518 $33,474 $22,194 $22,354 
U.S. government agency securities33,407 33,403 23,187 23,313 
Commercial paper
20,984 20,984 — — 
Asset backed securities— — 35,081 34,897 
Total marketable securities87,909 87,861 80,462 80,564 
Total available-for-sale securities$163,187 $163,139 $80,462 $80,564 
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one year
One year or greater
Total
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
Corporate bonds$25,895 $(41)$2,480 $(18)$28,375 $(59)
U.S. government agency securities15,756 (35)3,965 (9)19,721 (44)
Asset backed securities4,377 (5)10,935 (244)15,312 (249)
Total available-for-sale securities$46,028 $(81)$17,380 $(271)$63,408 $(352)
82
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2022, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one year
One year or greater
Total
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
U.S. government agency securities$37,458 $(337)$187,766 $(2,452)$225,224 $(2,789)
Corporate bonds35,055 (575)73,702 (1,092)108,757 (1,667)
Asset backed securities27,984 (735)15,536 (120)43,520 (855)
Total available-for-sale securities$100,497 $(1,647)$277,004 $(3,664)$377,501 $(5,311)
The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of December 31, 2023 and 2022 because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers.
The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s consolidated statements of operations. The gains and losses recorded were not significant for the years ended December 31, 2023, 2022, and 2021.
(4) INVENTORY
Inventory consisted of the following:
December 31,
(In thousands)20232022
Raw materials$58,593 $61,207 
Semi-finished and finished goods68,882 57,052 
Total inventory$127,475 $118,259 

83
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
(5) PROPERTY, PLANT AND EQUIPMENT
The carrying value and estimated useful lives of property, plant and equipment are as follows:
December 31,
(In thousands)Estimated Useful Life20232022
Property, plant and equipment
Landn/a$4,716 $4,716 
Leasehold and building improvements(1)214,562 200,588 
Land improvements15 years6,729 6,417 
Buildings
30 - 40 years
290,777 288,941 
Computer equipment and computer software3 years168,131 142,896 
Machinery and equipment
3 - 10 years
290,294 246,344 
Furniture and fixtures
3 - 10 years
35,756 34,047 
Assets under constructionn/a104,592 68,398 
Property, plant and equipment, at cost1,115,557 992,347 
Accumulated depreciation(417,203)(307,591)
Property, plant and equipment, net$698,354 $684,756 
_________________________________
(1)     Lesser of remaining lease term, building life, or estimated useful life.
At December 31, 2023, the Company had $104.6 million of assets under construction, which consisted of $53.2 million in machinery and equipment, $29.1 million of capitalized costs related to software projects, $15.7 million in leasehold and building improvements, and $6.6 million related to buildings. Depreciation will begin on these assets once they are placed into service upon completion.
(6) INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
The following table summarizes the net-book-value and estimated remaining life of the Company's intangible assets as of December 31, 2023:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated AmortizationNet Balance at December 31, 2023
Finite-lived intangible assets
Trade name11.6$104,000 $(27,903)$76,097 
Customer relationships7.04,000 (889)3,111 
Patents and licenses4.511,542 (9,600)1,942 
Acquired developed technology (1)7.3887,789 (328,543)559,246 
Total finite-lived intangible assets1,007,331 (366,935)640,396 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,257,331 $(366,935)$1,890,396 
84
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated AmortizationNet Balance at December 31, 2022
Finite-lived intangible assets
Trade name12.5$104,000 $(20,653)$83,347 
Customer relationships8.04,000 (444)3,556 
Patents and licenses4.211,542 (8,152)3,390 
Acquired developed technology (1)
7.8861,474 (245,527)615,947 
Total finite-lived intangible assets981,016 (274,776)706,240 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,231,016 $(274,776)$1,956,240 
______________
(1)The gross carrying amount includes an insignificant foreign currency translation adjustment related to the intangible asset     acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
As of December 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2024$92,908 
202591,860 
202690,800 
202790,800 
202890,800 
Thereafter183,228 
Total$640,396 
There were no impairment losses recorded on finite-lived intangible assets during the year ended December 31, 2023.
The Company recorded an IPR&D asset of $1.25 billion related to a project associated with the development of a U.S. Food and Drug Administration (“FDA”) approved, blood-based, multi-cancer early detection (“MCED”) test as part of the acquisition of Thrive Earlier Detection Corporation (“Thrive”) in January 2021. The Company performed a quantitative assessment as part of its annual IPR&D impairment analysis in the fourth quarter of 2023 under which it determined that the fair value exceeded the carrying value and no impairment loss was recorded.
On August 2, 2022, the Company completed a sale of the developed technology intangible asset related to the Oncotype DX Genomic Prostate Score test to MDxHealth SA (“MDxHealth”), which was measured using the income approach to determine the fair value. The gross value of the intangible asset was $59.0 million with accumulated amortization of $16.1 million as of the closing date, resulting in a carrying value of $42.9 million, which was derecognized from intangible assets, net in the consolidated balance sheets upon completion of the divestiture. Refer to Note 18 for further information on this sale.
During the third quarter of 2022, the remaining carrying value of $2.0 million related to the supply agreement intangible asset acquired as part of the combination with Genomic Health, Inc. (“Genomic Health”) was recorded as a non-cash, pre-tax impairment loss due to the termination of the agreement. The Company previously recorded a non-cash, pre-tax impairment loss of $20.2 million during the third quarter of 2021 due to lower than anticipated performance of the underlying product.
85
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
During the second quarter of 2022, the remaining carrying value of $6.6 million related to the developed technology intangible asset acquired as a result of the acquisition of Paradigm Diagnostics, Inc. was recorded as a non-cash, pre-tax impairment loss due to lower than anticipated performance of the underlying product.
The Company utilized the income approach to measure the fair value of the impaired intangible assets, which involved significant unobservable inputs (Level 3 inputs), including revenue projections, cash flow projections, and discount rates. Impairment losses recorded on intangible assets are included in impairment of long-lived assets in the Company’s consolidated statement of operations.
Goodwill
The change in the carrying amount of goodwill for the years ended December 31, 2023 and 2022 is as follows:
(In thousands)
Balance, January 1, 2022
$2,335,172 
OmicEra acquisition
10,809 
PreventionGenetics acquisition adjustment(58)
Effects of changes in foreign currency exchange rates (1)117 
Balance, December 31, 2022
2,346,040 
Resolution Bioscience acquisition (2)
20,692 
Effects of changes in foreign currency exchange rates (1)
388 
Balance December 31, 2023
$2,367,120 
_________________________________
(1)    Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
(2)    Refer to Note 18 for further discussion on the Company’s acquisition of Resolution Bioscience, Inc. (“Resolution Bioscience”).
There were no impairment losses recorded on goodwill for the years ended December 31, 2023, 2022, and 2021.
(7) FAIR VALUE MEASUREMENTS
The three levels of the fair value hierarchy established are as follows:
Level 1    Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2    Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3    Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.
86
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The following table presents the Company’s fair value measurements as of December 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair value at December 31, 2023Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$530,100 $530,100 $— $— 
Commercial paper72,243 — 72,243 — 
Restricted cash (1)
4,297 4,297 — — 
U.S. government agency securities3,035 — 3,035 — 
Marketable securities
U.S. government agency securities$56,716 $— $56,716 $— 
Corporate bonds55,828 — 55,828 — 
Asset backed securities34,897 — 34,897 — 
Commercial paper
20,984 — 20,984 — 
Equity securities
3,841 3,841 — — 
Non-marketable securities$7,650 $— $— $7,650 
Liabilities
Contingent consideration$(288,657)$— $— $(288,657)
Total$500,934 $538,238 $243,703 $(281,007)
The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at December 31, 2022Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$178,168 $178,168 $— $— 
Commercial paper63,021 — 63,021 — 
U.S. government agency securities1,304 — 1,304 — 
Restricted cash (1)
297 297 — — 
Marketable securities
U.S. government agency securities$225,223 $— $225,223 $— 
Corporate bonds114,671 — 114,671 — 
Asset backed securities44,521 — 44,521 — 
Equity securities (2)
5,149 5,149 — — 
Non-marketable securities$10,065 $— $— $10,065 
Liabilities
Contingent consideration$(306,927)$— $— $(306,927)
Total$335,492 $183,614 $448,740 $(296,862)
_________________________________
(1)Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company's credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties.
87
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
(2)Inclusive of the American Depository Shares of MDxHealth received as part of the sale of the Company’s GPS test, which are restricted to a holding period of six months after the date of the sale of August 2, 2022. The shares had a fair value of $4.6 million as of December 31, 2022.
There have been no changes in valuation techniques or transfers between fair value measurement levels during the year ended December 31, 2023. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors.
The Company has elected the fair value option under the income approach to measure certain Level 3 non-marketable securities. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option:
(In thousands)Non-Marketable Securities
Beginning balance, January 1, 2022
$3,090 
Purchase of non-marketable securities
10,000 
Change in fair value
1,038 
Conversion of non-marketable securities
(4,063)
Balance, December 31, 2022
10,065 
Purchases of non-marketable securities6,957 
Changes in fair value1,127 
Settlement of non-marketable securities
(10,499)
Ending balance, December 31, 2023
$7,650 
Contingent Consideration Liabilities
The fair value of the contingent consideration liabilities was $288.7 million and $306.9 million as of December 31, 2023 and 2022, respectively, which was included in other long-term liabilities in the consolidated balance sheets.
The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
(In thousands)Contingent Consideration
Balance, January 1, 2022 (1)
$359,021 
Purchase price contingent consideration (2)
4,600 
Changes in fair value(56,617)
Payments(77)
Balance, December 31, 2022
306,927 
Changes in fair value
(18,044)
Payments(226)
Balance, December 31, 2023
$288,657 
_________________________________
(1)    The change in fair value of the contingent consideration liability during the year ended December 31, 2021 was not significant.
(2)    The increase in contingent consideration liability is due to the contingent consideration associated with the acquisition of OmicEra. Refer to Note 18 for further information.
This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market.
88
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The fair value of the contingent consideration liabilities recorded from the Company’s acquisitions of Thrive, Ashion Analytics, LLC (“Ashion”), and OmicEra related to regulatory and product development milestones was $288.7 million and $306.8 million as of December 31, 2023 and 2022, respectively. The Company evaluates the fair value of the expected contingent consideration and the corresponding liabilities related to the regulatory and product development milestones using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the expected contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 89% and 91% as of December 31, 2023 and 2022, respectively, and a weighted average present-value factor of 5.8% and 6.2% as of December 31, 2023 and 2022, respectively. The projected fiscal year of payment range is from 2025 to 2030. Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.
The fair value of the contingent consideration liability related to certain revenue milestones associated with the Biomatrica, Inc. acquisition was not significant as of December 31, 2022, and the revenue milestone period ended September 30, 2023. The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone.
Non-Marketable Equity Investments
Non-marketable equity securities without readily determinable fair values, which are classified as a component of other long-term assets, net, had the following aggregate carrying amounts and downward and upward adjustments as of and for the years ended December 31, 2023 and 2022:
Year ended December 31,
(In thousands)
20232022
Upward adjustments (1)
$4,314 $779 
Downward adjustments and impairments (2)
(4,250)(10,821)
Aggregate carrying value
45,968 39,842 
_________________________________
(1)    Cumulative upward adjustments on non-marketable equity securities held as of December 31, 2023 was $5.1 million. The upward adjustments recorded were due to increases in the valuation of the underlying investee as determined by the value of the follow-on rounds of investment by other third-party investors. There were no upward adjustments recorded during the year ended December 31, 2021.
(2)    Cumulative downward adjustments and impairments on non-marketable equity securities held as of December 31, 2023 was $15.1 million. The adjustments recorded were due to adverse changes in the market and the investees’ ability to continue as a going concern. There were no downward adjustments recorded during the year ended December 31, 2021.
The Company recorded a realized gain of $5.4 million, a realized loss of $10.0 million, and a realized gain of $30.5 million on non-marketable securities for the years ended December 31, 2023, 2022, and 2021, respectively.
The Company has committed capital to venture capital investment funds (the “Funds”) of $17.5 million, of which $12.1 million remained callable through 2033 as of December 31, 2023. The aggregate carrying amount of the Funds, which are classified as a component of other long-term assets, net in the Company's consolidated balance sheets, were $5.2 million and $3.9 million as of December 31, 2023 and 2022, respectively. Gains and losses recorded on the Company's investments in the Funds were not significant for the years ended December 31, 2023, 2022, and 2021.
89
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Derivative Financial Instruments
The Company enters into foreign currency forward contracts on the last day of each month to mitigate the impact of adverse movements in foreign exchange rates related to the remeasurement of monetary assets and liabilities and hedge the Company’s foreign currency exchange rate exposure. As of December 31, 2023 and 2022, the Company had open foreign currency forward contracts with notional amounts of $39.5 million and $22.3 million, respectively. The Company’s foreign exchange derivative instruments are classified as Level 2 within the fair value hierarchy as they are valued using inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The fair value of the open foreign currency forward contracts was zero at December 31, 2023 and 2022, and there were no gains or losses recorded to adjust the fair value of the open foreign currency contract held as of December 31, 2023. The contracts are closed subsequent to each month-end, and the gains and losses recorded from the contracts were not significant for the years ended December 31, 2023 and 2022.
(8) ACCRUED LIABILITIES
Accrued liabilities at December 31, 2023 and 2022 consisted of the following:
December 31,
(In thousands)20232022
Compensation$247,619 $201,252 
Professional fees45,405 43,715 
Other17,274 22,329 
Research and trial related expenses14,219 17,455 
Assets under construction11,210 10,462 
Licenses5,956 4,003 
Total $341,683 $299,216 
(9) LONG-TERM DEBT
Accounts Receivable Securitization Facility
On June 29, 2022, the Company, through a wholly-owned special purpose entity, Exact Receivables LLC (“Exact Receivables”) entered into an accounts receivable securitization program (the “Securitization Facility”) with PNC Bank, National Association (“PNC”), with a scheduled maturity date of June 29, 2024. The Securitization Facility provides Exact Receivables with a revolving line-of-credit of up to $150.0 million of borrowing capacity, subject to certain borrowing base requirements, by collateralizing a security interest in the domestic customer accounts receivable of certain wholly-owned subsidiaries of the Company. The amount available under the Securitization Facility fluctuates over time based on the total amount of eligible customer accounts receivable generated by the Company during the normal course of operations. The Securitization Facility requires the Company to maintain minimum borrowings under the facility of $50.0 million. The debt issuance costs incurred related to the Securitization Facility were not significant and are being amortized over the life of the Securitization Facility through interest expense within the consolidated statements of operations.
In connection with the Securitization Facility, the Company also entered into two Receivables Purchase Agreements (“Receivable Purchase Agreements”) on June 29, 2022. The Receivable Purchase Agreements are among the Company and certain wholly-owned subsidiaries of the Company, and between the Company and Exact Receivables. Under the agreements, the wholly-owned subsidiaries sell all of their right, title and interest in their accounts receivables to Exact Receivables. The receivables are used to collateralize borrowings made under the Securitization Facility. The Company retains the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provides a performance guaranty.
90
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
As of December 31, 2023, the eligible borrowing base under the Securitization Facility was $108.5 million of which the Company elected to collateralize $50.0 million. As of December 31, 2023 and December 31, 2022, the Company had an outstanding balance of $50.0 million, which is included in debt, current portion and long-term debt, less current portion, respectively, on the Company’s consolidated balance sheets. The outstanding balance accrues interest at a rate equal to a daily secured overnight financing rate (“SOFR”) rate plus a SOFR adjustment and an applicable margin. The interest rate was 6.89% at December 31, 2023.
Revolving Loan Agreement
During November 2021, the Company entered into a revolving loan agreement (the “Revolving Loan Agreement”) with PNC. The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding.
Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. In October 2022 the Revolving Loan Agreement was amended to extend the maturity date from November 5, 2023 to November 5, 2025. There were no other amendments to the Revolver.
The Company has agreed to various financial covenants under the Revolving Loan Agreement, and as of December 31, 2023, the Company is in compliance with all covenants.
In December 2021 and January 2023, PNC issued letters of credit of $2.9 million and $1.5 million, respectively, which reduced the amount available for cash advances under the line of credit to $145.6 million and $147.1 million as of December 31, 2023 and December 31, 2022, respectively. As of December 31, 2023, the Company has not drawn funds from, nor are any amounts outstanding under, the Revolving Loan Agreement.
Construction Loan Agreement
During December 2017, the Company entered into a loan agreement with Fifth Third Bank (the “Construction Loan Agreement”), which provided the Company with a non-revolving construction loan (the “Construction Loan”) of $25.6 million- with a maturity date of December 10, 2022. The Company used the Construction Loan proceeds to finance the construction of an additional clinical laboratory and related facilities in Madison, Wisconsin. The Construction Loan was collateralized by the additional clinical laboratory and related facilities.
The Construction Loan Agreement bore interest at a rate equal to the sum of the 1-month LIBOR rate plus 2.25%. The interest incurred on the Construction Loan was not significant and was capitalized to the construction project. The Company also incurred minimal debt issuance costs which were recorded as a direct deduction from the liability, and amortized over the life of the Construction Loan.
As part of the Revolving Loan Agreement discussed above, the Company agreed to repay in full all outstanding debt owed to Fifth Third Bank under the Construction Loan Agreement, and as of December 31, 2021, the remaining outstanding balance had been fully repaid in connection with the termination of the Construction Loan Agreement. Any unamortized issuance costs at the time or repayment were recorded as a loss.
91
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
(10) CONVERTIBLE NOTES
Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2023:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2030 Convertible Notes - 2.000%
$572,993 $(4,349)$568,644 $684,475 2
2028 Convertible Notes - 0.375%
949,042 (10,499)938,543 887,354 2
2027 Convertible Notes - 0.375%
563,822 (5,429)558,393 549,839 2
2025 Convertible Notes - 1.000%
249,172 (476)248,696 293,300 2
Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2022:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2028 Convertible Notes - 0.375%
$1,150,000 $(15,775)$1,134,225 $908,500 2
2027 Convertible Notes - 0.375%
747,500 (9,445)738,055 612,950 2
2025 Convertible Notes - 1.000%
315,005 (1,179)313,826 326,808 2
____________________________
(1)     The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement.
Issuances and Settlements
In January 2018, the Company issued and sold $690.0 million in aggregate principal amount of 1.0% Convertible Notes (the “January 2025 Notes”) with a maturity date of January 15, 2025. The January 2025 Notes accrue interest at a fixed rate of 1.0% per year, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The net proceeds from the issuance of the January 2025 Notes were approximately $671.1 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.
In June 2018, the Company issued and sold an additional $218.5 million in aggregate principal amount of 1.0% Convertible Notes (the “June 2025 Notes”). The June 2025 Notes were issued under the same indenture pursuant to which the Company previously issued the January 2025 Notes (the “Indenture”). The January 2025 Notes and the June 2025 Notes (collectively, the “2025 Notes”) have identical terms (including the same January 15, 2025 maturity date) and are treated as a single series of securities. The net proceeds from the issuance of the June 2025 Notes were approximately $225.3 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.
In March 2019, the Company issued and sold $747.5 million in aggregate principal amount of 0.375% Convertible Notes (the “2027 Notes”) with a maturity date of March 15, 2027. The 2027 Notes accrue interest at a fixed rate of 0.375% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2019. The net proceeds from the issuance of the 2027 Notes were approximately $729.5 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.
92
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The Company utilized a portion of the proceeds from the issuance of the 2027 Notes to settle a portion of the 2025 Notes in privately negotiated transactions. In March 2019, the Company used cash of $494.1 million and an aggregate of 2.2 million shares of the Company’s common stock valued at $182.4 million for total consideration of $676.5 million to settle $493.4 million of the 2025 Notes, of which $0.7 million was used to pay off interest accrued on the 2025 Notes. The transaction resulted in a loss on settlement of convertible notes of $187.7 million, which is reflected in interest expense in the Company’s consolidated statement of operations. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of repurchase.
In February 2020, the Company issued and sold $1.15 billion in aggregate principal amount of 0.375% Convertible Notes (the “2028 Notes” and, collectively with the 2025 Notes and the 2027 Notes, the “Notes”) with a maturity date of March 1, 2028. The 2028 Notes accrue interest at a fixed rate of 0.375% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2020. The net proceeds from the issuance of the 2028 Notes were approximately $1.13 billion, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.
In February 2020, the Company used $150.1 million of the proceeds from the issuance of the 2028 Notes to settle $100.0 million of the 2025 Notes, of which $0.1 million was used to pay off interest accrued on the 2025 Notes. The transaction resulted in a loss on settlement of convertible notes of $50.8 million, which is recorded in interest expense in the Company’s consolidated statement of operations. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of repurchase.
In February 2023, the Company entered into a privately negotiated exchange and purchase agreement with a single holder of certain of the Company’s 2027 Notes and 2028 Notes. The Company issued the holder $500.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 (the “2030 Notes”) in exchange for $183.7 million of aggregate principal of 2027 Notes, $201.0 million of aggregate principal of 2028 Notes, and $138.0 million of cash. The extinguishment resulted in a gain on settlement of convertible notes of $17.7 million, which is included in interest expense in the consolidated statement of operations for the year ended December 31, 2023. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
In March 2023, the Company entered into a privately negotiated exchange agreement with two holders of certain of the 2025 Notes. The Company issued the holder $73.0 million aggregate principal amount of 2030 Notes in exchange for $65.8 million of aggregate principal of 2025 Notes. The extinguishment resulted in a loss on settlement of convertible notes of $7.4 million, which is included in interest expense in the consolidated statement of operations for the year ended December 31, 2023. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
The net proceeds from the issuance of the 2030 Notes were approximately $133.0 million, after deducting commissions and offering expenses payable by the Company. The 2030 Notes will mature on March 1, 2030 and bear interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023.
Summary of Conversion Features
Until the six-months immediately preceding the maturity date of the applicable series of the Company’s convertible notes (the “Notes”), each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert such Notes at any time. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election.
93
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
It is the Company’s intent and policy to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, 8.21, and 12.37 shares of common stock per $1,000 principal amount for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, $121.84, and $80.83 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively. The 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes are potentially convertible into up to 3.3 million, 5.0 million, 7.8 million, and 7.1 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indentures), will, under certain circumstances, be entitled to an increase in the conversion rate.
If the Company undergoes a “fundamental change” (as defined in the Indentures), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest.
Based on the closing price of the Company’s common stock of $73.98 on December 31, 2023, the if-converted values on the Notes do not exceed the principal amount.
The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company.
Ranking of Convertible Notes
The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company's existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries.
Issuance Costs
Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes:
(In thousands)
2030 Convertible Notes
$4,938 
2028 Convertible Notes
24,453 
2027 Convertible Notes
14,285 
2025 Convertible Notes
17,646 
Interest Expense
Interest expense on the Notes includes the following:
Year Ended December 31,
(In thousands)202320222021
Debt issuance costs amortization$5,350 $5,727 $5,727 
Debt discount amortization106 147 147 
Gain on settlement of convertible notes(10,324)— — 
Coupon interest expense18,072 10,266 10,266 
Total interest expense on convertible notes$13,204 $16,140 $16,140 
94
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The following table summarizes the effective interest rates of the Notes:
Year Ended December 31,
202320222021
2030 Convertible Notes
2.09 %— %— %
2028 Convertible Notes
0.63 %0.64 %0.64 %
2027 Convertible Notes
0.67 %0.68 %0.68 %
2025 Convertible Notes1.17 %1.18 %1.18 %
The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 1.04 years, 3.21 years, 4.17 years, and 6.17 years for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively.
(11) LICENSE AND COLLABORATION AGREEMENTS 
The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees.
Mayo Foundation for Medical Education Research
In June 2009, the Company entered into an exclusive, worldwide license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), under which Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition. The Company’s license agreement with Mayo was most recently amended and restated in September 2020.
The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property.
Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement.
The Company is also required to pay Mayo up to $3.0 million in sales-based milestone payments upon cumulative net sales of each product using the licensed Mayo intellectual property reaching specified levels.
The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement.
95
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company has incurred insignificant charges for the years ended December 31, 2023, 2022, and 2021, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company's consolidated statements of operations.
Johns Hopkins University
Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with Johns Hopkins University (“JHU”) for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU proprietary data in the development and commercialization of a blood-based, MCED test. The agreement terms would require the Company to pay single-digit sales-based royalties and up to $45.0 million in sales-based milestone payments if net sales of a licensed product using JHU proprietary data reach specified levels. The Company will record the sales-based royalties and sales-based milestones once achievement is deemed probable. The Company has not incurred charges related to the achievement of any sales-based royalties or sales-based milestones as of December 31, 2023.
Targeted Digital Sequencing (“TARDIS”) License Agreement
In January 2021, the Company entered into an exclusive, worldwide license to the proprietary TARDIS technology, which the Company intends to develop and commercialize as a molecular residual disease (“MRD”) test, from The Translational Genomics Research Institute (“TGen”), an affiliate of City of Hope. Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. The Company accounted for this transaction as an asset acquisition. In connection with the asset acquisition, the Company paid upfront fair value consideration of $52.3 million comprised of $25.0 million in cash and issuance of 191,336 shares of common stock valued at $27.3 million based on the average of the high and low market price of the Company’s shares on the acquisition date. In addition, the Company is obligated to make milestone payments to TGen of up to $45.0 million in sales-based milestone payments upon cumulative net sales related to MRD detection and/or treatment reaching specified levels. These payments are contingent upon achievement of these cumulative revenues on or before December 31, 2030. The upfront consideration was recorded to research and development expense in the consolidated statement of operations immediately after acquisition as the asset was deemed to be incomplete and had no alternative future use at the time of acquisition. The Company will record the sales milestones once achievement is deemed probable. No acquisition related costs were incurred in this asset acquisition during the year ended December 31, 2021.
Broad Institute, Inc.
In June 2023, the Company entered into an exclusive license agreement with Broad Institute, Inc. (“Broad Institute”) to utilize the Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (“MAESTRO”) technology in the Company’s MRD testing. Under the license agreement, the Company is obligated to make development milestone payments to Broad Institute of up to $6.5 million upon achievement of certain development milestones related to prospective MRD tests that use the MAESTRO technology. In addition, the Company is obligated to make sales-based milestone payments to Broad Institute that equate up to a mid-single-digit royalty upon the achievement of certain cumulative net sales targets of licensed products using the MAESTRO technology beginning at $500.0 million. The Company will record the development milestones once achieved and the sales milestones once achievement is deemed probable. The Company has not incurred any charges related to the achievement of development milestones or sales milestones as of December 31, 2023.
Watchmaker Genomics, Inc.
In July 2023, the Company entered into a co-exclusive development and license agreement with Watchmaker Genomics, Inc. (“Watchmaker”) under which the Company granted Watchmaker a co-exclusive license to the non-bisulfite technology for the detection of methylated DNA and other epigenetic modifications (“TAPS”). TAPS is based on patents obtained by the Company through an exclusive license agreement with the Ludwig Institute for Cancer Research. Under the agreement, both parties have the right to use and develop TAPS for commercial purposes. The Company has the potential to receive up to $82.0 million in sales-based milestone payments and mid-single digit royalties based on future Watchmaker net sales of licensed products including TAPS. Additionally, Watchmaker has the right to sublicense TAPS, and the Company has the potential to receive royalties based on future Watchmaker sublicense receipts.
96
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
(12) PFIZER PROMOTION AGREEMENT
In August 2018, the Company entered into a Promotion Agreement (the “Original Promotion Agreement”) with Pfizer, Inc. (“Pfizer”), which was amended and restated in October 2020 (the “Restated Promotion Agreement”). The Restated Promotion Agreement extended the relationship between the Company and Pfizer and restructured the manner in which the Company compensates Pfizer for promotion of the Cologuard test through a service fee, and provision of certain other sales and marketing services related to the Cologuard test. The Restated Promotion Agreement included fixed and performance-related fees, some of which retroactively went into effect on April 1, 2020. In November 2021, the Company and Pfizer entered into an amendment to the Restated Promotion Agreement (the “November 2021 Amendment”), which provided that after November 30, 2021, Pfizer will no longer promote the Cologuard test to healthcare providers. The November 2021 Amendment provided that the Company pay Pfizer a total of $35.9 million in three installments, which occurred during the second, third, and fourth quarters of 2022. The November 2021 Amendment eliminated the Company's obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Cologuard test prior to November 30, 2021. The $35.9 million fee incurred as a result of the November 2021 Amendment was recognized in full during the fourth quarter of 2021. All payments to Pfizer are recorded in sales and marketing expenses in the Company's consolidated statements of operations.
Under the Original Promotion Agreement, the service fee was calculated based on incremental gross profits over specified baselines during the term. Under the Restated Promotion Agreement (and prior to giving effect to the November 2021 Amendment), the service fee provided a fee-for-service model that included certain fixed fees and performance-related bonuses. The performance-related bonuses were contingent upon the achievement of certain annual performance criteria with any applicable expense being recognized ratably upon achievement of the payment becoming probable. The Company incurred charges of $7.5 million, and $81.3 million for the service fee during the years ended December 31, 2022 and 2021, respectively. The Company incurred charges of $85.8 million, and $121.0 million for promotion, sales and marketing services performed by Pfizer on behalf of the Company during the years ended December 31, 2022 and 2021, respectively. All services provided by Pfizer under the November 2021 Amendment ended in the third quarter of 2022, and there were no payments made or charges incurred during the year ended December 31, 2023.
(13) STOCKHOLDERS' EQUITY
Stock Issuances
When the Company completes a business combination or asset acquisition, which are further described in Note 18, the Company may issue shares of the Company's common stock. Stock issuances in relation to acquisitions during the years ended December 31, 2023, 2022 and 2021 were as follows:
(In thousands, except for per share data)
Period of AcquisitionShares IssuedFair Value of Shares Issued
OmicEraMay 2022265,186$14,792 
PreventionGeneticsDecember 20211,070,41084,252 
AshionApril 2021125,44416,224 
ThriveJanuary 20219,323,2661,191,420 
TARDIS license
January 2021191,33527,263 
97
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Changes in Accumulated Other Comprehensive Income (Loss)
The amount recognized in AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:
(In thousands)Cumulative Translation Adjustment
Unrealized Gain (Loss) on Securities (1)
AOCI
Balance at January 1, 2021
$— $526 $526 
Other comprehensive income (loss) before reclassifications
23 (1,648)(1,625)
Amounts reclassified from accumulated other comprehensive income (loss)
— (514)(514)
Net current period change in accumulated other comprehensive loss23 (2,162)(2,139)
Income tax benefit related to items of other comprehensive loss
— 170 170 
Balance at December 31, 2021$23 $(1,466)$(1,443)
Other comprehensive income (loss) before reclassifications30 (4,049)(4,019)
Amounts reclassified from accumulated other comprehensive income (loss)
— 226 226 
Net current period change in accumulated other comprehensive loss30 (3,823)(3,793)
Balance at December 31, 2022$53 $(5,289)$(5,236)
Other comprehensive income (loss) before reclassifications1,321 1,416 2,737 
Amounts reclassified from accumulated other comprehensive income (loss)
— 3,927 3,927 
Net current period change in accumulated other comprehensive income (loss)
1,321 5,343 6,664 
Balance at December 31, 2023$1,374 $54 $1,428 
_________________________________
(1)There was no tax impact from the amounts recognized in AOCI for the years ended December 31, 2023 and 2022.
Amounts reclassified from AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:
Year Ended December 31,
Details about AOCI Components (In thousands)Affected Line Item in the
Statements of Operations		202320222021
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investments
Investment income (loss)
$3,927 $226 $(514)
Total reclassifications$3,927 $226 $(514)
(14) STOCK-BASED COMPENSATION
Stock-Based Compensation Plans
The Company maintains the following plans for which awards were granted from or had awards outstanding in 2023: the 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan. These plans are collectively referred to as the “Stock Plans.”
The Stock Plans are administered by the Human Capital Committee of the Company’s Board of Directors (“Human Capital Committee”). The 2019 Omnibus Long-Term Incentive Plan provides that upon an acquisition of the Company, all equity will accelerate by a period of one year. In addition, upon the termination of an employee without cause or for good reason prior to the first anniversary of the completion of the acquisition, all equity awards then outstanding under the respective plan held by that employee will immediately vest.
98
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
2019 Omnibus Long-Term Incentive Plan. The Company adopted the 2019 Omnibus Long-Term Incentive Plan (the “2019 Stock Plan”) on July 25, 2019 to grant share-based awards to employees, officers, directors, consultants and advisors. Awards granted under the 2019 Stock Plan may include incentive stock options, as defined under the Internal Revenue Code, non-qualified options, restricted stock awards and other stock awards in amounts and with terms and conditions determined by the Human Capital Committee, subject to the provisions of the 2019 Stock Plan. The 2019 Stock Plan will expire on July 25, 2029 and after such date no further awards may be granted under the plan. Options granted under the 2019 Stock Plan expire ten years from the date of grant. Grants made from the 2019 Stock Plan generally vest over a period of three to four years. At December 31, 2023, options to purchase 404,833 shares were outstanding under the 2019 Stock Plan and 7,867,224 shares of restricted stock and restricted stock units were outstanding. The Company's stockholders approved amendments to the 2019 Stock Plan to increase the number of shares available for future grant thereunder by 14,000,000 and 4,340,000 shares on June 9, 2022 and June 8, 2023, respectively. At December 31, 2023, there were 16,046,161 shares available for future grant under the 2019 Stock Plan.
2010 Omnibus Long-Term Incentive Plan.  The Company adopted the 2010 Omnibus Long-Term Incentive Plan (the “2010 Stock Plan”) on July 16, 2010 to grant share-based awards to employees, officers, directors, consultants and advisors. Awards granted under the 2010 Stock Plan may include incentive stock options, as defined under the Internal Revenue Code, non-qualified options, restricted stock awards and other stock awards in amounts and with terms and conditions determined by the Human Capital Committee, subject to the provisions of the 2010 Stock Plan. The 2010 Stock Plan expired on July 16, 2020 and after such date no further awards may be granted under the plan. Options granted under the 2010 Stock Plan expire ten years from the date of grant. Grants made from the 2010 Stock Plan generally vest over a period of three to four years. At December 31, 2023, options to purchase 881,340 shares were outstanding under the 2010 Stock Plan and 3,340 shares of restricted stock and restricted stock units were outstanding. At December 31, 2023, there were no shares available for future grant under the 2010 Stock Plan.
2010 Employee Stock Purchase Plan.  The 2010 Employee Stock Purchase Plan (the “2010 Purchase Plan”) was adopted by the Company on July 16, 2010 to provide participating employees the right to purchase shares of common stock at a discount through a series of offering periods. The 2010 Purchase Plan will expire on October 31, 2030. The Company’s stockholders approved amendments to the 2010 Employee Stock Purchase Plan to increase the number of shares available for purchase thereunder by 500,000 shares, 2,000,000 shares, and 3,000,000 shares on July 24, 2014, July 28, 2016, and June 9, 2022, respectively. At December 31, 2023, there were 1,834,193 shares of common stock available for purchase by participating employees under the 2010 Purchase Plan.
Generally, all employees whose customary employment is more than 20 hours per week and more than five months in any calendar year are eligible to participate in the 2010 Purchase Plan. Participating employees authorize an amount, between 1% and 15% of the employee’s compensation, to be deducted from the employee’s pay during the offering period. On the last day of the offering period, the employee is deemed to have exercised the employee’s option to purchase shares of Company common stock, at the option exercise price, to the extent of accumulated payroll deductions. Under the terms of the 2010 Purchase Plan, the option exercise price is an amount equal to 85% of the fair market value, as defined under the 2010 Purchase Plan, and no employee can purchase more than $25,000 of Company common stock under the 2010 Purchase Plan in any calendar year. Rights granted under the 2010 Purchase Plan terminate upon an employee’s voluntary withdrawal from the 2010 Purchase Plan at any time or upon termination of employment. At December 31, 2023, there were 3,965,807 cumulative shares issued under the 2010 Purchase Plan.
Stock-Based Compensation Expense
The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards (“RSUs”), performance share units (“PSUs”), stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors.
99
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
A summary of non-cash stock-based compensation expense by expense category included in the Company's consolidated statements of operations for the years ended December 31, 2023, 2022, and 2021 is as follows:
Year Ended December 31,
(In thousands)
202320222021
Cost of sales
$20,761 $19,218 $16,835 
Research and development
41,242 33,825 49,723 
Sales and marketing
65,552 62,568 55,716 
General and administrative
103,757 91,212 216,952 
Total stock-based compensation$231,312 $206,823 $339,226 
As of December 31, 2023, there was approximately $354.8 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 2.42 years.
In connection with the acquisition of Thrive, the Company accelerated the vesting of shares of previously unvested stock options and restricted stock units for employees with qualifying termination events. During the year ended December 31, 2021, the Company accelerated 139,096 shares of previously unvested stock options and 58,171 shares of previously unvested restricted stock awards and restricted stock units and recorded $19.0 million of non-cash stock-based compensation for the accelerated awards. As further discussed in Note 18, the Company also recorded $86.2 million in stock-based compensation related to accelerated vesting of awards held by Thrive employees in connection with the acquisition.
Stock Options
The Company determined the fair value of each service-based option award on the date of grant using the Black-Scholes option-pricing model, which utilized several key assumptions including risk-free interest rate, expected term, expected volatility, and dividend yield. There were no option awards granted during the years ended December 31, 2023, 2022 and 2021.
A summary of stock option activity under the Stock Plans is as follows:
OptionsShares
Weighted Average Exercise Price
Weighted Average Remaining Contractual Term (Years)
Aggregate Intrinsic Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 2023
1,517,876 $44.82 4.7
Exercised(194,629)16.44 
Forfeited(37,074)95.02 
Outstanding, December 31, 2023
1,286,173 $47.67 3.8$42,878 
Vested and expected to vest, December 31, 2023
1,286,173 $47.67 3.8$42,878 
Exercisable, December 31, 2023
1,228,594 $45.32 3.7$42,878 
_________________________________
(1)     The total intrinsic value of options exercised during the years ended December 31, 2023, 2022, and 2021 was $11.7 million, $36.4 million, and $155.8 million, respectively, determined as of the date of exercise.
The Company received approximately $3.2 million, $6.5 million, and $14.4 million from stock option exercises during the years ended December 31, 2023, 2022 and 2021, respectively.
Restricted Stock and Restricted Stock Units
The fair value of restricted stock and restricted stock units is determined on the date of grant using the closing stock price on that day.
100
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
A summary of restricted stock and restricted stock unit activity is as follows:
Restricted SharesWeighted Average Grant Date Fair Value (1)
Outstanding, January 1, 2023
5,254,709 $85.87 
Granted3,510,373 62.36 
Released (2)(1,797,915)88.28 
Forfeited(694,404)73.54 
Outstanding, December 31, 2023
6,272,763 $73.39 
_________________________________
(1)     The weighted average grant date fair value of the restricted stock units granted during the years ended December 31, 2022 and 2021 was $68.18 and $129.16, respectively.
(2)     The fair value of restricted stock units vested and converted to shares of the Company's common stock was $158.2 million, $117.6 million, and $219.4 million for the years ended December 31, 2023, 2022, and 2021, respectively.
Performance Share Units
The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones.
A summary of performance share unit activity is as follows:
Performance Share Units (1)Weighted Average Grant Date Fair Value (2)
Outstanding, January 1, 2023967,846 $102.58 
Granted782,966 80.50 
Released (3)(12,284)78.32 
Forfeited(140,727)93.73 
Outstanding, December 31, 20231,597,801 $92.73 
_________________________________
(1)     The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of December 31, 2023 was 772,906.
(2)     The weighted average grant date fair value of the performance share units granted during the years ended December 31, 2022 and 2021 was $89.43 and $138.09, respectively.
(3)     The fair value of performance share units vested and converted to shares of the Company's common stock was $1.0 million and $27.2 million for the years ended December 31, 2023 and 2022, respectively. There were no performance share units vested and converted to shares of the Company's common stock during the year ended December 31, 2021.
101
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
Employee Stock Purchase Plan (“ESPP”)
A summary of ESPP activity is as follows:
Year Ended December 31,
(in thousands, except share and per share amounts)202320222021
Shares issued under the 2010 Purchase Plan924,448 668,605331,769
Cash received under the 2010 Purchase Plan$28,344 $25,491 $23,070 
Weighted average fair value per share of stock purchase rights granted during the period$16.32 $17.52 $34.93 
The 924,448 shares issued during the year ended December 31, 2023 were as follows:
Offering period ended
Number of Shares
Weighted Average price per Share
April 30, 2023544,453 $30.02 
October 31, 2023379,995 $31.57 
The fair value of ESPP shares is based on the assumptions in the following table:
Year Ended December 31,
202320222021
Risk-free interest rates
4.68% - 4.71%
1.49% - 4.71%
0.04% - 0.16%
Expected term (in years)
1.25
0.5 - 2
0.5 - 2
Expected volatility
63.13% - 67.30%
50.94% - 63.13%
43.00% - 68.51%
Dividend yield0%0%0%
Shares Reserved for Issuance
The Company has reserved shares of its authorized common stock for issuance pursuant to its employee stock purchase and equity plans, including all outstanding stock option grants noted above at December 31, 2023, as follows:
Shares reserved for issuance
2019 Stock Plan16,046,161 
2010 Purchase Plan
1,834,193 
17,880,354 
102
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
(15) COMMITMENTS AND CONTINGENCIES
Leases
The components of lease expense were as follows:
Year Ended December 31,
(In thousands)202320222021
Finance lease cost
Amortization of right-of-use assets$3,845 $4,612 $5,731 
Interest on lease liabilities800 808 1,018 
Operating lease cost36,576 36,291 31,730 
Short-term lease cost750 476 628 
Variable lease cost8,449 7,985 5,212 
Total lease Cost$50,420 $50,172 $44,319 
Supplemental disclosure of cash flow information related to the Company's cash and non-cash activities with its leases are as follows:
Year Ended December 31,
(In thousands)202320222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$39,301$33,448$27,461
Operating cash flows from finance leases783699938
Finance cash flows from finance leases3,5694,3455,290
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities (1)4,98624,57274,369
Right-of-use assets obtained in exchange for new finance lease liabilities5,44311,2765,460
Weighted-average remaining lease term - operating leases (in years)6.877.438.33
Weighted-average remaining lease term - finance leases (in years)2.803.272.95
Weighted-average discount rate - operating leases6.59 %6.37 %6.11 %
Weighted-average discount rate - finance leases7.43 %6.60 %5.36 %
_________________________________
(1)    This includes an insignificant amount of right-of-use assets acquired as part of the business combinations described in Note 18 for the years ended December 31, 2023 and 2022, and $39.6 million for the year ended December 31, 2021.
As of December 31, 2023 and 2022, the Company’s right-of-use assets from operating leases are $143.7 million and $167.0 million, respectively, which are reported in operating lease right-of-use assets in the Company’s consolidated balance sheets. As of December 31, 2023, the Company has outstanding operating lease obligations of $190.4 million, of which $29.4 million is reported in operating lease liabilities, current portion and $161.1 million is reported in operating lease liabilities, less current portion in the Company’s consolidated balance sheets. As of December 31, 2022, the Company had outstanding operating lease obligations of $210.8 million, of which $28.4 million is reported in operating lease liabilities, current portion and $182.4 million is reported in operating lease liabilities, less current portion in the Company’s consolidated balance sheets.
103
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
As of December 31, 2023 and 2022, the Company’s right-of-use assets from finance leases are $11.3 million and $10.2 million, respectively, which are reported in other long-term assets, net in the Company’s consolidated balance sheets. As of December 31, 2023, the Company has outstanding finance lease obligations of $11.9 million, of which $4.4 million is reported in other current liabilities and $7.5 million is reported in other long-term liabilities in the Company’s consolidated balance sheets. As of December 31, 2022, the Company had outstanding finance lease obligations of $10.6 million, of which $3.2 million is reported in other current liabilities and $7.4 million is reported in other long-term liabilities in the Company’s consolidated balance sheets.
Maturities of operating lease liabilities on an annual basis as of December 31, 2023 were as follows:
(In thousands)
2024$39,476 
202536,660 
202634,851 
202734,226 
202827,901 
Thereafter66,634 
Total minimum lease payments239,748 
Imputed interest(49,299)
Total$190,449 
Maturities of finance lease liabilities on an annual basis as of December 31, 2023 were as follows (amounts in thousands):
(In thousands)
2024$5,044
20254,552
20262,797
2027827
2028—
Thereafter—
Total minimum lease payments13,220
Imputed interest(1,279)
Total$11,941
Legal Matters
The Company accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices.
104
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
As of the date of this Annual Report on Form 10-K, amounts accrued for legal proceedings and regulatory matters were not significant except for the amounts accrued related to the matters discussed below. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings, including as described below. Except for the proceedings discussed below, the Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity.
DOS Rule Matter
In September 2023, the Company’s wholly owned subsidiary Genomic Health, Inc., which was acquired in November 2019, entered into a settlement agreement with the United States of America, acting through the Department of Justice (“DOJ”) and on behalf of the Office of Inspector General of the Department of Health and Human Services, and two qui tam relators to resolve the previously disclosed civil investigation concerning Genomic Health’s compliance with the Medicare Date of Service billing regulations (the “DOS Rule Matter”). Genomic Health entered into the settlement agreement to avoid the delay, uncertainty and expense of protracted litigation. The settlement agreement contains no admission of liability by Genomic Health.
Under the terms of the settlement agreement, the Company made a payment of $32.5 million in September 2023, of which $22.4 million and $10.1 million is included in general and administrative expenses in the Company’s consolidated statements of operations for the years ended December 31, 2023 and 2021, respectively. Following the United States’ receipt of the settlement payment, the Company was released from any civil or administrative monetary claims under the civil False Claims Act and other specified civil statutes and common law theories of liability concerning the conduct identified in the settlement agreement.
On September 29, 2023, the United States District Court for the Eastern District of New York unsealed two qui tam actions filed under the False Claims Act involving the DOS Rule Matter, and on October 2, 2023, those two actions were dismissed with prejudice pursuant to the terms of the settlement agreement.
Gift Card Matter
In September 2023, the Company entered into a settlement agreement to resolve the previously disclosed False Claims Act qui tam suit that alleged a violation of the Federal Anti-Kickback Statute and False Claims Act for offering gift cards to patients in exchange for returning the Cologuard screening test (the “Qui Tam Suit”). In accordance with the settlement agreement, the Company made payment of $13.8 million plus legal fees in October 2023, which is included in general and administrative expenses in the Company's consolidated statement of operations for the year ended December 31, 2023. Following payment of the settlement amount, the Company was released from any civil or administrative monetary claims under the civil False Claims Act and other specified civil statutes and common law theories of liability concerning the conduct identified in the settlement agreement. On November 1, 2023, the court dismissed the qui tam suit with prejudice pursuant to the terms of the settlement agreement.
(16) EMPLOYEE BENEFIT PLAN
The Company maintains a qualified 401(k) retirement savings plan for Exact Sciences employees (the “401(k) Plan”). The Company also maintains additional retirement savings plans that are acquired as a result of business combinations. These plans are maintained for a period of time before being merged into the 401(k) Plan. Under the terms of the 401(k) Plan, participants may elect to defer a portion of their compensation into the 401(k) Plan, subject to certain limitations. Company matching contributions may be made at the discretion of the Company's Human Capital Committee.
The Human Capital Committee approved 401(k) Plan matching contributions for the years ended December 31, 2023, 2022, and 2021 in the form of Company common stock equal to 100% of a participant's elective deferrals up to 6% of the participant’s eligible compensation for that year. The Company recorded compensation expense of approximately $40.6 million, $36.5 million, and $30.0 million, respectively, in the statements of operations for the years ended December 31, 2023, 2022, and 2021.
105
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
(17) WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS
During December 2021, the Company entered into an amended agreement (“Amended WEDC Agreement”) with the Wisconsin Economic Development Corporation (“WEDC”) to earn $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the agreement.
The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC.
The Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned.
As of December 31, 2023, the Company has earned $11.0 million of the refundable tax credits under the Amended WEDC Agreement. The unpaid portion is $9.3 million, of which $3.8 million is reported in prepaid expenses and other current assets and $5.5 million is reported in other long-term assets, net in the Company's consolidated balance sheets reflecting when collection of the refundable tax credits is expected to occur. During the years ended December 31, 2023, 2022, and 2021, the amounts recorded as an offset to capital expenditures and operating expenses for the tax credits earned were not significant.
(18) ACQUISITIONS AND DIVESTITURES
Business Combinations
Resolution Bioscience, Inc.
On September 12, 2023, the Company completed the acquisition of all of the outstanding capital stock of Resolution Bioscience, Inc. from Agilent Technologies, Inc. Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions through its Clinical Laboratory Improvement Amendments (“CLIA”) certified lab based in Kirkland, Washington. The acquisition provides the Company with a high-quality blood-based therapy selection platform, complementing its comprehensive, tissue-based OncoExTraTM test. The Company has included the financial results of Resolution Bioscience in the consolidated financial statements from the date of the acquisition.
The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:
(In thousands)
Cash$52,527 
Fair value of replaced equity awards1,675 
Total purchase price$54,202 
The Company replaced unvested RSUs with a combination-date fair value of $4.6 million. Of the total consideration for replaced equity awards, $1.7 million was allocated to the consideration transferred, and $2.9 million was deemed compensatory as it was attributable to post acquisition vesting. The compensatory replaced equity awards will be expensed over the remaining service periods on a straight-line basis.
106
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:
(In thousands)
Net operating assets$14,663 
Developed technology26,000 
Total identifiable assets acquired40,663 
Net operating liabilities(7,152)
Net identifiable assets acquired33,511 
Goodwill20,691 
Net assets acquired$54,202 
The Company recorded a $26.0 million identifiable intangible asset related to the developed technology associated with Resolution Bioscience’s liquid biopsy therapy selection tests. Developed technology represents purchased technology that had reached technological feasibility and for which Resolution Bioscience had substantially completed development as of the acquisition date. The fair value of the developed technology has been determined using the multi-period excess earnings method of the income approach, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected revenues, gross margins, operating expenses, obsolescence, and an estimated discount rate. The developed technology intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years.
The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the acquired workforce expertise and expected sales force and therapy selection product portfolio synergies. The total goodwill related to this acquisition is deductible for tax purposes.
The total purchase price allocation is preliminary and based upon estimates and assumptions that are subject to change within the measurement period as additional information for the estimates is obtained. The measurement period remains open pending the completion of valuation procedures related to the acquired assets and assumed liabilities, including in connection with the developed technology intangible asset.
The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Resolution Bioscience, as though the companies were combined as of the beginning of January 1, 2022.
Twelve Months Ended December 31,
(In thousands)20232022
Total revenues$2,507,111 $2,097,680 
Net loss before tax(237,854)(675,091)

The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the results that would have been achieved if the acquisition had taken place at such time. Expected cost savings and other synergistic benefits resulting from the acquisition were not reflected in the unaudited pro forma financial information. The Company did not have any significant, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported unaudited pro forma financial information. Revenue and net loss before tax from Resolution Bioscience included in the Company's consolidated statements of operations for the year ended December 31, 2023 was not significant.
Acquisition-related costs were not significant and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the acquisition.
107
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
OmicEra Diagnostics, GmbH
On May 2, 2022, the Company completed the acquisition (the “OmicEra Acquisition”) of all of the outstanding equity interests of OmicEra Diagnostics GmbH. The OmicEra Acquisition provided the Company a state-of-the-art proteomics lab based in Planegg, Germany. OmicEra combines its mass spectrometry-based proteome analysis technology with its in-house proteomics scientific expertise to discover more reliable and valuable protein biomarkers, which will expand the Company’s research and development capabilities. The Company has included the financial results of OmicEra in the consolidated financial statements from the date of the acquisition.
The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:
(In thousands)
Common stock issued$14,792 
Contingent consideration4,600 
Cash paid related to working capital adjustment16 
Total purchase price$19,408 
The fair value of the 265,186 common shares issued as part of the consideration transferred was determined on the basis of the average of the high and low market price of the Company’s shares on the acquisition date, which was $55.78.
The purchase agreement requires the Company to pay a maximum of $6.0 million of additional cash consideration to OmicEra upon the achievement of certain earnout conditions related to the identification of protein biomarkers, as well as the growth of the proteomics research and development team. The fair value of the contingent consideration at the acquisition date was $4.6 million. The fair value of the contingent consideration was estimated using a probability-weighted scenario-based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7.
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:
(In thousands)
Net operating assets$2,586 
Developed technology10,000 
Total identifiable assets acquired12,586 
Net operating liabilities(3,987)
Net identifiable assets acquired8,599 
Goodwill10,809 
Net assets acquired$19,408 
The Company recorded $10.0 million of identifiable intangible assets related to the developed technology associated with OmicEra’s proteome analysis platform. Developed technology represents purchased technology that had reached technological feasibility and for which OmicEra had substantially completed development as of the date of acquisition. The fair value of the developed technology has been determined using the income approach multi-period excess earnings method, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, margin, obsolescence factor, required rate of return, and tax rate. Cash flows were discounted to their present value as of the closing date. The developed technology intangible asset is amortized on a straight-line basis over its estimated useful life of 16 years.
108
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The calculation of the excess purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the acquired workforce expertise, the potential to enhance the capabilities of current and future products, and expected research and development synergies. The total goodwill related to this acquisition is deductible for tax purposes.
Pro forma impact and results of operations disclosures have not been included due to insignificance.
Acquisition-related costs were not significant and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the merger.
PreventionGenetics, LLC
On December 31, 2021, the Company completed the acquisition (the “PreventionGenetics Acquisition”) of all of the outstanding equity interests of PreventionGenetics, LLC. The PreventionGenetics Acquisition provided the Company a CLIA certified and College of American Pathologist (“CAP”) accredited sequencing lab based in Marshfield, Wisconsin. PreventionGenetics provides more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline, whole exome (“PGxome®”), and whole genome (“PGnome®”) sequencing tests. The Company has included the financial results of PreventionGenetics in the consolidated financial statements from the date of the acquisition.
The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following:
(In thousands)
Cash$101,129
Common stock issued84,252
Total purchase price$185,381
The fair value of the 1,070,410 common shares issued as part of consideration transferred was determined on the basis of the average of the high and low market price of the Company's shares on the acquisition date, which was $78.71.
Of the total $101.1 million of consideration settled through the payment of cash, $85.8 million was paid as of December 31, 2021. The remaining $15.3 million represented withheld cash consideration used to cover working capital adjustments or seller claims that arose following the completion of the acquisition. The withheld cash consideration was settled during the year ended December 31, 2022, and there is no remaining liability on the consolidated balance sheet.
Acquisition-related costs were not significant and were recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger.
Ashion Analytics, LLC
On April 14, 2021, the Company completed the acquisition (“Ashion Acquisition”) of all of the outstanding equity interests of Ashion Analytics, LLC from PMed Management, LLC (“PMed”), which is a subsidiary of The Translational Genomics Research Institute. The Ashion Acquisition provided the Company a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona. Ashion developed GEM ExTra®, a comprehensive genomic cancer test, and provides access to whole exome, matched germline, and transcriptome sequencing capabilities. The Company has included the financial results of Ashion in the consolidated financial statements from the date of the acquisition.
109
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following:
(In thousands)
Cash$74,775
Common stock issued16,224
Contingent consideration19,000
Total purchase price$109,999
The fair value of the 125,444 common shares issued as part of consideration transferred was determined on the basis of the average of the high and low market price of the Company's shares on the acquisition date, which was $129.33.
The contingent consideration arrangement requires the Company to pay $20.0 million of additional cash consideration to PMed upon the Company’s commercial launch, on or before the tenth anniversary of the Ashion Acquisition, of a test for MRD detection and/or treatment (the “Commercial Launch Milestone”). The fair value of the Commercial Launch Milestone at the acquisition date was $19.0 million. The contingent consideration arrangement also requires the Company to pay $30.0 million of additional cash upon the Company’s achievement, on or before the fifth anniversary of the Ashion Acquisition, of cumulative revenues from MRD products of $500.0 million (the “MRD Product Revenue Milestone”). No value was ascribed to the MRD Product Revenue Milestone based on probability assessments as of the acquisition date. The fair value of the Commercial Launch Milestone and MRD Product Revenue Milestone was estimated using a probability-weighted scenario based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7.
Acquisition-related costs were not significant and were recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger.
Thrive Earlier Detection Corporation
On January 5, 2021, the Company completed the acquisition (“Thrive Merger”) of all of the outstanding capital stock of Thrive Earlier Detection Corporation. Thrive, headquartered in Cambridge, Massachusetts, is a healthcare company dedicated to incorporating earlier cancer detection into routine medical care. The Company expects that combining Thrive’s early-stage MCED test with the Company’s scientific platform, clinical organization, and commercial infrastructure will bring an accurate blood-based, MCED test to patients faster. The Company has included the financial results of Thrive in the consolidated financial statements from the date of the acquisition.
The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following:
(In thousands)
Common stock issued$1,175,431
Cash584,996
Contingent consideration331,348
Fair value of replaced equity awards52,245
Previously held equity investment fair value43,034
Total purchase price$2,187,054
The Company issued 9,323,266 common shares that had a fair value of $1.19 billion based on the average of the high and low market price of the Company's shares on the acquisition date, which was $127.79. Of the total consideration for common stock issued, $1.18 billion was allocated to the purchase consideration and $16.0 million was recorded as compensation within general and administrative expenses in the consolidated statement of operations on the acquisition date due to accelerated vesting of legacy Thrive restricted stock awards (“RSA”) and RSU awards in connection with the acquisition.
110
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The Company paid $590.2 million in cash on the acquisition date. Of the total consideration for cash, $585.0 million was allocated to the purchase consideration and $5.2 million was recorded as compensation within general and administrative expenses on the acquisition date due to accelerated vesting of legacy Thrive RSU and RSAs that were cash-settled in connection with the acquisition.
The contingent consideration arrangement requires the Company to pay up to $450.0 million of additional cash consideration to Thrive’s former shareholders upon the achievement of two discrete events, FDA approval and CMS coverage, for $150.0 million and up to $300.0 million, respectively. The fair value of the contingent consideration arrangement at the acquisition date was $352.0 million. The fair value of the contingent consideration was estimated using a probability-weighted scenario based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7. Of the total fair value of the contingent consideration, $331.3 million was allocated to the consideration transferred, $6.4 million was allocated to the Company’s previous ownership interest in Thrive, and $14.3 million was deemed compensatory as participation is dependent on replaced unvested equity awards vesting which requires future service. Compensation expense related to the milestones could be up to $18.2 million undiscounted and will be recognized in the future once probable and payable.
The Company replaced unvested stock options, RSUs, and RSAs and vested stock options with an acquisition-date fair value of $197.0 million. Of the total consideration for replaced equity awards, $52.2 million was allocated to the consideration transferred and $144.8 million was deemed compensatory as it was attributable to post acquisition vesting. Of the total compensation related to replaced awards, $65.0 million was expensed on the acquisition date due to accelerated vesting of stock options in connection with the acquisition and $79.8 million relates to future services and will be expensed over the remaining service periods of the unvested stock options, RSUs, and RSAs on a straight-line basis. Including expense recognized for accelerated vesting of RSUs and RSAs described above, total expected stock-based compensation expense is $166.0 million, of which $86.2 million was recognized immediately to general and administrative expenses in the consolidated statement of operations due to accelerated vesting.
The fair value of the stock options assumed by the Company was determined using the Black-Scholes option pricing model. The fair value of the RSA and RSUs assumed by the Company was determined based on the average of the high and low market price of the Company’s shares on the acquisition date. The share conversion ratio of 0.06216 was applied to convert Thrive’s outstanding equity awards for Thrive’s common stock into equity awards for shares of the Company’s common stock.
The fair value of options assumed were based on the assumptions in the following table:
Option Plan Shares Assumed
Risk-free interest rates
0.11% - 0.12%
Expected term (in years)
1.26 - 1.57
Expected volatility
65.54% - 71.00%
Dividend yield
0%
Weighted average fair value per share of options assumed
$109.74 - $124.89
The Company previously held a preferred stock investment of $12.5 million in Thrive and recognized a gain of approximately $30.5 million on the transaction within investment income (expense), net on the Company’s consolidated statement of operations, which represented the adjustment of the Company’s historical investment to the acquisition date fair value. The fair value of the Company’s previous ownership in Thrive was determined based on the pro-rata share payout applied to the Company’s interest combined with the fair value of the Company’s share of the contingent consideration arrangement, as discussed above.
The net loss before tax of Thrive included in the Company’s consolidated statement of operations from the acquisition date of January 5, 2021 to December 31, 2022 was $255.0 million.
111
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Thrive, as though the companies were combined as of the beginning of January 1, 2020.
Year Ended December 31,
(In thousands)20212020
Total revenues$2,084,279 $1,767,087 
Net loss before tax(761,337)(1,014,352)
The unaudited pro forma financial information for all periods presented above has been calculated after adjusting the results of Thrive to reflect the business combination accounting effects resulting from this acquisition. The Company incurred $86.2 million of stock-based compensation expense related to accelerated vesting in connection with the acquisition, $13.5 million of stock-based compensation expense related to accelerated vesting for employees with qualifying termination events, and $10.3 million of transaction costs incurred to execute the acquisition during the first quarter of 2021. These expenses are included in general and administrative expenses on the consolidated statement of operations for the year ended December 31, 2021 and are reflected in pro forma earnings for the year ended December 31, 2020 in the table above. The Company recorded a realized gain of $30.5 million during the first quarter of 2021 in investment income (expense), net on the Company’s consolidated statement of operations relating to the Company’s pre-acquisition investment in Thrive. This gain has been reduced to $7.6 million due to the Company’s smaller ownership interest in Thrive on January 1, 2020, and is reflected in pro forma earnings for the year ended December 31, 2020 in the table above. The Company recorded a remeasurement of contingent consideration of $7.2 million related to Thrive in general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2021. This expense is reflected in the year ended December 31, 2020 in the table above. The historical consolidated financial statements have been adjusted in the unaudited pro forma combined financial information to give effect to pro forma events that are directly attributable to the business combination and factually supportable. The unaudited pro forma financial information is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2020.
During the year ended December 31, 2021, the Company incurred $10.3 million of acquisition-related costs recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger.
In connection with acquisition-related severances, the Company recorded $19.0 million of expense related to vesting of previously unvested equity awards and $3.9 million of additional benefit charges for the year ended December 31, 2021.
Asset Acquisitions
PFS Genomics Inc.
On May 3, 2021, the Company acquired 90% of the outstanding capital stock of PFS Genomics Inc. (“PFS”). On June 23, 2021, the Company completed the acquisition of the remaining 10% interest in PFS. The Company paid cash of $33.6 million for 100% of the outstanding capital stock in PFS. PFS is a healthcare company focused on personalizing treatment for breast cancer patients to improve outcomes and reduce unnecessary treatment. The Company expects this acquisition to expand its ability to help guide early-stage breast cancer treatment through individualized radiotherapy treatment decisions.
The transaction was treated as an asset acquisition under GAAP because substantially all of the fair value of the gross assets acquired were deemed to be associated with the acquired technology.
Acquisition related costs were not significant in this asset acquisition.
Divestitures
Oncotype DX Genomic Prostate Score Test
On August 2, 2022, pursuant to an asset purchase agreement (“Asset Purchase Agreement”) with MDxHealth SA, the Company completed the sale of the intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test, which will allow the Company to focus on the highest impact projects core to the Company’s vision.
112
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The closing date fair value of the consideration received for the asset was approximately $29.6 million, which consisted of the following:
(In thousands)
Cash$25,000 
MDxHealth American Depository Shares 4,631 
Contingent consideration— 
Total consideration$29,631 
The fair value of the 691,171 American Depository Shares received as part of the consideration transferred was determined on the basis of the average of the high and low market price of the MDxHealth’s shares on the date of divestiture, which was $6.70, and is included in marketable securities on the consolidated balance sheet.
The Asset Purchase Agreement required MDxHealth to pay the Company up to an additional $70.0 million of contingent consideration that would be earned and receivable in cash and/or equity based on the achievement of certain revenue milestones by MDxHealth between 2023 and 2025. Under the Asset Purchase Agreement, contingent consideration would have been recognized in the consolidated statement of operations when it was probable a significant reversal of a gain would not occur. As of December 31, 2022, no contingent consideration was probable of not resulting in a significant gain reversal due to minimum revenue thresholds in place and therefore it was fully constrained.
The carrying value of the developed technology intangible asset, which was previously included in intangible assets, net on the consolidated balance sheet, was $42.9 million as of the closing date. As a result of the sale, the Company recorded a loss of $13.2 million, which is included in other operating income (loss) in the consolidated statement of operations for the year ended December 31, 2022.
Further, the Company agreed to provide certain transitional services to MDxHealth through December 31, 2022 and lab testing services for a period of up to 24 months.
On August 23, 2023, the Company and MDxHealth executed the Second Amendment to the Asset Purchase Agreement (“Second Amendment”) related to the sale of the GPS test. Under the Second Amendment, the Company agreed to allow MDxHealth to defer the 2023 contingent consideration payment by three years in exchange for additional consideration and more favorable contingent consideration terms. The Company received additional consideration with a fair value of $3.1 million, which was recorded as a gain for the year ended December 31, 2023, and is included in other operating income (loss) in the consolidated statement of operations.
Under the Second Amendment, the maximum contingent consideration increased from $70.0 million to $82.5 million and the minimum revenue thresholds previously required to be met under the Asset Purchase Agreement were eliminated. As a result of the elimination of the minimum revenue thresholds, the Company determined that a significant reversal of a gain is not probable and therefore the contingent consideration is no longer constrained. The Company recorded a contingent consideration gain of $73.3 million during the year ended December 31, 2023, which is included in other operating income (loss) in the consolidated statement of operations. The gain was estimated using historical GPS test revenues by MDxHealth under the most likely amount method.
As of December 31, 2023, a portion of the contingent consideration is classified as a contract asset. The contract asset was $41.7 million and zero as of December 31, 2023 and 2022, respectively. The remaining balance of $31.6 million, which represents the amount earned during the 2023 earnout year, is classified as a receivable as of December 31, 2023. The contract asset and receivable are included in other long-term assets, net on the consolidated balance sheet.
Transaction-related costs were not significant and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the divestiture.
113
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
(19) SEGMENT INFORMATION
Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the financial information routinely reviewed by the Company’s Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company’s operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results.
The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.
Year Ended December 31,
(In thousands)202320222021
United States$2,346,489 $1,966,541 $1,657,174 
Outside of United States153,277 117,738 109,913 
Total revenues$2,499,766 $2,084,279 $1,767,087 
Long-lived assets located in countries outside of the U.S. are not significant.
(20) INCOME TAXES
Under financial accounting standards, deferred tax assets or liabilities are computed based on the differences between the financial statement and income tax bases of assets and liabilities using the enacted tax rates. Deferred income tax expense or benefit represents the change in the deferred tax assets or liabilities from period to period. At December 31, 2023, the Company had federal net operating loss, state net operating loss, and foreign net operating loss carryforwards of approximately $402.9 million, $66.0 million, and $10.4 million, respectively, for financial reporting purposes, which may be used to offset future taxable income. The Tax Cuts and Jobs Act (H.R. 1) of 2017 limits the deduction for net operating losses to 80% of current year taxable income and provides for an indefinite carryover period for federal net operating losses. Both provisions are applicable for losses arising in tax years beginning after December 31, 2017. As of December 31, 2023 the Company has $278.5 million of federal net operating loss carryovers incurred after December 31, 2017 with an unlimited carryover period and $124.4 million of federal net operating loss carryovers expiring at various dates through 2037. State and foreign net operating loss carryovers expire at various dates through 2043. All net operating loss carryforwards are subject to review and possible adjustment by federal, state and foreign taxing jurisdictions. The Company also had federal and state research tax credit carryforwards of $70.9 million and $33.0 million, respectively, which may be used to offset future income tax liability. The federal credit carryforwards expire at various dates through 2043 and are subject to review and possible adjustment by the Internal Revenue Service. The state credit carryforwards expire at various dates through 2038 with the exception of $19.7 million of California research and development tax credits that have an indefinite carryforward period. All state tax credits are subject to review and possible adjustment by local tax jurisdictions. In the event of a change of ownership, the federal and state net operating loss and research and development tax credit carryforwards may be subject to annual limitations provided by the Internal Revenue Code and similar state provisions.
Loss before provision for taxes consisted of the following:
Year Ended December 31,
(In thousands)202320222021
Loss before income taxes:
Domestic$(204,128)$(617,240)$(801,536)
Foreign2,382 (15,330)(40,970)
Total loss before income taxes$(201,746)$(632,570)$(842,506)
114
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
The expense (benefit) for income taxes consists of:
Year Ended December 31,
(In thousands)202320222021
Current expense (benefit):
Federal$— $— $— 
State2,266 2,170 1,388 
Foreign2,561 1,131 4,898 
Deferred tax expense (benefit):
Federal2,395 (3,292)(222,693)
State(1,829)(8,926)(30,528)
Foreign(2,990)(147)54 
Total income tax expense (benefit)$2,403 $(9,064)$(246,881)
The Company recorded income tax expense for the year ended December 31, 2023 of $2.4 million primarily related to current foreign and state tax expense.
The components of the net deferred tax asset with the approximate income tax effect of each type of carryforward, credit and temporary differences are as follows:
December 31,
(In thousands)20232022
Deferred tax assets:
Operating loss carryforwards$477,420 $553,320 
Tax credit carryforwards104,580 87,579 
Compensation related differences85,007 67,976 
Lease liabilities47,118 51,560 
Capitalized research and development191,468 108,117 
Other temporary differences10,275 19,353 
Tax assets before valuation allowance915,868 887,905 
Less - Valuation allowance(465,832)(419,356)
Total deferred tax assets450,036 468,549 
Deferred tax liabilities
Amortization$(415,064)$(435,991)
Property, plant and equipment(9,465)(4,653)
Lease assets(35,786)(40,674)
Other temporary differences(7,010)(6,944)
Total deferred tax liabilities(467,325)(488,262)
Net deferred tax liabilities$(17,289)$(19,713)
115
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income and the realization of deferred tax liabilities, management has determined that a valuation allowance of $465.8 million and $419.4 million at December 31, 2023 and 2022, respectively, is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Given the future limitations on and expiration of certain federal and state deferred tax assets, the recording of a valuation allowance resulted in a deferred tax liability of approximately $17.3 million remaining as of December 31, 2023, which is included in other long-term liabilities on the Company's consolidated balance sheet. The overall change in valuation allowance for December 31, 2023 and 2022 was an increase of $46.5 million and an increase of $157.1 million, respectively.
Activity associated with the Company's valuation allowance is as follows:
December 31,
(In thousands)202320222021
Balance as of January 1, $(419,356)$(262,238)$(293,397)
Valuation allowances established(44,759)(159,919)(206,574)
Changes to existing valuation allowances(1,242)2,780 (1,500)
Acquisition and purchase accounting(475)21 239,233 
Balance as of December 31,$(465,832)$(419,356)$(262,238)
During the year ended December 31, 2023, the Company recorded an increase to the valuation allowance of $44.8 million primarily related to losses from continuing operations.
During the year ended December 31, 2022, the Company recorded an increase to the valuation allowance of $159.9 million primarily related to losses from continuing operations.
During the year ended December 31, 2021, the Company recorded an increase to the valuation allowance of $206.6 million primarily related to losses from continuing operations. Offsetting the increase, the Company recorded a decrease to the valuation allowance of $239.2 million related to the Thrive Merger offset against goodwill.
The effective tax rate differs from the statutory tax rate due to the following:
December 31,
202320222021
U.S. Federal statutory rate21.0 %21.0 %21.0 %
State taxes3.9 3.9 3.6 
Federal and state tax rate changes1.1 (0.2)(0.3)
Foreign tax rate differential— (0.1)(0.6)
Acquired IPR&D asset expense— — (0.8)
Research and development tax credits7.6 2.3 0.7 
Stock-based compensation expense(4.4)(2.0)1.1 
Non-deductible executive compensation(3.5)(0.4)(0.2)
Transaction costs— — (0.1)
Loss on extinguishment - convertible debt(0.7)— — 
Other adjustments(2.5)1.2 1.2 
Valuation allowance(23.7)(24.4)3.7 
Effective tax rate(1.2)%1.3 %29.3 %
116
EXACT SCIENCES CORPORATION
Notes to Consolidated Financial Statements (Continued)
For the year ended December 31, 2023, the Company recognized a income tax expense, representing an effective tax rate of (1.2)%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of (1.2)% for the year ended December 31, 2023, was primarily attributable to the valuation allowance established against the Company's current period losses.
For the year ended December 31, 2022, the Company recognized an income tax benefit, representing an effective tax rate of 1.3%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 1.3% for the year ended December 31, 2022, was primarily attributable to the valuation allowance established against the Company's current period losses.
For the year ended December 31, 2021, the Company recognized an income tax benefit, representing an effective tax rate of 29.3%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 29.3% for the year ended December 31, 2021, was primarily attributable to an income tax benefit of $239.2 million recorded as a result of a change in the deferred tax asset valuation allowance resulting from the Thrive Merger.
The Company had unrecognized tax benefits related to federal and state research and development tax credits of $36.4 million, $28.3 million, and $21.8 million as of December 31, 2023, 2022, and 2021, respectively. These amounts have been recorded as a reduction to the Company's deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months.
The following is a tabular reconciliation of the amounts of unrecognized tax benefits:
December 31,
(In thousands)202320222021
January 1,$28,270 $21,780 $16,629 
Increase due to current year tax positions7,447 5,861 5,363 
Increase due to prior year tax positions1,108 629 — 
Decrease due to prior year tax positions(426)— (212)
Settlements— — — 
December 31,$36,399 $28,270 $21,780 
As of December 31, 2023, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2000 through 2023, and to state income tax examinations for the tax years 2000 through 2023. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for the years ended December 31, 2023, 2022 and 2021.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
There have been no disagreements with accountants on accounting or financial disclosure matters.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures.
As required by Rule 13a‑15(b) under the Securities Exchange Act of 1934 (the “Exchange Act”), our management, including our principal executive officer and principal financial officer, conducted an evaluation as of the end of the period covered by this report, of the effectiveness of our disclosure controls and procedures as defined in Rule 13a‑15(e) under the Exchange Act. Based on that evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of December 31, 2023 to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in Securities and Exchange Commission rules and forms and that material information relating to the Company is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosures.
117
Changes in Internal Control over Financial Reporting.
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) under the Exchange Act during the quarter ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Management’s Report on Internal Control over Financial Reporting.
Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a‑15(f) under the Exchange Act. The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
We conducted an evaluation, under the supervision and with the participation of our management, of the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework (2013). Based on our assessment, management, including our principal executive officer and principal financial officer, concluded that, as of December 31, 2023, our internal control over financial reporting was effective based on those criteria.
The effectiveness of the Company's internal control over financial reporting as of December 31, 2023 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.
Item 9B. Other Information
Rule 10b5-1 Trading Plans
During the fiscal quarter ended December 31, 2023, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as those terms are defined in Item 408 of Regulation S-K), except as follows:
On November 6, 2023, Daniel J. Levangie, a member of our board of directors, adopted a Rule 10b5-1 trading arrangement for the sale of 5,000 shares of our common stock. The arrangement's expiration date is March 15, 2024, subject to early termination for certain specified events set forth in the arrangement.
On November 13, 2023, James Doyle, a member of our board of directors, adopted a Rule 10b5-1 trading arrangement for the sale of 4,900 shares of our common stock. The arrangement's expiration date is August 30, 2024, subject to early termination for certain specified events set forth in the arrangement.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
118
PART III
Item 10. Directors, Executive Officers and Corporate Governance
The information required by this Item will be included in the Company’s definitive proxy statement to be filed with the SEC within 120 days after December 31, 2023, in connection with the solicitation of proxies for the Company’s 2024 Annual Meeting of Shareholders (the “2024 Proxy Statement”), and is incorporated herein by reference.
Item 11. Executive Compensation
The information required by this Item will be included in the 2024 Proxy Statement, and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item will be included in the 2024 Proxy Statement, and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this Item will be included in the 2024 Proxy Statement, and is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services
The information required by this Item will be included in the 2024 Proxy Statement, and is incorporated herein by reference.

119
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a)The following documents are filed as part of this Form 10‑K:
(1)    Financial Statements (see “Consolidated Financial Statements and Supplementary Data” at Item 8 and incorporated herein by reference).
(2)    Financial Statement Schedules (Schedules to the Financial Statements have been omitted because the information required to be set forth therein is not applicable or is shown in the accompanying Financial Statements or notes thereto).
(3)    Exhibits
Exhibit
Number		Exhibit DescriptionFiled with this ReportIncorporated by
Reference herein
from Form or
Schedule		Filing DateSEC File/ Registration Number
Agreement and Plan of Merger, dated July 28, 2019, by and among the Registrant, Spring Acquisition Corp. and Genomic Health, Inc.8-K
(Exhibit 2.1)		7/30/2019001-35092
Agreement and Plan of Merger, dated October 26, 2020, by and among the Registrant, certain subsidiaries of the Registrant, Thrive Earlier Detection Corp. and Shareholder Representative Services LLC8-K
(Exhibit 2.1)		10/27/2020001-35092
First Amendment to Agreement and Plan of Merger, dated December 23, 2020, by and among the Registrant, certain subsidiaries of the Registrant, Thrive Earlier Detection Corp. and Shareholder Representative Services LLC8-K
(Exhibit 2.1)		1/5/2021001-35092
Second Amendment to Agreement and Plan of Merger, dated January 4, 2021, by and among the Registrant, certain subsidiaries of the Registrant, Thrive Earlier Detection Corp. and Shareholder Representative Services LLC8-K
(Exhibit 2.2)		1/5/2021001-35092
Sixth Amended and Restated Certificate of Incorporation of the RegistrantS-1
(Exhibit 3.3)		12/4/2000333-48812
First Amendment to Sixth Amended and Restated Certificate of Incorporation of the Registrant
8-K
(Exhibit 3.1)		7/24/2020001-35092
Second Amendment to Sixth Amended and Restated Certificate of Incorporation of the Registrant
8-K
(Exhibit 3.1)
6/12/2023
001-35092
Seventh Amended and Restated By-Laws of the Registrant
8-K
(Exhibit 3.2)
6/12/2023001-35092
Specimen certificate representing the Registrant’s Common StockS-1
(Exhibit 4.1)		12/26/2000333-48812
120
Indenture, dated January 17, 2018, by and between the Registrant and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as Trustee
8-K
(Exhibit 4.1)		1/17/2018001-35092
First Supplemental Indenture, dated January 17, 2018, by and between the Registrant and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as Trustee (including the form of 1.0% Convertible Senior Notes due 2025)
8-K
(Exhibit 4.2)		1/17/2018001-35092
Second Supplemental Indenture, dated March 8, 2019, by and between the Registrant and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as Trustee (including the form of 0.3750% Convertible Senior Notes due 2027)8-K
(Exhibit 4.2)		3/8/2019001-35092
Third Supplemental Indenture, dated February 27, 2020, by and between the Registrant and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as Trustee (including the form of 0.3750% Convertible Senior Notes due 2028)
8-K
(Exhibit 4.2)
2/27/2020001-35092
Fourth Supplemental Indenture, dated March 1, 2023, between the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as Trustee (including the form of 2.00% Convertible Senior Notes due 2030)8-K
(Exhibit 4.2)		3/1/2023001-35092
Description of Common Stock10-K
(Exhibit 4.6)		2/16/2021001-35092
Lease Agreements
Second Amended and Restated Lease Agreement, dated September 28, 2018, by and between University Research Park Incorporated and the Registrant10-K
(Exhibit 10.1)		2/21/2019001-35092
Lease Agreement, dated June 25, 2013, by and between Tech Building I, LLC and Exact Sciences Laboratories, Inc.10-Q
(Exhibit 10.2)		8/2/2013001-35092
Lease Agreement, dated November 11, 2015, by and between Metropolitan Life Insurance Company and Genomic Health, Inc. 10-K
(Exhibit 10.3)		2/21/2020001-35092
First Amendment to Lease Agreement, dated October 4, 2019, by and between Metropolitan Life Insurance Company and Genomic Health, Inc.10-K
(Exhibit 10.4)		2/21/2020001-35092
121
Lease Agreement, dated September 23, 2005, by and between Metropolitan Life Insurance Company and Genomic Health, Inc.10-K
(Exhibit 10.5)		2/21/2020001-35092
First Amendment to Lease Agreement, dated September 5, 2006, by and between Metropolitan Life Insurance Company and Genomic Health, Inc.10-K
(Exhibit 10.6)		2/21/2020001-35092
Second Amendment to Lease Agreement, dated November 30, 2010, by and between Metropolitan Life Insurance Company and Genomic Health, Inc.10-K
(Exhibit 10.7)		2/21/2020001-35092
Third Amendment to Lease Agreement, dated November 11, 2015, by and between Metropolitan Life Insurance Company and Genomic Health, Inc.10-K
(Exhibit 10.8)		2/21/2020001-35092
Fourth Amendment to Lease Agreement, dated October 4, 2019, by and between Metropolitan Life Insurance Company and Genomic Health, Inc.10-K
(Exhibit 10.9)		2/21/2020001-35092
Agreements with Executive Officers and Directors
Employment Agreement, dated March 18, 2009, by and between Kevin T. Conroy and the Registrant8-K
(Exhibit 10.1)		3/18/2009000-32179
Employment Agreement, dated November 8, 2016, by and between Jeffrey T. Elliott and the Registrant10-K
(Exhibit 10.9)		2/21/2017001-35092
Employment Agreement, dated February 18, 2019, by and between Jacob Orville and the Registrant
10-K
(Exhibit 10.17)
2/21/2020001-35092
Employment Agreement, dated August 22, 2017, by and between Sarah Condella and the Registrant
10-K
(Exhibit 10.16)		2/16/2021001-35092
Employment Agreement, dated November 11, 2021, by and between Everett Cunningham and the Registrant
10-K
(Exhibit 10.15)
2/22/2022001-35092
Employment Agreement, dated September 2, 2022, by and between Brian Baranick and the Registrant10-Q
(Exhibit 10.1)		11/3/2022001-35092
Consulting Agreement, dated December 31, 2022, by and between Scott Coward and the Registrant10-K
(Exhibit 10.17)		2/21/2023001-35092
Equity Compensation Plans and Policies
The Registrant’s 2016 Inducement Award Plan10-Q
(Exhibit 10.3)		5/3/2016001-35092
The Registrant’s 2016 Inducement Award Plan Form Restricted Stock Unit Award AgreementS-8
(Exhibit 4.7)		5/3/2016333-211099
The Registrant’s 2010 Omnibus Long‑Term Incentive Plan (As Amended and Restated Effective July 27, 2017)10-Q
(Exhibit 10.1)		10/30/2017001-35092
122
The Registrant’s Executive Deferred Compensation Plan dated January 1, 201910-K
(Exhibit 10.22)		2/21/2019001-35092
Third Amendment to the Registrant's 2010 Employee Stock Purchase Plan10-Q
(Exhibit 10.1)		7/30/2019001-35092
The Registrant's 2019 Omnibus Long-Term Incentive PlanS-8
(Exhibit 4.4)		7/31/2019333-23916
The Registrant's 2019 Omnibus Long-Term Incentive Plan Form Stock Option Award Agreement
10-Q
(Exhibit 10.2)
8/1/2023001-35092
The Registrant's 2019 Omnibus Long-Term Incentive Plan Form Restricted Stock Unit Award Agreement
10-Q
(Exhibit 10.3)
8/1/2023001-35092
The Registrant's 2019 Omnibus Long-Term Incentive Plan Form Restricted Stock Award Agreement
10-Q
(Exhibit 10.4)
8/1/2023001-35092
The Registrant's 2019 Omnibus Long-Term Incentive Plan Form Deferred Stock Unit Award Agreement10-Q
(Exhibit 10.5)		8/1/2023001-35092
Genomic Health, Inc. Amended and Restated 2005 Stock Incentive Plan, as amended
S-8
(Exhibit 4.4)
11/8/2019333-234608
Thrive Earlier Detection Corp. 2019 Stock Option and Grant Plan
S-8
(Exhibit 4.6)
1/5/2021333-251900
The Registrant's Non-Employee Director Compensation Policy dated January 24, 202310-Q
(Exhibit 10.3)		5/9/2023001-35092
Amendment No. 1 to the Registrant's 2019 Omnibus Long-Term Incentive Plan8-K
(Exhibit 10.1)		6/9/2022001-35092
Amendment No. 2 to the Registrant's 2019 Omnibus Long-Term Incentive Plan8-K
(Exhibit 10.1)		6/12/2023001-35092
The Registrant's 2010 Employee Stock Purchase Plan (as amended and restated March 22, 2023)10-Q
(Exhibit 10.2)		5/9/2023001-35092
The Registrant's Equity Award, Death, Disability and Retirement PolicyX
Other
Technology License Agreement dated as of October 14, 2009 by and among Hologic, Inc., Third Wave Technologies, Inc., and the Registrant10-K
(Exhibit 10.39)		3/12/2010000-32179
Amendment dated December 7, 2012 to Technology License Agreement dated October 14, 2009 by and among Hologic, Inc., Third Wave Technologies, Inc., and the Registrant10-K
(Exhibit 10.37)		3/1/2013001-35092
123
Second Amended and Restated License Agreement dated effective January 31, 2020, by and between the Registrant and Mayo Foundation for Medical Education and Research10-Q
(Exhibit 10.1)		10/27/2020001-35092
Receivables Financing Agreement dated as of June 29, 2022 by and among Exact Receivables LLC, as borrower, the persons from time to time party thereto as lenders and group agents, PNC Bank, National Association, as administrative agent, Exact Sciences Laboratories, LLC, as initial servicer, and PNC Capital Markets, LLC, as structuring agent8-K
(Exhibit 10.1)		6/30/2022001-35092
Receivables Purchase Agreement dated as of June 29, 2022 by and among Exact Sciences Corporation, as seller, Exact Sciences Laboratories, LLC, as initial servicer, and Exact Receivables LLC, as buyer8-K
(Exhibit 10.2)		6/30/2022001-35092
Receivables Purchase Agreement dated as of June 29, 2022 by and among the entities from time to time party thereto as originators, Exact Sciences Laboratories, LLC, as initial servicer, and Exact Sciences Corporation, as buyer8-K
(Exhibit 10.3)		6/30/2022001-35092
Subsidiaries of the RegistrantX
Consent of PricewaterhouseCoopers, LLPX
24.1Power of Attorney (included on signature page)X
Certification Pursuant to Rule 13a‑14(a) or Rule 15d‑14(a) of the Securities Exchange Act of 1934X
Certification Pursuant to Rule 13a‑14(a) or Rule 15d‑14(a) of the Securities Exchange Act of 1934X
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
Incentive-Based Compensation Recovery PolicyX
101
The following materials from the Annual Report on Form 10-K of Exact Sciences Corporation for the year ended December 31, 2023 filed with the Securities and Exchange Commission on February 21, 2024, formatted in Inline eXtensible Business Reporting Language (“iXBRL”): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statement of Changes in Stockholders’ Equity, (iv) Consolidated Statements of Cash Flows and (v) related notes to these financial statements
X
124
104
The cover page from the Annual Report on Form 10-K of Exact Sciences Corporation for the year ended December 31, 2023 filed with the Securities and Exchange Commission on February 21, 2024, formatted in Inline eXtensible Business Reporting Language (“iXBRL”)
X
(*)    Indicates a management contract or any compensatory plan, contract or arrangement.
(**)    Confidential Treatment requested for certain portions of this Agreement.
(+)    Certain information has been omitted from this exhibit pursuant to Item 601 of Regulation S-K.
Item 16. Form 10-K Summary
Not applicable.
125
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
EXACT SCIENCES CORPORATION
Date: February 21, 2024By:/s/ Kevin T. Conroy
Kevin T. Conroy
President & Chief Executive Officer
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Exact Sciences Corporation, hereby severally constitute and appoint Kevin T. Conroy our true and lawful attorney, with full power to him to sign for us and in our names in the capacities indicated below, any amendments to this Annual Report on Form 10‑K, and generally to do all things in our names and on our behalf in such capacities to enable Exact Sciences Corporation to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all the requirements of the Securities Exchange Commission.
Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
NameTitleDate
s/ Kevin T. ConroyPresident and Chief Executive Officer (Principal Executive Officer) and Chairman of the BoardFebruary 21, 2024
Kevin T. Conroy
/s/ Jeffrey T. Elliott
Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
February 21, 2024
Jeffrey T. Elliott
/s/ Paul ClancyDirectorFebruary 21, 2024
Paul Clancy
/s/ D. Scott CowardDirectorFebruary 21, 2024
D. Scott Coward
/s/ James E. DoyleLead Independent DirectorFebruary 21, 2024
James E. Doyle
/s/ Freda Lewis-HallDirectorFebruary 21, 2024
Freda Lewis-Hall
/s/ Pierre JacquetDirectorFebruary 21, 2024
Pierre Jacquet
/s/ Daniel J. LevangieDirectorFebruary 21, 2024
Daniel J. Levangie
/s/ Shacey PetrovicDirectorFebruary 21, 2024
Shacey Petrovic
/s/ Tim Scannell
Director
February 21, 2024
Tim Scannell
/s/ Kathleen SebeliusDirectorFebruary 21, 2024
Kathleen Sebelius
/s/ Katherine S. ZanottiDirectorFebruary 21, 2024
Katherine S. Zanotti

126
 EX-10.33 2 exas-20231231xexx1033.htm EX-10.33 Document
EXHIBIT 10.33
EXACT SCIENCES CORPORATION
EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY
1.Introduction. This Equity Award Death, Disability and Retirement Policy, as amended (the “Policy”), specifies the treatment of each outstanding equity award (an “Equity Award”) granted by Exact Sciences Corporation, a Delaware corporation (including any successor thereto, the “Company”), in the event of the Death, Disability or Retirement (each as defined below) of the original grantee of such Equity Award (the “Grantee”). This Policy does not apply to (a) an Equity Award granted to an individual or entity in such individual’s or entity’s capacity as a non-employee service provider of the Company or a Subsidiary (as defined below), (b) an Equity Award held by an individual or entity other than the Grantee, or (c) an Equity Award granted under the Exact Sciences Corporation 2010 Employee Stock Purchase Plan, as may be amended or replaced (“ESPP”), regardless of whether such Equity Award was granted under the component of the ESPP intended to constitute an “employee stock purchase plan” under Section 423 of the Code (as defined below) or under the component of the ESPP that does not qualify as an “employee stock purchase plan” under Section 423 of the Code.
2.Effectiveness; Amendment; Termination. This Policy initially became effective on February 17, 2023 (the “Effective Date”) and was amended on October 25, 2023, and, as amended, applies to Equity Awards granted before, on or after such amendment date. The Company’s Board of Directors (or a duly delegated committee thereof) may, at any time and from time to time, amend, suspend, or terminate the Policy. Upon termination, the Policy will continue to apply to Equity Awards granted prior to such termination. No amendment, suspension, or termination of the Policy will, without the consent of a Grantee, materially impair the rights of, or obligations to, such Grantee with respect to an Equity Award granted prior to such amendment, suspension or termination. This Policy will be binding upon the Company’s successors and assigns.
3.Definitions. For purposes of this Policy:
a.“Code” means the Internal Revenue Code of 1986, as now in effect or as hereafter amended.
b.“Death” means the termination of a Grantee’s Service as a result of such Grantee’s death, as established by such Grantee’s death certificate.
c.“Disability” means a termination of a Grantee’s Service by the Company or a Subsidiary (i) as a result of such Grantee’s “disability,” if such term or term of similar import is defined in the applicable Grantee’s then-effective employment agreement or offer letter, and for all other Grantees, (ii) as a result of a determination by the Company’s group long-term disability plan carrier that the applicable Grantee has incurred a “disability,” as such term or term of similar import is defined in the Company’s group long-term disability plan, as may be amended from time to time, or (iii) for Grantees who are non-employee Service Providers at the time of such termination, following a determination by the Social Security Administration that such person has incurred a “disability,” provided that such non-employee Service Provider provides proof of such determination in a form satisfactory to the Company. Notwithstanding the foregoing, for Grantees whose primary work location is outside the United States, “disability” means a termination of such Grantee’s Service by the Company or a Subsidiary if: (i) at the time of termination, such Grantee is receiving disability benefits for a complete disability or such Grantee has been expressly determined to be completely disabled and eligible to receive benefits for a complete disability under applicable law, and (ii) the termination was a result of the complete disability.
d.“Equity Award” means a grant of an option, stock appreciation right, restricted stock, restricted stock unit, or other stock-based award.
e.“Retirement” means a termination of a Grantee’s Service voluntarily by the Grantee if such termination becomes effective on or after the date:
1


i.For a Grantee who holds a title of Vice President or below at the time of such resignation (as determined by the Company in its sole discretion), such Grantee attains age 55 and completes of 15 Years of Service (as defined below); and
ii.For a Grantee who holds a title above Vice President at the time of such resignation (as determined by the Company in its sole discretion), the Grantee: (1) attains age 55 and completes of 15 Years of Service or (2) attains age 60 and completes 10 Years of Service.
f.“Service” means service as a Service Provider to the Company or a Subsidiary. Unless otherwise stated in the award agreement corresponding to an Equity Award, then, with respect to such Equity Award, the corresponding Grantee’s change in position or duties will not result in terminated Service for purposes of determining Years of Service hereunder, so long as such Grantee continues to be a Service Provider to the Company or a Subsidiary following such change.
g.“Service Provider” means an employee, consultant or advisor of the Company or a Subsidiary, or a non-employee member of the Company’s Board of Directors, in each case who is paid compensation for such service directly by the Company or a Subsidiary.
h.“Subsidiary” means any “subsidiary corporation” of the Company within the meaning of Section 424(f) of the Code.
i.“Years of Service” means the total number of whole years of Service (rounded down) since a Grantee’s original date of Service with the Company or its Subsidiaries (as determined by the Company in its sole discretion and excluding Service prior to becoming an employee of the Company or its Subsidiaries). For this purpose, if such Grantee’s Service with the Company and its Subsidiaries previously terminated and such Grantee recommenced Service with the Company or its Subsidiaries more than one year after the termination date, the period of such previous Service will not count as Years of Service. If such Grantee’s Service with the Company and its Subsidiaries previously terminated and such Grantee recommenced Service with the Company or its Subsidiaries within one year or less of the termination date, the period of such previous Service will count as Years of Service. For Subsidiaries acquired by the Company, only employees of such Subsidiary who were employed on the date of the closing of the acquisition of such Subsidiary will be given credit for Years of Service with such Subsidiary prior to the date of such closing.
4.Retirement Benefits.
a.Advance Notice; Application. A Grantee will incur a Retirement for purposes of this Policy only if such Grantee delivers to the Company advance written notice of such Grantee’s voluntary termination of Service giving rise to such Retirement in accordance with this Section 4(a). For a Grantee who holds a title below Vice President at the time such notice is delivered to the Company, such notice must be delivered to the Company at least 2 months before such termination of Service. For a Grantee who holds a title of Vice President or above at the time such notice is delivered to the Company, such notice must be delivered to the Company at least 6 months before such termination of Service. The Retirement benefits under this Policy will apply to an Equity Award only if such Equity Award is granted at least 6 months prior to the date the notice described in this Section 4(a) is delivered to the Company. Notice may be provided in advance of the Retirement eligibility date, as long as the Grantee reaches Retirement eligibility by the termination date provided in the notice. For purposes of Sections 4(b) through (d) and Sections (5)(a) through (c), if, at the time of the termination of a Grantee’s Service, such Grantee is a non-employee member of the Company’s Board of Directors, such Grantee’s position shall be considered the equivalent of Executive Vice President.
b.Time-Based Equity Awards. With respect to an Equity Award held by a Grantee for which vesting is not contingent on the achievement of one or more performance goals (a “Time-Based Equity Award”), upon the Retirement of such Grantee:
2


i.If such Grantee holds a title below Vice President at such time (as determined by the Company in its sole discretion), the portion of such Equity Award scheduled to vest during the 2-year period following such Retirement will: (1) if such Equity Award is granted prior to the Effective Date, continue to vest as if such Grantee had not Retired and (2) if such Equity Award is granted on or after the Effective Date, become fully vested;
ii.If such Grantee holds the title of Vice President at such time (as determined by the Company in its sole discretion), such Equity Award will continue to vest for 2 years following the date of such Retirement as if such Grantee had not Retired;
iii.If such Grantee holds the title of Senior Vice President at such time (as determined by the Company in its sole discretion), such Equity Award will continue to vest for 3 years following the date of such Retirement as if such Grantee had not Retired; and
iv.If such Grantee holds the title of Executive Vice President or the equivalent or above at such time (as determined by the Company in its sole discretion), such Equity Award will continue to vest for 4 years following the date of such Retirement as if such Grantee had not Retired (or, if earlier, through the last vesting date of such Equity Award).
c.Performance-Based Equity Awards. With respect to an Equity Award held by a Grantee for which vesting is contingent on the achievement of continued service and one or more performance goals (a “Performance-Based Equity Award”), upon the Retirement of such Grantee, provided that at least 2/3rd of the performance period applicable to such Performance-Based Equity Award have elapsed on or prior to such Retirement, such Equity Award will remain outstanding and: (1) the performance goal(s) applicable to such Equity Award will be measured, and such Equity Award will correspondingly be determined performance-vested, if at all, based on such measurements, as if such Retirement had not occurred and (2) a prorated portion of such Equity Award that becomes performance-vested pursuant to the preceding clause (1) will, following such measurement and determination, immediately time-vest and accordingly become fully vested. Such proration will be based on the number of whole calendar days, rounded down, that elapsed in the performance period corresponding to such Equity Award through the date of such Retirement, divided by the number of calendar days in such performance period. With respect to a Performance-Based Equity Award held by a Grantee, if, on or prior to the Retirement of such Grantee, at least 2/3rd of the performance period applicable to such Performance-Based Equity Award has not elapsed, such Equity Award will be forfeited immediately upon such Retirement.
d.Stock Options.
i.With respect only to a stock option Equity Award granted on or after the Effective Date, upon the Retirement of the Grantee holding such Equity Award, if such Grantee holds the title of Vice President or below at such time (as determined by the Company in its sole discretion), the post-termination exercise period relating to such Retirement will be 1 year after the last vesting date applicable to such Equity Award, or, if earlier, the original expiration date of such Equity Award; and
ii.With respect only to a stock option Equity Award granted on or after the Effective Date, upon the Retirement of the Grantee holding such Equity Award, if such Grantee holds the title of Senior Vice President or above at such time (as determined by the Company in its sole discretion), the post-termination exercise period relating to such Retirement will be 2 years after the last vesting date applicable to such Equity Award, or, if earlier, the original expiration date of such Equity Award.
3


e.Restrictive Covenants. The Retirement benefits set forth above for an Equity Award will be contingent on the compliance, by the Grantee holding such Equity Award, with any confidentiality, non-competition, non-solicitation or similar obligations in favor of the Company or its Subsidiaries.
5.Death and Disability Benefits.
a.Time-Based Equity Awards.
i.With respect to a Time-Based Equity Award held by a Grantee, upon the Death of such Grantee, or upon the death of such Grantee following Retirement, such Equity Award will become fully vested.
ii.With respect to a Time-Based Equity Award held by a Grantee, upon the Disability of such Grantee, if such Grantee holds the title of Executive Vice President or the equivalent or above at such time (as determined by the Company in its sole discretion), such Equity Award will become fully vested.
iii.With respect to a Time-Based Equity Award held by a Grantee, upon the Disability of such Grantee, if such Grantee holds a title below Executive Vice President or the equivalent at such time (as determined by the Company in its sole discretion) such Equity Award will: (1) if such Equity Award is granted prior to the Effective Date, continue to vest as if such Grantee had not become Disabled and (2) if such Equity Award is granted on or after the Effective Date, become fully vested.
b.Performance-Based Equity Awards.
i.With respect to a Performance-Based Equity Award held by a Grantee, upon the Death, Disability, or death following the Retirement of such Grantee who holds the title of Executive Vice President or the equivalent or below at such time (as determined by the Company in its sole discretion), such Equity Award will remain outstanding and: (1) the performance goal(s) applicable to such Equity Award will be measured, and such Equity Award will correspondingly be determined performance-vested, if at all, based on such measurements, as if such Death, Disability or death had not occurred and (2) a prorated portion of such Equity Award that becomes performance-vested pursuant to the preceding clause (1) will, following such measurement and determination, immediately time-vest and accordingly become fully vested. Such proration will be based on the number of whole calendar days, rounded down, that elapsed in the performance period corresponding to such Equity Award through the date of such Death, Disability or death, divided by the number of calendar days in such performance period.
ii.With respect to a Performance-Based Equity Award held by the Grantee who is the Chief Executive Officer of the Company at the time of his or her Death, Disability or death following his or her Retirement, upon such Death, Disability or death, such Equity Award will remain outstanding and: (1) the performance goal(s) applicable to such Equity Award will be measured, and such Equity Award will correspondingly be determined performance-vested, if at all, based on such measurements, as if such Death, Disability or death had not occurred and (2) the portion of such Equity Award that becomes performance-vested pursuant to the preceding clause (1) will, following such measurement and determination, immediately time-vest and accordingly become fully vested.
c.Stock Options.
i.With respect only to a stock option Equity Award granted on or after the Effective Date, upon the Death or Disability of the Grantee holding such Equity Award, if such Grantee holds the
4


title of Vice President or below at such time (as determined by the Company in its sole discretion), the post-termination exercise period relating to such Death or Disability will be 1 year after the last vesting date applicable to such Equity Award, or, if earlier, the original expiration date of such Equity Award; and
ii.With respect only to a stock option Equity Award granted on or after the Effective Date, upon the Death or Disability of the Grantee holding such Equity Award, if such Grantee holds the title above Vice President at such time (as determined by the Company in its sole discretion), the post-termination exercise period relating to such Death or Disability will be 2 years after the last vesting date applicable to such Equity Award, or, if earlier, the original expiration date of such Equity Award).
6.Section 409A.
a.If Section 409A of the Code (“Section 409A”), is applicable to an Equity Award, the treatment of such Equity Award under this Policy is intended to comply with Section 409A. Without limiting the generality of the foregoing, if Section 409A is applicable to an Equity Award: (1) any payment provided under this Policy to the Grantee of such Equity Award as a result of such Grantee’s termination of employment will, if such Grantee is a “specified employee” within the meaning of Section 409A at the time of such termination, be delayed until the first business day after the 6-month period following such termination (or, if earlier, until Death), to the extent necessary to comply with Section 409A; (2) any payment or benefit subject to such Grantee’s execution and non-revocation of a release of claims, if such execution and non-revocation could be made in more than one taxable year of such Grantee, will be made in the later taxable year; and (3) all references herein to “termination date” or “termination of employment” or any term of such import will mean “separation from service” within the meaning of Section 409A(a)(2)(A)(i). For purposes of Section 409A, any right to a series of payments under this Policy will be treated as a right to a series of separate payments. Notwithstanding Section 2, this Policy may be amended from time, without Grantee consent, as the Company may determine to be necessary or appropriate in order to be exempt from the application of, or to comply with, Section 409A. The Company makes no representation or warranty regarding the treatment of this Plan or the benefits payable under this Plan or any Award Agreement under federal, state or local income tax laws, including Section 409A.
7.No Change to Existing Terms and Conditions. Except as otherwise expressly provided in this Policy, the terms and conditions applicable to an Equity Award outside of this Policy, including the terms and conditions of the equity plan governing such Equity Award, the award agreement evidencing such Equity Award, and a Grantee’s employment agreement or offer letter, will continue to apply to such Equity Award, provided that in the event of any conflict between this Policy and such terms and conditions, this Policy will govern to the extent it provides for more favorable treatment to the Grantee with respect to the Grantee’s Equity Awards upon the Grantee’s Death, Disability or Retirement. This Policy may not be construed to prevent the forfeiture or divestiture of any Equity Award if otherwise contemplated under the terms and conditions applicable to such Equity Award, including under any restrictive covenant agreement or clawback policy applicable to such Equity Award.
8.Payroll Taxes. In the event the Company or a Subsidiary is required to withhold any federal, state, or local employment taxes, payroll taxes or other similar withholding amounts prior to the settlement of an Equity Award that is subject to Section 409A of the Code, then the person holding such award may not elect the method by which the Company or such Subsidiary implements such withholding.
9.Governing Law. This Policy will be governed by and construed in accordance with the laws of the State of Wisconsin without giving effect to the principles of conflicts of law, provided that the provisions set forth herein that are required to be governed by the Delaware General Corporation Law will be governed by such law.
5

 EX-21 3 exas-20231231xexx21.htm EX-21 Document
EXHIBIT 21
SUBSIDIARIES OF EXACT SCIENCES CORPORATION
Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary.
Name of SubsidiaryJurisdiction of Incorporation or Organization
Percent of Outstanding Voting Securities Owned as of December 31, 2023
Genomic Health, Inc.Delaware100%
Exact Sciences Laboratories, LLCDelaware100%
Exact Sciences Thrive, LLCDelaware100%


 EX-23.1 4 exas-20231231xex231.htm EX-23.1 Document
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-190350; No. 333-207703; No. 333-211099; No. 333-212730; No. 333-219553; No. 333-229780; No. 333-232916; No. 333-219553; No. 333-234608; No. 333-251900; No. 333-266471 and No. 333-273572) and Form S-3 (No. 333-238845 and No. 333-272196) of Exact Sciences Corporation of our report dated February 21, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Chicago, Illinois
February 21, 2024

1

 EX-31.1 5 exas-20231231xexx311.htm EX-31.1 Document
EXHIBIT 31.1
CERTIFICATION
I, Kevin T. Conroy, certify that:
1.I have reviewed this annual report on Form 10‑K of Exact Sciences Corporation (the "registrant");
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a‑15(f) and 15d‑15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated: February 21, 2024/s/ Kevin T. Conroy
Name:Kevin T. Conroy
Title:President and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 6 exas-20231231xexx312.htm EX-31.2 Document
EXHIBIT 31.2
CERTIFICATION
I, Jeffrey T. Elliott, certify that:
1.I have reviewed this annual report on Form 10‑K of Exact Sciences Corporation (the "registrant");
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a‑15(f) and 15d‑15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting
Dated: February 21, 2024/s/ Jeffrey T. Elliott
Name:Jeffrey T. Elliott
Title:Executive Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)


 EX-32 7 exas-20231231xexx32.htm EX-32 Document
EXHIBIT 32
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002
In connection with the Annual Report on Form 10‑K of Exact Sciences Corporation (the “Company”) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Kevin T. Conroy, President and Chief Executive Officer of the Company and Jeffrey T. Elliott, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, to our knowledge that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 21, 2024/s/ Kevin T. Conroy
Name:Kevin T. Conroy
Title:President and Chief Executive Officer
(Principal Executive Officer)
Dated: February 21, 2024/s/ Jeffrey T. Elliott
Name:Jeffrey T. Elliott
Title:Executive Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)


 EX-97 8 exas-20231231xexx97.htm EX-97 Document

EXHIBIT 97
EXACT SCIENCES CORPORATION
INCENTIVE-BASED COMPENSATION RECOVERY POLICY
1.Policy Purpose Generally. The purpose of this Exact Sciences Corporation (the “Company”) Incentive-Based Compensation Recovery Policy (this “Policy”) is to enable the Company to recover erroneously awarded compensation, including in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to comply with the requirements set forth in Listing Rule 5608 of the corporate governance rules of The NASDAQ Stock Market (the “Listing Rule”), and to provide the Company certain additional recovery rights, and shall be construed and interpreted in accordance with such intent. Unless otherwise defined in this Policy, capitalized terms shall have the meaning ascribed to such terms in Section 10. This Policy shall become effective on December 1, 2023, and, at such time, shall supersede the Company’s Incentive Compensation Recoupment Policy. Where the context requires, reference to the Company shall include the Company’s subsidiaries and affiliates (as determined by the Committee in its discretion).
2.Policy Administration Generally. This Policy shall be administered by the Human Capital Committee of the Board (the “Committee”) unless the Board determines to administer this Policy itself. The Committee has full and final authority to make all determinations under this Policy. All determinations and decisions made by the Committee pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company, its affiliates, its stockholders and covered persons. Any action or inaction by the Committee with respect to a covered person under this Policy in no way limits the Committee’s actions or decisions not to act with respect to any other covered person under this Policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any covered person other than as set forth in this Policy.
3.Recovery of Incentive Compensation.
a.Mandatory Recovery in connection with Accounting Restatement.
i.This Section 3(a) applies to all Incentive-Based Compensation received by a person: (a) on or after October 2, 2023, and beginning service as an Executive Officer; (b) who served as an Executive Officer at any time during the performance period for such Incentive-Based Compensation; (c) while the Company had a class of securities listed on a national securities exchange or a national securities association; and (d) during the three completed fiscal years immediately preceding the Accounting Restatement Date. In addition to such last three completed fiscal years, the immediately preceding clause (d) includes any transition period that results from a change in the Company’s fiscal year within or immediately following such three completed fiscal years; provided, however, that a transition period between the last day of the Company’s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to twelve months shall be deemed a completed fiscal year. For purposes of this Section 3(a), Incentive-Based Compensation is deemed received in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the relevant Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition.
1

ii.In the event of an Accounting Restatement, the Company must recover, reasonably promptly, Erroneously Awarded Compensation, in amounts determined pursuant to this Policy. The Company’s obligation to recover Erroneously Awarded Compensation is not dependent on if or when the Company files restated financial statements. Recovery under this Policy with respect to an Executive Officer shall not require the finding of any misconduct by such Executive Officer or such Executive Officer being found responsible for the accounting error leading to an Accounting Restatement. In the event of an Accounting Restatement, the Company shall satisfy the Company’s obligations under this Policy to recover any amount owed from any applicable Executive Officer by exercising its sole and absolute discretion in how to accomplish such recovery. The Company’s recovery obligation pursuant to this Section 3(a) shall not apply to the extent that the Committee, or in the absence of the Committee, a majority of the independent directors serving on the Board, determines that such recovery would be impracticable and:
1.The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Stock Exchange; or
2.Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the registrant, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Code.
iii.The Company shall not indemnify any Executive Officer or former Executive Officer against the loss of Erroneously Awarded Compensation. Further, the Company shall not pay or reimburse an Executive Officer for purchasing insurance to cover any such loss.
b.Recovery in connection with Detrimental Conduct. In addition to the Company’s mandatory recovery obligations in connection with an Accounting Restatement as set forth in Section 3(a), in the event that an employee of the Company at the level of Vice President or above engages in fraud or misconduct that, in the sole discretion of the Committee, is likely to cause or has caused material financial, operational, or reputational harm to the Company (“Detrimental Conduct”), the Committee may, in its sole discretion, recover incentive compensation (including Incentive-Based Compensation) received by such person during and after the period in which such Detrimental Conduct occurred. Detrimental Conduct subject to this Section 3(b) must have occurred within the three years preceding the date on which the Committee determines that such Detrimental Conduct has occurred. For purposes of this Section 3(b), incentive compensation is deemed received in the Company’s fiscal period during which the performance goal specified in the incentive compensation award is attained, even if the payment or grant of the incentive compensation occurs after the end of that period. For the avoidance of doubt, incentive compensation that is subject to both a performance vesting condition and a service-based vesting condition shall be considered received when the relevant performance condition is achieved, even if the incentive compensation continues to be subject to the service-based vesting condition. The Committee shall determine the amount of incentive compensation to be recovered in its sole discretion based upon the relevant covered person’s relative degree of fault or involvement, the impact of the conduct on the Company, the magnitude of any loss caused and other relevant facts and circumstances. The Committee may effect recoupment in any manner consistent with applicable law.
4.Committee Indemnification. Any members of the Committee, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be fully indemnified by the Company to the fullest extent under applicable law
2

and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.
5.Severability. The provisions in this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision shall be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.
6.Amendment; Termination. The Board may amend this Policy from time to time in its sole and absolute discretion and shall amend this Policy as it deems necessary to reflect the Listing Rule. The Board may terminate this Policy at any time.
7.Other Recovery Obligations; General Rights. To the extent that the application of this Policy would provide for recovery of Incentive-Based Compensation that the Company recovers pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations, the amount the relevant individual has already reimbursed the Company shall be credited to the required recovery under this Policy. This Policy shall not limit the rights of the Company to take any other actions or pursue other remedies that the Company may deem appropriate under the circumstances and under applicable law. To the maximum extent permitted under the Listing Rule, this Policy shall be administered in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.
8.Successors. This Policy is binding and enforceable against all covered persons and their beneficiaries, heirs, executors, administrators or other legal representatives.
9.Governing Law; Venue. This Policy and all rights and obligations hereunder are governed by and construed in accordance with the internal laws of the State of Delaware, excluding any choice of law rules or principles that may direct the application of the laws of another jurisdiction. All actions arising out of or relating to this Policy shall be heard and determined exclusively in the Court of Chancery of the State of Delaware or, if such court declines to exercise jurisdiction or if subject matter jurisdiction over the matter that is the subject of any such legal action or proceeding is vested exclusively in the U.S. Federal courts, the U.S. District Court for the District of Delaware.
10.Definitions.
a.“Accounting Restatement” means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
b.“Accounting Restatement Date” means the earlier to occur of: (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if the Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.
c.“Board” means the board of directors of the Company.
d.“Code” means the U.S. Internal Revenue Code of 1986, as amended. Any reference to a section of the Code or regulation thereunder includes such section or regulation, any valid regulation or other official guidance promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation.
e.“Erroneously Awarded Compensation” means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-
3

Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes incurred or paid by the relevant Executive Officer; provided, however, that for Incentive-Based Compensation based on stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received; and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the Stock Exchange.
f.“Executive Officer” means the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. An executive officer of the Company’s parent or subsidiary is deemed an “Executive Officer” if the executive officer performs such policy making functions for the Company. For the avoidance of doubt, “Executive Officer” includes, but is not limited to, any person identified as an executive officer pursuant to Item 401(b) of Regulation S-K under the U.S. Securities Act of 1933, as amended.
g.“Financial Reporting Measure” means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measure; provided, however, that a Financial Reporting Measure is not required to be presented within the Company’s financial statements or included in a filing with the U.S. Securities and Exchange Commission to qualify as a “Financial Reporting Measure.” For purposes of this Policy, “Financial Reporting Measure” includes, but is not limited to, stock price and total stockholder return.
h.“Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.
i.“Stock Exchange” means the national stock exchange on which the Company’s common stock is listed.
4
 EX-101.SCH 9 exas-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Stockholders Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - INTANGIBLE ASSETS AND GOODWILL link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - CONVERTIBLE NOTES link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - PFIZER PROMOTION AGREEMENT link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - EMPLOYEE BENEFIT PLAN link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - MARKETABLE SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - CONVERTIBLE NOTES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Use of Estimates (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Research and Development Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Tax Positions (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - REVENUE - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - REVENUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses And Fair Value of Available For Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - FAIR VALUE MEASUREMENTS - Non-marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - LONG-TERM DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - CONVERTIBLE NOTES - Issuances and Settlements (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - CONVERTIBLE NOTES - Summary of Conversion Features (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - CONVERTIBLE NOTES - Ranking of Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - CONVERTIBLE NOTES - Schedule of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Johns Hopkins University (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - The Broad Institute (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Watchmaker Genomics (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - PFIZER PROMOTION AGREEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - STOCKHOLDERS' EQUITY - Stock Issued by Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of OCI (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of amounts reclassified from AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Fair Value of Options and ESPP (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - STOCK-BASED COMPENSATION - Stock Option, Restricted Stock, and Performance Shares (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - STOCK-BASED COMPENSATION - Issuance of Stock Under ESPP (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Share Issued During Period (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - STOCK-BASED COMPENSATION - Shares Reserved for Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - COMMITMENTS AND CONTINGENCIES - Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954540 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954540 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954541 - Disclosure - Legal Matters - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954542 - Disclosure - EMPLOYEE BENEFIT PLAN (Details) link:presentationLink link:calculationLink link:definitionLink 9954543 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDIT (Details) link:presentationLink link:calculationLink link:definitionLink 9954544 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954545 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Details of Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 9954545 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Details of Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 9954546 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Purchase Price Allocated to the Underlying Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954547 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954548 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Combination, Pro-Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954549 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Divestiture (Details) link:presentationLink link:calculationLink link:definitionLink 9954550 - Disclosure - SEGMENT INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954551 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954552 - Disclosure - INCOME TAXES - Income (Loss) Before Income Taxes, Domestic and Foreign (Details) link:presentationLink link:calculationLink link:definitionLink 9954553 - Disclosure - INCOME TAXES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954554 - Disclosure - INCOME TAXES - Deferred Tax Asset, Valuation Allowance RollForward (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 exas-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 exas-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 exas-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Payment 1 Business Acquisition, Payment Tranche One [Member] Business Acquisition, Payment Tranche One Schedule of accrued expenses Schedule of Accrued Liabilities [Table Text Block] Accrued liabilities Accrued liabilities Accrued Liabilities, Current Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in assets and liabilities, net of effects of acquisition: Increase (Decrease) in Operating Capital [Abstract] ASU 2016-02 Accounting Standards Update 2016-02 [Member] Expiration period from the date of grant Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Equity Award [Domain] Award Type [Domain] Investment, Name [Domain] Investment, Name [Domain] Allowance for Doubtful Accounts Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Impairment of long-lived assets Impairment of Intangible Assets (Excluding Goodwill) Cash Payments to Acquire Businesses, Gross Schedule of allocated to the underlying assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] LICENSE AND COLLABORATION AGREEMENTS Licensing Agreement Disclosure [Text Block] This element represents the entire disclosure related to licensing agreement entered by an entity during the period. Finance Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Finance Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Finance Leases, Future Minimum Payments Due, Fiscal Year Maturity Schedule of available-for-sale securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Stock-based compensation expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Amortization Deferred Tax Liabilities Amortization Deferred Tax Liabilities Amortization Exercisable at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Shares issued, price per share (in usd per share) Shares Issued, Price Per Share Credit earning rate Capital Investment Expenditures, Credit Earning Rate Capital Investment Expenditures, Credit Earning Rate MDxHealth MDxHealth [Member] MDxHealth Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five STOCKHOLDERS' EQUITY Equity [Text Block] Vested and expected to vest at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Accrued interest on notes Debt Instrument, Convertible, Equity Component, Interest Accrued Debt Instrument, Convertible, Equity Component, Interest Accrued Proceeds in connection with the Company's employee stock purchase plan Proceeds from Stock Plans Ownership [Axis] Ownership [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Accelerated vesting (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number Business Combination, Divestiture, And Asset Acquisition Business Combination, Divestiture, And Asset Acquisition [Text Block] Business Combination, Divestiture, And Asset Acquisition Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Business acquisition contingent consideration liability Business Combination, Contingent Consideration Arrangements, Increase Due to Acquisition Business Combination, Contingent Consideration Arrangements, Increase Due to Acquisition Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at December 31, 2023 and December 31, 2022 Preferred Stock, Value, Issued Net loss per share - diluted (in dollars per share) Earnings Per Share, Diluted Impairment of long-lived assets Impairment, Long-Lived Asset, Held-for-Use Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Financing Receivable, Amount Elected to Collateralize Financing Receivable, Amount Elected to Collateralize Financing Receivable, Amount Elected to Collateralize Settlements Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities Deferred tax benefit Deferred Income Tax Expense (Benefit) - SOCF Amount of deferred income tax expense (benefit) on the statement of cash flows Line of Credit Line of Credit [Member] 1-month LIBOR One Month London Interbank Offer Rate [Member] Interest rate at which a bank borrows funds from other banks in the one-month London interbank market. Commercial Launch Milestone Commercial Launch Milestone [Member] Commercial Launch Milestone Long-term assets: Assets, Noncurrent [Abstract] Expense (benefit) for income taxes Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol U.S. government agency securities US Government Agencies Debt Securities [Member] Differences between the effective income tax rate and the statutory tax rate Effective Income Tax Rate Reconciliation, Percent [Abstract] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Fair Value Disclosures [Abstract] Schedule of cash and cash equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Finite-lived and indefinite-lived intangible assets, gross Intangible Assets, Gross (Excluding Goodwill) Debt discount amortization Amortization of Debt Discount (Premium) Employee Stock Employee Stock [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Federal and state tax rate changes Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Schedule of unrecognized tax benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Cash and money market Cash And Money Market [Member] Represents information regarding cash and money market balances. Restricted Shares and Performance Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Marketable securities Marketable Securities, Current UnitedHealthcare United Health Care [Member] Represents information pertaining to united health care. Schedule of property, plant and equipment, net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Research Research Tax Credit Carryforward [Member] Financial Instruments [Domain] Financial Instruments [Domain] Shares available for future grant (in shares) Shares reserved for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Restricted cash (1) Restricted Cash [Member] Restricted Cash Entity Small Business Entity Small Business 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number 2028 Finance Lease, Liability, to be Paid, Year Five City Letter of Credit Letter of Credit [Member] Thrive Thrive Earlier Detection Corporation [Member] Thrive Earlier Detection Corporation Derivative, notional amount Derivative, Notional Amount Accounts Receivable Accounts Receivable [Member] Shares reserved for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Input, Probability of Success Measurement Input, Probability of Success [Member] Measurement Input, Probability of Success Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Summary of restricted stock and restricted stock unit activity under the Stock Plans Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Disposal Group, Contingent Consideration Arrangements, Gain (Loss) Disposal Group, Contingent Consideration Arrangements, Gain (Loss) Disposal Group, Contingent Consideration Arrangements, Gain (Loss) Retirement Benefits [Abstract] Retirement Benefits [Abstract] Additional benefit charges Postemployment Benefits, Period Expense Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Schedule of business acquisitions, by acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of valuation assumptions Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Schedule of potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Total interest expense on convertible notes Interest Expense, Debt Research and development Research and Development Expense [Member] Collaborative Arrangements Sales Milestone [Axis] Collaborative Arrangements Sales Milestone [Axis] Represents the ranges of sale milestones. The Broad Institute, LLC The Broad Institute, LLC [Member] The Broad Institute, LLC Acquisition related costs Business Combination, Acquisition Related Costs Award Type [Axis] Award Type [Axis] Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Offering Period End Date [Axis] Offering Period End Date [Axis] Information by offering period end date pertaining to the equity-based compensation arrangements. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period State of Wisconsin State of Wisconsin [Member] State of Wisconsin Reconciliation of the amounts of unrecognized tax benefits Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Sales Milestone Range One Sales Milestone Range One [Member] Represents information related to the first sales milestone range. Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag General and administrative General and Administrative Expense [Member] Goodwill [Line Items] Goodwill [Line Items] Property, plant and equipment, at cost Property, plant and equipment, gross Property, Plant and Equipment, Gross Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Schedule of expense (benefit) for income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Property, plant and equipment acquired but not paid Noncash or Part Noncash Acquisition, Fixed Assets Acquired Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating lease liabilities, current portion Operating lease liability, current Operating Lease, Liability, Current Interest on lease liabilities Finance Lease, Interest Expense Software projects Computer Software, Intangible Asset [Member] Number of shares (in shares) Stock issued under the Company's stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Number of tests provided Number Of Tests Provided Number Of Tests Provided 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Finite-lived intangible assets, net Finite-lived Intangible assets, net Finite-Lived Intangible Assets, Net Property, plant and equipment Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Deferred tax asset SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Non-deductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation Cost, Percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to executive compensation. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory Counterparty Name [Domain] Counterparty Name [Domain] Accumulated Amortization Finite-lived intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule of income before income tax, domestic and foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Total purchase price Total purchase price Business Combination, Consideration Transferred Schedule of share-based payment award, stock options, valuation assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Variable consideration Variable Price Contract [Member] The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payer reimbursement contracts. Accounting for Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Lease liabilities Deferred Tax Assets, Leasing Arrangements Deferred Tax Assets, Leasing Arrangements Securitized Receivables Securitized Receivables [Member] Securitized Receivables Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax PFIZER PROMOTION AGREEMENT Collaborative Arrangement Disclosure [Text Block] Options Employee Stock Option [Member] Shares issuable in connection with acquisitions Shares Issued Upon Acquisition [Member] Shares Issued Upon Acquisition Investments in Privately Held Companies Investment, Policy [Policy Text Block] Total operating expenses Costs and Expenses Maximum Maximum [Member] Compensation related differences Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation Share based compensation, costs not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Acquisition Goodwill, Acquired During Period Audit Information [Abstract] Audit Information Income tax benefit related to items of other comprehensive loss Comprehensive Income (Loss), Tax, Attributable to Parent Comprehensive Income (Loss), Tax, Attributable to Parent Weighted average price per share (in dollars per share) Employee Stock Purchase Plan Weighted Average Price Represents the weighted average price per share at which shares were issued during the period as a result of an employee stock purchase plan. Maximum credits to earn Capital Investment Expenditures, Maximum Credits Available To Earn Capital Investment Expenditures, Maximum Credits Available To Earn Inventory Inventory, Policy [Policy Text Block] Collaborative Arrangement Milestone [Axis] Collaborative Arrangement Milestone [Axis] Represents the ranges of sale milestones. 2026 Finance Lease, Liability, to be Paid, Year Three Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Business Basis of Accounting, Policy [Policy Text Block] Sales Milestone Range Three Sales Milestone Range Three [Member] Represents information related to the third sales milestone range one. Business Acquisition [Axis] Business Acquisition [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Variable Rate [Axis] Variable Rate [Axis] Revenue Revenue from Contract with Customer, Including Assessed Tax Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Incremental share based compensation expense Share-Based Payment Arrangement, Plan Modification, Incremental Cost In-process research and development Indefinite-Lived Intangible Assets (Excluding Goodwill) Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Offering Period End Date One Offering Period End Date One [Member] Represents information pertaining to the first offering period end date. OmicEra OmicEra [Member] OmicEra Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Goodwill, Foreign Currency Translation Gain (Loss) Goodwill, Foreign Currency Translation Gain (Loss) Total lease Cost Lease, Cost Purchases of marketable securities Payments to Acquire Marketable Securities Range [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] LONG-TERM DEBT Long-Term Debt [Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Net Carrying Amount Convertible Notes Payable Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Medicare Parts B & C Product [Member] Service Type [Axis] Service or Product Type [Axis] Service or Product Type Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Asset acquisitions, net of cash acquired Payments to Acquire Assets, Investing Activities Stock-based compensation Stock-based compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash and cash equivalents, federal government agency insured limit Cash, FDIC Insured Amount Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Advertising expense Advertising Expense Schedule of components of the net deferred tax asset Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] Derivative Financial Instruments Derivatives, Policy [Policy Text Block] Common shares not included in the computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating cash flows from operating leases Operating Lease, Payments Common stock, outstanding shares (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Other Stockholders' Equity, Other Auditor Location Auditor Location EMPLOYEE BENEFIT PLAN Retirement Benefits [Text Block] Cash equivalents Cash Equivalents [Member] Compensation consideration assumed and deemed compensatory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation, Deemed Compensatory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation, Deemed Compensatory Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Charges for promotion, sales and marketing Marketing Expense Finance lease cost Finance Lease, Liability [Abstract] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Equity securities Equity Securities, FV-NI, Current Debt Instrument [Axis] Debt Instrument [Axis] Repayments of debt Repayments of Debt Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Current expense (benefit): Current Income Tax Expense (Benefit) Total fair value of available-for-sale securities in a continuous unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Investment Income Investment Income [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Title of Individual [Axis] Title of Individual [Axis] Capitalized research and development Deferred Tax Assets, in Process Research and Development Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed Period for Capital Investment Expenditures and Creation of Full-time Positions to Earn Refundable Tax Credits The period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed. Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Marketable Securities Marketable Securities, Policy [Policy Text Block] Sales and marketing Selling and Marketing Expense Payments to acquire productive assets (in shares) Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable, Shares Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable, Shares Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months General and administrative General and administrative General and Administrative Expense OmicEra Diagnostics Acquisition OmicEra Diagnostics Acquisition [Member] OmicEra Diagnostics Acquisition Income tax benefit related to items of other comprehensive loss Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Professional fees Accrued Professional Fees, Current Revenue milestone Business Combination, Contingent Consideration, Revenue Milestone Business Combination, Contingent Consideration, Revenue Milestone Contract with Customer, Receivable, after Allowance for Credit Loss Contract with Customer, Receivable, after Allowance for Credit Loss Changes in fair value Business Combination, Contingent Consideration, Gain (Loss), Change in Fair Value Business Combination, Contingent Consideration, Gain (Loss), Change in Fair Value Total current assets Assets, Current Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Allocated to Consideration Transferred Allocated to Consideration Transferred [Member] Allocated to Consideration Transferred Contingent consideration, liability Beginning balance Ending balance Business Combination, Contingent Consideration, Liability Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Maximum value of shares that an employee is permitted to purchase Share Based Compensation Arrangement by Share Based Payment Award Maximum Value of Shares Per Employee The highest value of shares that an employee can purchase under the plan per period. Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] INTANGIBLE ASSETS AND GOODWILL Goodwill and Intangible Assets Disclosure [Text Block] MARKETABLE SECURITIES Cash, Cash Equivalents, and Marketable Securities [Text Block] Concentration risk (as a percent) Concentration Risk, Percentage Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five Issuance of common stock to fund the Company’s 2020 401(k) match Stock Issued During Period, Value, Employee Benefit Plan 2027 Finance Lease, Liability, to be Paid, Year Four Asset backed securities Asset-Backed Securities [Member] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Exercisable at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of estimated future amortization expense, intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Contingent consideration Business Combination, Contingent Consideration, Liability, Current Loss on sale of asset Gain (Loss) on Disposition of Other Assets Other operating income (loss) Other Operating Income (Expense), Net Furniture and fixtures Furniture and Fixtures [Member] Business Combination and Asset Acquisition [Abstract] Commercial paper Commercial Paper [Member] Total revenues Business Acquisition, Pro Forma Revenue CONVERTIBLE DEBT CONVERTIBLE DEBT N/A. Goodwill, impairment loss Goodwill, Impairment Loss Deferred tax asset valuation allowance Less - Valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Business Acquisition, Payment Tranche [Domain] Business Acquisition, Payment Tranche [Domain] Business Acquisition, Payment Tranche [Domain] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Semi-finished and finished goods Inventory Finished Semi Finished Goods Amount before valuation and LIFO reserves of completed merchandise/goods and merchandise/goods expected to be completed within one year of operating cycle that are expected to be sold within one year or operating cycle, if longer. Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, before Tax, Attributable to Parent Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, issued shares (in shares) Preferred Stock, Shares Issued Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Valuation assumptions Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Intangible assets, net Finite-lived and indefinite-lived intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other long-term assets Other Noncurrent Assets [Member] Tax assets before valuation allowance Deferred Tax Assets, Gross Developed technology Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Antidilutive Securities [Axis] Antidilutive Securities [Axis] Fair value of stock issued in acquisition Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Settlements Settlements Settlements Other Investments Not Readily Marketable Other Investments Not Readily Marketable [Table Text Block] Common Stock Common Stock [Member] Compensation expense related to issuance of stock options and restricted stock awards (in shares) Compensation Expense Related to Issuance of Stock Options and Restricted Stock Awards, Shares This element represents number of stock options and restricted stock awards issued as a compensation expense by an entity during the period. SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Compensation expense related to issuance of stock options and restricted stock awards Compensation Expense Related to Issuance of Stock Options and Restricted Stock Awards, Values This element represents equity impact of the value of stock options and restricted stock awards issued as a compensation expense by an entity during the period. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Loss on Sale of Investments Loss on Sale of Investments Income Statement Location [Domain] Income Statement Location [Domain] Investments, All Other Investments [Abstract] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Aggregate Intrinsic Value Share Based Compensation Arrangement by Share Based Payment Award, Options, Intrinsic Value [Abstract] Recognized interest or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Minimum Minimum [Member] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Contingent consideration Disposal Group, Including Discontinued Operations, Contingent Consideration Disposal Group, Including Discontinued Operations, Contingent Consideration Other Investment Not Readily Marketable, Fair Value Other Investment Not Readily Marketable, Fair Value Contingent payment obligations Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Deferred tax assets: Deferred Tax Assets, Net [Abstract] Other Noncash Expense Other Noncash Expense Other temporary differences Deferred Tax Assets, Other Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Other investing activities Payments for (Proceeds from) Other Investing Activities Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Accumulated Deficit Retained Earnings [Member] Other income (expense) Nonoperating Income (Expense) [Abstract] Net loss per share - basic (in dollars per share) Earnings Per Share, Basic Cash received under the 2010 Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Total intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Schedule of debt, net of discounts and deferred financing costs Convertible Debt [Table Text Block] Committed capital callable Investment Company, Committed Capital, Amount Callable Investment Company, Committed Capital, Amount Callable Schedule of gross unrealized losses and fair values of investments in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Basis of Presentation and Principles of Consolidation Consolidation, Policy [Policy Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Genomic Health acquisition adjustment Goodwill, Purchase Accounting Adjustments Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Amount Convertible Debt, Fair Value Disclosures Purchase of employee stock purchase plan shares (in shares) Purchase of Employee Stock Purchase Plan Shares Represents the equity impact of the number of employee stock purchase plans purchased by the entity during the period. Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable Debt Conversion, Converted Instrument, Potential Shares Issued Debt Conversion, Converted Instrument, Potential Shares Issued Debt Conversion, Converted Instrument, Potential Shares Issued Entity Public Float Entity Public Float Fair value measurements Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Offering Period End Date [Domain] Offering Period End Date [Domain] Represents the offering period end dates pertaining to the equity-based compensation arrangements. Property, Plant and Equipment [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Increase (decrease) in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Compensation consideration assumed and allocated to consideration transferred Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation Allocated to Consideration Transferred Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation Allocated to Consideration Transferred Disposal group, not discontinued operation, gain (loss) on disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Due in one year or less, Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Other comprehensive loss, before tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Lease assets Deferred Tax Liabilities, Leasing Arrangements Deferred tax expense (benefit): Deferred Income Tax Expense (Benefit) Proceeds from stock option exercises Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Qui Tam Suit Qui Tam Suit [Member] Qui Tam Suit Finance lease obligations Total Finance Lease, Liability Purchases of non-marketable securities Purchases of non-marketable securities Purchases of non-marketable securities Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity issued to acquire business (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Percentage of participant's salary matched by employer Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Omnibus Long Term Incentive Plan 2019 Omnibus Long Term Incentive Plan2019 [Member] Omnibus Long Term Incentive Plan2019 Depreciation Depreciation And Amortization Of Fixed Assets The amount of expense recognized in the current period that reflects the allocation of the cost of fixed assets over the assets' useful lives. Issuance of common stock to fund business combinations (in shares) Stock Issued During Period, Shares, Acquisitions Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Document Period End Date Document Period End Date Revenue Revenue from Contract with Customer Benchmark [Member] Finance lease liability, noncurrent Finance Lease, Liability, Noncurrent Weighted-average discount rate - finance leases Finance Lease, Weighted Average Discount Rate, Percent Pfizer Inc Pfizer Inc [Member] This member represents information regarding Pfizer Inc. Revenue recognized from changes in transaction price Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Business combination, pro forma information Business Acquisition, Pro Forma Information [Table Text Block] Reclassification Out Of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Income tax benefit (expense) Total income tax expense (benefit) Income Tax Expense (Benefit) Outside of United States Non-US [Member] Finance lease, right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Cash and Cash Equivalents [Abstract] Payments for Legal Settlements Payments for Legal Settlements Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Equity [Abstract] Equity [Abstract] Available-for-sale securities Debt Securities, Available-for-Sale [Line Items] INVENTORY Inventory Disclosure [Text Block] Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Weighted-average remaining lease term - operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Resolution Bioscience Resolution Bioscience [Member] Resolution Bioscience Cash and money market Money Market Funds [Member] Share-based Payment Arrangement, Performance Shares, Activity Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] PFIZER PROMOTION AGREEMENT PFIZER PROMOTION AGREEMENT n/a Tax credit carryforwards Tax Credit Carryforward, Amount Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Business combination, net of cash acquired and issuance costs Consideration transferred, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired CONVERTIBLE NOTES Convertible Notes [Text Block] The entire disclosure of convertible notes. Credit Facility [Domain] Credit Facility [Domain] Payments to acquire businesses and accelerated vesting of awards Payments To Acquire Businesses And Accelerated Vesting Of Awards Payments To Acquire Businesses And Accelerated Vesting Of Awards Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Variable rate Debt Instrument, Basis Spread on Variable Rate Estimated Useful Life Property, Plant and Equipment, Useful Life Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Watchmaker Genomics, Inc Watchmaker Genomics, Inc [Member] Watchmaker Genomics, Inc Summary of valuation allowance Summary of Valuation Allowance [Table Text Block] Right-of-use assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Collaboration Arrangement, Milestones To Be Received Collaboration Arrangement, Milestones To Be Received Collaboration Arrangement, Milestones To Be Received Equity interest in acquiree after subsequent acquisition Business Combination, Step Acquisition, Equity Interest in Acquiree, Including Subsequent Acquisition, Percentage Imputed interest Finance Lease, Liability, Undiscounted Excess Amount REVENUE Revenue from Contract with Customer [Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Refundable tax credits earned Refundable Tax Credit Earned to Date The amount of refundable tax credits earned, relating to capital investments and job creation, as of the end of the reporting period. Measurement Input, Present-value Factor Measurement Input, Present-value Factor [Member] Measurement Input, Present-value Factor Additional Paid In Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Balance Sheet Location [Axis] Balance Sheet Location [Axis] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Screening Screening [Member] Screening Cover [Abstract] Debt issuance costs amortization Amortization of Debt Issuance Costs United States UNITED STATES Convertible debt, remaining discount amortization period Debt Instrument, Convertible, Remaining Discount Amortization Period Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Fair Value, Recurring Fair Value, Recurring [Member] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss Other long-term liabilities Other Liabilities, Noncurrent Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Debt instrument, covenant, maximum outstanding cash advances threshold Debt Instrument, Covenant, Maximum Outstanding Cash Advances Threshold Debt Instrument, Covenant, Maximum Outstanding Cash Advances Threshold Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Operating lease, term extension Lessee, Operating Lease, Renewal Term Gain on settlement of convertible notes Gain on Settlement of Convertible Notes Gain on Settlement of Convertible Notes Equity Component [Domain] Equity Component [Domain] Finance lease liability, current Finance Lease, Liability, Current Option exercise price, expressed as a percentage of fair market value Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent State State and Local Jurisdiction [Member] Other temporary differences Deferred Tax Liabilities, Other Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Loss from operations Operating Income (Loss) Acquisition and purchase accounting SEC Schedule, 12-09, Valuation Allowances And Reserves, Business Acquired And Purchase Accounting Adjustments SEC Schedule, 12-09, Valuation Allowances And Reserves, Business Acquired And Purchase Accounting Adjustments Total deferred tax liabilities Deferred Tax Liabilities, Gross Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Fair Value Estimate of Fair Value Measurement [Member] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Additional disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Customer relationships Customer Relationships [Member] Variable Rate [Domain] Variable Rate [Domain] Entity Voluntary Filers Entity Voluntary Filers Allocated to Compensation Allocated to Compensation [Member] Allocated to Compensation Range [Domain] Statistical Measurement [Domain] Amount settled Debt instrument, Amount Settled In Extinguishment Debt instrument, Amount Settled In Extinguishment Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Operating lease, remaining lease term Lessee, Operating Lease, Remaining Lease Term Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Effects of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Debt instrument, covenant, collateral minimum market value Debt Instrument, Covenant, Minimum Market Value Debt Instrument, Covenant, Minimum Market Value Shares issuable upon the release of performance share units Performance Shares Performance Shares [Member] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Exercisable at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Business combination, pro forma loss Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Buildings under construction Building Improvements [Member] Investment, Name [Axis] Investment, Name [Axis] Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method DOS Rule Investigation DOS Rule Investigation [Member] DOS Rule Investigation Total other income (expense) Nonoperating Income (Expense) U.S. Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 3326029000 Commitments and Contingencies Assets under construction Construction in Progress, Gross Collaborative Arrangements Development Milestone Amount Collaborative Arrangements Development Milestone Amount Collaborative Arrangements Development Milestone Amount Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Loans Payable, Current Loans Payable, Current PreventionGenetics PreventionGenetics LLC [Member] PreventionGenetics LLC Proceeds From Sale Of Investments In Privately-Held Companies Proceeds From Sale Of Investments In Privately-Held Companies Proceeds From Sale Of Investments In Privately-Held Companies Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] INCOME TAXES Income Tax Disclosure [Text Block] Ashion Analytics Ashion Analytics [Member] Ashion Analytics Concentration of Credit Risk Concentration Risk [Line Items] Leases Lessee, Leases [Policy Text Block] Cash paid related to working capital adjustment Business Combination, Working Capital Adjustment, Cash Business Combination, Working Capital Adjustment, Cash Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Acquisition Business Acquisition [Line Items] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Non-marketable securities Security Owned Not Readily Marketable, Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Business combination, equity interest in acquiree, remeasurement gain Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Carrying amount of goodwill Goodwill [Roll Forward] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Committed capital Investment Company, Committed Capital Shares outstanding (in shares) Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Non-cash stock-based compensation expense Share-Based Payment Arrangement, Accelerated Cost Available-for-sale debt securities Estimated Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Computer equipment and computer software Office Equipment And Computer Software [Member] Information relating to office equipment and computer software. Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Weighted average fair value per share of options granted during the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Centers for Medicare and Medicaid Services Medicare [Member] Represents information related to the Centers for Medicare and Medicaid Services (Medicare). Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] 2025 Finance Lease, Liability, to be Paid, Year Two Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Due after one year through four years, Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Corporate bonds Corporate Bond Securities [Member] Transaction costs Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Percent Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Repayments of convertible debt Repayments of Convertible Debt Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Licenses Accrued Licenses Current Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for licenses. Schedule of shares of common stock issued Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Refundable tax credit receivable Refundable Tax Credit Receivable The amount of refundable tax credit receivable as of the end of the reporting period. Changes in fair value Changes in fair value Changes in fair value in non-marketable securities Total reclassifications Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Losses in Accumulated Other Comprehensive Income (Loss) Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Exercise of common stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Convertible notes, net Convertible Notes Payable, Noncurrent Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Noncash or part noncash divestiture, amount of consideration received, shares Noncash or Part Noncash Divestiture, Amount of Consideration Received, Shares Noncash or Part Noncash Divestiture, Amount of Consideration Received, Shares Fair value of replaced equity awards Business Combination, Fair value of Replaced Equity Awards Business Combination, Fair value of Replaced Equity Awards Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Business Acquisition, Payment Tranche [Axis] Business Acquisition, Payment Tranche [Axis] Business Acquisition, Payment Tranche Proceeds from Sale of Productive Assets Proceeds from Sale of Productive Assets Weighted-average remaining useful life of finite-lived intangible asset (in years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Genomic Health Inc Genomic Health Inc [Member] Genomic Health Inc Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Patents and licenses Patents [Member] Goodwill Beginning of the period Ending of the period Goodwill Increase due to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Period by which all options to purchase common stock will accelerate upon an acquisition of the company Share Based Compensation Arrangement by Share Based Payment Award Period by which Options will Accelerate upon Acquisition of Entity Represents the period by which all options to purchase common stock will accelerate upon an acquisition of the entity. Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Asset Acquisition [Domain] Asset Acquisition [Domain] Measurement Basis [Axis] Measurement Basis [Axis] Cash Disposal Group, Including Discontinued Operations, Consideration, Cash Disposal Group, Including Discontinued Operations, Consideration, Cash Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Accounts receivable, net Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Convertible Notes Payable2030 Convertible Notes Payable2030 [Member] Convertible Notes Payable2030 Proceeds from Accounts Receivable Securitization Proceeds from Accounts Receivable Securitization Unrealized gain (loss) on available-for-sale investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Operating lease liabilities, less current portion Operating lease liability, noncurrent Operating Lease, Liability, Noncurrent Schedule of contractual maturities of available-for-sale investments Investments Classified by Contractual Maturity Date [Table Text Block] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Gain (Loss) On Contingent Consideration From Disposition Of Asset Gain (Loss) On Contingent Consideration From Disposition Of Asset Gain (Loss) On Contingent Consideration From Disposition Of Asset Issuance of common stock to fund the Company's 401(k) match (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Unamortized Debt Discount and Issuance Costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Contingent Consideration Commitments and Contingencies, Policy [Policy Text Block] Repayments of convertible debt in cash and by issuance of shares Repayments of Convertible Debt in Cash and by Issuance of Shares Repayments of Convertible Debt in Cash and by Issuance of Shares Operating lease maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Foreign Exchange Forward Foreign Exchange Forward [Member] Venture Capital Investment Fund Venture Capital Investment Fund [Member] Venture Capital Investment Fund Oncotype DX Genomic Prostate Score Test Oncotype DX Genomic Prostate Score Test [Member] Oncotype DX Genomic Prostate Score Test Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cost of Goods and Service Cost of Goods and Service [Policy Text Block] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Product and Service [Domain] Product and Service [Domain] Proceeds from Debt, Net of Issuance Costs Proceeds from Debt, Net of Issuance Costs Offering Period End Date Two Offering Period End Date Two [Member] Represents information pertaining to the second offering period end date. Principal Amount Convertible Notes Payable, Gross Convertible Notes Payable, Gross Components of lease expense Lease, Cost [Table Text Block] Inventory, net Increase (Decrease) in Inventories Employees with Qualifying Termination Events Employees with Qualifying Termination Events [Member] Employees with Qualifying Termination Events Noncash or part noncash divestiture, amount of consideration received, fair value Noncash or Part Noncash Divestiture, Amount of Consideration Received, Fair Value Noncash or Part Noncash Divestiture, Amount of Consideration Received, Fair Value Plan Name [Domain] Plan Name [Domain] Interest expense Interest Expense Loss on extinguishment of debt Gain on settlement of convertible notes Gain (Loss) on Extinguishment of Debt Outstanding at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Contingent consideration liability, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Use of Estimates Use of Estimates, Policy [Policy Text Block] Compensation consideration assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-based Compensation Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-based Compensation Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Time period after the last licensed patent expires that the license agreement will remain in effect Time Period After Last Licensed Patent Expires That License Agreement Remains In Effect Represents the time period after the last licensed patent expires that the license agreement will remain in effect. Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Unrealized Gain (Loss) on Securities (1) AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Decrease due to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Business combination, cash withheld Business Combination, Consideration Transferred, Cash Withheld For Future Claims And Adjustments Business Combination, Consideration Transferred, Cash Withheld For Future Claims And Adjustments Auditor Firm ID Auditor Firm ID Amortization of acquired intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Risk-free interest rates, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Increase due to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Increase (Decrease) in Other Operating Liabilities Increase (Decrease) in Other Operating Liabilities Shares issuable upon exercise of stock options Stock Options Employee And Non Employees Stock Option [Member] An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize individuals, in addition to their regular compensation and benefits. Cash, cash equivalents and restricted cash at the beginning of period Cash, cash equivalents and restricted cash at the end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Variable lease cost Variable Lease, Cost Operating lease cost Operating Lease, Cost 2027 Convertible notes Convertible Notes Payable2027 [Member] Represents information pertaining to convertible notes, maturing on 2027. Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, issued shares (in shares) Common Stock, Shares, Issued Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Cumulative Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Matching contribution by employer Defined Contribution Plan, Employer Matching Contribution, Percent of Match Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Weighted average period for recognition of unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Other financing activities Proceeds from (Payments for) Other Financing Activities Comprehensive loss, net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Interest Expense Schedule of Interest Expense [Table Text Block] Schedule of Interest Expense Long-term debt, less current portion Loans Payable, Noncurrent Service or Product Type [Domain] Service or Product Type [Domain] Service or Product Type Number of outstanding performance share units (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Federal Domestic Tax Authority [Member] Type of Adoption [Domain] Accounting Standards Update [Domain] Short-term lease cost Short-Term Lease, Cost Replaced restricted stock awards for business combinations Stock issued during period, value, acquisitions Stock Issued During Period, Value, Acquisitions Entity Address, Address Line One Entity Address, Address Line One Purchase of employee stock purchase plan shares Purchase of Employee Stock Purchase Plan Values Represents the equity impact of the value of purchase of employee stock purchase plan by an entity during the period. 2024 Finance Lease, Liability, to be Paid, Year One Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Derivative, fair value Derivative, Fair Value, Net Weighted Average Remaining Contractual Term Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Accrued interest or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Operating loss carryforwards Operating Loss Carryforwards Product Development and Other Milestone-based Payments Product Development and Other Milestone-based Payments [Member] Product Development and Other Milestone-based Payments Schedule of net-book value and estimated remaining life and finite lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Other current liabilities Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Total cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Net Income (Loss) Operating lease, termination period Lessee, Operating Lease, Termination Period Lessee, Operating Lease, Termination Period FDA Approval FDA Approval [Member] FDA Approval Other Commitments [Domain] Other Commitments [Domain] Inventory Inventory Inventory, Net Land Land [Member] Further grants or awards after termination of plan (in shares) Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period After Termination of Plan Represents the number of share options (or share units) granted or awarded after termination of the share-based compensation plan. Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Financial Instrument [Axis] Financial Instrument [Axis] Advertising Costs Advertising Cost [Policy Text Block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Thrive, Ashion and OmicEra Thrive, Ashion and OmicEra [Member] Thrive, Ashion and OmicEra Supplemental disclosure of non-cash investing and financing activities: Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] International International Sales [Member] International Sales Inventory Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Noncash or Part Noncash Divestitures [Table] Noncash or Part Noncash Divestitures [Table] Noncash or Part Noncash Divestitures [Line Items] Noncash or Part Noncash Divestitures [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Face amount Debt Instrument, Face Amount Deferred tax liabilities Deferred Tax Liabilities, Net [Abstract] MDxHealth American Depository Shares Noncash or Part Noncash Divestiture, Amount of Consideration Received Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Components of net deferred tax assets Components of Deferred Tax Assets [Abstract] Entity Address, State or Province Entity Address, State or Province Restricted Shares and RSUs Restricted Stock Awards And Restricted Stock Units R S U [Member] Represents the details relating to the restricted stock awards and restricted stock units (RSUs) as awarded by the entity to their employees as a form of incentive compensation. Total minimum lease payments Finance Lease, Liability, to be Paid Repurchase price, as percentage of principal amount, if company undergoes change of control Debt Instrument Repurchase Price Due to Change in Control as Percentage of Principal Amount Represents the price at which the debt may be repurchased, as a percentage of the principal amount if the entity undergoes a change of control. Conversion price per share of common stock (in usd per share) Debt Instrument, Convertible, Conversion Price Conversion rate, number of shares to be issued per $1,000 of principal amount Debt Instrument, Convertible, Conversion Ratio Disposal Group Name [Domain] Disposal Group Name [Domain] Securities Owned Not Readily Marketable Securities Owned Not Readily Marketable [Table Text Block] Net loss before tax Business Acquisition, Pro Forma Income (Loss), Before Tax Business Acquisition, Pro Forma Income (Loss), Before Tax California CALIFORNIA Net sales of a licensed product Collaborative Arrangements Sales Milestone Amount Represents the amount of net sales of a licensed product considered as a milestone under the collaborative arrangement. Operating loss carryforwards with expiration date Operating Loss Carryforwards, Subject To Expiration Operating Loss Carryforwards, Subject To Expiration Changes in Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) [Line Items] Coupon interest expense Coupon Interest Expense Coupon Interest Expense Other adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Class of Stock [Domain] Class of Stock [Domain] Conversions Conversions Conversions Customer [Domain] Customer [Domain] Schedule of amounts reclassified from accumulated other comprehensive income (loss) Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Schedule of inventory Schedule of Inventory, Current [Table Text Block] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of months of customary employment required to participate in the plan Share Based Compensation Arrangement by Share Based Payment Award Requisite Number of Months of Employment Represents the number of months for which an employee is required to provide service to participate under an equity-based compensation arrangement. Litigation Settlement, Expense Litigation Settlement, Expense Effective tax rate Effective tax rate Effective Income Tax Rate Reconciliation, Percent Investment owned, fair value Investment Owned, Fair Value Recognition of lease liabilities Total Operating Lease, Liability Disposal group, contingent consideration arrangements, range of outcomes, value, high Disposal Group, Contingent Consideration Arrangements, Range Of Outcomes, Value, High Disposal Group, Contingent Consideration Arrangements, Range Of Outcomes, Value, High Commercial Service [Member] Asset Acquisition [Axis] Asset Acquisition [Axis] Total consideration Disposal Group, Including Discontinued Operation, Consideration Stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price AOCI AOCI Attributable to Parent [Member] Percent of equity acquired Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Total cash, cash equivalents, and marketable securities Cash, Cash Equivalents, and Short-Term Investments Valuation allowances established Valuation allowances established SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Compensation expense in connection with the 401 (k) Plan Defined Contribution Plan, Cost Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] LICENSE AGREEMENTS [Abstract] Plan Name [Axis] Plan Name [Axis] ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Employee Stock Purchase Plan 2010 Employee Stock Purchase Plan2010 [Member] Represents information pertaining to the 2010 employee stock purchase plan. Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net operating assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Operating Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Operating Assets Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—181,364,180 and 177,925,631 shares at December 31, 2023 and December 31, 2022 Common Stock, Value, Issued Due after one year through four years, Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Trade name Trade Names [Member] Payments Payment for Contingent Consideration Liability, Investing Activities Finance cash flows from finance leases Finance Lease, Principal Payments Finance lease maturity Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Revenue from Contract with Customer [Abstract] Restricted cash — included in other long-term assets, net as of December 31, 2023 and 2021, and prepaid expenses and other current assets as of December 31, 2022 Restricted Cash Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Litigation Case [Domain] Litigation Case [Domain] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Entity Filer Category Entity Filer Category Statement [Table] Statement [Table] Omnibus Long Term Incentive Plan 2010 Omnibus Long Term Incentive Plan2010 [Member] Represents information pertaining to the 2010 omnibus long -term incentive plan. Current Fiscal Year End Date Current Fiscal Year End Date Schedule of differences between the effective income tax rate and the statutory tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Noncash or Part Noncash Divestitures Schedule of Noncash or Part Noncash Divestitures [Table Text Block] Beginning of the period Ending of the period Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] Expected volatility, minimum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Collateralized Debt Instruments Debt, Policy [Policy Text Block] Preferred stock, authorized shares (in shares) Preferred Stock, Shares Authorized Asset acquisition IPR&D expense Asset acquisition IPR&D expense Asset acquisition IPR&D expense Gain on Sale of Investments Gain on Sale of Investments Buildings Building [Member] Schedule of carrying amount of goodwill Schedule of Goodwill [Table Text Block] Preferred stock, outstanding shares (in shares) Preferred Stock, Shares Outstanding Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Marketable Securities [Line Items] Marketable Securities [Line Items] Other Other Accrued Liabilities, Current Investments in privately held companies Payments to Acquire Other Investments SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Comprehensive loss, before tax Comprehensive Income (Loss), Before Tax, Attributable to Parent Comprehensive Income (Loss), Before Tax, Attributable to Parent Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Unrecognized tax benefit that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Shares issuable upon the release of restricted stock awards Restricted Stock Restricted Stock [Member] Total Fair Value, Net Asset (Liability) Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Shares issuable upon conversion of convertible notes Convertible Notes Payable [Member] Number of hours per week of customary employment required to participate in the plan Share Based Compensation Arrangement by Share Based Payment Award Requisite Number of Hours Per Week of Employment Represents the number of hours per week for which an employee is required to provide service to participate under an equity-based compensation arrangement. Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Amount agreed to be paid upon reaching the specified amount of net sales Collaborative Arrangements Amount Agreed to Pay upon Achievement of Sale Milestones Represents the amount payable by the entity upon achievement of certain sale milestones under the collaborative arrangement. Net loss before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Precision Oncology Precision Oncology [Member] Precision Oncology Service fee based on incremental gross profits over specified baselines and royalties Service Fee Based on Incremental Gross Profits Over Specified Baselines and Royalties Represents service fee based on incremental gross profits over specified baselines and royalties. Conversion of convertible notes, net of tax (in shares) Stock issued in conversion of convertible notes (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Payments to acquire productive assets Payments to Acquire Productive Assets Disposal Group Classification [Domain] Disposal Group Classification [Domain] Net identifiable assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Weighted Average Remaining Life (Years) Finite-Lived Intangible Asset, Useful Life Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Non-cash lease expense Operating Lease, Expense Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Revenue from external customers by geographic areas Revenue from External Customers by Geographic Areas [Table Text Block] Foreign Foreign Tax Authority [Member] City Area Code City Area Code Product and Service [Axis] Product and Service [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Marketable Securities [Table] Marketable Securities [Table] 2025 Convertible notes Convertible Notes Payable2025 [Member] Represents information pertaining to convertible notes, maturing on 2025. Capital investment expenditures over specified period, requirement to earn the refundable tax credits Capital Investment Expenditures, Requirement for Refundable Tax Credits The amount of expenditures in capital investments the Company is required to make over a specified period to earn the refundable tax credits. Land improvements Land Improvements [Member] Summary of stock option activity under the Stock Plans Share-Based Payment Arrangement, Option, Activity [Table Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Full-time positions that must be created over a specified time period to earn the refundable tax credits Number of Full-time Positions Required to be Created to Earn Refundable Tax Credits Represents the number of full-time positions that must be created over a specified time period to earn the refundable tax credits. Manufactured Product, Other Manufactured Product, Other [Member] Goodwill and Intangible Assets Disclosure [Abstract] 2028 Convertible notes Convertible Notes Payable2028 [Member] Convertible Notes Payable2028 Stock issued to acquire productive assets, value Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Amended Wisconsin Economic Development Tax Credit Agreement Amended Wisconsin Economic Development Tax Credit Agreement [Member] Amended Wisconsin Economic Development Tax Credit Agreement Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Other Product and Service, Other [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall Fair Value, Assets Measured on Recurring Basis [Table Text Block] WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS [Text Block] The entire disclosure relating to the Wisconsin Economic Development Tax Credit. Foreign currency adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Developed Technology Rights [Member] Developed Technology Rights [Member] Guarantees and Indemnifications Guarantees, Indemnifications and Warranties Policies [Policy Text Block] CSM Coverage Center for Medicare And Medicaid Services (CMS) Coverage [Member] Center for Medicare And Medicaid Services (CMS) Coverage Schedule of non-cash stock-based compensation expense by department Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Investment income (loss), net Investment Income (Expense), Nonoperating Investment Income (Expense), Nonoperating Other long-term assets, net Other Assets, Noncurrent Ownership [Domain] Ownership [Domain] Period of lab testing services Period Of Lab Testing Services Period Of Lab Testing Services Operating lease right-of-use assets Recognition of ROU assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Revolver Revolving Loan Agreement [Member] Revolving Loan Agreement Assets under construction Construction Payable, Current Service Agreements [Member] Service Agreements [Member] Risk-free interest rates, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Expected volatility, maximum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Percentage of employee's compensation to be deducted from the employee's pay Share Based Compensation Arrangement by Share Based Payment Award Contribution by Eligible Employee Percent Represents the percentage of compensation that can be contributed by the employee towards the purchase of the entity's common stock. Daily Bloomberg Short-Term Bank Yield Index Rate Daily Bloomberg Short-Term Bank Yield Index Rate [Member] Daily Bloomberg Short-Term Bank Yield Index Rate Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] In-process research and development In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Contract termination fee Contract Termination Fee Contract Termination Fee MRD Product Revenue Milestone MRD Product Revenue Milestone [Member] MRD Product Revenue Milestone Previously held equity investment fair value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Vested and expected to vest at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Leasehold and building improvements Buildings And Leasehold Improvements [Member] Represents information pertaining to buildings and leasehold improvements. Schedule of fair value of contingent consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Schedule of Allocation of Transaction Costs Related to Convertible Debt Schedule of Allocation of Transaction Costs Related to Convertible Debt [Table Text Block] Schedule of Allocation of Transaction Costs Related to Convertible Debt Maturities and sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities Common stock, authorized shares (in shares) Common Stock, Shares Authorized Construction Loans Construction Loans [Member] Estimated Fair Value Debt Securities, Available-for-Sale Gains in Accumulated Other Comprehensive Income (Loss) Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Marketable securities Short-Term Investments [Member] Equity Securities, FV-NI, Gain (Loss) Equity Securities, FV-NI, Gain (Loss) Assets under construction Asset under Construction [Member] Allocated to Previous Ownership Interest Allocated to Previous Ownership Interest [Member] Allocated to Previous Ownership Interest Payments contingent on milestones Payments Contingent on Milestones Payable Represents potential future payments still contingent upon achievement of milestones under a collaborative arrangement. TARDIS Technology TARDIS Technology [Member] TARDIS Technology Measurement Input Type [Axis] Measurement Input Type [Axis] Title of Individual [Domain] Title of Individual [Domain] Total identifiable assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Fair value of equity instruments other than options Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Other Commitments [Axis] Other Commitments [Axis] Contingent consideration Business Combination, Consideration Transferred, Liabilities Incurred Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Tax Positions Income Tax, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Outstanding at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Changes to existing valuation allowances SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Entity Registrant Name Entity Registrant Name Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS. WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS. Wisconsin Economic Development Tax Credit Disclosure [Abstract] Foreign tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Acquired In-process Research and Development (IPR&D) In Process Research and Development, Policy [Policy Text Block] Post-combination expense for acceleration of unvested equity Acceleration Of Unvested Equity, Post Combination, Expense Acceleration Of Unvested Equity, Post Combination, Expense Disposal Group, Contingent Consideration Arrangements, Additional Consideration Disposal Group, Contingent Consideration Arrangements, Additional Consideration Disposal Group, Contingent Consideration Arrangements, Additional Consideration Payments on construction loan Repayments of Construction Loans Payable Cost of sales Cost of Sales [Member] Remeasurement of contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability COVID-19 Testing COVID-19 Testing [Member] COVID-19 Testing Auditor Name Auditor Name Proceeds from lines of credit Proceeds from Lines of Credit Total transaction costs Debt Instrument Convertible Transaction Costs The transaction costs of the liability and equity component of convertible debt which may be settled upon conversion. Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Disposal Group Name [Axis] Disposal Group Name [Axis] Exercisable at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Software Development Costs Internal Use Software, Policy [Policy Text Block] Entity Central Index Key Entity Central Index Key Research and trial related expenses Accrued Research and Trial Related Expenses Current Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for research and trial related expenses. Stock-based compensation expense Share-Based Payment Arrangement, Expense Cost Finite-Lived Intangible Assets, Gross Income Tax Authority [Domain] Income Tax Authority [Domain] Compensation Employee-related Liabilities, Current Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of disaggregation by revenue source Disaggregation of Revenue [Table Text Block] Employee Stock Purchase Plan 2019 Employee Stock Purchase Plan 2019 [Member] Employee Stock Purchase Plan 2019 CONVERTIBLE NOTES [Abstract] CONVERTIBLE NOTES Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Legal Entity [Axis] Legal Entity [Axis] Summary of shares of authorized common stock reserved for issuance Schedule of Share Based Compensation Arrangement by Share Based Payment Award Shares Reserved for Issuance [Table Text Block] Tabular disclosure of maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors) and reserved for issuance, for awards under the equity-based compensation plan. Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract] Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Licensing Agreements Licensing Agreements [Member] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Due in one year or less, Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Business Combinations and Asset Acquisitions Business Combinations Policy [Policy Text Block] Operating loss carryforwards with no expiration date Operating Loss Carryforwards, Not Subject To Expiration Operating Loss Carryforwards, Not Subject To Expiration Long-term Debt, Excluding Current Maturities Long-Term Debt, Excluding Current Maturities Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Weighted-average remaining lease term - finance leases (in years) Finance Lease, Weighted Average Remaining Lease Term Leasehold improvements Leasehold Improvements [Member] Deferred tax liability Net deferred tax liabilities Deferred Tax Liabilities, Net Sales and marketing Selling and Marketing Expense [Member] Weighted average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Additional cash consideration to be paid Business Combination, Contingent Consideration, Additional Payment Business Combination, Contingent Consideration, Additional Payment Increase in number of shares reserved for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses: Operating Expenses [Abstract] Collaborative Arrangement Milestone [Domain] Collaborative Arrangement Milestone [Domain] Collaborative Arrangement Milestone [Domain] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Components of lease expense Lease, Cost [Abstract] Total assets Assets Thereafter Finance Lease, Liability, to be Paid, after Year Five Machinery and equipment Equipment [Member] Investment income, net Investment Income, Nonoperating Collaborative Arrangements Sales Milestone [Domain] Collaborative Arrangements Sales Milestone [Domain] Information by range of sale milestones pertaining to the collaborative arrangement. Proceeds from issuance of convertible notes Net proceeds from issuance Proceeds from Convertible Debt Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Effective interest rate Debt Instrument, Interest Rate During Period Released (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Raw materials Inventory, Raw Materials and Supplies, Gross Net current period change in accumulated other comprehensive income (loss) Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Other adjustments Effective Income Tax Rate Reconciliation, Loss On Extinguishment Of Debt, Percent Effective Income Tax Rate Reconciliation, Loss On Extinguishment Of Debt, Percent Total marketable securities Marketable Securities Value of stock after conversion of convertible notes Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments Common stock issued Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Contract with Customer, Asset, after Allowance for Credit Loss Contract with Customer, Asset, after Allowance for Credit Loss Long-term debt Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Mayo M A Y O Foundation [Member] Represents the pertinent information about MAYO Foundation for Medical Education and Research (MAYO). Compensation Expense Compensation Expense [Member] Compensation Expense Acquired IPR&D asset expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Common Stock Issued Schedule of Common Stock Issued [Table Text Block] Schedule of Common Stock Issued Cost of sales (exclusive of amortization of acquired intangible assets) Cost of Revenue Proceeds from exercise of common stock options Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement Statement [Line Items] Conversion of convertible notes, net of tax Stock Issued During Period, Value, Conversion of Convertible Securities Concentration Risk [Table] Concentration Risk [Table] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share conversion ratio Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Issued Exchange Ratio Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Issued Exchange Ratio PFS Genomics PFS Genomics [Member] PFS Genomics Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] EX-101.PRE 13 exas-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 exas-20231231_g1.jpg begin 644 exas-20231231_g1.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2023
Feb. 21, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-35092    
Entity Registrant Name EXACT SCIENCES CORPORATION    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 5505 Endeavor Lane    
Entity Address, City or Town Madison    
Entity Address, State or Province WI    
Entity Tax Identification Number 02-0478229    
Entity Address, Postal Zip Code 53719    
City Area Code 608    
Local Phone Number 284‑5700    
Title of 12(b) Security Common Stock, $0.01 Par Value    
Trading Symbol EXAS    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 16,796,351,138
Entity Common Stock, Shares Outstanding   181,530,967  
Documents Incorporated by Reference The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended December 31, 2023. Portions of such proxy statement are incorporated by reference into Part III of this Form 10‑K.    
Entity Central Index Key 0001124140    
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Document Financial Statement Error Correction [Flag] false    

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Firm ID 238
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Chicago, Illinois
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 605,378 $ 242,493
Marketable securities 172,266 389,564
Accounts receivable, net 203,623 158,043
Inventory 127,475 118,259
Prepaid expenses and other current assets 85,627 73,898
Total current assets 1,194,369 982,257
Long-term assets:    
Property, plant and equipment, net 698,354 684,756
Operating lease right-of-use assets 143,708 167,003
Goodwill 2,367,120 2,346,040
Intangible assets, net 1,890,396 1,956,240
Other long-term assets, net 177,387 90,577
Total assets 6,471,334 6,226,873
Current liabilities:    
Accounts payable 78,816 74,916
Accrued liabilities 341,683 299,216
Operating lease liabilities, current portion 29,379 28,366
Other current liabilities 14,823 10,249
Total current liabilities 514,701 412,747
Convertible notes, net 2,314,276 2,186,106
Long-term debt, less current portion 0 50,000
Other long-term liabilities 335,982 352,459
Operating lease liabilities, less current portion 161,070 182,399
Total liabilities 3,326,029 3,183,711
3326029000
Stockholders’ equity:    
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at December 31, 2023 and December 31, 2022 0 0
Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—181,364,180 and 177,925,631 shares at December 31, 2023 and December 31, 2022 1,815 1,780
Additional paid-in capital 6,611,237 6,311,644
Accumulated other comprehensive income (loss) 1,428 (5,236)
Accumulated deficit (3,469,175) (3,265,026)
Total stockholders’ equity 3,145,305 3,043,162
Total liabilities and stockholders’ equity 6,471,334 6,226,873
Loans Payable, Current $ 50,000 $ 0
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized shares (in shares) 5,000,000 5,000,000
Preferred stock, issued shares (in shares) 0 0
Preferred stock, outstanding shares (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares (in shares) 400,000,000 400,000,000
Common stock, issued shares (in shares) 181,364,180 177,925,631
Common stock, outstanding shares (in shares) 181,364,180 177,925,631
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Revenue $ 2,499,766 $ 2,084,279 $ 1,767,087
Operating expenses:      
Cost of sales (exclusive of amortization of acquired intangible assets) 654,248 574,394 458,757
Research and development 425,882 393,418 385,646
Sales and marketing 727,090 846,011 861,889
General and administrative 893,204 737,304 801,262
Amortization of acquired intangible assets 92,160 97,450 95,001
Impairment of long-lived assets 621 15,969 20,210
Total operating expenses 2,793,205 2,664,546 2,622,765
Other operating income (loss) 78,427 (13,244) 0
Loss from operations (215,012) (593,511) (855,678)
Other income (expense)      
Investment income (loss), net 32,713 (19,425) 31,778
Interest expense (19,447) (19,634) (18,606)
Total other income (expense) 13,266 (39,059) 13,172
Net loss before tax (201,746) (632,570) (842,506)
Income tax benefit (expense) (2,403) 9,064 246,881
Net loss $ (204,149) $ (623,506) $ (595,625)
Net loss per share - basic (in dollars per share) $ (1.13) $ (3.54) $ (3.48)
Net loss per share - diluted (in dollars per share) $ (1.13) $ (3.54) $ (3.48)
Weighted average common shares outstanding - basic (in shares) 180,144 176,351 171,348
Weighted average common shares outstanding - diluted (in shares) 180,144 176,351 171,348
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Net loss $ (204,149) $ (623,506) $ (595,625)
Other comprehensive loss, before tax:      
Unrealized gain (loss) on available-for-sale investments 5,343 (3,823) (2,162)
Foreign currency adjustment 1,321 30 23
Comprehensive loss, before tax (197,485) (627,299) (597,764)
Income tax benefit related to items of other comprehensive loss 0 0 170
Comprehensive loss, net of tax $ (197,485) $ (627,299) $ (597,594)
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid In Capital
AOCI
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   159,423,410      
Beginning balance at Dec. 31, 2020 $ 2,235,553 $ 1,595 $ 4,279,327 $ 526 $ (2,045,895)
Increase (Decrease) in Stockholders' Equity          
Conversion of convertible notes, net of tax (in shares)   580      
Exercise of common stock options (in shares)   1,295,104      
Exercise of common stock options 14,437 $ 13 14,424    
Issuance of common stock to fund the Company's 401(k) match (in shares)   162,606      
Issuance of common stock to fund the Company’s 2020 401(k) match 22,934 $ 2 22,932    
Compensation expense related to issuance of stock options and restricted stock awards (in shares)   1,879,169      
Compensation expense related to issuance of stock options and restricted stock awards 334,023 $ 19 334,004    
Purchase of employee stock purchase plan shares (in shares)   331,769      
Purchase of employee stock purchase plan shares 23,070 $ 3 23,067    
Issuance of common stock to fund business combinations (in shares)   10,581,429      
Replaced restricted stock awards for business combinations 1,355,170 $ 106 1,355,064    
Net loss (595,625)       (595,625)
Other comprehensive loss (1,969)     (1,969)  
Ending balance (in shares) at Dec. 31, 2021   173,674,067      
Ending balance at Dec. 31, 2021 3,387,636 $ 1,738 6,028,861 (1,443) (2,641,520)
Increase (Decrease) in Stockholders' Equity          
Conversion of convertible notes, net of tax 43   43    
Exercise of common stock options (in shares)   706,134      
Exercise of common stock options 6,524 $ 6 6,518    
Issuance of common stock to fund the Company's 401(k) match (in shares)   391,129      
Issuance of common stock to fund the Company’s 2020 401(k) match 29,202 $ 4 29,198    
Compensation expense related to issuance of stock options and restricted stock awards (in shares)   2,220,510      
Compensation expense related to issuance of stock options and restricted stock awards 206,823 $ 22 206,801    
Purchase of employee stock purchase plan shares (in shares)   668,605      
Purchase of employee stock purchase plan shares 25,491 $ 7 25,484    
Issuance of common stock to fund business combinations (in shares)   265,186      
Replaced restricted stock awards for business combinations 14,792 $ 3 14,789    
Other (7)   (7)    
Net loss (623,506)       (623,506)
Other comprehensive loss $ (3,793)     (3,793)  
Ending balance (in shares) at Dec. 31, 2022 177,925,631 177,925,631      
Ending balance at Dec. 31, 2022 $ 3,043,162 $ 1,780 6,311,644 (5,236) (3,265,026)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares) 194,629 194,597      
Exercise of common stock options $ 3,197 $ 2 3,195    
Issuance of common stock to fund the Company's 401(k) match (in shares)   517,550      
Issuance of common stock to fund the Company’s 2020 401(k) match 35,100 $ 5 35,095    
Compensation expense related to issuance of stock options and restricted stock awards (in shares)   1,801,954      
Compensation expense related to issuance of stock options and restricted stock awards 231,312 $ 18 231,294    
Purchase of employee stock purchase plan shares (in shares)   924,448      
Purchase of employee stock purchase plan shares 28,344 $ 10 28,334    
Issuance of common stock to fund business combinations (in shares)   0      
Replaced restricted stock awards for business combinations 1,675 $ 0 1,675    
Net loss (204,149)       (204,149)
Other comprehensive loss $ 6,664     6,664  
Ending balance (in shares) at Dec. 31, 2023 181,364,180 181,364,180      
Ending balance at Dec. 31, 2023 $ 3,145,305 $ 1,815 $ 6,611,237 $ 1,428 $ (3,469,175)
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders Equity (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2023
Statement of Financial Position [Abstract]      
Common stock, par value (in dollars per share) $ 0.01   $ 0.01
Other $ (7)    
Conversion of convertible notes, net of tax   $ 43  
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:      
Net loss $ (204,149) $ (623,506) $ (595,625)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation 114,448 100,108 85,345
Equity Securities, FV-NI, Gain (Loss) 4,098 (21,774) 29,008
Deferred tax benefit (955) (11,901) (253,169)
Stock-based compensation 231,312 206,823 253,063
Post-combination expense for acceleration of unvested equity 0 0 80,960
Amortization of acquired intangible assets 92,160 97,450 95,001
Asset acquisition IPR&D expense 500   85,337
Loss on sale of asset 0 13,244 0
Impairment of long-lived assets 621 15,969 20,210
Remeasurement of contingent consideration liabilities (18,044) (56,617) 6,360
Non-cash lease expense 27,891 28,639 25,825
Changes in assets and liabilities, net of effects of acquisition:      
Accounts receivable, net (43,416) 61,088 25,150
Inventory, net (7,690) (13,231) (9,221)
Operating lease liabilities (26,701) (20,646) (16,685)
Accounts payable and accrued liabilities 82,750 (52,180) 169,800
Net cash provided by (used in) operating activities 156,119 (223,559) (102,236)
Cash flows from investing activities:      
Purchases of marketable securities (139,854) (131,486) (1,164,050)
Maturities and sales of marketable securities 363,156 453,072 794,322
Purchases of property, plant and equipment (124,190) (214,462) (135,766)
Proceeds from Sale of Productive Assets 0 25,000 0
Investments in privately held companies (16,564) (42,823) (18,044)
Business combination, net of cash acquired and issuance costs (52,413) (14,686) (499,730)
Asset acquisitions, net of cash acquired (500) 0 (58,073)
Other investing activities 250 (549) (744)
Net cash provided by (used in) investing activities 49,679 74,066 (1,082,085)
Cash flows from financing activities:      
Proceeds from issuance of convertible notes 137,976 0 0
Proceeds from exercise of common stock options 3,197 6,524 14,437
Proceeds in connection with the Company's employee stock purchase plan 28,344 25,491 23,070
Payments on construction loan 0 0 (23,749)
Other financing activities (9,751) (5,530) (5,286)
Net cash provided by financing activities 159,766 76,485 8,472
Effects of exchange rate changes on cash and cash equivalents 1,321 30 23
Net increase (decrease) in cash, cash equivalents and restricted cash 366,885 (72,978) (1,175,826)
Cash, cash equivalents and restricted cash at the beginning of period 242,790 315,768 1,491,594
Cash, cash equivalents and restricted cash at the end of period 609,675 242,790 315,768
Supplemental disclosure of non-cash investing and financing activities:      
Property, plant and equipment acquired but not paid 18,505 15,943 33,177
Business acquisition contingent consideration liability 0 4,600 350,348
Supplemental disclosure of cash flow information:      
Interest paid 18,776 11,519 10,735
Reconciliation of cash, cash equivalents and restricted cash:      
Cash and cash equivalents 605,378 242,493 315,471
Restricted cash — included in other long-term assets, net as of December 31, 2023 and 2021, and prepaid expenses and other current assets as of December 31, 2022 4,297 297 297
Total cash, cash equivalents and restricted cash 609,675 242,790 315,768
Proceeds from Accounts Receivable Securitization 0 50,000 0
Gain (Loss) On Contingent Consideration From Disposition Of Asset (73,300) 0 0
Other Noncash Expense 399 10,835 12,356
Increase (Decrease) in Other Operating Assets (11,618) (84) (24,672)
Increase (Decrease) in Other Operating Liabilities 6,333 (1,324) (33,263)
Proceeds From Sale Of Investments In Privately-Held Companies 19,794 0 0
Gain on settlement of convertible notes $ (10,324) $ 0 $ 0
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business
Exact Sciences Corporation (together with its subsidiaries, “Exact” or the “Company”) was incorporated in February 1995. Exact is a leading, global advanced cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard® and Oncotype DX®. Exact is currently working to develop additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.
Basis of Presentation and Principles of Consolidation
The accompanying consolidated financial statements include the accounts of Exact Sciences Corporation and those of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.
Use of Estimates
The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company's financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, contingent consideration, and accounting for income taxes.
Cash and Cash Equivalents
The Company considers cash on hand, demand deposits in a bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents.
Marketable Securities
Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value. The unrealized gains and losses, net of tax, on the Company's debt securities are reported in other comprehensive income. Marketable equity securities are measured at fair value and the unrealized gains and losses, net of tax, are recognized in other income (expense) in the consolidated statements of operations. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method. Such amortization is included in investment income, net. Realized gains and losses and declines in value as a result of credit losses on available-for-sale securities are included in the consolidated statements of operations as investment income, net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in the consolidated statements of operations as investment income, net.
The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current.
The Company periodically evaluates its available-for-sale debt securities in unrealized loss positions to determine whether any impairment is a result of a credit loss or other factors. This evaluation includes, but is not limited to, significant quantitative and qualitative assessments and estimates regarding credit ratings, significance of a security’s loss position, adverse conditions specifically related to the security, and the payment structure of the security.
Allowance for Doubtful Accounts
The Company estimates an allowance for doubtful accounts against accounts receivable using historical collection trends, aging of accounts, current and future implications surrounding the ability to collect such as economic conditions, and regulatory changes. The allowance for doubtful accounts is evaluated on a regular basis and adjusted when trends, significant events, or other substantive evidence such as an adverse change in a payer's ability to pay indicate that expected collections will be less than previously estimated. At December 31, 2023 and 2022, the allowance for doubtful accounts recorded was not significant to the Company's consolidated balance sheets. For the years ended December 31, 2023, 2022 and 2021, there was an insignificant amount of bad debt expense written off against the allowance and charged to operating expense.
Inventory
Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method (“FIFO”). The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale, no longer meets quality specifications, or has a cost basis in excess of its estimated realizable value and records a charge to cost of sales for such inventory as appropriate.
Direct and indirect manufacturing costs incurred during process validation with probable future economic benefit are capitalized. Validation costs incurred for other research and development activities, which are not permitted to be sold, are expensed to research and development in the Company’s consolidated statements of operations.
Property, Plant and Equipment
Property, plant and equipment are stated at cost and depreciated using the straight-line method over the assets’ estimated useful lives. Land is stated at cost and does not depreciate. Additions and improvements are capitalized, including direct and indirect costs incurred to validate equipment and bring to working conditions. Revalidation costs, including maintenance and repairs are expensed when incurred.
Software Development Costs
Costs related to internal use software, including hosted arrangements, are incurred in three stages: the preliminary project stage, the application development stage, and the post-implementation stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred during the application development stage that meet the criteria for capitalization are capitalized and amortized, when the software is ready for its intended use, using the straight‑line method over the estimated useful life of the software, or the duration of the hosting agreement.
Investments in Privately Held Companies
The Company determines whether its investments in privately held companies are debt or equity based on their characteristics. The Company also evaluates the investee to determine if the entity is a variable interest entity (“VIE”) and, if so, whether the Company is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required. If consolidation is not required and the Company does not have voting control of the entity, the investment is evaluated to determine if the equity method of accounting should be applied. The equity method applies to investments in common stock or in substance common stock where the Company exercises significant influence over the investee.
Investments in privately held companies determined to be equity securities without readily determinable fair values are accounted for under the measurement alternative method as permitted in Accounting Standards Codification (“ASC”) 321, Investments - Equity Securities. The Company adjusts the carrying value of its non-marketable equity securities for changes from observable transactions for identical or similar investments of the same issuer, less impairment. All gains and losses on non-marketable equity securities, realized and unrealized, are recognized in investment income, net in the consolidated statements of operations.
Investments in privately held companies determined to be debt securities are accounted for as available-for-sale or held-to-maturity securities unless the fair value option is elected.
Derivative Financial Instruments
The Company hedges a portion of its foreign currency exposures related to outstanding monetary assets and liabilities using foreign currency forward contracts. The foreign currency forward contracts are included in prepaid expenses and other current assets or in accrued liabilities in the consolidated balance sheets, depending on the contracts’ net position. These contracts are not designated as hedges, and as a result, changes in their fair value are recorded in other income (expense) in the consolidated statements of operations.
Business Combinations and Asset Acquisitions
Business Combinations are accounted for under the acquisition method in accordance with ASC 805, Business Combinations. The acquisition method requires identifiable assets acquired and liabilities assumed and any non-controlling interest in the business acquired be recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. The amount by which the fair value of consideration transferred as the purchase price exceeds the net fair value of assets acquired and liabilities assumed is recorded as goodwill. Acquisitions that do not meet the definition of a business combination under ASC 805 are accounted for as asset acquisitions. Asset acquisitions are accounted for by allocating the cost of the acquisition to the individual assets acquired and liabilities assumed on a relative fair value basis. Goodwill is not recognized in an asset acquisition with any consideration in excess of net assets acquired allocated to acquired assets on a relative fair value basis. Transaction costs are expensed in a business combination and are considered a component of the cost of the acquisition in an asset acquisition.
Intangible Assets
Purchased intangible assets are recorded at fair value. The Company uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. The Company’s finite-lived intangible assets are being amortized on a straight-line basis over their estimated useful lives.
Patent costs are capitalized as incurred, only if the Company determines that there is some probable future economic benefit derived from the transaction. A capitalized patent is amortized over its estimated useful life, beginning when such patent is approved. Capitalized patent costs are expensed upon disapproval, upon a decision by the Company to no longer pursue the patent or when the related intellectual property is either sold or deemed to be no longer of value to the Company. The Company determined that all patent costs incurred during the years ended December 31, 2023, 2022 and 2021 should be expensed and not capitalized as the future economic benefit derived from the patent costs incurred cannot be determined.
Acquired In-process Research and Development (“IPR&D”)
Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The primary basis for determining technological feasibility of these projects is obtaining regulatory approval to market the underlying product. The amounts capitalized are accounted for as indefinite-lived intangible assets and are subject to impairment testing until completion or abandonment of the research and development efforts associated with the projects. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. The value assigned to acquired IPR&D is determined using the multi-period excess earnings method approach, which utilizes significant unobservable inputs (Level 3 inputs) including projected revenues, projected gross margin, projected operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success. There are often major risks and uncertainties associated with IPR&D projects as the Company is required to obtain regulatory approvals in order to market the resulting products. Such approvals require completing clinical trials that demonstrate the product's effectiveness. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods.
Capitalized IPR&D projects are tested for impairment annually in the fourth quarter, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, and upon successful completion of the project. The Company considers various factors for potential impairment, including the current legal and regulatory environment, current and future strategic initiatives and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors' products could result in partial or full impairment of the related intangible assets.
Contingent Consideration Liabilities
Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain regulatory and product development milestones being achieved. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected probabilities of success, projected payment dates, present value-factors, and projected revenues (for revenue-based considerations). Changes in probabilities of success, present-value factors, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within general and administrative expenses on the Company’s consolidated statements of operations. Cash contingent consideration payments up to the acquisition date fair value of the contingent consideration liability are classified as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are classified as operating activities in the consolidated statements of cash flows.
Contingent Consideration Asset
The sale of the Company’s intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test (“GPS test”) resulted in the recognition of variable consideration in accordance with ASC 606. The Company estimates the amount of variable consideration that it is entitled to each quarter using the most likely amount method and considers whether there are any constraints on the consideration. If it is probable that a significant reversal of a gain would not occur, the Company will record a gain. To determine the classification of the consideration, the Company determines if the consideration is conditional on something other than the passage of time. Revenue-based contingent consideration that is conditional on something other than the passage of time, including future revenues from sales related to the GPS test, result in the variable consideration being classified as a contract asset. At the time the amount earned is determined, and passage of time is the only condition remaining, the contract asset is reclassified to a receivable.
Collateralized Debt Instruments
Debt instruments that are collateralized by security interests in financial assets held by the Company are accounted for as a secured borrowing and therefore: (i) the asset balances pledged as collateral are included within the applicable balance sheet line item and the borrowings are included within long-term debt in the consolidated balance sheet; (ii) interest expense is included within the consolidated statements of operations; and (iii) in the case of collateralized accounts receivable, receipts from customers related to the underlying accounts receivable are reflected as operating cash flows, and (iv) borrowings and repayments under the collateralized loans are reflected as financing cash flows within the consolidated statements of cash flows.
Goodwill
The Company evaluates goodwill for possible impairment at the reporting unit level on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting the Company's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value.
Impairment of Long-Lived Assets
The Company evaluates the fair value of long-lived assets, which include property, plant and equipment, leases, finite-lived intangible assets, and investments in privately held companies, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Net Loss Per Share
Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
December 31,
(In thousands)202320222021
Shares issuable upon conversion of convertible notes23,231 20,309 20,309 
Shares issuable upon the release of restricted stock awards6,273 5,255 4,321 
Shares issuable upon the release of performance share units1,598 968 878 
Shares issuable upon exercise of stock options1,286 1,518 2,284 
Shares issuable in connection with acquisitions— — 45 
32,388 28,050 27,837 
Accounting for Stock-Based Compensation
The Company requires all share-based payments to employees, including grants of employee stock options, restricted stock, restricted stock units, shares purchased under an employee stock purchase plan (if certain parameters are not met), and performance share units to be recognized in the financial statements based on their grant date fair values. The estimated fair value of these awards is recognized to expense using the straight-line method over the requisite service period, which is generally the vesting period. The Company will recognize expense on an accelerated basis for restricted stock units upon an employee's death, disability, or upon retirement eligibility, provided certain criteria are met. Forfeitures of any share-based awards are recognized as they occur.
The fair values and recognition of the Company’s share-based payment awards are determined as follows:
The fair value of each service-based option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions:
Expected Term—Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants.
Expected Volatility—Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards.
Risk-Free Interest Rate—The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term.
The fair value of service-based awards for each restricted stock unit award is determined on the date of grant using the closing stock price on that day.
The fair value of performance-based equity awards that do not include a market condition is determined on the date of grant using the closing stock price on that day. The fair value of performance-based equity awards that include a market condition is determined on the date of grant using a Monte Carlo valuation technique. The expense recognized each period is also dependent on the probability of what performance conditions will be met which is determined by management's evaluation of internal and external factors. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the goals and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance targets and operational milestones are not achieved, the award would not vest resulting in no stock-based compensation being recognized and any previously recognized stock-based compensation expense being reversed.
Research and Development Costs
Research and development costs are expensed as incurred. These expenses include the costs of the Company's proprietary research and development efforts, as well as costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use. Acquired IPR&D assets that are acquired in an asset acquisition and which have no alternative future use are classified as an investing cash outflow in the consolidated statements of cash flows. Upfront and milestone payments due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred. Milestone payments due to third parties upon, or subsequent to, regulatory approval are capitalized and amortized into research and development costs over the shorter of the remaining license or product patent life, when there are no corresponding revenues related to the license or product. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received, rather than when the payment is made.
Advertising Costs
The Company expenses the costs of media advertising at the time the advertising takes place. The Company expensed approximately $137.9 million, $170.3 million, and $144.0 million of media advertising during the years ended December 31, 2023, 2022, and 2021, respectively, which is recorded in sales and marketing expenses on the Company’s consolidated statements of operations.
Fair Value Measurements
The Financial Accounting Standards Board (“FASB”) has issued authoritative guidance that requires fair value to be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under that standard, fair value measurements are separately disclosed by level within the fair value hierarchy. The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.
Leases
The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles, and certain laboratory and office equipment, and finance leases for certain equipment and vehicles.
The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (“ROU”) assets and lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations.
As the implicit interest rate is not readily determinable in most of the Company’s leases, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the United States (“U.S.”) Treasury rate and an indicative Moody's rating for operating leases or finance leases.
The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease for up to 10 years, and some of which include options to terminate the lease within 1 year. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest expense on the Company’s consolidated statements of operations.
The Company accounts for leases acquired in business combinations by measuring the lease liability at the present value of the remaining lease payments as if the acquired lease were a new lease for the Company. This measurement includes recognition of a lease intangible for any below-market terms present in the leases acquired. The below-market lease intangible is included in the ROU asset on the consolidated balance sheets and are amortized over the remaining lease term. The Company has not acquired any leases with above-market terms.
The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.
Revenue Recognition
Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype®, PreventionGenetics, LLC (“PreventionGenetics”), and COVID-19 tests. The services are considered completed when the performance obligation is fulfilled, which is upon release of an approved patient test result to the healthcare provider. The Company follows ASC 606, Revenue from Contracts with Customers, to account for its laboratory service revenues.
Laboratory testing services
The Company’s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services (“CMS”) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, or in the context of certain lab service or reference agreements, the Company requires payment prior to the commencement of the Company's performance obligations.
The Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patient’s test result to the ordering healthcare provider. Or, in the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window. The Company elects the practical expedient to not disclose unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year.
The Company’s transaction price is comprised of fixed and variable consideration and is allocated entirely to a single performance obligation defined as the point in time an approved patient test result is released to the ordering healthcare provider. Fixed consideration exists in arrangements where the Company has agreed to provide laboratory testing services to a customer for a specified rate and is expected to be collected in full at that rate. Variable consideration is primarily derived from payer and patient billing and can be impacted by several factors such as the amount of contractual adjustments, any patient co-payments, deductibles or patient adherence incentives, the existence of secondary payers, and claim denials. Estimates of variable consideration are calculated using the expected value method and is the sum of probability-weighted amounts in a range of possible consideration amounts. Several factors are evaluated during this process, such as historical collections experience, current contractual and statutory requirements, customer mix, patient insurance eligibility and payer reimbursement contracts, and known or anticipated reimbursement trends not yet reflected in the data. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made.
The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease in the estimate of the transaction price (i.e., an upward or downward revenue adjustment) in the period identified.
When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon completion of the performance obligations associated with the Company's tests, with recognition, generally occurring at the date of cash receipt.
Contract Balances
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets. Generally, billing occurs after the release of an approved patient test result to the healthcare provider, resulting in an account receivable. However, the Company sometimes receives advance payment from a patient or a direct bill payer before services are performed, resulting in deferred revenue. The deferred revenue recorded is recognized as revenue at the point in time an approved patient test result is released to the patient's healthcare provider. In the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window.
Practical Expedients
The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.
The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company’s consolidated statements of operations.
The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications (e.g. adherence reminder letters). These costs are expensed as incurred and recorded within general and administrative expenses in the Company’s consolidated statements of operations.
Cost of Sales
Cost of sales reflects the aggregate costs incurred in delivering the Company's products and services and includes material and service costs, personnel costs, including stock-based compensation expense, equipment and infrastructure expenses associated with laboratory testing services, shipping charges, and allocated overhead such as rent, information technology costs, equipment depreciation and utilities. Costs associated with the shipment of Cologuard test collection kits are recognized upon shipment, and costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test.
Foreign Currency Transactions
The functional currency for most of the Company’s international subsidiaries is the U.S. dollar. When the functional currency differs from the local currency, monetary assets and liabilities are remeasured at the current period-end exchange rate, while non-monetary assets and liabilities are remeasured at the historical rate. The gains and losses as a result of exchange rate adjustments of these subsidiaries are recognized in the consolidated statements of operations. Net foreign currency transaction gains or losses were not significant to the consolidated statements of operations for the periods presented.
For the Company’s international subsidiaries where the functional currency is other than the U.S. dollar, the financial statements are translated into the U.S. dollar, and the cumulative adjustments resulting from the translation into the U.S. dollar are included in the Company's consolidated balance sheet as a component of accumulated other comprehensive income (loss) (“AOCI”).
Concentration of Credit Risk
Financial instruments that subject the Company to credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2023, the Company had cash and cash equivalents deposited in financial institutions in which the balances exceed the federal government agency insured limit of $250,000 by approximately $529.0 million. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.
Through December 31, 2023, the Company’s revenues have been primarily derived from the sale of Cologuard, Oncotype, and COVID-19 tests. The following is a breakdown of revenue and accounts receivable from major payers:
% Revenue for the years ended December 31,% Accounts Receivable at December 31,
Major Payer202320222021202320222021
Centers for Medicare and Medicaid Services17%14%20%10%14%11%
UnitedHealthcare12%12%11%10%9%8%
State of Wisconsin—%3%8%—%5%9%
Tax Positions
A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income, the Company has determined that a valuation allowance at December 31, 2023 and 2022 is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the Company's effective tax rate.
Guarantees and Indemnifications
The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a directors and officers insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2023 and 2022.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In July 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-03, Presentation of Financial Statement (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718). This update amends various Securities and Exchange Commission (“SEC”) paragraphs in the Accounting Standards Codification to reflect the issuance of SEC Staff Accounting Bulletin No. 120, among other things. The Company adopted this conforming guidance upon issuance during the third quarter of fiscal year 2023. There was no significant impact to the Company’s consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
 The following table presents the Company’s revenues disaggregated by revenue source:
Year Ended December 31,
(In thousands)202320222021
Screening
Medicare Parts B & C$701,400 $545,458 $438,646 
Commercial992,244 743,238 569,944 
Other171,057 136,007 53,718 
Total Screening1,864,701 1,424,703 1,062,308 
Precision Oncology
Medicare Parts B & C$188,689 $197,327 $197,394 
Commercial181,318 177,518 180,177 
International153,277 117,738 109,913 
Other105,826 108,905 74,192 
Total Precision Oncology629,110 601,488 561,676 
COVID-19 Testing$5,955 $58,088 $143,103 
Total$2,499,766 $2,084,279 $1,767,087 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $25.2 million and $20.3 million for the years ended December 31, 2023 and 2022, respectively. The Company recorded a downward adjustment to revenue from a change in transaction price of $11.8 million for the year ended December 31, 2021.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s consolidated balance sheets, was not significant as of December 31, 2023 and 2022.
Revenue recognized for the year ended December 31, 2023 and 2022, which was included in the deferred revenue balance at the beginning of the year
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
MARKETABLE SECURITIES
 12 Months Ended
Dec. 31, 2023
Cash and Cash Equivalents [Abstract]  
MARKETABLE SECURITIES MARKETABLE SECURITIES
The following table sets forth the Company’s cash, cash equivalents, and marketable securities at December 31, 2023 and 2022:
December 31,
(In thousands)20232022
Cash and cash equivalents
Cash and money market$530,100 $178,168 
Cash equivalents75,278 64,325 
Total cash and cash equivalents605,378 242,493 
Marketable securities
Available-for-sale debt securities$168,425 $384,415 
Equity securities3,841 5,149 
Total marketable securities172,266 389,564 
Total cash, cash equivalents, and marketable securities$777,644 $632,057 
Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2023, consisted of the following:
(In thousands)Amortized Cost
Gains in AOCI (1)
Losses in AOCI (1)
Estimated Fair Value
Cash equivalents
Commercial paper$72,243 $— $— $72,243 
U.S. government agency securities3,035 — — 3,035 
Total cash equivalents75,278 — — 75,278 
Marketable securities
U.S. government agency securities$56,594 $166 $(44)$56,716 
Corporate bonds55,712 175 (59)55,828 
Asset backed securities35,081 65 (249)34,897 
Commercial paper
20,984 — — 20,984 
Total marketable securities168,371 406 (352)168,425 
Total available-for-sale debt securities$243,649 $406 $(352)$243,703 
_________________________________
(1)     There was no tax impact from the gains and losses in AOCI.
Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2022, consisted of the following:
(In thousands)Amortized Cost
Gains in AOCI (1)
Losses in AOCI (1)
Estimated Fair Value
Cash equivalents
Commercial paper$63,021 $— $— $63,021 
U.S. government agency securities1,304 — — 1,304 
Total cash equivalents64,325 — — 64,325 
Marketable securities
U.S. government agency securities$228,012 $— $(2,789)$225,223 
Corporate bonds116,318 20 (1,667)114,671 
Asset backed securities45,374 2 (855)44,521 
Total marketable securities389,704 22 (5,311)384,415 
Total available-for-sale debt securities$454,029 $22 $(5,311)$448,740 
_________________________________
(1)     There was no tax impact from the gains and losses in AOCI.
The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at December 31, 2023:
Due one year or lessDue after one year through five years
(In thousands)CostFair ValueCostFair Value
Cash equivalents
Commercial paper$72,243 $72,243 $— $— 
U.S. government agency securities3,035 3,035 — — 
Total cash equivalents75,278 75,278 — — 
Marketable securities
Corporate bonds$33,518 $33,474 $22,194 $22,354 
U.S. government agency securities33,407 33,403 23,187 23,313 
Commercial paper
20,984 20,984 — — 
Asset backed securities— — 35,081 34,897 
Total marketable securities87,909 87,861 80,462 80,564 
Total available-for-sale securities$163,187 $163,139 $80,462 $80,564 
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one year
One year or greater
Total
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
Corporate bonds$25,895 $(41)$2,480 $(18)$28,375 $(59)
U.S. government agency securities15,756 (35)3,965 (9)19,721 (44)
Asset backed securities4,377 (5)10,935 (244)15,312 (249)
Total available-for-sale securities$46,028 $(81)$17,380 $(271)$63,408 $(352)
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2022, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one year
One year or greater
Total
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
U.S. government agency securities$37,458 $(337)$187,766 $(2,452)$225,224 $(2,789)
Corporate bonds35,055 (575)73,702 (1,092)108,757 (1,667)
Asset backed securities27,984 (735)15,536 (120)43,520 (855)
Total available-for-sale securities$100,497 $(1,647)$277,004 $(3,664)$377,501 $(5,311)
The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of December 31, 2023 and 2022 because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers.
The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s consolidated statements of operations. The gains and losses recorded were not significant for the years ended December 31, 2023, 2022, and 2021.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORY
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
INVENTORY INVENTORY
Inventory consisted of the following:
December 31,
(In thousands)20232022
Raw materials$58,593 $61,207 
Semi-finished and finished goods68,882 57,052 
Total inventory$127,475 $118,259 
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT PROPERTY, PLANT AND EQUIPMENT
The carrying value and estimated useful lives of property, plant and equipment are as follows:
December 31,
(In thousands)Estimated Useful Life20232022
Property, plant and equipment
Landn/a$4,716 $4,716 
Leasehold and building improvements(1)214,562 200,588 
Land improvements15 years6,729 6,417 
Buildings
30 - 40 years
290,777 288,941 
Computer equipment and computer software3 years168,131 142,896 
Machinery and equipment
3 - 10 years
290,294 246,344 
Furniture and fixtures
3 - 10 years
35,756 34,047 
Assets under constructionn/a104,592 68,398 
Property, plant and equipment, at cost1,115,557 992,347 
Accumulated depreciation(417,203)(307,591)
Property, plant and equipment, net$698,354 $684,756 
_________________________________
(1)     Lesser of remaining lease term, building life, or estimated useful life.
At December 31, 2023, the Company had $104.6 million of assets under construction, which consisted of $53.2 million in machinery and equipment, $29.1 million of capitalized costs related to software projects, $15.7 million in leasehold and building improvements, and $6.6 million related to buildings. Depreciation will begin on these assets once they are placed into service upon completion.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND GOODWILL
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS AND GOODWILL INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
The following table summarizes the net-book-value and estimated remaining life of the Company's intangible assets as of December 31, 2023:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated AmortizationNet Balance at December 31, 2023
Finite-lived intangible assets
Trade name11.6$104,000 $(27,903)$76,097 
Customer relationships7.04,000 (889)3,111 
Patents and licenses4.511,542 (9,600)1,942 
Acquired developed technology (1)7.3887,789 (328,543)559,246 
Total finite-lived intangible assets1,007,331 (366,935)640,396 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,257,331 $(366,935)$1,890,396 
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated AmortizationNet Balance at December 31, 2022
Finite-lived intangible assets
Trade name12.5$104,000 $(20,653)$83,347 
Customer relationships8.04,000 (444)3,556 
Patents and licenses4.211,542 (8,152)3,390 
Acquired developed technology (1)
7.8861,474 (245,527)615,947 
Total finite-lived intangible assets981,016 (274,776)706,240 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,231,016 $(274,776)$1,956,240 
______________
(1)The gross carrying amount includes an insignificant foreign currency translation adjustment related to the intangible asset     acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
As of December 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2024$92,908 
202591,860 
202690,800 
202790,800 
202890,800 
Thereafter183,228 
Total$640,396 
There were no impairment losses recorded on finite-lived intangible assets during the year ended December 31, 2023.
The Company recorded an IPR&D asset of $1.25 billion related to a project associated with the development of a U.S. Food and Drug Administration (“FDA”) approved, blood-based, multi-cancer early detection (“MCED”) test as part of the acquisition of Thrive Earlier Detection Corporation (“Thrive”) in January 2021. The Company performed a quantitative assessment as part of its annual IPR&D impairment analysis in the fourth quarter of 2023 under which it determined that the fair value exceeded the carrying value and no impairment loss was recorded.
On August 2, 2022, the Company completed a sale of the developed technology intangible asset related to the Oncotype DX Genomic Prostate Score test to MDxHealth SA (“MDxHealth”), which was measured using the income approach to determine the fair value. The gross value of the intangible asset was $59.0 million with accumulated amortization of $16.1 million as of the closing date, resulting in a carrying value of $42.9 million, which was derecognized from intangible assets, net in the consolidated balance sheets upon completion of the divestiture. Refer to Note 18 for further information on this sale.
During the third quarter of 2022, the remaining carrying value of $2.0 million related to the supply agreement intangible asset acquired as part of the combination with Genomic Health, Inc. (“Genomic Health”) was recorded as a non-cash, pre-tax impairment loss due to the termination of the agreement. The Company previously recorded a non-cash, pre-tax impairment loss of $20.2 million during the third quarter of 2021 due to lower than anticipated performance of the underlying product.
During the second quarter of 2022, the remaining carrying value of $6.6 million related to the developed technology intangible asset acquired as a result of the acquisition of Paradigm Diagnostics, Inc. was recorded as a non-cash, pre-tax impairment loss due to lower than anticipated performance of the underlying product.
The Company utilized the income approach to measure the fair value of the impaired intangible assets, which involved significant unobservable inputs (Level 3 inputs), including revenue projections, cash flow projections, and discount rates. Impairment losses recorded on intangible assets are included in impairment of long-lived assets in the Company’s consolidated statement of operations.
Goodwill
The change in the carrying amount of goodwill for the years ended December 31, 2023 and 2022 is as follows:
(In thousands)
Balance, January 1, 2022
$2,335,172 
OmicEra acquisition
10,809 
PreventionGenetics acquisition adjustment(58)
Effects of changes in foreign currency exchange rates (1)117 
Balance, December 31, 2022
2,346,040 
Resolution Bioscience acquisition (2)
20,692 
Effects of changes in foreign currency exchange rates (1)
388 
Balance December 31, 2023
$2,367,120 
_________________________________
(1)    Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
(2)    Refer to Note 18 for further discussion on the Company’s acquisition of Resolution Bioscience, Inc. (“Resolution Bioscience”).
There were no impairment losses recorded on goodwill for the years ended December 31, 2023, 2022, and 2021.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The three levels of the fair value hierarchy established are as follows:
Level 1    Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2    Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3    Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.
The following table presents the Company’s fair value measurements as of December 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair value at December 31, 2023Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$530,100 $530,100 $— $— 
Commercial paper72,243 — 72,243 — 
Restricted cash (1)
4,297 4,297 — — 
U.S. government agency securities3,035 — 3,035 — 
Marketable securities
U.S. government agency securities$56,716 $— $56,716 $— 
Corporate bonds55,828 — 55,828 — 
Asset backed securities34,897 — 34,897 — 
Commercial paper
20,984 — 20,984 — 
Equity securities
3,841 3,841 — — 
Non-marketable securities$7,650 $— $— $7,650 
Liabilities
Contingent consideration$(288,657)$— $— $(288,657)
Total$500,934 $538,238 $243,703 $(281,007)
The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at December 31, 2022Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$178,168 $178,168 $— $— 
Commercial paper63,021 — 63,021 — 
U.S. government agency securities1,304 — 1,304 — 
Restricted cash (1)
297 297 — — 
Marketable securities
U.S. government agency securities$225,223 $— $225,223 $— 
Corporate bonds114,671 — 114,671 — 
Asset backed securities44,521 — 44,521 — 
Equity securities (2)
5,149 5,149 — — 
Non-marketable securities$10,065 $— $— $10,065 
Liabilities
Contingent consideration$(306,927)$— $— $(306,927)
Total$335,492 $183,614 $448,740 $(296,862)
_________________________________
(1)Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company's credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties.
(2)Inclusive of the American Depository Shares of MDxHealth received as part of the sale of the Company’s GPS test, which are restricted to a holding period of six months after the date of the sale of August 2, 2022. The shares had a fair value of $4.6 million as of December 31, 2022.
There have been no changes in valuation techniques or transfers between fair value measurement levels during the year ended December 31, 2023. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors.
The Company has elected the fair value option under the income approach to measure certain Level 3 non-marketable securities. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option:
(In thousands)Non-Marketable Securities
Beginning balance, January 1, 2022
$3,090 
Purchase of non-marketable securities
10,000 
Change in fair value
1,038 
Conversion of non-marketable securities
(4,063)
Balance, December 31, 2022
10,065 
Purchases of non-marketable securities6,957 
Changes in fair value1,127 
Settlement of non-marketable securities
(10,499)
Ending balance, December 31, 2023
$7,650 
Contingent Consideration Liabilities
The fair value of the contingent consideration liabilities was $288.7 million and $306.9 million as of December 31, 2023 and 2022, respectively, which was included in other long-term liabilities in the consolidated balance sheets.
The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
(In thousands)Contingent Consideration
Balance, January 1, 2022 (1)
$359,021 
Purchase price contingent consideration (2)
4,600 
Changes in fair value(56,617)
Payments(77)
Balance, December 31, 2022
306,927 
Changes in fair value
(18,044)
Payments(226)
Balance, December 31, 2023
$288,657 
_________________________________
(1)    The change in fair value of the contingent consideration liability during the year ended December 31, 2021 was not significant.
(2)    The increase in contingent consideration liability is due to the contingent consideration associated with the acquisition of OmicEra. Refer to Note 18 for further information.
This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market.
The fair value of the contingent consideration liabilities recorded from the Company’s acquisitions of Thrive, Ashion Analytics, LLC (“Ashion”), and OmicEra related to regulatory and product development milestones was $288.7 million and $306.8 million as of December 31, 2023 and 2022, respectively. The Company evaluates the fair value of the expected contingent consideration and the corresponding liabilities related to the regulatory and product development milestones using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the expected contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 89% and 91% as of December 31, 2023 and 2022, respectively, and a weighted average present-value factor of 5.8% and 6.2% as of December 31, 2023 and 2022, respectively. The projected fiscal year of payment range is from 2025 to 2030. Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.
The fair value of the contingent consideration liability related to certain revenue milestones associated with the Biomatrica, Inc. acquisition was not significant as of December 31, 2022, and the revenue milestone period ended September 30, 2023. The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone.
Non-Marketable Equity Investments
Non-marketable equity securities without readily determinable fair values, which are classified as a component of other long-term assets, net, had the following aggregate carrying amounts and downward and upward adjustments as of and for the years ended December 31, 2023 and 2022:
Year ended December 31,
(In thousands)
20232022
Upward adjustments (1)
$4,314 $779 
Downward adjustments and impairments (2)
(4,250)(10,821)
Aggregate carrying value
45,968 39,842 
_________________________________
(1)    Cumulative upward adjustments on non-marketable equity securities held as of December 31, 2023 was $5.1 million. The upward adjustments recorded were due to increases in the valuation of the underlying investee as determined by the value of the follow-on rounds of investment by other third-party investors. There were no upward adjustments recorded during the year ended December 31, 2021.
(2)    Cumulative downward adjustments and impairments on non-marketable equity securities held as of December 31, 2023 was $15.1 million. The adjustments recorded were due to adverse changes in the market and the investees’ ability to continue as a going concern. There were no downward adjustments recorded during the year ended December 31, 2021.
The Company recorded a realized gain of $5.4 million, a realized loss of $10.0 million, and a realized gain of $30.5 million on non-marketable securities for the years ended December 31, 2023, 2022, and 2021, respectively.
The Company has committed capital to venture capital investment funds (the “Funds”) of $17.5 million, of which $12.1 million remained callable through 2033 as of December 31, 2023. The aggregate carrying amount of the Funds, which are classified as a component of other long-term assets, net in the Company's consolidated balance sheets, were $5.2 million and $3.9 million as of December 31, 2023 and 2022, respectively. Gains and losses recorded on the Company's investments in the Funds were not significant for the years ended December 31, 2023, 2022, and 2021.
Derivative Financial Instruments
The Company enters into foreign currency forward contracts on the last day of each month to mitigate the impact of adverse movements in foreign exchange rates related to the remeasurement of monetary assets and liabilities and hedge the Company’s foreign currency exchange rate exposure. As of December 31, 2023 and 2022, the Company had open foreign currency forward contracts with notional amounts of $39.5 million and $22.3 million, respectively. The Company’s foreign exchange derivative instruments are classified as Level 2 within the fair value hierarchy as they are valued using inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The fair value of the open foreign currency forward contracts was zero at December 31, 2023 and 2022, and there were no gains or losses recorded to adjust the fair value of the open foreign currency contract held as of December 31, 2023. The contracts are closed subsequent to each month-end, and the gains and losses recorded from the contracts were not significant for the years ended December 31, 2023 and 2022.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACCRUED LIABILITIES
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
ACCRUED LIABILITIES ACCRUED LIABILITIES
Accrued liabilities at December 31, 2023 and 2022 consisted of the following:
December 31,
(In thousands)20232022
Compensation$247,619 $201,252 
Professional fees45,405 43,715 
Other17,274 22,329 
Research and trial related expenses14,219 17,455 
Assets under construction11,210 10,462 
Licenses5,956 4,003 
Total $341,683 $299,216 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
LONG-TERM DEBT
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
LONG-TERM DEBT LONG-TERM DEBT
Accounts Receivable Securitization Facility
On June 29, 2022, the Company, through a wholly-owned special purpose entity, Exact Receivables LLC (“Exact Receivables”) entered into an accounts receivable securitization program (the “Securitization Facility”) with PNC Bank, National Association (“PNC”), with a scheduled maturity date of June 29, 2024. The Securitization Facility provides Exact Receivables with a revolving line-of-credit of up to $150.0 million of borrowing capacity, subject to certain borrowing base requirements, by collateralizing a security interest in the domestic customer accounts receivable of certain wholly-owned subsidiaries of the Company. The amount available under the Securitization Facility fluctuates over time based on the total amount of eligible customer accounts receivable generated by the Company during the normal course of operations. The Securitization Facility requires the Company to maintain minimum borrowings under the facility of $50.0 million. The debt issuance costs incurred related to the Securitization Facility were not significant and are being amortized over the life of the Securitization Facility through interest expense within the consolidated statements of operations.
In connection with the Securitization Facility, the Company also entered into two Receivables Purchase Agreements (“Receivable Purchase Agreements”) on June 29, 2022. The Receivable Purchase Agreements are among the Company and certain wholly-owned subsidiaries of the Company, and between the Company and Exact Receivables. Under the agreements, the wholly-owned subsidiaries sell all of their right, title and interest in their accounts receivables to Exact Receivables. The receivables are used to collateralize borrowings made under the Securitization Facility. The Company retains the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provides a performance guaranty.
As of December 31, 2023, the eligible borrowing base under the Securitization Facility was $108.5 million of which the Company elected to collateralize $50.0 million. As of December 31, 2023 and December 31, 2022, the Company had an outstanding balance of $50.0 million, which is included in debt, current portion and long-term debt, less current portion, respectively, on the Company’s consolidated balance sheets. The outstanding balance accrues interest at a rate equal to a daily secured overnight financing rate (“SOFR”) rate plus a SOFR adjustment and an applicable margin. The interest rate was 6.89% at December 31, 2023.
Revolving Loan Agreement
During November 2021, the Company entered into a revolving loan agreement (the “Revolving Loan Agreement”) with PNC. The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding.
Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. In October 2022 the Revolving Loan Agreement was amended to extend the maturity date from November 5, 2023 to November 5, 2025. There were no other amendments to the Revolver.
The Company has agreed to various financial covenants under the Revolving Loan Agreement, and as of December 31, 2023, the Company is in compliance with all covenants.
In December 2021 and January 2023, PNC issued letters of credit of $2.9 million and $1.5 million, respectively, which reduced the amount available for cash advances under the line of credit to $145.6 million and $147.1 million as of December 31, 2023 and December 31, 2022, respectively. As of December 31, 2023, the Company has not drawn funds from, nor are any amounts outstanding under, the Revolving Loan Agreement.
Construction Loan Agreement
During December 2017, the Company entered into a loan agreement with Fifth Third Bank (the “Construction Loan Agreement”), which provided the Company with a non-revolving construction loan (the “Construction Loan”) of $25.6 million- with a maturity date of December 10, 2022. The Company used the Construction Loan proceeds to finance the construction of an additional clinical laboratory and related facilities in Madison, Wisconsin. The Construction Loan was collateralized by the additional clinical laboratory and related facilities.
The Construction Loan Agreement bore interest at a rate equal to the sum of the 1-month LIBOR rate plus 2.25%. The interest incurred on the Construction Loan was not significant and was capitalized to the construction project. The Company also incurred minimal debt issuance costs which were recorded as a direct deduction from the liability, and amortized over the life of the Construction Loan.
As part of the Revolving Loan Agreement discussed above, the Company agreed to repay in full all outstanding debt owed to Fifth Third Bank under the Construction Loan Agreement, and as of December 31, 2021, the remaining outstanding balance had been fully repaid in connection with the termination of the Construction Loan Agreement. Any unamortized issuance costs at the time or repayment were recorded as a loss.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONVERTIBLE NOTES
 12 Months Ended
Dec. 31, 2023
CONVERTIBLE DEBT  
CONVERTIBLE NOTES CONVERTIBLE NOTES
Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2023:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2030 Convertible Notes - 2.000%
$572,993 $(4,349)$568,644 $684,475 2
2028 Convertible Notes - 0.375%
949,042 (10,499)938,543 887,354 2
2027 Convertible Notes - 0.375%
563,822 (5,429)558,393 549,839 2
2025 Convertible Notes - 1.000%
249,172 (476)248,696 293,300 2
Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2022:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2028 Convertible Notes - 0.375%
$1,150,000 $(15,775)$1,134,225 $908,500 2
2027 Convertible Notes - 0.375%
747,500 (9,445)738,055 612,950 2
2025 Convertible Notes - 1.000%
315,005 (1,179)313,826 326,808 2
____________________________
(1)     The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement.
Issuances and Settlements
In January 2018, the Company issued and sold $690.0 million in aggregate principal amount of 1.0% Convertible Notes (the “January 2025 Notes”) with a maturity date of January 15, 2025. The January 2025 Notes accrue interest at a fixed rate of 1.0% per year, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The net proceeds from the issuance of the January 2025 Notes were approximately $671.1 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.
In June 2018, the Company issued and sold an additional $218.5 million in aggregate principal amount of 1.0% Convertible Notes (the “June 2025 Notes”). The June 2025 Notes were issued under the same indenture pursuant to which the Company previously issued the January 2025 Notes (the “Indenture”). The January 2025 Notes and the June 2025 Notes (collectively, the “2025 Notes”) have identical terms (including the same January 15, 2025 maturity date) and are treated as a single series of securities. The net proceeds from the issuance of the June 2025 Notes were approximately $225.3 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.
In March 2019, the Company issued and sold $747.5 million in aggregate principal amount of 0.375% Convertible Notes (the “2027 Notes”) with a maturity date of March 15, 2027. The 2027 Notes accrue interest at a fixed rate of 0.375% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2019. The net proceeds from the issuance of the 2027 Notes were approximately $729.5 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.
The Company utilized a portion of the proceeds from the issuance of the 2027 Notes to settle a portion of the 2025 Notes in privately negotiated transactions. In March 2019, the Company used cash of $494.1 million and an aggregate of 2.2 million shares of the Company’s common stock valued at $182.4 million for total consideration of $676.5 million to settle $493.4 million of the 2025 Notes, of which $0.7 million was used to pay off interest accrued on the 2025 Notes. The transaction resulted in a loss on settlement of convertible notes of $187.7 million, which is reflected in interest expense in the Company’s consolidated statement of operations. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of repurchase.
In February 2020, the Company issued and sold $1.15 billion in aggregate principal amount of 0.375% Convertible Notes (the “2028 Notes” and, collectively with the 2025 Notes and the 2027 Notes, the “Notes”) with a maturity date of March 1, 2028. The 2028 Notes accrue interest at a fixed rate of 0.375% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2020. The net proceeds from the issuance of the 2028 Notes were approximately $1.13 billion, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.
In February 2020, the Company used $150.1 million of the proceeds from the issuance of the 2028 Notes to settle $100.0 million of the 2025 Notes, of which $0.1 million was used to pay off interest accrued on the 2025 Notes. The transaction resulted in a loss on settlement of convertible notes of $50.8 million, which is recorded in interest expense in the Company’s consolidated statement of operations. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of repurchase.
In February 2023, the Company entered into a privately negotiated exchange and purchase agreement with a single holder of certain of the Company’s 2027 Notes and 2028 Notes. The Company issued the holder $500.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 (the “2030 Notes”) in exchange for $183.7 million of aggregate principal of 2027 Notes, $201.0 million of aggregate principal of 2028 Notes, and $138.0 million of cash. The extinguishment resulted in a gain on settlement of convertible notes of $17.7 million, which is included in interest expense in the consolidated statement of operations for the year ended December 31, 2023. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
In March 2023, the Company entered into a privately negotiated exchange agreement with two holders of certain of the 2025 Notes. The Company issued the holder $73.0 million aggregate principal amount of 2030 Notes in exchange for $65.8 million of aggregate principal of 2025 Notes. The extinguishment resulted in a loss on settlement of convertible notes of $7.4 million, which is included in interest expense in the consolidated statement of operations for the year ended December 31, 2023. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
The net proceeds from the issuance of the 2030 Notes were approximately $133.0 million, after deducting commissions and offering expenses payable by the Company. The 2030 Notes will mature on March 1, 2030 and bear interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023.
Summary of Conversion Features
Until the six-months immediately preceding the maturity date of the applicable series of the Company’s convertible notes (the “Notes”), each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert such Notes at any time. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election.
It is the Company’s intent and policy to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, 8.21, and 12.37 shares of common stock per $1,000 principal amount for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, $121.84, and $80.83 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively. The 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes are potentially convertible into up to 3.3 million, 5.0 million, 7.8 million, and 7.1 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indentures), will, under certain circumstances, be entitled to an increase in the conversion rate.
If the Company undergoes a “fundamental change” (as defined in the Indentures), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest.
Based on the closing price of the Company’s common stock of $73.98 on December 31, 2023, the if-converted values on the Notes do not exceed the principal amount.
The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company.
Ranking of Convertible Notes
The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company's existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries.
Issuance Costs
Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes:
(In thousands)
2030 Convertible Notes
$4,938 
2028 Convertible Notes
24,453 
2027 Convertible Notes
14,285 
2025 Convertible Notes
17,646 
Interest Expense
Interest expense on the Notes includes the following:
Year Ended December 31,
(In thousands)202320222021
Debt issuance costs amortization$5,350 $5,727 $5,727 
Debt discount amortization106 147 147 
Gain on settlement of convertible notes(10,324)— — 
Coupon interest expense18,072 10,266 10,266 
Total interest expense on convertible notes$13,204 $16,140 $16,140 
The following table summarizes the effective interest rates of the Notes:
Year Ended December 31,
202320222021
2030 Convertible Notes
2.09 %— %— %
2028 Convertible Notes
0.63 %0.64 %0.64 %
2027 Convertible Notes
0.67 %0.68 %0.68 %
2025 Convertible Notes1.17 %1.18 %1.18 %
The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 1.04 years, 3.21 years, 4.17 years, and 6.17 years for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND COLLABORATION AGREEMENTS
 12 Months Ended
Dec. 31, 2023
LICENSE AGREEMENTS [Abstract]  
LICENSE AND COLLABORATION AGREEMENTS LICENSE AND COLLABORATION AGREEMENTS 
The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees.
Mayo Foundation for Medical Education Research
In June 2009, the Company entered into an exclusive, worldwide license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), under which Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition. The Company’s license agreement with Mayo was most recently amended and restated in September 2020.
The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property.
Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement.
The Company is also required to pay Mayo up to $3.0 million in sales-based milestone payments upon cumulative net sales of each product using the licensed Mayo intellectual property reaching specified levels.
The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement.
In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company has incurred insignificant charges for the years ended December 31, 2023, 2022, and 2021, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company's consolidated statements of operations.
Johns Hopkins University
Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with Johns Hopkins University (“JHU”) for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU proprietary data in the development and commercialization of a blood-based, MCED test. The agreement terms would require the Company to pay single-digit sales-based royalties and up to $45.0 million in sales-based milestone payments if net sales of a licensed product using JHU proprietary data reach specified levels. The Company will record the sales-based royalties and sales-based milestones once achievement is deemed probable. The Company has not incurred charges related to the achievement of any sales-based royalties or sales-based milestones as of December 31, 2023.
Targeted Digital Sequencing (“TARDIS”) License Agreement
In January 2021, the Company entered into an exclusive, worldwide license to the proprietary TARDIS technology, which the Company intends to develop and commercialize as a molecular residual disease (“MRD”) test, from The Translational Genomics Research Institute (“TGen”), an affiliate of City of Hope. Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. The Company accounted for this transaction as an asset acquisition. In connection with the asset acquisition, the Company paid upfront fair value consideration of $52.3 million comprised of $25.0 million in cash and issuance of 191,336 shares of common stock valued at $27.3 million based on the average of the high and low market price of the Company’s shares on the acquisition date. In addition, the Company is obligated to make milestone payments to TGen of up to $45.0 million in sales-based milestone payments upon cumulative net sales related to MRD detection and/or treatment reaching specified levels. These payments are contingent upon achievement of these cumulative revenues on or before December 31, 2030. The upfront consideration was recorded to research and development expense in the consolidated statement of operations immediately after acquisition as the asset was deemed to be incomplete and had no alternative future use at the time of acquisition. The Company will record the sales milestones once achievement is deemed probable. No acquisition related costs were incurred in this asset acquisition during the year ended December 31, 2021.
Broad Institute, Inc.
In June 2023, the Company entered into an exclusive license agreement with Broad Institute, Inc. (“Broad Institute”) to utilize the Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (“MAESTRO”) technology in the Company’s MRD testing. Under the license agreement, the Company is obligated to make development milestone payments to Broad Institute of up to $6.5 million upon achievement of certain development milestones related to prospective MRD tests that use the MAESTRO technology. In addition, the Company is obligated to make sales-based milestone payments to Broad Institute that equate up to a mid-single-digit royalty upon the achievement of certain cumulative net sales targets of licensed products using the MAESTRO technology beginning at $500.0 million. The Company will record the development milestones once achieved and the sales milestones once achievement is deemed probable. The Company has not incurred any charges related to the achievement of development milestones or sales milestones as of December 31, 2023.
Watchmaker Genomics, Inc.
In July 2023, the Company entered into a co-exclusive development and license agreement with Watchmaker Genomics, Inc. (“Watchmaker”) under which the Company granted Watchmaker a co-exclusive license to the non-bisulfite technology for the detection of methylated DNA and other epigenetic modifications (“TAPS”). TAPS is based on patents obtained by the Company through an exclusive license agreement with the Ludwig Institute for Cancer Research. Under the agreement, both parties have the right to use and develop TAPS for commercial purposes. The Company has the potential to receive up to $82.0 million in sales-based milestone payments and mid-single digit royalties based on future Watchmaker net sales of licensed products including TAPS. Additionally, Watchmaker has the right to sublicense TAPS, and the Company has the potential to receive royalties based on future Watchmaker sublicense receipts.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
PFIZER PROMOTION AGREEMENT
 12 Months Ended
Dec. 31, 2023
PFIZER PROMOTION AGREEMENT  
PFIZER PROMOTION AGREEMENT PFIZER PROMOTION AGREEMENT
In August 2018, the Company entered into a Promotion Agreement (the “Original Promotion Agreement”) with Pfizer, Inc. (“Pfizer”), which was amended and restated in October 2020 (the “Restated Promotion Agreement”). The Restated Promotion Agreement extended the relationship between the Company and Pfizer and restructured the manner in which the Company compensates Pfizer for promotion of the Cologuard test through a service fee, and provision of certain other sales and marketing services related to the Cologuard test. The Restated Promotion Agreement included fixed and performance-related fees, some of which retroactively went into effect on April 1, 2020. In November 2021, the Company and Pfizer entered into an amendment to the Restated Promotion Agreement (the “November 2021 Amendment”), which provided that after November 30, 2021, Pfizer will no longer promote the Cologuard test to healthcare providers. The November 2021 Amendment provided that the Company pay Pfizer a total of $35.9 million in three installments, which occurred during the second, third, and fourth quarters of 2022. The November 2021 Amendment eliminated the Company's obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Cologuard test prior to November 30, 2021. The $35.9 million fee incurred as a result of the November 2021 Amendment was recognized in full during the fourth quarter of 2021. All payments to Pfizer are recorded in sales and marketing expenses in the Company's consolidated statements of operations.
Under the Original Promotion Agreement, the service fee was calculated based on incremental gross profits over specified baselines during the term. Under the Restated Promotion Agreement (and prior to giving effect to the November 2021 Amendment), the service fee provided a fee-for-service model that included certain fixed fees and performance-related bonuses. The performance-related bonuses were contingent upon the achievement of certain annual performance criteria with any applicable expense being recognized ratably upon achievement of the payment becoming probable. The Company incurred charges of $7.5 million, and $81.3 million for the service fee during the years ended December 31, 2022 and 2021, respectively. The Company incurred charges of $85.8 million, and $121.0 million for promotion, sales and marketing services performed by Pfizer on behalf of the Company during the years ended December 31, 2022 and 2021, respectively. All services provided by Pfizer under the November 2021 Amendment ended in the third quarter of 2022, and there were no payments made or charges incurred during the year ended December 31, 2023.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY
Stock Issuances
When the Company completes a business combination or asset acquisition, which are further described in Note 18, the Company may issue shares of the Company's common stock. Stock issuances in relation to acquisitions during the years ended December 31, 2023, 2022 and 2021 were as follows:
(In thousands, except for per share data)
Period of AcquisitionShares IssuedFair Value of Shares Issued
OmicEraMay 2022265,186$14,792 
PreventionGeneticsDecember 20211,070,41084,252 
AshionApril 2021125,44416,224 
ThriveJanuary 20219,323,2661,191,420 
TARDIS license
January 2021191,33527,263 
Changes in Accumulated Other Comprehensive Income (Loss)
The amount recognized in AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:
(In thousands)Cumulative Translation Adjustment
Unrealized Gain (Loss) on Securities (1)
AOCI
Balance at January 1, 2021
$— $526 $526 
Other comprehensive income (loss) before reclassifications
23 (1,648)(1,625)
Amounts reclassified from accumulated other comprehensive income (loss)
— (514)(514)
Net current period change in accumulated other comprehensive loss23 (2,162)(2,139)
Income tax benefit related to items of other comprehensive loss
— 170 170 
Balance at December 31, 2021$23 $(1,466)$(1,443)
Other comprehensive income (loss) before reclassifications30 (4,049)(4,019)
Amounts reclassified from accumulated other comprehensive income (loss)
— 226 226 
Net current period change in accumulated other comprehensive loss30 (3,823)(3,793)
Balance at December 31, 2022$53 $(5,289)$(5,236)
Other comprehensive income (loss) before reclassifications1,321 1,416 2,737 
Amounts reclassified from accumulated other comprehensive income (loss)
— 3,927 3,927 
Net current period change in accumulated other comprehensive income (loss)
1,321 5,343 6,664 
Balance at December 31, 2023$1,374 $54 $1,428 
_________________________________
(1)There was no tax impact from the amounts recognized in AOCI for the years ended December 31, 2023 and 2022.
Amounts reclassified from AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:
Year Ended December 31,
Details about AOCI Components (In thousands)Affected Line Item in the
Statements of Operations		202320222021
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investments
Investment income (loss)
$3,927 $226 $(514)
Total reclassifications$3,927 $226 $(514)
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
Stock-Based Compensation Plans
The Company maintains the following plans for which awards were granted from or had awards outstanding in 2023: the 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan. These plans are collectively referred to as the “Stock Plans.”
The Stock Plans are administered by the Human Capital Committee of the Company’s Board of Directors (“Human Capital Committee”). The 2019 Omnibus Long-Term Incentive Plan provides that upon an acquisition of the Company, all equity will accelerate by a period of one year. In addition, upon the termination of an employee without cause or for good reason prior to the first anniversary of the completion of the acquisition, all equity awards then outstanding under the respective plan held by that employee will immediately vest.
2019 Omnibus Long-Term Incentive Plan. The Company adopted the 2019 Omnibus Long-Term Incentive Plan (the “2019 Stock Plan”) on July 25, 2019 to grant share-based awards to employees, officers, directors, consultants and advisors. Awards granted under the 2019 Stock Plan may include incentive stock options, as defined under the Internal Revenue Code, non-qualified options, restricted stock awards and other stock awards in amounts and with terms and conditions determined by the Human Capital Committee, subject to the provisions of the 2019 Stock Plan. The 2019 Stock Plan will expire on July 25, 2029 and after such date no further awards may be granted under the plan. Options granted under the 2019 Stock Plan expire ten years from the date of grant. Grants made from the 2019 Stock Plan generally vest over a period of three to four years. At December 31, 2023, options to purchase 404,833 shares were outstanding under the 2019 Stock Plan and 7,867,224 shares of restricted stock and restricted stock units were outstanding. The Company's stockholders approved amendments to the 2019 Stock Plan to increase the number of shares available for future grant thereunder by 14,000,000 and 4,340,000 shares on June 9, 2022 and June 8, 2023, respectively. At December 31, 2023, there were 16,046,161 shares available for future grant under the 2019 Stock Plan.
2010 Omnibus Long-Term Incentive Plan.  The Company adopted the 2010 Omnibus Long-Term Incentive Plan (the “2010 Stock Plan”) on July 16, 2010 to grant share-based awards to employees, officers, directors, consultants and advisors. Awards granted under the 2010 Stock Plan may include incentive stock options, as defined under the Internal Revenue Code, non-qualified options, restricted stock awards and other stock awards in amounts and with terms and conditions determined by the Human Capital Committee, subject to the provisions of the 2010 Stock Plan. The 2010 Stock Plan expired on July 16, 2020 and after such date no further awards may be granted under the plan. Options granted under the 2010 Stock Plan expire ten years from the date of grant. Grants made from the 2010 Stock Plan generally vest over a period of three to four years. At December 31, 2023, options to purchase 881,340 shares were outstanding under the 2010 Stock Plan and 3,340 shares of restricted stock and restricted stock units were outstanding. At December 31, 2023, there were no shares available for future grant under the 2010 Stock Plan.
2010 Employee Stock Purchase Plan.  The 2010 Employee Stock Purchase Plan (the “2010 Purchase Plan”) was adopted by the Company on July 16, 2010 to provide participating employees the right to purchase shares of common stock at a discount through a series of offering periods. The 2010 Purchase Plan will expire on October 31, 2030. The Company’s stockholders approved amendments to the 2010 Employee Stock Purchase Plan to increase the number of shares available for purchase thereunder by 500,000 shares, 2,000,000 shares, and 3,000,000 shares on July 24, 2014, July 28, 2016, and June 9, 2022, respectively. At December 31, 2023, there were 1,834,193 shares of common stock available for purchase by participating employees under the 2010 Purchase Plan.
Generally, all employees whose customary employment is more than 20 hours per week and more than five months in any calendar year are eligible to participate in the 2010 Purchase Plan. Participating employees authorize an amount, between 1% and 15% of the employee’s compensation, to be deducted from the employee’s pay during the offering period. On the last day of the offering period, the employee is deemed to have exercised the employee’s option to purchase shares of Company common stock, at the option exercise price, to the extent of accumulated payroll deductions. Under the terms of the 2010 Purchase Plan, the option exercise price is an amount equal to 85% of the fair market value, as defined under the 2010 Purchase Plan, and no employee can purchase more than $25,000 of Company common stock under the 2010 Purchase Plan in any calendar year. Rights granted under the 2010 Purchase Plan terminate upon an employee’s voluntary withdrawal from the 2010 Purchase Plan at any time or upon termination of employment. At December 31, 2023, there were 3,965,807 cumulative shares issued under the 2010 Purchase Plan.
Stock-Based Compensation Expense
The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards (“RSUs”), performance share units (“PSUs”), stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors.
A summary of non-cash stock-based compensation expense by expense category included in the Company's consolidated statements of operations for the years ended December 31, 2023, 2022, and 2021 is as follows:
Year Ended December 31,
(In thousands)
202320222021
Cost of sales
$20,761 $19,218 $16,835 
Research and development
41,242 33,825 49,723 
Sales and marketing
65,552 62,568 55,716 
General and administrative
103,757 91,212 216,952 
Total stock-based compensation$231,312 $206,823 $339,226 
As of December 31, 2023, there was approximately $354.8 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 2.42 years.
In connection with the acquisition of Thrive, the Company accelerated the vesting of shares of previously unvested stock options and restricted stock units for employees with qualifying termination events. During the year ended December 31, 2021, the Company accelerated 139,096 shares of previously unvested stock options and 58,171 shares of previously unvested restricted stock awards and restricted stock units and recorded $19.0 million of non-cash stock-based compensation for the accelerated awards. As further discussed in Note 18, the Company also recorded $86.2 million in stock-based compensation related to accelerated vesting of awards held by Thrive employees in connection with the acquisition.
Stock Options
The Company determined the fair value of each service-based option award on the date of grant using the Black-Scholes option-pricing model, which utilized several key assumptions including risk-free interest rate, expected term, expected volatility, and dividend yield. There were no option awards granted during the years ended December 31, 2023, 2022 and 2021.
A summary of stock option activity under the Stock Plans is as follows:
OptionsShares
Weighted Average Exercise Price
Weighted Average Remaining Contractual Term (Years)
Aggregate Intrinsic Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 2023
1,517,876 $44.82 4.7
Exercised(194,629)16.44 
Forfeited(37,074)95.02 
Outstanding, December 31, 2023
1,286,173 $47.67 3.8$42,878 
Vested and expected to vest, December 31, 2023
1,286,173 $47.67 3.8$42,878 
Exercisable, December 31, 2023
1,228,594 $45.32 3.7$42,878 
_________________________________
(1)     The total intrinsic value of options exercised during the years ended December 31, 2023, 2022, and 2021 was $11.7 million, $36.4 million, and $155.8 million, respectively, determined as of the date of exercise.
The Company received approximately $3.2 million, $6.5 million, and $14.4 million from stock option exercises during the years ended December 31, 2023, 2022 and 2021, respectively.
Restricted Stock and Restricted Stock Units
The fair value of restricted stock and restricted stock units is determined on the date of grant using the closing stock price on that day.
A summary of restricted stock and restricted stock unit activity is as follows:
Restricted SharesWeighted Average Grant Date Fair Value (1)
Outstanding, January 1, 2023
5,254,709 $85.87 
Granted3,510,373 62.36 
Released (2)(1,797,915)88.28 
Forfeited(694,404)73.54 
Outstanding, December 31, 2023
6,272,763 $73.39 
_________________________________
(1)     The weighted average grant date fair value of the restricted stock units granted during the years ended December 31, 2022 and 2021 was $68.18 and $129.16, respectively.
(2)     The fair value of restricted stock units vested and converted to shares of the Company's common stock was $158.2 million, $117.6 million, and $219.4 million for the years ended December 31, 2023, 2022, and 2021, respectively.
Performance Share Units
The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones.
A summary of performance share unit activity is as follows:
Performance Share Units (1)Weighted Average Grant Date Fair Value (2)
Outstanding, January 1, 2023967,846 $102.58 
Granted782,966 80.50 
Released (3)(12,284)78.32 
Forfeited(140,727)93.73 
Outstanding, December 31, 20231,597,801 $92.73 
_________________________________
(1)     The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of December 31, 2023 was 772,906.
(2)     The weighted average grant date fair value of the performance share units granted during the years ended December 31, 2022 and 2021 was $89.43 and $138.09, respectively.
(3)     The fair value of performance share units vested and converted to shares of the Company's common stock was $1.0 million and $27.2 million for the years ended December 31, 2023 and 2022, respectively. There were no performance share units vested and converted to shares of the Company's common stock during the year ended December 31, 2021.
Employee Stock Purchase Plan (“ESPP”)
A summary of ESPP activity is as follows:
Year Ended December 31,
(in thousands, except share and per share amounts)202320222021
Shares issued under the 2010 Purchase Plan924,448 668,605331,769
Cash received under the 2010 Purchase Plan$28,344 $25,491 $23,070 
Weighted average fair value per share of stock purchase rights granted during the period$16.32 $17.52 $34.93 
The 924,448 shares issued during the year ended December 31, 2023 were as follows:
Offering period ended
Number of Shares
Weighted Average price per Share
April 30, 2023544,453 $30.02 
October 31, 2023379,995 $31.57 
The fair value of ESPP shares is based on the assumptions in the following table:
Year Ended December 31,
202320222021
Risk-free interest rates
4.68% - 4.71%
1.49% - 4.71%
0.04% - 0.16%
Expected term (in years)
1.25
0.5 - 2
0.5 - 2
Expected volatility
63.13% - 67.30%
50.94% - 63.13%
43.00% - 68.51%
Dividend yield0%0%0%
Shares Reserved for Issuance
The Company has reserved shares of its authorized common stock for issuance pursuant to its employee stock purchase and equity plans, including all outstanding stock option grants noted above at December 31, 2023, as follows:
Shares reserved for issuance
2019 Stock Plan16,046,161 
2010 Purchase Plan
1,834,193 
17,880,354 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Leases
The components of lease expense were as follows:
Year Ended December 31,
(In thousands)202320222021
Finance lease cost
Amortization of right-of-use assets$3,845 $4,612 $5,731 
Interest on lease liabilities800 808 1,018 
Operating lease cost36,576 36,291 31,730 
Short-term lease cost750 476 628 
Variable lease cost8,449 7,985 5,212 
Total lease Cost$50,420 $50,172 $44,319 
Supplemental disclosure of cash flow information related to the Company's cash and non-cash activities with its leases are as follows:
Year Ended December 31,
(In thousands)202320222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$39,301$33,448$27,461
Operating cash flows from finance leases783699938
Finance cash flows from finance leases3,5694,3455,290
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities (1)4,98624,57274,369
Right-of-use assets obtained in exchange for new finance lease liabilities5,44311,2765,460
Weighted-average remaining lease term - operating leases (in years)6.877.438.33
Weighted-average remaining lease term - finance leases (in years)2.803.272.95
Weighted-average discount rate - operating leases6.59 %6.37 %6.11 %
Weighted-average discount rate - finance leases7.43 %6.60 %5.36 %
_________________________________
(1)    This includes an insignificant amount of right-of-use assets acquired as part of the business combinations described in Note 18 for the years ended December 31, 2023 and 2022, and $39.6 million for the year ended December 31, 2021.
As of December 31, 2023 and 2022, the Company’s right-of-use assets from operating leases are $143.7 million and $167.0 million, respectively, which are reported in operating lease right-of-use assets in the Company’s consolidated balance sheets. As of December 31, 2023, the Company has outstanding operating lease obligations of $190.4 million, of which $29.4 million is reported in operating lease liabilities, current portion and $161.1 million is reported in operating lease liabilities, less current portion in the Company’s consolidated balance sheets. As of December 31, 2022, the Company had outstanding operating lease obligations of $210.8 million, of which $28.4 million is reported in operating lease liabilities, current portion and $182.4 million is reported in operating lease liabilities, less current portion in the Company’s consolidated balance sheets.
As of December 31, 2023 and 2022, the Company’s right-of-use assets from finance leases are $11.3 million and $10.2 million, respectively, which are reported in other long-term assets, net in the Company’s consolidated balance sheets. As of December 31, 2023, the Company has outstanding finance lease obligations of $11.9 million, of which $4.4 million is reported in other current liabilities and $7.5 million is reported in other long-term liabilities in the Company’s consolidated balance sheets. As of December 31, 2022, the Company had outstanding finance lease obligations of $10.6 million, of which $3.2 million is reported in other current liabilities and $7.4 million is reported in other long-term liabilities in the Company’s consolidated balance sheets.
Maturities of operating lease liabilities on an annual basis as of December 31, 2023 were as follows:
(In thousands)
2024$39,476 
202536,660 
202634,851 
202734,226 
202827,901 
Thereafter66,634 
Total minimum lease payments239,748 
Imputed interest(49,299)
Total$190,449 
Maturities of finance lease liabilities on an annual basis as of December 31, 2023 were as follows (amounts in thousands):
(In thousands)
2024$5,044
20254,552
20262,797
2027827
2028—
Thereafter—
Total minimum lease payments13,220
Imputed interest(1,279)
Total$11,941
Legal Matters
The Company accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices.
As of the date of this Annual Report on Form 10-K, amounts accrued for legal proceedings and regulatory matters were not significant except for the amounts accrued related to the matters discussed below. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings, including as described below. Except for the proceedings discussed below, the Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity.
DOS Rule Matter
In September 2023, the Company’s wholly owned subsidiary Genomic Health, Inc., which was acquired in November 2019, entered into a settlement agreement with the United States of America, acting through the Department of Justice (“DOJ”) and on behalf of the Office of Inspector General of the Department of Health and Human Services, and two qui tam relators to resolve the previously disclosed civil investigation concerning Genomic Health’s compliance with the Medicare Date of Service billing regulations (the “DOS Rule Matter”). Genomic Health entered into the settlement agreement to avoid the delay, uncertainty and expense of protracted litigation. The settlement agreement contains no admission of liability by Genomic Health.
Under the terms of the settlement agreement, the Company made a payment of $32.5 million in September 2023, of which $22.4 million and $10.1 million is included in general and administrative expenses in the Company’s consolidated statements of operations for the years ended December 31, 2023 and 2021, respectively. Following the United States’ receipt of the settlement payment, the Company was released from any civil or administrative monetary claims under the civil False Claims Act and other specified civil statutes and common law theories of liability concerning the conduct identified in the settlement agreement.
On September 29, 2023, the United States District Court for the Eastern District of New York unsealed two qui tam actions filed under the False Claims Act involving the DOS Rule Matter, and on October 2, 2023, those two actions were dismissed with prejudice pursuant to the terms of the settlement agreement.
Gift Card Matter
In September 2023, the Company entered into a settlement agreement to resolve the previously disclosed False Claims Act qui tam suit that alleged a violation of the Federal Anti-Kickback Statute and False Claims Act for offering gift cards to patients in exchange for returning the Cologuard screening test (the “Qui Tam Suit”). In accordance with the settlement agreement, the Company made payment of $13.8 million plus legal fees in October 2023, which is included in general and administrative expenses in the Company's consolidated statement of operations for the year ended December 31, 2023. Following payment of the settlement amount, the Company was released from any civil or administrative monetary claims under the civil False Claims Act and other specified civil statutes and common law theories of liability concerning the conduct identified in the settlement agreement. On November 1, 2023, the court dismissed the qui tam suit with prejudice pursuant to the terms of the settlement agreement.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLAN
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLAN EMPLOYEE BENEFIT PLAN
The Company maintains a qualified 401(k) retirement savings plan for Exact Sciences employees (the “401(k) Plan”). The Company also maintains additional retirement savings plans that are acquired as a result of business combinations. These plans are maintained for a period of time before being merged into the 401(k) Plan. Under the terms of the 401(k) Plan, participants may elect to defer a portion of their compensation into the 401(k) Plan, subject to certain limitations. Company matching contributions may be made at the discretion of the Company's Human Capital Committee.
The Human Capital Committee approved 401(k) Plan matching contributions for the years ended December 31, 2023, 2022, and 2021 in the form of Company common stock equal to 100% of a participant's elective deferrals up to 6% of the participant’s eligible compensation for that year. The Company recorded compensation expense of approximately $40.6 million, $36.5 million, and $30.0 million, respectively, in the statements of operations for the years ended December 31, 2023, 2022, and 2021.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS
 12 Months Ended
Dec. 31, 2023
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS.  
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS
During December 2021, the Company entered into an amended agreement (“Amended WEDC Agreement”) with the Wisconsin Economic Development Corporation (“WEDC”) to earn $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the agreement.
The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC.
The Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned.
As of December 31, 2023, the Company has earned $11.0 million of the refundable tax credits under the Amended WEDC Agreement. The unpaid portion is $9.3 million, of which $3.8 million is reported in prepaid expenses and other current assets and $5.5 million is reported in other long-term assets, net in the Company's consolidated balance sheets reflecting when collection of the refundable tax credits is expected to occur. During the years ended December 31, 2023, 2022, and 2021, the amounts recorded as an offset to capital expenditures and operating expenses for the tax credits earned were not significant.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combination, Divestiture, And Asset Acquisition ACQUISITIONS AND DIVESTITURES
Business Combinations
Resolution Bioscience, Inc.
On September 12, 2023, the Company completed the acquisition of all of the outstanding capital stock of Resolution Bioscience, Inc. from Agilent Technologies, Inc. Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions through its Clinical Laboratory Improvement Amendments (“CLIA”) certified lab based in Kirkland, Washington. The acquisition provides the Company with a high-quality blood-based therapy selection platform, complementing its comprehensive, tissue-based OncoExTraTM test. The Company has included the financial results of Resolution Bioscience in the consolidated financial statements from the date of the acquisition.
The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:
(In thousands)
Cash$52,527 
Fair value of replaced equity awards1,675 
Total purchase price$54,202 
The Company replaced unvested RSUs with a combination-date fair value of $4.6 million. Of the total consideration for replaced equity awards, $1.7 million was allocated to the consideration transferred, and $2.9 million was deemed compensatory as it was attributable to post acquisition vesting. The compensatory replaced equity awards will be expensed over the remaining service periods on a straight-line basis.
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:
(In thousands)
Net operating assets$14,663 
Developed technology26,000 
Total identifiable assets acquired40,663 
Net operating liabilities(7,152)
Net identifiable assets acquired33,511 
Goodwill20,691 
Net assets acquired$54,202 
The Company recorded a $26.0 million identifiable intangible asset related to the developed technology associated with Resolution Bioscience’s liquid biopsy therapy selection tests. Developed technology represents purchased technology that had reached technological feasibility and for which Resolution Bioscience had substantially completed development as of the acquisition date. The fair value of the developed technology has been determined using the multi-period excess earnings method of the income approach, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected revenues, gross margins, operating expenses, obsolescence, and an estimated discount rate. The developed technology intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years.
The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the acquired workforce expertise and expected sales force and therapy selection product portfolio synergies. The total goodwill related to this acquisition is deductible for tax purposes.
The total purchase price allocation is preliminary and based upon estimates and assumptions that are subject to change within the measurement period as additional information for the estimates is obtained. The measurement period remains open pending the completion of valuation procedures related to the acquired assets and assumed liabilities, including in connection with the developed technology intangible asset.
The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Resolution Bioscience, as though the companies were combined as of the beginning of January 1, 2022.
Twelve Months Ended December 31,
(In thousands)20232022
Total revenues$2,507,111 $2,097,680 
Net loss before tax(237,854)(675,091)

The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the results that would have been achieved if the acquisition had taken place at such time. Expected cost savings and other synergistic benefits resulting from the acquisition were not reflected in the unaudited pro forma financial information. The Company did not have any significant, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported unaudited pro forma financial information. Revenue and net loss before tax from Resolution Bioscience included in the Company's consolidated statements of operations for the year ended December 31, 2023 was not significant.
Acquisition-related costs were not significant and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the acquisition.
OmicEra Diagnostics, GmbH
On May 2, 2022, the Company completed the acquisition (the “OmicEra Acquisition”) of all of the outstanding equity interests of OmicEra Diagnostics GmbH. The OmicEra Acquisition provided the Company a state-of-the-art proteomics lab based in Planegg, Germany. OmicEra combines its mass spectrometry-based proteome analysis technology with its in-house proteomics scientific expertise to discover more reliable and valuable protein biomarkers, which will expand the Company’s research and development capabilities. The Company has included the financial results of OmicEra in the consolidated financial statements from the date of the acquisition.
The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:
(In thousands)
Common stock issued$14,792 
Contingent consideration4,600 
Cash paid related to working capital adjustment16 
Total purchase price$19,408 
The fair value of the 265,186 common shares issued as part of the consideration transferred was determined on the basis of the average of the high and low market price of the Company’s shares on the acquisition date, which was $55.78.
The purchase agreement requires the Company to pay a maximum of $6.0 million of additional cash consideration to OmicEra upon the achievement of certain earnout conditions related to the identification of protein biomarkers, as well as the growth of the proteomics research and development team. The fair value of the contingent consideration at the acquisition date was $4.6 million. The fair value of the contingent consideration was estimated using a probability-weighted scenario-based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7.
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:
(In thousands)
Net operating assets$2,586 
Developed technology10,000 
Total identifiable assets acquired12,586 
Net operating liabilities(3,987)
Net identifiable assets acquired8,599 
Goodwill10,809 
Net assets acquired$19,408 
The Company recorded $10.0 million of identifiable intangible assets related to the developed technology associated with OmicEra’s proteome analysis platform. Developed technology represents purchased technology that had reached technological feasibility and for which OmicEra had substantially completed development as of the date of acquisition. The fair value of the developed technology has been determined using the income approach multi-period excess earnings method, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, margin, obsolescence factor, required rate of return, and tax rate. Cash flows were discounted to their present value as of the closing date. The developed technology intangible asset is amortized on a straight-line basis over its estimated useful life of 16 years.
The calculation of the excess purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the acquired workforce expertise, the potential to enhance the capabilities of current and future products, and expected research and development synergies. The total goodwill related to this acquisition is deductible for tax purposes.
Pro forma impact and results of operations disclosures have not been included due to insignificance.
Acquisition-related costs were not significant and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the merger.
PreventionGenetics, LLC
On December 31, 2021, the Company completed the acquisition (the “PreventionGenetics Acquisition”) of all of the outstanding equity interests of PreventionGenetics, LLC. The PreventionGenetics Acquisition provided the Company a CLIA certified and College of American Pathologist (“CAP”) accredited sequencing lab based in Marshfield, Wisconsin. PreventionGenetics provides more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline, whole exome (“PGxome®”), and whole genome (“PGnome®”) sequencing tests. The Company has included the financial results of PreventionGenetics in the consolidated financial statements from the date of the acquisition.
The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following:
(In thousands)
Cash$101,129
Common stock issued84,252
Total purchase price$185,381
The fair value of the 1,070,410 common shares issued as part of consideration transferred was determined on the basis of the average of the high and low market price of the Company's shares on the acquisition date, which was $78.71.
Of the total $101.1 million of consideration settled through the payment of cash, $85.8 million was paid as of December 31, 2021. The remaining $15.3 million represented withheld cash consideration used to cover working capital adjustments or seller claims that arose following the completion of the acquisition. The withheld cash consideration was settled during the year ended December 31, 2022, and there is no remaining liability on the consolidated balance sheet.
Acquisition-related costs were not significant and were recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger.
Ashion Analytics, LLC
On April 14, 2021, the Company completed the acquisition (“Ashion Acquisition”) of all of the outstanding equity interests of Ashion Analytics, LLC from PMed Management, LLC (“PMed”), which is a subsidiary of The Translational Genomics Research Institute. The Ashion Acquisition provided the Company a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona. Ashion developed GEM ExTra®, a comprehensive genomic cancer test, and provides access to whole exome, matched germline, and transcriptome sequencing capabilities. The Company has included the financial results of Ashion in the consolidated financial statements from the date of the acquisition.
The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following:
(In thousands)
Cash$74,775
Common stock issued16,224
Contingent consideration19,000
Total purchase price$109,999
The fair value of the 125,444 common shares issued as part of consideration transferred was determined on the basis of the average of the high and low market price of the Company's shares on the acquisition date, which was $129.33.
The contingent consideration arrangement requires the Company to pay $20.0 million of additional cash consideration to PMed upon the Company’s commercial launch, on or before the tenth anniversary of the Ashion Acquisition, of a test for MRD detection and/or treatment (the “Commercial Launch Milestone”). The fair value of the Commercial Launch Milestone at the acquisition date was $19.0 million. The contingent consideration arrangement also requires the Company to pay $30.0 million of additional cash upon the Company’s achievement, on or before the fifth anniversary of the Ashion Acquisition, of cumulative revenues from MRD products of $500.0 million (the “MRD Product Revenue Milestone”). No value was ascribed to the MRD Product Revenue Milestone based on probability assessments as of the acquisition date. The fair value of the Commercial Launch Milestone and MRD Product Revenue Milestone was estimated using a probability-weighted scenario based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7.
Acquisition-related costs were not significant and were recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger.
Thrive Earlier Detection Corporation
On January 5, 2021, the Company completed the acquisition (“Thrive Merger”) of all of the outstanding capital stock of Thrive Earlier Detection Corporation. Thrive, headquartered in Cambridge, Massachusetts, is a healthcare company dedicated to incorporating earlier cancer detection into routine medical care. The Company expects that combining Thrive’s early-stage MCED test with the Company’s scientific platform, clinical organization, and commercial infrastructure will bring an accurate blood-based, MCED test to patients faster. The Company has included the financial results of Thrive in the consolidated financial statements from the date of the acquisition.
The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following:
(In thousands)
Common stock issued$1,175,431
Cash584,996
Contingent consideration331,348
Fair value of replaced equity awards52,245
Previously held equity investment fair value43,034
Total purchase price$2,187,054
The Company issued 9,323,266 common shares that had a fair value of $1.19 billion based on the average of the high and low market price of the Company's shares on the acquisition date, which was $127.79. Of the total consideration for common stock issued, $1.18 billion was allocated to the purchase consideration and $16.0 million was recorded as compensation within general and administrative expenses in the consolidated statement of operations on the acquisition date due to accelerated vesting of legacy Thrive restricted stock awards (“RSA”) and RSU awards in connection with the acquisition.
The Company paid $590.2 million in cash on the acquisition date. Of the total consideration for cash, $585.0 million was allocated to the purchase consideration and $5.2 million was recorded as compensation within general and administrative expenses on the acquisition date due to accelerated vesting of legacy Thrive RSU and RSAs that were cash-settled in connection with the acquisition.
The contingent consideration arrangement requires the Company to pay up to $450.0 million of additional cash consideration to Thrive’s former shareholders upon the achievement of two discrete events, FDA approval and CMS coverage, for $150.0 million and up to $300.0 million, respectively. The fair value of the contingent consideration arrangement at the acquisition date was $352.0 million. The fair value of the contingent consideration was estimated using a probability-weighted scenario based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7. Of the total fair value of the contingent consideration, $331.3 million was allocated to the consideration transferred, $6.4 million was allocated to the Company’s previous ownership interest in Thrive, and $14.3 million was deemed compensatory as participation is dependent on replaced unvested equity awards vesting which requires future service. Compensation expense related to the milestones could be up to $18.2 million undiscounted and will be recognized in the future once probable and payable.
The Company replaced unvested stock options, RSUs, and RSAs and vested stock options with an acquisition-date fair value of $197.0 million. Of the total consideration for replaced equity awards, $52.2 million was allocated to the consideration transferred and $144.8 million was deemed compensatory as it was attributable to post acquisition vesting. Of the total compensation related to replaced awards, $65.0 million was expensed on the acquisition date due to accelerated vesting of stock options in connection with the acquisition and $79.8 million relates to future services and will be expensed over the remaining service periods of the unvested stock options, RSUs, and RSAs on a straight-line basis. Including expense recognized for accelerated vesting of RSUs and RSAs described above, total expected stock-based compensation expense is $166.0 million, of which $86.2 million was recognized immediately to general and administrative expenses in the consolidated statement of operations due to accelerated vesting.
The fair value of the stock options assumed by the Company was determined using the Black-Scholes option pricing model. The fair value of the RSA and RSUs assumed by the Company was determined based on the average of the high and low market price of the Company’s shares on the acquisition date. The share conversion ratio of 0.06216 was applied to convert Thrive’s outstanding equity awards for Thrive’s common stock into equity awards for shares of the Company’s common stock.
The fair value of options assumed were based on the assumptions in the following table:
Option Plan Shares Assumed
Risk-free interest rates
0.11% - 0.12%
Expected term (in years)
1.26 - 1.57
Expected volatility
65.54% - 71.00%
Dividend yield
0%
Weighted average fair value per share of options assumed
$109.74 - $124.89
The Company previously held a preferred stock investment of $12.5 million in Thrive and recognized a gain of approximately $30.5 million on the transaction within investment income (expense), net on the Company’s consolidated statement of operations, which represented the adjustment of the Company’s historical investment to the acquisition date fair value. The fair value of the Company’s previous ownership in Thrive was determined based on the pro-rata share payout applied to the Company’s interest combined with the fair value of the Company’s share of the contingent consideration arrangement, as discussed above.
The net loss before tax of Thrive included in the Company’s consolidated statement of operations from the acquisition date of January 5, 2021 to December 31, 2022 was $255.0 million.
The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Thrive, as though the companies were combined as of the beginning of January 1, 2020.
Year Ended December 31,
(In thousands)20212020
Total revenues$2,084,279 $1,767,087 
Net loss before tax(761,337)(1,014,352)
The unaudited pro forma financial information for all periods presented above has been calculated after adjusting the results of Thrive to reflect the business combination accounting effects resulting from this acquisition. The Company incurred $86.2 million of stock-based compensation expense related to accelerated vesting in connection with the acquisition, $13.5 million of stock-based compensation expense related to accelerated vesting for employees with qualifying termination events, and $10.3 million of transaction costs incurred to execute the acquisition during the first quarter of 2021. These expenses are included in general and administrative expenses on the consolidated statement of operations for the year ended December 31, 2021 and are reflected in pro forma earnings for the year ended December 31, 2020 in the table above. The Company recorded a realized gain of $30.5 million during the first quarter of 2021 in investment income (expense), net on the Company’s consolidated statement of operations relating to the Company’s pre-acquisition investment in Thrive. This gain has been reduced to $7.6 million due to the Company’s smaller ownership interest in Thrive on January 1, 2020, and is reflected in pro forma earnings for the year ended December 31, 2020 in the table above. The Company recorded a remeasurement of contingent consideration of $7.2 million related to Thrive in general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2021. This expense is reflected in the year ended December 31, 2020 in the table above. The historical consolidated financial statements have been adjusted in the unaudited pro forma combined financial information to give effect to pro forma events that are directly attributable to the business combination and factually supportable. The unaudited pro forma financial information is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2020.
During the year ended December 31, 2021, the Company incurred $10.3 million of acquisition-related costs recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger.
In connection with acquisition-related severances, the Company recorded $19.0 million of expense related to vesting of previously unvested equity awards and $3.9 million of additional benefit charges for the year ended December 31, 2021.
Asset Acquisitions
PFS Genomics Inc.
On May 3, 2021, the Company acquired 90% of the outstanding capital stock of PFS Genomics Inc. (“PFS”). On June 23, 2021, the Company completed the acquisition of the remaining 10% interest in PFS. The Company paid cash of $33.6 million for 100% of the outstanding capital stock in PFS. PFS is a healthcare company focused on personalizing treatment for breast cancer patients to improve outcomes and reduce unnecessary treatment. The Company expects this acquisition to expand its ability to help guide early-stage breast cancer treatment through individualized radiotherapy treatment decisions.
The transaction was treated as an asset acquisition under GAAP because substantially all of the fair value of the gross assets acquired were deemed to be associated with the acquired technology.
Acquisition related costs were not significant in this asset acquisition.
Divestitures
Oncotype DX Genomic Prostate Score Test
On August 2, 2022, pursuant to an asset purchase agreement (“Asset Purchase Agreement”) with MDxHealth SA, the Company completed the sale of the intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test, which will allow the Company to focus on the highest impact projects core to the Company’s vision.
The closing date fair value of the consideration received for the asset was approximately $29.6 million, which consisted of the following:
(In thousands)
Cash$25,000 
MDxHealth American Depository Shares 4,631 
Contingent consideration— 
Total consideration$29,631 
The fair value of the 691,171 American Depository Shares received as part of the consideration transferred was determined on the basis of the average of the high and low market price of the MDxHealth’s shares on the date of divestiture, which was $6.70, and is included in marketable securities on the consolidated balance sheet.
The Asset Purchase Agreement required MDxHealth to pay the Company up to an additional $70.0 million of contingent consideration that would be earned and receivable in cash and/or equity based on the achievement of certain revenue milestones by MDxHealth between 2023 and 2025. Under the Asset Purchase Agreement, contingent consideration would have been recognized in the consolidated statement of operations when it was probable a significant reversal of a gain would not occur. As of December 31, 2022, no contingent consideration was probable of not resulting in a significant gain reversal due to minimum revenue thresholds in place and therefore it was fully constrained.
The carrying value of the developed technology intangible asset, which was previously included in intangible assets, net on the consolidated balance sheet, was $42.9 million as of the closing date. As a result of the sale, the Company recorded a loss of $13.2 million, which is included in other operating income (loss) in the consolidated statement of operations for the year ended December 31, 2022.
Further, the Company agreed to provide certain transitional services to MDxHealth through December 31, 2022 and lab testing services for a period of up to 24 months.
On August 23, 2023, the Company and MDxHealth executed the Second Amendment to the Asset Purchase Agreement (“Second Amendment”) related to the sale of the GPS test. Under the Second Amendment, the Company agreed to allow MDxHealth to defer the 2023 contingent consideration payment by three years in exchange for additional consideration and more favorable contingent consideration terms. The Company received additional consideration with a fair value of $3.1 million, which was recorded as a gain for the year ended December 31, 2023, and is included in other operating income (loss) in the consolidated statement of operations.
Under the Second Amendment, the maximum contingent consideration increased from $70.0 million to $82.5 million and the minimum revenue thresholds previously required to be met under the Asset Purchase Agreement were eliminated. As a result of the elimination of the minimum revenue thresholds, the Company determined that a significant reversal of a gain is not probable and therefore the contingent consideration is no longer constrained. The Company recorded a contingent consideration gain of $73.3 million during the year ended December 31, 2023, which is included in other operating income (loss) in the consolidated statement of operations. The gain was estimated using historical GPS test revenues by MDxHealth under the most likely amount method.
As of December 31, 2023, a portion of the contingent consideration is classified as a contract asset. The contract asset was $41.7 million and zero as of December 31, 2023 and 2022, respectively. The remaining balance of $31.6 million, which represents the amount earned during the 2023 earnout year, is classified as a receivable as of December 31, 2023. The contract asset and receivable are included in other long-term assets, net on the consolidated balance sheet.
Transaction-related costs were not significant and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the divestiture.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the financial information routinely reviewed by the Company’s Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company’s operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results.
The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.
Year Ended December 31,
(In thousands)202320222021
United States$2,346,489 $1,966,541 $1,657,174 
Outside of United States153,277 117,738 109,913 
Total revenues$2,499,766 $2,084,279 $1,767,087 
Long-lived assets located in countries outside of the U.S. are not significant.
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
Under financial accounting standards, deferred tax assets or liabilities are computed based on the differences between the financial statement and income tax bases of assets and liabilities using the enacted tax rates. Deferred income tax expense or benefit represents the change in the deferred tax assets or liabilities from period to period. At December 31, 2023, the Company had federal net operating loss, state net operating loss, and foreign net operating loss carryforwards of approximately $402.9 million, $66.0 million, and $10.4 million, respectively, for financial reporting purposes, which may be used to offset future taxable income. The Tax Cuts and Jobs Act (H.R. 1) of 2017 limits the deduction for net operating losses to 80% of current year taxable income and provides for an indefinite carryover period for federal net operating losses. Both provisions are applicable for losses arising in tax years beginning after December 31, 2017. As of December 31, 2023 the Company has $278.5 million of federal net operating loss carryovers incurred after December 31, 2017 with an unlimited carryover period and $124.4 million of federal net operating loss carryovers expiring at various dates through 2037. State and foreign net operating loss carryovers expire at various dates through 2043. All net operating loss carryforwards are subject to review and possible adjustment by federal, state and foreign taxing jurisdictions. The Company also had federal and state research tax credit carryforwards of $70.9 million and $33.0 million, respectively, which may be used to offset future income tax liability. The federal credit carryforwards expire at various dates through 2043 and are subject to review and possible adjustment by the Internal Revenue Service. The state credit carryforwards expire at various dates through 2038 with the exception of $19.7 million of California research and development tax credits that have an indefinite carryforward period. All state tax credits are subject to review and possible adjustment by local tax jurisdictions. In the event of a change of ownership, the federal and state net operating loss and research and development tax credit carryforwards may be subject to annual limitations provided by the Internal Revenue Code and similar state provisions.
Loss before provision for taxes consisted of the following:
Year Ended December 31,
(In thousands)202320222021
Loss before income taxes:
Domestic$(204,128)$(617,240)$(801,536)
Foreign2,382 (15,330)(40,970)
Total loss before income taxes$(201,746)$(632,570)$(842,506)
The expense (benefit) for income taxes consists of:
Year Ended December 31,
(In thousands)202320222021
Current expense (benefit):
Federal$— $— $— 
State2,266 2,170 1,388 
Foreign2,561 1,131 4,898 
Deferred tax expense (benefit):
Federal2,395 (3,292)(222,693)
State(1,829)(8,926)(30,528)
Foreign(2,990)(147)54 
Total income tax expense (benefit)$2,403 $(9,064)$(246,881)
The Company recorded income tax expense for the year ended December 31, 2023 of $2.4 million primarily related to current foreign and state tax expense.
The components of the net deferred tax asset with the approximate income tax effect of each type of carryforward, credit and temporary differences are as follows:
December 31,
(In thousands)20232022
Deferred tax assets:
Operating loss carryforwards$477,420 $553,320 
Tax credit carryforwards104,580 87,579 
Compensation related differences85,007 67,976 
Lease liabilities47,118 51,560 
Capitalized research and development191,468 108,117 
Other temporary differences10,275 19,353 
Tax assets before valuation allowance915,868 887,905 
Less - Valuation allowance(465,832)(419,356)
Total deferred tax assets450,036 468,549 
Deferred tax liabilities
Amortization$(415,064)$(435,991)
Property, plant and equipment(9,465)(4,653)
Lease assets(35,786)(40,674)
Other temporary differences(7,010)(6,944)
Total deferred tax liabilities(467,325)(488,262)
Net deferred tax liabilities$(17,289)$(19,713)
A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income and the realization of deferred tax liabilities, management has determined that a valuation allowance of $465.8 million and $419.4 million at December 31, 2023 and 2022, respectively, is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Given the future limitations on and expiration of certain federal and state deferred tax assets, the recording of a valuation allowance resulted in a deferred tax liability of approximately $17.3 million remaining as of December 31, 2023, which is included in other long-term liabilities on the Company's consolidated balance sheet. The overall change in valuation allowance for December 31, 2023 and 2022 was an increase of $46.5 million and an increase of $157.1 million, respectively.
Activity associated with the Company's valuation allowance is as follows:
December 31,
(In thousands)202320222021
Balance as of January 1, $(419,356)$(262,238)$(293,397)
Valuation allowances established(44,759)(159,919)(206,574)
Changes to existing valuation allowances(1,242)2,780 (1,500)
Acquisition and purchase accounting(475)21 239,233 
Balance as of December 31,$(465,832)$(419,356)$(262,238)
During the year ended December 31, 2023, the Company recorded an increase to the valuation allowance of $44.8 million primarily related to losses from continuing operations.
During the year ended December 31, 2022, the Company recorded an increase to the valuation allowance of $159.9 million primarily related to losses from continuing operations.
During the year ended December 31, 2021, the Company recorded an increase to the valuation allowance of $206.6 million primarily related to losses from continuing operations. Offsetting the increase, the Company recorded a decrease to the valuation allowance of $239.2 million related to the Thrive Merger offset against goodwill.
The effective tax rate differs from the statutory tax rate due to the following:
December 31,
202320222021
U.S. Federal statutory rate21.0 %21.0 %21.0 %
State taxes3.9 3.9 3.6 
Federal and state tax rate changes1.1 (0.2)(0.3)
Foreign tax rate differential— (0.1)(0.6)
Acquired IPR&D asset expense— — (0.8)
Research and development tax credits7.6 2.3 0.7 
Stock-based compensation expense(4.4)(2.0)1.1 
Non-deductible executive compensation(3.5)(0.4)(0.2)
Transaction costs— — (0.1)
Loss on extinguishment - convertible debt(0.7)— — 
Other adjustments(2.5)1.2 1.2 
Valuation allowance(23.7)(24.4)3.7 
Effective tax rate(1.2)%1.3 %29.3 %
For the year ended December 31, 2023, the Company recognized a income tax expense, representing an effective tax rate of (1.2)%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of (1.2)% for the year ended December 31, 2023, was primarily attributable to the valuation allowance established against the Company's current period losses.
For the year ended December 31, 2022, the Company recognized an income tax benefit, representing an effective tax rate of 1.3%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 1.3% for the year ended December 31, 2022, was primarily attributable to the valuation allowance established against the Company's current period losses.
For the year ended December 31, 2021, the Company recognized an income tax benefit, representing an effective tax rate of 29.3%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 29.3% for the year ended December 31, 2021, was primarily attributable to an income tax benefit of $239.2 million recorded as a result of a change in the deferred tax asset valuation allowance resulting from the Thrive Merger.
The Company had unrecognized tax benefits related to federal and state research and development tax credits of $36.4 million, $28.3 million, and $21.8 million as of December 31, 2023, 2022, and 2021, respectively. These amounts have been recorded as a reduction to the Company's deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months.
The following is a tabular reconciliation of the amounts of unrecognized tax benefits:
December 31,
(In thousands)202320222021
January 1,$28,270 $21,780 $16,629 
Increase due to current year tax positions7,447 5,861 5,363 
Increase due to prior year tax positions1,108 629 — 
Decrease due to prior year tax positions(426)— (212)
Settlements— — — 
December 31,$36,399 $28,270 $21,780 
As of December 31, 2023, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2000 through 2023, and to state income tax examinations for the tax years 2000 through 2023. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for the years ended December 31, 2023, 2022 and 2021.
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Business
Business
Exact Sciences Corporation (together with its subsidiaries, “Exact” or the “Company”) was incorporated in February 1995. Exact is a leading, global advanced cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard® and Oncotype DX®. Exact is currently working to develop additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.
Basis of Presentation and Principles of Consolidation
Basis of Presentation and Principles of Consolidation
The accompanying consolidated financial statements include the accounts of Exact Sciences Corporation and those of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.
Use of Estimates
Use of Estimates
The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company's financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, contingent consideration, and accounting for income taxes.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers cash on hand, demand deposits in a bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents.
Marketable Securities
Marketable Securities
Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value. The unrealized gains and losses, net of tax, on the Company's debt securities are reported in other comprehensive income. Marketable equity securities are measured at fair value and the unrealized gains and losses, net of tax, are recognized in other income (expense) in the consolidated statements of operations. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method. Such amortization is included in investment income, net. Realized gains and losses and declines in value as a result of credit losses on available-for-sale securities are included in the consolidated statements of operations as investment income, net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in the consolidated statements of operations as investment income, net.
The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current.
The Company periodically evaluates its available-for-sale debt securities in unrealized loss positions to determine whether any impairment is a result of a credit loss or other factors. This evaluation includes, but is not limited to, significant quantitative and qualitative assessments and estimates regarding credit ratings, significance of a security’s loss position, adverse conditions specifically related to the security, and the payment structure of the security.
Allowance for Doubtful Accounts
Allowance for Doubtful Accounts
The Company estimates an allowance for doubtful accounts against accounts receivable using historical collection trends, aging of accounts, current and future implications surrounding the ability to collect such as economic conditions, and regulatory changes. The allowance for doubtful accounts is evaluated on a regular basis and adjusted when trends, significant events, or other substantive evidence such as an adverse change in a payer's ability to pay indicate that expected collections will be less than previously estimated. At December 31, 2023 and 2022, the allowance for doubtful accounts recorded was not significant to the Company's consolidated balance sheets. For the years ended December 31, 2023, 2022 and 2021, there was an insignificant amount of bad debt expense written off against the allowance and charged to operating expense.
Inventory
Inventory
Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method (“FIFO”). The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale, no longer meets quality specifications, or has a cost basis in excess of its estimated realizable value and records a charge to cost of sales for such inventory as appropriate.
Direct and indirect manufacturing costs incurred during process validation with probable future economic benefit are capitalized. Validation costs incurred for other research and development activities, which are not permitted to be sold, are expensed to research and development in the Company’s consolidated statements of operations.
Property, Plant and Equipment
Property, Plant and Equipment
Property, plant and equipment are stated at cost and depreciated using the straight-line method over the assets’ estimated useful lives. Land is stated at cost and does not depreciate. Additions and improvements are capitalized, including direct and indirect costs incurred to validate equipment and bring to working conditions. Revalidation costs, including maintenance and repairs are expensed when incurred.
Software Development Costs
Software Development Costs
Costs related to internal use software, including hosted arrangements, are incurred in three stages: the preliminary project stage, the application development stage, and the post-implementation stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred during the application development stage that meet the criteria for capitalization are capitalized and amortized, when the software is ready for its intended use, using the straight‑line method over the estimated useful life of the software, or the duration of the hosting agreement.
Investments in Privately Held Companies
Investments in Privately Held Companies
The Company determines whether its investments in privately held companies are debt or equity based on their characteristics. The Company also evaluates the investee to determine if the entity is a variable interest entity (“VIE”) and, if so, whether the Company is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required. If consolidation is not required and the Company does not have voting control of the entity, the investment is evaluated to determine if the equity method of accounting should be applied. The equity method applies to investments in common stock or in substance common stock where the Company exercises significant influence over the investee.
Investments in privately held companies determined to be equity securities without readily determinable fair values are accounted for under the measurement alternative method as permitted in Accounting Standards Codification (“ASC”) 321, Investments - Equity Securities. The Company adjusts the carrying value of its non-marketable equity securities for changes from observable transactions for identical or similar investments of the same issuer, less impairment. All gains and losses on non-marketable equity securities, realized and unrealized, are recognized in investment income, net in the consolidated statements of operations.
Investments in privately held companies determined to be debt securities are accounted for as available-for-sale or held-to-maturity securities unless the fair value option is elected.
Derivative Financial Instruments
Derivative Financial Instruments
The Company hedges a portion of its foreign currency exposures related to outstanding monetary assets and liabilities using foreign currency forward contracts. The foreign currency forward contracts are included in prepaid expenses and other current assets or in accrued liabilities in the consolidated balance sheets, depending on the contracts’ net position. These contracts are not designated as hedges, and as a result, changes in their fair value are recorded in other income (expense) in the consolidated statements of operations.
Business Combinations and Asset Acquisitions
Business Combinations and Asset Acquisitions
Business Combinations are accounted for under the acquisition method in accordance with ASC 805, Business Combinations. The acquisition method requires identifiable assets acquired and liabilities assumed and any non-controlling interest in the business acquired be recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. The amount by which the fair value of consideration transferred as the purchase price exceeds the net fair value of assets acquired and liabilities assumed is recorded as goodwill. Acquisitions that do not meet the definition of a business combination under ASC 805 are accounted for as asset acquisitions. Asset acquisitions are accounted for by allocating the cost of the acquisition to the individual assets acquired and liabilities assumed on a relative fair value basis. Goodwill is not recognized in an asset acquisition with any consideration in excess of net assets acquired allocated to acquired assets on a relative fair value basis. Transaction costs are expensed in a business combination and are considered a component of the cost of the acquisition in an asset acquisition.
Intangible Assets
Intangible Assets
Purchased intangible assets are recorded at fair value. The Company uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. The Company’s finite-lived intangible assets are being amortized on a straight-line basis over their estimated useful lives.
Patent costs are capitalized as incurred, only if the Company determines that there is some probable future economic benefit derived from the transaction. A capitalized patent is amortized over its estimated useful life, beginning when such patent is approved. Capitalized patent costs are expensed upon disapproval, upon a decision by the Company to no longer pursue the patent or when the related intellectual property is either sold or deemed to be no longer of value to the Company. The Company determined that all patent costs incurred during the years ended December 31, 2023, 2022 and 2021 should be expensed and not capitalized as the future economic benefit derived from the patent costs incurred cannot be determined.
Acquired In-process Research and Development (IPR&D)
Acquired In-process Research and Development (“IPR&D”)
Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The primary basis for determining technological feasibility of these projects is obtaining regulatory approval to market the underlying product. The amounts capitalized are accounted for as indefinite-lived intangible assets and are subject to impairment testing until completion or abandonment of the research and development efforts associated with the projects. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. The value assigned to acquired IPR&D is determined using the multi-period excess earnings method approach, which utilizes significant unobservable inputs (Level 3 inputs) including projected revenues, projected gross margin, projected operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success. There are often major risks and uncertainties associated with IPR&D projects as the Company is required to obtain regulatory approvals in order to market the resulting products. Such approvals require completing clinical trials that demonstrate the product's effectiveness. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods.
Capitalized IPR&D projects are tested for impairment annually in the fourth quarter, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, and upon successful completion of the project. The Company considers various factors for potential impairment, including the current legal and regulatory environment, current and future strategic initiatives and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors' products could result in partial or full impairment of the related intangible assets.
Contingent Consideration
Contingent Consideration Liabilities
Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain regulatory and product development milestones being achieved. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected probabilities of success, projected payment dates, present value-factors, and projected revenues (for revenue-based considerations). Changes in probabilities of success, present-value factors, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within general and administrative expenses on the Company’s consolidated statements of operations. Cash contingent consideration payments up to the acquisition date fair value of the contingent consideration liability are classified as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are classified as operating activities in the consolidated statements of cash flows.
Contingent Consideration Asset
The sale of the Company’s intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test (“GPS test”) resulted in the recognition of variable consideration in accordance with ASC 606. The Company estimates the amount of variable consideration that it is entitled to each quarter using the most likely amount method and considers whether there are any constraints on the consideration. If it is probable that a significant reversal of a gain would not occur, the Company will record a gain. To determine the classification of the consideration, the Company determines if the consideration is conditional on something other than the passage of time. Revenue-based contingent consideration that is conditional on something other than the passage of time, including future revenues from sales related to the GPS test, result in the variable consideration being classified as a contract asset. At the time the amount earned is determined, and passage of time is the only condition remaining, the contract asset is reclassified to a receivable.
Collateralized Debt Instruments
Collateralized Debt Instruments
Debt instruments that are collateralized by security interests in financial assets held by the Company are accounted for as a secured borrowing and therefore: (i) the asset balances pledged as collateral are included within the applicable balance sheet line item and the borrowings are included within long-term debt in the consolidated balance sheet; (ii) interest expense is included within the consolidated statements of operations; and (iii) in the case of collateralized accounts receivable, receipts from customers related to the underlying accounts receivable are reflected as operating cash flows, and (iv) borrowings and repayments under the collateralized loans are reflected as financing cash flows within the consolidated statements of cash flows.
Goodwill
Goodwill
The Company evaluates goodwill for possible impairment at the reporting unit level on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting the Company's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
The Company evaluates the fair value of long-lived assets, which include property, plant and equipment, leases, finite-lived intangible assets, and investments in privately held companies, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Net Loss Per Share
Net Loss Per Share
Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.
Accounting for Stock-Based Compensation
Accounting for Stock-Based Compensation
The Company requires all share-based payments to employees, including grants of employee stock options, restricted stock, restricted stock units, shares purchased under an employee stock purchase plan (if certain parameters are not met), and performance share units to be recognized in the financial statements based on their grant date fair values. The estimated fair value of these awards is recognized to expense using the straight-line method over the requisite service period, which is generally the vesting period. The Company will recognize expense on an accelerated basis for restricted stock units upon an employee's death, disability, or upon retirement eligibility, provided certain criteria are met. Forfeitures of any share-based awards are recognized as they occur.
The fair values and recognition of the Company’s share-based payment awards are determined as follows:
The fair value of each service-based option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions:
Expected Term—Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants.
Expected Volatility—Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards.
Risk-Free Interest Rate—The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term.
The fair value of service-based awards for each restricted stock unit award is determined on the date of grant using the closing stock price on that day.
The fair value of performance-based equity awards that do not include a market condition is determined on the date of grant using the closing stock price on that day. The fair value of performance-based equity awards that include a market condition is determined on the date of grant using a Monte Carlo valuation technique. The expense recognized each period is also dependent on the probability of what performance conditions will be met which is determined by management's evaluation of internal and external factors. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the goals and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance targets and operational milestones are not achieved, the award would not vest resulting in no stock-based compensation being recognized and any previously recognized stock-based compensation expense being reversed.
Research and Development Costs
Research and Development Costs
Research and development costs are expensed as incurred. These expenses include the costs of the Company's proprietary research and development efforts, as well as costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use. Acquired IPR&D assets that are acquired in an asset acquisition and which have no alternative future use are classified as an investing cash outflow in the consolidated statements of cash flows. Upfront and milestone payments due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred. Milestone payments due to third parties upon, or subsequent to, regulatory approval are capitalized and amortized into research and development costs over the shorter of the remaining license or product patent life, when there are no corresponding revenues related to the license or product. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received, rather than when the payment is made.
Advertising Costs
Advertising Costs
The Company expenses the costs of media advertising at the time the advertising takes place. The Company expensed approximately $137.9 million, $170.3 million, and $144.0 million of media advertising during the years ended December 31, 2023, 2022, and 2021, respectively, which is recorded in sales and marketing expenses on the Company’s consolidated statements of operations.
Fair Value Measurements
Fair Value Measurements
The Financial Accounting Standards Board (“FASB”) has issued authoritative guidance that requires fair value to be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under that standard, fair value measurements are separately disclosed by level within the fair value hierarchy. The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.
Leases
Leases
The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles, and certain laboratory and office equipment, and finance leases for certain equipment and vehicles.
The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (“ROU”) assets and lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations.
As the implicit interest rate is not readily determinable in most of the Company’s leases, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the United States (“U.S.”) Treasury rate and an indicative Moody's rating for operating leases or finance leases.
The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease for up to 10 years, and some of which include options to terminate the lease within 1 year. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest expense on the Company’s consolidated statements of operations.
The Company accounts for leases acquired in business combinations by measuring the lease liability at the present value of the remaining lease payments as if the acquired lease were a new lease for the Company. This measurement includes recognition of a lease intangible for any below-market terms present in the leases acquired. The below-market lease intangible is included in the ROU asset on the consolidated balance sheets and are amortized over the remaining lease term. The Company has not acquired any leases with above-market terms.
The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.
Revenue Recognition
Revenue Recognition
Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype®, PreventionGenetics, LLC (“PreventionGenetics”), and COVID-19 tests. The services are considered completed when the performance obligation is fulfilled, which is upon release of an approved patient test result to the healthcare provider. The Company follows ASC 606, Revenue from Contracts with Customers, to account for its laboratory service revenues.
Laboratory testing services
The Company’s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services (“CMS”) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, or in the context of certain lab service or reference agreements, the Company requires payment prior to the commencement of the Company's performance obligations.
The Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patient’s test result to the ordering healthcare provider. Or, in the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window. The Company elects the practical expedient to not disclose unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year.
The Company’s transaction price is comprised of fixed and variable consideration and is allocated entirely to a single performance obligation defined as the point in time an approved patient test result is released to the ordering healthcare provider. Fixed consideration exists in arrangements where the Company has agreed to provide laboratory testing services to a customer for a specified rate and is expected to be collected in full at that rate. Variable consideration is primarily derived from payer and patient billing and can be impacted by several factors such as the amount of contractual adjustments, any patient co-payments, deductibles or patient adherence incentives, the existence of secondary payers, and claim denials. Estimates of variable consideration are calculated using the expected value method and is the sum of probability-weighted amounts in a range of possible consideration amounts. Several factors are evaluated during this process, such as historical collections experience, current contractual and statutory requirements, customer mix, patient insurance eligibility and payer reimbursement contracts, and known or anticipated reimbursement trends not yet reflected in the data. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made.
The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease in the estimate of the transaction price (i.e., an upward or downward revenue adjustment) in the period identified.
When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon completion of the performance obligations associated with the Company's tests, with recognition, generally occurring at the date of cash receipt.
Contract Balances
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets. Generally, billing occurs after the release of an approved patient test result to the healthcare provider, resulting in an account receivable. However, the Company sometimes receives advance payment from a patient or a direct bill payer before services are performed, resulting in deferred revenue. The deferred revenue recorded is recognized as revenue at the point in time an approved patient test result is released to the patient's healthcare provider. In the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window.
Practical Expedients
The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.
The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company’s consolidated statements of operations.
The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications (e.g. adherence reminder letters). These costs are expensed as incurred and recorded within general and administrative expenses in the Company’s consolidated statements of operations.
Foreign Currency Transactions
Foreign Currency Transactions
The functional currency for most of the Company’s international subsidiaries is the U.S. dollar. When the functional currency differs from the local currency, monetary assets and liabilities are remeasured at the current period-end exchange rate, while non-monetary assets and liabilities are remeasured at the historical rate. The gains and losses as a result of exchange rate adjustments of these subsidiaries are recognized in the consolidated statements of operations. Net foreign currency transaction gains or losses were not significant to the consolidated statements of operations for the periods presented.
For the Company’s international subsidiaries where the functional currency is other than the U.S. dollar, the financial statements are translated into the U.S. dollar, and the cumulative adjustments resulting from the translation into the U.S. dollar are included in the Company's consolidated balance sheet as a component of accumulated other comprehensive income (loss) (“AOCI”).
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that subject the Company to credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2023, the Company had cash and cash equivalents deposited in financial institutions in which the balances exceed the federal government agency insured limit of $250,000 by approximately $529.0 million. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.
Through December 31, 2023, the Company’s revenues have been primarily derived from the sale of Cologuard, Oncotype, and COVID-19 tests. The following is a breakdown of revenue and accounts receivable from major payers:
% Revenue for the years ended December 31,% Accounts Receivable at December 31,
Major Payer202320222021202320222021
Centers for Medicare and Medicaid Services17%14%20%10%14%11%
UnitedHealthcare12%12%11%10%9%8%
State of Wisconsin—%3%8%—%5%9%
Tax Positions
Tax Positions
A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income, the Company has determined that a valuation allowance at December 31, 2023 and 2022 is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the Company's effective tax rate.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In July 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-03, Presentation of Financial Statement (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718). This update amends various Securities and Exchange Commission (“SEC”) paragraphs in the Accounting Standards Codification to reflect the issuance of SEC Staff Accounting Bulletin No. 120, among other things. The Company adopted this conforming guidance upon issuance during the third quarter of fiscal year 2023. There was no significant impact to the Company’s consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.
Cost of Goods and Service
Cost of Sales
Cost of sales reflects the aggregate costs incurred in delivering the Company's products and services and includes material and service costs, personnel costs, including stock-based compensation expense, equipment and infrastructure expenses associated with laboratory testing services, shipping charges, and allocated overhead such as rent, information technology costs, equipment depreciation and utilities. Costs associated with the shipment of Cologuard test collection kits are recognized upon shipment, and costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test.
Guarantees and Indemnifications
Guarantees and Indemnifications
The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a directors and officers insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2023 and 2022.
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
December 31,
(In thousands)202320222021
Shares issuable upon conversion of convertible notes23,231 20,309 20,309 
Shares issuable upon the release of restricted stock awards6,273 5,255 4,321 
Shares issuable upon the release of performance share units1,598 968 878 
Shares issuable upon exercise of stock options1,286 1,518 2,284 
Shares issuable in connection with acquisitions— — 45 
32,388 28,050 27,837 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation by revenue source The following table presents the Company’s revenues disaggregated by revenue source:
Year Ended December 31,
(In thousands)202320222021
Screening
Medicare Parts B & C$701,400 $545,458 $438,646 
Commercial992,244 743,238 569,944 
Other171,057 136,007 53,718 
Total Screening1,864,701 1,424,703 1,062,308 
Precision Oncology
Medicare Parts B & C$188,689 $197,327 $197,394 
Commercial181,318 177,518 180,177 
International153,277 117,738 109,913 
Other105,826 108,905 74,192 
Total Precision Oncology629,110 601,488 561,676 
COVID-19 Testing$5,955 $58,088 $143,103 
Total$2,499,766 $2,084,279 $1,767,087 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
MARKETABLE SECURITIES (Tables)
 12 Months Ended
Dec. 31, 2023
Cash and Cash Equivalents [Abstract]  
Schedule of cash and cash equivalents
The following table sets forth the Company’s cash, cash equivalents, and marketable securities at December 31, 2023 and 2022:
December 31,
(In thousands)20232022
Cash and cash equivalents
Cash and money market$530,100 $178,168 
Cash equivalents75,278 64,325 
Total cash and cash equivalents605,378 242,493 
Marketable securities
Available-for-sale debt securities$168,425 $384,415 
Equity securities3,841 5,149 
Total marketable securities172,266 389,564 
Total cash, cash equivalents, and marketable securities$777,644 $632,057 
Schedule of available-for-sale securities
Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2023, consisted of the following:
(In thousands)Amortized Cost
Gains in AOCI (1)
Losses in AOCI (1)
Estimated Fair Value
Cash equivalents
Commercial paper$72,243 $— $— $72,243 
U.S. government agency securities3,035 — — 3,035 
Total cash equivalents75,278 — — 75,278 
Marketable securities
U.S. government agency securities$56,594 $166 $(44)$56,716 
Corporate bonds55,712 175 (59)55,828 
Asset backed securities35,081 65 (249)34,897 
Commercial paper
20,984 — — 20,984 
Total marketable securities168,371 406 (352)168,425 
Total available-for-sale debt securities$243,649 $406 $(352)$243,703 
_________________________________
(1)     There was no tax impact from the gains and losses in AOCI.
Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2022, consisted of the following:
(In thousands)Amortized Cost
Gains in AOCI (1)
Losses in AOCI (1)
Estimated Fair Value
Cash equivalents
Commercial paper$63,021 $— $— $63,021 
U.S. government agency securities1,304 — — 1,304 
Total cash equivalents64,325 — — 64,325 
Marketable securities
U.S. government agency securities$228,012 $— $(2,789)$225,223 
Corporate bonds116,318 20 (1,667)114,671 
Asset backed securities45,374 2 (855)44,521 
Total marketable securities389,704 22 (5,311)384,415 
Total available-for-sale debt securities$454,029 $22 $(5,311)$448,740 
_________________________________
(1)     There was no tax impact from the gains and losses in AOCI.
Schedule of contractual maturities of available-for-sale investments
The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at December 31, 2023:
Due one year or lessDue after one year through five years
(In thousands)CostFair ValueCostFair Value
Cash equivalents
Commercial paper$72,243 $72,243 $— $— 
U.S. government agency securities3,035 3,035 — — 
Total cash equivalents75,278 75,278 — — 
Marketable securities
Corporate bonds$33,518 $33,474 $22,194 $22,354 
U.S. government agency securities33,407 33,403 23,187 23,313 
Commercial paper
20,984 20,984 — — 
Asset backed securities— — 35,081 34,897 
Total marketable securities87,909 87,861 80,462 80,564 
Total available-for-sale securities$163,187 $163,139 $80,462 $80,564 
Schedule of gross unrealized losses and fair values of investments in an unrealized loss position
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one year
One year or greater
Total
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
Corporate bonds$25,895 $(41)$2,480 $(18)$28,375 $(59)
U.S. government agency securities15,756 (35)3,965 (9)19,721 (44)
Asset backed securities4,377 (5)10,935 (244)15,312 (249)
Total available-for-sale securities$46,028 $(81)$17,380 $(271)$63,408 $(352)
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2022, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one year
One year or greater
Total
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
U.S. government agency securities$37,458 $(337)$187,766 $(2,452)$225,224 $(2,789)
Corporate bonds35,055 (575)73,702 (1,092)108,757 (1,667)
Asset backed securities27,984 (735)15,536 (120)43,520 (855)
Total available-for-sale securities$100,497 $(1,647)$277,004 $(3,664)$377,501 $(5,311)
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORY (Tables)
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of inventory
Inventory consisted of the following:
December 31,
(In thousands)20232022
Raw materials$58,593 $61,207 
Semi-finished and finished goods68,882 57,052 
Total inventory$127,475 $118,259 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT, AND EQUIPMENT (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of property, plant and equipment, net
The carrying value and estimated useful lives of property, plant and equipment are as follows:
December 31,
(In thousands)Estimated Useful Life20232022
Property, plant and equipment
Landn/a$4,716 $4,716 
Leasehold and building improvements(1)214,562 200,588 
Land improvements15 years6,729 6,417 
Buildings
30 - 40 years
290,777 288,941 
Computer equipment and computer software3 years168,131 142,896 
Machinery and equipment
3 - 10 years
290,294 246,344 
Furniture and fixtures
3 - 10 years
35,756 34,047 
Assets under constructionn/a104,592 68,398 
Property, plant and equipment, at cost1,115,557 992,347 
Accumulated depreciation(417,203)(307,591)
Property, plant and equipment, net$698,354 $684,756 
_________________________________
(1)     Lesser of remaining lease term, building life, or estimated useful life.
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND GOODWILL (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of net-book value and estimated remaining life and finite lived intangible assets
The following table summarizes the net-book-value and estimated remaining life of the Company's intangible assets as of December 31, 2023:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated AmortizationNet Balance at December 31, 2023
Finite-lived intangible assets
Trade name11.6$104,000 $(27,903)$76,097 
Customer relationships7.04,000 (889)3,111 
Patents and licenses4.511,542 (9,600)1,942 
Acquired developed technology (1)7.3887,789 (328,543)559,246 
Total finite-lived intangible assets1,007,331 (366,935)640,396 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,257,331 $(366,935)$1,890,396 
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated AmortizationNet Balance at December 31, 2022
Finite-lived intangible assets
Trade name12.5$104,000 $(20,653)$83,347 
Customer relationships8.04,000 (444)3,556 
Patents and licenses4.211,542 (8,152)3,390 
Acquired developed technology (1)
7.8861,474 (245,527)615,947 
Total finite-lived intangible assets981,016 (274,776)706,240 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,231,016 $(274,776)$1,956,240 
______________
(1)The gross carrying amount includes an insignificant foreign currency translation adjustment related to the intangible asset     acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
Schedule of estimated future amortization expense, intangible assets
As of December 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2024$92,908 
202591,860 
202690,800 
202790,800 
202890,800 
Thereafter183,228 
Total$640,396 
Schedule of carrying amount of goodwill
The change in the carrying amount of goodwill for the years ended December 31, 2023 and 2022 is as follows:
(In thousands)
Balance, January 1, 2022
$2,335,172 
OmicEra acquisition
10,809 
PreventionGenetics acquisition adjustment(58)
Effects of changes in foreign currency exchange rates (1)117 
Balance, December 31, 2022
2,346,040 
Resolution Bioscience acquisition (2)
20,692 
Effects of changes in foreign currency exchange rates (1)
388 
Balance December 31, 2023
$2,367,120 
_________________________________
(1)    Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
(2)    Refer to Note 18 for further discussion on the Company’s acquisition of Resolution Bioscience, Inc. (“Resolution Bioscience”).
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS (Tables)
 12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall
The following table presents the Company’s fair value measurements as of December 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair value at December 31, 2023Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$530,100 $530,100 $— $— 
Commercial paper72,243 — 72,243 — 
Restricted cash (1)
4,297 4,297 — — 
U.S. government agency securities3,035 — 3,035 — 
Marketable securities
U.S. government agency securities$56,716 $— $56,716 $— 
Corporate bonds55,828 — 55,828 — 
Asset backed securities34,897 — 34,897 — 
Commercial paper
20,984 — 20,984 — 
Equity securities
3,841 3,841 — — 
Non-marketable securities$7,650 $— $— $7,650 
Liabilities
Contingent consideration$(288,657)$— $— $(288,657)
Total$500,934 $538,238 $243,703 $(281,007)
The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at December 31, 2022Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$178,168 $178,168 $— $— 
Commercial paper63,021 — 63,021 — 
U.S. government agency securities1,304 — 1,304 — 
Restricted cash (1)
297 297 — — 
Marketable securities
U.S. government agency securities$225,223 $— $225,223 $— 
Corporate bonds114,671 — 114,671 — 
Asset backed securities44,521 — 44,521 — 
Equity securities (2)
5,149 5,149 — — 
Non-marketable securities$10,065 $— $— $10,065 
Liabilities
Contingent consideration$(306,927)$— $— $(306,927)
Total$335,492 $183,614 $448,740 $(296,862)
_________________________________
(1)Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company's credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties.
(2)Inclusive of the American Depository Shares of MDxHealth received as part of the sale of the Company’s GPS test, which are restricted to a holding period of six months after the date of the sale of August 2, 2022. The shares had a fair value of $4.6 million as of December 31, 2022.
Schedule of fair value of contingent consideration
The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
(In thousands)Contingent Consideration
Balance, January 1, 2022 (1)
$359,021 
Purchase price contingent consideration (2)
4,600 
Changes in fair value(56,617)
Payments(77)
Balance, December 31, 2022
306,927 
Changes in fair value
(18,044)
Payments(226)
Balance, December 31, 2023
$288,657 
_________________________________
(1)    The change in fair value of the contingent consideration liability during the year ended December 31, 2021 was not significant.
(2)    The increase in contingent consideration liability is due to the contingent consideration associated with the acquisition of OmicEra. Refer to Note 18 for further information.
Other Investments Not Readily Marketable
Non-Marketable Equity Investments
Non-marketable equity securities without readily determinable fair values, which are classified as a component of other long-term assets, net, had the following aggregate carrying amounts and downward and upward adjustments as of and for the years ended December 31, 2023 and 2022:
Year ended December 31,
(In thousands)
20232022
Upward adjustments (1)
$4,314 $779 
Downward adjustments and impairments (2)
(4,250)(10,821)
Aggregate carrying value
45,968 39,842 
_________________________________
(1)    Cumulative upward adjustments on non-marketable equity securities held as of December 31, 2023 was $5.1 million. The upward adjustments recorded were due to increases in the valuation of the underlying investee as determined by the value of the follow-on rounds of investment by other third-party investors. There were no upward adjustments recorded during the year ended December 31, 2021.
(2)    Cumulative downward adjustments and impairments on non-marketable equity securities held as of December 31, 2023 was $15.1 million. The adjustments recorded were due to adverse changes in the market and the investees’ ability to continue as a going concern. There were no downward adjustments recorded during the year ended December 31, 2021.
Securities Owned Not Readily Marketable
The Company has elected the fair value option under the income approach to measure certain Level 3 non-marketable securities. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option:
(In thousands)Non-Marketable Securities
Beginning balance, January 1, 2022
$3,090 
Purchase of non-marketable securities
10,000 
Change in fair value
1,038 
Conversion of non-marketable securities
(4,063)
Balance, December 31, 2022
10,065 
Purchases of non-marketable securities6,957 
Changes in fair value1,127 
Settlement of non-marketable securities
(10,499)
Ending balance, December 31, 2023
$7,650 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACCRUED LIABILITIES (Tables)
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Schedule of accrued expenses
Accrued liabilities at December 31, 2023 and 2022 consisted of the following:
December 31,
(In thousands)20232022
Compensation$247,619 $201,252 
Professional fees45,405 43,715 
Other17,274 22,329 
Research and trial related expenses14,219 17,455 
Assets under construction11,210 10,462 
Licenses5,956 4,003 
Total $341,683 $299,216 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONVERTIBLE NOTES (Tables)
 12 Months Ended
Dec. 31, 2023
CONVERTIBLE DEBT  
Schedule of debt, net of discounts and deferred financing costs
Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2023:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2030 Convertible Notes - 2.000%
$572,993 $(4,349)$568,644 $684,475 2
2028 Convertible Notes - 0.375%
949,042 (10,499)938,543 887,354 2
2027 Convertible Notes - 0.375%
563,822 (5,429)558,393 549,839 2
2025 Convertible Notes - 1.000%
249,172 (476)248,696 293,300 2
Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2022:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2028 Convertible Notes - 0.375%
$1,150,000 $(15,775)$1,134,225 $908,500 2
2027 Convertible Notes - 0.375%
747,500 (9,445)738,055 612,950 2
2025 Convertible Notes - 1.000%
315,005 (1,179)313,826 326,808 2
____________________________
(1)     The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement.
Schedule of Allocation of Transaction Costs Related to Convertible Debt The following table summarizes the original issuance costs at the time of issuance for each set of Notes:
(In thousands)
2030 Convertible Notes
$4,938 
2028 Convertible Notes
24,453 
2027 Convertible Notes
14,285 
2025 Convertible Notes
17,646 
Schedule of Interest Expense
Interest expense on the Notes includes the following:
Year Ended December 31,
(In thousands)202320222021
Debt issuance costs amortization$5,350 $5,727 $5,727 
Debt discount amortization106 147 147 
Gain on settlement of convertible notes(10,324)— — 
Coupon interest expense18,072 10,266 10,266 
Total interest expense on convertible notes$13,204 $16,140 $16,140 
The following table summarizes the effective interest rates of the Notes:
Year Ended December 31,
202320222021
2030 Convertible Notes
2.09 %— %— %
2028 Convertible Notes
0.63 %0.64 %0.64 %
2027 Convertible Notes
0.67 %0.68 %0.68 %
2025 Convertible Notes1.17 %1.18 %1.18 %
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of business acquisitions, by acquisition Stock issuances in relation to acquisitions during the years ended December 31, 2023, 2022 and 2021 were as follows:
(In thousands, except for per share data)
Period of AcquisitionShares IssuedFair Value of Shares Issued
OmicEraMay 2022265,186$14,792 
PreventionGeneticsDecember 20211,070,41084,252 
AshionApril 2021125,44416,224 
ThriveJanuary 20219,323,2661,191,420 
TARDIS license
January 2021191,33527,263 
The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:
(In thousands)
Cash$52,527 
Fair value of replaced equity awards1,675 
Total purchase price$54,202 
The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:
(In thousands)
Common stock issued$14,792 
Contingent consideration4,600 
Cash paid related to working capital adjustment16 
Total purchase price$19,408 
The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following:
(In thousands)
Cash$101,129
Common stock issued84,252
Total purchase price$185,381
The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following:
(In thousands)
Cash$74,775
Common stock issued16,224
Contingent consideration19,000
Total purchase price$109,999
The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following:
(In thousands)
Common stock issued$1,175,431
Cash584,996
Contingent consideration331,348
Fair value of replaced equity awards52,245
Previously held equity investment fair value43,034
Total purchase price$2,187,054
Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI)
The amount recognized in AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:
(In thousands)Cumulative Translation Adjustment
Unrealized Gain (Loss) on Securities (1)
AOCI
Balance at January 1, 2021
$— $526 $526 
Other comprehensive income (loss) before reclassifications
23 (1,648)(1,625)
Amounts reclassified from accumulated other comprehensive income (loss)
— (514)(514)
Net current period change in accumulated other comprehensive loss23 (2,162)(2,139)
Income tax benefit related to items of other comprehensive loss
— 170 170 
Balance at December 31, 2021$23 $(1,466)$(1,443)
Other comprehensive income (loss) before reclassifications30 (4,049)(4,019)
Amounts reclassified from accumulated other comprehensive income (loss)
— 226 226 
Net current period change in accumulated other comprehensive loss30 (3,823)(3,793)
Balance at December 31, 2022$53 $(5,289)$(5,236)
Other comprehensive income (loss) before reclassifications1,321 1,416 2,737 
Amounts reclassified from accumulated other comprehensive income (loss)
— 3,927 3,927 
Net current period change in accumulated other comprehensive income (loss)
1,321 5,343 6,664 
Balance at December 31, 2023$1,374 $54 $1,428 
_________________________________
(1)There was no tax impact from the amounts recognized in AOCI for the years ended December 31, 2023 and 2022.
Schedule of amounts reclassified from accumulated other comprehensive income (loss)
Amounts reclassified from AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:
Year Ended December 31,
Details about AOCI Components (In thousands)Affected Line Item in the
Statements of Operations		202320222021
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investments
Investment income (loss)
$3,927 $226 $(514)
Total reclassifications$3,927 $226 $(514)
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of non-cash stock-based compensation expense by department
A summary of non-cash stock-based compensation expense by expense category included in the Company's consolidated statements of operations for the years ended December 31, 2023, 2022, and 2021 is as follows:
Year Ended December 31,
(In thousands)
202320222021
Cost of sales
$20,761 $19,218 $16,835 
Research and development
41,242 33,825 49,723 
Sales and marketing
65,552 62,568 55,716 
General and administrative
103,757 91,212 216,952 
Total stock-based compensation$231,312 $206,823 $339,226 
Schedule of valuation assumptions
The fair value of ESPP shares is based on the assumptions in the following table:
Year Ended December 31,
202320222021
Risk-free interest rates
4.68% - 4.71%
1.49% - 4.71%
0.04% - 0.16%
Expected term (in years)
1.25
0.5 - 2
0.5 - 2
Expected volatility
63.13% - 67.30%
50.94% - 63.13%
43.00% - 68.51%
Dividend yield0%0%0%
Summary of stock option activity under the Stock Plans
A summary of stock option activity under the Stock Plans is as follows:
OptionsShares
Weighted Average Exercise Price
Weighted Average Remaining Contractual Term (Years)
Aggregate Intrinsic Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 2023
1,517,876 $44.82 4.7
Exercised(194,629)16.44 
Forfeited(37,074)95.02 
Outstanding, December 31, 2023
1,286,173 $47.67 3.8$42,878 
Vested and expected to vest, December 31, 2023
1,286,173 $47.67 3.8$42,878 
Exercisable, December 31, 2023
1,228,594 $45.32 3.7$42,878 
_________________________________
(1)     The total intrinsic value of options exercised during the years ended December 31, 2023, 2022, and 2021 was $11.7 million, $36.4 million, and $155.8 million, respectively, determined as of the date of exercise.
Summary of restricted stock and restricted stock unit activity under the Stock Plans
A summary of restricted stock and restricted stock unit activity is as follows:
Restricted SharesWeighted Average Grant Date Fair Value (1)
Outstanding, January 1, 2023
5,254,709 $85.87 
Granted3,510,373 62.36 
Released (2)(1,797,915)88.28 
Forfeited(694,404)73.54 
Outstanding, December 31, 2023
6,272,763 $73.39 
_________________________________
(1)     The weighted average grant date fair value of the restricted stock units granted during the years ended December 31, 2022 and 2021 was $68.18 and $129.16, respectively.
(2)     The fair value of restricted stock units vested and converted to shares of the Company's common stock was $158.2 million, $117.6 million, and $219.4 million for the years ended December 31, 2023, 2022, and 2021, respectively.
Share-based Payment Arrangement, Performance Shares, Activity
A summary of performance share unit activity is as follows:
Performance Share Units (1)Weighted Average Grant Date Fair Value (2)
Outstanding, January 1, 2023967,846 $102.58 
Granted782,966 80.50 
Released (3)(12,284)78.32 
Forfeited(140,727)93.73 
Outstanding, December 31, 20231,597,801 $92.73 
_________________________________
(1)     The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of December 31, 2023 was 772,906.
(2)     The weighted average grant date fair value of the performance share units granted during the years ended December 31, 2022 and 2021 was $89.43 and $138.09, respectively.
(3)     The fair value of performance share units vested and converted to shares of the Company's common stock was $1.0 million and $27.2 million for the years ended December 31, 2023 and 2022, respectively. There were no performance share units vested and converted to shares of the Company's common stock during the year ended December 31, 2021.
Schedule of shares of common stock issued
A summary of ESPP activity is as follows:
Year Ended December 31,
(in thousands, except share and per share amounts)202320222021
Shares issued under the 2010 Purchase Plan924,448 668,605331,769
Cash received under the 2010 Purchase Plan$28,344 $25,491 $23,070 
Weighted average fair value per share of stock purchase rights granted during the period$16.32 $17.52 $34.93 
Schedule of Common Stock Issued
The 924,448 shares issued during the year ended December 31, 2023 were as follows:
Offering period ended
Number of Shares
Weighted Average price per Share
April 30, 2023544,453 $30.02 
October 31, 2023379,995 $31.57 
Summary of shares of authorized common stock reserved for issuance
The Company has reserved shares of its authorized common stock for issuance pursuant to its employee stock purchase and equity plans, including all outstanding stock option grants noted above at December 31, 2023, as follows:
Shares reserved for issuance
2019 Stock Plan16,046,161 
2010 Purchase Plan
1,834,193 
17,880,354 
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES (Tables)
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Components of lease expense
The components of lease expense were as follows:
Year Ended December 31,
(In thousands)202320222021
Finance lease cost
Amortization of right-of-use assets$3,845 $4,612 $5,731 
Interest on lease liabilities800 808 1,018 
Operating lease cost36,576 36,291 31,730 
Short-term lease cost750 476 628 
Variable lease cost8,449 7,985 5,212 
Total lease Cost$50,420 $50,172 $44,319 
Supplemental disclosure of cash flow information related to the Company's cash and non-cash activities with its leases are as follows:
Year Ended December 31,
(In thousands)202320222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$39,301$33,448$27,461
Operating cash flows from finance leases783699938
Finance cash flows from finance leases3,5694,3455,290
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities (1)4,98624,57274,369
Right-of-use assets obtained in exchange for new finance lease liabilities5,44311,2765,460
Weighted-average remaining lease term - operating leases (in years)6.877.438.33
Weighted-average remaining lease term - finance leases (in years)2.803.272.95
Weighted-average discount rate - operating leases6.59 %6.37 %6.11 %
Weighted-average discount rate - finance leases7.43 %6.60 %5.36 %
_________________________________
(1)    This includes an insignificant amount of right-of-use assets acquired as part of the business combinations described in Note 18 for the years ended December 31, 2023 and 2022, and $39.6 million for the year ended December 31, 2021.
Operating lease maturity
Maturities of operating lease liabilities on an annual basis as of December 31, 2023 were as follows:
(In thousands)
2024$39,476 
202536,660 
202634,851 
202734,226 
202827,901 
Thereafter66,634 
Total minimum lease payments239,748 
Imputed interest(49,299)
Total$190,449 
Finance lease maturity
Maturities of finance lease liabilities on an annual basis as of December 31, 2023 were as follows (amounts in thousands):
(In thousands)
2024$5,044
20254,552
20262,797
2027827
2028—
Thereafter—
Total minimum lease payments13,220
Imputed interest(1,279)
Total$11,941
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)
 12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of business acquisitions, by acquisition Stock issuances in relation to acquisitions during the years ended December 31, 2023, 2022 and 2021 were as follows:
(In thousands, except for per share data)
Period of AcquisitionShares IssuedFair Value of Shares Issued
OmicEraMay 2022265,186$14,792 
PreventionGeneticsDecember 20211,070,41084,252 
AshionApril 2021125,44416,224 
ThriveJanuary 20219,323,2661,191,420 
TARDIS license
January 2021191,33527,263 
The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:
(In thousands)
Cash$52,527 
Fair value of replaced equity awards1,675 
Total purchase price$54,202 
The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:
(In thousands)
Common stock issued$14,792 
Contingent consideration4,600 
Cash paid related to working capital adjustment16 
Total purchase price$19,408 
The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following:
(In thousands)
Cash$101,129
Common stock issued84,252
Total purchase price$185,381
The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following:
(In thousands)
Cash$74,775
Common stock issued16,224
Contingent consideration19,000
Total purchase price$109,999
The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following:
(In thousands)
Common stock issued$1,175,431
Cash584,996
Contingent consideration331,348
Fair value of replaced equity awards52,245
Previously held equity investment fair value43,034
Total purchase price$2,187,054
Schedule of allocated to the underlying assets acquired and liabilities assumed
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:
(In thousands)
Net operating assets$14,663 
Developed technology26,000 
Total identifiable assets acquired40,663 
Net operating liabilities(7,152)
Net identifiable assets acquired33,511 
Goodwill20,691 
Net assets acquired$54,202 
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:
(In thousands)
Net operating assets$2,586 
Developed technology10,000 
Total identifiable assets acquired12,586 
Net operating liabilities(3,987)
Net identifiable assets acquired8,599 
Goodwill10,809 
Net assets acquired$19,408 
Schedule of share-based payment award, stock options, valuation assumptions
The fair value of options assumed were based on the assumptions in the following table:
Option Plan Shares Assumed
Risk-free interest rates
0.11% - 0.12%
Expected term (in years)
1.26 - 1.57
Expected volatility
65.54% - 71.00%
Dividend yield
0%
Weighted average fair value per share of options assumed
$109.74 - $124.89
Business combination, pro forma information
The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Resolution Bioscience, as though the companies were combined as of the beginning of January 1, 2022.
Twelve Months Ended December 31,
(In thousands)20232022
Total revenues$2,507,111 $2,097,680 
Net loss before tax(237,854)(675,091)
The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Thrive, as though the companies were combined as of the beginning of January 1, 2020.
Year Ended December 31,
(In thousands)20212020
Total revenues$2,084,279 $1,767,087 
Net loss before tax(761,337)(1,014,352)
Schedule of Noncash or Part Noncash Divestitures
The closing date fair value of the consideration received for the asset was approximately $29.6 million, which consisted of the following:
(In thousands)
Cash$25,000 
MDxHealth American Depository Shares 4,631 
Contingent consideration— 
Total consideration$29,631 
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Revenue from external customers by geographic areas
The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.
Year Ended December 31,
(In thousands)202320222021
United States$2,346,489 $1,966,541 $1,657,174 
Outside of United States153,277 117,738 109,913 
Total revenues$2,499,766 $2,084,279 $1,767,087 
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of income before income tax, domestic and foreign
Loss before provision for taxes consisted of the following:
Year Ended December 31,
(In thousands)202320222021
Loss before income taxes:
Domestic$(204,128)$(617,240)$(801,536)
Foreign2,382 (15,330)(40,970)
Total loss before income taxes$(201,746)$(632,570)$(842,506)
Schedule of expense (benefit) for income taxes
The expense (benefit) for income taxes consists of:
Year Ended December 31,
(In thousands)202320222021
Current expense (benefit):
Federal$— $— $— 
State2,266 2,170 1,388 
Foreign2,561 1,131 4,898 
Deferred tax expense (benefit):
Federal2,395 (3,292)(222,693)
State(1,829)(8,926)(30,528)
Foreign(2,990)(147)54 
Total income tax expense (benefit)$2,403 $(9,064)$(246,881)
Schedule of components of the net deferred tax asset
The components of the net deferred tax asset with the approximate income tax effect of each type of carryforward, credit and temporary differences are as follows:
December 31,
(In thousands)20232022
Deferred tax assets:
Operating loss carryforwards$477,420 $553,320 
Tax credit carryforwards104,580 87,579 
Compensation related differences85,007 67,976 
Lease liabilities47,118 51,560 
Capitalized research and development191,468 108,117 
Other temporary differences10,275 19,353 
Tax assets before valuation allowance915,868 887,905 
Less - Valuation allowance(465,832)(419,356)
Total deferred tax assets450,036 468,549 
Deferred tax liabilities
Amortization$(415,064)$(435,991)
Property, plant and equipment(9,465)(4,653)
Lease assets(35,786)(40,674)
Other temporary differences(7,010)(6,944)
Total deferred tax liabilities(467,325)(488,262)
Net deferred tax liabilities$(17,289)$(19,713)
Summary of valuation allowance
Activity associated with the Company's valuation allowance is as follows:
December 31,
(In thousands)202320222021
Balance as of January 1, $(419,356)$(262,238)$(293,397)
Valuation allowances established(44,759)(159,919)(206,574)
Changes to existing valuation allowances(1,242)2,780 (1,500)
Acquisition and purchase accounting(475)21 239,233 
Balance as of December 31,$(465,832)$(419,356)$(262,238)
Schedule of differences between the effective income tax rate and the statutory tax rate
The effective tax rate differs from the statutory tax rate due to the following:
December 31,
202320222021
U.S. Federal statutory rate21.0 %21.0 %21.0 %
State taxes3.9 3.9 3.6 
Federal and state tax rate changes1.1 (0.2)(0.3)
Foreign tax rate differential— (0.1)(0.6)
Acquired IPR&D asset expense— — (0.8)
Research and development tax credits7.6 2.3 0.7 
Stock-based compensation expense(4.4)(2.0)1.1 
Non-deductible executive compensation(3.5)(0.4)(0.2)
Transaction costs— — (0.1)
Loss on extinguishment - convertible debt(0.7)— — 
Other adjustments(2.5)1.2 1.2 
Valuation allowance(23.7)(24.4)3.7 
Effective tax rate(1.2)%1.3 %29.3 %
Schedule of unrecognized tax benefits
The following is a tabular reconciliation of the amounts of unrecognized tax benefits:
December 31,
(In thousands)202320222021
January 1,$28,270 $21,780 $16,629 
Increase due to current year tax positions7,447 5,861 5,363 
Increase due to prior year tax positions1,108 629 — 
Decrease due to prior year tax positions(426)— (212)
Settlements— — — 
December 31,$36,399 $28,270 $21,780 
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Common shares not included in the computation of diluted net loss per share      
Antidilutive shares (in shares) 32,388 28,050 27,837
Shares issuable in connection with acquisitions      
Common shares not included in the computation of diluted net loss per share      
Antidilutive shares (in shares) 0 0 45
Shares issuable upon exercise of stock options      
Common shares not included in the computation of diluted net loss per share      
Antidilutive shares (in shares) 1,286 1,518 2,284
Shares issuable upon the release of restricted stock awards      
Common shares not included in the computation of diluted net loss per share      
Antidilutive shares (in shares) 6,273 5,255 4,321
Shares issuable upon the release of performance share units      
Common shares not included in the computation of diluted net loss per share      
Antidilutive shares (in shares) 1,598 968 878
Shares issuable upon conversion of convertible notes      
Common shares not included in the computation of diluted net loss per share      
Antidilutive shares (in shares) 23,231 20,309 20,309
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Research and Development Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Research and development $ 425,882 $ 393,418 $ 385,646
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Advertising expense $ 137.9 $ 170.3 $ 144.0
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)
 12 Months Ended
Dec. 31, 2023
Lessee, Lease, Description [Line Items]  
Operating lease, term extension 10 years
Operating lease, termination period 1 year
Minimum  
Lessee, Lease, Description [Line Items]  
Operating lease, remaining lease term 1 year
Maximum  
Lessee, Lease, Description [Line Items]  
Operating lease, remaining lease term 15 years
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Concentration of Credit Risk      
Cash and cash equivalents, federal government agency insured limit $ 529.0    
Revenue | Customer Concentration Risk | Centers for Medicare and Medicaid Services      
Concentration of Credit Risk      
Concentration risk (as a percent) 17.00% 14.00% 20.00%
Revenue | Customer Concentration Risk | UnitedHealthcare      
Concentration of Credit Risk      
Concentration risk (as a percent) 12.00% 12.00% 11.00%
Revenue | Customer Concentration Risk | State of Wisconsin      
Concentration of Credit Risk      
Concentration risk (as a percent) 0.00% 3.00% 8.00%
Accounts Receivable | Customer Concentration Risk | Centers for Medicare and Medicaid Services      
Concentration of Credit Risk      
Concentration risk (as a percent) 10.00% 14.00% 11.00%
Accounts Receivable | Customer Concentration Risk | UnitedHealthcare      
Concentration of Credit Risk      
Concentration risk (as a percent) 10.00% 9.00% 8.00%
Accounts Receivable | Customer Concentration Risk | State of Wisconsin      
Concentration of Credit Risk      
Concentration risk (as a percent) 0.00% 5.00% 9.00%
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Tax Positions (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Deferred tax asset valuation allowance $ 465,832 $ 419,356  
Increase (decrease) in valuation allowance 46,500 157,100  
Income tax benefit (expense) $ (2,403) $ 9,064 $ 246,881
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE - Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Revenue recognized $ 2,499,766 $ 2,084,279 $ 1,767,087
Screening      
Disaggregation of Revenue [Line Items]      
Revenue recognized 1,864,701 1,424,703 1,062,308
Screening | Medicare Parts B & C      
Disaggregation of Revenue [Line Items]      
Revenue recognized 701,400 545,458 438,646
Screening | Commercial      
Disaggregation of Revenue [Line Items]      
Revenue recognized 992,244 743,238 569,944
Screening | Other      
Disaggregation of Revenue [Line Items]      
Revenue recognized 171,057 136,007 53,718
Precision Oncology      
Disaggregation of Revenue [Line Items]      
Revenue recognized 629,110 601,488 561,676
Precision Oncology | Medicare Parts B & C      
Disaggregation of Revenue [Line Items]      
Revenue recognized 188,689 197,327 197,394
Precision Oncology | Commercial      
Disaggregation of Revenue [Line Items]      
Revenue recognized 181,318 177,518 180,177
Precision Oncology | Other      
Disaggregation of Revenue [Line Items]      
Revenue recognized 105,826 108,905 74,192
Precision Oncology | International      
Disaggregation of Revenue [Line Items]      
Revenue recognized 153,277 117,738 109,913
COVID-19 Testing      
Disaggregation of Revenue [Line Items]      
Revenue recognized $ 5,955 $ 58,088 $ 143,103
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Variable consideration      
Disaggregation of Revenue [Line Items]      
Revenue recognized from changes in transaction price $ 25.2 $ 20.3 $ 11.8
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Marketable Securities [Line Items]    
Total cash and cash equivalents $ 605,378 $ 242,493
Available-for-sale debt securities 243,703 448,740
Equity securities 3,841 5,149
Total marketable securities 172,266 389,564
Total cash, cash equivalents, and marketable securities 777,644 632,057
Cash equivalents    
Marketable Securities [Line Items]    
Total cash and cash equivalents 75,278 64,325
Available-for-sale debt securities 75,278 64,325
Marketable securities    
Marketable Securities [Line Items]    
Available-for-sale debt securities 168,425 384,415
Cash and money market    
Marketable Securities [Line Items]    
Total cash and cash equivalents $ 530,100 $ 178,168
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Available-for-sale securities    
Amortized Cost $ 243,649 $ 454,029
Gains in Accumulated Other Comprehensive Income (Loss) 406 22
Losses in Accumulated Other Comprehensive Income (Loss) (352) (5,311)
Estimated Fair Value 243,703 448,740
Cash equivalents    
Available-for-sale securities    
Amortized Cost 75,278 64,325
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 75,278 64,325
Marketable securities    
Available-for-sale securities    
Amortized Cost 168,371 389,704
Gains in Accumulated Other Comprehensive Income (Loss) 406 22
Losses in Accumulated Other Comprehensive Income (Loss) (352) (5,311)
Estimated Fair Value 168,425 384,415
U.S. government agency securities | Cash equivalents    
Available-for-sale securities    
Amortized Cost 3,035 1,304
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 3,035 1,304
U.S. government agency securities | Marketable securities    
Available-for-sale securities    
Amortized Cost 56,594 228,012
Gains in Accumulated Other Comprehensive Income (Loss) 166 0
Losses in Accumulated Other Comprehensive Income (Loss) (44) (2,789)
Estimated Fair Value 56,716 225,223
Commercial paper | Cash equivalents    
Available-for-sale securities    
Amortized Cost 72,243 63,021
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 72,243 63,021
Commercial paper | Marketable securities    
Available-for-sale securities    
Amortized Cost 20,984  
Gains in Accumulated Other Comprehensive Income (Loss) 0  
Losses in Accumulated Other Comprehensive Income (Loss) 0  
Estimated Fair Value 20,984  
Corporate bonds | Marketable securities    
Available-for-sale securities    
Amortized Cost 55,712 116,318
Gains in Accumulated Other Comprehensive Income (Loss) 175 20
Losses in Accumulated Other Comprehensive Income (Loss) (59) (1,667)
Estimated Fair Value 55,828 114,671
Asset backed securities | Marketable securities    
Available-for-sale securities    
Amortized Cost 35,081 45,374
Gains in Accumulated Other Comprehensive Income (Loss) 65 2
Losses in Accumulated Other Comprehensive Income (Loss) (249) (855)
Estimated Fair Value $ 34,897 $ 44,521
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Available-for-sale securities  
Due in one year or less, Cost $ 163,187
Due in one year or less, Fair Value 163,139
Due after one year through four years, Cost 80,462
Due after one year through four years, Fair Value 80,564
Cash equivalents  
Available-for-sale securities  
Due in one year or less, Cost 75,278
Due in one year or less, Fair Value 75,278
Due after one year through four years, Cost 0
Due after one year through four years, Fair Value 0
Cash equivalents | Commercial paper  
Available-for-sale securities  
Due in one year or less, Cost 72,243
Due in one year or less, Fair Value 72,243
Due after one year through four years, Cost 0
Due after one year through four years, Fair Value 0
Cash equivalents | U.S. government agency securities  
Available-for-sale securities  
Due in one year or less, Cost 3,035
Due in one year or less, Fair Value 3,035
Due after one year through four years, Cost 0
Due after one year through four years, Fair Value 0
Marketable securities  
Available-for-sale securities  
Due in one year or less, Cost 87,909
Due in one year or less, Fair Value 87,861
Due after one year through four years, Cost 80,462
Due after one year through four years, Fair Value 80,564
Marketable securities | Commercial paper  
Available-for-sale securities  
Due in one year or less, Cost 20,984
Due in one year or less, Fair Value 20,984
Due after one year through four years, Cost 0
Due after one year through four years, Fair Value 0
Marketable securities | U.S. government agency securities  
Available-for-sale securities  
Due in one year or less, Cost 33,407
Due in one year or less, Fair Value 33,403
Due after one year through four years, Cost 23,187
Due after one year through four years, Fair Value 23,313
Marketable securities | Corporate bonds  
Available-for-sale securities  
Due in one year or less, Cost 33,518
Due in one year or less, Fair Value 33,474
Due after one year through four years, Cost 22,194
Due after one year through four years, Fair Value 22,354
Marketable securities | Asset backed securities  
Available-for-sale securities  
Due in one year or less, Cost 0
Due in one year or less, Fair Value 0
Due after one year through four years, Cost 35,081
Due after one year through four years, Fair Value $ 34,897
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses And Fair Value of Available For Sale Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Marketable Securities [Line Items]    
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months $ 46,028 $ 100,497
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (81) (1,647)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater 17,380 277,004
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss (271) (3,664)
Total fair value of available-for-sale securities in a continuous unrealized loss position 63,408 377,501
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position (352) (5,311)
Marketable securities | Corporate bonds    
Marketable Securities [Line Items]    
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months 25,895 35,055
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (41) (575)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater 2,480 73,702
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss (18) (1,092)
Total fair value of available-for-sale securities in a continuous unrealized loss position 28,375 108,757
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position (59) (1,667)
Marketable securities | U.S. government agency securities    
Marketable Securities [Line Items]    
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months 15,756 37,458
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (35) (337)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater 3,965 187,766
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss (9) (2,452)
Total fair value of available-for-sale securities in a continuous unrealized loss position 19,721 225,224
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position (44) (2,789)
Marketable securities | Asset backed securities    
Marketable Securities [Line Items]    
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months 4,377 27,984
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (5) (735)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater 10,935 15,536
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss (244) (120)
Total fair value of available-for-sale securities in a continuous unrealized loss position 15,312 43,520
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position $ (249) $ (855)
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORY (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 58,593 $ 61,207
Semi-finished and finished goods 68,882 57,052
Inventory $ 127,475 $ 118,259
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, plant and equipment    
Property, plant and equipment, at cost $ 1,115,557 $ 992,347
Accumulated depreciation (417,203) (307,591)
Property, plant and equipment, net 698,354 684,756
Land    
Property, plant and equipment    
Property, plant and equipment, at cost 4,716 4,716
Leasehold and building improvements    
Property, plant and equipment    
Property, plant and equipment, at cost $ 214,562 200,588
Land improvements    
Property, plant and equipment    
Estimated Useful Life 15 years  
Property, plant and equipment, at cost $ 6,729 6,417
Buildings    
Property, plant and equipment    
Property, plant and equipment, at cost $ 290,777 288,941
Buildings | Minimum    
Property, plant and equipment    
Estimated Useful Life 30 years  
Buildings | Maximum    
Property, plant and equipment    
Estimated Useful Life 40 years  
Computer equipment and computer software    
Property, plant and equipment    
Estimated Useful Life 3 years  
Property, plant and equipment, at cost $ 168,131 142,896
Machinery and equipment    
Property, plant and equipment    
Property, plant and equipment, at cost $ 290,294 246,344
Machinery and equipment | Minimum    
Property, plant and equipment    
Estimated Useful Life 3 years  
Machinery and equipment | Maximum    
Property, plant and equipment    
Estimated Useful Life 10 years  
Furniture and fixtures    
Property, plant and equipment    
Property, plant and equipment, at cost $ 35,756 34,047
Furniture and fixtures | Minimum    
Property, plant and equipment    
Estimated Useful Life 3 years  
Furniture and fixtures | Maximum    
Property, plant and equipment    
Estimated Useful Life 10 years  
Assets under construction    
Property, plant and equipment    
Property, plant and equipment, at cost $ 104,592 $ 68,398
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, plant and equipment    
Property, plant and equipment, gross $ 1,115,557 $ 992,347
Assets under construction    
Property, plant and equipment    
Property, plant and equipment, gross 104,592 68,398
Assets under construction 104,600  
Buildings under construction    
Property, plant and equipment    
Assets under construction 6,600  
Leasehold improvements    
Property, plant and equipment    
Assets under construction 15,700  
Machinery and equipment    
Property, plant and equipment    
Property, plant and equipment, gross 290,294 $ 246,344
Assets under construction 53,200  
Software projects    
Property, plant and equipment    
Assets under construction $ 29,100  
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Cost $ 1,007,331 $ 981,016
Accumulated Amortization (366,935) (274,776)
Finite-lived intangible assets, net 640,396 706,240
In-process research and development 1,250,000 1,250,000
Finite-lived and indefinite-lived intangible assets, gross 2,257,331 2,231,016
Finite-lived and indefinite-lived intangible assets, net $ 1,890,396 $ 1,956,240
Trade name    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Life (Years) 11 years 7 months 6 days 12 years 6 months
Cost $ 104,000 $ 104,000
Accumulated Amortization (27,903) (20,653)
Finite-lived intangible assets, net $ 76,097 $ 83,347
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Life (Years) 7 years 8 years
Cost $ 4,000 $ 4,000
Accumulated Amortization (889) (444)
Finite-lived intangible assets, net $ 3,111 $ 3,556
Patents and licenses    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Life (Years) 4 years 6 months 4 years 2 months 12 days
Cost $ 11,542 $ 11,542
Accumulated Amortization (9,600) (8,152)
Finite-lived intangible assets, net $ 1,942 $ 3,390
Developed Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Life (Years) 7 years 3 months 18 days 7 years 9 months 18 days
Cost $ 887,789 $ 861,474
Accumulated Amortization (328,543) (245,527)
Finite-lived intangible assets, net $ 559,246 $ 615,947
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
2024 $ 92,908  
2025 91,860  
2026 90,800  
2027 90,800  
2028 90,800  
Thereafter 183,228  
Finite-lived intangible assets, net $ 640,396 $ 706,240
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Sep. 30, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Aug. 02, 2022
Jan. 05, 2021
Finite-Lived Intangible Assets [Line Items]                
Cost       $ 1,007,331,000 $ 981,016,000      
Finite-lived intangible assets, accumulated amortization       366,935,000 274,776,000      
Finite-lived Intangible assets, net       640,396,000 706,240,000      
Goodwill, impairment loss       0 0 $ 0    
Thrive                
Finite-Lived Intangible Assets [Line Items]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets               $ 1,250,000,000
Oncotype DX Genomic Prostate Score Test | Disposal Group, Disposed of by Sale, Not Discontinued Operations                
Finite-Lived Intangible Assets [Line Items]                
Cost             $ 59,000,000  
Finite-lived intangible assets, accumulated amortization             16,100,000  
Finite-lived Intangible assets, net             $ 42,900,000  
In-process research and development                
Finite-Lived Intangible Assets [Line Items]                
Impairment of long-lived assets     $ 20,200,000          
Service Agreements [Member]                
Finite-Lived Intangible Assets [Line Items]                
Impairment of long-lived assets $ 2,000,000              
Developed Technology Rights [Member]                
Finite-Lived Intangible Assets [Line Items]                
Cost       887,789,000 861,474,000      
Finite-lived intangible assets, accumulated amortization       328,543,000 245,527,000      
Finite-lived Intangible assets, net       $ 559,246,000 $ 615,947,000      
Impairment of long-lived assets   $ 6,600,000            
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Sep. 12, 2023
May 02, 2022
Carrying amount of goodwill        
Beginning of the period $ 2,346,040 $ 2,335,172    
Goodwill, Foreign Currency Translation Gain (Loss) 388 117    
Ending of the period 2,367,120 2,346,040    
Goodwill 2,367,120 2,346,040    
PreventionGenetics        
Carrying amount of goodwill        
Genomic Health acquisition adjustment   58    
OmicEra        
Carrying amount of goodwill        
Acquisition   $ (10,809)    
Goodwill       $ 10,809
Resolution Bioscience        
Carrying amount of goodwill        
Acquisition $ (20,692)      
Goodwill     $ 20,691  
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Fair value measurements      
Total cash and cash equivalents $ 605,378 $ 242,493  
Equity securities 3,841 5,149  
Non-marketable securities 7,650 10,065 $ 3,090
Purchases of non-marketable securities 6,957 10,000  
Changes in fair value 1,127 1,038  
Settlements (10,499)    
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 4,314 779  
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount (4,250) (10,821)  
Other Investment Not Readily Marketable, Fair Value 45,968 39,842  
Fair Value, Recurring      
Fair value measurements      
Equity securities 3,841 5,149  
Non-marketable securities 7,650 10,065  
Contingent consideration (288,657) (306,927)  
Total 500,934 335,492  
Fair Value, Recurring | MDxHealth      
Fair value measurements      
Equity securities   4,600  
Fair Value, Recurring | Corporate bonds      
Fair value measurements      
Estimated Fair Value 55,828 114,671  
Fair Value, Recurring | U.S. government agency securities      
Fair value measurements      
Estimated Fair Value 56,716 225,223  
Fair Value, Recurring | Asset backed securities      
Fair value measurements      
Estimated Fair Value 34,897 44,521  
Fair Value, Recurring | Commercial paper      
Fair value measurements      
Estimated Fair Value 20,984    
Fair Value, Recurring | Cash and money market      
Fair value measurements      
Total cash and cash equivalents 530,100 178,168  
Fair Value, Recurring | Commercial paper      
Fair value measurements      
Total cash and cash equivalents 72,243 63,021  
Fair Value, Recurring | U.S. government agency securities      
Fair value measurements      
Total cash and cash equivalents 3,035 1,304  
Fair Value, Recurring | Restricted cash (1)      
Fair value measurements      
Total cash and cash equivalents 4,297 297  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring      
Fair value measurements      
Equity securities 3,841 5,149  
Non-marketable securities 0 0  
Contingent consideration 0 0  
Total 538,238 183,614  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Corporate bonds      
Fair value measurements      
Estimated Fair Value 0 0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | U.S. government agency securities      
Fair value measurements      
Estimated Fair Value 0 0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Asset backed securities      
Fair value measurements      
Estimated Fair Value 0 0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Commercial paper      
Fair value measurements      
Estimated Fair Value 0    
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Cash and money market      
Fair value measurements      
Total cash and cash equivalents 530,100 178,168  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Commercial paper      
Fair value measurements      
Total cash and cash equivalents 0 0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | U.S. government agency securities      
Fair value measurements      
Total cash and cash equivalents 0 0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Restricted cash (1)      
Fair value measurements      
Total cash and cash equivalents 4,297 297  
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring      
Fair value measurements      
Equity securities 0 0  
Non-marketable securities 0 0  
Contingent consideration 0 0  
Total 243,703 448,740  
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Corporate bonds      
Fair value measurements      
Estimated Fair Value 55,828 114,671  
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | U.S. government agency securities      
Fair value measurements      
Estimated Fair Value 56,716 225,223  
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Asset backed securities      
Fair value measurements      
Estimated Fair Value 34,897 44,521  
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Commercial paper      
Fair value measurements      
Estimated Fair Value 20,984    
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Cash and money market      
Fair value measurements      
Total cash and cash equivalents 0 0  
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Commercial paper      
Fair value measurements      
Total cash and cash equivalents 72,243 63,021  
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | U.S. government agency securities      
Fair value measurements      
Total cash and cash equivalents 3,035 1,304  
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Restricted cash (1)      
Fair value measurements      
Total cash and cash equivalents 0 0  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring      
Fair value measurements      
Equity securities 0 0  
Non-marketable securities 7,650 10,065  
Contingent consideration (288,657) (306,927)  
Total (281,007) (296,862)  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Corporate bonds      
Fair value measurements      
Estimated Fair Value 0 0  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | U.S. government agency securities      
Fair value measurements      
Estimated Fair Value 0 0  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Asset backed securities      
Fair value measurements      
Estimated Fair Value 0 0  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Commercial paper      
Fair value measurements      
Estimated Fair Value 0    
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Cash and money market      
Fair value measurements      
Total cash and cash equivalents 0 0  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Commercial paper      
Fair value measurements      
Total cash and cash equivalents 0 0  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | U.S. government agency securities      
Fair value measurements      
Total cash and cash equivalents 0 0  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Restricted cash (1)      
Fair value measurements      
Total cash and cash equivalents $ 0 $ 0  
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS - Narrative (Details)
 12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Contingent consideration, liability $ 288,657,000 $ 306,927,000 $ 359,021,000
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 5,100,000    
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 15,100,000    
Gain on Sale of Investments 5,400,000   $ 30,500,000
Loss on Sale of Investments   10,000,000  
Venture Capital Investment Fund      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Investment owned, fair value 5,200,000 $ 3,900,000  
Committed capital 17,500,000    
Committed capital callable $ 12,100,000    
Weighted Average | Product Development and Other Milestone-based Payments | Measurement Input, Probability of Success      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Contingent consideration liability, measurement input 0.89 0.91  
Weighted Average | Product Development and Other Milestone-based Payments | Measurement Input, Present-value Factor      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Contingent consideration liability, measurement input 0.058 0.062  
Foreign Exchange Forward      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Derivative, notional amount $ 39,500,000 $ 22,300,000  
Derivative, fair value 0 0  
Thrive, Ashion and OmicEra | Fair Value      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Contingent consideration, liability $ 288,700,000 $ 306,800,000  
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Fair Value Disclosures [Abstract]      
Beginning balance $ 306,927 $ 359,021  
Changes in fair value 18,044 56,617  
Business acquisition contingent consideration liability 0 4,600 $ 350,348
Ending balance 288,657 306,927 $ 359,021
Payments $ 226 $ 77  
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE MEASUREMENTS - Non-marketable Securities (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Fair Value Disclosures [Abstract]  
Conversions $ (4,063)
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACCRUED LIABILITIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Compensation $ 247,619 $ 201,252
Professional fees 45,405 43,715
Other 17,274 22,329
Assets under construction 11,210 10,462
Research and trial related expenses 14,219 17,455
Licenses 5,956 4,003
Accrued liabilities $ 341,683 $ 299,216
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
LONG-TERM DEBT - Narrative (Details) - USD ($)
 1 Months Ended 12 Months Ended
Nov. 30, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jun. 29, 2022
Dec. 31, 2019
Long-term debt            
Financing Receivable, Amount Elected to Collateralize   $ 50,000,000        
Construction Loans            
Long-term debt            
Face amount           $ 25,600,000
Construction Loans | 1-month LIBOR            
Long-term debt            
Variable rate     2.25%      
Line of Credit | City Letter of Credit | Revolver            
Long-term debt            
Proceeds from lines of credit   1,500,000   $ 2,900,000    
Line of Credit | Revolving Credit Facility | Revolver            
Long-term debt            
Borrowing capacity $ 150,000,000          
Debt instrument, covenant, collateral minimum market value 150,000,000          
Debt instrument, covenant, maximum outstanding cash advances threshold $ 20,000,000          
Remaining borrowing capacity   145,600,000 $ 147,100,000      
Line of Credit | Revolving Credit Facility | Daily Bloomberg Short-Term Bank Yield Index Rate | Revolver            
Long-term debt            
Variable rate 0.60%          
Securitized Receivables            
Long-term debt            
Borrowing capacity         $ 150,000,000  
Long-term Debt, Excluding Current Maturities   50,000,000 $ 50,000,000      
Line of Credit Facility, Current Borrowing Capacity   $ 108,500,000        
Line of Credit Facility, Interest Rate at Period End   6.89%        
Securitized Receivables | Minimum            
Long-term debt            
Long-term Debt, Excluding Current Maturities         $ 50,000,000  
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Feb. 29, 2020
Mar. 31, 2019
Jun. 30, 2018
Jan. 31, 2018
Convertible Notes Payable2030            
Long-term debt            
Interest rate (as a percent) 2.00%          
Principal Amount $ 572,993          
Unamortized Debt Discount and Issuance Costs (4,349)          
Net Carrying Amount 568,644          
Convertible Notes Payable2030 | Significant Other Observable Inputs (Level 2) | Fair Value            
Long-term debt            
Amount $ 684,475          
2028 Convertible notes            
Long-term debt            
Interest rate (as a percent) 0.375% 0.375% 0.375%      
Principal Amount $ 949,042 $ 1,150,000        
Unamortized Debt Discount and Issuance Costs (10,499) (15,775)        
Net Carrying Amount 938,543 1,134,225        
2028 Convertible notes | Significant Other Observable Inputs (Level 2) | Fair Value            
Long-term debt            
Amount $ 887,354 $ 908,500        
2027 Convertible notes            
Long-term debt            
Interest rate (as a percent) 0.375% 0.375%   0.375%    
Principal Amount $ 563,822 $ 747,500        
Unamortized Debt Discount and Issuance Costs (5,429) (9,445)        
Net Carrying Amount 558,393 738,055        
2027 Convertible notes | Significant Other Observable Inputs (Level 2) | Fair Value            
Long-term debt            
Amount $ 549,839 $ 612,950        
2025 Convertible notes            
Long-term debt            
Interest rate (as a percent) 1.00% 1.00%     1.00% 1.00%
Principal Amount $ 249,172 $ 315,005        
Unamortized Debt Discount and Issuance Costs (476) (1,179)        
Net Carrying Amount 248,696 313,826        
2025 Convertible notes | Significant Other Observable Inputs (Level 2) | Fair Value            
Long-term debt            
Amount $ 293,300 $ 326,808        
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONVERTIBLE NOTES - Issuances and Settlements (Details) - USD ($)
shares in Millions
 1 Months Ended 12 Months Ended
Mar. 31, 2023
Feb. 29, 2020
Mar. 31, 2019
Jun. 30, 2018
Jan. 31, 2018
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Mar. 06, 2023
Mar. 01, 2023
Debt Instrument [Line Items]                    
Net proceeds from issuance           $ 137,976,000 $ 0 $ 0    
Loss on extinguishment of debt $ 17,700,000 $ 50,800,000       $ (10,324,000) $ 0 $ 0    
2025 Convertible notes                    
Debt Instrument [Line Items]                    
Stock issued in conversion of convertible notes (in shares)     2.2              
Value of stock after conversion of convertible notes     $ 182,400,000              
Repayments of convertible debt in cash and by issuance of shares     676,500,000              
Repayments of debt     493,400,000              
Accrued interest on notes     700,000              
Loss on extinguishment of debt 7,400,000   187,700,000              
2025 Convertible notes                    
Debt Instrument [Line Items]                    
Face amount       $ 218,500,000 $ 690,000,000          
Interest rate (as a percent)       1.00% 1.00% 1.00% 1.00%      
Net proceeds from issuance       $ 225,300,000 $ 671,100,000          
Repayments of convertible debt   150,100,000                
Accrued interest on notes   100,000                
Amount settled 65,800,000 100,000,000                
Debt Conversion, Converted Instrument, Potential Shares Issued           3.3        
2027 Convertible notes                    
Debt Instrument [Line Items]                    
Face amount     $ 747,500,000              
Interest rate (as a percent)     0.375%     0.375% 0.375%      
Net proceeds from issuance     $ 729,500,000              
Amount settled 183,700,000                  
Debt Conversion, Converted Instrument, Potential Shares Issued           5.0        
2027 Convertible notes | 2025 Convertible notes                    
Debt Instrument [Line Items]                    
Repayments of convertible debt     $ 494,100,000              
2028 Convertible notes                    
Debt Instrument [Line Items]                    
Face amount   $ 1,150,000,000                
Interest rate (as a percent)   0.375%       0.375% 0.375%      
Net proceeds from issuance   $ 1,130,000,000                
Amount settled 201,000,000                  
Debt Conversion, Converted Instrument, Potential Shares Issued           7.8        
Convertible Notes Payable2030                    
Debt Instrument [Line Items]                    
Face amount                   $ 500,000,000
Interest rate (as a percent)           2.00%        
Net proceeds from issuance 138,000,000                  
Proceeds from Debt, Net of Issuance Costs $ 133,000,000                  
Debt Conversion, Converted Instrument, Potential Shares Issued           7.1        
Convertible Notes Payable2030 | 2025 Convertible notes                    
Debt Instrument [Line Items]                    
Face amount                 $ 73,000,000  
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONVERTIBLE NOTES - Summary of Conversion Features (Details)
shares in Millions
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Debt Instrument [Line Items]  
Repurchase price, as percentage of principal amount, if company undergoes change of control 100
Shares issued, price per share (in usd per share) $ 73.98
2025 Convertible notes  
Debt Instrument [Line Items]  
Conversion rate, number of shares to be issued per $1,000 of principal amount 13.26
Conversion price per share of common stock (in usd per share) $ 75.43
Debt Conversion, Converted Instrument, Potential Shares Issued | shares 3.3
2027 Convertible notes  
Debt Instrument [Line Items]  
Conversion rate, number of shares to be issued per $1,000 of principal amount 8.96
Conversion price per share of common stock (in usd per share) $ 111.66
Debt Conversion, Converted Instrument, Potential Shares Issued | shares 5.0
2028 Convertible notes  
Debt Instrument [Line Items]  
Conversion rate, number of shares to be issued per $1,000 of principal amount 8.21
Conversion price per share of common stock (in usd per share) $ 121.84
Debt Conversion, Converted Instrument, Potential Shares Issued | shares 7.8
Convertible Notes Payable2030  
Debt Instrument [Line Items]  
Conversion rate, number of shares to be issued per $1,000 of principal amount 12.37
Conversion price per share of common stock (in usd per share) $ 80.83
Debt Conversion, Converted Instrument, Potential Shares Issued | shares 7.1
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONVERTIBLE NOTES - Ranking of Convertible Notes (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
2027 Convertible notes  
Debt Instrument [Line Items]  
Total transaction costs $ 14,285
2028 Convertible notes  
Debt Instrument [Line Items]  
Total transaction costs 24,453
Convertible Notes Payable2030  
Debt Instrument [Line Items]  
Total transaction costs 4,938
2025 Convertible notes  
Debt Instrument [Line Items]  
Total transaction costs $ 17,646
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONVERTIBLE NOTES - Schedule of Interest Expense (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 31, 2023
Feb. 29, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]          
Debt issuance costs amortization     $ 5,350 $ 5,727 $ 5,727
Debt discount amortization     106 147 147
Gain on settlement of convertible notes $ 17,700 $ 50,800 (10,324) 0 0
Coupon interest expense     18,072 10,266 10,266
Total interest expense on convertible notes     $ 13,204 $ 16,140 $ 16,140
2025 Convertible notes          
Debt Instrument [Line Items]          
Effective interest rate     1.17% 1.18% 1.18%
Convertible debt, remaining discount amortization period     1 year 14 days    
2027 Convertible notes          
Debt Instrument [Line Items]          
Effective interest rate     0.67% 0.68% 0.68%
Convertible debt, remaining discount amortization period     3 years 2 months 15 days    
2028 Convertible notes          
Debt Instrument [Line Items]          
Effective interest rate     0.63% 0.64% 0.64%
Convertible debt, remaining discount amortization period     4 years 2 months 1 day    
Convertible Notes Payable2030          
Debt Instrument [Line Items]          
Effective interest rate     2.09% 0.00% 0.00%
Convertible debt, remaining discount amortization period     6 years 2 months 1 day    
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Oct. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Research and development $ 425,882 $ 393,418 $ 385,646  
Licensing Agreements | Mayo        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Time period after the last licensed patent expires that the license agreement will remain in effect 5 years      
Licensing Agreements | Mayo | Sales Milestone Range Three        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Amount agreed to be paid upon reaching the specified amount of net sales       $ 3,000
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND COLLABORATION AGREEMENTS - Johns Hopkins University (Details)
$ in Millions
Jan. 05, 2021
USD ($)
Thrive | Licensing Agreements  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Payments contingent on milestones $ 45.0
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND COLLABORATION AGREEMENTS - The Broad Institute (Details) - The Broad Institute, LLC - Licensing Agreements
$ in Thousands
Jun. 30, 2023
USD ($)
Sales Milestone Range One  
Investments, All Other Investments [Abstract]  
Net sales of a licensed product $ 500,000
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Net sales of a licensed product 500,000
Product Development and Other Milestone-based Payments  
Investments, All Other Investments [Abstract]  
Collaborative Arrangements Development Milestone Amount 6,500
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Collaborative Arrangements Development Milestone Amount $ 6,500
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND COLLABORATION AGREEMENTS - Watchmaker Genomics (Details) - Watchmaker Genomics, Inc - Licensing Agreements
$ in Millions
Jul. 31, 2023
USD ($)
Investments, All Other Investments [Abstract]  
Collaboration Arrangement, Milestones To Be Received $ 82.0
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Collaboration Arrangement, Milestones To Be Received $ 82.0
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
PFIZER PROMOTION AGREEMENT (Details) - Manufactured Product, Other - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Nov. 30, 2021
Pfizer Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Contract termination fee     $ 35.9
Pfizer Inc      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Service fee based on incremental gross profits over specified baselines and royalties $ 7.5 $ 81.3  
Charges for promotion, sales and marketing $ 85.8 $ 121.0  
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Stock Issued by Acquisition (Details) - USD ($)
 1 Months Ended
Apr. 14, 2021
Jan. 11, 2021
Jan. 05, 2021
May 31, 2022
Dec. 31, 2021
Apr. 30, 2021
Jan. 31, 2021
May 01, 2022
PreventionGenetics                
Changes in Accumulated Other Comprehensive Income (Loss)                
Equity issued to acquire business (in shares)         1,070,410      
Fair value of stock issued in acquisition         $ 84,252,000      
Ashion Analytics                
Changes in Accumulated Other Comprehensive Income (Loss)                
Equity issued to acquire business (in shares) 125,444         125,444    
Fair value of stock issued in acquisition           $ 16,224,000    
Thrive                
Changes in Accumulated Other Comprehensive Income (Loss)                
Equity issued to acquire business (in shares)     9,323,266       9,323,266  
Fair value of stock issued in acquisition     $ 1,190,000,000       $ 1,191,420,000  
TARDIS Technology                
Changes in Accumulated Other Comprehensive Income (Loss)                
Equity issued to acquire business (in shares)   191,335            
Fair value of stock issued in acquisition   $ 27,263,000            
OmicEra                
Changes in Accumulated Other Comprehensive Income (Loss)                
Equity issued to acquire business (in shares)       265,186        
Fair value of stock issued in acquisition               $ 14,792,000
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Schedule of OCI (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance $ 3,043,162 $ 3,387,636 $ 2,235,553
Other comprehensive income (loss) before reclassifications 2,737 (4,019) (1,625)
Amounts reclassified from accumulated other comprehensive income (loss) 3,927 226 (514)
Net current period change in accumulated other comprehensive income (loss) 6,664 (3,793) (2,139)
Income tax benefit related to items of other comprehensive loss     170
Ending balance 3,145,305 3,043,162 3,387,636
AOCI      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (5,236) (1,443) 526
Ending balance 1,428 (5,236) (1,443)
Cumulative Translation Adjustment      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 53 23 0
Other comprehensive income (loss) before reclassifications 1,321 30 23
Amounts reclassified from accumulated other comprehensive income (loss) 0 0 0
Net current period change in accumulated other comprehensive income (loss) 1,321 30 23
Income tax benefit related to items of other comprehensive loss     0
Ending balance 1,374 53 23
Unrealized Gain (Loss) on Securities (1)      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (5,289) (1,466) 526
Other comprehensive income (loss) before reclassifications 1,416 (4,049) (1,648)
Amounts reclassified from accumulated other comprehensive income (loss) 3,927 226 (514)
Net current period change in accumulated other comprehensive income (loss) 5,343 (3,823) (2,162)
Income tax benefit related to items of other comprehensive loss     170
Ending balance $ 54 $ (5,289) $ (1,466)
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY - Schedule of amounts reclassified from AOCI (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Changes in Accumulated Other Comprehensive Income (Loss)      
General and administrative $ (893,204) $ (737,304) $ (801,262)
Total reclassifications 3,927 226 (514)
Reclassification Out Of Accumulated Other Comprehensive Income | Unrealized Gain (Loss) on Securities (1)      
Changes in Accumulated Other Comprehensive Income (Loss)      
Investment income, net $ 3,927 $ 226 $ (514)
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Stock-Based Compensation Plans (Details)
 12 Months Ended
Dec. 31, 2023
shares
Jun. 08, 2023
shares
Jun. 09, 2022
shares
Jul. 28, 2016
shares
Jul. 24, 2014
shares
Dec. 31, 2023
USD ($)
item
shares
Dec. 31, 2022
shares
Stock-based compensation              
Period by which all options to purchase common stock will accelerate upon an acquisition of the company           1 year  
Shares outstanding (in shares) 1,286,173         1,286,173 1,517,876
Shares available for future grant (in shares) 17,880,354         17,880,354  
Omnibus Long Term Incentive Plan 2019              
Stock-based compensation              
Further grants or awards after termination of plan (in shares)           0  
Shares available for future grant (in shares) 16,046,161         16,046,161  
Increase in number of shares reserved for issuance (in shares)   4,340,000 14,000,000        
Omnibus Long Term Incentive Plan 2019 | Minimum              
Stock-based compensation              
Vesting period           3 years  
Omnibus Long Term Incentive Plan 2019 | Maximum              
Stock-based compensation              
Vesting period           4 years  
Omnibus Long Term Incentive Plan 2019 | Stock Options              
Stock-based compensation              
Expiration period from the date of grant           10 years  
Shares outstanding (in shares) 404,833         404,833  
Omnibus Long Term Incentive Plan 2019 | Restricted Stock              
Stock-based compensation              
Shares outstanding (in shares) 7,867,224         7,867,224  
Omnibus Long Term Incentive Plan 2010              
Stock-based compensation              
Further grants or awards after termination of plan (in shares)           0  
Shares available for future grant (in shares) 0         0  
Omnibus Long Term Incentive Plan 2010 | Minimum              
Stock-based compensation              
Vesting period           3 years  
Omnibus Long Term Incentive Plan 2010 | Maximum              
Stock-based compensation              
Vesting period           4 years  
Omnibus Long Term Incentive Plan 2010 | Stock Options              
Stock-based compensation              
Expiration period from the date of grant           10 years  
Shares outstanding (in shares) 881,340         881,340  
Omnibus Long Term Incentive Plan 2010 | Restricted Stock              
Stock-based compensation              
Shares outstanding (in shares) 3,340         3,340  
Employee Stock Purchase Plan 2010              
Stock-based compensation              
Shares available for future grant (in shares) 1,834,193         1,834,193  
Increase in number of shares reserved for issuance (in shares)     3,000,000 2,000,000 500,000    
Option exercise price, expressed as a percentage of fair market value           85.00%  
Maximum value of shares that an employee is permitted to purchase | $           $ 25,000  
Number of shares (in shares) 3,965,807         924,448  
Employee Stock Purchase Plan 2010 | Minimum              
Stock-based compensation              
Number of hours per week of customary employment required to participate in the plan | item           20  
Number of months of customary employment required to participate in the plan           5 months  
Percentage of employee's compensation to be deducted from the employee's pay           1.00%  
Employee Stock Purchase Plan 2010 | Maximum              
Stock-based compensation              
Percentage of employee's compensation to be deducted from the employee's pay           15.00%  
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Stock-based compensation expense      
Stock-based compensation expense $ 231,312 $ 206,823 $ 339,226
Cost of sales      
Stock-based compensation expense      
Stock-based compensation expense 20,761 19,218 16,835
Research and development      
Stock-based compensation expense      
Stock-based compensation expense 41,242 33,825 49,723
General and administrative      
Stock-based compensation expense      
Stock-based compensation expense 103,757 91,212 216,952
Sales and marketing      
Stock-based compensation expense      
Stock-based compensation expense $ 65,552 $ 62,568 $ 55,716
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Stock-Based Compensation Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jan. 05, 2021
Mar. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Stock-based compensation          
Unrecognized compensation cost     $ 354,800    
Weighted average period for recognition of unrecognized compensation cost     2 years 5 months 1 day    
Stock-based compensation     $ 231,312 $ 206,823 $ 253,063
Thrive          
Stock-based compensation          
Stock-based compensation         19,000
Non-cash stock-based compensation expense $ 65,000        
Thrive | General and administrative          
Stock-based compensation          
Non-cash stock-based compensation expense   $ 86,200     $ 86,200
Stock Options | Thrive          
Stock-based compensation          
Accelerated vesting (in shares)         139,096
Restricted Shares and RSUs | Thrive          
Stock-based compensation          
Accelerated vesting (in shares)         58,171
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Schedule of Fair Value of Options and ESPP (Details) - Employee Stock
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Valuation assumptions      
Risk-free interest rates, minimum 4.68% 1.49% 0.04%
Risk-free interest rates, maximum 4.71% 4.71% 0.16%
Expected volatility, minimum (as a percent) 63.13% 50.94% 43.00%
Expected volatility, maximum (as a percent) 67.30% 63.13% 68.51%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00% 0.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 1 year 3 months    
Minimum      
Valuation assumptions      
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term   6 months 6 months
Maximum      
Valuation assumptions      
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term   2 years 2 years
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Stock Option, Restricted Stock, and Performance Shares (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Shares      
Outstanding at the beginning of the period (in shares) 1,517,876    
Exercised (in shares) (194,629)    
Forfeited (in shares) (37,074)    
Outstanding at the end of the period (in shares) 1,286,173 1,517,876  
Vested and expected to vest (in shares) 1,286,173    
Exercisable at the end of the period (in shares) 1,228,594    
Weighted Average Exercise Price      
Outstanding at the beginning of the period (in dollars per share) $ 44.82    
Exercised (in dollars per share) 16.44    
Forfeited (in dollars per share) 95.02    
Outstanding at the end of the period (in dollars per share) 47.67 $ 44.82  
Vested and expected to vest (in dollars per share) 47.67    
Exercisable at the end of the period (in dollars per share) $ 45.32    
Weighted Average Remaining Contractual Term      
Outstanding at the end of the period 3 years 9 months 18 days 4 years 8 months 12 days  
Vested and expected to vest at end of period 3 years 9 months 18 days    
Exercisable at the end of the period 3 years 8 months 12 days    
Aggregate Intrinsic Value      
Outstanding at the end of the period $ 42,878,000    
Vested and expected to vest at the end of the period 42,878,000    
Exercisable at the end of the period 42,878,000    
Additional disclosures      
Total intrinsic value of options exercised 11,700,000 $ 36,400,000 $ 155,800,000
Proceeds from stock option exercises $ 3,200,000 $ 6,500,000 $ 14,400,000
Restricted Shares and RSUs      
Restricted Shares and Performance Shares      
Outstanding at the beginning of the period (in shares) 5,254,709    
Granted (in shares) 3,510,373    
Released (in shares) (1,797,915)    
Forfeited (in shares) (694,404)    
Outstanding at the end of the period (in shares) 6,272,763 5,254,709  
Weighted Average Grant Date Fair Value      
Outstanding at the beginning of the period (in dollars per share) $ 85.87    
Granted (in dollars per share) 62.36 $ 68.18 $ 129.16
Released (in dollars per share) 88.28    
Forfeited (in dollars per share) 73.54    
Outstanding at the end of the period (in dollars per share) $ 73.39 $ 85.87  
Fair value of equity instruments other than options $ 158,200,000 $ 117,600,000 $ 219,400,000
Performance Shares      
Restricted Shares and Performance Shares      
Outstanding at the beginning of the period (in shares) 967,846    
Granted (in shares) 782,966    
Released (in shares) (12,284)    
Forfeited (in shares) (140,727)    
Outstanding at the end of the period (in shares) 1,597,801 967,846  
Weighted Average Grant Date Fair Value      
Outstanding at the beginning of the period (in dollars per share) $ 102.58    
Granted (in dollars per share) 80.50 $ 89.43 $ 138.09
Released (in dollars per share) 78.32    
Forfeited (in dollars per share) 93.73    
Outstanding at the end of the period (in dollars per share) $ 92.73 $ 102.58  
Fair value of equity instruments other than options $ 1,000,000 $ 27,200,000 $ 0
Number of outstanding performance share units (in shares) 772,906    
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Issuance of Stock Under ESPP (Details) - Employee Stock Purchase Plan 2010 - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Stock-based compensation        
Stock issued under the Company's stock purchase plan (in shares) 3,965,807 924,448    
Employee Stock        
Stock-based compensation        
Stock issued under the Company's stock purchase plan (in shares)   924,448 668,605 331,769
Cash received under the 2010 Purchase Plan   $ 28,344 $ 25,491 $ 23,070
Weighted average fair value per share of options granted during the period (in dollars per share)   $ 16.32 $ 17.52 $ 34.93
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Schedule of Share Issued During Period (Details) - Employee Stock Purchase Plan 2010 - $ / shares
 12 Months Ended
Dec. 31, 2023
Nov. 01, 2023
Apr. 30, 2023
Dec. 31, 2023
Stock-based compensation        
Stock issued under the Company's stock purchase plan (in shares) 3,965,807     924,448
Offering Period End Date One        
Stock-based compensation        
Stock issued under the Company's stock purchase plan (in shares)     544,453  
Weighted average price per share (in dollars per share)     $ 30.02  
Offering Period End Date Two        
Stock-based compensation        
Stock issued under the Company's stock purchase plan (in shares)   379,995    
Weighted average price per share (in dollars per share)   $ 31.57    
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Shares Reserved for Issuance (Details)
Dec. 31, 2023
shares
Shares reserved for issuance  
Shares reserved for issuance (in shares) 17,880,354
Employee Stock Purchase Plan 2019  
Shares reserved for issuance  
Shares reserved for issuance (in shares) 16,046,161
Employee Stock Purchase Plan 2010  
Shares reserved for issuance  
Shares reserved for issuance (in shares) 1,834,193
XML 106 R92.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES - Lease Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Finance lease cost      
Amortization of right-of-use assets $ 3,845 $ 4,612 $ 5,731
Interest on lease liabilities 800 808 1,018
Operating lease cost 36,576 36,291 31,730
Short-term lease cost 750 476 628
Variable lease cost 8,449 7,985 5,212
Total lease Cost $ 50,420 $ 50,172 $ 44,319
XML 107 R93.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:      
Operating cash flows from operating leases $ 39,301 $ 33,448 $ 27,461
Operating cash flows from finance leases 783 699 938
Finance cash flows from finance leases 3,569 4,345 5,290
Non-cash investing and financing activities:      
Right-of-use assets obtained in exchange for new operating lease liabilities 4,986 24,572 74,369
Right-of-use assets obtained in exchange for new finance lease liabilities $ 5,443 $ 11,276 $ 5,460
Weighted-average remaining lease term - operating leases (in years) 6 years 10 months 13 days 7 years 5 months 4 days 8 years 3 months 29 days
Weighted-average remaining lease term - finance leases (in years) 2 years 9 months 18 days 3 years 3 months 7 days 2 years 11 months 12 days
Weighted-average discount rate - operating leases 6.59% 6.37% 6.11%
Weighted-average discount rate - finance leases 7.43% 6.60% 5.36%
ASU 2016-02      
Non-cash investing and financing activities:      
Right-of-use assets obtained in exchange for new operating lease liabilities     $ 39,600
XML 108 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Recognition of ROU assets $ 143,708 $ 167,003
Recognition of lease liabilities 190,449 210,800
Operating lease liability, current 29,379 28,366
Operating lease liability, noncurrent 161,070 182,399
Finance lease, right-of-use asset $ 11,300 $ 10,200
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Other long-term assets, net Other long-term assets, net
Finance lease obligations $ 11,941 $ 10,600
Finance lease liability, current $ 4,400 $ 3,200
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Other current liabilities Other current liabilities
Finance lease liability, noncurrent $ 7,500 $ 7,400
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other long-term liabilities Other long-term liabilities
XML 109 R95.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Operating Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]    
2024 $ 39,476  
2025 36,660  
2026 34,851  
2027 34,226  
2028 27,901  
Thereafter 66,634  
Total minimum lease payments 239,748  
Imputed interest (49,299)  
Total $ 190,449 $ 210,800
XML 110 R96.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Finance Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finance Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]    
2024 $ 5,044  
2025 4,552  
2026 2,797  
2027 827  
2028 0  
Thereafter 0  
Total minimum lease payments 13,220  
Imputed interest (1,279)  
Total $ 11,941 $ 10,600
XML 111 R97.htm IDEA: XBRL DOCUMENT v3.24.0.1
Legal Matters - COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Oct. 31, 2023
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2021
DOS Rule Investigation        
Loss Contingencies [Line Items]        
Litigation Settlement, Expense     $ 22,400 $ 10,100
Payments for Legal Settlements   $ 32,500    
Qui Tam Suit        
Loss Contingencies [Line Items]        
Payments for Legal Settlements $ 13,800      
XML 112 R98.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE BENEFIT PLAN (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Retirement Benefits [Abstract]      
Matching contribution by employer 100.00% 100.00% 100.00%
Percentage of participant's salary matched by employer 6.00% 6.00% 6.00%
Compensation expense in connection with the 401 (k) Plan $ 40.6 $ 36.5 $ 30.0
XML 113 R99.htm IDEA: XBRL DOCUMENT v3.24.0.1
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDIT (Details) - Amended Wisconsin Economic Development Tax Credit Agreement
$ in Millions
 1 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
position
Dec. 31, 2023
USD ($)
Agreements    
Refundable tax credits earned $ 18.5 $ 11.0
Capital investment expenditures over specified period, requirement to earn the refundable tax credits $ 350.0  
Full-time positions that must be created over a specified time period to earn the refundable tax credits | position 1,300  
Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed 5 years  
Credit earning rate 10.00%  
Maximum credits to earn $ 7.0  
Refundable tax credit receivable   9.3
Prepaid expenses and other current assets    
Agreements    
Refundable tax credit receivable   3.8
Other long-term assets    
Agreements    
Refundable tax credit receivable   $ 5.5
XML 114 R100.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 12, 2023
USD ($)
Aug. 02, 2022
USD ($)
$ / shares
shares
May 02, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
test
$ / shares
Jun. 23, 2021
USD ($)
Apr. 14, 2021
USD ($)
$ / shares
shares
Jan. 11, 2021
USD ($)
shares
Jan. 05, 2021
USD ($)
$ / shares
shares
May 31, 2022
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Apr. 30, 2021
USD ($)
shares
Jan. 31, 2021
USD ($)
shares
Mar. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
$ / shares
Aug. 23, 2023
USD ($)
May 01, 2022
USD ($)
May 03, 2021
Acquisition                                        
Shares issued, price per share (in usd per share) | $ / shares                           $ 73.98            
Contingent consideration, liability       $ 359,021,000           $ 359,021,000       $ 288,657,000 $ 306,927,000 $ 359,021,000 $ 359,021,000      
Stock-based compensation expense                           231,312,000 206,823,000   339,226,000      
Remeasurement of contingent consideration liabilities                           (18,044,000) (56,617,000)   6,360,000      
Stock-based compensation                           231,312,000 206,823,000   253,063,000      
Stock issued during period, value, acquisitions                           1,675,000 14,792,000   1,355,170,000      
Consideration transferred, net of cash acquired                           52,413,000 14,686,000   499,730,000      
Noncash or part noncash divestiture, amount of consideration received, fair value | $ / shares   $ 6.70                                    
Finite-lived Intangible assets, net                           640,396,000 $ 706,240,000          
Period of lab testing services   24 months                                    
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]                             Other operating income (loss)          
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Contract with Customer, Receivable, after Allowance for Credit Loss                           31,600,000            
Contract with Customer, Asset, after Allowance for Credit Loss                           41,700,000 $ 0          
TARDIS Technology                                        
Acquisition                                        
Asset acquisition, consideration transferred             $ 52,300,000                          
Payments to acquire productive assets             $ 25,000,000                          
Payments to acquire productive assets (in shares) | shares             191,336                          
Stock issued to acquire productive assets, value             $ 27,300,000                          
Payments contingent on milestones             $ 45,000,000                          
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Oncotype DX Genomic Prostate Score Test                                        
Acquisition                                        
Total consideration   $ 29,631,000                                    
Noncash or part noncash divestiture, amount of consideration received, shares | shares   691,171                                    
Disposal group, contingent consideration arrangements, range of outcomes, value, high   $ 70,000,000                               $ 82,500,000    
Finite-lived Intangible assets, net   $ 42,900,000                                    
Disposal group, not discontinued operation, gain (loss) on disposal                             13,200,000          
Disposal Group, Contingent Consideration Arrangements, Gain (Loss)                           73,300,000            
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Disposal Group, Contingent Consideration Arrangements, Gain (Loss)                           73,300,000            
Thrive                                        
Acquisition                                        
Investment owned, fair value               $ 12,500,000                        
Business combination, equity interest in acquiree, remeasurement gain                         $ 7,600,000              
Remeasurement of contingent consideration liabilities                                 7,200,000      
Customer relationships                                        
Acquisition                                        
Finite-lived Intangible assets, net                           $ 3,111,000 $ 3,556,000          
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Weighted Average Remaining Life (Years)                           7 years 8 years          
Trade name                                        
Acquisition                                        
Finite-lived Intangible assets, net                           $ 76,097,000 $ 83,347,000          
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Weighted Average Remaining Life (Years)                           11 years 7 months 6 days 12 years 6 months          
General and administrative                                        
Acquisition                                        
Stock-based compensation expense                           $ 103,757,000 $ 91,212,000   $ 216,952,000      
Investment Income | Thrive                                        
Acquisition                                        
Business combination, equity interest in acquiree, remeasurement gain                         30,500,000              
OmicEra                                        
Acquisition                                        
Total purchase price     $ 19,408,000                                  
Equity issued to acquire business (in shares) | shares                 265,186                      
Shares issued, price per share (in usd per share) | $ / shares     $ 55.78                                  
Contingent payment obligations     $ 6,000,000                                  
Contingent consideration, liability     4,600,000                                  
Developed technology     $ 10,000,000                                  
Weighted-average remaining useful life of finite-lived intangible asset (in years)     16 years                                  
Fair value of stock issued in acquisition                                     $ 14,792,000  
Common stock issued     $ 14,792,000                                  
OmicEra Diagnostics Acquisition                                        
Acquisition                                        
Equity issued to acquire business (in shares) | shares                 265,186                      
PreventionGenetics                                        
Acquisition                                        
Total purchase price       $ 185,381,000                                
Equity issued to acquire business (in shares) | shares                   1,070,410                    
Shares issued, price per share (in usd per share) | $ / shares       $ 78.71           $ 78.71           $ 78.71 $ 78.71      
Number of tests provided | test       5,000                                
Cash       $ 101,129,000                                
Business combination, cash withheld                             $ 15,300,000          
Fair value of stock issued in acquisition       84,252,000           $ 84,252,000           $ 84,252,000 $ 84,252,000      
Common stock issued       84,252,000                                
PreventionGenetics | Payment 1                                        
Acquisition                                        
Cash       $ 85,800,000                                
Ashion Analytics                                        
Acquisition                                        
Total purchase price           $ 109,999,000                            
Equity issued to acquire business (in shares) | shares           125,444         125,444                  
Shares issued, price per share (in usd per share) | $ / shares           $ 129.33                            
Cash           $ 74,775,000                            
Fair value of stock issued in acquisition                     $ 16,224,000                  
Common stock issued           16,224,000                            
Ashion Analytics | Commercial Launch Milestone                                        
Acquisition                                        
Contingent consideration, liability           19,000,000                            
Additional cash consideration to be paid           20,000,000                            
Ashion Analytics | MRD Product Revenue Milestone                                        
Acquisition                                        
Contingent consideration, liability           30,000,000                            
Revenue milestone           $ 500,000,000                            
Thrive                                        
Acquisition                                        
Total purchase price               $ 2,187,054,000                        
Equity issued to acquire business (in shares) | shares               9,323,266       9,323,266                
Shares issued, price per share (in usd per share) | $ / shares               $ 127.79                        
Contingent consideration, liability               $ 450,000,000                        
Cash               584,996,000                        
Fair value of stock issued in acquisition               1,190,000,000       $ 1,191,420,000                
Common stock issued               1,175,431,000                        
Payments to acquire businesses and accelerated vesting of awards               590,200,000                        
Stock-based compensation expense               166,000,000                        
Compensation consideration assumed               197,000,000                        
Compensation consideration assumed and allocated to consideration transferred               52,200,000                        
Compensation consideration assumed and deemed compensatory               144,800,000                        
Non-cash stock-based compensation expense               65,000,000                        
Share based compensation, costs not yet recognized               $ 79,800,000                        
Share conversion ratio               0.06216                        
Business combination, pro forma loss                               $ 255,000,000        
Acquisition related costs                         10,300,000       10,300,000      
Stock-based compensation                                 19,000,000      
Additional benefit charges                                 3,900,000      
Thrive | Employees with Qualifying Termination Events                                        
Acquisition                                        
Non-cash stock-based compensation expense                         13,500,000              
Thrive | Fair Value                                        
Acquisition                                        
Contingent consideration, liability               $ 352,000,000                        
Thrive | FDA Approval                                        
Acquisition                                        
Contingent consideration, liability               150,000,000                        
Thrive | CSM Coverage                                        
Acquisition                                        
Contingent consideration, liability               300,000,000                        
Thrive | Allocated to Consideration Transferred | Fair Value                                        
Acquisition                                        
Contingent consideration, liability               331,300,000                        
Thrive | Allocated to Previous Ownership Interest | Fair Value                                        
Acquisition                                        
Contingent consideration, liability               6,400,000                        
Thrive | Allocated to Compensation | Fair Value                                        
Acquisition                                        
Contingent consideration, liability               14,300,000                        
Thrive | Compensation Expense                                        
Acquisition                                        
Contingent payment obligations               18,200,000                        
Thrive | General and administrative                                        
Acquisition                                        
Incremental share based compensation expense               16,000,000                        
Stock-based compensation expense               $ 5,200,000                        
Non-cash stock-based compensation expense                         $ 86,200,000       $ 86,200,000      
PFS Genomics                                        
Acquisition                                        
Total purchase price         $ 33,600,000                              
Percent of equity acquired         10.00%                             90.00%
Equity interest in acquiree after subsequent acquisition         100.00%                              
Resolution Bioscience                                        
Acquisition                                        
Total purchase price $ 54,202,000                                      
Developed technology 26,000,000                                      
Cash 52,527,000                                      
Common stock issued $ 1,675,000                                      
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method 4.6 million                                      
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory $ 2,900,000                                      
Acquired Finite-Lived Intangible Assets [Line Items]                                        
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method 4.6 million                                      
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory $ 2,900,000                                      
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method 4.6 million                                      
XML 115 R101.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Details of Consideration Transferred (Details) - USD ($)
Sep. 12, 2023
May 02, 2022
Dec. 31, 2021
Apr. 14, 2021
Jan. 05, 2021
OmicEra          
Acquisition          
Common stock issued   $ 14,792,000      
Contingent consideration   4,600,000      
Cash paid related to working capital adjustment   16,000      
Total purchase price   $ 19,408,000      
PreventionGenetics          
Acquisition          
Common stock issued     $ 84,252,000    
Cash     101,129,000    
Total purchase price     $ 185,381,000    
Ashion Analytics          
Acquisition          
Common stock issued       $ 16,224,000  
Contingent consideration       19,000,000  
Cash       74,775,000  
Total purchase price       $ 109,999,000  
Thrive          
Acquisition          
Common stock issued         $ 1,175,431,000
Contingent consideration         331,348,000
Cash         584,996,000
Total purchase price         2,187,054,000
Fair value of replaced equity awards         52,245,000
Previously held equity investment fair value         $ 43,034,000
Resolution Bioscience          
Acquisition          
Common stock issued $ 1,675,000        
Cash 52,527,000        
Total purchase price $ 54,202,000        
XML 116 R102.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Purchase Price Allocated to the Underlying Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Sep. 12, 2023
May 02, 2022
Dec. 31, 2021
Jun. 23, 2021
Apr. 14, 2021
Jan. 05, 2021
Dec. 31, 2023
Dec. 31, 2022
Acquisition                
Goodwill     $ 2,335,172       $ 2,367,120 $ 2,346,040
Customer relationships                
Acquisition                
Weighted Average Remaining Life (Years)             7 years 8 years
Trade name                
Acquisition                
Weighted Average Remaining Life (Years)             11 years 7 months 6 days 12 years 6 months
Developed Technology Rights [Member]                
Acquisition                
Weighted Average Remaining Life (Years)             7 years 3 months 18 days 7 years 9 months 18 days
OmicEra                
Acquisition                
Net operating assets   $ 2,586            
Developed technology   10,000            
Total identifiable assets acquired   12,586            
Net identifiable assets acquired   8,599            
Goodwill   10,809            
Net assets acquired   19,408            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities   (3,987)            
Total purchase price   $ 19,408            
PreventionGenetics                
Acquisition                
Total purchase price     $ 185,381          
Ashion Analytics                
Acquisition                
Total purchase price         $ 109,999      
Thrive                
Acquisition                
Total purchase price           $ 2,187,054    
PFS Genomics                
Acquisition                
Total purchase price       $ 33,600        
Resolution Bioscience                
Acquisition                
Net operating assets $ 14,663              
Developed technology 26,000              
Total identifiable assets acquired 40,663              
Net identifiable assets acquired 33,511              
Goodwill 20,691              
Net assets acquired 54,202              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities (7,152)              
Total purchase price 54,202              
Resolution Bioscience | Developed Technology Rights [Member]                
Acquisition                
Developed technology $ 26,000              
Weighted Average Remaining Life (Years) 17 years              
XML 117 R103.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details) - Options - Thrive
Jan. 05, 2021
$ / shares
Acquisition  
Risk-free interest rates, minimum 0.11%
Risk-free interest rates, maximum 0.12%
Expected volatility, minimum (as a percent) 65.54%
Expected volatility, maximum (as a percent) 71.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00%
Minimum  
Acquisition  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 1 year 3 months 3 days
Weighted average fair value per share of options granted during the period (in dollars per share) $ 109.74
Maximum  
Acquisition  
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 1 year 6 months 25 days
Weighted average fair value per share of options granted during the period (in dollars per share) $ 124.89
XML 118 R104.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Combination, Pro-Forma Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Acquisition        
Total revenues $ 2,507,111 $ 2,097,680    
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]        
Total revenues 2,507,111 2,097,680    
Business Acquisition, Pro Forma Net Income (Loss) $ (237,854) $ (675,091)    
Thrive        
Acquisition        
Total revenues     $ 2,084,279 $ 1,767,087
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]        
Total revenues     2,084,279 1,767,087
Net loss before tax     $ (761,337) $ (1,014,352)
XML 119 R105.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Divestiture (Details) - USD ($)
$ in Thousands
 12 Months Ended
Aug. 02, 2022
Dec. 31, 2023
Dec. 31, 2022
Noncash or Part Noncash Divestitures [Line Items]      
Contract with Customer, Asset, after Allowance for Credit Loss   $ 41,700 $ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Oncotype DX Genomic Prostate Score Test      
Noncash or Part Noncash Divestitures [Line Items]      
Cash $ 25,000    
MDxHealth American Depository Shares 4,631    
Contingent consideration 0    
Total consideration $ 29,631    
Disposal Group, Contingent Consideration Arrangements, Additional Consideration   $ 3,100  
XML 120 R106.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]      
Revenue $ 2,499,766 $ 2,084,279 $ 1,767,087
United States      
Segment Reporting Information [Line Items]      
Revenue 2,346,489 1,966,541 1,657,174
Outside of United States      
Segment Reporting Information [Line Items]      
Revenue $ 153,277 $ 117,738 $ 109,913
XML 121 R107.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating Loss Carryforwards [Line Items]      
Income tax benefit (expense) $ (2,403,000) $ 9,064,000 $ 246,881,000
Deferred tax asset valuation allowance 465,832,000 419,356,000  
Deferred tax liability 17,289,000 19,713,000  
Increase (decrease) in valuation allowance $ 46,500,000 $ 157,100,000  
Effective tax rate (1.20%) 1.30% 29.30%
Unrecognized tax benefit that would impact effective tax rate $ 36,400,000 $ 28,300,000 $ 21,800,000
Accrued interest or penalties 0 0 0
Recognized interest or penalties 0 0 0
Deferred tax asset      
Operating Loss Carryforwards [Line Items]      
Valuation allowances established 44,759,000 159,919,000 206,574,000
Acquisition and purchase accounting (475,000) $ 21,000 239,233,000
Deferred tax asset | Thrive      
Operating Loss Carryforwards [Line Items]      
Acquisition and purchase accounting 239,200,000    
Deferred tax asset | Genomic Health Inc      
Operating Loss Carryforwards [Line Items]      
Acquisition and purchase accounting     $ 239,200,000
Federal      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforwards 402,900,000    
Operating loss carryforwards with no expiration date 278,500,000    
Operating loss carryforwards with expiration date 124,400,000    
Federal | Research      
Operating Loss Carryforwards [Line Items]      
Tax credit carryforwards 70,900,000    
State      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforwards 66,000,000    
State | Research      
Operating Loss Carryforwards [Line Items]      
Tax credit carryforwards 33,000,000    
State | Research | California      
Operating Loss Carryforwards [Line Items]      
Tax credit carryforwards 19,700,000    
Foreign      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforwards $ 10,400,000    
XML 122 R108.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Income (Loss) Before Income Taxes, Domestic and Foreign (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Domestic $ (204,128) $ (617,240) $ (801,536)
Foreign 2,382 (15,330) (40,970)
Net loss before tax $ (201,746) $ (632,570) $ (842,506)
XML 123 R109.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Expense (benefit) for income taxes      
Total income tax expense (benefit) $ 2,403 $ (9,064) $ (246,881)
Deferred tax assets:      
Operating loss carryforwards 477,420 553,320  
Tax credit carryforwards 104,580 87,579  
Compensation related differences 85,007 67,976  
Lease liabilities 47,118 51,560  
Capitalized research and development 191,468 108,117  
Other temporary differences 10,275 19,353  
Tax assets before valuation allowance 915,868 887,905  
Less - Valuation allowance (465,832) (419,356)  
Total deferred tax assets 450,036 468,549  
Deferred tax liabilities      
Amortization (415,064) (435,991)  
Property, plant and equipment (9,465) (4,653)  
Lease assets (35,786) (40,674)  
Other temporary differences (7,010) (6,944)  
Total deferred tax liabilities (467,325) (488,262)  
Net deferred tax liabilities $ (17,289) $ (19,713)  
Differences between the effective income tax rate and the statutory tax rate      
U.S. Federal statutory rate 21.00% 21.00% 21.00%
State taxes 3.90% 3.90% 3.60%
Federal and state tax rate changes 1.10% (0.20%) (0.30%)
Foreign tax rate differential 0.00% (0.10%) (0.60%)
Acquired IPR&D asset expense 0.00% 0.00% (0.80%)
Research and development tax credits 7.60% 2.30% 0.70%
Stock-based compensation expense (4.40%) (2.00%) 1.10%
Non-deductible executive compensation (3.50%) (0.40%) (0.20%)
Transaction costs 0.00% 0.00% (0.10%)
Other adjustments (0.70%) 0.00% 0.00%
Other adjustments (2.50%) 1.20% 1.20%
Valuation allowance (23.70%) (24.40%) 3.70%
Effective tax rate (1.20%) 1.30% 29.30%
Reconciliation of the amounts of unrecognized tax benefits      
Beginning of the period $ 28,270 $ 21,780 $ 16,629
Increase due to current year tax positions 7,447 5,861 5,363
Increase due to prior year tax positions 1,108 629 0
Decrease due to prior year tax positions (426) 0 (212)
Settlements 0 0 0
Ending of the period 36,399 28,270 21,780
Federal      
Expense (benefit) for income taxes      
Current expense (benefit): 0 0 0
Deferred tax expense (benefit): 2,395 (3,292) (222,693)
State      
Expense (benefit) for income taxes      
Current expense (benefit): 2,266 2,170 1,388
Deferred tax expense (benefit): (1,829) (8,926) (30,528)
Foreign      
Expense (benefit) for income taxes      
Current expense (benefit): 2,561 1,131 4,898
Deferred tax expense (benefit): $ (2,990) $ (147) $ 54
XML 124 R110.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Deferred Tax Asset, Valuation Allowance RollForward (Details) - Deferred tax asset - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
Beginning balance $ (419,356) $ (262,238) $ (293,397)
Valuation allowances established (44,759) (159,919) (206,574)
Changes to existing valuation allowances (1,242) 2,780 (1,500)
Acquisition and purchase accounting (475) 21 239,233
Ending balance $ (465,832) $ (419,356) $ (262,238)
EXCEL 126 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 127 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 128 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 130 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 486 597 1 false 147 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.exactsciences.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.exactsciences.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets Sheet http://www.exactsciences.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Operations Sheet http://www.exactsciences.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders??? Equity Sheet http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders??? Equity Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Stockholders Equity (Parenthetical) Sheet http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical Consolidated Statements of Stockholders Equity (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - Consolidated Statements of Cash Flows Sheet http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 9 false false R10.htm 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 0000011 - Disclosure - REVENUE Sheet http://www.exactsciences.com/role/REVENUE REVENUE Notes 11 false false R12.htm 0000012 - Disclosure - MARKETABLE SECURITIES Sheet http://www.exactsciences.com/role/MARKETABLESECURITIES MARKETABLE SECURITIES Notes 12 false false R13.htm 0000013 - Disclosure - INVENTORY Sheet http://www.exactsciences.com/role/INVENTORY INVENTORY Notes 13 false false R14.htm 0000014 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENT PROPERTY, PLANT AND EQUIPMENT Notes 14 false false R15.htm 0000015 - Disclosure - INTANGIBLE ASSETS AND GOODWILL Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILL INTANGIBLE ASSETS AND GOODWILL Notes 15 false false R16.htm 0000016 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 16 false false R17.htm 0000017 - Disclosure - ACCRUED LIABILITIES Sheet http://www.exactsciences.com/role/ACCRUEDLIABILITIES ACCRUED LIABILITIES Notes 17 false false R18.htm 0000018 - Disclosure - LONG-TERM DEBT Sheet http://www.exactsciences.com/role/LONGTERMDEBT LONG-TERM DEBT Notes 18 false false R19.htm 0000019 - Disclosure - CONVERTIBLE NOTES Notes http://www.exactsciences.com/role/CONVERTIBLENOTES CONVERTIBLE NOTES Notes 19 false false R20.htm 0000020 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS Sheet http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTS LICENSE AND COLLABORATION AGREEMENTS Notes 20 false false R21.htm 0000021 - Disclosure - PFIZER PROMOTION AGREEMENT Sheet http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENT PFIZER PROMOTION AGREEMENT Notes 21 false false R22.htm 0000022 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 22 false false R23.htm 0000023 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 23 false false R24.htm 0000024 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 24 false false R25.htm 0000025 - Disclosure - EMPLOYEE BENEFIT PLAN Sheet http://www.exactsciences.com/role/EMPLOYEEBENEFITPLAN EMPLOYEE BENEFIT PLAN Notes 25 false false R26.htm 0000026 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS Sheet http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITS WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS Notes 26 false false R27.htm 0000027 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Sheet http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONS BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Notes 27 false false R28.htm 0000028 - Disclosure - SEGMENT INFORMATION Sheet http://www.exactsciences.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 28 false false R29.htm 0000029 - Disclosure - INCOME TAXES Sheet http://www.exactsciences.com/role/INCOMETAXES INCOME TAXES Notes 29 false false R30.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 30 false false R31.htm 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 31 false false R32.htm 9954473 - Disclosure - REVENUE (Tables) Sheet http://www.exactsciences.com/role/REVENUETables REVENUE (Tables) Tables http://www.exactsciences.com/role/REVENUE 32 false false R33.htm 9954474 - Disclosure - MARKETABLE SECURITIES (Tables) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESTables MARKETABLE SECURITIES (Tables) Tables http://www.exactsciences.com/role/MARKETABLESECURITIES 33 false false R34.htm 9954475 - Disclosure - INVENTORY (Tables) Sheet http://www.exactsciences.com/role/INVENTORYTables INVENTORY (Tables) Tables http://www.exactsciences.com/role/INVENTORY 34 false false R35.htm 9954476 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables) Sheet http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTTables PROPERTY, PLANT, AND EQUIPMENT (Tables) Tables 35 false false R36.htm 9954477 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables INTANGIBLE ASSETS AND GOODWILL (Tables) Tables http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILL 36 false false R37.htm 9954478 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTS 37 false false R38.htm 9954479 - Disclosure - ACCRUED LIABILITIES (Tables) Sheet http://www.exactsciences.com/role/ACCRUEDLIABILITIESTables ACCRUED LIABILITIES (Tables) Tables http://www.exactsciences.com/role/ACCRUEDLIABILITIES 38 false false R39.htm 9954480 - Disclosure - CONVERTIBLE NOTES (Tables) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESTables CONVERTIBLE NOTES (Tables) Tables http://www.exactsciences.com/role/CONVERTIBLENOTES 39 false false R40.htm 9954481 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.exactsciences.com/role/STOCKHOLDERSEQUITY 40 false false R41.htm 9954482 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.exactsciences.com/role/STOCKBASEDCOMPENSATION 41 false false R42.htm 9954483 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIES 42 false false R43.htm 9954484 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) Sheet http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) Tables http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONS 43 false false R44.htm 9954485 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.exactsciences.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://www.exactsciences.com/role/SEGMENTINFORMATION 44 false false R45.htm 9954486 - Disclosure - INCOME TAXES (Tables) Sheet http://www.exactsciences.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.exactsciences.com/role/INCOMETAXES 45 false false R46.htm 9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) Details 46 false false R47.htm 9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Research and Development Costs (Details) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESResearchandDevelopmentCostsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Research and Development Costs (Details) Details 47 false false R48.htm 9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) Details 48 false false R49.htm 9954491 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) Details http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 49 false false R50.htm 9954492 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details) Details 50 false false R51.htm 9954493 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Tax Positions (Details) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTaxPositionsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Tax Positions (Details) Details 51 false false R52.htm 9954495 - Disclosure - REVENUE - Schedule of Disaggregation of Revenue (Details) Sheet http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails REVENUE - Schedule of Disaggregation of Revenue (Details) Details 52 false false R53.htm 9954496 - Disclosure - REVENUE - Narrative (Details) Sheet http://www.exactsciences.com/role/REVENUENarrativeDetails REVENUE - Narrative (Details) Details 53 false false R54.htm 9954497 - Disclosure - MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) Details 54 false false R55.htm 9954498 - Disclosure - MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) Details 55 false false R56.htm 9954499 - Disclosure - MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details) Details 56 false false R57.htm 9954500 - Disclosure - MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses And Fair Value of Available For Sale Securities (Details) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses And Fair Value of Available For Sale Securities (Details) Details 57 false false R58.htm 9954501 - Disclosure - INVENTORY (Details) Sheet http://www.exactsciences.com/role/INVENTORYDetails INVENTORY (Details) Details http://www.exactsciences.com/role/INVENTORYTables 58 false false R59.htm 9954502 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) Sheet http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) Details 59 false false R60.htm 9954503 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) Sheet http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) Details 60 false false R61.htm 9954504 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) Details 61 false false R62.htm 9954505 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) Details 62 false false R63.htm 9954506 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) Details 63 false false R64.htm 9954507 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) Details 64 false false R65.htm 9954508 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) Details 65 false false R66.htm 9954509 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails FAIR VALUE MEASUREMENTS - Narrative (Details) Details 66 false false R67.htm 9954510 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) Details 67 false false R68.htm 9954511 - Disclosure - FAIR VALUE MEASUREMENTS - Non-marketable Securities (Details) Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNonmarketableSecuritiesDetails FAIR VALUE MEASUREMENTS - Non-marketable Securities (Details) Details 68 false false R69.htm 9954512 - Disclosure - ACCRUED LIABILITIES (Details) Sheet http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails ACCRUED LIABILITIES (Details) Details http://www.exactsciences.com/role/ACCRUEDLIABILITIESTables 69 false false R70.htm 9954513 - Disclosure - LONG-TERM DEBT - Narrative (Details) Sheet http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails LONG-TERM DEBT - Narrative (Details) Details 70 false false R71.htm 9954514 - Disclosure - CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) Details 71 false false R72.htm 9954515 - Disclosure - CONVERTIBLE NOTES - Issuances and Settlements (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails CONVERTIBLE NOTES - Issuances and Settlements (Details) Details 72 false false R73.htm 9954516 - Disclosure - CONVERTIBLE NOTES - Summary of Conversion Features (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails CONVERTIBLE NOTES - Summary of Conversion Features (Details) Details 73 false false R74.htm 9954517 - Disclosure - CONVERTIBLE NOTES - Ranking of Convertible Notes (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails CONVERTIBLE NOTES - Ranking of Convertible Notes (Details) Details 74 false false R75.htm 9954518 - Disclosure - CONVERTIBLE NOTES - Schedule of Interest Expense (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails CONVERTIBLE NOTES - Schedule of Interest Expense (Details) Details 75 false false R76.htm 9954519 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) Sheet http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) Details http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTS 76 false false R77.htm 9954520 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Johns Hopkins University (Details) Sheet http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails LICENSE AND COLLABORATION AGREEMENTS - Johns Hopkins University (Details) Details 77 false false R78.htm 9954521 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - The Broad Institute (Details) Sheet http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails LICENSE AND COLLABORATION AGREEMENTS - The Broad Institute (Details) Details 78 false false R79.htm 9954522 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Watchmaker Genomics (Details) Sheet http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails LICENSE AND COLLABORATION AGREEMENTS - Watchmaker Genomics (Details) Details 79 false false R80.htm 9954523 - Disclosure - PFIZER PROMOTION AGREEMENT (Details) Sheet http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails PFIZER PROMOTION AGREEMENT (Details) Details http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENT 80 false false R81.htm 9954524 - Disclosure - STOCKHOLDERS' EQUITY - Stock Issued by Acquisition (Details) Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails STOCKHOLDERS' EQUITY - Stock Issued by Acquisition (Details) Details 81 false false R82.htm 9954526 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of OCI (Details) Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails STOCKHOLDERS' EQUITY - Schedule of OCI (Details) Details 82 false false R83.htm 9954527 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of amounts reclassified from AOCI (Details) Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails STOCKHOLDERS' EQUITY - Schedule of amounts reclassified from AOCI (Details) Details 83 false false R84.htm 9954528 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Plans (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails STOCK-BASED COMPENSATION - Stock-Based Compensation Plans (Details) Details 84 false false R85.htm 9954529 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) Details 85 false false R86.htm 9954530 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Additional Information (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails STOCK-BASED COMPENSATION - Stock-Based Compensation Additional Information (Details) Details 86 false false R87.htm 9954531 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Fair Value of Options and ESPP (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails STOCK-BASED COMPENSATION - Schedule of Fair Value of Options and ESPP (Details) Details 87 false false R88.htm 9954532 - Disclosure - STOCK-BASED COMPENSATION - Stock Option, Restricted Stock, and Performance Shares (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails STOCK-BASED COMPENSATION - Stock Option, Restricted Stock, and Performance Shares (Details) Details 88 false false R89.htm 9954533 - Disclosure - STOCK-BASED COMPENSATION - Issuance of Stock Under ESPP (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails STOCK-BASED COMPENSATION - Issuance of Stock Under ESPP (Details) Details 89 false false R90.htm 9954534 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Share Issued During Period (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails STOCK-BASED COMPENSATION - Schedule of Share Issued During Period (Details) Details 90 false false R91.htm 9954535 - Disclosure - STOCK-BASED COMPENSATION - Shares Reserved for Issuance (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails STOCK-BASED COMPENSATION - Shares Reserved for Issuance (Details) Details 91 false false R92.htm 9954536 - Disclosure - COMMITMENTS AND CONTINGENCIES - Lease Expense (Details) Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails COMMITMENTS AND CONTINGENCIES - Lease Expense (Details) Details 92 false false R93.htm 9954537 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) Details 93 false false R94.htm 9954538 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details) Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails COMMITMENTS AND CONTINGENCIES - Additional Information (Details) Details 94 false false R95.htm 9954539 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Operating Lease Liabilities (Details) Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Operating Lease Liabilities (Details) Details 95 false false R96.htm 9954540 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Finance Lease Liabilities (Details) Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Finance Lease Liabilities (Details) Details 96 false false R97.htm 9954541 - Disclosure - Legal Matters - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails Legal Matters - COMMITMENTS AND CONTINGENCIES (Details) Details 97 false false R98.htm 9954542 - Disclosure - EMPLOYEE BENEFIT PLAN (Details) Sheet http://www.exactsciences.com/role/EMPLOYEEBENEFITPLANDetails EMPLOYEE BENEFIT PLAN (Details) Details http://www.exactsciences.com/role/EMPLOYEEBENEFITPLAN 98 false false R99.htm 9954543 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDIT (Details) Sheet http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails WISCONSIN ECONOMIC DEVELOPMENT TAX CREDIT (Details) Details http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITS 99 false false R100.htm 9954544 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details) Sheet http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details) Details 100 false false R101.htm 9954545 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Details of Consideration Transferred (Details) Sheet http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Details of Consideration Transferred (Details) Details 101 false false R102.htm 9954546 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Purchase Price Allocated to the Underlying Assets Acquired and Liabilities Assumed (Details) Sheet http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Purchase Price Allocated to the Underlying Assets Acquired and Liabilities Assumed (Details) Details 102 false false R103.htm 9954547 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details) Sheet http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details) Details 103 false false R104.htm 9954548 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Combination, Pro-Forma Information (Details) Sheet http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Combination, Pro-Forma Information (Details) Details 104 false false R105.htm 9954549 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Divestiture (Details) Sheet http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Divestiture (Details) Details 105 false false R106.htm 9954550 - Disclosure - SEGMENT INFORMATION (Details) Sheet http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails SEGMENT INFORMATION (Details) Details http://www.exactsciences.com/role/SEGMENTINFORMATIONTables 106 false false R107.htm 9954551 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails INCOME TAXES - Narrative (Details) Details 107 false false R108.htm 9954552 - Disclosure - INCOME TAXES - Income (Loss) Before Income Taxes, Domestic and Foreign (Details) Sheet http://www.exactsciences.com/role/INCOMETAXESIncomeLossBeforeIncomeTaxesDomesticandForeignDetails INCOME TAXES - Income (Loss) Before Income Taxes, Domestic and Foreign (Details) Details 108 false false R109.htm 9954553 - Disclosure - INCOME TAXES - Additional Information (Details) Sheet http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails INCOME TAXES - Additional Information (Details) Details 109 false false R110.htm 9954554 - Disclosure - INCOME TAXES - Deferred Tax Asset, Valuation Allowance RollForward (Details) Sheet http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails INCOME TAXES - Deferred Tax Asset, Valuation Allowance RollForward (Details) Details 110 false false All Reports Book All Reports exas-20231231.htm exas-20231231.xsd exas-20231231_cal.xml exas-20231231_def.xml exas-20231231_lab.xml exas-20231231_pre.xml exas-20231231_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 133 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "exas-20231231.htm": { "nsprefix": "exas", "nsuri": "http://www.exactsciences.com/20231231", "dts": { "inline": { "local": [ "exas-20231231.htm" ] }, "schema": { "local": [ "exas-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "exas-20231231_cal.xml" ] }, "definitionLink": { "local": [ "exas-20231231_def.xml" ] }, "labelLink": { "local": [ "exas-20231231_lab.xml" ] }, "presentationLink": { "local": [ "exas-20231231_pre.xml" ] } }, "keyStandard": 499, "keyCustom": 98, "axisStandard": 43, "axisCustom": 5, "memberStandard": 72, "memberCustom": 64, "hidden": { "total": 13, "http://fasb.org/us-gaap/2023": 9, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 486, "entityCount": 1, "segmentCount": 147, "elementCount": 958, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1600, "http://xbrl.sec.gov/dei/2023": 38 }, "report": { "R1": { "role": "http://www.exactsciences.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.exactsciences.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.exactsciences.com/role/ConsolidatedBalanceSheets", "longName": "0000003 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R4": { "role": "http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations", "longName": "0000005 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R6": { "role": "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss", "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss", "shortName": "Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R7": { "role": "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "longName": "0000007 - Statement - Consolidated Statements of Stockholders\u2019 Equity", "shortName": "Consolidated Statements of Stockholders\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical", "longName": "0000008 - Statement - Consolidated Statements of Stockholders Equity (Parenthetical)", "shortName": "Consolidated Statements of Stockholders Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows", "longName": "0000009 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.exactsciences.com/role/REVENUE", "longName": "0000011 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.exactsciences.com/role/MARKETABLESECURITIES", "longName": "0000012 - Disclosure - MARKETABLE SECURITIES", "shortName": "MARKETABLE SECURITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.exactsciences.com/role/INVENTORY", "longName": "0000013 - Disclosure - INVENTORY", "shortName": "INVENTORY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENT", "longName": "0000014 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILL", "longName": "0000015 - Disclosure - INTANGIBLE ASSETS AND GOODWILL", "shortName": "INTANGIBLE ASSETS AND GOODWILL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTS", "longName": "0000016 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.exactsciences.com/role/ACCRUEDLIABILITIES", "longName": "0000017 - Disclosure - ACCRUED LIABILITIES", "shortName": "ACCRUED LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.exactsciences.com/role/LONGTERMDEBT", "longName": "0000018 - Disclosure - LONG-TERM DEBT", "shortName": "LONG-TERM DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.exactsciences.com/role/CONVERTIBLENOTES", "longName": "0000019 - Disclosure - CONVERTIBLE NOTES", "shortName": "CONVERTIBLE NOTES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "exas:ConvertibleNotesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "exas:ConvertibleNotesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTS", "longName": "0000020 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS", "shortName": "LICENSE AND COLLABORATION AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "exas:LicensingAgreementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "exas:LicensingAgreementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENT", "longName": "0000021 - Disclosure - PFIZER PROMOTION AGREEMENT", "shortName": "PFIZER PROMOTION AGREEMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITY", "longName": "0000022 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATION", "longName": "0000023 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000024 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.exactsciences.com/role/EMPLOYEEBENEFITPLAN", "longName": "0000025 - Disclosure - EMPLOYEE BENEFIT PLAN", "shortName": "EMPLOYEE BENEFIT PLAN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITS", "longName": "0000026 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS", "shortName": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "exas:WISCONSINECONOMICDEVELOPMENTTAXCREDITSTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "exas:WISCONSINECONOMICDEVELOPMENTTAXCREDITSTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONS", "longName": "0000027 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "exas:BusinessCombinationDivestitureAndAssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "exas:BusinessCombinationDivestitureAndAssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.exactsciences.com/role/SEGMENTINFORMATION", "longName": "0000028 - Disclosure - SEGMENT INFORMATION", "shortName": "SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.exactsciences.com/role/INCOMETAXES", "longName": "0000029 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.exactsciences.com/role/REVENUETables", "longName": "9954473 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESTables", "longName": "9954474 - Disclosure - MARKETABLE SECURITIES (Tables)", "shortName": "MARKETABLE SECURITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.exactsciences.com/role/INVENTORYTables", "longName": "9954475 - Disclosure - INVENTORY (Tables)", "shortName": "INVENTORY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTTables", "longName": "9954476 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables)", "shortName": "PROPERTY, PLANT, AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables", "longName": "9954477 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)", "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9954478 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.exactsciences.com/role/ACCRUEDLIABILITIESTables", "longName": "9954479 - Disclosure - ACCRUED LIABILITIES (Tables)", "shortName": "ACCRUED LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESTables", "longName": "9954480 - Disclosure - CONVERTIBLE NOTES (Tables)", "shortName": "CONVERTIBLE NOTES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYTables", "longName": "9954481 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R41": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954482 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESTables", "longName": "9954483 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables", "longName": "9954484 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R44": { "role": "http://www.exactsciences.com/role/SEGMENTINFORMATIONTables", "longName": "9954485 - Disclosure - SEGMENT INFORMATION (Tables)", "shortName": "SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.exactsciences.com/role/INCOMETAXESTables", "longName": "9954486 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails", "longName": "9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESResearchandDevelopmentCostsDetails", "longName": "9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Research and Development Costs (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Research and Development Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails", "longName": "9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdvertisingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:AdvertisingCostsPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdvertisingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:AdvertisingCostsPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails", "longName": "9954491 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails", "longName": "9954492 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTaxPositionsDetails", "longName": "9954493 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Tax Positions (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Tax Positions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role": "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails", "longName": "9954495 - Disclosure - REVENUE - Schedule of Disaggregation of Revenue (Details)", "shortName": "REVENUE - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.exactsciences.com/role/REVENUENarrativeDetails", "longName": "9954496 - Disclosure - REVENUE - Narrative (Details)", "shortName": "REVENUE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-103", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-103", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "longName": "9954497 - Disclosure - MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details)", "shortName": "MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:MarketableSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R55": { "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "longName": "9954498 - Disclosure - MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details)", "shortName": "MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails", "longName": "9954499 - Disclosure - MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details)", "shortName": "MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails", "longName": "9954500 - Disclosure - MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses And Fair Value of Available For Sale Securities (Details)", "shortName": "MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses And Fair Value of Available For Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.exactsciences.com/role/INVENTORYDetails", "longName": "9954501 - Disclosure - INVENTORY (Details)", "shortName": "INVENTORY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "longName": "9954502 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R60": { "role": "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "longName": "9954503 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "us-gaap:ConstructionInProgressGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R61": { "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails", "longName": "9954504 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details)", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R62": { "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails", "longName": "9954505 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details)", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "longName": "9954506 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R64": { "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails", "longName": "9954507 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details)", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R65": { "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "longName": "9954508 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:SecurityOwnedNotReadilyMarketableFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R66": { "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "longName": "9954509 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R67": { "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails", "longName": "9954510 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "exas:BusinessCombinationContingentConsiderationGainLossChangeInFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R68": { "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNonmarketableSecuritiesDetails", "longName": "9954511 - Disclosure - FAIR VALUE MEASUREMENTS - Non-marketable Securities (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Non-marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-6", "name": "exas:Conversions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "exas:Conversions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails", "longName": "9954512 - Disclosure - ACCRUED LIABILITIES (Details)", "shortName": "ACCRUED LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails", "longName": "9954513 - Disclosure - LONG-TERM DEBT - Narrative (Details)", "shortName": "LONG-TERM DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-4", "name": "exas:FinancingReceivableAmountElectedToCollateralize", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "exas:FinancingReceivableAmountElectedToCollateralize", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "longName": "9954514 - Disclosure - CONVERTIBLE NOTES - Schedule of Convertible Notes (Details)", "shortName": "CONVERTIBLE NOTES - Schedule of Convertible Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-256", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-256", "name": "exas:ConvertibleNotesPayableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R72": { "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "longName": "9954515 - Disclosure - CONVERTIBLE NOTES - Issuances and Settlements (Details)", "shortName": "CONVERTIBLE NOTES - Issuances and Settlements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-277", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R73": { "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails", "longName": "9954516 - Disclosure - CONVERTIBLE NOTES - Summary of Conversion Features (Details)", "shortName": "CONVERTIBLE NOTES - Summary of Conversion Features (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "exas:DebtInstrumentRepurchasePriceDueToChangeInControlAsPercentageOfPrincipalAmount", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "exas:DebtInstrumentRepurchasePriceDueToChangeInControlAsPercentageOfPrincipalAmount", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails", "longName": "9954517 - Disclosure - CONVERTIBLE NOTES - Ranking of Convertible Notes (Details)", "shortName": "CONVERTIBLE NOTES - Ranking of Convertible Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-291", "name": "exas:DebtInstrumentConvertibleTransactionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-291", "name": "exas:DebtInstrumentConvertibleTransactionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails", "longName": "9954518 - Disclosure - CONVERTIBLE NOTES - Schedule of Interest Expense (Details)", "shortName": "CONVERTIBLE NOTES - Schedule of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "exas:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "exas:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "longName": "9954519 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details)", "shortName": "LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-303", "name": "exas:TimePeriodAfterLastLicensedPatentExpiresThatLicenseAgreementRemainsInEffect", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R77": { "role": "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "longName": "9954520 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Johns Hopkins University (Details)", "shortName": "LICENSE AND COLLABORATION AGREEMENTS - Johns Hopkins University (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-304", "name": "exas:PaymentsContingentOnMilestonesPayable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-304", "name": "exas:PaymentsContingentOnMilestonesPayable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails", "longName": "9954521 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - The Broad Institute (Details)", "shortName": "LICENSE AND COLLABORATION AGREEMENTS - The Broad Institute (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-308", "name": "exas:CollaborativeArrangementsSalesMilestoneAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-7", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": null }, "R79": { "role": "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails", "longName": "9954522 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Watchmaker Genomics (Details)", "shortName": "LICENSE AND COLLABORATION AGREEMENTS - Watchmaker Genomics (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-309", "name": "exas:CollaborationArrangementMilestonesToBeReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": null }, "R80": { "role": "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "longName": "9954523 - Disclosure - PFIZER PROMOTION AGREEMENT (Details)", "shortName": "PFIZER PROMOTION AGREEMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-310", "name": "exas:ContractTerminationFee", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-310", "name": "exas:ContractTerminationFee", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails", "longName": "9954524 - Disclosure - STOCKHOLDERS' EQUITY - Stock Issued by Acquisition (Details)", "shortName": "STOCKHOLDERS' EQUITY - Stock Issued by Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-315", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-321", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R82": { "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails", "longName": "9954526 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of OCI (Details)", "shortName": "STOCKHOLDERS' EQUITY - Schedule of OCI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R83": { "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails", "longName": "9954527 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of amounts reclassified from AOCI (Details)", "shortName": "STOCKHOLDERS' EQUITY - Schedule of amounts reclassified from AOCI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R84": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "longName": "9954528 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Plans (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "exas:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodByWhichOptionsWillAccelerateUponAcquisitionOfEntity", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "exas:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodByWhichOptionsWillAccelerateUponAcquisitionOfEntity", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails", "longName": "9954529 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-364", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R86": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "longName": "9954530 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Additional Information (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "longName": "9954531 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Fair Value of Options and ESPP (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Fair Value of Options and ESPP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-395", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "exas:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-395", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "exas:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails", "longName": "9954532 - Disclosure - STOCK-BASED COMPENSATION - Stock Option, Restricted Stock, and Performance Shares (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock Option, Restricted Stock, and Performance Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R89": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "longName": "9954533 - Disclosure - STOCK-BASED COMPENSATION - Issuance of Stock Under ESPP (Details)", "shortName": "STOCK-BASED COMPENSATION - Issuance of Stock Under ESPP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-363", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-390", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R90": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails", "longName": "9954534 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Share Issued During Period (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Share Issued During Period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-363", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-393", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "exas:ScheduleOfCommonStockIssuedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R91": { "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails", "longName": "9954535 - Disclosure - STOCK-BASED COMPENSATION - Shares Reserved for Issuance (Details)", "shortName": "STOCK-BASED COMPENSATION - Shares Reserved for Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "exas:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-402", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "exas:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R92": { "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails", "longName": "9954536 - Disclosure - COMMITMENTS AND CONTINGENCIES - Lease Expense (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails", "longName": "9954537 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "longName": "9954538 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R95": { "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails", "longName": "9954539 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Operating Lease Liabilities (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails", "longName": "9954540 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Finance Lease Liabilities (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Finance Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails", "longName": "9954541 - Disclosure - Legal Matters - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "Legal Matters - COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-405", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-405", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.exactsciences.com/role/EMPLOYEEBENEFITPLANDetails", "longName": "9954542 - Disclosure - EMPLOYEE BENEFIT PLAN (Details)", "shortName": "EMPLOYEE BENEFIT PLAN (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails", "longName": "9954543 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDIT (Details)", "shortName": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDIT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-408", "name": "exas:RefundableTaxCreditEarnedToDate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-408", "name": "exas:RefundableTaxCreditEarnedToDate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "longName": "9954544 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-452", "name": "exas:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "1", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R101": { "role": "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "longName": "9954545 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Details of Consideration Transferred (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Details of Consideration Transferred (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-417", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-417", "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R102": { "role": "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954546 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Purchase Price Allocated to the Underlying Assets Acquired and Liabilities Assumed (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Purchase Price Allocated to the Underlying Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-419", "name": "exas:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetOperatingAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R103": { "role": "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "longName": "9954547 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-437", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-437", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails", "longName": "9954548 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Combination, Pro-Forma Information (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Combination, Pro-Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R105": { "role": "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails", "longName": "9954549 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Divestiture (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Divestiture (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "exas:DisposalGroupIncludingDiscontinuedOperationsConsiderationCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNoncashOrPartNoncashDivestituresTextBlock", "us-gaap:ScheduleOfNoncashOrPartNoncashDivestituresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R106": { "role": "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails", "longName": "9954550 - Disclosure - SEGMENT INFORMATION (Details)", "shortName": "SEGMENT INFORMATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-457", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R107": { "role": "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "longName": "9954551 - Disclosure - INCOME TAXES - Narrative (Details)", "shortName": "INCOME TAXES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R108": { "role": "http://www.exactsciences.com/role/INCOMETAXESIncomeLossBeforeIncomeTaxesDomesticandForeignDetails", "longName": "9954552 - Disclosure - INCOME TAXES - Income (Loss) Before Income Taxes, Domestic and Foreign (Details)", "shortName": "INCOME TAXES - Income (Loss) Before Income Taxes, Domestic and Foreign (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true, "unique": true } }, "R109": { "role": "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "longName": "9954553 - Disclosure - INCOME TAXES - Additional Information (Details)", "shortName": "INCOME TAXES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } }, "R110": { "role": "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails", "longName": "9954554 - Disclosure - INCOME TAXES - Deferred Tax Asset, Valuation Allowance RollForward (Details)", "shortName": "INCOME TAXES - Deferred Tax Asset, Valuation Allowance RollForward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-478", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-480", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "exas-20231231.htm", "unique": true } } }, "tag": { "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "exas_AccelerationOfUnvestedEquityPostCombinationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AccelerationOfUnvestedEquityPostCombinationExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Post-combination expense for acceleration of unvested equity", "label": "Acceleration Of Unvested Equity, Post Combination, Expense", "documentation": "Acceleration Of Unvested Equity, Post Combination, Expense" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201602Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201602Member", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASU 2016-02", "label": "Accounting Standards Update 2016-02 [Member]", "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)." } } }, "auth_ref": [ "r706" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/ACCRUEDLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "ACCRUED LIABILITIES", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r45" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r44", "r1015" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r953" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r359", "r360" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails", "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r48" ] }, "exas_AccruedLicensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AccruedLicensesCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses", "label": "Accrued Licenses Current", "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for licenses." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r48" ] }, "exas_AccruedResearchAndTrialRelatedExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AccruedResearchAndTrialRelatedExpensesCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and trial related expenses", "label": "Accrued Research and Trial Related Expenses Current", "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for research and trial related expenses." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r86", "r252", "r793" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain (Loss) on Securities (1)", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r266", "r267", "r268", "r270", "r278", "r279", "r1062" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in Accumulated Other Comprehensive Income (Loss)", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r277", "r278", "r695", "r696", "r697", "r698", "r699", "r700" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r57", "r58", "r161", "r262", "r789", "r818", "r822" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r277", "r278", "r695", "r696", "r697", "r698", "r699", "r700" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r9", "r24", "r58", "r652", "r655", "r734", "r813", "r814", "r1062", "r1063", "r1064", "r1083", "r1084", "r1085" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Translation Adjustment", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r10", "r24", "r58", "r278", "r279", "r696", "r697", "r698", "r699", "r700", "r1062" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining useful life of finite-lived intangible asset (in years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r181" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r153" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r582", "r583", "r584", "r836", "r1083", "r1084", "r1085", "r1169", "r1198" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]", "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r244", "r307", "r308", "r309", "r310", "r319", "r361", "r362", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r445", "r582", "r583", "r584", "r616", "r617", "r618", "r619", "r632", "r633", "r634", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r680", "r681", "r686", "r687", "r688", "r689", "r701", "r702", "r707", "r708", "r709", "r710", "r730", "r731", "r732", "r733", "r734", "r773", "r774", "r775", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising Costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r225" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising expense", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r590" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r576", "r589" ] }, "exas_AllocatedToCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AllocatedToCompensationMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocated to Compensation", "label": "Allocated to Compensation [Member]", "documentation": "Allocated to Compensation" } } }, "auth_ref": [] }, "exas_AllocatedToConsiderationTransferredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AllocatedToConsiderationTransferredMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocated to Consideration Transferred", "label": "Allocated to Consideration Transferred [Member]", "documentation": "Allocated to Consideration Transferred" } } }, "auth_ref": [] }, "exas_AllocatedToPreviousOwnershipInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AllocatedToPreviousOwnershipInterestMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocated to Previous Ownership Interest", "label": "Allocated to Previous Ownership Interest [Member]", "documentation": "Allocated to Previous Ownership Interest" } } }, "auth_ref": [] }, "exas_AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Wisconsin Economic Development Tax Credit Agreement", "label": "Amended Wisconsin Economic Development Tax Credit Agreement [Member]", "documentation": "Amended Wisconsin Economic Development Tax Credit Agreement" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt discount amortization", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r17", "r135", "r170", "r480" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt issuance costs amortization", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r165", "r480", "r704", "r1071" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows", "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r17", "r80", "r84" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r328" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r68" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares not included in the computation of diluted net loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r639" ] }, "exas_AshionAnalyticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AshionAnalyticsMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ashion Analytics", "label": "Ashion Analytics [Member]", "documentation": "Ashion Analytics" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r1163" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, consideration transferred", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r1011", "r1164", "r1165", "r1166" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued to acquire productive assets, value", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable", "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1164", "r1165", "r1166" ] }, "exas_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire productive assets (in shares)", "label": "Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable, Shares", "documentation": "Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable, Shares" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r1163" ] }, "exas_AssetAcquisitionIPRDExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AssetAcquisitionIPRDExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition IPR&D expense", "label": "Asset acquisition IPR&D expense", "documentation": "Asset acquisition IPR&D expense" } } }, "auth_ref": [] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r1002", "r1091", "r1094", "r1095" ] }, "us-gaap_AssetUnderConstructionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetUnderConstructionMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets under construction", "label": "Asset under Construction [Member]", "documentation": "Asset in process of being built." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r209", "r256", "r291", "r337", "r345", "r350", "r399", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r641", "r645", "r685", "r785", "r881", "r1015", "r1028", "r1124", "r1125", "r1179" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r247", "r265", "r291", "r399", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r641", "r645", "r685", "r1015", "r1124", "r1125", "r1179" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term assets:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "exas_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.exactsciences.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1034", "r1035", "r1036" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.exactsciences.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r1034", "r1035", "r1036" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.exactsciences.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r1034", "r1035", "r1036" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains in Accumulated Other Comprehensive Income (Loss)", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r367" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Losses in Accumulated Other Comprehensive Income (Loss)", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r368" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through four years, Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1093" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through four years, Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r372", "r783" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due in one year or less, Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1092" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due in one year or less, Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r371", "r782" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated\u00a0Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r365", "r415", "r778", "r1089" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r123", "r126" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r178" ] }, "us-gaap_BuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingImprovementsMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings under construction", "label": "Building Improvements [Member]", "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r186" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r186" ] }, "exas_BuildingsAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BuildingsAndLeaseholdImprovementsMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold and building improvements", "label": "Buildings And Leasehold Improvements [Member]", "documentation": "Represents information pertaining to buildings and leasehold improvements." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r631", "r1005", "r1006" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r106", "r109", "r631", "r1005", "r1006" ] }, "exas_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIssuedExchangeRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIssuedExchangeRatio", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share conversion ratio", "label": "Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Issued Exchange Ratio", "documentation": "Business Acquisition Equity Interest Issued Or Issuable Number Of Shares Issued Exchange Ratio" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of stock issued in acquisition", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity." } } }, "auth_ref": [ "r205" ] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity issued to acquire business (in shares)", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": [ "r205" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r631" ] }, "exas_BusinessAcquisitionPaymentTrancheAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessAcquisitionPaymentTrancheAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Payment Tranche [Axis]", "label": "Business Acquisition, Payment Tranche [Axis]", "documentation": "Business Acquisition, Payment Tranche" } } }, "auth_ref": [] }, "exas_BusinessAcquisitionPaymentTrancheDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessAcquisitionPaymentTrancheDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Payment Tranche [Domain]", "label": "Business Acquisition, Payment Tranche [Domain]", "documentation": "Business Acquisition, Payment Tranche [Domain]" } } }, "auth_ref": [] }, "exas_BusinessAcquisitionPaymentTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessAcquisitionPaymentTrancheOneMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment 1", "label": "Business Acquisition, Payment Tranche One [Member]", "documentation": "Business Acquisition, Payment Tranche One" } } }, "auth_ref": [] }, "exas_BusinessAcquisitionProFormaIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessAcquisitionProFormaIncomeLossBeforeTax", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss before tax", "label": "Business Acquisition, Pro Forma Income (Loss), Before Tax", "documentation": "Business Acquisition, Pro Forma Income (Loss), Before Tax" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]", "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]", "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]", "documentation": "Schedule of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": [ "r32" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, pro forma information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r1046", "r1047" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Pro Forma Net Income (Loss)", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r629", "r630" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r629", "r630" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition related costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r105" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price", "totalLabel": "Total purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r4", "r5", "r21" ] }, "exas_BusinessCombinationConsiderationTransferredCashWithheldForFutureClaimsAndAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationConsiderationTransferredCashWithheldForFutureClaimsAndAdjustments", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, cash withheld", "label": "Business Combination, Consideration Transferred, Cash Withheld For Future Claims And Adjustments", "documentation": "Business Combination, Consideration Transferred, Cash Withheld For Future Claims And Adjustments" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 3.0 }, "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails_1": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r4", "r5" ] }, "exas_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCompensatory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCompensatory", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory", "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails_1": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 1.0 }, "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r4", "r5", "r116", "r636" ] }, "exas_BusinessCombinationContingentConsiderationAdditionalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationContingentConsiderationAdditionalPayment", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional cash consideration to be paid", "label": "Business Combination, Contingent Consideration, Additional Payment", "documentation": "Business Combination, Contingent Consideration, Additional Payment" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement of contingent consideration liabilities", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r638", "r1070" ] }, "exas_BusinessCombinationContingentConsiderationArrangementsIncreaseDueToAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationContingentConsiderationArrangementsIncreaseDueToAcquisition", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition contingent consideration liability", "label": "Business Combination, Contingent Consideration Arrangements, Increase Due to Acquisition", "documentation": "Business Combination, Contingent Consideration Arrangements, Increase Due to Acquisition" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent payment obligations", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r118" ] }, "exas_BusinessCombinationContingentConsiderationGainLossChangeInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationContingentConsiderationGainLossChangeInFairValue", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Changes in fair value", "label": "Business Combination, Contingent Consideration, Gain (Loss), Change in Fair Value", "documentation": "Business Combination, Contingent Consideration, Gain (Loss), Change in Fair Value" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, liability", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r6", "r117", "r637" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r117" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration liability, measurement input", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r677" ] }, "exas_BusinessCombinationContingentConsiderationRevenueMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationContingentConsiderationRevenueMilestone", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue milestone", "label": "Business Combination, Contingent Consideration, Revenue Milestone", "documentation": "Business Combination, Contingent Consideration, Revenue Milestone" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method", "documentation": "The method of determining the fair value of the equity interests of the acquirer, including the number of instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r205" ] }, "exas_BusinessCombinationDivestitureAndAssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationDivestitureAndAssetAcquisitionTextBlock", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Divestiture, And Asset Acquisition", "label": "Business Combination, Divestiture, And Asset Acquisition [Text Block]", "documentation": "Business Combination, Divestiture, And Asset Acquisition" } } }, "auth_ref": [] }, "exas_BusinessCombinationFairValueOfReplacedEquityAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationFairValueOfReplacedEquityAwards", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails_1": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of replaced equity awards", "label": "Business Combination, Fair value of Replaced Equity Awards", "documentation": "Business Combination, Fair value of Replaced Equity Awards" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business combination, pro forma loss", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total identifiable assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r110", "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net identifiable assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r110", "r111" ] }, "exas_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetOperatingAssets", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Operating Assets", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Operating Assets" } } }, "auth_ref": [] }, "exas_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation consideration assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-based Compensation", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-based Compensation" } } }, "auth_ref": [] }, "exas_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareBasedCompensationAllocatedToConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareBasedCompensationAllocatedToConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation consideration assumed and allocated to consideration transferred", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation Allocated to Consideration Transferred", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation Allocated to Consideration Transferred" } } }, "auth_ref": [] }, "exas_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareBasedCompensationDeemedCompensatory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareBasedCompensationDeemedCompensatory", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation consideration assumed and deemed compensatory", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation, Deemed Compensatory", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Share-Based Compensation, Deemed Compensatory" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r111" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails_1": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Previously held equity investment fair value", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r31" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest in acquiree after subsequent acquisition", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Including Subsequent Acquisition, Percentage", "documentation": "Percentage of voting equity interests acquired in a business combination achieved in stages, including equity interests in the acquiree held by the acquirer immediately before the acquisition date and acquired at the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of equity acquired", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, equity interest in acquiree, remeasurement gain", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination." } } }, "auth_ref": [ "r107" ] }, "exas_BusinessCombinationWorkingCapitalAdjustmentCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "BusinessCombinationWorkingCapitalAdjustmentCash", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid related to working capital adjustment", "label": "Business Combination, Working Capital Adjustment, Cash", "documentation": "Business Combination, Working Capital Adjustment, Cash" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations and Asset Acquisitions", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r104" ] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "CA", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California", "label": "CALIFORNIA" } } }, "auth_ref": [] }, "exas_CONVERTIBLENOTESAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CONVERTIBLENOTESAbstract", "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES [Abstract]", "documentation": "CONVERTIBLE NOTES" } } }, "auth_ref": [] }, "exas_COVID19TestingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "COVID19TestingMember", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "COVID-19 Testing", "label": "COVID-19 Testing [Member]", "documentation": "COVID-19 Testing" } } }, "auth_ref": [] }, "exas_CapitalInvestmentExpendituresCreditEarningRate": { "xbrltype": "percentItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CapitalInvestmentExpendituresCreditEarningRate", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit earning rate", "label": "Capital Investment Expenditures, Credit Earning Rate", "documentation": "Capital Investment Expenditures, Credit Earning Rate" } } }, "auth_ref": [] }, "exas_CapitalInvestmentExpendituresMaximumCreditsAvailableToEarn": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CapitalInvestmentExpendituresMaximumCreditsAvailableToEarn", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum credits to earn", "label": "Capital Investment Expenditures, Maximum Credits Available To Earn", "documentation": "Capital Investment Expenditures, Maximum Credits Available To Earn" } } }, "auth_ref": [] }, "exas_CapitalInvestmentExpendituresRequirementForRefundableTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CapitalInvestmentExpendituresRequirementForRefundableTaxCredits", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital investment expenditures over specified period, requirement to earn the refundable tax credits", "label": "Capital Investment Expenditures, Requirement for Refundable Tax Credits", "documentation": "The amount of expenditures in capital investments the Company is required to make over a specified period to earn the refundable tax credits." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets", "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r63", "r250", "r972" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r250" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 1.0 }, "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r64" ] }, "exas_CashAndMoneyMarketMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CashAndMoneyMarketMember", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and money market", "label": "Cash And Money Market [Member]", "documentation": "Represents information regarding cash and money market balances." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIES" ], "lang": { "en-us": { "role": { "terseLabel": "MARKETABLE SECURITIES", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": [ "r1088" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash, cash equivalents, and marketable securities", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r1061" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r63", "r175", "r289" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r8", "r175" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsMember", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r250" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents, federal government agency insured limit", "label": "Cash, FDIC Insured Amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails", "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:", "verboseLabel": "Non-cash investing and financing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "exas_CenterForMedicareAndMedicaidServicesCMSCoverageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CenterForMedicareAndMedicaidServicesCMSCoverageMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CSM Coverage", "label": "Center for Medicare And Medicaid Services (CMS) Coverage [Member]", "documentation": "Center for Medicare And Medicaid Services (CMS) Coverage" } } }, "auth_ref": [] }, "exas_ChangesInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ChangesInFairValue", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value", "label": "Changes in fair value", "documentation": "Changes in fair value in non-marketable securities" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r239", "r259", "r260", "r261", "r291", "r322", "r323", "r325", "r327", "r331", "r332", "r399", "r456", "r458", "r459", "r460", "r463", "r464", "r485", "r486", "r489", "r492", "r499", "r685", "r829", "r830", "r831", "r832", "r836", "r837", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r869", "r890", "r909", "r945", "r946", "r947", "r948", "r949", "r1041", "r1073", "r1086" ] }, "exas_CollaborationArrangementMilestonesToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CollaborationArrangementMilestonesToBeReceived", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Arrangement, Milestones To Be Received", "label": "Collaboration Arrangement, Milestones To Be Received", "documentation": "Collaboration Arrangement, Milestones To Be Received" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENT" ], "lang": { "en-us": { "role": { "verboseLabel": "PFIZER PROMOTION AGREEMENT", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r224", "r227", "r238" ] }, "exas_CollaborativeArrangementMilestoneAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CollaborativeArrangementMilestoneAxis", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement Milestone [Axis]", "label": "Collaborative Arrangement Milestone [Axis]", "documentation": "Represents the ranges of sale milestones." } } }, "auth_ref": [] }, "exas_CollaborativeArrangementMilestoneDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CollaborativeArrangementMilestoneDomain", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement Milestone [Domain]", "label": "Collaborative Arrangement Milestone [Domain]", "documentation": "Collaborative Arrangement Milestone [Domain]" } } }, "auth_ref": [] }, "exas_CollaborativeArrangementsAmountAgreedToPayUponAchievementOfSaleMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CollaborativeArrangementsAmountAgreedToPayUponAchievementOfSaleMilestones", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount agreed to be paid upon reaching the specified amount of net sales", "label": "Collaborative Arrangements Amount Agreed to Pay upon Achievement of Sale Milestones", "documentation": "Represents the amount payable by the entity upon achievement of certain sale milestones under the collaborative arrangement." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "verboseLabel": "Agreements", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r639" ] }, "exas_CollaborativeArrangementsDevelopmentMilestoneAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CollaborativeArrangementsDevelopmentMilestoneAmount", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements Development Milestone Amount", "label": "Collaborative Arrangements Development Milestone Amount", "documentation": "Collaborative Arrangements Development Milestone Amount" } } }, "auth_ref": [] }, "exas_CollaborativeArrangementsSalesMilestoneAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CollaborativeArrangementsSalesMilestoneAmount", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales of a licensed product", "label": "Collaborative Arrangements Sales Milestone Amount", "documentation": "Represents the amount of net sales of a licensed product considered as a milestone under the collaborative arrangement." } } }, "auth_ref": [] }, "exas_CollaborativeArrangementsSalesMilestoneAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CollaborativeArrangementsSalesMilestoneAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements Sales Milestone [Axis]", "label": "Collaborative Arrangements Sales Milestone [Axis]", "documentation": "Represents the ranges of sale milestones." } } }, "auth_ref": [] }, "exas_CollaborativeArrangementsSalesMilestoneDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CollaborativeArrangementsSalesMilestoneDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements Sales Milestone [Domain]", "label": "Collaborative Arrangements Sales Milestone [Domain]", "documentation": "Information by range of sale milestones pertaining to the collaborative arrangement." } } }, "auth_ref": [] }, "exas_CommercialLaunchMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CommercialLaunchMilestoneMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Launch Milestone", "label": "Commercial Launch Milestone [Member]", "documentation": "Commercial Launch Milestone" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r190", "r1022", "r1023", "r1024", "r1025" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "3326029000", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r54", "r141", "r786", "r868" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r188", "r447", "r448", "r954", "r1119" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r87", "r955" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1018", "r1019", "r1020", "r1022", "r1023", "r1024", "r1025", "r1083", "r1084", "r1169", "r1195", "r1198" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r152" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized shares (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r152", "r869" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued shares (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r152" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding shares (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r25", "r152", "r869", "r887", "r1198", "r1199" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value Authorized\u2014400,000,000 shares issued and outstanding\u2014181,364,180 and 177,925,631 shares at December\u00a031, 2023 and December\u00a031, 2022", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r152", "r788", "r1015" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "exas_CompensationExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CompensationExpenseMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Expense", "label": "Compensation Expense [Member]", "documentation": "Compensation Expense" } } }, "auth_ref": [] }, "exas_CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsShares", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense related to issuance of stock options and restricted stock awards (in shares)", "label": "Compensation Expense Related to Issuance of Stock Options and Restricted Stock Awards, Shares", "documentation": "This element represents number of stock options and restricted stock awards issued as a compensation expense by an entity during the period." } } }, "auth_ref": [] }, "exas_CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsValues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsValues", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense related to issuance of stock options and restricted stock awards", "label": "Compensation Expense Related to Issuance of Stock Options and Restricted Stock Awards, Values", "documentation": "This element represents equity impact of the value of stock options and restricted stock awards issued as a compensation expense by an entity during the period." } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of net deferred tax assets", "label": "Components of Deferred Tax Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense (benefit) for income taxes", "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "exas_ComprehensiveIncomeLossBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ComprehensiveIncomeLossBeforeTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss, before tax", "label": "Comprehensive Income (Loss), Before Tax, Attributable to Parent", "documentation": "Comprehensive Income (Loss), Before Tax, Attributable to Parent" } } }, "auth_ref": [] }, "exas_ComprehensiveIncomeLossTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ComprehensiveIncomeLossTaxAttributableToParent", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax benefit related to items of other comprehensive loss", "label": "Comprehensive Income (Loss), Tax, Attributable to Parent", "documentation": "Comprehensive Income (Loss), Tax, Attributable to Parent" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss, net of tax", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r59", "r273", "r275", "r281", "r779", "r799" ] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software projects", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r970", "r1115", "r1116" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r71", "r73", "r133", "r134", "r358", "r953" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r71", "r73", "r133", "r134", "r358", "r823", "r953" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r71", "r73", "r133", "r134", "r358", "r953", "r1045" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r145", "r229" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r953" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r71", "r73", "r133", "r134", "r358" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r70", "r71", "r73", "r74", "r133", "r208", "r953" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r71", "r73", "r133", "r134", "r358", "r953" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r119", "r978" ] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets under construction", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r186" ] }, "us-gaap_ConstructionLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionLoansMember", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction Loans", "label": "Construction Loans [Member]", "documentation": "A borrowing arrangement which provides the entity constructing a facility (such as a building and a landfill) with funds to effect construction, generally on a draw down, or as needed, basis." } } }, "auth_ref": [ "r1029" ] }, "us-gaap_ConstructionPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionPayableCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets under construction", "label": "Construction Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "exas_ContractTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ContractTerminationFee", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract termination fee", "label": "Contract Termination Fee", "documentation": "Contract Termination Fee" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Asset, after Allowance for Credit Loss", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r501", "r502", "r522" ] }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerBasisOfPricingAxis", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Basis of Pricing [Axis]", "label": "Contract with Customer, Basis of Pricing [Axis]", "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer." } } }, "auth_ref": [ "r998", "r1127" ] }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerBasisOfPricingDomain", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Basis of Pricing [Domain]", "label": "Contract with Customer, Basis of Pricing [Domain]", "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts." } } }, "auth_ref": [ "r998", "r1127" ] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized from changes in transaction price", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." } } }, "auth_ref": [ "r994" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Receivable, after Allowance for Credit Loss", "label": "Contract with Customer, Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional." } } }, "auth_ref": [ "r501", "r503", "r522", "r952" ] }, "exas_Conversions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "Conversions", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNonmarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversions", "label": "Conversions", "documentation": "Conversions" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of debt, net of discounts and deferred financing costs", "label": "Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Convertible notes, net", "label": "Convertible Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r52" ] }, "exas_ConvertibleNotesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ConvertibleNotesAbstract", "lang": { "en-us": { "role": { "terseLabel": "CONVERTIBLE DEBT", "label": "CONVERTIBLE DEBT", "documentation": "N/A." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Carrying Amount", "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r42", "r212", "r1191" ] }, "exas_ConvertibleNotesPayable2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ConvertibleNotesPayable2025Member", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 Convertible notes", "label": "Convertible Notes Payable2025 [Member]", "documentation": "Represents information pertaining to convertible notes, maturing on 2025." } } }, "auth_ref": [] }, "exas_ConvertibleNotesPayable2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ConvertibleNotesPayable2027Member", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027 Convertible notes", "label": "Convertible Notes Payable2027 [Member]", "documentation": "Represents information pertaining to convertible notes, maturing on 2027." } } }, "auth_ref": [] }, "exas_ConvertibleNotesPayable2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ConvertibleNotesPayable2028Member", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028 Convertible notes", "label": "Convertible Notes Payable2028 [Member]", "documentation": "Convertible Notes Payable2028" } } }, "auth_ref": [] }, "exas_ConvertibleNotesPayable2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ConvertibleNotesPayable2030Member", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Payable2030", "label": "Convertible Notes Payable2030 [Member]", "documentation": "Convertible Notes Payable2030" } } }, "auth_ref": [] }, "exas_ConvertibleNotesPayableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ConvertibleNotesPayableGross", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails": { "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Amount", "label": "Convertible Notes Payable, Gross", "documentation": "Convertible Notes Payable, Gross" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableMember", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issuable upon conversion of convertible notes", "label": "Convertible Notes Payable [Member]", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r147", "r210" ] }, "exas_ConvertibleNotesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ConvertibleNotesTextBlock", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTES" ], "lang": { "en-us": { "role": { "terseLabel": "CONVERTIBLE NOTES", "label": "Convertible Notes [Text Block]", "documentation": "The entire disclosure of convertible notes." } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales (exclusive of amortization of acquired intangible assets)", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r167", "r291", "r399", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r685", "r1124" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods and Service", "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r1050" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r166" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r294", "r295", "r468", "r487", "r735", "r975", "r977" ] }, "exas_CouponInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "CouponInterestExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Coupon interest expense", "label": "Coupon Interest Expense", "documentation": "Coupon Interest Expense" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current expense (benefit):", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r202", "r615", "r623", "r1076" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r72", "r358" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r113" ] }, "exas_DOSRuleInvestigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DOSRuleInvestigationMember", "presentation": [ "http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DOS Rule Investigation", "label": "DOS Rule Investigation [Member]", "documentation": "DOS Rule Investigation" } } }, "auth_ref": [] }, "exas_DailyBloombergShortTermBankYieldIndexRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DailyBloombergShortTermBankYieldIndexRateMember", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Daily Bloomberg Short-Term Bank Yield Index Rate", "label": "Daily Bloomberg Short-Term Bank Yield Index Rate [Member]", "documentation": "Daily Bloomberg Short-Term Bank Yield Index Rate" } } }, "auth_ref": [] }, "exas_DebtConversionConvertedInstrumentPotentialSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DebtConversionConvertedInstrumentPotentialSharesIssued", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Conversion, Converted Instrument, Potential Shares Issued", "label": "Debt Conversion, Converted Instrument, Potential Shares Issued", "documentation": "Debt Conversion, Converted Instrument, Potential Shares Issued" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "exas_DebtInstrumentAmountSettledInExtinguishment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DebtInstrumentAmountSettledInExtinguishment", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount settled", "label": "Debt instrument, Amount Settled In Extinguishment", "documentation": "Debt instrument, Amount Settled In Extinguishment" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r42", "r147", "r148", "r210", "r212", "r297", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r705", "r988", "r989", "r990", "r991", "r992", "r1074" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price per share of common stock (in usd per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r191", "r467" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion rate, number of shares to be issued per $1,000 of principal amount", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r51", "r92", "r194", "r195", "r467" ] }, "exas_DebtInstrumentConvertibleEquityComponentInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DebtInstrumentConvertibleEquityComponentInterestAccrued", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest on notes", "label": "Debt Instrument, Convertible, Equity Component, Interest Accrued", "documentation": "Debt Instrument, Convertible, Equity Component, Interest Accrued" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt, remaining discount amortization period", "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period", "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r38" ] }, "exas_DebtInstrumentConvertibleTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DebtInstrumentConvertibleTransactionCosts", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total transaction costs", "label": "Debt Instrument Convertible Transaction Costs", "documentation": "The transaction costs of the liability and equity component of convertible debt which may be settled upon conversion." } } }, "auth_ref": [] }, "exas_DebtInstrumentCovenantMaximumOutstandingCashAdvancesThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DebtInstrumentCovenantMaximumOutstandingCashAdvancesThreshold", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, maximum outstanding cash advances threshold", "label": "Debt Instrument, Covenant, Maximum Outstanding Cash Advances Threshold", "documentation": "Debt Instrument, Covenant, Maximum Outstanding Cash Advances Threshold" } } }, "auth_ref": [] }, "exas_DebtInstrumentCovenantMinimumMarketValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DebtInstrumentCovenantMinimumMarketValue", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, collateral minimum market value", "label": "Debt Instrument, Covenant, Minimum Market Value", "documentation": "Debt Instrument, Covenant, Minimum Market Value" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r136", "r138", "r465", "r705", "r989", "r990" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r50", "r136", "r477" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r50", "r466" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r297", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r705", "r988", "r989", "r990", "r991", "r992", "r1074" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r52", "r297", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r705", "r988", "r989", "r990", "r991", "r992", "r1074" ] }, "exas_DebtInstrumentRepurchasePriceDueToChangeInControlAsPercentageOfPrincipalAmount": { "xbrltype": "pureItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DebtInstrumentRepurchasePriceDueToChangeInControlAsPercentageOfPrincipalAmount", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase price, as percentage of principal amount, if company undergoes change of control", "label": "Debt Instrument Repurchase Price Due to Change in Control as Percentage of Principal Amount", "documentation": "Represents the price at which the debt may be repurchased, as a percentage of the principal amount if the entity undergoes a change of control." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESRankingofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r52", "r92", "r93", "r135", "r136", "r138", "r144", "r193", "r195", "r297", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r705", "r988", "r989", "r990", "r991", "r992", "r1074" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails": { "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized Debt Discount and Issuance Costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r137", "r471", "r482", "r989", "r990" ] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Collateralized Debt Instruments", "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r20" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss", "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r415" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r220", "r419", "r986" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r220", "r419" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r220", "r419", "r986" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r220", "r419" ] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Available-for-sale debt securities", "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1102" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total fair value of available-for-sale securities in a continuous unrealized loss position", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r218", "r417", "r986" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r219", "r418" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of gross unrealized losses and fair values of investments in an unrealized loss position", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r217", "r986", "r1103" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax expense (benefit):", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r17", "r202", "r235", "r622", "r623", "r1076" ] }, "exas_DeferredIncomeTaxExpenseBenefitSOCF": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DeferredIncomeTaxExpenseBenefitSOCF", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax benefit", "label": "Deferred Income Tax Expense (Benefit) - SOCF", "documentation": "Amount of deferred income tax expense (benefit) on the statement of cash flows" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r149", "r150", "r211", "r609" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Tax assets before valuation allowance", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r610" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research and development", "label": "Deferred Tax Assets, in Process Research and Development", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r103", "r1161" ] }, "exas_DeferredTaxAssetsLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DeferredTaxAssetsLeasingArrangements", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Deferred Tax Assets, Leasing Arrangements", "documentation": "Deferred Tax Assets, Leasing Arrangements" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1160" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Deferred Tax Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r103", "r1161" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other temporary differences", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r103", "r1161" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforwards", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r102", "r103", "r1161" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation related differences", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation." } } }, "auth_ref": [ "r103", "r1161" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTaxPositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset valuation allowance", "negatedLabel": "Less - Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r611" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "negatedTotalLabel": "Net deferred tax liabilities", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r98", "r1160" ] }, "exas_DeferredTaxLiabilitiesAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DeferredTaxLiabilitiesAmortization", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization", "label": "Deferred Tax Liabilities Amortization", "documentation": "Deferred Tax Liabilities Amortization" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Lease assets", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r103", "r1161" ] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Tax Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other temporary differences", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r103", "r1161" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Property, plant and equipment", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r103", "r1161" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/EMPLOYEEBENEFITPLANDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense in connection with the 401 (k) Plan", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r541" ] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.exactsciences.com/role/EMPLOYEEBENEFITPLANDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of participant's salary matched by employer", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.exactsciences.com/role/EMPLOYEEBENEFITPLANDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Matching contribution by employer", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "exas_DepreciationAndAmortizationOfFixedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DepreciationAndAmortizationOfFixedAssets", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation And Amortization Of Fixed Assets", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of fixed assets over the assets' useful lives." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r856", "r859", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r882", "r883", "r884", "r885", "r897", "r898", "r899", "r900", "r903", "r904", "r905", "r906", "r930", "r931", "r934", "r935", "r1018", "r1020" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, fair value", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r684" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r124", "r125", "r127", "r128", "r856", "r859", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r882", "r883", "r884", "r885", "r897", "r898", "r899", "r900", "r903", "r904", "r905", "r906", "r930", "r931", "r934", "r935", "r977", "r1018", "r1020" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1167", "r1168" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Financial Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r26", "r120", "r121", "r122", "r129", "r296" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology Rights [Member]", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r204" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails", "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r521", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails", "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r521", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of disaggregation by revenue source", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1127" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r543", "r546", "r577", "r578", "r581", "r1008" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r245" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "exas_DisposalGroupContingentConsiderationArrangementsAdditionalConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DisposalGroupContingentConsiderationArrangementsAdditionalConsideration", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Contingent Consideration Arrangements, Additional Consideration", "label": "Disposal Group, Contingent Consideration Arrangements, Additional Consideration", "documentation": "Disposal Group, Contingent Consideration Arrangements, Additional Consideration" } } }, "auth_ref": [] }, "exas_DisposalGroupContingentConsiderationArrangementsGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DisposalGroupContingentConsiderationArrangementsGainLoss", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Contingent Consideration Arrangements, Gain (Loss)", "label": "Disposal Group, Contingent Consideration Arrangements, Gain (Loss)", "documentation": "Disposal Group, Contingent Consideration Arrangements, Gain (Loss)" } } }, "auth_ref": [] }, "exas_DisposalGroupContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DisposalGroupContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group, contingent consideration arrangements, range of outcomes, value, high", "label": "Disposal Group, Contingent Consideration Arrangements, Range Of Outcomes, Value, High", "documentation": "Disposal Group, Contingent Consideration Arrangements, Range Of Outcomes, Value, High" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r18", "r34" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total consideration", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "exas_DisposalGroupIncludingDiscontinuedOperationsConsiderationCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationsConsiderationCash", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Disposal Group, Including Discontinued Operations, Consideration, Cash", "documentation": "Disposal Group, Including Discontinued Operations, Consideration, Cash" } } }, "auth_ref": [] }, "exas_DisposalGroupIncludingDiscontinuedOperationsContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationsContingentConsideration", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Disposal Group, Including Discontinued Operations, Contingent Consideration", "documentation": "Disposal Group, Including Discontinued Operations, Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group, not discontinued operation, gain (loss) on disposal", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r443", "r1071", "r1117" ] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation." } } }, "auth_ref": [ "r444" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r1005", "r1006" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1034", "r1035", "r1036" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1034", "r1035", "r1036", "r1038" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1037" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1032" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r282", "r311", "r312", "r313", "r314", "r315", "r320", "r322", "r325", "r326", "r327", "r329", "r669", "r670", "r780", "r800", "r982" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r282", "r311", "r312", "r313", "r314", "r315", "r322", "r325", "r326", "r327", "r329", "r669", "r670", "r780", "r800", "r982" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r68", "r69" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effects of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r693" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "totalLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r599" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Differences between the effective income tax rate and the statutory tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Federal statutory rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r293", "r599", "r625" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r1158", "r1162" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal and state tax rate changes", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r625", "r1158" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign tax rate differential", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r1158", "r1162" ] }, "exas_EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebtPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebtPercent", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other adjustments", "label": "Effective Income Tax Rate Reconciliation, Loss On Extinguishment Of Debt, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Loss On Extinguishment Of Debt, Percent" } } }, "auth_ref": [] }, "exas_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationCostPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationCostPercent", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible executive compensation", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation Cost, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to executive compensation." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired IPR&D asset expense", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense." } } }, "auth_ref": [ "r1158", "r1162" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r1158", "r1162" ] }, "exas_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Transaction Costs, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other adjustments", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1158", "r1162" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State taxes", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r1158", "r1162" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development tax credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1158", "r1162" ] }, "exas_EmployeeAndNonEmployeesStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "EmployeeAndNonEmployeesStockOptionMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issuable upon exercise of stock options", "terseLabel": "Stock Options", "label": "Employee And Non Employees Stock Option [Member]", "documentation": "An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize individuals, in addition to their regular compensation and benefits." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r48" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation, costs not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r580" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period for recognition of unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r580" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1156" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "exas_EmployeeStockPurchasePlan2010Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "EmployeeStockPurchasePlan2010Member", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan 2010", "label": "Employee Stock Purchase Plan2010 [Member]", "documentation": "Represents information pertaining to the 2010 employee stock purchase plan." } } }, "auth_ref": [] }, "exas_EmployeeStockPurchasePlan2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "EmployeeStockPurchasePlan2019Member", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan 2019", "label": "Employee Stock Purchase Plan 2019 [Member]", "documentation": "Employee Stock Purchase Plan 2019" } } }, "auth_ref": [] }, "exas_EmployeeStockPurchasePlanWeightedAveragePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "EmployeeStockPurchasePlanWeightedAveragePrice", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average price per share (in dollars per share)", "label": "Employee Stock Purchase Plan Weighted Average Price", "documentation": "Represents the weighted average price per share at which shares were issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [] }, "exas_EmployeesWithQualifyingTerminationEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "EmployeesWithQualifyingTerminationEventsMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees with Qualifying Termination Events", "label": "Employees with Qualifying Termination Events [Member]", "documentation": "Employees with Qualifying Termination Events" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1031" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1031" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1031" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1039" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1031" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1031" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1031" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1031" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1040" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r25", "r242", "r277", "r278", "r279", "r304", "r305", "r306", "r308", "r316", "r318", "r330", "r403", "r409", "r500", "r582", "r583", "r584", "r618", "r619", "r650", "r652", "r653", "r654", "r655", "r657", "r668", "r695", "r696", "r697", "r698", "r699", "r700", "r734", "r813", "r814", "r815", "r836", "r909" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r396", "r397", "r398" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r257", "r682", "r974" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 21.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities, FV-NI, Gain (Loss)", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r802", "r1100" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r394" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r394" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount", "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r395" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r395" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r473", "r684", "r989", "r990" ] }, "us-gaap_ExtinguishmentOfDebtAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAxis", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extinguishment of Debt [Axis]", "label": "Extinguishment of Debt [Axis]", "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtTypeDomain", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extinguishment of Debt, Type [Domain]", "label": "Extinguishment of Debt, Type [Domain]", "documentation": "Type of debt extinguished." } } }, "auth_ref": [ "r91" ] }, "exas_FDAApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "FDAApprovalMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FDA Approval", "label": "FDA Approval [Member]", "documentation": "FDA Approval" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value measurements", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r673", "r674", "r678" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r673", "r674", "r678" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r130", "r207" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r130", "r131", "r132" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r473", "r527", "r528", "r529", "r530", "r531", "r532", "r674", "r739", "r740", "r741", "r989", "r990", "r1002", "r1003", "r1004" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r39", "r130", "r473", "r989", "r990" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r673", "r674", "r676", "r677", "r679" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r473", "r989", "r990" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r672" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted\u00a0Prices in\u00a0Active Markets\u00a0for Identical\u00a0Assets (Level\u00a01)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r473", "r527", "r532", "r674", "r739", "r1002", "r1003", "r1004" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level\u00a02)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r473", "r527", "r532", "r674", "r740", "r989", "r990", "r1002", "r1003", "r1004" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level\u00a03)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r473", "r527", "r528", "r529", "r530", "r531", "r532", "r674", "r741", "r989", "r990", "r1002", "r1003", "r1004" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r473", "r527", "r528", "r529", "r530", "r531", "r532", "r739", "r740", "r741", "r989", "r990", "r1002", "r1003", "r1004" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r672", "r679" ] }, "us-gaap_FairValueNetAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetAssetLiability", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Fair Value, Net Asset (Liability)", "documentation": "Fair value of asset after deduction of liability." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r714", "r721", "r1014" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r716", "r725" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finance lease obligations", "terseLabel": "Total", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r712", "r729" ] }, "us-gaap_FinanceLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityAbstract", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease cost", "label": "Finance Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liability, current", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r712" ] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r713" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease maturity", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1177" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liability, noncurrent", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r712" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": [ "r713" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r729" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Imputed interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r729" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r715", "r725" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease, right-of-use asset", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r711" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r714", "r721", "r1014" ] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": [ "r713" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate - finance leases", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r728", "r1014" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term - finance leases (in years)", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r727", "r1014" ] }, "exas_FinanceLeasesFutureMinimumPaymentsDueFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "FinanceLeasesFutureMinimumPaymentsDueFiscalYearMaturityAbstract", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "label": "Finance Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "documentation": "Finance Leases, Future Minimum Payments Due, Fiscal Year Maturity" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r410", "r411", "r412", "r413", "r414", "r416", "r420", "r421", "r481", "r497", "r658", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r798", "r986", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1096", "r1097", "r1098", "r1099" ] }, "exas_FinancingReceivableAmountElectedToCollateralize": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "FinancingReceivableAmountElectedToCollateralize", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Amount Elected to Collateralize", "label": "Financing Receivable, Amount Elected to Collateralize", "documentation": "Financing Receivable, Amount Elected to Collateralize" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Life (Years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "terseLabel": "Finite-lived intangible assets, accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r254", "r441" ] }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed." } } }, "auth_ref": [ "r81" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r183" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r183" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r183" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r183" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r183" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r439", "r440", "r441", "r442", "r772", "r776" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r182", "r776" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r772" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r81", "r83" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finite-lived intangible assets, net", "terseLabel": "Finite-lived Intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r182", "r772" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Transactions", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r690" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r875", "r879", "r884", "r899", "r905", "r932", "r933", "r934", "r1020" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "exas_GainLossOnContingentConsiderationFromDispositionOfAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "GainLossOnContingentConsiderationFromDispositionOfAsset", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain (Loss) On Contingent Consideration From Disposition Of Asset", "label": "Gain (Loss) On Contingent Consideration From Disposition Of Asset", "documentation": "Gain (Loss) On Contingent Consideration From Disposition Of Asset" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on sale of asset", "label": "Gain (Loss) on Disposition of Other Assets", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": [ "r1071" ] }, "us-gaap_GainOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainOnSaleOfInvestments", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on Sale of Investments", "label": "Gain on Sale of Investments", "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale." } } }, "auth_ref": [ "r1065", "r1066", "r1071", "r1189" ] }, "exas_GainOnSettlementOfConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "GainOnSettlementOfConvertibleNotes", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on settlement of convertible notes", "label": "Gain on Settlement of Convertible Notes", "documentation": "Gain on Settlement of Convertible Notes" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on extinguishment of debt", "negatedTerseLabel": "Gain on settlement of convertible notes", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r17", "r89", "r90" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "negatedTerseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r168", "r892" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r164" ] }, "exas_GenomicHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "GenomicHealthIncMember", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genomic Health Inc", "label": "Genomic Health Inc [Member]", "documentation": "Genomic Health Inc" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 }, "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/ConsolidatedBalanceSheets", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning of the period", "periodEndLabel": "Ending of the period", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r253", "r426", "r777", "r987", "r1015", "r1105", "r1112" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r430", "r987" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILL" ], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS AND GOODWILL", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r180" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r425", "r438", "r987" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Foreign Currency Translation Gain (Loss)", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r434" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, impairment loss", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r17", "r427", "r433", "r438", "r987" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r987" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genomic Health acquisition adjustment", "label": "Goodwill, Purchase Accounting Adjustments", "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r1", "r1111" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount of goodwill", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantees and Indemnifications", "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]", "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities." } } }, "auth_ref": [ "r454" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1034", "r1035", "r1036" ] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r17", "r35" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 }, "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows", "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets", "label": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r17", "r85", "r187" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired In-process Research and Development (IPR&D)", "label": "In Process Research and Development, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESIncomeLossBeforeIncomeTaxesDomesticandForeignDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESIncomeLossBeforeIncomeTaxesDomesticandForeignDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r292", "r624" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.exactsciences.com/role/INCOMETAXESIncomeLossBeforeIncomeTaxesDomesticandForeignDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/INCOMETAXESIncomeLossBeforeIncomeTaxesDomesticandForeignDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r162", "r214", "r337", "r344", "r349", "r352", "r781", "r795", "r984" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/INCOMETAXESIncomeLossBeforeIncomeTaxesDomesticandForeignDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESIncomeLossBeforeIncomeTaxesDomesticandForeignDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r292", "r624" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r1005", "r1006" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r444", "r446", "r893" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r446", "r893" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r22" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r293", "r594", "r600", "r606", "r613", "r620", "r626", "r627", "r628", "r834" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTaxPositionsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit (expense)", "totalLabel": "Total income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r222", "r236", "r317", "r318", "r341", "r598", "r621", "r803" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Positions", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r276", "r596", "r597", "r606", "r607", "r612", "r614", "r828" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities, net of effects of acquisition:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r1048", "r1070" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (Decrease) in Other Operating Assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Other Operating Liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r184" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r83", "r768", "r769", "r770", "r772", "r979" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finite-lived and indefinite-lived intangible assets, gross", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r253" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Finite-lived and indefinite-lived intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r79", "r82" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r137", "r216", "r280", "r340", "r703", "r894", "r1026", "r1197" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total interest expense on convertible notes", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r170", "r478", "r483", "r991", "r992" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r284", "r287", "r288" ] }, "us-gaap_InternalUseSoftwarePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InternalUseSoftwarePolicy", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Software Development Costs", "label": "Internal Use Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally." } } }, "auth_ref": [ "r2", "r3" ] }, "exas_InternationalSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "InternationalSalesMember", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "International Sales [Member]", "documentation": "International Sales" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/INVENTORY" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORY", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r422" ] }, "exas_InventoryFinishedSemiFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "InventoryFinishedSemiFinishedGoods", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INVENTORYDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/INVENTORYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Semi-finished and finished goods", "label": "Inventory Finished Semi Finished Goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise/goods and merchandise/goods expected to be completed within one year of operating cycle that are expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.exactsciences.com/role/INVENTORYDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets", "http://www.exactsciences.com/role/INVENTORYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r264", "r973", "r1015" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r223", "r249", "r263", "r422", "r423", "r424", "r767", "r980" ] }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/INVENTORYDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/INVENTORYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials and Supplies, Gross", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": [ "r1060" ] }, "us-gaap_InvestmentCompanyCommittedCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyCommittedCapital", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Committed capital", "label": "Investment Company, Committed Capital", "documentation": "Amount of funds committed to investment company from investors." } } }, "auth_ref": [ "r838" ] }, "exas_InvestmentCompanyCommittedCapitalAmountCallable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "InvestmentCompanyCommittedCapitalAmountCallable", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Committed capital callable", "label": "Investment Company, Committed Capital, Amount Callable", "documentation": "Investment Company, Committed Capital, Amount Callable" } } }, "auth_ref": [] }, "exas_InvestmentIncomeExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "InvestmentIncomeExpenseNonoperating", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Investment income (loss), net", "label": "Investment Income (Expense), Nonoperating", "documentation": "Investment Income (Expense), Nonoperating" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Income", "label": "Investment Income [Member]", "documentation": "Primary financial statement caption encompassing investment income." } } }, "auth_ref": [ "r37" ] }, "us-gaap_InvestmentIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNonoperating", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment income, net", "label": "Investment Income, Nonoperating", "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations." } } }, "auth_ref": [ "r169" ] }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment owned, fair value", "label": "Investment Owned, Fair Value", "documentation": "Fair value of investment in security owned." } } }, "auth_ref": [ "r824", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r857", "r860", "r861", "r872", "r873", "r914", "r916", "r917", "r918", "r925", "r926", "r927", "r928", "r929", "r936", "r937", "r939", "r940", "r941", "r1020", "r1028", "r1196" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Privately Held Companies", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r801", "r824", "r825", "r826", "r827", "r919", "r920" ] }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAllOtherInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of contractual maturities of available-for-sale investments", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "exas_LICENSEAGREEMENTSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "LICENSEAGREEMENTSAbstract", "lang": { "en-us": { "role": { "label": "LICENSE AGREEMENTS [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LandImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandImprovementsMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land improvements", "label": "Land Improvements [Member]", "documentation": "Additions or improvements to real estate held." } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r1128" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease Cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r720", "r1014" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of lease expense", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of lease expense", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1176" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r186" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r719" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r719" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r718" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1177" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r729" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r729" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r729" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, remaining lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1174" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, term extension", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1175" ] }, "exas_LesseeOperatingLeaseTerminationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "LesseeOperatingLeaseTerminationPeriod", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, termination period", "label": "Lessee, Operating Lease, Termination Period", "documentation": "Lessee, Operating Lease, Termination Period" } } }, "auth_ref": [] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "City Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r47", "r291", "r399", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r642", "r645", "r646", "r685", "r867", "r983", "r1028", "r1124", "r1179", "r1180" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r157", "r213", "r791", "r1015", "r1075", "r1101", "r1170" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r49", "r248", "r291", "r399", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r642", "r645", "r646", "r685", "r1015", "r1124", "r1179", "r1180" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "exas_LicensingAgreementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "LicensingAgreementDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "LICENSE AND COLLABORATION AGREEMENTS", "label": "Licensing Agreement Disclosure [Text Block]", "documentation": "This element represents the entire disclosure related to licensing agreement entered by an entity during the period." } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreements", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r114", "r593", "r1157" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Current Borrowing Capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r46" ] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Interest Rate at Period End", "label": "Line of Credit Facility, Interest Rate at Period End", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": [ "r46" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r46" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r46" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement, Expense", "label": "Litigation Settlement, Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Payable, Current", "label": "Loans Payable, Current", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r48" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Excluding Current Maturities", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r258" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBT" ], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM DEBT", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r189" ] }, "us-gaap_LongTermLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermLoansPayable", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, less current portion", "label": "Loans Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r52" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r52" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r52", "r88" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r449", "r450", "r451", "r455", "r1120", "r1121" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r449", "r450", "r451", "r455", "r1120", "r1121" ] }, "us-gaap_LossOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossOnSaleOfInvestments", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on Sale of Investments", "label": "Loss on Sale of Investments", "documentation": "The difference between the carrying value and the sale price of an investment. A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale." } } }, "auth_ref": [ "r1065", "r1066", "r1071", "r1189" ] }, "exas_MAYOFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "MAYOFoundationMember", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mayo", "label": "M A Y O Foundation [Member]", "documentation": "Represents the pertinent information about MAYO Foundation for Medical Education and Research (MAYO)." } } }, "auth_ref": [] }, "exas_MDxHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "MDxHealthMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MDxHealth", "label": "MDxHealth [Member]", "documentation": "MDxHealth" } } }, "auth_ref": [] }, "exas_MRDProductRevenueMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "MRDProductRevenueMilestoneMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MRD Product Revenue Milestone", "label": "MRD Product Revenue Milestone [Member]", "documentation": "MRD Product Revenue Milestone" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r358", "r997", "r1127", "r1193", "r1194" ] }, "us-gaap_ManufacturedProductOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManufacturedProductOtherMember", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufactured Product, Other", "label": "Manufactured Product, Other [Member]", "documentation": "Article or substance produced by labor or machinery, classified as other." } } }, "auth_ref": [ "r1128" ] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total marketable securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r142", "r1059" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r1059" ] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesLineItems", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Line Items]", "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r143" ] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTable", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Table]", "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingExpense", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges for promotion, sales and marketing", "label": "Marketing Expense", "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs." } } }, "auth_ref": [ "r168" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r450", "r451", "r452", "r453", "r542", "r766", "r810", "r858", "r859", "r915", "r921", "r923", "r924", "r938", "r965", "r966", "r985", "r993", "r1007", "r1017", "r1126", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186" ] }, "exas_MeasurementInputPresentValueFactorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "MeasurementInputPresentValueFactorMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Present-value Factor", "label": "Measurement Input, Present-value Factor [Member]", "documentation": "Measurement Input, Present-value Factor" } } }, "auth_ref": [] }, "exas_MeasurementInputProbabilityOfSuccessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "MeasurementInputProbabilityOfSuccessMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Probability of Success", "label": "Measurement Input, Probability of Success [Member]", "documentation": "Measurement Input, Probability of Success" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r675" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "exas_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "MedicareMember", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Centers for Medicare and Medicaid Services", "label": "Medicare [Member]", "documentation": "Represents information related to the Centers for Medicare and Medicaid Services (Medicare)." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r450", "r451", "r452", "r453", "r542", "r766", "r810", "r858", "r859", "r915", "r921", "r923", "r924", "r938", "r965", "r966", "r985", "r993", "r1007", "r1017", "r1126", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and money market", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1129" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r358", "r997", "r1127", "r1193", "r1194" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r286" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r286" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r175", "r176", "r177" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "exas_ComprehensiveIncomeLossBeforeTaxAttributableToParent", "weight": 1.0, "order": 2.0 }, "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r163", "r177", "r215", "r246", "r271", "r274", "r279", "r291", "r307", "r311", "r312", "r313", "r314", "r317", "r318", "r324", "r337", "r344", "r349", "r352", "r399", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r670", "r685", "r797", "r889", "r907", "r908", "r984", "r1026", "r1124" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outside of United States", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1200", "r1201", "r1202", "r1203" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment acquired but not paid", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r65", "r66", "r67" ] }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MDxHealth American Depository Shares", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction." } } }, "auth_ref": [ "r65", "r66", "r67" ] }, "exas_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedFairValue", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash or part noncash divestiture, amount of consideration received, fair value", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Fair Value", "documentation": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Fair Value" } } }, "auth_ref": [] }, "exas_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedShares", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash or part noncash divestiture, amount of consideration received, shares", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Shares", "documentation": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Shares" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashDivestituresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashDivestituresLineItems", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash or Part Noncash Divestitures [Line Items]", "label": "Noncash or Part Noncash Divestitures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashDivestituresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashDivestituresTable", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash or Part Noncash Divestitures [Table]", "label": "Noncash or Part Noncash Divestitures [Table]", "documentation": "A table that contains information regarding the sale of an asset or business through a noncash (or part noncash) transaction. At a minimum, the table includes sufficient information to provide an understanding of the nature and purpose of the divesture, as well as the asset divested of and the noncash consideration received (that is, debt, stock, and so forth.) Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r65", "r66", "r67" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r169" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "exas_NumberOfFullTimePositionsRequiredToBeCreatedToEarnRefundableTaxCredits": { "xbrltype": "integerItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "NumberOfFullTimePositionsRequiredToBeCreatedToEarnRefundableTaxCredits", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Full-time positions that must be created over a specified time period to earn the refundable tax credits", "label": "Number of Full-time Positions Required to be Created to Earn Refundable Tax Credits", "documentation": "Represents the number of full-time positions that must be created over a specified time period to earn the refundable tax credits." } } }, "auth_ref": [] }, "exas_NumberOfTestsProvided": { "xbrltype": "integerItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "NumberOfTestsProvided", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tests provided", "label": "Number Of Tests Provided", "documentation": "Number Of Tests Provided" } } }, "auth_ref": [] }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r58" ] }, "exas_OfferingPeriodEndDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OfferingPeriodEndDateAxis", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering Period End Date [Axis]", "label": "Offering Period End Date [Axis]", "documentation": "Information by offering period end date pertaining to the equity-based compensation arrangements." } } }, "auth_ref": [] }, "exas_OfferingPeriodEndDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OfferingPeriodEndDateDomain", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering Period End Date [Domain]", "label": "Offering Period End Date [Domain]", "documentation": "Represents the offering period end dates pertaining to the equity-based compensation arrangements." } } }, "auth_ref": [] }, "exas_OfferingPeriodEndDateOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OfferingPeriodEndDateOneMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering Period End Date One", "label": "Offering Period End Date One [Member]", "documentation": "Represents information pertaining to the first offering period end date." } } }, "auth_ref": [] }, "exas_OfferingPeriodEndDateTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OfferingPeriodEndDateTwoMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering Period End Date Two", "label": "Offering Period End Date Two [Member]", "documentation": "Represents information pertaining to the second offering period end date." } } }, "auth_ref": [] }, "exas_OfficeEquipmentAndComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OfficeEquipmentAndComputerSoftwareMember", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and computer software", "label": "Office Equipment And Computer Software [Member]", "documentation": "Information relating to office equipment and computer software." } } }, "auth_ref": [] }, "exas_OmicEraDiagnosticsAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OmicEraDiagnosticsAcquisitionMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OmicEra Diagnostics Acquisition", "label": "OmicEra Diagnostics Acquisition [Member]", "documentation": "OmicEra Diagnostics Acquisition" } } }, "auth_ref": [] }, "exas_OmicEraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OmicEraMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OmicEra", "label": "OmicEra [Member]", "documentation": "OmicEra" } } }, "auth_ref": [] }, "exas_OmnibusLongTermIncentivePlan2010Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OmnibusLongTermIncentivePlan2010Member", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Omnibus Long Term Incentive Plan 2010", "label": "Omnibus Long Term Incentive Plan2010 [Member]", "documentation": "Represents information pertaining to the 2010 omnibus long -term incentive plan." } } }, "auth_ref": [] }, "exas_OmnibusLongTermIncentivePlan2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OmnibusLongTermIncentivePlan2019Member", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Omnibus Long Term Incentive Plan 2019", "label": "Omnibus Long Term Incentive Plan2019 [Member]", "documentation": "Omnibus Long Term Incentive Plan2019" } } }, "auth_ref": [] }, "exas_OncotypeDXGenomicProstateScoreTestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OncotypeDXGenomicProstateScoreTestMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDivestitureDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oncotype DX Genomic Prostate Score Test", "label": "Oncotype DX Genomic Prostate Score Test [Member]", "documentation": "Oncotype DX Genomic Prostate Score Test" } } }, "auth_ref": [] }, "exas_OneMonthLondonInterbankOfferRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OneMonthLondonInterbankOfferRateMember", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1-month LIBOR", "label": "One Month London Interbank Offer Rate [Member]", "documentation": "Interest rate at which a bank borrows funds from other banks in the one-month London interbank market." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r337", "r344", "r349", "r352", "r984" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r722", "r1014" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-cash lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1173" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition of lease liabilities", "verboseLabel": "Total", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r712" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current portion", "verboseLabel": "Operating lease liability, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r712" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, less current portion", "verboseLabel": "Operating lease liability, noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r712" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r717", "r725" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease right-of-use assets", "terseLabel": "Recognition of ROU assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r711" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate - operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r728", "r1014" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term - operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r727", "r1014" ] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesonOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r102" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "exas_OperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards with no expiration date", "label": "Operating Loss Carryforwards, Not Subject To Expiration", "documentation": "Operating Loss Carryforwards, Not Subject To Expiration" } } }, "auth_ref": [] }, "exas_OperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "OperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards with expiration date", "label": "Operating Loss Carryforwards, Subject To Expiration", "documentation": "Operating Loss Carryforwards, Subject To Expiration" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r101" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r48" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets, net", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r255" ] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Axis]", "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsDomain", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Domain]", "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "exas_ComprehensiveIncomeLossBeforeTaxAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r11", "r161", "r691", "r692", "r694" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net current period change in accumulated other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent", "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r14", "r23", "r206" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r14", "r23", "r206", "r272", "r275" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive loss, before tax:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax benefit related to items of other comprehensive loss", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r14", "r23", "r206" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss": { "parentTag": "exas_ComprehensiveIncomeLossBeforeTaxAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-for-sale investments", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r266", "r269", "r393" ] }, "us-gaap_OtherInvestmentNotReadilyMarketableFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInvestmentNotReadilyMarketableFairValue", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investment Not Readily Marketable, Fair Value", "label": "Other Investment Not Readily Marketable, Fair Value", "documentation": "Value of the other investment not readily marketable determined by management based upon fair value methods, including pricing of similar securities and valuation techniques, that was used to record the investment for financial reporting purposes." } } }, "auth_ref": [ "r139" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r48", "r1015" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r53" ] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncash Expense", "label": "Other Noncash Expense", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r177" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating income (loss)", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "exas_PFSGenomicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PFSGenomicsMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PFS Genomics", "label": "PFS Genomics [Member]", "documentation": "PFS Genomics" } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents and licenses", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r204" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments", "label": "Payment for Contingent Consideration Liability, Investing Activities", "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability." } } }, "auth_ref": [ "r12" ] }, "exas_PaymentsContingentOnMilestonesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PaymentsContingentOnMilestonesPayable", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments contingent on milestones", "label": "Payments Contingent on Milestones Payable", "documentation": "Represents potential future payments still contingent upon achievement of milestones under a collaborative arrangement." } } }, "auth_ref": [] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for Legal Settlements", "label": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r15" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other investing activities", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1042", "r1067" ] }, "us-gaap_PaymentsToAcquireAssetsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAssetsInvestingActivities", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Asset acquisitions, net of cash acquired", "label": "Payments to Acquire Assets, Investing Activities", "documentation": "Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities." } } }, "auth_ref": [ "r1067" ] }, "exas_PaymentsToAcquireBusinessesAndAcceleratedVestingOfAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PaymentsToAcquireBusinessesAndAcceleratedVestingOfAwards", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire businesses and accelerated vesting of awards", "label": "Payments To Acquire Businesses And Accelerated Vesting Of Awards", "documentation": "Payments To Acquire Businesses And Accelerated Vesting Of Awards" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails_1": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r60", "r635" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Business combination, net of cash acquired and issuance costs", "terseLabel": "Consideration transferred, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r60" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r1090" ] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investments in privately held companies", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": [ "r173" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire productive assets", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r221", "r1164", "r1165", "r1166" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r174" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/EMPLOYEEBENEFITPLAN" ], "lang": { "en-us": { "role": { "terseLabel": "EMPLOYEE BENEFIT PLAN", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r524", "r525", "r526", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r1004" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issuable upon the release of performance share units", "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "exas_PeriodForCapitalInvestmentExpendituresAndCreationOfFullTimePositionsToEarnRefundableTaxCredits": { "xbrltype": "durationItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PeriodForCapitalInvestmentExpendituresAndCreationOfFullTimePositionsToEarnRefundableTaxCredits", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed", "label": "Period for Capital Investment Expenditures and Creation of Full-time Positions to Earn Refundable Tax Credits", "documentation": "The period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed." } } }, "auth_ref": [] }, "exas_PeriodOfLabTestingServices": { "xbrltype": "durationItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PeriodOfLabTestingServices", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of lab testing services", "label": "Period Of Lab Testing Services", "documentation": "Period Of Lab Testing Services" } } }, "auth_ref": [] }, "exas_PfizerIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PfizerIncMember", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pfizer Inc", "label": "Pfizer Inc [Member]", "documentation": "This member represents information regarding Pfizer Inc." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r683" ] }, "us-gaap_PostemploymentBenefitsPeriodExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PostemploymentBenefitsPeriodExpense", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional benefit charges", "label": "Postemployment Benefits, Period Expense", "documentation": "Period expense related to postemployment benefits." } } }, "auth_ref": [] }, "exas_PrecisionOncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PrecisionOncologyMember", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Precision Oncology", "label": "Precision Oncology [Member]", "documentation": "Precision Oncology" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r151", "r485" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized shares (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r151", "r869" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, issued shares (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r151", "r485" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, outstanding shares (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r151", "r869", "r887", "r1198", "r1199" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value Authorized\u20145,000,000 shares issued and outstanding\u2014no shares at December\u00a031, 2023 and December\u00a031, 2022", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r151", "r787", "r1015" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1061" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "exas_PreventionGeneticsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PreventionGeneticsLLCMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PreventionGenetics", "label": "PreventionGenetics LLC [Member]", "documentation": "PreventionGenetics LLC" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromAccountsReceivableSecuritization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromAccountsReceivableSecuritization", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Accounts Receivable Securitization", "label": "Proceeds from Accounts Receivable Securitization", "documentation": "Proceeds from securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from issuance of convertible notes", "terseLabel": "Net proceeds from issuance", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Debt, Net of Issuance Costs", "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r283" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock options", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r13", "r33" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from lines of credit", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r61", "r1074" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1043", "r1068" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities and sales of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "exas_ProceedsFromSaleOfInvestmentsInPrivatelyHeldCompanies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ProceedsFromSaleOfInvestmentsInPrivatelyHeldCompanies", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds From Sale Of Investments In Privately-Held Companies", "label": "Proceeds From Sale Of Investments In Privately-Held Companies", "documentation": "Proceeds From Sale Of Investments In Privately-Held Companies" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Sale of Productive Assets", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r172" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock option exercises", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r13", "r33" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds in connection with the Company's employee stock purchase plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r1128" ] }, "exas_ProductDevelopmentAndOtherMilestoneBasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ProductDevelopmentAndOtherMilestoneBasedPaymentsMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Development and Other Milestone-based Payments", "label": "Product Development and Other Milestone-based Payments [Member]", "documentation": "Product Development and Other Milestone-based Payments" } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare Parts B & C", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r995" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r354", "r771", "r804", "r805", "r806", "r807", "r808", "r809", "r968", "r995", "r1016", "r1049", "r1122", "r1123", "r1127", "r1193" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r354", "r771", "r804", "r805", "r806", "r807", "r808", "r809", "r968", "r995", "r1016", "r1049", "r1122", "r1123", "r1127", "r1193" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r246", "r271", "r274", "r285", "r291", "r307", "r317", "r318", "r337", "r344", "r349", "r352", "r399", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r640", "r643", "r644", "r670", "r685", "r781", "r796", "r835", "r889", "r907", "r908", "r984", "r1012", "r1013", "r1027", "r1064", "r1124" ] }, "exas_PromotionAgreementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PromotionAgreementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "PFIZER PROMOTION AGREEMENT", "label": "PFIZER PROMOTION AGREEMENT", "documentation": "n/a" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENT" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY, PLANT AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r185", "r230", "r233", "r234" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, at cost", "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r186", "r251", "r794" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r19", "r784", "r794", "r1015" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r19", "r230", "r233", "r792" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of property, plant and equipment, net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r186" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "exas_PurchaseOfEmployeeStockPurchasePlanShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PurchaseOfEmployeeStockPurchasePlanShares", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of employee stock purchase plan shares (in shares)", "label": "Purchase of Employee Stock Purchase Plan Shares", "documentation": "Represents the equity impact of the number of employee stock purchase plans purchased by the entity during the period." } } }, "auth_ref": [] }, "exas_PurchaseOfEmployeeStockPurchasePlanValues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PurchaseOfEmployeeStockPurchasePlanValues", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of employee stock purchase plan shares", "label": "Purchase of Employee Stock Purchase Plan Values", "documentation": "Represents the equity impact of the value of purchase of employee stock purchase plan by an entity during the period." } } }, "auth_ref": [] }, "exas_PurchasesOfNonMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "PurchasesOfNonMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of non-marketable securities", "label": "Purchases of non-marketable securities", "documentation": "Purchases of non-marketable securities" } } }, "auth_ref": [] }, "exas_QuiTamSuitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "QuiTamSuitMember", "presentation": [ "http://www.exactsciences.com/role/LegalMattersCOMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qui Tam Suit", "label": "Qui Tam Suit [Member]", "documentation": "Qui Tam Suit" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r450", "r451", "r452", "r453", "r525", "r542", "r572", "r573", "r574", "r742", "r766", "r810", "r858", "r859", "r915", "r921", "r923", "r924", "r938", "r965", "r966", "r985", "r993", "r1007", "r1017", "r1020", "r1118", "r1126", "r1182", "r1183", "r1184", "r1185", "r1186" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r450", "r451", "r452", "r453", "r525", "r542", "r572", "r573", "r574", "r742", "r766", "r810", "r858", "r859", "r915", "r921", "r923", "r924", "r938", "r965", "r966", "r985", "r993", "r1007", "r1017", "r1020", "r1118", "r1126", "r1182", "r1183", "r1184", "r1185", "r1186" ] }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total reclassifications", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r41", "r58" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Out Of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of amounts reclassified from accumulated other comprehensive income (loss)", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of the amounts of unrecognized tax benefits", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "exas_RefundableTaxCreditEarnedToDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "RefundableTaxCreditEarnedToDate", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable tax credits earned", "label": "Refundable Tax Credit Earned to Date", "documentation": "The amount of refundable tax credits earned, relating to capital investments and job creation, as of the end of the reporting period." } } }, "auth_ref": [] }, "exas_RefundableTaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "RefundableTaxCreditReceivable", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable tax credit receivable", "label": "Refundable Tax Credit Receivable", "documentation": "The amount of refundable tax credit receivable as of the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConstructionLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConstructionLoansPayable", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on construction loan", "label": "Repayments of Construction Loans Payable", "documentation": "The cash outflow from repayment of borrowings to finance the cost of construction." } } }, "auth_ref": [ "r62" ] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of convertible debt", "label": "Repayments of Convertible Debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r62" ] }, "exas_RepaymentsOfConvertibleDebtInCashAndByIssuanceOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "RepaymentsOfConvertibleDebtInCashAndByIssuanceOfShares", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of convertible debt in cash and by issuance of shares", "label": "Repayments of Convertible Debt in Cash and by Issuance of Shares", "documentation": "Repayments of Convertible Debt in Cash and by Issuance of Shares" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r1069" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r294", "r295", "r468", "r487", "r735", "r976", "r977" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESResearchandDevelopmentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r146", "r592", "r1187" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Costs", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r591" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research", "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r101" ] }, "exas_ResolutionBioscienceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ResolutionBioscienceMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Resolution Bioscience", "label": "Resolution Bioscience [Member]", "documentation": "Resolution Bioscience" } } }, "auth_ref": [] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash \u2014 included in other long-term assets, net as of December 31, 2023 and 2021, and prepaid expenses and other current assets as of December 31, 2022", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1058", "r1072", "r1188", "r1192" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r250" ] }, "exas_RestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "RestrictedCashMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash (1)", "label": "Restricted Cash [Member]", "documentation": "Restricted Cash" } } }, "auth_ref": [] }, "exas_RestrictedStockAwardsAndRestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "RestrictedStockAwardsAndRestrictedStockUnitsRSUMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Shares and RSUs", "label": "Restricted Stock Awards And Restricted Stock Units R S U [Member]", "documentation": "Represents the details relating to the restricted stock awards and restricted stock units (RSUs) as awarded by the entity to their employees as a form of incentive compensation." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issuable upon the release of restricted stock awards", "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r68" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r154", "r196", "r790", "r817", "r822", "r833", "r870", "r1015" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r242", "r304", "r305", "r306", "r308", "r316", "r318", "r403", "r409", "r582", "r583", "r584", "r618", "r619", "r650", "r653", "r654", "r657", "r668", "r813", "r815", "r836", "r1198" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r338", "r339", "r343", "r347", "r348", "r354", "r356", "r358", "r520", "r521", "r771" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r338", "r339", "r343", "r347", "r348", "r354", "r356", "r358", "r520", "r521", "r771" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r358", "r1044" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r237", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r967" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.exactsciences.com/role/REVENUE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r237", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r523" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from external customers by geographic areas", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r36" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "exas_RevolvingLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "RevolvingLoanAgreementMember", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolver", "label": "Revolving Loan Agreement [Member]", "documentation": "Revolving Loan Agreement" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r726", "r1014" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r726", "r1014" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties [Abstract]", "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "exas_SECSchedule1209ValuationAllowancesAndReservesBusinessAcquiredAndPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "SECSchedule1209ValuationAllowancesAndReservesBusinessAcquiredAndPurchaseAccountingAdjustments", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition and purchase accounting", "label": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Business Acquired And Purchase Accounting Adjustments", "documentation": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Business Acquired And Purchase Accounting Adjustments" } } }, "auth_ref": [] }, "exas_SalesMilestoneRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "SalesMilestoneRangeOneMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Milestone Range One", "label": "Sales Milestone Range One [Member]", "documentation": "Represents information related to the first sales milestone range." } } }, "auth_ref": [] }, "exas_SalesMilestoneRangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "SalesMilestoneRangeThreeMember", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Milestone Range Three", "label": "Sales Milestone Range Three [Member]", "documentation": "Represents information related to the third sales milestone range one." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/ACCRUEDLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of accrued expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r58", "r1171", "r1172" ] }, "exas_ScheduleOfAllocationOfTransactionCostsRelatedToConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ScheduleOfAllocationOfTransactionCostsRelatedToConvertibleDebtTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allocation of Transaction Costs Related to Convertible Debt", "label": "Schedule of Allocation of Transaction Costs Related to Convertible Debt [Table Text Block]", "documentation": "Schedule of Allocation of Transaction Costs Related to Convertible Debt" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of available-for-sale securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair value of contingent consideration", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r106", "r109", "r631" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of business acquisitions, by acquisition", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r106", "r109" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of cash and cash equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r639" ] }, "exas_ScheduleOfCommonStockIssuedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ScheduleOfCommonStockIssuedTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock Issued", "label": "Schedule of Common Stock Issued [Table Text Block]", "documentation": "Schedule of Common Stock Issued" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of expense (benefit) for income taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r201" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of components of the net deferred tax asset", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r200" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of differences between the effective income tax rate and the statutory tax rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r199" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of non-cash stock-based compensation expense by department", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r97" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r396", "r397", "r398" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r81", "r83", "r772" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of net-book value and estimated remaining life and finite lived intangible assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r81", "r83" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r987" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of carrying amount of goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r987", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of income before income tax, domestic and foreign", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1076" ] }, "exas_ScheduleOfInterestExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ScheduleOfInterestExpenseTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest Expense", "label": "Schedule of Interest Expense [Table Text Block]", "documentation": "Schedule of Interest Expense" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/INVENTORYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r43", "r158", "r159", "r160" ] }, "us-gaap_ScheduleOfNoncashOrPartNoncashDivestituresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNoncashOrPartNoncashDivestituresTextBlock", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Noncash or Part Noncash Divestitures", "label": "Schedule of Noncash or Part Noncash Divestitures [Table Text Block]", "documentation": "Tabular disclosure of the sale of an asset or business through a noncash (or part noncash) transaction. It may include the nature and purpose of the divesture, as well as the asset divested of and the noncash consideration received (that is, debt, stock, and so forth.) Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r65", "r66", "r67" ] }, "us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments Not Readily Marketable", "label": "Other Investments Not Readily Marketable [Table Text Block]", "documentation": "Tabular disclosure of other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price." } } }, "auth_ref": [ "r139" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of allocated to the underlying assets acquired and liabilities assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r203" ] }, "us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Securities Owned Not Readily Marketable", "label": "Securities Owned Not Readily Marketable [Table Text Block]", "documentation": "Tabular disclosure of not readily marketable securities and investments including, but not limited to, description of security or investment, fair value and value as measured by quoted price." } } }, "auth_ref": [ "r139" ] }, "exas_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReservedForIssuanceTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of shares of authorized common stock reserved for issuance", "label": "Schedule of Share Based Compensation Arrangement by Share Based Payment Award Shares Reserved for Issuance [Table Text Block]", "documentation": "Tabular disclosure of maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors) and reserved for issuance, for awards under the equity-based compensation plan." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r544", "r545", "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of shares of common stock issued", "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "documentation": "Tabular disclosure of employee stock purchase plan activity." } } }, "auth_ref": [ "r96" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of stock option activity under the Stock Plans", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r29", "r30", "r95" ] }, "exas_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of valuation assumptions", "label": "Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of share-based payment award, stock options, valuation assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r198" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of restricted stock and restricted stock unit activity under the Stock Plans", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of unrecognized tax benefits", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r1010", "r1159" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of estimated future amortization expense, intangible assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r83" ] }, "exas_ScreeningMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ScreeningMember", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Screening", "label": "Screening [Member]", "documentation": "Screening" } } }, "auth_ref": [] }, "exas_SecuritizedReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "SecuritizedReceivablesMember", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securitized Receivables", "label": "Securitized Receivables [Member]", "documentation": "Securitized Receivables" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1030" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1033" ] }, "us-gaap_SecurityOwnedNotReadilyMarketableFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityOwnedNotReadilyMarketableFairValue", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-marketable securities", "label": "Security Owned Not Readily Marketable, Fair Value", "documentation": "Value of the not readily marketable security or category which has been determined by management based upon fair value methods, including pricing of similar securities and valuation techniques and is included in the schedule of financial condition or the balance sheet." } } }, "auth_ref": [ "r140" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r356", "r357", "r851", "r853", "r855", "r916", "r922", "r927", "r940", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r969", "r996", "r1020", "r1127", "r1193" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r333", "r334", "r335", "r336", "r337", "r342", "r346", "r350", "r351", "r352", "r353", "r354", "r355", "r358" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r164" ] }, "us-gaap_ServiceAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceAgreementsMember", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service Agreements [Member]", "label": "Service Agreements [Member]", "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service." } } }, "auth_ref": [ "r115" ] }, "exas_ServiceFeeBasedOnIncrementalGrossProfitsOverSpecifiedBaselinesAndRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ServiceFeeBasedOnIncrementalGrossProfitsOverSpecifiedBaselinesAndRoyalties", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service fee based on incremental gross profits over specified baselines and royalties", "label": "Service Fee Based on Incremental Gross Profits Over Specified Baselines and Royalties", "documentation": "Represents service fee based on incremental gross profits over specified baselines and royalties." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r995" ] }, "exas_ServiceOrProductTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ServiceOrProductTypeAxis", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service Type [Axis]", "label": "Service or Product Type [Axis]", "documentation": "Service or Product Type" } } }, "auth_ref": [] }, "exas_ServiceOrProductTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ServiceOrProductTypeDomain", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service or Product Type [Domain]", "label": "Service or Product Type [Domain]", "documentation": "Service or Product Type" } } }, "auth_ref": [] }, "exas_Settlements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "Settlements", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlements", "label": "Settlements", "documentation": "Settlements" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash stock-based compensation expense", "label": "Share-Based Payment Arrangement, Accelerated Cost", "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for issuance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1008" ] }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardContributionByEligibleEmployeePercent", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of employee's compensation to be deducted from the employee's pay", "label": "Share Based Compensation Arrangement by Share Based Payment Award Contribution by Eligible Employee Percent", "documentation": "Represents the percentage of compensation that can be contributed by the employee towards the purchase of the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r564" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r564" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r562" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "periodEndLabel": "Outstanding at the end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r559", "r560" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Shares and Performance Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r559", "r560" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Released (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r563" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of equity instruments other than options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r566" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Released (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r563" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation assumptions", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r573" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, maximum (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, minimum (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rates, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rates, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "verboseLabel": "Stock-based compensation", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r544", "r545", "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r572", "r573", "r574", "r575" ] }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumValueOfSharesPerEmployee", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum value of shares that an employee is permitted to purchase", "label": "Share Based Compensation Arrangement by Share Based Payment Award Maximum Value of Shares Per Employee", "documentation": "The highest value of shares that an employee can purchase under the plan per period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of outstanding performance share units (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in number of shares reserved for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharesReservedforIssuanceDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for future grant (in shares)", "verboseLabel": "Shares reserved for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r94" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional disclosures", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at the end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r553" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at the end of the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r553" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r566" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r557" ] }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAfterTerminationOfPlan": { "xbrltype": "sharesItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAfterTerminationOfPlan", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Further grants or awards after termination of plan (in shares)", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period After Termination of Plan", "documentation": "Represents the number of share options (or share units) granted or awarded after termination of the share-based compensation plan." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value per share of options granted during the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r565" ] }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Intrinsic Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at the end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r94" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "periodEndLabel": "Outstanding at the end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r551", "r552" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r551", "r552" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r568" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at the end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r567" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r567" ] }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]" } } }, "auth_ref": [] }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodByWhichOptionsWillAccelerateUponAcquisitionOfEntity": { "xbrltype": "durationItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodByWhichOptionsWillAccelerateUponAcquisitionOfEntity", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period by which all options to purchase common stock will accelerate upon an acquisition of the company", "label": "Share Based Compensation Arrangement by Share Based Payment Award Period by which Options will Accelerate upon Acquisition of Entity", "documentation": "Represents the period by which all options to purchase common stock will accelerate upon an acquisition of the entity." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental share based compensation expense", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r579" ] }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteNumberOfHoursPerWeekOfEmployment": { "xbrltype": "integerItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteNumberOfHoursPerWeekOfEmployment", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of hours per week of customary employment required to participate in the plan", "label": "Share Based Compensation Arrangement by Share Based Payment Award Requisite Number of Hours Per Week of Employment", "documentation": "Represents the number of hours per week for which an employee is required to provide service to participate under an equity-based compensation arrangement." } } }, "auth_ref": [] }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteNumberOfMonthsOfEmployment": { "xbrltype": "durationItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteNumberOfMonthsOfEmployment", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of months of customary employment required to participate in the plan", "label": "Share Based Compensation Arrangement by Share Based Payment Award Requisite Number of Months of Employment", "documentation": "Represents the number of months for which an employee is required to provide service to participate under an equity-based compensation arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Award [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r547", "r548", "r549", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r556" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r557" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting for Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r543", "r550", "r569", "r570", "r571", "r572", "r575", "r585", "r586", "r587", "r588" ] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Performance Shares, Activity", "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares." } } }, "auth_ref": [ "r40" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated vesting (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number", "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period from the date of grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1009" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofFairValueofOptionsandESPPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r571" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at the end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r94" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at the end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r94" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at the end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r197" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r567" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option exercise price, expressed as a percentage of fair market value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofConversionFeaturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued, price per share (in usd per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "exas_SharesIssuedUponAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "SharesIssuedUponAcquisitionMember", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issuable in connection with acquisitions", "label": "Shares Issued Upon Acquisition [Member]", "documentation": "Shares Issued Upon Acquisition" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r942", "r943", "r944", "r971" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r723", "r1014" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "exas_StateOfWisconsinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "StateOfWisconsinMember", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State of Wisconsin", "label": "State of Wisconsin [Member]", "documentation": "State of Wisconsin" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r239", "r259", "r260", "r261", "r291", "r322", "r323", "r325", "r327", "r331", "r332", "r399", "r456", "r458", "r459", "r460", "r463", "r464", "r485", "r486", "r489", "r492", "r499", "r685", "r829", "r830", "r831", "r832", "r836", "r837", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r869", "r890", "r909", "r945", "r946", "r947", "r948", "r949", "r1041", "r1073", "r1086" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofamountsreclassifiedfromAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r25", "r56", "r242", "r277", "r278", "r279", "r304", "r305", "r306", "r308", "r316", "r318", "r330", "r403", "r409", "r500", "r582", "r583", "r584", "r618", "r619", "r650", "r652", "r653", "r654", "r655", "r657", "r668", "r695", "r696", "r697", "r698", "r699", "r700", "r734", "r813", "r814", "r815", "r836", "r909" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r356", "r357", "r851", "r853", "r855", "r916", "r922", "r927", "r940", "r951", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r969", "r996", "r1020", "r1127", "r1193" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r304", "r305", "r306", "r330", "r771", "r824", "r848", "r860", "r862", "r863", "r864", "r865", "r866", "r869", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r882", "r883", "r884", "r885", "r886", "r888", "r891", "r892", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r909", "r1021" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r304", "r305", "r306", "r330", "r771", "r824", "r848", "r860", "r862", "r863", "r864", "r865", "r866", "r869", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r882", "r883", "r884", "r885", "r886", "r888", "r891", "r892", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r909", "r1021" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock to fund business combinations (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r151", "r152", "r196" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails", "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Conversion of convertible notes, net of tax (in shares)", "terseLabel": "Stock issued in conversion of convertible notes (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r25", "r55", "r92", "r196", "r475" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock to fund the Company's 401(k) match (in shares)", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONScheduleofShareIssuedDuringPeriodDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationPlansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares (in shares)", "terseLabel": "Stock issued under the Company's stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r25", "r151", "r152", "r196" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockOptionRestrictedStockandPerformanceSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock options (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r25", "r151", "r152", "r196", "r556" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Replaced restricted stock awards for business combinations", "terseLabel": "Stock issued during period, value, acquisitions", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r25", "r56", "r196" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of convertible notes, net of tax", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r25", "r56", "r196" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESIssuancesandSettlementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of stock after conversion of convertible notes", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments", "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock to fund the Company\u2019s 2020 401(k) match", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONIssuanceofStockUnderESPPDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash received under the 2010 Purchase Plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r25", "r151", "r152", "r196" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r25", "r56", "r196" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.exactsciences.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets", "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r152", "r155", "r156", "r179", "r871", "r887", "r910", "r911", "r1015", "r1028", "r1075", "r1101", "r1170", "r1198" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r192", "r290", "r484", "r486", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r498", "r500", "r659", "r912", "r913", "r950" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of valuation allowance", "label": "Summary of Valuation Allowance [Table Text Block]", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r100" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "exas_TARDISTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "TARDISTechnologyMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TARDIS Technology", "label": "TARDIS Technology [Member]", "documentation": "TARDIS Technology" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforwards", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r102" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r101" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r101" ] }, "exas_TheBroadInstituteLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "TheBroadInstituteLLCMember", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Broad Institute, LLC", "label": "The Broad Institute, LLC [Member]", "documentation": "The Broad Institute, LLC" } } }, "auth_ref": [] }, "exas_ThriveAshionAndOmicEraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ThriveAshionAndOmicEraMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thrive, Ashion and OmicEra", "label": "Thrive, Ashion and OmicEra [Member]", "documentation": "Thrive, Ashion and OmicEra" } } }, "auth_ref": [] }, "exas_ThriveEarlierDetectionCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "ThriveEarlierDetectionCorporationMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessCombinationProFormaInformationDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSDetailsofConsiderationTransferredDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationAdditionalInformationDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYStockIssuedbyAcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thrive", "label": "Thrive Earlier Detection Corporation [Member]", "documentation": "Thrive Earlier Detection Corporation" } } }, "auth_ref": [] }, "exas_TimePeriodAfterLastLicensedPatentExpiresThatLicenseAgreementRemainsInEffect": { "xbrltype": "durationItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "TimePeriodAfterLastLicensedPatentExpiresThatLicenseAgreementRemainsInEffect", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time period after the last licensed patent expires that the license agreement will remain in effect", "label": "Time Period After Last Licensed Patent Expires That License Agreement Remains In Effect", "documentation": "Represents the time period after the last licensed patent expires that the license agreement will remain in effect." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r1087", "r1178" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativeDetails", "http://www.exactsciences.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSPurchasePriceAllocatedtotheUnderlyingAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade name", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r112" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r481", "r497", "r658", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r798", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1096", "r1097", "r1098", "r1099" ] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Adoption [Domain]", "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r244", "r307", "r308", "r309", "r310", "r319", "r361", "r362", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r445", "r582", "r583", "r584", "r616", "r617", "r618", "r619", "r632", "r633", "r634", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r680", "r681", "r686", "r687", "r688", "r689", "r701", "r702", "r707", "r708", "r709", "r710", "r730", "r731", "r732", "r733", "r734", "r773", "r774", "r775", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnsHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTheBroadInstituteDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r639" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesAndFairValueofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government agency securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r981", "r1002", "r1190" ] }, "exas_UnitedHealthCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "UnitedHealthCareMember", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UnitedHealthcare", "label": "United Health Care [Member]", "documentation": "Represents information pertaining to united health care." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of the period", "periodEndLabel": "Ending of the period", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r595", "r602" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease due to prior year tax positions", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r603" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest or penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r601" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized interest or penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r601" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase due to current year tax positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r604" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase due to prior year tax positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r603" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlements", "label": "Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities", "documentation": "Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r99" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefit that would impact effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r605" ] }, "us-gaap_UnusualOrInfrequentItemAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualOrInfrequentItemAxis", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Axis]", "label": "Unusual or Infrequent Item, or Both [Axis]", "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r171" ] }, "us-gaap_UnusualOrInfrequentItemDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualOrInfrequentItemDomain", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unusual or Infrequent Item, or Both [Domain]", "label": "Unusual or Infrequent Item, or Both [Domain]", "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r171" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r75", "r76", "r77", "r226", "r228", "r231", "r232" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTaxPositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r608" ] }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward." } } }, "auth_ref": [ "r1077", "r1078", "r1079", "r1080", "r1081" ] }, "us-gaap_ValuationAllowancesAndReservesAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesAdjustments", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes to existing valuation allowances", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment", "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Beginning balance", "negatedPeriodEndLabel": "Ending balance", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r298", "r303" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowances established", "negatedTerseLabel": "Valuation allowances established", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": [ "r301" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r298", "r299", "r300", "r302", "r303" ] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails", "http://www.exactsciences.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r298", "r299", "r300", "r302", "r303" ] }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "auth_ref": [ "r298", "r299", "r300", "r302", "r303" ] }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ValuationAndQualifyingAccountsDisclosureTable", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDeferredTaxAssetValuationAllowanceRollForwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "auth_ref": [ "r298", "r299", "r300", "r302", "r303" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r724", "r1014" ] }, "exas_VariablePriceContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "VariablePriceContractMember", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable consideration", "label": "Variable Price Contract [Member]", "documentation": "The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payer reimbursement contracts." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "exas_VentureCapitalInvestmentFundMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "VentureCapitalInvestmentFundMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Venture Capital Investment Fund", "label": "Venture Capital Investment Fund [Member]", "documentation": "Venture Capital Investment Fund" } } }, "auth_ref": [] }, "exas_WISCONSINECONOMICDEVELOPMENTTAXCREDITSTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "WISCONSINECONOMICDEVELOPMENTTAXCREDITSTextBlock", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITS" ], "lang": { "en-us": { "role": { "terseLabel": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS", "label": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS [Text Block]", "documentation": "The entire disclosure relating to the Wisconsin Economic Development Tax Credit." } } }, "auth_ref": [] }, "exas_WatchmakerGenomicsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "WatchmakerGenomicsIncMember", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSWatchmakerGenomicsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Watchmaker Genomics, Inc", "label": "Watchmaker Genomics, Inc [Member]", "documentation": "Watchmaker Genomics, Inc" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r965", "r966", "r1181", "r1183", "r1186" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r321", "r327" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.exactsciences.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r320", "r327" ] }, "exas_WisconsinEconomicDevelopmentTaxCreditDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exactsciences.com/20231231", "localname": "WisconsinEconomicDevelopmentTaxCreditDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS.", "label": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS.", "documentation": "Wisconsin Economic Development Tax Credit Disclosure [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "SubTopic": "50", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-6" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "SubTopic": "40", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a-c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481244/470-50-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "940", "SubTopic": "820", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481753/940-820-50-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "940", "SubTopic": "820", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481753/940-820-50-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483613/220-20-50-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//460/tableOfContent" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-25" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r967": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r968": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r969": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r970": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r971": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r972": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r975": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r976": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r977": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r978": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r979": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r980": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r981": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r983": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r984": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r985": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r987": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r990": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r993": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r995": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r996": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r997": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r998": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r999": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1002": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r1021": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r1030": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1031": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1032": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1033": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1034": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1035": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1036": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1037": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1038": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1039": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1040": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1041": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 134 0001124140-24-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001124140-24-000012-xbrl.zip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g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c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

JFR5?^52[@,:S\2?%TVLZ+6/55XI M$%A?1-74C92;5B;E3T[N $9BY%8YNU,<6*U\ES@_:.BN,V"%T>PIVT+V\I/, M?# C_V-A(M,T=E_/4FV_@J%"E5HM):F3X6[G[-)J=B_FF^@AZ_=I#OI:.^YL M?<>@>UK=QL5\X[!LQ\BMRS%/&F,R \<8&.MU0 M=^3-WWG:6-,R#6P%3G_:_/C8M)ER6-#E#OS3GRGA.71E1&).!1_[GLT1Q=>E M=+$@%K32+.8J6?$7QXO^AA[3W_EH.'S=ZT,I>_UC9(6_XKR&Z^=XA)MJ-CU^N[G^EOUH?WY->0;$GX+C3!-0O.8SV:0J8 M2LY%5&Q2QZWBAN>I57E?<); ('WNI%&B?QA1G7L:41$G540F1:0Z/:@TOB== ML.2ICC%5THM'2&WJRT<>4 RH5#.^/U*'O23-J? "SFF(A<55=C R'E6(!-5-]VUA!&=+48H;9:"2:PP MN?-B6MOG\913BS) ^F/F$.& M^7@XA3X.IY&8-IJ%7'+&,5YZ"41>.5&1GZLG!,ML.G_N+1P9?_F(7GH5P[,8 ML[19U9&K58J4KPQVR;[23-E%0J3?F/=^]1O'FU;,H7& ?BA5[W;(L1/3%%9* M<:!!WKSIG_,4,<[[BK.'A=Z"!CH!@8QCT)(F(4^-& [1-C8-X;E MP$<%(>I MOP"EX9 :)C]X9K"RS\0D8ID2JCQ(P2U:4!UO3*/72?JQW![$\^DOZ8?R'1?& M6GE3-;RN-.X;HR0E"Q^%:!1AM%"8]N2_04($0"!8Y6U28)P1B\K;7ES!C44L ME,6X3#:'FAY.O2" *E3I0HXT!\OQIR=F\3$G.*<6/ MCB\2N!F-&H;%Y"(1DSLJ8\6T%12(Y.,+>'*Y/Q,YE M3 4$4?PDXOT@;,%F+8*A$#]^'6:IFRO;Q85Q+;R1@S14/[\I #;SZ))%7A'> M+##M<_G/8AI:EC.41L9S_KZIT'?F(9D=>IJHN>4O/ T+'W M4/0P(%A13R=EUZ9NY=RH>TD M-!H1DSR)="D/!;;C%I(REN 7)^97MB*2605KSD##_>R2]2MS% 'I87%2]&DE MJA7@GN@$BP[(P@ MCK#@V8O" '^2YU4#QQ^@)WKI!7!Y@ 8]$IE">G"7J64@AKE+?VU^:R:?.3J< M!@,UV_Z/P$,*HW!AG/(_S/!+&6":Z4<@Y]D1J)(2L0-\?P]#%Z,T0H;B1N*,.7BTGM+D8 N1%F? MZB.XHS_/36>*ZB)LDY#2H0+RIPMV(!;DCY*EZB7< ^3$(7*+6:I@$.VH/*&8 MZ@U?AT+62A$YMXI &$H3P[&D/'K <[34)"5)%I@UY4[C))J9E$D#[S6IDBAA M3V)8+\I]=)9-U2RO%(XB5*#$5Q3HPGV\:A2TY^I"N55P*U&7%.+O'A-KV^JM;5-V;"I=NFNL*XM'#.>N9?7 MBXO(E>'3D.JBEAYHQ?,$[,7Q5SQ($P[26'00"F8M.TPI?7!GQVIV)/OIQ*4G M>1 KPYON* %NA?.T%F'+A7&;9Z-IBID2FTSUK1Q[577.0ET9";]\O9XB^XK: M90VQ 8NA*N.I>Q.R&"Y0=7/3)';PO<;^9:7)#CK?+IB/EU'Y]/58"\Z MGZ[.6]]%/EVW-)^NM[B\@?L;2[R0]E*_8XTTYLPY1^8)-V6$ J?F1#UBK0(( M550&'X44C:D@@.P/:3\656&AN*T^0.A!Y R3<&*"2*HI-S MN#^,,-\D"Z5(#2.MDI<2V^[ !^N M]>8>FUO<2W/ITBS\S)A8[JCB6D7$E*PGI8)_7L7.6[(8@>.9^3*K3AI#LASL M$5;+';E,D"\4W/5%\5>(U\X3 ,((4T8"GHZ58"UNJ'2&H+0 62[K>D+U&;*( MVXD1F$6HN!'^ J1=4>,+2US=7QL]4&IR5^*&3-S)9"(:*Z@8*H*AJ88EUL W M40+;.6F TEJ_">*$.51P@7''(CE%Q>X4DR@<>CP0%,;Q6EHG:)?3"/V$PF51 M A>3VH#P1Z2-&(LD2V(R&$%#6L,W X(#YOHL_?UX A_2(ECY/@F%'2ZBH1F6 M(T&@?[+P'(D)>'\XD"8$.0%.;M4VFB7 8GS/$/X _4W&=YGP62"P- 42:X_BH9-S MZ:DU58KOGQJ)4&<IAH?C$EPN:PB +JO0IX RQJ9^\N(N(2B1."2KO@E]=P&4]3RG6X M#09A,IMLI_JZ@TVTEAL \R8EQG[/F_1TL:$6, 9NI_SU+U:W]7&?5>.F<4H4GO]>NHBYW^7Z]F\WG\ZM/EV8N/STSBB]6J"6J)SS M6:*B\@*TQ1X^4W_H <*I#8-$3YYTGANB-*5R4Y>8Q*,86U8'*-WU(^;XR6B MNQ&->Z*\T!0-9$@:=AH=4Y(@3\BX3F4-Z322RV) )92BAPBA@,*R[Y%,X*ZK M]WO-Y@=?%Q/ID:2DS7FHQ(WGN1=/1D^X9O(XS;O24S6,S%M>2>!PMR 6!'OC M1V#+3-01N" *LI$GM+:%@,;6+ M"QTI](1!@LG/Z C$CH+"N4=!#4X53DI+W(9(-T'Q*CA9EO;8(JXHR MYD$H6N)@]FXL"M21L/E=X99^9QCH@@U058_XI^<:]Y*S2?9X_?M]EC,04.HW M4!'Y<2UX8RTM!C'7":]'%##A"M;IE8]%6SB\Z?*D#D7I$9*;!(FAR"70C3Q"U*KA?6HBPFQ-)< M:7E2EY&_E=]$3L5".*0*!\E$(1TY'!^QD(9R\ $@#C;U$%*>6Y0QBLXLAP ( M#LL815<\;@F3-I!E&RCM44S>#42\:1">9RDU+L-B2_2^4HJ+_(WCCH0\S1)! M3)'2!M=#WQ"/Q\8XJ(IQ(2^21GW'&\/*@>?X("0_BRXQY*-;A+-4NRJR2%RE M)U%Z$;( @!JSBELBICVE+FU*SQA!=,P5@!$Y381+]-,0F&[)%OB/+T ORH.: M*D)Y$Q]8,ZUIHLLE#FZFMZ&TF1,H0QI9UCS03#,'IY6?T>_8^VDJUH+4F97>MIGZN4B!Y0C[(PA?T#;(]5#*/Y&@;L/% M^HRE#J7SX2! MN471XRTLIA=,)RZJP\(5E[FS>#+,2OOE;;TX..+IX[^H-(,+%U@4DVB#1#00 M O3&.BCD1[R#%GR@IE^B!UV6C(A %1R2:_EX@W$<#CRZ$+)K> %KNE*6TTLV MP#3@W9ZS:GEJ?12'/N6O??*&PDR(4UT&R!74 ]294C9%Y)C5V\LN43DK;$C/ MQ"Q)?*E"9BG+W)^8ZKEJFZQ79#:O>[1*>'G]3<[WD9>,2O42E^BBBO"*H8+6A[]0VH\F8GTOBAP$5?(+#R&3K]_'Q7< MLJE'G_Q]JM*663 7@KZF;+]4QIU-Y71'N3V MBY2F*K)5+76@$FZO(VT&+R.'QJ\\Z>I8 F19:9Y$L]SE"[],+!PS\2AGV8MV MN)3\1P'>+$>01YAX81FUFP+3(V(9\UFE\/(WB7GI/J3GF132.7_JFT/(9K[; M+!]$0\PY.X82P+4,3@L82)+IS@N8![ MVF6KL,$B-+GI/0?CK%5,;@*0DQF],O=R4S^G^!FPD5)'Y\UI!":.D_/=I7&5 MSVE:XV$<=/4Z]C33DE2B!5J55-38<$A!)Q[?4;0'T18;.SCFJ9(>@VKV4 !-:[B7:TP)NW%(J9/Q8^B?23 M8N!,8R9]=5D5E=!>E=)AREF8 QS7[1ZHC6G6[#3EEB+_\]7F6EYUS;4._N+H M8N(T-T&DJ1!5%[ EL$#*IJ,1/=(U0""3SB%X8]]RO*Z\H"RSBZ4()[D1L[%$+ M"?<:#?^P684=;$-)U^IJ*, M4)5%?WZLF:=R6#0*MH$Y\X[-M5*/L2OD[? >T7QAFG'G6-OE7(LF"W3\(R!( M>1[.M7(9P<[3$U)=(E$Z16'2)'W SK0V)]>R&4.CA?:R%'F4Y3)HR$:>#.") M;"1ZA8FL.,:>PK[\((L=+!O 8!;:Y7C!,'* CF WTT@AI*(Y^TKH&P=_>I,) M2>813JD0D:\L20"M//54N,;-R53KM(L:*YJ*SK #V^^0(,L?_FX"#N7OD;HR87[S:49%:2? MB*IGWV2M?LMYM[0E7IRHY*%%4&!I;I;/%5 MX-(_?Q/=V[S9O=I[ M2NVD1 0G:A!=:87+W BNQIXS&I$DO,*8:$.IA#ZCDJ:WO4%)T(C2^4!/V)B+ M+Q#&G+%BO@BW]7%JJ;J'W-BA=-!P#ISSM61SCI[%K0&^\2Y9A+(IO%53C.]6 ME*5A;2(3(X540RQ-:UWAG:E9Q\&>%G*B^KG))+::T,O"2!+R..0.ZU)+EHE6 M1AJHO2=II_<"67&3MW3F-2)-(MBU;-<_][3,H50F6JGHF+G(4L),,@E0NF9I MUD&F!"WV3G(B2C\QF%*O.6F(Q,0.]1%CA5Z3V+9J]D$^L%Y'.-.2IO@(L?122(A<^ M=QXOF7*-,LU7Q&6%VH!IT -*UD<5B+GD)WQ"MT/ /1U/7'\*N,).:06XX_^P MVPT3;@6SX#<81M)Z?4C&-1SSRZ>;ZQO^^BO*@%UW3D:_?W;9MONOS,DH;SF2 M952(KB-!_KGRS^/H"OOIE_O-FXZ+5[95^U;BPUOR\ MW2Q_R:(G%FVJ?]'NVGI/>D_'O:?>ZWOZA>B8TS*P"V1%_WW6/,ML2A?#&1\: MA@7LYIH\0]ZE:_/26&13$XOY/UE5#.)#*!EP9 M((Y2%IZX)P:A*RGBOBN9<,EBX*R(;B6G]]EPOC/-'L_^.\GP.Y3AFUY_]C,A MP%&^-[ 5CT&&K(&'^7A0F('ZV0I@6>6\)P0R6X-L79!9FO@T\6GBJP/Q+9'M M\R7M@P%CP^''-T)D=PK!E'[#=:."4WSDGX/_1 M=[N/N^U4>[=]NM]FYM%%WZ;NMQM[UJ[S8W=4??[7[OME_MW;8T M3Z[-W78:U=YM&^[66G*W:YL7HF/6(9D0?,[A_Z35I6]"[L*YUT;NY7 [ @2V MJD7@#B"P71%STO>WPOW9U=Y?5]_?;N^O6>W]]580(/K^*KR_5K7WUZ]0<=?W MM\+]5>L,PPS8OKZ^W5U?M?XNRSJ[[%6M?A=LK$-0ORE%'+/X_HY#RH/8"_9I M71XW!F_BU5,S=JE5^OF?+ I+,=O&J44]V[(_ULMU<-R76ZU;SVJ>73;U]>WN M^JKUW%FMY=)%7U]UU]?=Q#FW!FMM:]:ZA\NMUG%E=/'T$[IRN C3ZB?#]8T M4>D_#7%VIP/>_R#MMYG X44?#NJ-B7VHL4!P:!J\S9%H=LK?*#N4,&R.24-1 M> $;M9OVO1\TJ@B[)V!%&Z^-Q+X!Z;2+B&8GBT7*]D#=I?'A1VS$ 1?XIYP_ MKE;>I5V@U"HY47H7>S3[AO>*XNT*>1?7J3J*(YU2(?MB\KD9U*4A[2H[G%+7 M)M@>9<#S)@C%@LLXZ\7MBIYQI?!7\N?S!6_T4LQ4I$I AOT[L3E*_KX4$.4G M?KG4F%GI=^F#DXJ9RR^ 6(<P".I;.D&2I$ZWU.D!:,]W7C!U$_XC6K/-#2E%O'V.-_L,A0 OS0(F74 ?D4&2%RN:1-*&8^OOP9N,TK<94I^RD(S!IP)#L MB43#UOCRU#)?+$[]:")J34:]X++6Y?/%L?^>8N,U674,&.P,O&3&&2^-Z2^T7S]L?/3&T_'RNBA28BM,;"T7/"/XFMQ MAG(@NL]_-$9EO:EI1)P":(=Z&(L[R$9&34A;X5Q0C&VBL0Q83#T5B;K8E)X% MG(4GG*_2[%7L:YV-8:(!S'R[MVZ9*>,>+Q'"SM)M4\:19/VAB MTEZ .N(%%5A%J ]C?_#BL7F?9]G2CN919%#0)2\5(EAP6B M%35B<(:[* S"J1C!*IK5+=(B[<9+& #H@B Y:1AU8]N]@M M/.2Z;7[X\4$EN7+#"3+CR@%A=__ IW'T_Q)[Q,' M1RVZL?''A,9.I VT[O](QS9_"R]HI?,&++;E,7UKW2]V4:>N_IA)OK7&- M%C[_>XHC L4SK1X^D_^L3=N@3@]JE]9SV!)PH_R'XI&NU7N_9;"_"F04-"@7 M.88 M\6!>#AF)9S&QGW:#88.]5FV-;Q.&XVG.'7_^3K%J0EH?4^1,QFEJGLI M5EZ';B:Q2#Y2!UZN,0 V.\),@*7QJ>%07>;7J8\C7 )"8#B*B>(3[2?12@\G M<.2%J"-X 0WB!&$@F[S"A7-EC#K$IB].QW:BIN1%KO%O4&9QA 9-U$7O">^0 MCL1#+XIX/]<@S)F'T@X)E[>P+NORI^?TK=GY^*Z"U8R=B98X$N>O^' MHE]VZJ9?@KXW\+F]?C.FX4T+)VCO"J0?:@:BG(IVAZBO44>X/E.XZU'N= LSYY#8DJF83N&B[:=>8JA;>_;XOG!7@ MFB@H$(]H%M(CP]Z1OD=S*D,:R0"8BGXSV5(["R;0<^@AHZ&JZ=(\&/'(E+F/ M:I=+E6 E<)G1X2HG"2=U:.@()F@W]G35/3FOC__!Z+E_?G_P^E.(4(HW9$R M>,\;RIRX<].Y L;3;AJ >PC[]%+BI$XM-YXVW\<(2OB1\)2RUS MPNXB@,(3J9&':R?K&UX'))._H2!;52AWZ\8^[MD3T4[FN)$^FE[C_8>Q7E><'B\7W+4+?HM*E=,I=5H(GJ7LF#D4-/7[!F2 M/ZK'02XKI_ZLS_ BEJ@LCWK#XM#-R$,Y6)SY4#JNHGQB ;8QC53.B4Q3<:8 MGV% 6P$%G6A>J=K[+8LKT*P%;YSN1&[>K&<6O&7%)"K\)=^ MW?B+?): MU;+/%NLL2JOG??B=WMGOC?4"OJ)GZA=0)N4T\;\#\EQ/8]"]6%02Z+5* KW6 M?*#W^^>_??[VQ^=YA[IZ-8N\6[1>R5OL4J=6W5)6>)Q^O7L #BA'(@(@;H?B M7LAS6W()=@EX[/E+R+<_YTJ14"OBU]NQN]E^<,S0+.V4'H?3:,#0C?*6B[7) M;?DJW1Q$B_1V[Z+=ZM>L?;1E770LO:D5-V4W-^FTO6DA[%$VF/XGAFL_O]YO M^Z#[PJP&AGJ\N::/Y/-/'-4+<+G".K68N0_.S]7& MU#4S@[YY=MEM6"8<9JX^5+@3-K@K2>;56B*J0U6:8H1%-/>/\6TSRY;S9[9:75J0C$5-2D["#45*SI8A)&JK5E? M]GJ0*V4@!TYEG?U36>?LLM^W3;LUW_U\32I[!=NW(9!$E"OB(,FB7&X?_[]6#@>K67,MXB%,L-1XZT'?%13V52/HQTBE]OZI MU 9!8/8Z+;/;F)^Z\C9U?HV,G/N/?#9Q"*39LA$YY[O&:^0\8>3< M?Y"QB5,LS4;'-IN-JGQMVT3.@TZN71&%[B)9/G4;X#N?9G686Z2??VOJV0'' M]"I-/7M%8&SL#Z\=Y%9/"R@[XA')N/VG!31QFF^O9W9Z\Z,)#C::I"GF:"EF M_R'^)HX/[G?-IKVQ8U53C*:8K5/,_C,6FEU!,7T=3CZXU#,=C5F)RO:?M-'$ ML=H]RVQ6%H[1 ;]:H=C^TQ::E+;0-=L:Q8X2Q?K[3UMH8=I"KV$"FM4$Q4[) MI76#5=P!-6W1F>K;)+3])V^T+""T=M.T-R>T^IBQ&L4R%-M_Y@'V2K.LKMG5 MF>K'B6+[SQ]H8?Y HV_VK:JR![1K06>JUX; ]I\#T<(4N:4S*S>F MQ_U'!%O=L\N.W357H^;.4'/_X;=6 M'\OR+;/3W=@6T]GHU>16W/[MYM.YU3<>&,VVWG77R8WHL7;07+M;V,K'/QXV M!$_LG0^U&\"'S'Z[*G.]#@)2$Z$FPC6((&-?^V5;S[-(V6_V^V>U4[$O8\)IK6O^D"5P3^.H$OO^ 9[N%!-[H MM4R[6U5AKR9P3>":P'D+T?T3.";-@/3N I%7E<"]/P(GP^07&N.Z>&YS_4?_ MIMWVTGFYV6!P+\!+AW?Y#D#22<)H9L!KGKT!2W\]!(0QKC$W8NI$+HWGOJ/O M$ "_L8 !]&(C87$2&R\C#VYF/JDB76SE%S[YX:/CTP+);,*,3_^@-V-NIS/! M9WS&*8)>?)$.G%\V!;LNMW*5&,P9C.#0DS"B@>,36"AT#1:XICH'&8GS%?! Y,S# _0)VYK&.-8]- "1!U,?![+C]S3G7; .N'4 ,OS$ M90F.0@\87!=#@!KXF@#.Y06*&X\GL>CI&T'G/[-I)!J,_)E?NO^ W.,#](13L\YIV>Q-\%F"X'3YDN[[#3:_& M-#L9T^R 5M2^F$\",P#M?+H*0/PUP= Z/#!T<3SFQ;S'*@4#K$=(/6-.%".= M*#-]N6QI6J:!@UP)8CB>U 1DBR?(*9Z9/YO'R C7<$"BO 0OQ-S2DR*AK(>H MZUY1^_"N"(NYK8M%OOVR>WKMFJPBUWY5N@KNV;(ONCA%?1+&'O[F0\0X(++A MZ?\G/\Y=: Z-[!'G$;2$:;+X$45'X#-D]R0D>HT"@)0_1Y'/$7-^ MG#M#V.P'QW]Q9C&J,*HVJ]UV.ZU6L]WKVDW8DV,W'P>/KMO^7^!A#R0S M@1\@ 0/RQ/_UBW.Y4#O9/:;-#28F3/O\CZOK!^/^^N;SM^O/]\;U[?>[V^]7 M#S>WWVJ_]6\A*B/ K@'@I/T#KW.-+U[@!-A?Q+A/X /DC+'Q[IIS%^:^+R.L M OM)YR)8YS9GW_3H52(_;9Z5:9J"WY"R65/E4Q&#?_U+S[:Z'V.014,619EZ M9J(R#PHJ*)M[ WE8LFZ _560*6'6V%&/&(L MB>$53FP$(5AM@$7>$*PP6-,A[7:)8+]80W*4W$M-[N$5C /<$G)<59U7%:VJ M!L2O$2$MC"]77E7QRM/K<1+Z_I$!W,AR%.8&OG8>UF6W>#'/-O!LRSFHA84W M2ZVX/;&:=\WWAE#RODU!'_,&\T&4@A;GQ"/\W^=_3[UG4*> "UT%[N].](.1 M8^&> 2D1_3S *K_ZX>!'IF[UY[E.NX_O8*":39 %1U.0E+]???]_GQ^N?OWZ MV;C_?/W']YN'F\_W4D<3^RQ(H 5XQU:>=>J)6//?]8,3CEP M DG)^2-W&L7#'2Z#'8:^'[X@]=!-&S%P/"3@9%3.)P% )OUIL Q.)A'R.,47 M6$4B#%+I$N+_L*I7!, DEI_S'_>M2[Z_7[I5XT+:\W/V\WR MERQZ8M&FP"3J6'7]R-V[VWC,\33DJR M,H"B^7HC G+35=)V M5CCO"8',7H=FJB@#J75@$S4?DLA%V;ZU2M.*@/O6M7>ZMU/J;))BTC@,V$QH MA;NN[CGFS(*R(QY/?H#56)("5&ZJ?7&\Z&^./V6?O'C@A_$T6C%PD.4%=&@F M7\.$/=>DU8$F%$THKQ#*DE2:[1$*9NYW>Z;5J4LOVU-J-'J]*P5-=^FS&DN: M*FR/Q)IGE]VV:7=U^\?C1*PE+1&VAUBML\M.RVS:&U<@U[#IXX&T$CYGBVL+A-5^36 M VM^+PNI[M,C6[OG3\FS>B63W<^!KL]CH%[@$X_)IJBAO4>GZ#VREC1#^@28 ME>7]I*CW)8SN ?&R.JS!()HREZ:?L#A96^3@?+M.SVQM;H]HGZNFFNU3S9(& M!#NBFM[99;/7,EM67:CFE!RPJ'0GLUTH9-I1ML0TYU>1$=R7YV_>VL34!V(R M>RVK)@XQC4 [M*6K0* N]72T6G69 G^"'M72U&/M3:TCRRZK*EB;XG 7]%2(O* ONMN>KDKOM^4KH MPRP67AY\-$7I/A43CY@Q\)TXIDI[(HP7+QF)DO[%W186EPN;])07XR.BT#^M M73ZZ"N)6^Z+1[]6P6+>6%<1Z4ZMNRFY746M]ZH7#!U7I>C7&AH=_,I?#XSJ, M5RG&VQP2KV+$+ALTK0:FWQPOH.Y 5[?7-\8[J]AZ28,J!=77$'OO[@E6]2,P MV;E0$!CF81J4B*GKR_=1M71*9>5Z;[HG0#PZ'7$7"]!'6-M)U?G[!*#PJVJ MJA=J$/C5U'6RU%6DIP*U#0:\NS9S?XN 6/X((@80 ')#2X:3U=QLC*'WD[GG M?[(H+".?[MDE]?FS/VKZT?1SLO2#HN=-]-/3]*/IYWCH9S>E#-U^S92V4ZID M^./B_L)X"F%+ 4T3<9Y8,-"5#3NBO^9!65>]!I9)-)IUZ1NBL7&GV+AK:Z1G M5:9-:80[)81[J_K>LS7"G33"[4;?[37K)49/L%A,=]VJ!T$N:ZY8-P6X555+ M1EUS=DIHO'/-N5VU'U(CJD;4;6C<'8VH&E$K5PPJT]2[!R3O3Z'05S=#U,^_ M_OPIY?5M)W:C0\$G&0I>4FY>-TN\=W;9[ICM?E4M.&J@&VKJ.EGJJLA!,$\F M?>RM6E6')$TCFD;6.MN[6A!)P3DQ1R3]QMEE2:N3N6I131Z:/.HK0G;C$>E; MI'=UK;K(E%/*U;L.HTD8 8XM8=52A;L%W&J^5?;J"K?&IT-D4CO24-LD M"GMV7<:FGE)$XBJ.66+@D9A;DS;L1T]UGAM/&NC/EX7C8ZK MH^/6--7NV66G+J.0-$Y5K*AN":F6*JH]G(:ZB::J$>H0F=2.-%6<.M4R>_V- M&S+7RY?ZEKZ&8HES_/V'SCXZ'+_>*6M95\,5C$;0W0UM.BX@R.XA*;&=1@/D M0L/L]ZH:D+ W3X9&RK[1[8XU&IZ&KHD\;X7:B#7<: MS9K)U!,LBZ[=#,VC)[W&8>F]+4PG[9G-KO;>GB0^;LE[VVFTSRY;C;KDE&FD MJMA]NR6L6N*^[30HUC2?$J7=M[5#J!U*SNF]E,8M&EV2D*AAS8Z5+,"S0H.B15LS>+J5V)Q:7K6 M]'S\]+R6N;N?*M:.U=C4V-6TK&GY^&EY9VIZ57X&R^+:=[>Q\7R,O5,X>2A^ MH0C3?D;8_^^R_ULX1CZ7H6;U).U[@&QP1YO]\& '. M&2].; 2AD3@_#6\\ =PQAE$X-I(1,YYHZ+$3N(:?F^E[44A]XXCW;3J&/0[X MOY%6O&#J$":JH!*[:]D77<"?CY,P]O W'R(&@LU[9A_%-').C\J# B,;V2/. M(V#?-%G\B()[VQF(O.(E8#U##F#*GZ,H0Z(G=OX((OW'N3.$S7YP_!=G%B-I M*&<:>X%/KMO^W^[9Y0-%NL.A<8U D55#/-;YX@1-0SNU] A]@*[O8>'?-N0MSBZ/%Z<\"^Y$IU>W^NXS#!$GR,J"0O1L0!,@)W(.9%2@!00@*'O3&+V0?[EH^O% M$]^9?? "@@0]]#%_62AO"MH'717_.N.D%PW.346T1+Q9?'T!7_TR_WFK?='H M]TJ_:EQ8:W[>;I:_9-$3BS9E61<=JZ\W=<";LMNO+K4DJE>+X%UO&?OG;I2; M@+./9!1.81TWGG-.O'+ )2UB7X$#EWEU@D0:PC$PAK,3(*Q:B;-U76$U"/U& M=HDP1@PP<38HQ5DEK>(88?@U9]&M!<1C)+K/<>*-N<;I>)'Q-\>?LASIO35_ M8@V/2:T=AM=53$6JJ+'W*C#=5]-QO;<=[.V4VJ8L+#O5?=MU6] EN9 '-4&M M8]EGEYVFV;"/J(! 4]?)4M>N2X"M9M7SLC3]:/HY//IY:RVSU=+TH^GG>.AG M1QDH[9HI;:?4]'T[0[YT:X35Z*]_6-95Y^S2,IN-NK10T-BX4VS;8V 7O%=XN.VN@#;?1RZI7'J0'!J38U\2TBUD4;>;&!N5:J[L*>Q7'+#'P2,S5(P1W0W;V0:FR3?OLLM4VF]V- MDVOKXY?1Z+@Z.FY+DVWB^%B-4@>"4FLJLEO"J64C%9JML\M>>SZUZ!!]QT>. M4#L4F95IJCCSM&6VC[*J^D#*3*H;>%V1D7C**:7683EEFSA=MM&LJ,$7O-"X>.2ZN.7N[ED[@WMEEVVQ:\YK/6Z>5:3RM'9[N4/97 MII+W4:2WS):U<3W)#M"S(L?R :CI6QKWO4&JE9XCN'W@' ][:Q^48=-JH(N^ M93;LC<=]5XH0-:U+7I'[\I+XS);XJ#T6KB4'#GMEM;9RUNW<*U\/ #W@8>'[X=VXZ>-&W M5Z24F^ 9,)_&_%Z+:;3,_76& W\1E:>._[N3(!W-/H%DI"'-#[#$U@X 8HZU F^#^K(7$.$HJ=CV"TL$A,H!5" .>&4ZQG^;LP!!(Q& MCMV]#N$N@QF5#'<_QBNXS!9.]6TNG=S["ESU,-\5GCBX$;5Z4ZMNJIIAOBN. MW2S]6?\PIW-^FC(C#)@Q8TYDA)'ALW@5K_ZQ@L(9PJ8R@"0CT-V>1L;0>^:? MY&%S5#.BC6V,AW[CC-;Z(<>* Z.KF -Z+"##<;]*Y0K<9T,X# M]Y=]\9Z)C.)7!-&K;5A;U8TXU'2DZ>C@Z6B!/'J=AJJ;VE@1#9U25TD]/WJ? MY-BLG5&%)4YFHUE5@=.!U=AIA-NE$=)N:&33R+9SI;U=W71%C7BGB'AOT7+; MU4U*K&'CR0/IYZ/'1M>#0!N]NNF][>;99;=MVMV-.ZBO>;T'T.]-8VIM%.:6 MQE*-I=O#TLHU[ M%B%>TZH+U]OUS(]%/2\[^VB8^'J+ ]Z:4D^8KIXZN[53?=M E@VSWZN+):HQ MKOX8]W8AT-'8IK%M]\EUG6.L/=>(MSO$>TN27$<7:^\1?:[BF"4&'HFYVK&[ M&R+L[%:[?9WZ^G4K(M/85G]L>PN?[S8TIFE,VY=#MXNQJ[;9Z,V/J-+(IY%O M>P[=+H:Q6F:O7Y=(P@D6:8\KJ_JHR,X\Y4(MJU$WYVZW>7;9ZYK]1L73AW5) MH<;4ZIS"W19A::^SL0:CL51CZ:[4[C8@;<-L=2J>!*V15B/M=M3U#B%LNU-5 MZ$U7;%>AP9<,E]R>LWK9,WJ*\_:!W-BSH2E=4[JF]"U0^G;,[GY59K>F>TWWFNYW2/=O%O:]1E6> MB[W3//DU?J& 75IFP8_T;3J&&Q[("Q/_+'J7BG>"D,_NH7A#?P01@QT J_T: MQO%=&'L(M/0>'O"G#[#ZKWXX^)&!V^*(X053YEXEXC-\-X.KF<#;D^C_9^_= MFQ-'LO3AKY+!S.Q61\B,+@A$U081+I>KU_-6V_4KN_?RUX2,$J-I(=&ZV,5^ M^O><3$D()! ""03.CMT: [KDY=SSG.? )JX4M,Q,_\5VDQ555*#-^"M<1O:9 M+9+M6M0%VC1.4?.BLJC+E +Y.8[W!OM(XJ/3: :CA8<$)(2?@6:" #@E63SB MP&?XS70M,H'%(Z^X>@'Q)D71&PNV)!/"(;8+-ZX_C\X7.J:S9QIW M0=84B:BRJDG$?'GQZ8L9PFW/"WC4*PU"5K ^AN]>/'_!!N50]R6RS%^7FFX[PXVI54*5-ASV.5SCF2,Y: ML->..0_HQ^2/3Y8=S!US\=%VV8ZQFSZM/A\A!=;XBI$4__G3FVV%4Q1Z79D+ MOCAZ&+\Y_KD+/_T]_[VF=8?&H/ GN:M4_%[7BE^RZ8Y-@S+$F,28+G],0V/K MDPY-ZJD,G[G+_<.C5(EF;AF#S*=^W2K36-.8@T(3\AL-4"_">SV7D@68<@W7 MB;ZKU7V(UY1X/A@>%-1ZNY>7K]5Q?)S=5I"=HZVX ,>N[#[!I#_ZOX"ZUFX[0+R+,,3ID.7=9CG>_U+\R#VOIGA+T3P41"R(^IZ46 M1"R(^.R7NIR(WT,J5NN:9S1"NV)L8FR7/K8Z:\#:CG @.IPT=D1<-,7+.>@M MQ<7>?JQXDQX:%1\P8L#P:6JZBOH;7#D-*I_WJIV1JDO&\.!>YUN86X#,"V;: M.+:FZ_$XFD4.G@GC947\HW5&O7PM72Y**-A&L,VEZJ"$6Q[\;Y[[0OW* M.@C1:J6>(0L5)'CIO:N@=6;:007IG5%!LSJA@MI 6I?,-D?DFF)>J:QH$!'7 MD+2!<'8$RUR\IBGFF1WTR: STO.E7D?7)^\)0%7TR&IQ&X\31^BP_%*7!GJ_ M)=!O@OIJEO)');\=Y/\002X/D/^"SMZ?E#LT!C24@>BD8?]@RUP0WSL4VTH#52!$7TN-'9,4;:O5S[$@\9\4?;1)=9[ M2OJILZW)+GG'HK=0*0+[:7WQ80^84-(&!T.>M2=^?.'$5U&T'Y7Z=A#Z>F=T MB"FZ CX+Q!>.WRSQI5V;'0%8ZHX+6I97/$ 2+"Q:_8!9O#8D#H1R%SPN>+P5RKV6 /9 [G5& M?4WJR<(]%^PMV+M%*GS/LX.!K&-Y1?X\ZHP4]0Z=5?!SW/#"9-/+PH''.]93 MNP/L-)%VO_ I+)S]2I<-)OZVBB,>SU5>WF(^P[RB/0-A_7%E8FN?CZ;S9BX"7/1L,Q#;31[>AWW/S7WC#">3QF;( MR0?8"5'2<&> 8*F/5\&8S-:,A4Q]Y/V_V!.9FH8Z&*JZU>_U--T8J!J,R52U MY_&S9>G_''1&K&D/MGI!;^YN M[V]N'\G-PX_O#S^NG^X>[EL_]'LOQ+Y 'BXXDU>L&\]7VS7=L6TZY#&$+[! M-B ?8A>*6K\4,=::^(F%KZX/0M3,Z%^BK*_*.27WD03-$Z([V@I:5H9M(Z0FL1G1T:-5)Z MG=% DP;RPH9BK.E&]'PZOHA76^W/&PBL)@V-"PI)7SCU593] M1R6_'?SY(7I6HNW3&1!:B^CL4']>E5FG%%V[H"20"Z>^-HFYZH"E8'*/%#6/ M3"S$7.L([8AT5H_##F,8]31)+R O(J6F=D%)SKG>O!>JL= M<='VZ4QR?-X3O&P5(:6W.:JA]C"D+4N]85TA;0$L+3C_@CF_DGUR5-8_\)Q! M94>G_5X-YPQ"! @1<,$BH#42X.!87Q^/- :2+!]\IB$X7W#^Y7-^>Y1_S7E3 M*A902_U^7@X(Y2]$@! !)U#^-47 #406&4BZG&\))U2\X&_!WR=3\8UD"ZK# MSDB7-.6L&T!NZ"NUL8_4>75GN?%F\.8%H=AFQ0Q9"Y6D[PD#H@^)Z=.ROBI M%L2&!]D^QT8+B$E\&D1.B'U2QCZU[)#=TB5W(7F#WRT:4G\&0[+X2UPO>QD, M@_ZT@W!;PQ:-=6/!SBWDF8[-**"LG\QX:H()B@.>,9Q)WC^&C9"W:MF]6\P4 MWLYG 3]-?&]&)DXT#G'/W1>X&68 *T5\MFSP[Y3Z'+K?Y-.SXTY/K%<,#HU/ M\,WSPRG,/ B2'^P@B*@/B[.]%U([*.;%M%W>GB?>*1];6EFP1-A@I[Q%#]Y) M_XSL<+'R+2.RL1/A@VPWVWT'OO9F5"(NQ;_9@L54^V]_,51E\"E 0;CLS!0L M^S'!^GISRGTBQ*E2 MZ:YU%BB4&2@HR[M^*3TPG#:V!,KT_VF6)HK;8WWH_4+^8Z71WOJY^+HFNH.] M=4//7WRQ@S'L0N33)[C\L^.-_TAUAR9WDH9)U+H.X^_P813TS!QYPH]H9W1W M_U^W]T\//_XWW^TON_R5!O@XGE(K3[\!=KOE8PV-RP-G3SXE/8 MMHMM40[IS!ES@2Q&!N?B*NWH5=JMZMQ:4PV4[G X;%G;'D7I]I4V#DI5#VDF MM"-2[8[=56 M;;FIO"-)/-*9?36Q73N8@I/-&E\G'UX\;R?8MAUK,\ZP!*,&!45_FL&26;[& M:XNKGOS]*RYS97;I ;L8DF%4!!MJ1M4("M@B,9NB !U!SB2Y $>Y40IX/Y4V M=K)GK:JJ$QI6EC0(]J0.I%X!I&(#F3.7GCPC&%@P\ '^ MUCX,C,!9BB&I>AX"^PP9>*>DF/4#V4I),C&YC/[CV?_[:.,Y8[S5/;4[P'/! M)'7CHT\=&,0K71X'_FWUU#5^L[R\Q7R&]8G"S;?D8N,G.IDUM+7,@LR_%7(* M="7-*9CZ2\OTA5X]^]3\X\J"U,YF#D]Q$XAOIX%8S);,U8R-1'6?.7\@T"@<&R#?#4'1/P,:'E/_YN M;N:%X]-G<4+([?][A_O6#_W>PU2NT,,% M7R84@8]HNF,;W)''96K1AYLD.>67(G;<1]8=/7-'KYJY\]W'=*IP\=TQW?#: MM6[_C.PYKL?63!ZC()/'R&?R?/_Q\/WVQ]/_2N3[M^O[)W)]_X7<_K_?[[[_ M=GO_5&-VS\9)% Q]N'->#YM0P335PFR?,\D.'9N^O\!D1YY$R5+W@M">,;:( M CJ)'.* FF69=O-X724RQY5-$_WF/"?4IYC-R7.'@HO+'-*-KMYK8Y).*S.' M6CDH53MU.I-(CA+)4760PUGL\VVJ2'[GBN2;/:$B44PDBHE$L=J#8-^WF6:- M=06K:8'W?;886_SL:HJ3A[O5KJJWG*B_ 15?G.[<<>[NW\T]I[YK'D#KMGO3 M"<>%GD4HJK;]-&)C&.-7?X]2W9[<&?6D@5(1:/MXN2R";L^%;DN.P6NF6^4D M=%MG$]FST+74#.C4^51\1/:4:>E_+^H.SB\XN^6?L* MH))C_)H%D K^IM*3]+[H.7F9Y-0_*CEI&+Z0)=TP6D).%^P]5M5?%^E*;C\\ M50<[TSL/XV(4=X7H85SCCU;D(X+&DLP1Z5M?/]3E*!NBW&%GT30XJFC2.Z.^ M-% K)K")]3$:(S.J)EKPB.M74IK)8V<:Y;20W AAK(T M&(C&X)=)3B5]QNHE)UT&*2%-("@AA%HR6S2I(LSC+\.O$GX M9OHUYLA&CCJL:"N M 0WT5,D8GN?!X#[N5OR(*[P>$YI1X9V(,GXSQXAP["\V9)HUXVD(KS;#;GHS MZK!7I Y+G=I^,X/!)G'"J3V50#]J\%GOTBIZ-&LO4!D%.O M+VF]MI#3A3JU7R,?=CWR:8QK]A/_/LY9ZX4I]&;"U+JQCT+O-1.EUHD2J&GA'!(X:)^YCI*PGR04]F\_!XSX;C7H=!#0,"(,4 M8;TY0C]BR]S2T^(61I)WJYX1IOR^HX=X^AGOEGJ0/10+N99+342/'?8VA M^FK#<\Z_'7(XM#:KL:TER1(Q0YALL$MM\A$1-3+,> AXY'GSXW&Y$?.$)471 M)5VOFLUR=/Q203L' FS63#MZ9S03^RS38*C6B+M$0&9+XDJ$(^-NAK.FT:UW//)C[_['O-PJ%RO*@WQGU ME(&DROF&0I7[40L?H54D5Z)83D9R+ E\ +YI#2W01<><79T'E[;#<5BU)]X] M%+U G*_-F=H#@;YO=$;]H2%I>M4C[_9UBA#,)ICM>-[G/LPVQ"ABK_J!:'NZ M.AQY-QGF]#_+_BN#C<[B:J_FPQIKR-I7)X36_J#\0C@5Y/_]1@-X*N)I^W1F MVB["[#B(OD-"ZL^D)?:.8T^H1#R_")%[0KMK^1)[-.=H&R#Y%NAUM3.Z#DF" M',P74E,D@MBI$@FGE&!QC>DNR-2TR%\/.9(Y@[]!U>/%A"RM$K/JI MU!C(["BKFY<9!-;3P:$"79B;#H E\C:UQU/VG1T@0<#5U2:[EM39Z&25SDC7 MNOE#NW2NMDMFQ8GD4M4]U(\W+<0#&G;S_EYV"\?FW Y!^OX?M=@Q1T!8PQKX M%'IIG1<"ZO^+CL.@\FS[QYLMUEGHW7R -;N)3CEXF,1^JCC-(](JMOK)3M(BU0_]6& M'Z,YW(.5@#Q>T.@9YO4G)W_W1]_^O=YV^WY/KQ\?;ID;4I^?7AXN@ M5+V.!C+ON'])_NACPOYK2WKI;JOSW^P#B.%K&)3Y0LF/5!QC&03Y\+]8S[ ? M!.S:>IP'OL-NRW;32+K764P]FR21/8<\ HE[#":<$W,46<)3=N=A)LH@)=3GQ\PPYH'4WO>5ESX M\W,8D_1M>OQGY'M,V2:5^IXQZ*N/:RYH=H9Z?I04GM5<1_.(1JG:"TWZ)Z\T'3(I/X$YYK#[TM#33\\ M>"6(LJU$>1R:W,=(TCNC?D^6M*K-64]"A.\I(';G7LU];TP#!*0)J.F/I^QH M,XZ/K?1P%2$QT66FO1+KSK7H9+/4NOTY=B)XK7:*/_FT53C:>J[R\Q7R&>47AYEMR( M?6K^<65.8+ ?3>?-7 2XZ%E86-M-'M['C('UN6^#[;\(\, M/A^O@C&9K1D+F?HH!/Y2#ML] %^8@>UZ$W*#\L-%+]A<@YP^*:45XT7?_L_U MS1-YO+F[O;^Y?20W#S^^/_RX?KI[N&_]T.^]$.&7/5QP)J\88B-86J8[MDV' M/(;P!<.S)Q]NO!B*^IP)&$>C6M=?0JHW4T!JRTADI:O-X*%7VZD*/ M.B[TP(*1YA&+:PQ9%>C6@C_.YZC^$ :IY[#>D+7.2)6EOB[0K06S7*HRJ5Z+ M9,B]SLC0)*TGT*T%NO6%.0P56*>2PZ #RPATZZ/*1.W(!G9?H%N?%SE5M$?W MIZ>=T:T->0!$U.L)1)WV4\^QB&0=39$ M=&M5H%L?42 >%UO(4&2!;GUF]%31/#MU;8^A*.#C28J>I[!SC!9>.'$=B[;V ML-X4%:TW;=B6\W1U$80[S,S3FS'S M% V1KPT1A#NBY-2/;.;AT41?D7J#? Q%A.':25 5[;S]*:HN.T_OC-2>+NEJ M_OQ+Q.E:1U['HJY]++U^9]17=&EX^$EJ"R-U OFZA2!)5=RZ=XSM>FRS!1MC M&8HD*^> [BK(\&CFSNF-'42D&O2DP2!/F0+W^F*(\C@TN8^)A-VJY+ZD]NH* MAPG<:X%[W;J F,"]/J'$:ACWUE#E]N'>"@(K(S"!>]WJ[3DG_E?:Q_\"]_IB M0CH[&KP"25,@:=8A*QO O394E>%>:PU$P 0ZKN#I2^3I\PHCJEK]843!V8*S M+Y&S&]36=>!>JSWT9H9Z S'94^->'WFW&<+K/U?^*P-6C5>(0=2N)$PA,H\4W$?;9=0B<3 M.@X1A&\.V^E9A+J6Q$X*EDL89-=P^[+[--DQ' 3Q8+%\$(JSN4^G%+;OE?WN MS6AW+2DWAUZ_-0=U79(^CJ?4BASJ3;882U^C,/)IUDZZ_3G'"C"&.OX$C_\, M"_['4I2"^*8@8.?PHM"/:"$D=9;E6XI2?;T9+5J3&#DO$:DG;(V0^=)% J)A MJX0DYXUM=MF;'4X+L:JWI^L@\1!JCJ<)'TV0((((HV8H%. S*C2"><$!XX0@ MQM<./E:1O6>*3 ?0O _O7F5>0XS=Q7)Z+_7:LT3\55?I$N=$5]-?4HKUWC9NW-8YA+:VB2JAX\Y&:;V]1&" M:J_:1$WMC/J]6OJ_U[VE!Z?"%+> /\O3:68AD#?\Q_6(/9N;ML_R-AP/=AY3 M#\:XJA8!VBHY7;8B'P^1\6 93Y QE0&N6V\NJ'5+&R1GEZT]RY0/^+"X.W M[G!9[(EM9C)2>=;,M6M]@Z]MQPYM&L!O0*1622G/;AP^7'*X!M9&5]4WL#>\ MW,'I9Y)73#+WO7^QA)>"9(9,;2RNH\DS:+YZGL428K[XT0NYMF8P@2#D?>[3 M!)^O7ZZ3Y!YBSN$E,#V)/#MP[]6S&>"'6>2$]M48\W4P"<)W%O#"D(Y7GO/; MS>V7]$$A#7"@9&[ZFS*/GJ8^IE#.R7]($WGC_WU@;)+TX?;[OD'Z8; MF?X"V4+IDBR-S:F/FX%$1OZ,3-CE$![VRGDM"-@:989F,TQE>)B3H<@,,YNN MZ2P"FZ4')/IB;^ 3D3*!4D)_D;6J/I_!(MCX^K#=NWM0,^9WP M2,*;J=.?F#?"?J3+Q+%EH_6\/"%OYE*B=,L[I9^!_'QPR77T$@&EJ+QWJI1- MS&&Y5PX-V3X&P#\)'15B)>9RX]9RYQ[XW;,J-F$&&^'4]5X[EZF"K& M&0JSAN"Y*4FL$0.G7IY#R"D@GFAN3OBNBB)RL"(B*^ ?5L&;Z2_E6J\STH?= M37&*62S7F-PR,ZV(5[*VJBN"_6=Y4!E"9MXZR/-^5RF9MQDD>SL&GD9:L>#- M4IRBB9]!R)CK N&8Z[&SM9J9._8G4;O#[7//\@M(RE0/DXGOS?(6D41<&B8B M%Z;'S%%&*G'B* FF%"VG: ZK$8N*F'B8D(#)!2#Y@2V[!-8%9#.PX+T'W*X8 M+)EO@F(T MNU2'/4QJJG[.T-V@,U)+1F MP+AH-H[M.2.=V*!D4B=>=6;M.8QU0,%;T3A<=\WR:>$9"1(S+4C- 6;ESCUN M%G_DK==>Z3(9]V^KJ=NQS)&7MYC/(!JC*5 ME1<@S=\@T[L(<6".-NK%XU-:+A6:4=KM_US?/)''F[O;^YO;1W+S\./[PX_K MI[N'^]8/'0V4 $713=;D 7L-A(\-'NHC^BN\L.7##9(R.%QL,"(IB(DD M](A-826">TLFL'FK7S.(/CL8L]I'5J37)7=;8^+Y,/AZ$5Z&<&#BCH?%ERR" M'E\?^X?KI5PK_F*0B$Q\!# %UXA!)??NY &T8FV1")75J>Q5?O@P21Z6KR;L MR3F- =_ALRZAQA"9,BXM3<(-:X6\0#*PR$%R2A.L'=.LUBR+Y-)3$'5-TW1)&1S<%O,"2P;;UX@N@0')^'T'""&1^[I;8&%' M]DL24WCDXSL#.ZG,DFIGI& *^:9CNC/-;CT+1/OOS(_&Q?Z5NI1A[&0#+$NX M&E'(T6"#M[ZZ&[M]CWSP!P-Z/6:Q#%B3ZR6>4!%K:9V1GD\:/WK'MCI;;+6= MHVX9]A,[KN2^.XL%Y0">UD"CL@U5A3ZK6Y_U=V.OKWR3;N(]>EIBB9R0RYJ%7TE&B75[K;IS&WK]27Y< !.X;8= M@6A^4);\@?3RV?:"L4WQT"QK6WY0#^DA7I/B>\>LJO2U(SIY?4R'DOK#@X,N M%3?N3)1HR[CW<"/V9,KWTKFV25-VT!EI1EU(:F>H0T]JRN9KZII1CSM*5H'& M+]#X#Z\^WMO@-YC!WQ](BBH0]VM&W"_X[V) ^#7\M>3'-MJL/8=TG""N>,+U]02;![K7Q[Z69#2C)/)1N!H[J9JK:4;V'* M810$:?56/AMPC50*?>:UZIW":Y(BGFZ^MJ-*[4=+TMZV)(CW5J -JNBIE;K# MN_NOFQ35,B_T6Z[(=&+_I-;5_U'?2S66O-18PP,,^28&I,L'!,D;&1#PDNOE ME'GY%R4 %GMD0"9%W7$BI%+..,@F.(_RXA2L<=TIA_(4>;D?!K^0:FFX7V'E M_PL3O+^ .(/5CT#;Y1-Q=36?B*NK^43\52U,^&UC=F^(*+'$P33WM/XZDU(_M:F/3>87V$P$ MK$<[F*+-@;U$JF?MKNK?P?I*7&G'"#<54R7/\UPJ,6@/E! @74$*_U'THG%9N@MV' EK@2 [YPE:,L20"L88S68Y MH 7QQF 3XFU!-)G8:$Z$9.+3/R-F)J)\? 5[8\:J8A"!!:;'%H,C JS4IYOX M[XN'OSR;@5U>QW NE,FI4&TC>7Y/MX)5S'#3G=4M_;E"N'E:S5K\F5DJ294. MTA2U8T,6U&WH+)!R8$_23\N"G4>K&M\.G$0;^VT%5"L*LY%V?F MLQ>%B4!+OV6/X%O+T!%8U1[ZP6]>Y" #I..B>PJ%H==4C2X8&JBVT[Q&5:V M BZCJN,( 9 2E VEOR#4EI[-8%"GW-('J(R?[TRO[^V0*(R7U3FB\K\!BOS M]W ,>3WY;S'2V ,B&48^I@I\1BNPP%?,E_G#=P5%FYO]OF)O4SOG0D_NSC'5 MQ!AH)5R=ZPBY5#RQ+N+[:V[I2DE,K%)> C,RKY-]3. #BQS/I4.Q>D7VM5)< MGFHC.F@(YF&XD.!:Q]G9FCJ7BM*>WI6'1@LK2I4VEKF*0>U<$*R+7J"U] (M M6 *NF]NT"%^78A3NL[TG4@G^,PUV_<;^=?X=N_UWB]L>7 M<8?_0S:<\5YI[#&#K?+ HC@/2W?T+HNO$D>WQ$*%J\Y_P2)IJXO4)J2 4^0) MW3 H)0:Z0_^,;)!HW!K$&!U8KR$P,7HB>$%CY8,U+?>^SQ9C.X.QU5E^V.^J M^AFP)>/!F>?211P2K;NZ\."*PM8M6^5_7Q%X>QN M#&:D2;*FM\3S$W15 M+UV=X-BJ7]^QE2"J5A+5J8YJ^H805I=,5RFW[J3FK-M+[D@6O%2(EY0> M9E_NXM&)^\_O_O?4Y>OHGM?!BJ9U2UBY:>>EYJD9)0?3UPFVS5?/?P1=^)@2 MV1?Z'"X_537-!G)GI/>E@=)OB1H5;"+89 N;E!RS[\M.V06+"!;9 MPB(E)^&-:1)5:!+!)N?#)B4'^TUH$JUMFN0]=9"]\?PY8O!1\NRY5G-1"W$. MK1@ER0V-J2"L=-8E0SVXV9;(;V@E797D-S0ALUN7WB!HJEZ:*CG!;TQ6]86L MNFBZ*CG!;T)6773=:=OM2P:31W!*U!+95\?AL9*$AL9D-^8S]"3C\.3L]H0Z M!%UEZ*HDH:$)V=VZ? 9!4[72U/!$!WR&+&351=/5\4_$C-:=B+6E[O08W8DJ M0IZ(BM.F&.]$YVR&VAFILC0T>BUQ\@1=U4M7QS^8,NH[F!(TU4J:.M&!C-$3 MLNJBZ>KX!S)&ZPYD:@IRGK'QB54=86'BR;$5WY(EAWU]O;8*$ZB6ADA.J6DAH($CHDDFHY "FG(2VZWJC;8$F03_UTD_) M081##)R;V49IA$ M%4PBF.2,F*3$%6O0XM+:97$=.YY_"M+X9IO/MM-L@K*X__SN?U\%H6X(8T;D M'I"%@6U1WT2Q(\(4[UEI?J@U3O$Y"N -07#CS9YMEY'7DNQNLE272.3%3>3[ M\&-E+8JI%H8!>C2?Z/N+,#5;0%F7S#6U!BWJ8IKM_EGK\D@$TPBFV3^(<1RF M$=U_!=.:#K'1F!]]GP@F"L^\8\:;(WE17@* MCO--?@V]^4>YJ\./@>?8%O_MDJ5,O8O3;OE4J_N8QE3O:"C+X [T-&D@U]407/"QX.,+YN-#_?X 9@!_-B+FR=<8J:1)6Y_U,*&^@X MWANL!N&IZ'.?!MAZBH3PXXTW@V$M6#AS\"D@$Z $\HJD0&;4Q'94,W:M&1!O M0K[0,9T]4Y_+9DV1B"JK*C$=#Y[^9H=3]DR'OE*'?;1=]D7FH5.;^J8_GBX( M_/8VM_Y[_OZ5UY:!3^)'>5BM_K6O%+-MVQ:5"*TNTK0S&H,QZ4JF]] M5$D(M!613F--T@V*->,=2@HO@D=804[3;)E;2=;0EB48@TRB?IL6 ?4X88J< MF&$JK4DBJ-_IJOR_R NIQ776=]\>PX-MEW^\!LODE1*>OQGP[\#@(7>HN''X M\65H$P7DPS?4;/PKY;W2V",,P)[ 8-R0/(!N]LG#,SSIE6G9.W<>K2V4*A8J M)+^[WM9%TE87:=^3J0HF<16@C1-E)IK!5")C^)?09<-4B8" )V#"AL#)P-;L M@H:1-FI:^5/EMXJQ'6%L=>8,][NJWO+P##(GX\29Y](%X97.(F?X/>>D5 E- MJ7()$'!37=B'LMH9*0-#4OH7U')",,KE,DH)LG%SC*()1A&,C M;,L$'LH]D0DL>.2,>*0$5;D1'FE=B4F=_9C.P57;!(HO $GK9[ 2B.GFK+5^ M9]37)%D5&).725@E&-.-2.[Z.ND)HFHE494DWC?%@2"XF;Q'SA;KC0CQ\T8>I?HXKR=EN3)0KD2)HL>IM< M)EV5E XW(NZQHE.3#]6L\/( MATRRINC%U!3SU7?^EF9PY;MZKX^["]! M5*TDJA,B2-MQP)N)WA\ =G'):69%4[PD M'5IRKMQ0H_6A8H"UK^J2JM8%)],"XTSPR>7R2?V-XX=*ZT[)!8L(%MG" M(B7GVDVI$E46JD3PR1GQ24DO2%1K309BMH/2D_N#@-%F1K]!*PBK)5VA":+DL4OO+S=N*_DO(UORY++OK[>VU4EN"9W1KJD](8M<>H$"=5+ M0B5'4;60D")(Z())2"LY<2DGH:WZ7E/;%E<2]%,O_908]I,F7F;2P2%@]O+K7N/;C/M&#(RU*1M-"GLL6"YV.R)/?U MEKB8@E$$H^QOQ._+*-OU:GWG?8))!).:ZEOX H8,Y91@S ,;(OZ)HH=$:AXSUKS0ZV1BL]1 M &\(@AMO]FR[C+R69'>3I;I$(B]N(M^''RNK4:,STN2^-%3S.$JYWJ["UA1< MT]ZH15U,L]U!:UTVB6 :P33[1S&.PC0]63"-8)HSLL_*PAK'L\]Z2HOLL_<0 MXGCR0M,Y=J_KN!DYG_A'#;;&\B(\!T_FNTNW\DL4-+6O3[NE5*U.9!I:O:S\,'?6=K'T?=:Q;W^9]E_JR6(F;K)F>F_V&ZR;HH*KULII52,A/]M MUZ)N^/$*OSD^2;-I9CHB'?_UJ^O2[VH]7(?UIDUS'ZC=AW<3G\Y]&F";!?[+ ME#H6>5X0DX13V[>NYJ8?+LC$=DV7=;FWW2"TPXBQJAD0_)EX$[B)3RM#.?8K?623TX)F4W'@S6)7%O\,+?6K9(=SI6S B[\4W9UWR!)?X M\7#A)0%YLQV'..8\H"2:PUOQ&?"*61SXP[?C5^G[ N+Y[!N?SKQ7&$E\P?H M??IG9/M\B#!A]MATRC8-NF2M(A:8?\RBC!%[\2@1!_?1#'9JO$*P\8[TU.X M6\O.O<#&>SZRM;!?Z:&SY(\AWZN-5,":S-6,A4Q^UY5_LB4Q-0QT,5=WJ]WJ:;@S M(IY,3%5['C];EO[/06?TQ,I]@$,P?H[,\Q]_-T<;Q?#Q*6U02&FW_W-]\T0> M;^YN[V]N'\G-PX_O#S^NG^X>[EL_]'LOA(>!*,1C"M3M3#1^3>7K8PA?<#'V M@9]I1-1:K\UG_ZZ)H]A>,705S:)Q[Y"_(X-4&MX16_??GYG]1TPBFHH#&%VZRL)L7[ M ]-)GQ6K2W9^._@4D%^_/X+Z"T*)O$WM\93 4U-]R96L2::>@Z,D^K^(EZ?=7K_:6]CG!;W?X&-QPHPHE-%QC]%UC_V3/U^6^:$D^Z3.]O M-TSCK]"$9Y^SC'-"OH&-!$J9FD"ESY2ZQ/7(>&JZ+_ &VV4;RD5"2,=3U_XS MHMR.\N&5$^H'<%/XAO=E]G]&36S&Q2PHA[Y2)R 6[!P0'E+4@IH^H3!OJWB= M-4Y[Q%\-3X9V"KA\)2(P@=0#0AW* MI>(:H$Q2:8"P7>V,?DCT^6'UXI=L MNF/3H!2EVU>WO[PDG:,561M&F5'+@WAWZ)9[$3S""G)!L2US*ZF V+($W(AO MTR(@A$*F[>%C,83"OJ4:%0*#58#)3A/T_9S*O%C02>0?)IA78";'-E@S+<7K M6N1+.W.H.OUV'RE4Z^URJ@+*'E9^2/+PX /#Z@*B]8F'[4-,_![YX"T%=*M! M)A 4&^;6#:BX]*<9?$QV*'B8@"9>,NC^8+B](2]QENLZTS\W(*KVL>$-BUA@ MP&+IZC1C*NS$=>\#-7@;U_$-">[BZ&\^%P09QC$)H MNY.EN^08;RW9A7-@NEN5%9RN=$8]2>[GNW!63FPY0]5V(MH*YU M1GUIJ.?K0 ]*\&X'BYXS'M#R$+O )Q3>X#&YK@9O$)%\):6@VEIX@Z>AC4<: MA@[/\1#>X"F]P;+2!\:!R]VJKN!T9H3VAOF^'\(=;(H";E?R/39XA=I)3T.+ MBU7$66DMB]-N^51%/)5T5VW0>>YW1@.IK]=\D'K@SAYV)T[O 8A4 M-:]:'W1&JF%T-UGF:6:U:U6;FG[ZJ7$0SNZFAF<[)(UK;-X8P94P&W].QUCE MY2R2+'W<<)XI3"UT57DRL..!?8^U;"O$8;L)(2T+1&(#@0132L.@6TNF<+*R MU^,_(YL7FP6?%YE/&]8YGSZL#W,5)_ =OKM24G&;^+KV--Y-7 EV[X##FW[:F>D]Z6^5!GC%-88&XQ2D/"MIG='@ M$#9JE_HZ(Z=8Y..VSMHLR<<]AJ_8V]S^0?B*[?,5MUNB)_,*+XR'#TM;.K&M MBEE.AB3W\LCK^Z*YMH.7S]A_/,B.%2[C(6S8F!W;[XQ4-8_"=J[^X+D;LH>D M$&Y1@CM*R/)<*N7]'/[4N33M%E UI@\>P];G"4Y2O^X2GX.V6 "]MQB*5OF% M$T;^7\PA&A> 5>R<);@H@=(DL6!76&J9ZX6L',">(.QL6(!@NGL2:7O7>P-\ M,4\U0V#@;;MAQP=-N!\[K+Z-6*8TP:S?>(,9!-[89BEZ;W8XY4CTRU,LW.Z' MF3V^]00QHHA@,*'02^2P5T':YM(*;NGG(V4HPCJU)HX,UW( 6 MNR4?#E=^# OZXOGP,@;Y:J;@F^G^2/@]+G;VJ>8,A'"XQ&M==CF QV;8(X%N M1:Y9 73E3V0IZ>7H_^\=[=\0:/\M&(M ^V_ST(^!]M\K1/O7SRK;>K\J"LS$ M]M$HFOC>K! L/Z.*61+VT]0'<2R1ZV"*#[MV36,7<]ZQH##8^ZBIOSC02K!<-0L_=I^1# MU;235T;TC8:*/E3M]!4M_2$O^]B$/'9 V0?' D^0R"G'DJ=!#J2;$SO].>

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

03%LZ)[5/FB=W%%US$%\1&*Q,#OUV]_8WJ0^G^8I'1&IA.(G+0 MQ',PVAQA\-/'X%'(XIX_7>_U=.*]SG<_FS\L66'C0MBX&)V!M@/![D*O\PUN MJ>*.3\@03I]:GO"SA4CZWK^H5F7/*Q[)"U5T75$3OJ0F7!4UX0T8BZ@);_+0 M=U(3/EB"LKN@D\1WST7?^]:_,_V0_Y&U%O+M(GJJGFL7L<.7'W"O"LOQ:+^9 M@C:,^TY M.7'>QN=",Z&4ZN$31&49%H1/6 U%TB>*:7NZ-O2H('9Z8HR 3U5DB\E>M*5"S>-3IR03Q=U _N@Y#2>,<%-6!A!%>$.N389YEC_!3]8[/2W?"J@B>]99^-5R0/$T<7?6 M#=H:8/@BKBM8OV/BNG548E'6]2SCC>TW,CK]D_A>(<\-3LYI_%7]7)-2%(IO M5:R0G%9?K14#6YB65ZSU^X"N5E MVD5H\LEY;ZATE'Z>]!8Y,$E V0RD*8RV..P(YB/TC5,#GR70967M@ Q9B#+E=HV<&%7#TV!;>KV\SY^4MV7+?]E M:\5"T\2*?#NT2PI^'TT'$[E@W0@)#S*1&/FR+!$!J)2G'Z5..=9]F>\SI_S1 M-,YX2!/LZSD'R1N_*Y0A_L!/M^-;GNA':>)O,./*AR*:>G+>EPO**V8.1196 M9F;JQAYI'B!%*V:]18!J*8DAA@(FW,+79UCRSZHO9ONDLTJSI! 4E ?6^G)< M14QQ!1;Q7*"*Q_?,7CV2\!4+U519U>A;X8/1E7ZGZ6SA@HWOE,]HO@@NTR2E M2@WEZP3NM=D)VM3W'EF=XTP6&,[.AWVGI1NLN)F]'-/%/ OXL@L3P%_G2S74 M#ERS8 K9=\+M^+P4-@1>,SN.IWBIZ6!X@?$SZUN8;$$X@2=,/&=$:[EXS9]+ M,W-\AH/%)SN.,&$0!P3"'27YP4H-R_1]"D4QH]%'L" .;'0V91'SD8 I;;K' M2')9+9*I0,K*X/E;@IE2^W(AW*G>16/I,>Q7V.R0?$,M?:HFM*\R>DUO@!SOTH*UTP&QE8]FU^K<#3]W0L+K7JL M\:>=1-SX\NJ+I5.HE7S-=^')])PBG^$-[,U[:K^=3NP1L,\G^G#CY)S50'+1 M1/F?03S@LL5'C767AZL-361=R/-?(Q^7:J[6"%7&B%>#8]?&1#E1VS4V!^"5 M+V!XTMR;C"W!<]YSR\.L5O.1YACBIB3W4[PICC:%Z\YLC\7=H U]QIY@A8:W MXV_FXP-[_#U_>F$KYV=XV"1#CWA>I,_[8!*]*NA*ARC,,ZFLK#A*F]MC-VL M:C:K]9>[>TH060MF_CEE MU,ER4V?,V!$VL:.74_NHU%R8,A I-*U0RS/&IFJ>O%D4\H)196K\SK75@O$] MHP4P-E\\GQH=Y?8BN'=!#A&$>XIE+V!5S7/>=45I7X(#M98!?I$,=+.D)*V/ M-;UE(9TYR8]:/U5Z06PQ+A#&,\VWM$)'<*%NJ%2T?X!B82F7/;-^UN74#,N% MU4Z8-H=8?*WP"0,$M"E/<]V>'(^*.J8.6>I,D=GD5.4L?*3H (K M>WH&11$M]4A9H1!Q; IZAUY3@1D<_YRIVRT?TJRFR$36&(K-,E>4 \BDONN, ML[>PSR*]%8ENMPCXV\2O3EBX#)VD%""NSM#5:B#GSVXR+%_8NZP M2<.;R! 3[S## K/AF)R"E1#4*<.BQ3"H@%L)V:_6Z-] MYF(7]Y(__A]@7UV">0Q$XU/YM([3KRO@]"O=,I3ZK"BM,H4E^)TK3X%Z.S"- M5Y Y 7$SXU9/SC%/('^Z82[8[#C:J'901&/I-)BPSCO;MA1+(8[<5!9AU6?] M(PFX7F#ATP7Z _CNKYY_"9"T//XITQBHH8Z1;58+0*W0'(U1$P]I/7?IRN4 M(^-BT1\2E__';]_4&Z^?[U]L=OG"[FOFBEF^*/ M_&:Z)O-3FO^)8GQWND@=YGV!CD /O/)*YAP42IE^F8CRCG M,*TH.2 QXV[-&1 E?C3C,]"C+"K2L_F3S$,.%:$,29F51&,P"/@!0#$(KP^& M*RPU#?:\V.053<29G)$DX>AR8I.Q=)NLT!5_);SP)YXU(:C2'1C-]BA>&7;' M-3V%0$OK=@QF&CV6\O 4!K.L"M^4[@)\H$-U^1D]1QM.IPNC?C)]"I^%RVDE M*P\#\2*?GV/AT++&VUWFL780LR2+>?&!H>D>YNU!!S>?GG@ \>,Y.$[6'F-4 MZL6.3Q4Q@LI0J-)&VO.F=B4APYNN?84'7[\![6/*]L**UPI)^RE9+:0=Q"M!M)11 M9&4B0,B),1YV;(B#Q>YC;EF2[8.X]+ X4DQUE0X.\OKN(.JKC4'7:&1]=6WM MS5L_*%7;=\]UQ6A5T_79"D=1R7],+<2U5(&!LO=QW2>E1Q^(OO6" M$X^4$W/]L_? B;2/_;#7ZQCZQB6L@A,%)S9EWM4X<=@ 3AP@)_:,?D?IZP? MB<< C'$;A1C_QP#\YF:Z (%:B1=[<@-X<0B\:&@=M5^6-;=K\"=!9/42V1*D ML5T0F8%MDI1^IZ\-!)&UDLC4!A"9@AV;AIVA4I;N+F#LM@6H%9^_[BFH)["T MMK@X[1%33="$*H8#]>&PT^^5);3O9Y^;':(0'"XX? 4.[S6 PS7D<'F@@TM5 M<\!?<+C@\&/G\ 8_G8M/5S\\_I^O?]IX:%$FTZ;/F(K4' =6F]HOL5T[_F28[,.R3;/A\92Q(A5D&:+(>PQW$U< M3+2/,0QGBPW2"DJ*VL(*^O%5^!Q:#!OWVT4@J)S0 ME:[B06<>R LY-ZEK0#R##EN:PE]P+1"= J1)P>\,SP]^?\4=I$NX?F9V#[Y^<]WH%>#+I MV'';*HY_"2I G>/'\U*YFS\J3<>?!0#H4$"FE(_]N,(-^^1./>#=N%;^V7Q' M=!A:(P5,XHW'6+<^CK!0&7F+0ZE9EI2\A1 QGW!%V?Z>KB8/*H0^P@D <6-9(SEO6!#>L;T= U*61@ET1!]A3^O/(J7/H#;/RIBJJ1AGO4WR92Y9]%1= R)WRL>7:#KDK8"M'?([JUAD/ T7,P3:T;_ 2XM1 M /G,8U6;'32P(+[E7Q%PY<"DP$V)!F(X-#W=M,V557.IL[7;*N@&K M,Z=(Z07V !]T:OT[W*N9>43E_<78@D,?,2N#V&1NF(^"VQXR+#ONO" .S:L+ M@G5B3YF[D1=/!8*4P0@M78HY,N(<7"K1^4J&"NN8)9%#"+ M F91C2L*F$4!\TX.JK,&6NIUDN!3W7F/=2_NNL\68^//KJD$B)[.]QM.Y;'C MM>O&N&U.YRF:8K.3RX(0(*8&BNG MZ?0,U&!Z1U'S124_I=U0]'ZP7[-,$$A/L M4Y83V@3VZ9^<#V2E8VCY,H^=LT]-A6@'8;WRLX*M>62+JCT+EJV%U9Y+RJC6 MX#*^9]69;$#!E09EC4NK9F$WH%JBY736%+-H;8JC< D=3=O$*!+4UD1JVZ(5 ML2ZU]67,NNT,^PV@MF, P6'%[$Y)E'?7\3!1&+?]Q6F1_-IB#.[Z+?1-#YLU MF/[[34B>@^^>2[N=>0Z,^HGF#8&?5%W *1BC4SI]O08OJ?E5LD(8"&%P\*;S M]H2!>G+>T]2.L9&Y(X2!$ 9"&.S*L]F>,-!.S@M3;S7("CH!;C*&@G:Y=Z8(F>Y^*PXK(/T"/7K/[_"ZO] M+ROSZ+>DS.-ADK2NECYPO(./M,PC&VV*JSVP(/%(RCM$@[K#'I0H[Q#E':*\ M0Y1WB/*.0UDR4=Z179!+#C^3,\Y$?4?;QW9,]1U?&>J *.\XY@3;:E A2YI& M<<%9XL_/QG[']AL9G?Y)?*\P[&N(VWZ2N MH-'#HW&;OE)DR^[Q@]I2%6LZ"F>JEI23.TNJE)1=FL:(*:VDE- M2QIOU4U-VLFYWAD,F](OFFOZN;1]EM/;6#34IKMUBLHRS#<'$C&?9I)3I6JR@C//DGJR MV@G+.#G7.NHP#_FZX#JFH)^=&6?/L W79&ZVO&2QJILUR[OQ(0*,V MJ*+@* #0:@>LK\'RT=#RT>5\('&]G 4!82@XN,4VJP*E (+P0KGU'3"PR@XG%["A-Z4B(D(1HD_^QOAUHU$ITO0S1X9%R M-Z\Y)%A4!\%6'U98HC"NF)3G218'GQFSX*ADNDB1\&MV<;JS0(!K8C#& M/C=,]2((2!A@V. >^PKW>&PB2"&S4165/>- MK#@\3&!%@:8HT!0%FN(Z2Z9689?60P->Y2R#0( "-@UX3U&[JM%P0N*]--PG MUF8N:R?NO,'<$81@#BB04NE8=;5#U<3!2Z@.F[M<9FFN>DAE<'*N]_L=7=T8 MTZ,Y^7B"4]K**4L@%;;**<.3<\/0.EIC.*7.),-#4+:PJW'L97-%*Q)^MJ&9 MX,,EW:&-> V\F)-S1=8[QD @3;61K*J*\;K(2CDY'_0[1C]?RG+0Z6:,0+2& MBV\\+2)NP+I2Q4.MX[F?FY.ENJ MP)9&1Y;S^<('ZX((XMM$V.^2^+23\UZ_,^QOC)#:1*N^Z3KA&S$#(CGI:;6P MY7>M!,B;&>29$#<&UN+"]TWWB36>K,Y:.L:6.HK2%(!/04\[D.M;I"?CY-Q0 M.D:O*4[AL9UV7)I3.X1Q_ F&NT\"8OK6A*;!C,@+<;PI;JNPXAMCQ=^X=[X' MCE7P@^\5V$Y7Z4Y5Y[_>R;DR5#IZKRDXCH*^]FFHUTY?"#0B#\!@:(HC>&P1 M]MMP0OSBI$9AF#=&KM-=JLY= ^2NCMH70'YM)*+*)Z/K$=$038".9FQ<%=DL M$[S14ODA25*3'@D6%$@OIA.Q.+J)*>8F".A]VMT;%88=-MM5E=V_^%Y0W?-5 MY)/SH6)T!K59W@TO5!34MQ6AOR;UX;'IH-\9RAN;#CN@OF.SV;^! R:=2O]3 MDTHX7FNK&GI21G.L]4 *:0$QN&SE5%>1UD!/V9*&V_"8@ MG,*,KXB[E"]*W6OBRQ$;3U5%^'=2/:2IX!&H(7=DK:[T F&XMX'VJLK[M6C/ M0'MAT#'TC=,=#\=L;[0&F"D[W$72RR'>?VR'ZA?/'@SF3VK-B9+!8RZ$JL,! MG<^^R0#!9 FMNC+IH;=@U(.AU@ [17!&:SECQ;RTVCBC#YRA&9WAL 90LH98 M40>C/.]\;PK#>>](4\=T&283^7=DKY^*)@)6-3O/&3Z+=^L.]^K"'5W'.U6= MZ08(Z*GW\@<2(A)ZV(2UNF>\'<(:8J?J7D%^PZ'&1 ^I$&3_\="VL]=:;\C*Z+U5]N(:"V!O28187EU9ZAO(J&;94\W6BH7Y!AL>LXD#GMW);03Q/H, MUU5G.,PXZ/4[FKI);$0D&[2)_E:4]_70'V8=# 8=M;=)EJ)(.*B%2K[/=T'8 M8M+!LGM$;Z'M+TZ+9-9:CDYU:84E[?V..LBG2%6V3YO?&4QPK^#>1EDK8-D^W&3^_A.=G\Y$NG.!YO;8J,?D;86(WN^">@6.+C53 F MLS%CD28^,OQ?[+%,S(':'ZK&J*?KFC'HJQJ,R52U1^MQ-#+^Z&,=,_*3-Y8N M45:X>-!GGI6:IU!2N_[GQ>6#=']Y<_W]\OI>NKS]<7?[X^+AYO9[ MXX?^W0OA8:&'"TX%%H5<_6J[IFO9IB/=8T,Z>O0B?;ADXH6,/A8QUIS\24#1 M#0.%NQ7?>Q$F7^N%_>2:UCSNHJB4'E<,E%.$GR:DJ&)'L@.X8NKYN)[VN",] MF@%\\EQZ WMCW(F.O-@C/!;I2':(]SUC ;]C_R3.._P.4W:]$#^@3GDF$CX4 M1^/Y.*#X(45C>+7A=[SYD97+>4H]>,XF'QY89+BYS23L2;*C)3@/IX$<$F =>@9?B"IF%VU6U<:2^ MN'%D;<5VO8RE,J"UF]U\^7[21A+7JM(TC#U,8TAK!A=UPX1=*NGOB1/$3E0= MQ(Z;$@MM$^>]@SSA$H21PF/$6=;+4#NG1TY\E!I*FE#"M+9%V9;L[0P8:PO/WNWFK.Z$"GSS#^N%JF+0E9S%)=*37B6U- M<"-!8#@1:R$K>?1HV?'#\4]7V:#ITI8,)(2&3A=X+ M[J C61/,,\#'%VT-=JE=0K;2*TP%* Q&ZM-DI9K[U>;9@9;)KWVW%^5@]D MOMEN7]-6:+;;..,(EPEE$L@Y#PQ&Y+"D@6[*@47\!!Q=H0'NH76[-0;=X:!? M4V-9;: WK]MMZP>E:OMNP:L8H@?OSB/ H@>OZ,';D!Z\8LE66#)%M"W.+,@7 M[MXPG^I7TXW0909'94]G^4=^WG=4)WIZ?[#X3"_O!P47[@BAP?T7$G#2K7S$ MI^DUHE2UXPQ><-TQ<=UP+UQG@/;MJ1U5RP>L!=<)KFL[UPWDO7!=#[ANJ'6T M8;[_1:.XKL[*Y'[#&:8 5S>02( A1SN8D)$H5MXF'RJ;\.'EQ/2?R.C!N_0" MB@K NDE6YTM$>-$[?6.3)%%1NMQ,"E,;06'8F\48=H:*(+'VD9C6"!(;8D"M MUS':5BS?= ."G6G3!!;R9@1H6.N3(=51>8 M_0= 5!N:#IAB"9]V2%P*"/5.?]"4AKB"PIID.FQ$69A*U3'D!H!_'%.TX<+Z M=V2S8AR:C3>-?&M"D=$L"U/B8#XBX+ '.X&"Q]Y?7]Y;$S**'**H\G!)$# * M8"Q!0'?4)R/XZ8YOYD6RES,<6L"$V**EH%^G< D;1V;U6@Y[(C<=K(E\[JQH M[=T&DLM9$GL@N:HV")Y":L..JFW<;;99<8M&FR"S24:EV9X"!GP<^"G_>3RZ@/ZL]E;"9* M4/,K2J\B'X\_L7[TG9B^1%PL^2XK#L^4F?+R>C);G\PQ 6K!A!A4+L^N[90^ M4\&L(\""O@@F8NK#O3YLC43QG1 _P(OQ/,:^]QR#L5 D@BEAF 9!5UJU!O< M247=-:FH32 50Z8Y0]U\QM#&M-)F8E%V32Q:(XA%H=D_W;Q)NS&QW([' 0G# M>/WC12Q;9ER,+:QR#@RGH>'-[)ZH-+S9S8<-,C JR4[@4CU,?/N%2+\1H D? M%@D77C*?3-L-0NG)\T8(";41J 5?G=OQ]7C,4#(24.@?,)(?L(VN93LV73:* MYU8 =F&L G;!32@J11HJ51 ^AL3K0&%Z? H!1#N=<*; ;4%DH"CT$+THN29% MT&(@&&CZ+9.J"Y;D8) Q@)P'Q3_M%3K"T%H^*%7=&I[%L0)5'%&9O0!S$& . MVU^R>L <#NDL]??N?5?ZRD$$4S,!3812\EDA[[%EO4Q*+7TPHA^QY]0"'+V; M[U_GC=A53->+D._*?;PI,QSB7_=9_W"<3-$ M;U\,80B&$ S10(;H[XLA>H(A5F6(8^C&2/'U,2BTH+KOR')35S#IH+=_3-@Q5(KB-!,9_V3\ZU@H,3D>G<"FKJ[9B:!H*:6DQ-_1U3TQ"I*7]. M)Q+>MT4/7W--'I)C'-8T8#WE?;@UJCM7WC'L_[4+;Z3= $I-[!YF/10 _(MZ MYV;24GF&X&JZNZ2DOFZJ4D[.Y8*#> '1M&G7]>J1E(&EM4C8FW/9J4#G8 M/_'F[L=_FL_3SU>L'R.V&T;U?Q?_HOGQRKA9$905!M8*@:E3MJQ(4/3?*=^L1A_7;2ZGSK)^GCV9 M<([/:'.QXN'C]/JK6K\U*O$BZ_=^8OKD"V[.969OL':]F'W4DW.]NTD_"N%F M-930:E3N=1":AHJ_ 5CF@M :EYU7!WGI34I*.@9W'C;M--TU4/[$BBA*0]8F M.#)_OF9;@"*FK,M U_&&S///'?&MLH!8W\#45P%WWT):6V(.[('6>NBY-: 5 MFJ"U'4?X]T!K_4VS2T6 8&5J>?#A9DXH%FR,2-Y?(P]@(Q[)[ !R1I"P1H63 MV/Y G,2VG/**LP#V3WE#07F'1GE-LA!*:;" U@;RIJFH(F2P,I%\\X) H@<% M"-P9V<&$GO^?(FW0<6(@840>0Q$VV$G8 /?CUKV>V8W;\15LP$*6*3EQ$WY; MXPAKM_; "N14P0H8J*(0I>7T5GQRL"]Z:USATS'$"F[#"?$E,\7P/K)8P1ZS M!^C2%_4CG>$*1%SU2065OU^L;$15'X1&+_[D@DV=4$QJ>&#@G;:$W;/.[:J:UP MZ<5=X&Z3)G"%+#24BZWF0^FYV@20[/V@QA\'U^P@8K$ZKRC(*QL7)@J&$0S3 M&(99QXA;G6&P=^90<$Q-?1@6]Q7'OWGS5[HE,[TK^:-UM=O'QI)3+[#QFD^T M=2GL;]I/\J^S?4#Y8LOI+>8C+&P4EM^265;6X&Q/C4$5I3?;RS/[[\2/AS,U MG\CIHT_,GZ?F&$;[R71>S?< Y4RV^:?MQD_O >7E)E\ZQ?%X:U-D!#S"IKUT MQS\!RQ ?KX(QF8T9BS3Q4=;\Q1[+Q!RH(!6,44_7-6/05S48DZEJC];C:&3\ MT3\YI]UJL;,P"AEVV&>>E[9DW3VIY=KF45*[_N?%Y8-T?WES_?WR^EZZO/UQ M=_OCXN'F]GOCA_[="^%AH8<+3B4F;67\U7;!Z[9-1Z*P^#3J+GW@@I^,/A8Q MUIS\B;5 SS!.]<+FPDWK)/S5\U=J3J[ENV8_N? >[)MM4T5)O6->Z]Z!"Z8^ M"0AM18T=S NZ%0/!-]0_U$K\P[]V)>R\'(/X6D1Z).$K(2Y=&YP[HB]+:3O% M,0?PS\X9VS#]E8+]A,5=G)N[+GK9NF!"R:ID]&H&F8[N9ACZ]F/$6D@OZ+M. M KS$#B9(<;RO>(8@_RN0K,A'!$P)YF![(]X?OELJBPZ<']5R?G2S#/E(7#*V MPU49LE&NIU'L>NZ,"QNU&+V2Q5B9]53!>O6PGM((UMNN$]LO<6*;RGO;78U! MV6JLS'S*,N8K)!U253)9I?"=IV./.HE MX:"2]>UEEG>(I_+# L-" BYW<,[(8SXN+JRA"7\%D4,7Q^1]D&#MZ#:,^*$: M742&N5PDT=@#D!O'OO=,[WR8^$B"OQ'_B?@')[H>,O)H8HZ 1C)2*4-0@42# M'_BEE[!FVEW*7P&*LCI-SE/D+&_^GADJ,.87/M"'B1G^PXN MZMC/=L@T,#,P8F$V\N "7#YF6L"> V!C(2GII*_?+Y<+;A W1*8*0ZL\S,0 M^V3>.)T)*^=]ZUD&B%7G[;B$%7YXC@/&Y*OICVAH[P$>]L7QK)\9Z@8;A0#1 M3S$JYD>D,%;$X]!4T318\8P]I$FD#!N9!DR:R %KR)])>XFI-&8Y^+-TVSXM M4[\+%@;6@=E422R?GI# >CCF-""?X@^?1W8P= MHYJU3\WM"*7U)V1]F@ M%*7;4\2@5AR4JBU\U)+4J(4'O"M>IABYZPK.:UFH?3<'?8-E\7?**;'.ED!= M5VF]WHBLL=6F^.$&50_H.;! @EQBT?KT4.'$M]DT@%;:*@D2*\SWB)9,%4M6 M=._[%F(L_RZ3<[ M16?]&$DN*EOB/:T6*= ROA36X@XZ:C^/HKQ1SE7]657U5%H*1A.,MC!DMSU. M,S FU^D/!*<)3CM*3E/4'7$:'O?W.CUU> "<5E/=-V,2M:L:#6>4&]?RB1DD M$?0X_8$> F,@,\X;+D=M$<68&W/B6HP8;QTV3V)'P%]][_F2;> =35^!J^_B M_:O.M_V3\WY'UYM2GREHKDZ:ZS63Y@8GYT9GT-NXRX>@N0;27+^9-#=$FM-Z M3>E86%,=^L&:(%/84;\N T2@/.W: +G#[:N!+16L;.\HZFF]J+U#+&D=.V[<:*E)3!1&O-PU/7)!;K=)K/9-B M<^E%SR;;T\KN8"R&^Z0*0$0;#B/:D-FQ?]CA!*['"KZTV*.2..\US6(7=+=_ MZV$'=-<7=-=FNJLS,%$KW36N_>G/=)+WTV6F()8X+V.-MPX.%_W7N[)#Q>\+'CY0*L85+FN*@;!RX*7!2_O MM5!"5>HJE&@",Z\ Q-Q\B*2+A6@Q&= 5R_3]]S&#[V P%5%H.Q2DPB6AY#&L M,/>)P]Q1B)E2X"0.FC2+&&<'4A ]_@OQ3."=OW?ONPD6TPR4*BR#RT!1$IPQ M_ $/8P,8MRPG0"ML$A11S9,8EM,&3Z(0+#Z17O&?M8.4-]^_KNZU,U2V.^*: M#GKD%^[H!DN)21#RYO5+?70YPWWJ!M9Z3<.^L"P_(J-*P]8V",WM<;7U363P M'I?;V" BM]2X8@XX!,S MS$" F6QR>&\6VI.J#Y2P6M)H_PZF+/K8*;K %0W3I9AE"P#XJ$!L1>A M[:Y*2L9!D-)%3$MPDP^N)26,.]^SR B6(6@@.= G?K)#,*>M%>9ZG8+\H:&: M[G#)C \.I/0"13##D)4>WZ4?D4/8EBJ:B4.Y$4^L(AK/E$NR\(8XB]3 M'_ZVIQ2C$%Y%@1B]\=BVX/VXVNGO*>_QWSNH9Q$>DN$^DPQ$8Q"#W8%RB#]R M:&S+ R^+S3^#MN9B&HJMC7< M/'@E,#=LTN*CZ_9LAR5+*=$]91BB'3898SX=/P+Y3[' MJ0R!W3BE@(LX!;-M;+,MS3 "WIV\$ES*9SL(Z(Q@UX/80GD..+XVC#U!S)R= MO\.\V%ED4PKA:%G1<\1L)7P(F$K/8&%:L?&T/CO-7E/ 4HBZ.H55@XO0AT5T M4L26I OCO%-#-J!>K$^>P#W']R8;F5+4 M%XG#VA^J(G5 /&4G=/J ;I_8JF M3L8?H"XE>&BQE2.A@LP8_#^HG 1&/SAS)Q-# UO?2J>,4M".IVUEIYU*1#^> M-ECQV#@BU@-PN4N8TT_]!6HTI*;'O'TE@0%P"JI_5*;Z)5"U5 O ]_^.3-!( MR[M Q=YRK%>PFP'5TJC-0$&:?D8)OTN._1-E-U4<6&=-IS>.7,8@JFH-4IJ#B&5Y*.,W$ X-D$(H'_Z-\C M('(6X5Z5AU8RC\?EYG$&D3S9M H>7AJD7>WH(K_Q"4PC'XP:'IZQT':E Z#RY0D\ M$9]QK&61*34)TY@$M^6< W1&OQ#+C *J81E0/$IK(,X,$GVGPAX_F^\4IAX6 M_X72.'@X),03'C3/DX7O2A=.X%''X%],C/.PXGM6BL,WLXX@-NN(0O258N< M96SF#(F2B!W\9-(Y<:AP5(^$ACIAS#'?/*93SV@E]&9M/F\:X31#WE(%0U3T M8N H,*$-BBQ>2#U:.L /^NZX8MQ_EB^ :\\..KX!RGS[CL9(1%$L!TOU".A MW)>NBHDGJ>#DQ-LY'X58Y.Y7$FNE'G$7= F\\B<3("B"\+ R8*]/AP*^+FM5 M(5G@7J)VQJX.*!]@*C1(P7W,,&1$<(^"VJ,VPZW_9+KVGV9"QK2/#@BS$?@- M6<_TP^7M_>U')+*8#G:MBHMW>5[;\KQ>_/K)9RU!??.9O'K^3^F#*BO:Q^Z6 M)[!PN&F4!LFD>#_K#G!EPC:=)0U7JM$N=L-*8SN/:?P)-%%"BP,"/J[#M"K/X[WS8MU;*JX1[Z)B^WQLTNO$QE2'Z92>@*'BM-T-SA\& M"\X?%G?ZV/.1Q!=^)'$+J^.#O$VB:U7ZES3646'^H_QHG"H@U4TJ4NX7@?0A[V9(2@_\[Q*_ MXB.X,AXUJ='>(C[-T:$-E4^R:Q_RM3=]'^]$*7^"=YS B$Z77HB#8D(5W\ , MQ\P@D9HE71[@S'Z0)XSZHL:^/_W[QPZH##3Y41"P%C\;->9IRM;?NM)W$+ET M=WOQYEZ!(4,N] U,/??))AUL-<6NXIO^Z/&$L&3W.\D&FM*2C4BR!@*3 MA?6,#F9=!1/3)XGEAX%V#Q?$LWXRIS/S!% =F3Y:(^H !])O-.M,,>A$]$[6 M)P#AC&$73E=X$X[!XDW#TM,%ZK $&;./'T9DWGUP>CB[R8H6[_*O)K[BRH.A M;'M[]5_[6[*?Y__[T3\[7UOE(Z+4*C)DCRI>&EYVLX?P M/Y)PS%R$:=V E8$A* MG*7-GJ4-RL_2JG" ?B).X([D!&ZG9%LLT>XN?CQ(-SEH[]+MJPL\-[&G5%%RWX/5$-!H)ON=KE_F M!!C__,&S\>_1'6*\"Y?07&9!<;N@N%ZS*0[\]CCCFY,5I1CTJ8#<@AD:>@!/ M-F#%'T&'EQ@P P!VM"1EB[L;*2X7@.IXA1\FDXIW5. MAWO3.A_,C_O+CYE=%57O#A%*AFI"=GJ)L8*19T4L Q+/05E PPQHOA;+U % M]Q6T9AQ.XMFA?R\_^)QY:[_7->:W0Z=P'/O:$>4CFTK^WP)2#*0/ 4EB)Y>8 MZ.78(Y8(570UM9"BZ91A*V)7\2LS-'E\13)#*66' 3,?EM@.'\L/&QJ^SFJ5 M=4Y97OJ0?N1IG(4KG98->S05;Y0D<89EEAZ+V:6G?B%?;Z!P=^: !W,)$)%D MXKVZR=F@9;'(&SWP*AH1W 2/H=7S\-S0*]BZ/6V%5KH5L2B.1TH1;5([CP+H MP# =/;U#8IQ#SZ&TR7Y.3:6NS,PECM;) MW\Q_[L)/9_GOA]VAWBO\1>XJA=^7/4G3NOV!5LNC%+6K*_V6/THM_BE^U!+< MU07PJLPFVPV(UF"9W4(IDG,&=:&^1QB[7P%E]1!G*%V1P/+MZ4Q@NR53_)H] MG['CLJ*VS?(F:T,\OE.2_1$;$-RHH%^.?>^9&G.@J^@7L:IMVXK OJ.:!MNK M=5/#,T8DZS/,O[&#D*='%8BH92C8*3R>LA <;QD&Y+,]&CED[7C/M@(0\JK! MD!GGF3"A^'GO ^01DDD83C^=G;V^OG9AF-TG[^7LPKU)'2G81 NFI7*8BB M+, /KYU:=FP)*P;BK<380@PXQC'I$?MOQ'_"X@[FU_T:.>^2.L!C>F7806<, MKS6?/9X=';,=!H#OIS1I^L("#X.%0FD619?>\@MQP36QI+\1TPDG'0G$='<% M:;1\I0O[(VRX5<6";E^;127=X/3O$M52'V)+!8@VU[NHQ0O0/]/D,Z3"(YHS MR*]3S9"':I$JFSNY8,&-Q3I]":\]!;0=KZ6W@=V6@]=6S\%F5 M-1W4^$C] Q3W::*XU4J*NVWJ^=8*/4RD4UFEBKQ$0R?)_]%C8(]LT[=)4H&8 MO>YAXF.6U[4)VTCS]4*>F)?J\TQ*'3J2"'#LAO2D-#D4E[Y]NZS@<*PH Y# MK_: M?A!*%Z!\1W%^^RK:.,EKY]#.=:ECH8^%/EY1'Y\9J(V5UDU,:&.AC84V+M#& M:JR-]=9JXWN"6%O5U?&OIAMATI%.E;$B?./][V>I+E:%+CZ8B0E=+'1Q2W1Q M-54L#Q55-OKPP5 50S\S55E3@!/^)&^GVA]:-WP#8M68@6*S"CF/ 81&>/:9- %!KIEDXO')[5HT>J^J[/U5F-9_6U5JH^=0S_0R[ M!K9N9IJFG>J#@;**ZM.$ZA.JK[FJK[(;2C^JE,-T_8Q/2>/18&U'!['[*!O@ M292YD'#]VG#556N53LR[@UH;0[/],U47)Z5"*0JEV#ZEJ.'@#52*9G"*@%9R M3U'?R-M;JAYW!K7[(6)1235YSAF#"3GZM)QC<'/.%,0OR'3M:\O,1'1/1/>$ MKLWI6C76M>U-R%'4)%\U@[[N2 >F?J4/K.],'(X<4ZC6L80V-CID=,G1X[HG MK@U/_T[AQD<1[4]C5#^.:KOV;F6)I=#>0GL+[=U"[3V4%:VG*Q2PU^@/C3^, M&>W=2K2#;";M8LW]FPFK*,W#\C9:;K+;[ MK57;F9:S+-=8U-@H6X]#9N0HW]031KG!H(\:V5/X"*K.DGDCUPBJ0;5D5I.1SX04(I?(MNA8?6;#O8> MHA=635S:DLA\Q.WRL/-1!Q5H]XBUY/^7TY(M#*@/SA#:2A$!]6:K M-:$DCUA)KA)03P/IN58-BIPXG<,W'E0';6DDRK*577P7*Y9$GCPFE*93F@2O-BAI33S1F>VO/"IHL!/ M2]R7W13A-BC@ETDCT=!=D>N-^ EW)>.N&,)=.9R9"7=%!/R.2&E6U)B]1&.V MN&)TY8!?JD1IFHG<$SIT6SJTE84N0H<*'2ITZ+'IT'ZB0]M;OEG4^GQ9ZHDF MTW.S//B34*(U*=%*,)*',4^A1(42%4KT^)3H(%&B@]8J40:=6$F';B5]4^C0 MC X="!UZ.#,3.E3H4*%#RW1H6F$_;*T.Y?!_(GVS02IT*%3HX!$\JFF*OVAL*"$3CPJGQ7,A[[Y!WUX[7CV%X8"@5Y MK#$&I=^ZF8D8@]"0+=&0=87ITRB]DN:+*>IN].,^F@721FN+E&32)% I:_'[ MJVEYC]*M_V([#BE0D%+EA3N>-GQ4B1Y,'S[DA7Z+._&)LP2AYX6>;Z&>+VOI M@WH^K:U2M"/6\Q?1$_;64U6JY?LY+7]O^N8$P\0CXCCFGM5\ X5L,9I]*^NG M1*,@H2>%GFRCGJ0.L:HF>E+)Z,D4IE?16QDO7JHBY]*]526G)*]A*B0,IZ_K?$79VQHI3X@94^TAW M#CR0BKH[S[$MFX@J+&%"M<*$6B_CO"?+AJKTTHQS66,9YYIE#7K]C!'5;Z\1 M]3!C]?SG7P:JTO\ZR8F MS"*A[XY3W_'V[SU%Z:M:[\Q4>J>@Y#09V[_KHXR>&P@]E^@YZ:OG/\,M<(-M MT7A[Z%D_I=]=.[XJ"3H"AK56(FJ:=JB J<)A&=:IMB<8A.M:)3;1,?)3K5"G=E")\' M1@J1-(@ADE2UU^\]IDC-:HOA TO^#\Y$[_.:Y0;^:+H.(8 @1 M1^R+Y#-]5+5]SD@,B=1&T$#ABX@ WG%KQ!Y\2A&1Y!X/X&GCD9EIHJ>VP MH /0;"[K?_%H'JLF(80?9=U%L,C8Y$"D=;0_(M?G 3FA!)NMMH02%$JP8E[' M4-;5H:J>FBI\ML1(N#^W4&FZ88SYU:G!2=6QZKM"C(V]%;J MNI8Z?#1E0QO.):,(72=TW<'INDW*'@U13A;'\I$ !AX3SH[85YF=P)JHUA4H7*OVX5'K:]45M)XK?QBJ] M.04*0K=O6;=K0KZ7>CV$MV>B4^W$\&O?MTNU'H+U;HNU/J!34RH M=:'6A5HO4>LQ\#[5Z&(ASL&\:2<&(U5DFY@W2:*V0%98":#8:-])O3 1A(D@ M3(26:<8X*ZVG]/L]FI6FJIJ2STK;$:K>WOK7_4)<[]FVI+\1TPDG'=2!W6*8 M!%66#:X%9Q5E1S(#R62WB+ZTI2N-:6T'X_+K[?7X%>5LT.;$.[TG#X1"%PK] MR!1ZIBNMDC;C463P<<'5U=.6M&JK 01]U,K7)JPG\<%Y#1'9R'.E2\^?=IG? M.Y-?AQK^%]IJ=F<9YT)O;U5O]UJKM\^,=O;(I6K;P#)1H;:%VCY*M4TCU+J> MB5!K<9^@3';=T> ;_A<\UW-/DU+H*]L'/>[YUU)*<,*$174 M94IP4-0>KWTZL,=TH&@JL#CRBW*V%"P&V0(MQ MPV9M 578 L(6*+$%%%4XQ,(8$,9 2W5@<70XA5/1C@P_;#%2IO0AS)6X@K+>+$0BT*M=AE_O#3$E6%7T_IFI*L.^,C#^ M)&^GBOR'EK8BTO3_;K&>)=;$A7<]O4O?;*!!\!"3TE6>/ 2^HC>6;JW0>R2^ MI- 4(GDH/3*=:SY[[I/T-WR$;77^\R]*3_Z,94(=B35U^(?Y0J3D+38)9J[! M)\Q&;(_0Y2SO9:0-V^=S:BP6J\BMFQD\_513E;YH1BYTZ5'J4@UTJ=Q709>J MBJ8H1C+%>44L\HPZD_4,I\>3*^A;H6GWH6DK=70_C(EJ M%)I"$='=9JO&+2A:T(R( M ^"FQ 6)&NU@KLJ=V,EY).$K(>Z[[T&QGA@DC7 MH\@R$\P"& C!1)8C]G".HB.L(I^I?4Q@:6,L4;@X(I9X-(JVK-#1D+.%CEJ^ MT+'_OUJK87\0B]@OZ%T$TE?;-5T+1EYR.O=KY!))'5)EJLX&#*_?@#"D[,.^ M?;NDJ'S@X?C>*_$[5-M.B1]X;B"-?>]9"F$BM)H"_S\U_? =K_$)? 4W.JCS M_8"^Y,GWHJD$;C(X5QWI[ONE],5T?W:D[Y0B0#5?!(%GV?0OA@4X G>9ZG5J M"= [.WR4]Y9-7 N':#XB37D^AC&3 <-]H0V/A 5] 1/#9U%-?.>E.;5#^.4W MT_])PLPM\)[("B,?EXZ^ZEAM@J.I]*!-XD79I[ (A$5P/!9!IM)C.0JN(5%)4(%"Q4L5/#1J>!, M7JM%:KWD>/@3VR3=1AJ#K73E0]#$DEJC@; M^5^,O"GF+&0OCR\:RKU$YIK^H^F2X/3VS2'OL;A59;E]Y\A"W#;D,B%N#U?< M#CGFT_" &O&43J+?6I61=,$Y_6(&H 5F6LC^@+6"P;X+,&4AZ!LJZ!M(58J\ MS4,F*GSV,2T$9!][CN.]8BGE,YY#VZ839Z_"CQ>N&YD."(VIYX=X^/35\Y\E M!%M#2[$\\Y3B.. #WHGI2PQ-(D;.8V$ #A*A26/;@1]?[7 R'P=@R:T\%@!" M[-D. GPV#H,\^H@UP9ZELF?I'7PMS )-7]N5;BB6CT3^&8+TLQ$%Z$L4P#=! MP">$D_X&3X],>,$'C$JH\F?[GU]^?*.?E<\?/TD?[(^(,Q2 M&1YP%],QX3I M2O<30HM2/]CS5]PC8 9F#C.,W2EA:\*N+;V8 AK1N6*B+^OP,O$9ML\@U/A9IK MDU,7G:9W"5,\-L6%6;HGLY1KS]";@J!%NY3=?HKL\TGMQPML V6YX:=3_&9/ M=N.'__[(J##_[XV+F(+H^YC@Y[I 9=3GLN"9:$'A$;7IOL/?/%3F^>\2&!)N M9_82WT<.P%N[L^18O%Z]AB]7^7J!23:V<83H&SZ C1W2]?+)OR,2(%.C5+& MC4S@;LK "#-%SY7L(*V=;<,J_:_R1>+SMUTF[% B3K#D%L$NO6>;2C\NP&%5 MN)4N33.G(H<]Y?[T[UTIOW;VZ/^<+#>M56UPLIR/=]^7 MC"XGG;#2ZV;4USUSME8A%2J LI2A#/9&&-^]4#*G4P?D"@C. M*/?@*U"RKIS4X/=KO0*_O[FN_=['LC4O?B%'[Y1LBX73_?O]Q?7]H MPBB;Z8&V.RIJWC:5JF6>_1'GYZ$QHQ@?1JNFWS&01P8+W>$O2'"<4>6-(@>L M)S/"\T:J['SFI\!P'@DM66'%*W:(ZG%B.F,$S\ '4;+C%U!TC,B%F^CSS"B< M>#ZLPBB1KKN- @U[74WM5PT"Z;VN+M<3V="Z?6U0RY-@4(9AU(%U7^A=]-9U MN-EZ[\GWNO[GQ>6#=']Y<_W]\OI>NKS]<7?[X^+AYO9[L^$FZDVBV>L67(%3 M]BD)(DAQ_*#^R,Y>9_GE_=,V,BWV.J>SX$SZ.WD!_^>AB\K?]]Z+N&8W+,)5 M 57+TU"B)Z-2O ;K4DJS#&NZZ&4+/F^F['"\](F?$*G9ME:8P9U/ AI9X)ZT M^3S]+%U.;()!3+!"*(#T[7B, %<%(;]JL:JF&)9WM_^X_B'=?I4N'AYN?WR_ M_K_2Q?\YCV\CBQR.P1RU$.UL.9/(2Z@X+:\-7 MCC2E]=5@9$[L9_P?#I;&LR(V4'@H/LHUGUDJ!L[*,J>FQ>QCFX<2L:^)X[UV M:.#0C-M$\N0*#((5!>RY 2[S$IB_,PBW)^+RJ:+IZTGP$9_A/@6S@\%K/?8% M-Z+AYR"R)MGQP2.(2\WD!8<"8K\IS=N*0?YA6SE5 M\)?[L[UV\J3,Z0F_'='@>$+;5?;CY$ .YS6EV^M5\Z;*OS?DFL[YE>Y 'C9P M4,KBE]=]E+P=4W:P3#LOR=3_#GRY1^S,9B[*@QTZ8E7F5P4=V16B!HJQ0MC@ M,!S )?[?>D3A>Z_LLWJ0M1>)=T-U:XE;(WVX\VW7LJ?8Y&[^QX_\3M/V832Q M*O_BF?YHY\O;P'2)Q9&B-7ANWY M--\M%OB5$]N$<-^/<-_KVFR%8X6(WYJ(WRNQH(B_,R-'NL1B-6&7GU_QX+,P MH1LO9?=J&]7+-$*\MM>"ONI*]Q8, ORMUWWXYD+$"A%[D"*V?L818K:]8O97 M>O!]W96NO/=:3AT.7,I^(^9(NG%'9$KH ;@DQ*X0NRO%#^IF)"%UVRMUO_ID M9$K?R*L=G/[-=!PA=X68%6)VI;6IGW.$H&VOH+VSB>\3L'*M?T>D86=P0LP* M,=M4WJF=;X20;:^0O3)=FSC2KUW0RR^F^V2+.((0M$+0KEB?N07>$<*VO<+V M?F):Y%VZ(R'6$UE"T@I)*R3M*FM3/^,(,5N#F#VT"G&4P?! Z=XR79=D E"[ MS2YM9G9O3A:+E-NF2.1#X[.M\)B0V.TUC/]NAA,'J[GOR2-Q["@0IK$PC1LH MB!O(/MM@'2%JVRUJX6Z72/==Z?^9+HS'%M)62%LA;5>5MEO@GH42*8?HQ:9^ M_K\?_;,Y--D\M#+V2CDB:.5>.;3RV:,W>H?_3<)GY_S_!U!+ P04 " "G MB%58 'HP;^ B !(G@$ $0 &5X87,M,C R,S$R,S$N>'-D[5UM<]LXDOX^ MOP+GJ[J;K8K&+TDF<6XR6[)$>70KBUI)SLM]F:))R.*:(C0DY=CSZZ\;($5* M? %)23%FJ:VIC24!W0">!M#=:#1^^?O3PB&/U/-MYGX\.?_I[(10UV26[=Y_ M/+F=]EKO3_[^ZP\__/(?K=:7J_& =)FY6E W(!V/&@&UR#<[F)-@3LEGYCW8 MCP89.48P8]ZBU?J55^NPY;-GW\\#M8R[ M\_/6&WKVAKXV+W\^NWC'B3[Y'WQS3A<&@:ZY_H!Y2?WS[$KP^RG^ MCHS.6F?GK8OS5%5YS8O6V>O69B.M8%TMV<*WI^+'$V($@6??K0+: ["[=&:L M'*BR7EY>G3RBOV2W(E#U>OH5_MLXO0!PJL,T3 MXO*\X5,KJK>/-L1SM5H;HGH[MB%S7N;)@JPF_^SOVHSU)*_ WX3?+9>V.V/B"_@*I\N':,Z,Z2S:05([:<;"Q/_Y M8'BFQQS)*G:Z]-B2>H%-_>0NS G,/3K[>()[<2O:(WY?>O0G:$E4),5@<^+C MS\"!^K!9\?X.X@Y%)%#V/Y[X (5#Q1"IW'^+SJKV'ZK8KOUOT7O'N*O:>ZA" MG;]\QTW#J=IQJ&*NG#I2C]6G\#NQK8\G'09&Q,BXA^;A][?COD2=X\SC6A'I MB'@LC;^>\?^=DU9L?+0(KTFPZB^GVQ6V2*U\:NGNK_SO[4D>5@Z+%%3<&J;2 M]39G56:U\,MH. L&N;VR[*#OHG7%6U)IK%.5I4-^L3GDG !)4&C0R'>8ZS/' MMM#DO3(<5%(GD2$B+"&)'6 )_9'C0JSD- M;&CG?C#:)"D%[$UYP,B/&[3_UE UZ/ELYD.NQYO6OT)ED-."MS;(N!BHH3- M2$SV"-FLPQ;0L3EU??N1#IB_'^325*4 _EP>P WJ!,D?@9Q- F8^S)EC4<_7 M_EC9P?->D,P@*X7R77DHD^3_ZS_?7YR_^Q\BV!PAS1C[_6R057A(P7Y?#^P0 MY>,FFEX[#7_><]BW/:W$:VI2)"\KK,! E7"R#0)L29 F M,6T2$6\0@&/MDS:\U2HA%-610G"^#4%8LT'C"Q+W#VW:OAIH$ZT#XSNM.ATR M"4A'_F)[Y&,R)*;3(!SZ0Y"\J3[^6FGPXUK2$7^]/>+KN@T:Y=%8'VGCZ=?1 M !?M85?[YVU_= /#4&G4\ZE(47BSC4)$ZQ7AU B0(VMZ#4*FCR-YW8?YWYY, MM.D$QN%:U[N?^X-!Q1F13T>*SMOT'(FH$4&.XQ,1;! \O79__*D]N-5N8%QO MQQI*9[5](IN"%)*?MR%!.H03(DE*#<("%,+QK=8=]-M7_4'U#3NCNA2%=]LH MA$1(@DJ#$!CHP^NI-K[I:E?5=HZ-BM)1?[\]ZEB]A?4)$FC0@'=T4%;&4UR( MA_JTHL"G*DL'_G)[X!,D"*?1H+$'DU,;3C38^#KZ8-"^TL?M:5\?MJ_'6HUM M0$Y-ALY%RG .:?*]>8,JB.;$VIQ2B1)JD%P0+=O^E.^.//=@+LXM6%E?VP1'2DP M*7L\02W<3Q+T&H2.=C,:Z%\U[4H;:KW^%)T3E5#)JB]%(V5_1U1(2(8[21J$ MPN?^! 1PTA]J\(]^T^]TM4_:0.?.H6G[2V>L=?L5%;"2)*58I0SS-6$2428) MT@1HDY!X@P"\NL61GL#(W%SUAWR)QU6*.Y/:'=B!)WW^724(2Q.5@IBRZR/2 M)$F;+X2<.DF2;Q",$^T:A;@_[.GCFQIJ0[JZ%)J4\1\2(0DJ#4*@/P2)!/'^ M4E$[2-:3CGG*[A>U":_>H,$N=\0]8HX-XUTMYJ$BZ0+(+B_?OGGS+F5MEC]% M)S]&;)H4PE(.@*EQYQP$V9"P%->T\5H!5\&D2:B&@0LU8-NL*<4E96 I%R.22/D9J(0+FC@5N?LIGF!_;""*C?I8%A.XFC^2J2 %QY M_@L"? EG?)2%7(C&T$7#,^>&:W7I(W78$N^S=Y@?''"!*,%4*B,I_TLE&8E: M0* ))-$&PAMQE)=S/8H#!*(!M3P M#ZE(;-*7 K]+J$J+"&9'M'/1Z## T U$FC VZWC4LH.Q[3\<3@"D+*4RL4N8 M"\_V$O/G.5YX"P@VX2@I!3%(3R/F[O/7H?KNUC4,+=52UCM"IM*?XI1U\4@P>2$#+!S6"3#7X3 M,FHRPD/#P^WR<1*)BR#BQ@_ =3#SX:3MWU M>1<^4G13GL'L(,S-V\R;P"A-J+GR;,S5 MOW]9D/.2RD/*/UA&'M9\"3 FR)G$K(\RD<+IUK6HYSR#_G)C!.$P 7J]R2&% MHP)3J92D/(1EI"1N (E;P,6G-SG*2Q%TUQ[S_5O7HX9C_TDM],!3O^U:/)SN=1J/U+/N*<[K@G?NVU2V4HY"B7W:#97$=%2 MOG98)&XK$8WE<0Q1<[DA&S68A"T^+C[?62!^/U=97'\_/PKLOX? KL#PI.T% M\P+[3]Y@[6E)7;_63KH?CE+!JIC9>5NP.'^2; )6W 4DTW0=E*KJM"50IX1 MA2N!_*A926=B9PZ+*O5M]YHQZYOM. >;\[FO>SZMA4^HKDW:,NSDF&>?@XK'_--)W3,F&QP/@K$>@(R=V%X M#S :=[L>:M2A+X4^Y<4NF.[,;<6\FG[:D$X/40?3?"I2Y%)>ZLPL$PU$)OG0 MQTX[:B$A*3XIY_+F"R*-WS^W4WDDS _F\HL6L,H,6^G4-D MRYR).1'.ZH@S#%+?]U>1XW)"@\"I'_E;D;04X92G*@OA-1/NQTRP.:*+\VRU M !WA.9IF/G#I48R6V=,TEI.7HIQR3F7.8\$HGL;(BD2\CE##*(T-]P&4_\.L MUU+B4IA3KJ@LF$,VQ]5:OBOWW8!"UX(=#APJ$Y>"G'(^R?;DB%&CSQ"D#X'= M&,^LEL9O_QI:PYOFWKLVWM>#Y($@7 MLY)A7^^A.2C&V9*0+XD9'^4A"Z3IG%YYS+#ZKA_8P2JH9R;7YB*5@I1WJJ04 M $?"69(USZ, 9$'SV0C,^<)XH-XU==G"-FLI;SNPD8I RLU54@1BEB3BV4@1 MR'M,LE;HI826%,QTP&7N^Y2-!"N=2W42,/,!70[4NGMNFW^L;''%O-9%Z M MP4H*>SHWHASVD"]),B;(F;0;+1&I5-E\W[HR@&:'+=!AQ%LY61$M$9N:C(A*/811SPF9\ MQ'@FDOTN)3(.4GE(9T_,EX>(&:X80C8XO^.*D;>\\PDAO&?=E8?9"ZEG,^L0 M.XF$E50.LCV"\GU$9&,//82",Q&LCQ(1P\071LQ0[CU2"];+:";M41)D+*02 MD.U(S)$ L=)'[ CPBU>')N)>\! 4ST*]4_1-)=)2G#/BZ(H>G K3:#?:Q"R M8+):+D4@J>'$HRKR(_8<]FU'.W._G*6RD1%\5RP;R48D:T;9&K$AC3[[F#FSCSG9J7SS;/W>I ML*2GX!KK7B7*N1 MELI .KP9&9"0@U0FFHBN=C,:Z%\U[4H;:KW^%--TUD&R@(P4M=3)1T2,A-1X M\M!&HO.Y/P$1Q9>JX1_]IM_I:I^T@<[3IT[;7SICK=NO%7EB3! -\/)@(%HU$M>SCYCN%L-9F(D5[M[?4FQ[P6A:7<&CXA=TX$=#4,UQ_ M1CV/UCJLVCMSJ;"D#B\J"DO(*+Q0G,B(E&C,48[V &5%#?\ [(^RI+HLC5;X MDK1/1YYMTK;C,!,3\P1H9A?2('Q-%PK84#!;ZO%89>N?;=1*I6I M8[N*4ADUF/ 6DW632< (-#KY3$Z8_#EJ-X_S29JG8=./,EP@'UN1&3PFV*:PP>Z^'9W8['DH=I@53P4H>6 M%04O:@Y)M.<5/OK:XDUJ_,%F]96FBP\$X)5^[Z!F9B%#J=BDCIMV6*\2_!LI M(A/M&ITP_6%/']_P@:L5[)9+10;FV_3%"4&+)(@U$IG^$*09ILT7;3?73Q$= M*3H9S[ A-<+)-=Y[DQC:O@L#3O$]P2L*FPX5GZ?&$_6[\ <]RL2<>>F2,B_Z8*QM]"QLC2E0*?\ M\UM 'R/#LG#L4N$2 E'GAG=L<8&)_@U/B,?,<4#HT=C9$=]:O*2X9SQ!M8%[ MQ!5GLW N;!AI$6N2X/WO+A2_G#[Y'XSETH9Y@-^(SZ[+1-OY5_ -%;&U7&0 M7?_W+KT+,#>6MUJ(9P.BW)?X&GKPC)<^F0N_1/D2VZ;IK:AU0HP[J 3B\?%D M9C@^/2&NL: ?3VK3OO71ZLP&OA7_[YAR!B4Z+#'6-I![B]HW6*/_'V6MQ.]<>4>WSQ:UB'QW2V M#^.IPV'PGD'S+'GF=B;_2$+)JN[?U$SF#+HDQTU+V<8JA-25!:TQ=)ASY1R?_/Z @X M7YR=7][0Q1WUDH,@VB[&H%350ZX1%EL8MENBDP-8X2G=#-Z>4F\1>65Y:W*Q M+EG[0+MC5*G,PF_ WK3>H,;X@)WNTF(0B^LH@5Z7@@ILVD*G=ZWD\YOZK&<_ M44L<[A7H.V4)[+!PO=@L/:L_2\^4PKG#L!%,N,C:GH>RB"76TMGEE/(Z6KKZ MX3I;OJ\1*B".L'5&G_S$*64Y5.7U%8%V\^6$D?&,;;HXNWA7W,\2%97H8+8= MD1FU@W=(/]O!?$X==#N*1X4[CF$O?%RSW8-ZPHWJOD#W'UWG4YN#SZ\ MK*CIR^L$W-,[JV M<>\R/"_T$PG+)1M%F:I*[!(9R49E>F%N!24ZE"&38VJR>]?^DUI]"[WK,QM; MN1E.V\X*IXT#&I.][E)@&7_#O.B=UL^['$=MB)W-TYM_RACI #3-*X MDR/J?5U'U'NEH!*G$?IL8-Q-,;S,O0^](07V14$5!0XU8(FC+C1*_9KNW/0;=@')E@E8'^I[XT[:BI;%S,^DPV!&,>YFE6H^8$M/AU@4* MEIBG'6AZ<4_S2BO1%>X=7Z>0UERK"TIY^\GVWBZ!4+SIZ#,-=/ @ MW\GP$DUY>>UD,]94K.H3&@0.AE-J3ZA,0;/GBR*/=B4:JEH\NFLRK-K]$CYQ M.O(8+-T!G9C,HZA7R@ZURM978CFYH0;&A8LXN.4J@-;>"8? LSZ;K$!T?8G) M5X6"$EW68$$T,;9B?8,&#QO17>*:T&S.?LA=N>3_P M8;Z;1=-A[WP..7I+P:3$\/6Z[?9RZ;%'PRD6C(R"2N _;8^[_S^ MN;@7>:65Z,HZ7@9#(_ZY,AQ[ADDB$D%]&BJODAE\ K3!H( [LSH^ MSBZMZB84/^>#<2_%Z&6750*C"O$]XDI+!%!X4P,L#/YP!?2C[OG0?O@I>Z@J M=$XPR@I#_*%?/(""ZYRI.(L:,1N'9OOR^O!G[K\'<=+@'U3CNO21.FS)'591 M2^-[=3)'W[.2S\;>%R&5-<9 Z,D,IQ= M6 G02T0'BEN\N\071A1>^@9PSBDLD/<+KG$65E(U]B)#*4^D7\+@?0Q)2;A% MY1=[=R&IREW?$O$T%?:C8@)*S.^Z[C#MB9HKK)?<==$Q=BC_FYRA&MICU["= M9Q WAB#?3^;,"U#-NC+<79Y?I7"EH M?89/8/H;L0@^7(\JQ459&,FX$C*DC-OKH&5]]EDP#+-:< MY"OTW#KW)>KR_AF]M%;]V0C,^<)XH%YX]HKX%^]^A554N& MC9LKOD):NKH2 MNWIFK$IQ!PNK*-$I$0(A42R2991=FMHK()[(#BAS+.:7?VD/(*Y]'IWCYA?9 M!W%F3;RE&P@O,C^88".C\"9G/6+JHAS%*_%SFUM^M!,=F(W #$KLP+)CUSJD M5#V3C>Y]!8S0!:U.O2@(;!.]Z2>24\\:6K*]'94'U(W&72W34LD4\RWT=;KK:JSLSD M&Z6^2$)R8[OV8K6(.@:61L_V38ZS1,H?7 $#J#!U@=!RXH=-*B>J/'P35/%_"Y$'Z1I3D]J/_&XJCQC6'&J& M7FT'K5'/<.P_\Q>4RG04/<>+TJ!@A##ZNAY!#\B_[YM3^L5SH(QZD\B.+EX* M,@HJMAK@32?F\CDFHL,J3V8I!57F8A2HD8CX[-&B8,KLXJINVKDJ92((:ZV# MB,6CH.\U:*DZ,+L&_O0QU@HL%I/GGCETF%$>MY?6?3;B2DKXI"/#KUR@2B6" MRIJ&L$4M&&_WO4?Y;^5C)\O5_:M)@R"^8EJRNA9XPPD2^>O.%],?DME-SB2G1F M0DVT1S'73*R%2^ JKJ-$MPZ?5.<%\_FHJY7$+WK(0N'",NKN>J'S)CQZ!A1" M6'G 0GPOV/HDTI7H,W&>*O6>52>H[!B-J<\<$:YOL_!]).F%I]P:*IS8YIH( MPAS@6HR%YT#/XC[XW*9BA])GZ...O:'5C9#J'%1=!!+1C;#W/=ILY>O?7)CR M0]XD2+,M;*.%2N,194%$$5242Z@15 M3>?TRF,&?\H*F=#!H",[1,JOH<*JJ"]<^V[E#YBX6-QW,X14N5MV+;O!&W4D^ M_:8]F3QC\ABY2A?0?;*JL,]6&+_ERJ-EUE%8YC%;$RQTSS>&]T E6V=^>37F M5\9Q646A%TB%D=IXD3D*>-SAQ.Y035#EE."3X7&3<^39)HW. (H%J;"*&K*4 M?C9J.@?UN?)C4QNUE.C:/U?VU%A,8.$J[DRZG KZPJ#?T883K7T]UC1\&5Z: MJ[6@PDO[AO,?V=O/4WU_J7?Z2MS*$F%QFQG#]!FF%]O'G:\2U!6YX+7U_N\C M=0&N&^,) X/T58#H6=RL@^W:>N3WCW 9\M'S7?I5X8I4%16K#*-W_2B&/AO3 MI6.84>2IQ,E6AY2R)O3G_J2C#R?]H0;_Z#?]3E?[I WT$:Z0T_:7SECK]J<3 MN<)3F8XJ6DON(]K;:=:J/\.=IJ!J['+XUA JFX9GHFX_!<7,":_[A*'795\L M*DM%5==BK+N'+D(\5IMM@[F^"I4 '"6ALH&P#R:J3*;,VU_I6V&80-QPO>^RMR:R*NC M@@F;>351^E""K)82DR**.O?UV9"YPD>(C8JB.DIDZ2FJJJH>-<%$SOILGK'G05 MG[&HEM4\K[X2*.\:6WT-!3%;AMATVK. >HGH?GV&YZS[5U@J,7_IY!(YM[SW M=%G\$-?$#YQW<#/%6KE$RZD\RY(<)7OF\M(R%*;Q2=P50SJD_'*H:*%]GV)F^!%-93H4C+" M8>LU&XDN+*^H1 <+$YJ+--V8MASOFX)RG[_*5R2CQH%31C+V.#8_MZ^26JKZ MK(H0"CTI83[Z]J-A.V)71M#J@2XAJ:QK9COIK.P8/K_\BY_"SV:V25%3B/9* MU,56H#),V"SX)LU>4+Z^$BO9F#XRYY&'"QCQU3F92[ZHCA+=JGH-KFU9?)]"7U7%/=._./W&:G@E$[74D(V-D]HQ74:Y,3#\C*> [/"8S#Y/N>0Q MIQT]KF7@54DHYIKV,GK4M.2!\.YL#K0PE@P.E68(+ JO+UE9G<#ZFW$W-)M@ MK:/NBI8\JY+74V(&Y+_N_;;NL^!O_QH=?"VY05"BH@IG1AG*-"J(&"/0+3(X MI/445C#+W="IF9Z1LCA@I.Q'V=Y_I-[;R4 '[3.G#=[Y*E<_ZQ3-UM>&C1:U2#].5M!YW M(JG$LH69='0W3L;,3Z@WU(;"=*ZRJLI.M@K)]=?F;BCX^TC8GZ:IZK'R-J;R M0-""&JI$=6X?LO5'XZXTLW-1'65='V7BRKY;(%DE7]XR/,/;6%:$(R*\K7GU MG- BD]5ZY)3=OW*N=,B4NB*$+/B>*7R!!0]SN!/Z\;Q$P/##P:VB=,1-)1 MG$78'M[D,:(?UENP>+#3[[OB]E3N(.V5Q\O?*!]YS*34\C'/.EJ)^BP^N<%H M%,]^A%XYS[]1ARN"AEL8UEB/FJI+99B<]3=J.,%<&OJ65UJ)Q7.76$3)0KH/ MTH?)#% Z)"4*\EM?F QW\2OJTID=3/1.3QH@6%A750F7I!2YW"DAR:52,R#+ M2^^Q'C[+DO%<296\&(5DE%47Q.:$K^^E,XK*-?J2M571[L59%&Q!\JCMK*+* M@IB;!7_K.7)^*I=_8;P:E0/'Z92.2/?P$(H3AJ46GW*6YH(55C,?\%JH#8 .4U @ 5 97AA&ULY7U9Z[?T7?OJ\WW;4OCK%O4!3E88Q:U$B4 M/7Y"U)(EX1H$- HB?/K;Q:XB M(8JD#',D1'6R2 L_)K/PJM\K*_+?_^^UL M],L7G,Z&D_&??^5_9+_^@N,TR_'$XQS#'_\G4X__3+_!/^\O?)])_#+^&7MZ,P+Y/I&<0$3M;!0*T8K_\_%/ MHEACA! 0&!I03$<(D7-0R!3*Y T3=O'0T7#\SS_5+S',\!=B;SQ;_/CG7S_- MYY__]-MO7[]^_>.W.!W]<3+]^)M@3/YV_>E?KS[^[<'GO\K%I[GW_K?%O]Y\ M=#9<]D%Z+/_MOWY__3Y]PK, P_%L'L:IOF V_--L\OV7HQ!QM/CMX'P&'T/X/'@]#'$X&LZ'.#L\GTYI M0PQ,5@I#-H3>PD!9P\$AH90YK0KAQMF4[ZY396I&7"U$6L(L+N1Z]8K?Z@+^ MAJ/Y[/HWBR5=+.?C5%RNYQ9\3<)X]C9:[)*F,$T/0'1W%UU] MXK?9^=G9XIDPG./9]=^7Z>2LJ?3GD[:+?BE<8F);Z9]\QBGQ/_[X&DF=7'-Y M<4T31GJUMPZ"L 54#@6L>!,@D5("%9B':)T"XQ,S+C'A=&N'Z!%25L&"_C&QT&+QFR'A%AT#83D& MC990F"FL2U%!%(F\&"U2,%H+;4QW[G!'GM";R3A=+;#GM)U(V7H!5HN2O2:6(W:GZ_KM_6XG]>W6NIG,#R?C+SB=#PETUT!\,YGC#1!9 M#C(D58!I0=%Z%!9\T!8T$]8:H37/JC$ GB&II^[O5FAH*87.O-];ALEE[TU) M"&@D^76!!PK7B1X7+;=):B62Z-@!7L\WV(,/O)UOT&;MVT7&LQG.9P.&0;*: MEXG&.5)128#3,D/RSG%>O$+&6X?!BS[0:27@K>K1:[&6Z/Q_,P_ECUZA4].#_ZED;G]13P MKY-)_CHCPYUU= MMY/R87:)PT%QB5PH-,"MT@0YQDDO4:1=BE92&@K L7DR[RF"^N3?MC &S1:_ M&1YNM U:(71PE2]RH%0($GSQ%I*E,(Q9FYUWC46_CG+?E=/:0,H;+6DS@;Z= M3@AE\XNWHS">'XSST7^?#S_76AZR,8-@F'.)_&41LR!?7&5PN7A($@,S)L=D M6ONL3]&SBN#-CR/X9DO?# SOYY/TST^3$:WDK%(SOQAH9R)7U9=@(A,=1E 0 MQE-U/0LW.26/KM]&OH4H#26^U;+W2XPR7E8>0^CMV&8C\>'X?-P'D:WB!LH MFXSP)8)1DE0L5HX3P,QYB/PG1,X=OL%M$OL0S3<#YPD9R[P"TP MD0PI14UTN> A..NM(<,O)2FEA5!J")'K3UP8T(M3C- W"$X7VSD0AO% M6[OACU8$]:8V9GLD/'%FOM:2=QE:NE!\R-T487[TKI\[@ER^N2*=PJ-5B+IZ%3)<1T-YZ2EZA?E)0-OBP5/OEMPM3(6 M6^N))TZ5-LH^?:: Y^C;9_)2D5;XUB'O-8\V*^4+NNJ7.E#9(03K+*!VWG"2 MIF_N#JY 5I_,X^:86)*8:BJ/YE=IWF'"X9=:O41AS#5%,:%/T1<(,=22&-J# M0:8(+AGK94H256M'Z2EZ^F0WVT&CF00:5F%\H7=/IA?U4$ G[XUU$HQ4Q%HQ MM2Q*DB.7K4^DBUGDK37A[??WR2"VD_G&*]Q,QK^'Z3\I/"6TO<=T/KU3V>H$ MMR*B@DQ?0?%Z)3[I"!D=NN"R1M':)7J"G#XEEMHAH-7ZM_.1P^Q3]<3H?]6] M^Q)&"]]L?ABFTPORS:X.4Y3DT:@$F!BY9M9E"%B(-%\,YFA$C*TOTZQ$6)^R M2.U TEXF]^#R;[_=7Z_7]'.S=@WOY_1UX>-/RE5A"?WK75K6[]OPR%,[:>"P M"@>-.CG<5-Y\SR@/,FD"BJ@$)!8C*.<3^/I%14__4C4![ZS8Z3L9VX??LT64 M=^7]S@::BV"0%W)H&'DUWA);(;N:]8R\V)R3:QUYW*=AS3 #.M48VXK^87"] MQ8(W/)$@)^<<7Q&[-;Z?TF;[^W#^Z?!\-B)LL52&#D@IJEPQDHRD@9IXB'$7D M&!\MDP5#*:W=X$>)Z9/M[RNDVDBR';!P?@O;U@69)'G ]+8,*H@$L7[GHDV9 MAT2NPN1HG P+(K"E"6*[UUK?Y@F M7_5E?7)BV\J\D^5N6(AV+S&;A$66+#G )1.+BI@-Q2M K7G((:'%UG7]3V?" M-^/II%RE#0=)JEC(0@ JP>N-<0&>!0<\,N&=SR33UAVH[A#0)Y]O*VDOR^EO MMLSM:H7.)M/Y\'\6K)^4^PTB!D9;Q\EE '29@+?0D M17W2?C(O@D3B^+8>C[:\OO MDN,I.0$YD7.F7.VGN*B<\$82LH4PS8O.'J>F3P5(3;'12 -#XQG2(^I)2\O MR$L$R2-V@692[DL!N>P!7-+2K&/6N=MWN2H#Z5'#6%13LQ MM&L!@V/RVT=$T4$^&XZ'LWGUXK_<1 HJ1ZL5F3B;ZMFEX C1,@9&U$XXW M[WOZ#$E]ZAO2%!TM1;&_:K0[5W@76?F&16D/']YY;=HS_#0J45MR\?GFTG.. M/FF1-.BD$ED,[L!I73O(!.,UA>RH.VAP\1@Y6V5K'KG??9E6IX3MZ&19UGR3X*ZW6MPBR@2JSM@'--HC.=?>+:[^BWC8@N9/1 MZ5PD;?)\CY#Y&(&.*]*X4H/'5!.13D(,B0-W!ID06C&OM\',%FC9V7'&+N'2 M0@Z= N5I/!OOM3".0^$!09&+#LZ14TZ*7N/D>"%JS\64RC"#<)U4O/7+5M]4.Z[ >W2LL(>8::CBI02I;>H M PA;EZA80<&V8B"YUMX&"L2;3ZAYHB)E/WG2_0!LPOB'\13#:/@_ MF/]],EHT7;X"\\GX^XVQIX#-?782:W^%5*\36ZPU_R*"2"*GB(YGL2MEN"TO M?PS3P^S3J]'D:]OP_.:AW8?ER^EO%([7>^+T@K?3R9W% MQ8<9YN/QY>EW3>R22?QRV7\GIUPAJ*$(QD'IHL'5"QLH,8>4+'L0G;8P,2M2 MMW6SBW"Q6._3R4'Z[_/A%!_M?LR@LG4B&QUC\]D! MJU/7KU*<;L#UH#%&-[)KUZOZ/GTOSDFGUIM/E_W^%E=T+_\E#VPP*?&0:^%< M/4;+BYJ24.-5[PR+3N;6IYOKT->KN']?^&HEO^X0MJPUP* P0_A&!9BT)WO- M$<@UY8"!:_0BV-@\O;H286NZ9C\GIK:66'=@NCSJ7[8"L@3FF2Y@2BRD3DV] MOBD%9.>\BT%GKEM/RUZ=NC7/W'].6+617B-ST8C6M#ZR7YO(/AWC[PIHG0JR.UVV"(:_ MU_;.!LF0=0Y1@E0FUUJ$!$[G!-$QIU1DZ$3G_M9]HM8\^/\Y-==6DNI,89T4 M^DT^KSQ?ETKJHJR1OM8Y*0=*2 E!!0UM"BBW/%Y>MQ:OA.(S37?ITMMZFI"&I M4 \"9(#H"P.>BP^FU([IZR^=L(IQ-_\=8V7VSM9 M329RZQQS!%J7ZMSB>+19U0?U-L[X%0R>?%]U!!LX5ZWB2H 6% MX:H8#IZA H\RR^ EB[9U/X5.&>K3_:P]@'6_ &EX^>OSE;8^*;6<8CX]7U3T MO9X0G:3(:T9R8$L,&"4"*XDH$\J#UW56;3+9F!*4UZU#HE7H6C.'O)$[?H8]H68A!R.9!]AKT]>D: MV1YT6U/Q-6V5?Z\G^SN*^Z?#-,=\U;/][B]N??*R#H\4[Q1));_$R__?*.*C M;^E3&'_$=V&.1Z5@F@^B,J;V)"'.,!*/MM3^[KD6+!MF@PJ%MY[&MUL..\IV MW#2VO'-PZI2-A!)I:M\,K1DX9 A"U3"@U$Y:K0^]5Z>N3SF 'F-\21%W%^+O M.AFW+%F(=:J/9PI,2*Y./J-H8W'MGJ4H2\R*\1TEXS;,]NZLGKM.W+GB@!G$FT?BT(+ZXIKWX=WPUSQGENX_/#PW%;\S>!YR>)) MNS&H(23B0/-A4E/8EM>ZZV $;?@ MNE;@\&P% 3PE&,=OZS Q20AY\"2XH'%T#JQO*G;N^$-NMK0N KENG]1 MIDA3HX!H2P"E:G=/J3T88[GD)9MH6^_P)63TR:'O""U++ZQM(8R66: RG"_N M=3IMR;\W#+32]/X8,Y";52O0K#.L^"!C!V6H5V_OD]>\(PQLN/0M&XK?LR1W MY]-<%93Q5#FIH\B5K5.+:JT=Q0WF?N@4[:M<]$[8JU/KNJ. -U'T+0IBWV) MGZ>8AN&JW\;=9K2OAM^N^XL.C)(.&9G\:*VGS4I4!?+/(84@O#&.X?W+MH]4 MPJ[ZQA_@+D>.P\LST)7F!I?FRW5[L3!^0!2):M[N*1S1('E@OI" = M)P(%_C8ZX-GXP@02 VHEE;(A 6M>S?BA7;.=":I#Q__Z /FZ((%BS8RQB$J, MH%"T1(B%OI/6"R>D,2:V5C[/$O4#7-GHWMO?1E!M5!)1@*,K4)^4#XOC&5RT MGYA?O)W,YK<O$AB3W:E'7@$0-+8'V$&(AI!MI@E8\.L=6TD;KOWO-JQ<_ M,FAV(9T.55 ]Z!O3'RTNG@B9'&H',4KRPZ(KX'V($- :RUTR++0^WWV2H)42 ME.PGL6?M1;0#P_6]\FD@;8@LFPRVMNY6TB XJQ,80]K$<<%+![/"GJ=K)0SM MNVW1[@S8A@)KUT_PFM/7E:YK76@8CZ:H2"X])UY-,G64@P 6&>:D9)2J==^K MI82L!):?+!V^O43:Q5RU/>!\/L++@3"W;EV]FC)U_J?K(<2V]6\N!0MAAR(7U''.Z8@P;ELR$GG MFD>I8_MBQ^WGQ?&?)'_<@8P:A>'UQ8LV,I<)I>.W[U[>V,QBB2\E0 6'-2G@ M(2HRG)A8;=//E;H_GORQ>/OQEZP$@I\D+=QTP=L->_K>RGC1T&-Q$'R%QQPI M(',V0\FA3I^* ESBEOAEW(66TV>Y#];^K>YQ%J=;!><3BO'M MU@+864G9M:==N5<<-3<4RG-6\\Z2UV8_F=1A0%=,\M8WKSU=@[R5ZA'9SX&I MKJ77[I+#XASC>\/-5U_>#*_M[,!:+*(24RA4(\X54NP6+9$EC+,H>/OQ,$_1 MLQ* ?K9\;S,!]>,2\B 5EDO& -(1H2K81-0R"04EX3LX(63KDNB&=UTV6RUZ M_KVG'A!VIM,+@LG?PN@D_FUKWDUV)L#[= M(]@=[N[OP?8R;#FY^A;# ZELB9:10HC5AC ?(0J5P6<>9/$!UE_B M/ Q'&PU#VN9US<8D->.YU3SCA]!<]$N:3.>G.#V[W< Z<"V-E09,8NZR96BH ME[1EK1"PJ J*'1C,1ZCKQCJ^HAA]H5-?#F=I-)F=3W&@C>04DAM@QM[_BJ2,+N82XGEO)%LA:S21N*[AF9G'I+ $5E14D9?#2D48O M],4YSH$EZV7BR#EK#:%-YS[LT41V@9:MQ;%OJWCPA4Q!I?_59%J3S]_9Z,PR M/O_*'5G'-7EO9"%K,]Y; R7OT7!U>%AO$\SF1]^N[NL?I#0]KT'X'*>$V\OA MF >CT>1K;5-(?WHXQ7QU/U0'R7T2=312R@1G[R%ZGX!Y9$D&S[&TKL?NF*6M M#\WO$72/W)3.SRK$,/]U2F_[/@?TSAS2@9=6Y3H6R-'7>BO,UT9'JEZ;E-P@ M^N!;WVUM0GB?;'B?L/_@V'[G*&E7%;(AZ37=]IUTGE$S4RC,%XG5XFX%%.\[ MT!3@9V\ER\T'FC8AO%A2DJUU]F:4]JG35I\AO ,<[-LC7V)>L,8N-R'H7ISV)E3MR*]OOX([ MSTT]AS,7O],E/L_MKZG(VUAL+499ZJR1I<,D6*&BM MSZEXU[QM3:<,_3@N?WO,KV;(8<+Q6CRIE W>9>=^Z M4KPM!S^Z75P+M]T:PK7 T%/+-V#H,$KCH AOZZ R46>I* A..2LBRX6UOGS7 MEH,?W;;M$=!;@:'[','QF[\=O3D]>?>/+2+Z!\]H%G\_35VC:/FZA<3%&YP/ MO$"&]9Q=JMJ\1M0;O#Y+\#QD):V0L?E@R-OOW^H.Q,V#7@W'P]DGS._Q;'C] M_5\GDSP;%"'1YR @R21J4U=!$84V4$I$ZU J=*M-N'[^77TR@AN+^,X5A\;K MV_"&PQ5=[\+7W\E+G@[#:%&%Z_^V[D[='[T[_\?;UP9O3@S'V883D?U=M>V^1^MWQC,[O2DO-&5NCM=/(9I_.+.MQQ3IBI M!46?:^%0!65DC"N/!H)FB_)H5MMP2\A8R)WP(;3O ?,4/0T:O"]_]B*C/M A M972,@8Z>MJ!!\I!JW]-HA/>BG@NZG7&[H*A/IJP93I:T?F\EE'8%!]\S/[<; MYM+W(US2.?=1%@;>G[\G6_/7DY.7?CU^__FYJJ@LYQ\5-ZOM=/&A9 M7X11/=N>A7'^^T+&F ^^X#1\Q#8V>=!9 MI:CJ 5#MT2"T-LQS%5H[[D]3M*U"?^+IMS3 [9T^L&B<1A4@^7HUS'H%/E@/ M,8@HN/0A.[^[-7B$RC4]A&Z5=$-0W5?3'/P!)V7[@PK)@0K. A=)R[H MP,%;LAJ,QRR4C@)5ZZL,S]'4IY!X/Q!:7S0-BU:G^BL[[:ZL#'L2:44)(#RW4].O<,JK<%/EDA8DC9^-8*NX6/LR]5W0 _ M:_LZZXBHX<;)6!ZG[.$2:"^L49Q#RB&!JKYUE>ME8FS ?]C4V/WU;5:8L8*G0]I3(*=M(VR6%(K6\1^H M%&B!J.O,4='!:(U=Q&1K;O# $U?,,K"9D<=GH@'' B./S]IL-"=[TCXV;:^C M>Q6GK8.MK37T.@+<1<16\SPHE?5D-@!=[<@EHH80F87 LY8Z&.%":\._3OZY M7V:^.80:"JKCR_\ P?46?'>284>52YUU*6@=)GG(@!4P1 MFO#,B;]W79#-*^V1.&V)KG714(S'N) 'ZD-8WM+%/O^+H"U[==> Y>5EK MTYTV"E2Q";S@2#%;U+'6(_K[0S)V#+W[%/?)'/<&@EN)=4]0/"ASG-[L'1D3 MK0]GX!)B+>0)$)R(Y%EH1=Z%D+GYU@'!S@>X)@0M:)^?3 6EM MF>NL>^FS \7KR95-%DI4F8L40Y2M2_4VHW05W.UJ:EEO<+>1&/<(N5."$ XH MNE9.D%X6I4Z.E74PA0T*8L)H7+#1[#+.?8K454"WJSEGO0+=^H+<)^J^3@:& M.1M5Y"!#)E(Q9G"&=#*BM]D97I35^\?O/QS]?G3P_L.[H\6-EEM9AYOFPIMG6]9]1;.\RE:\MI::+F38#BE*$]=( 5Z(:].() MZI;17N-!"Y9R^^9%R^CH5=:C#1Y6F5BSUO)WUO#S=ONRVY?B!TP5X41M%A.Q MWIHDPF(H"#D&%TMQ/-K6$>.JM/4J1]$-8#H14]-Q1ZMUNGU%-%HQ8Q*H(,-!!YR:IQ" M @_SB H3S[YU!=BCQ&P=>9%L)Q=(T+EL=_B06Z^#XO4ZG5:V=K)*A-E$P&4\ M,*82=_1#ZS#L.:+Z%).UPH7?:2+=5I*- M!DI@'%3""$XG!.LP$IDV*=O:5CU-49]BL6Z TE B;0:C7Q'T#F=(CZK^_6EM M2W0%Y*MTY@U]%ATWQ2M 60C%W!N(AA.4LQ4*34[F_H7S1_J#K?7:/L56;6'1 ML0C:Q>CD)\VGYVG16R-<5!?]ANU8^^U&#E[6QB\AU<8O2H'E-@IF3.+-"ZP? MIZ9/L5,W"J21))HJC]?#= >B+ 9274* "+712_$:G-,(.B67.9-.W.^F\[26 MN/?\/IUQ=J<.MEG49OO^9/YIT5_[$1Y3G> KA04NJ[EBQ*B7LA8R(9=22RME MZ[W_-$5].HSL9O\WE$CW(>OAR9N_';T[K=7.;TY.[TP$GHR_X'1>#U'?3.9; M-2A:_R7-0MPM^6LUZ_C>NZ[,PD YK@3/&D1BAC0&)D)83)"Y,BIRS&0BVEOF M9:1L960>>>;5!5D?C"U"UDYB"90/D7BT HHLP2D94[[?"_ 14_/46_H4O[80 M]AUSTVQYFW97/UYX.;5CVX=QN![U54\8)N?C^=LIG@W/S\A17GQT-CNO5Q'K M(+!%F0<349=@,N02+ 51N4"(I9"VC3YJKR7774Q5V(+D7C60:(FP?8ATGV;M M>M+;]M>6UG['#HS:*MRUN]M[]U5Q/C ^.F5-#74= 5 +!P%YG3UCDNC.]Q.HA,!*E4 6+- M@T=U9\O@^I5];R;C18K9+R=\J%KT$UST3."@JQ.B# MIA#.$=8L-Q"D2+5F5$45G-:B=>O!9XGJ4P:V]>YO*Y&.@/)J.":'B!33PB4: ML)*M==F#DY;\(84(/I8$Y(\K$W(2O+A.,7*7GCZE7;N%QQ9RZ-XO?7]Z'QUMXHRL^N9D/N@DGC3S/18+M<'+V>8J?"$## M+W@\)KJP^@+TJ63B=OPR(%9T(,6NN:@L/J*T0$Y[P% M*Y-U,AE=;.NTR[8T;ZNKWF$:A=EL6(9I(?%7M"L/)FEXE95\B]/A)-\0LG35 M N,4P]4[ATHHTK&Q5O?H!%*9S&B/1FM;MQ?8GNI>><4[!>Y]+;EC!+0[X$C# M2ZKN,S![FEA3-&=D4R!RHE-YSB$4%8$9P:PS+HG2NA1Y0U+[Y-3O%:*[$/4N M')F]/C-W\]>G-X?/3^-889ML@\K?6&AGFGS3EK9/L7 M[ZF>W8!)62P3 C):B@V3#>"X+6!ME*8877OD-M[?-R_?5J?]+4R'%<'?N>$R MU4M '##60M8Z@"ZFA*!<">A,H(W3^O;9 R+Z=(BRF9SO*Y3MUKF="?N\J%\> M?_Q.1_(66:2P!+4A--P+=6TFS!N+_@ER^I0W:H.!5FO?[MK3 M)_*73G%Z]IT_J97041:HK5M(#=4QDDHF<.1A1^(VIMS:.7U(19]R0FU$O^5* M=[+]W]75.RD?9I>]".YTW9V"FE] MJN!KKQ9:R62OP<3W?-OO87YU/W@ROFL!;]6?=1-O;$C$+D*2%NO3+&HAF.'R M5U^\#1?U''/V\AP'CEP5Y84#+!3.*J8]1"8U<,;J-$;D%EN' :O2MJU.?/(] M'\;YZD2GEM.3A&O+%OIIP",*\M<7FUW4\B8%T:.MHZ1LB5R*+%OW\MR(T'[% M3AV@[;XZ[5Z<'85?W^^L>JE=5#R \+F.[M 9HL$(63->O E%B-;351XAI5^! MV [0TT(D/Z#QW6R,11=D]-< =S2*8G58\X1:%%/+: G6P4:(.G/(1NLH"O-1 MM+XQT0L3?.L]U[W18N2.\R AI\AI*9@%TM@&F/(HK2>O6+0NYUN3Q!_3[*Z! ML+7,[I8B;&9P5R7R09]E%:0/IMZY+IE6QFD!CF(Z,$7*X&6)(;6N"]^4UA_3 M9.\ >5L)=><0O-ME.495DC&B^C"IDJK!T=) SE'5SELQB9U&&X\1VJ^D;8_ MM[DX=XZ\FS[+1GJ!I)[!2)=!*5H7\H$C2*60MH8OR/>E]/K8*+M7>-M(B'N! MVF5WY1*=YRJ9"HE ,9LP$&7T(%PV2ENC F]]]K0VD?U*/?<,;.N+<3^*K:I? ME-HRB0&2( *5RJ1^):SH, M>8:$_65BUEF;=A/,'KSR#K99B=UR"UY%)H[RVV+LU^CJ:6 MA\&W,IW.HA.8@-4C:<6- >^+@)"#"LDE:8O?!:-]RJ T1<=3Y[^;B:&3\H#G MSTQJ5R!IA(>D8CTSL0J<2YX4/_D :+PQMGEC^G4([%,F9/<(:B*V'\YP[N@@ MXUDB^FH\.SK$>!;>498B5;: =3R=4D* RY)#4%Q99I+BS7,)>S&?2Z,B[=%8 M4UU5EQ3ISB!VDS-,*B6-)H&42+ZG MH?7P"Q)5$9HCQ?)V'_IJU83O#B=R[E==K2VLG4)I<P?2NJ+:K4JJV3XKC B&"4B\CID5HH!+AE'0 M$K1C%#GIYI=F5Z6M3\<">T?2VL+:&93NG<#ZP&/EGGE.!M@Z=GE'5Z:(23 7 MBNQ@+.OJ!/8I_[]74&TNMNYS%R\^O#]^0W$XQ>@OCM\G M!X?_^>'X_?'B=U>Q]Z*UZ_>9,:?3,)X5G$XQ;Y'U;TY#L\Q%MZO3*'&Q?,3/ M4C+XP*.7/"4'+&9"7Q2FWMA,P(3QPDG2=J5UV>$Z]&W5-&[)B_X^F?ZSMBL* MGX?S,#K(_^]\-J_;LDYQ&V0OM# :07"AR>U,$D+U'K@TN0B36/'I.>QN\N(^ MY2LZ \^=#G1=2J;CL6=+E^)64O)XG&J3ESQ0M !,EP!&U?D#M@ZET-%#3EIJ M$:15S3-DVU'G[0PM^"!>TD8411GIN3 1D08'2 M%)+2BI GA,4(KUFB:/2'\W M XM/RCO\/ KIVOTX^!JF>3;0PD9A2X2$H=;H: DQ"08N! )_Y#GFC:/K9][] MP[J)FZ!F%_+I92B34/EB+ ?.72$EFB31[BL#PF)(K&B_1TO9(I39U>%='\UF M4_%WB=_W<_R\T-.S8?WQ+MW'XRL5CC?;D0\B17Z^CO/A+M?LE@_@O*78$#V7 MP2EC9.N+0BWH[M,AX3X1VZW ^Q-UOSV?ID]AAF^GPX0'H\7FP#R?S#_A!XH9 MIZ.+X?CCHL?7[(KG',:WW5WZM_.SG9P,M29UY_%[IVO=79#_#M/DX[A.,CO. MY+$.RZ(C[%TZ#Y;16:>:Q1B\%\I #(OV"6C <55'NDKCI6?DDK2NIVW,0@?6 M9&-R;OVF#OS@*+,!HVM1?"'_SDGN@'2@0W0156I]_Z4C5GHU8F"?&V %N[1S MZ'3I56W,S.5'!NB+-B%[2$XELODZ@]=6@V7,I4 F.(H=^%A;=C=<3*UN,F MKYX_"+8DPTL!&30MB4 ),7(%3$4C5"I6-W 7.:@4VFQR3D,JM./ZV6SI_ GO7"N;/G='L"QV]5"/'XWD8?QS2AV<# MSH+2Z#FQ4"=.!T,ZD9$K@!Y5X3F*8/HPIJUW0Y_ TWVZ_?C-XJ5/;P8BWB+PZ-M\&FBO$DBG%\>TQ69O)O2OXSDQ2:_Y M>'WX,PC29.&, @I;3.U+XB!D'>MT=2%,-(')ULY_A^QL:QPV(.U*_@.I2=#1 M:LCHZXF98^"80N",%E$'P4IL74R_.;5]7(.+0H)F.OM0I"Z\=8W]%N3VR4'YB="[$1IVZHTRU=*FU+K1XE/T;*L+KY]]]ZEOIQ-"__SB[2B,Y^23USJ8S[5N=:!K75;( M%J2JE84E"0@^DA->2H@FI<@]ZXC]%4GLD\5NAJ3[2JM+L;6I*EY.X9V)@2+; ME),(8)A,M ""B JAT'>.SXNB?4TPKOJM/AK Y*+I8[V;.UG*Z3N:?<#H( M&C4Z5GLDRUB;OP<(TGE(P1;NDD@86W?H?(**[QUC9UM1=8RD M@?71BQPC&%2AD%7]+Y4HQ=)+<9A!).5!UJ$&D M7T RR2=C6,[-FQVO[I;VPPG; A>/[82M1=$%^"\SZO7TV1 G40<'155*DD9P MBTN)2JB':)AX[7O%@4>4;+""ZG\1,K8>22WWPCR M @5G24<58^N4U?,H:,!;O8!Q":/1:/*U=ND:)%ZGN!0'N188*8P%'.<)>"A* MLJQM4JUON:Y 5J\*G;>&R+/HWU(NW6V&RPNV1H409= 0!*N\,@7!I3H%QBF' MTI%VQJXQTKO[S]VC8OW%;YSO)TJ.OGW&\0Q?X!C+<#XHD3&O308GR0-6AAL( MV7%@R1E+\4[1*G>2RW] 2G/7\!ZGOI3$C2"OWP2L _W(&'$D=H6RJ!T3P;7N M<_L,27UR$%O@XUD/<0N)--L(A[5#Q7C^&$W61N%542!J9R\/IZV=*KGV@BJ4^5W2#\/YW>)PQRL MU3G5$&T1!)+_(0J"\;4-2R1'5;7NZ+4+3L"TAF- MLM%"BB:!0B+0)V_ HR*HLQR8N7=/]?G#_4??UJ?V-0VAT,UJ=Z="CL=OIY,Z MRO$=SI!>\(ELZ$O\@J/)916*L)S\.1:RW=ACLM*,P=86$K2*I#6$7V"4\Q@O 6' MRA9CI!>I==RV.G7=K$.]1S-.P]%P\9(WDUKQ>$X?BR.\;AQ;FX4T<"B M";0\&AS+"$JFNFRUBX?.W E:4&U;IYPVH[17Y]L]PN66,MTI_JXNI-SYQ,LA M_6%-T [#:&"58T)K#\[G O6P"F(=\E2LX\&';)EO74;4@NX^A=D]@F93<;>) MJE8AN^8.3L9'WVH>X7PX^U1U^DEYB7'^%J>I*O@ZZ"Q[K<&&&@T*6\!'S2$4 MZTNPI1B]6MC5A)P^A>@=HV]/,MP=]I9Y&8M6K"'5?SZ1@#7(E@Y?(6Y=]-&:A3TF*'AGUKD"P4R0OVX[O/X4IO@@S MS+=/H.K.'!A%.]%P#3E$#8HOQB)'3WP$;G@)/(C6Q9WMN5@%S_9?#\\=0F&G MD%X<\7^? CD;6!<2\YA!^\7896[ VQ) %K(N,DOFS#YBJ?MTK@)+]Z\'RZW$ MN5/@O9_3KVI+(7K:Z-;]_4'"X"W#"$D$2Q1G RZJ :ER#+G:$OK4HUMZ%T% MB/Y?#XA-Q+M30![,7V$=8S&JI)_3\R[N?'B08@H4\WGPWI%_';.O?=XXF)(< MUO-=#*UO<34@>Z6T//O7PV=+:>\WSC_ZANF\_MU]I^,Z,#1)L<@Q@=0B0NW0 M5D\8%&!=2R'K[8][QW"- _[G*%P)HS_)V5%_1+V7',#1.*3Y(OI;[#*%&!&% M@5!J"UY!7P*Z (ZV7^1.*=%\=O?FU*X$TUW58/9(E3:0[8K]EZY^7[]$"K/^ M\H?_#U!+ P04 " "GB%58MB(G*!?< #@, H %0 &5X87,M,C R,S$R M,S%?9&5F+GAM;.R]V7);29(F?-]/D5-S.UX9^U+6W6/4EBT;2=0O*:NZKVBQ M>(CH! $5 "I3_?2_!TB0% F0!T0< *S;::2FW"^//3 MBW$Z/\/1[*?G$PPSS#_]/IB=_C0[Q9_^,9[\-O@:?GH_#+,RGIP!_/O\GST? M?_DV&7P^G?TDF%"+/UO\=O(W&832@5D(5GI0CB7PF!.(J)V-0B%:\7\^_TT4 M:XP0 @)# XKI""%R#@J90IF\8<+./W0X&/WVM_H_,4SQ)UK>:#K_]M_^__;J M3Z>#97]('\M__L^W;SZF4SP+,!A-9V&4KA] C\^SJW]X$XW^^>*7]*?3P=^F M\W__9IS";*Z@!Y?PT\J_J-_!XL^@_@BX ,G_^L+B9Z<3 M+"O1+Y9<0>D*YW_73_MY8TRG!&22SB,"_11'E>(-,2[[],TQ7WT69"SA?#AK MB/CN9S?%.SX+@Y8"OO/1#=#./PC.\"SBI"74[S[W!LX%R-L(ZT?B'R'-IFE M^RU._YK&9S_/,3X?CZ;CX2#7W?7CC/ZW;K?3#V;? M'EX /6)**(7DXN)%_]]K?/J-91!?!J-!W8+>T+>7CZAH^UP0_C'#4<:+S6F! M9#A.W_W1L&Z-XRM=#D/$X?RG)^=3^!S"EY.K1Q)T?$U?3D]4#@H3'30%,8&R M5M%90B\R=YQ[%:1CG-UEPG3!K!*F<**=XUB,@"PM Y5T@JCI*R^X2(4E';CL:TUS!-^OYYHQ1Y/%RB[? MPK4.DS(9GS75YVS<3(P7FB+0?_EI/"$6D_U$OYIO#7]+P_$4\[_]938YQ^L? MCD9,NT=,J ]);L*QX] MQ. Y9&Y-UCYDB:DO8BP#U) G]QSP]_#F$8I>Q9F-!;Z,0ANRX1:F%_.CJ1.H MDULF1R,V+ 74D 4K3:9[.+"YXL9]27UKE @Y"&V\@Y0%@M+5!?,:P15OI"7< MW(8?EPK?6:.[9\(ZPNZ! 03G;#R:6UQOYT;J"9/:%Q7)G\[)@I+*@HN1/.N2 M&*TR8)&M[84[(%IJ?IEE?U?M#90S;BG9NZIFFZKZ*.>Y$,/P?1CDUZ/GXWCSCU(Z/SL? M5N?K>':*D[KP"9[6;?(KOAZ1EX:70*-)PG%C@1DA0 46R2(BR"5F742(3O E M_O%FU.@*[B!HTHLF[E)&;$J9#SBCM6)^&2:CP>CS]!*5,70H)A- 2$.[628I MA"0C&*YBH973OL<;\V,YDD,@0P,9W]6\W%3SQ,()ABF^P(O_OA[=#=)\& ^' MK\:3W\,DGW#MHH]&$D76@K<6H2BEDXU!^-S:B%@3XO:YTC@^T:=*>K ^ M;IA#'T_#!*?'Y[.:^Z@)I9/$"!0W"EBP-7-3WQ5G$J3D@G?:2,5R?S;G'3S; MYT:OREQMF&ZFB1Z,DKNK/A%!"2-1@S2%ENI%ILU4T?]$F9RPF)5M'[]<'O,^ M5$9L*/4>+(TYHM?3Z3GF%^<3(N9[G S&^8*OS\>CR\3T<;GX>C:(0_R(B?YT M-L#IB7:*YV0RB!PB' M?ZFZFK[\ R=I,,5\$GG)3&D+6A9"'+2$F&.$DE"'Y!WSK+7'M#[*)\RYS;5V MEV>J)Y[]/0S/<3G@Y%)(V:>:F]!T6#M#^[-S$'W060C:M7M([:T)\DFRK)'. M[I),][J9O3S[,AQ_0WR&(]+3[/TPC$ZD2!X+N;%.TYNAHD<(UF=P/LGLF'!: MM,\2KH?Q25*LC<;N,LSTN8TM@^ML*#E'!YAM(+@A093D<3#G%-+!+PIN4?]4O\@// Z:=Q74(MI3PN-S?>HU'^ M@-/99)#F14;TBZ,JL>G%ZW.2/>8L2%SH60(E48!C*8)$+T-@R@JO'JJ)>1?B-&OC^?I%.2UG%9[-YS?(L?USW\\KTIJ(O+V8!QGH2FR<..*FM M$E6)BLM4=">J=7[D 7.H'[$O";$^.A+?%>8EA[W(9"D6!.DL><.J6I#,:6 ^ MIUQ*45ZQ5NPX^!VF'[$O84>;"/PJ=^,HD4BF$/)ALVN; M^ES"QXTCW_<6UG#O::?,%@P6#Y#.+]Z\^W1/N&OMWH&OC'7]^^/?KP7\>O M/K[^Y=WK5Z^?'[W[=/3\^?&O[SZ]?O?+^^,WKY^_?OF1]LNZ;=**YZ_^BUI5 M/)Q^C[?;Q?"-GM?JJGB[13>Z/'XTF@WR8'@^HU/JFC0O_TC#<_KP5\3[>I#1 M 36;4VQ1S;V ]N:J!+@D*[@) @HOJ8:*-=&,OHU,!90*>?&E]>6*1M@WWFO3 M*>;S(1Z7#1$M+NX6FWFD_+]?P-%_[LV_(/F%]4#=PR%GD :4R]66 B!*OK]1'K0V*>C#&_7]O* M?>A0\A&TW[0KVA@R=2+JA M)G?!N(Q")AT86./(]V#2@4].@>!%V"A<";RU+[L;ICW0#>&')=HZ"FQ(L'FR M]R+8FE9=K30LF&TN!' @CV@F[ARN,= ;6;K>U=O!BXUKL43ZC=64/,F?/<".C!.M!-^#Q?^-C2NC\[&YZ/9B5>&&5<,6&&0 MS&B7:1%"0N$F2V69B#'N5Z3G OB^,&W+<<_M*WVEH;NKW-2;FOB;]IZ2^OXQ MV\U$W;/$1@FH-SB=(KZYR*5.TV3PY7)!EQRE X]Q9LD!DIZ!TC5QRNKYQYSB M&(71H74VY %(FVZ7RS_^(K)J60TBT'N(# 4HQ3*$D"-D87DT+B6N6E\BO ?. MMA(Y+3EP>Y]J)>U=)UNFD]G)AS#ZC/.84]'),\$\^8)S.40/'LD@)'EH,@:= M*-ITX0E]Z@V.T'?7_/CN@;M*7#33WGA3*3;TK:] 7)IO76"LDQ;HHM3V5O+# M4?\-A'];?1M(KD=%YD*FC,\.L.C*2"_!JQ( -7)+-E:QL5,)]ZX5N"*8WEY_ MZPBLL=[>DJ3.SL\6OC7CJ7BN0)G 046%4,LLZXH8,H 6$0>;0P@C'6UP@W!(:^#E+@AW]?JU$9Y-Q_Z RKO MT3+K(:Q\<:X?DR5 _N'H\_R _X!5#HOO/N'D[(3YX@(*!%:7J62DM6*1P(H4 M@2D7=-*]F,,/(=N^T]^_C=Q4&SUTWER.0G@)+'B?_UJGJ9=@JJ,%H'G^Z*)@^"5F$;)0 G9#7U2/$ M>D4Y:%$X>I=9Z-:3HM/C#D/[/8EW9:)J5\&\YV/Z5Z/99+Z@<7D^P3R8?1A, M?^L]OO?@D[<;\EM/$(VB@-\]M#[LFK0JYEPL\=7E4&LAN*-M!8FY(DLM,'H? M5>-M?36:!DFT[S_Y(I3!2C'UXC$9<0GI=?0%O*TF:;%/Q[CK.MW(IS[X]H_?Y]"Q,?KLH.Z,#UAID8"0YX2J4 J'>59,Y M(D.C:=&]<^86IEU%"5NH_2$F;2+^7N8=W<:W0+>H4.V KZ=:XX>P[:;6N*U& M'Z1+ W7L@C8E!:,Q( A;&ZV(&A>HAEQF,HEZ61%YI\3"WM/E@8+AW;)E'2WT M4O3W%4?G>)'$KSC3[!^#V>GS\^EL?(:315V:M84VU41+%K%NK[;.D)-@1';, M1BZ8;MVPI!.P[?M=;?5YIRBPM3+ZF,F64JWGF'[ A(.O-TJ3&)=%:*QE'4F# MLIS<05]E@*&($%*POGE5SPHL!\:+)B+?RA'S[1/]T_FF*712UN<":,DL4U94 MELH 5C#'>.(ZB?;-(U;".6QS]5%"[Z%^^.YJZ1]>\K\+M&T9J=>P]L8^?9P* M'_2)-Y/_-K:,&Q C[591B00A2UDGU6;PR&,=1%=X)FO+L][#/WU38WU;M'=F MK"/V/AAQ:=W<@;BH>-;,6:_K%)TD0!G#P;.L@=6KR0Q=%LV':3T :0^LB\>J M[S8M&LJ^>=[_O\>3!;Z+VY<&DQ#,T O (J&Q2D+ DB Q;8*0)O!N)L6#R?_; M3SX ZZ&!2!M>-*EHZG6)X_(=IDM&=P'5L$AN)9#ME\QMJJ%Q7^)M7)&U&ERV MJ'.6=3>SF?R8PL EVH!$TH9IKYSJ5@:R7SJ_I\IN*RI?1ZJM\_5O,0]2F"Q< M5H-*"!$<&*,XJ.3)>36>@1$E,QNRB.G!9.N2S]UND58C28_;B*GUM?!?2728 M_P/#<';Z_!H2!IUL8A$*J_8GJY 0(T0?LXJA<,5=)\TM__P?7H,-Q-:\K4.= MWWQ<_C&8IC%M18N+YK2*((*M ]VBJ9<()42A&43'BRN%B:AR)TTN__P?7I,- MQ-9'="5,3U^]>/W\]6AZ/L&\N%:7K>$V6-!&U[BB"A!D#,!$9L&3C1YS\SG4 MRX#L@5/TIDUAP<9B[B'H?F>M[\F+H!^$STBVFE L&G+^!/)ZMS-72MK:-R(P M84SDF;=NX7H?GL-A0BNAK]S6VU? ?7CY]Y?O?GVYZ (W+B\&T_#Y\P0_7Q9Y M7>:8-BAU6_<1K6K:-EI:H^*U[Q]YO'CD-=\2>HM<%3!6>[+;D(&7CH/-UG+F MD^"\=1+L(4R;[CTK/O\B%H$E2FYHJ/)^,L[G:785SPXA):ZS@^QI0U8^&S+/ MR%#C(COEG=0Q=YOEMNH)NPK;M=/?N+4Q5M#S;L(U#74 MQD/ZW4"46]0T"S%$\ARN+ .ZX"\B*, M3)W4M^(!!Z#&%J)K_18^/_[[ZQ?YZBSYG5_J*M# U[P M!$'$' -+-I1.'N$#&:UESSX8 [B)LGG+J :YJ]7 ME^_GIS M'=U5>",!-\Y@KP9G;!26?'\@,D=0L68=-"H(TC@=HU.E209[RUJ_)X.]):6O M(]<>RM0N@2T.&<85YD"[EK=U2'$MP5%>0508^'S2EFY=JO@=@.VFV!HIY7;S MVT=+M(<$R^6Z%LVFLD\NU4+Z6,>$YA@A!HT0,SIK'$M1MHYJ?@?@$-3[>(GV M]_9>KW ^N'-1:T'<$I'\-J>5J@/[R"+QA$T$Y3"%G!.V3J'>A^<0E-],W@V- MMKG+\'HTP\E%*XLP_!B&5RVWC4DY6B\!.:-3"ZT&5PLVDDFU[K6@NCV*;86O MM>H)/[):VXFNAV[E#]R:N^A33/[AT71:>YOD3^&/DVQ*PEI9)0.A54[6-MI. M@Q12%1UU+-DU?N4? 7/[F?1>\UI]*VJ+7:,O<]'OPJ16!WQMD$Z_\U&-T^;W M0]U6>ISV&"$BT@9!>WV]PV+JM)L(3#.=F=>6179(Z7&FZ&U!)B!D%6I JX[0 MUII\H62"C4P9'IYB>GP='JR5'E]'X+M.C]^H,[JS&3X+T\'TN+R?#%+=$:M+ MG4/4)C*$X$(&)8L'SZP'XVH]HHQEZ;2ALH::>DBJ84)(=>2RO)$*3WR\7"@?LH:/-& MLF]:M^#<+9D>OKF[/UQ:0S>M$YE_#Y-!W8 K(EP@OG+\N8Z!"] L%%#9%:@W ME\&(*+CUEB33+3=]ST-V4GW<@UK&/C\H$_WE.YE"U M\"[NL1F-J: $5#Q6(Z^ KRD!X:16#.D4%JW;UMT#Y^"LE%:B[^&JR@IHBPA4 M!W ]V2/W MN-$=),C=WHL8$.>C W[@<9$T^N-C$./!#(Q#,$B19T1!0J1:-5 MZX%0.R#( X;%;OBQCNBW9(:^H3-P,!S,OCT_/SL?SF-9S\,LG?[ZY2C_-_U- M=<4_C2^WU^>G=8["Z]'+Z6QP-K_-]VD21E/Z2)+Y_!P]X4Z6.J@1A/*T]R(R MB$IZ<"H';F4)P;:.S6QA67L8,]XDV+-O1-ABC/GMT8?_]_+3T;,W+S^^?$[_ MYM/KEQ^O+S_5:XIAE.M_7O[S?/ U#&G5FTPHW.1QK6+5S9;<*)[]-DQ^HX\G M2^UZ[N4UKZ-29+%9!5[FVEF_U#TR!0A%*RF#5<:U=H'O!;3IIKOLPR_,5&4# MN1+<0,K*@#(V GD6=,Z0]1ISQ&"PM26_$LRV8MCM='][3VLCY[V)7M/K>'3G MK;SH6):D)[?6@9&R=BH-M+'*'*'$S$0NRD?=O&_Y2C2[\O\::7O)+?4&4N^E MH_!BLOURC,M_NNAMVP%[3Z[A)KAW%+YNQ($[:?HM*W#?2*BB+9PP@M>N]@VI MM:O*26"&>VD$-R:T/M?WCWP/A;OWD'OKZ*WY_9T+8&_'(_QVL>,O[H@ABYH9 M!:D(!&K7B!#+GGT3M4+Y_6. M#'/@,TO@H\@V1\.RL(T)L!K-P;"@D#:8WCG4_P M!$7(0=4K,E*:VL4NUY$_A-8:Q91268G6)T1G<-LG2G^1V7XTTL,N\@+C['KQ M1U_#8%CE\6H\J1=SKF]2I#0YQSR_N4/QS20R+5%G35P^94^3_[=HW[U==W@Q/NZW(3@V)JTTOOB/">(Z!B M**4M)=G6^] R'(?$CHWEW(,CNVRU)SJ7Y(1-(#4+%QW)G0X:4BE%,H\6?6JL M^V4X#DGW&\NYA]N4]>R['=4=Y65&U E97DSQ@*!31%"NWNCUC$%03GA7AY.8 M/AR6;N@.B2<]Z>0N>]1N:EENGXG7\NNMGN7A1VZGIF7-I3>J:UD\__B>YU]3 M-^>HO8WS7AQT&D6M(6HNP7"GHS=&:=[ZXME: /LUIB_BU3$&3,(5* 5K4QM+ MKV^)=42+II\B6HFM3[\.L+95"],?7]8SEM?7Q;Y4R;P:C,(H#<+P]6A*SZL? M.0]P:HQ1^FQKS$&1I27? _^U;P* MM=213XL.'>0#'IU5>)T^:\NXV-=UM)3>JGE.G:3D&I"D/&>:7??&5LS MON3H!&"8):W)T!DA0P3-5(DL"I-N#Y-Z DQ]($NV]T1=1ZE]7";Z^,OX*TY& M<\%\)C-\;D7?/%TNX_X^HK0J1Y!2US:S+E8W#"'&5!QS/ 71NC*C*[;MNZV[ M8\#M"TE]J*^764QG9V3>T/K?AR]73;K)-OHPG88;/QE4\MZC,@I%.:@=2)P-*UL2FJ/4-/&L= MBE>,-Q]N?1^@)\V>5HKJ(2)?6Z+-GH7T&]Z%IH.5(M:\.+\@N $?)"?#5[&L M8L'H6YM2]\!YP@QJI:0>HOHK"ZRB4QBU99"\#+0GYD*X1(+L>$F9T?]A:_+L M6Y%JWP&()K+?;KEJ%V1/O5QU+>UU+TU\C.BW6ZZ:9!;&10NL<#*_9;W83?\' M2)86I[?!"-?:TOU1RE5[XL0Z$M]:N2HG)VP^+8=,( )5+6S'6()ZEDF6K%2] M#![>[W+5M335J5QU'3%OMUPULFQ,L 7J#"Q09#9!T*F0&RZ"1V.TQM;[P ]2 MKKH)"QH)O(=MX'X[Z>B,< _^!_/S\72VJJCM&9;Q!(^&P_'O57;T3Y]/, ]( M?M,I,3U+JF1'9D#Y!+*4R6 MV0@5L'F]9!/@ATS<[6NVA[WXL8NHK];U(J(/"DURH 6+H'*(X+W3D'W4(2F1 MLFE]@C8V$R\^#JY1Y7)X=Q"%99$,E)%\EZ"F&[15;[ M#<=N'IKR-Z^O!;'1X:9IC5Q^W4(&ZQK.W4XKZ6&'L MI";51JY,G0;#K>6@&)V_,7(/DOF8E//UR3N@Y?'E.3NHXN]J4F=648$QT/WKH$M(O76_TV;6) M)-]#Z*]I-5Z7M?QYKVD% 9L0I,_K(H_1[K[?:Y+!1VEB MJ&,N/+W1VI+99^OQ3&^Z2CP(W_K\VW^F/O)>T]X0=1VE]G*%8-F]ABQUTDD$ MD#;3Z<]8H8.?11!H+-<:C8[MQ]<B*WX#;A5"_JV_J])I1&1>8]%"1S5G$NP!>R MZ]IDT8U$I)/=QKNJ]]4IQ=Y['K^+C!Z'B$_X5A\EUQ(OG@GAF+!8IT M%I2FXSHX;4#G''EA0EG5NNONYJCWO0!EDW3KEG6ZA>+13BNXZC)[@LXGX[D% M9$&"DE;4RV822K"91RYS8*UO5FR&^$\V-M'E%NI$5Z$_*C.<$/A/IY/Q^>?3 M5X.O\W5,OW^MF"'19:O!.UE;I]=NADERT,&CC2I*[?NN%]UH 7_RM ]-]V$6 M;KB8Z_?/QF)K=@68J/9)TN0EU4ZZ1958&'KRR5L[(LW _TG7UAK>F\+3)<7; M6.W\JV7MI"EJ$U3;*59M+\"MC SFRJ(R28"U3('**D+DQ%ARS12S4?-B6I?) M[&AD<%!!1US$KU-2/C&7A1T2BM>,BM;84]'QF\CNZ[CPQ>1\Y[7W@J MN=="90M6% ;**P0G9""S0RDK7=*);6,2UGZ.S%M+TYU'YJTA\>U6%'9!]M3+ M3=?2WAHC\QXA^NV2PZ)&S;6$Q$NM>HH!@A"US7V1-M3QLZKU]8\?I=RT)TZL M(_$>N'!/!5R07!=F,A2GZ[SA&,E731$L]XXV2#IBV1,=F[:6SKJ7'*XC\!ZB MJZO*1? MJ8\L--P;HJZCU*W7] A/1XBLETZR#Z"*%K7EB07).!F8S@7&6]=C'')-SUJZ M7JNF9QU%[;0 42CM0BV4S!9!A63 R9!!6)^$L-J;U)I03Z0 <1-N]:*^/E+; M]W5;SDE)Z3B8>KE&D?4++J" D'PLY/R8]A/+#K=T;!,RM5+2UGL4/1^/9H/1 M^?C\5I+I_7AZD=#"Z?33:1AQ\9;^\G1*YJ,N"4T!H6@-RK$ ]/\3Z**4)A'6 M1DR-*==V!?LV,'.3=,D.==O#@=IV-3=:B,T;+:*R4A(SF3V(NP MN= [[F3S^L=>%_0GC_O0_-;[R3ZTN,6BCB=OQJ//M5$RUR+,O39O#2BF:35" M9EI<'8%%)K%AK5/K;5?P)W&;Z';O3(7;J[GS&LJ<6;",W+6[W%*[X-;MUR/(6#*2L9V2HB4DEB[NIJ&P9([[4)+8 M;G_#3K"?.O,VT>)=(NJ^ZG/??SA^__+#I_]Z_^;HW:>C=R]>_G^_OG[_]N6[ M3]O4RSGPS>#KQO5WF[XQ%9UM2T7WJAF]OUD_ 4GLV_OAV$T M.QKEVO#J2PU!7;/821E-*G7BEJ\]DWP&QQ4=FBGED%3T6;6.Z#V,:N.BEJMR M^Y7/NDC?>Q6TKL-.HU8U5)8*.$;O -23KO7*!6=-^5$4'6+NJI.F' M#N-^U=)#C&;UZND#+O,#72#V5#O3 =YN2F*:J[8K=3;4RXXH)"WMW*X$(!,U M$E1G(5B'P$S1V0@97?,;SSNCS@,U*OO G'74T0-CWH117HQZ-S[X6"?LL.J\ MJ-J>1/@"+$=9N#".Q]9!W>NG;]^3:ZZ<<1/)-LQI5;?HY-GY8%AGB-3T]!L, M4SP=#_/KLR^3\5?\KKP:)/S$B$9GJ64(AK3.OJS',GAL**AQ'O(LBSH M>HG&E6*B]74 8.2$)BI:H)%UOI"4):?DVP^A^ [!X>E] PDW3#_,]Z;C4@8) MKQ9(BWT^/OMR/L/)QW&9_1XF> FR)"&2,A%83+3>.E(J<,RTWIB-9"%;DSJ= M 5V?>#AJ[T_0/20,KA!>PDF2TR-9!J>4!!49\3*)>G<%%?%3N*!;SX*[!>%P MB-!"QBM#\QMHG1: 8A!P$RL2!U M$E+DUG;_:C2'1X1&DK_+"=.DJG<^B>[Y>%Z)FJJD%]ABY#*B!A]EG:22'(1: MYYZB2AA"9$*W#H/?A^?P>-%,^G>981_+C.ED=O(AC#Y?A#XP&%8D5GHF7>.M M H*K8R8)5,@,8[&=C@7ZU!OJI^^N5?_= P\R /UXD38T^Z] +.C5 <8Z8>0N M&F[_'C\<(MY ^+?5MX'D&OKQM^%DZ9DC8Q$TG1Z@E-7@4BW6DXXY,BH<;14_ M@@)7!&K;ZV\=@376VUN2U-GYV=7%?DPA>@<.C0!5A"87@#P"0<<^KX=_,IW. MUP(;B3V<0N9-8RCSH&$/VX 24&@RQB!O'KRYM$1$(]T^&>?O/-& M,->I_<%#RKOYT!]0>8^6V3938XNZFX(GA5EE[-SJ,H;,.2G H]? BD%K6(RI MFUI;I,:N8>V1Z?NF2?U':U7T< UH)<1Y+\037QP6RPUPG:HS+Y"<>5M EJ)X M2-QDU3I@JLQ!A;-W.[#\_!D:B9\+?8/GEEE?*[,)D0U[]B M'Y78=SZ\]Z+K^Y>SO?KJ6&1"HS4DS0OYL<[5DJ($-B433,3@FC=WV:/ZZA)0 M>DWN X^)T0I1-9:=WZFOTAU%>O18='U%>OHY:=%<<^#/'/^NH-5?NH M*MGU];(C"NGD?2%S#J*Q@G9N0ZYI$0&TKK.P>/!"MDZ<_LCUU7TS9QUU]-4Y M:U66-ZK(E>,1>);UD(\.O*6U\Y0S[;;T_["7UED_5(Y]+06NDV-?1_H]A!@7 M!8)+BD.--JQX[\$Y.H,59QIBU@QRCM8&9PU3S4*QH)/D^RK/OJ1S/ M9(3QXCEME)A H94$S1?:+9DHRF=F5//K&3]:^?XFK&@E^QXB>K=K";U)01N9 MP&E>>Z05^JJ@ &$<6FY*Y+(U%7Z(>LU-U+^)C'OH%W.[_O'[V MYN71QX\O/WT\>O?BE^/C%_]X_>;-=?>:5_5I6)O6Y%L[XO1=;48\'YM?%=SKJS.>#55R+[DO.Y9U+-O;\-_CR?/AV$ZG<=3<^ N\!#)R(T* M%$^23%!7@#-5,,H<=6Z=^UH#WNYS8&T)>H" MMZ?,V)I0=S:8JQ_5=Z=8,[WM =U,+?EE LDWLHF,[2+!1:5 UN(KRYGSOG6- MS%[0[.&I6GO)LG74U0.[/DU"Q@KG*F K$_/(%1AC)2@C,AD3VH.I$UMSS":: MUI7\MS%LWX?M56EW1[$]7N)]Q#;.I[/Q&4X^X'!>G3L]'7Q90+-"!JV#!4;^ M-"C)'43- CG8+B,OUL?FUSKN@7/8O&BEASZ*-\+L1DJG*)>3D!IXKCVY;++$ M5TYKCCP5@RX&W;P'YTT ATV#Q\NZEY$27W$X_H+Y$Z;3T7@X_OSM0PV97"5] M;<[A=W"5CG2G6.F>[/LJG1:46JNK!RKD_7W1B@TKDH@G('!D= MJLC!D7# EL*,8SF7YO;N_8B>%FG654$/=LWKT:60ER-\^4<:GM>RR%_&X_S[ M8#@\2466P*V#9$*AD]60*(P2(!"C*":2T]:Z)F!=C =(HE[5U$/1T=*3]BY* MGR6/=:1K\B;62]$)HN(,D'%,7(<4FX^)[H;L("G47"4]M*1Q1C1!!VS M!RMK$%O43JFN]DFVSHJ@8G!.]DR;9;B> &DV5L?*CI5;K55J<8=]G8_?0HW0 M5NZQ=^);;5^<370@PRYCK*6B5N7R=1W M <$E+X I5(E+EW+S/.4/6M^S#EVK+4JR@Y>CJT$XE1 M\: +NB*:MT\XK/J>M0BR47U/=T7M0<%%%[A_UO?TH/J-ZWO6U]L>T,T[E;00 M&K2--1([GY:,&I04T14CO%+^$&G6M+YG>RQ;1UT]L&M^98+,X^D'G")]\NG1 M*%]F$6]\N]I)'+'4)LDYNI^6F>B,+&5D$/@>7 J:LF@_[70[E ML$G20OX]["L/52+(I QZPL,S(UO1E C1UYM:G/M<"G&9M8X^_?"5(9O0I*4^ M>DBQ'<].:R>1L[/!;$[B^3$<2A;<14$F9*K=/K,#QSDM7UC-%/AT0BV-3^#MO'-( M)'0A2K V>N1%6:9;^SG;),$#[LRV.+".E'MQ3]+X##_.PFQNW%S>S?UXBEBO MDA_E/)=T&+X83&M8L4X >_:-OODRGH;A+Y/Q^9>805DM@\J*A=0^%[:-E1WXV;6'].BAO&0M MP#?LQ2ZP>SHN'PEY-^?I/K+HMOF^10KTX0T^$C[/VC*9/'B>D)Q8\D\\&@F$ MW >+WAD5#YFY#Q@!!TS<=33?D+ 7PX9)K/4/7_SG+S@:GPW2^\EX6H7\,8TG M^ FGB]!;\3XE14<7TYF1.%P!I[4"[6WUR#-/7:@3G MM.O:>D5+T(:HG(FR>2Q]-X1YP![:+5_644/?/+GXAL[F\NS;QS#$=^/9\B/[ M\C!U2GB3(C,9S!,"V70.R7PZG=#N^3),A@.AKW+.1=](3(RH3(-*]]LN@UB"0*'Z0%-&2?99FM9UN\VK_//2$VN3K2 M5 W;IIY%(2V989*$2NX#4HN@H2D'3NFCQ8'I"]$2E%JK:;E5^ M;4C D#;(3%QW482*+H+#$FG##%9GP44,K1-7/V1/B)Y(LZX*>BAA>WWV)0PF M-2UW7![N-""S5")(#58+7@=C2PC"<'+D948K0^&N-5_6 GB ].E/03V4@"QP M7(-^4T]8YRVS/A&I4TJ@E-,0. 8PVDAMO#"F>=W2#$DK.*7?G9]5N=W; M#Z6V7;*F9++?M*:E:D46?D('T>?$&+.YA-;=&[>XO .D[+Z28V5T<4>S=9Z? MTEJ09+5XQ_N>E+/R@5N=>]-MV8VZ7"R><)MU@G6"4;P!F)]#9(Y"$J*UCK9,<* M*-OJ3+&9?E>WH7B\7/>EY\2JX"Q&]!&U YZY Q6"AIAR@\DF=$%X)_9K[55N796XS%ZV EAL@CT-A0DQS,(" MAZ2LC7+^IK1NC/UC9;_ZYA^/?L$1S@9I^N;-\\4X92Y9 M1./!LHJ+:0U>> $RV\Q]UN0SL(>,V(<>LH]9KK7T,>Y!F U3%A>5SV>#]'(2 M+I%HF007&$#(6D#-E0U?O>Q!Z7(QPNL]?OY :?CX7E= MV[/!^-([6U1GA<)I(0:8=QZ4+PF\=!&TD5DGKZ)CHI,>5S_CH)3:2)0]1/07 M-NN'\7#X:CSY/4SRB>,NY\@R6$R!(!$NKSTMLP147HFB76N_;PF,[1.@K?>W MJ61[2!Y?!?X=X\Y:ER YVDQ4%A*\*I+TXE-DD@=K6[>AW%W296-%K%#L6E+L MP;A>X%A$/%^<3P:CS^]Q,ACG$P*@0QU&JDU(E;D1O"<_%)4K5CF!1K9N)' ? MGL/1^L;2[G$3?W\^2:=ABDN.[G#HTE@3/21FKX=&T.Z6 MA,F0O'.@E-40)1,0-*:^L+S<8-ED#Y\722P;22U4[C9$O)8.!HF)Q MI#)F>>O,[_=K:)\8?'7T^L/?C][\^O+MRZ./OWZ@_[S[]/$Z-_8J#"9_#\/S M39K9K_N(5LF_C9;6JJG]XB&7J>7O4LIO,=3F _FXIJ/I%:Z[_2B_&X\FBV^? MA>G@1A(\!O0:8P%=5+W2Q WQKP2PR7&O@HR!M>9?TP5L7%W8 ,Q%:D69XE ) M!*S=H)11I;:R#>!8=";Z(-IW;FT&?FM-]G?&W3LEC3O1^[XD3J]6_^S;U9?_ M,< )(3O]]J8VL)R'^9DAJZ$(!B)P\B6E3."#KV58)6JI,F?M!_=U0K:KM.J. M6+.*N^VTUT?=]@+:I5SF_L9=O(L[O1W ]M6Z?QV@.VKO3E?#:= M2X!?ID62$=*H7,!AJ+?QA /R=0MD0RX;UJ18:C[P836<'935]J?(59394 M] M7'9; DTL)@24D!U9G\!9)FBQ>/"Q,#"9HS;<^MC^.N1J.$^-((_1PI9V$+FH M>M!9H? (,M?++:@EA,0R,)\\T9=,PO;#YE;#>6H$>8P6^IAR?7WDWA##JPG^ M\[R&7.?G+2_6,4[.K,B)?-M0-#C+&&B;&(\\B-2\A+4#K#_]KI9ZZY-:RP N M&D9V@+A%5^L6O)T[6&U4V\$$;J&7+?E4MZ%:S8VHES*5X@)4T>0(1)G!\6 # M.N>";%VJL3/J=/>?=L:<==2Q+2_\:B^^/'/1&%\*!DA:T<9K4P*"*"#)Z!@* M-+:_1,,]N/;#!-I(H5V\[4VTT8,/]3Q,ZXBU^I^7_SP?? W#J\D:3B>;D^)T M+'M1)P)F""K6J>XR*"6\%\T-G]5HGK:]TTA+/92-?,#I;#)(,\S+,2[_Z:*X MM0/VGNR?37#OQC!JQ8'QCA78P[&WT1H$+U'%0"YHXK6_/RKP7&K [)60/#C1 MW(+:/_(]8%KM(_?6T5L/G'L['N&WMV'R&\Y>G8_R%:J@8TG1T_E=._\CDW2< M>PE<>_HIB01%:^-J.9+MFU/;T^:XN2KZL*S&9V=D9PS"\'T@@^,2E%(R%B[( M ! QTCKI*Z>1 =,A)>N9=;9UXF(ID"=$C\T5TO'7\9?<3*J/L'19W(X MR)Q\@7'VL5J.E\;EQG%PT15@23JKF':.B\:$Z8KM"7&H M%W4UC#HNKI'=D,XBPIY0,.0::'FY-O&*$)(3(!W/M5>Z"[;;O)YEG_X$&-!& MLCUX7J\&HS"JN]KK$8$[GS.S&F0Z*A%H/:!1UNN\-4M#>QHX+[SS4:!M7IV_ M LK3]ME;Z*>'FOWY-8*"DRJ6BSGJM.1YM_[;:*>?Z".GRW^UF)3:82T].? M MU[&C3$<+@HSW3+L]F$I-UX08,6":CYJHU5-*@B](+[BAP\$&5IAJ71N^_TQ] M*+&R[T1=1ZD]$'31+!Z?C>MB;EF$,9 QD*($660B*<5",#&#+D:BT8QIWM[C MNP?0]FVVW>GZCB?82E$]Q LZNQ@$Q5K//7C!R"B99Z-8<."S-PF=C=:U;H"[ MOQ[AWG"K%_7UL%G-;>)G(?V&=]\ GC &;PWD6N"EN%?@2DD08LDVUK%QHO4H M@'O@/&$RM5)2#W5-RZ-IK&C,HI KG8J][! =:-DFI&"Y*\(UOW*W)V'-O>', MYHII&*283F8W.E_62,SLVUNGB'6:\L78RN2-]CD!Y]Z# MLCY!-+15QLRER\:88#J%/0G(#3+1=]=$VA3CTPQO;%6S#4?T5=RK<"V&WW9 MMDXTXP'NW8]FNS&)[6IUW*M*&AI-'1"FH+,+A=X<;>L=&!O!B:@@B.R\9Z'X M;N[='I)E15A@7[FRCB9:-T-\^^*/_\ PG"UR TZ0'6^M!BED!%7[/,<<$C , MCD[T'#'>JIU;D76Y]<';LV]:"WS<2%I;JX&\;B$RF-:. '2JGF2O95$*R6WS M-6E< D2+ GC@FAM3#&_>CK@SN!W6S^Z\AT0_&NR!:D=?PV!8;:]7XTF=^ MQO/JZ[O!B98Z:Q8D6%%]P90U.*TX9"^USEDE=*$QIY;A>,K\V5@O/41T+M%\ M._Y]A+3NV0<,>3"\+*B;@C9.,_"ED.7F$RZZPEW(\MM%!\3926;,:&T0 M#-8#G'90")P94$@.@U BTZ;:F'V/1_N4V;@E'?=0'7,EPW@ QFSD!H3<:>WEB-WT#QE=C7248:(TM'2A4_>,F7P%H56C2UY\%E/D2!]J.$N2\Q& M++F<1_AZ='T@6V188B!'E.QT?+ZPQ%_@#"=G9 S=M,5__5*;A;^?#!)>=X(_&HW.P_#HK+:( M/XF2,6YI@PHBT($F,X+'&K,*(8BH@X^J]>V//M;Q%/FY-[RXRW6_ ZZ_&/\^ M>FA55NN8$2-P6T<@F"3!YO:FQR6DXUL= M[/ N3&I0Y6OS<0YW/KC7(0[W+Z/UZ(9G81@(U,=3Q-DOD_'Y%V+;58'>QUF8 MS8W+Y^%+7>(-"A81D[,*R7VHDQ<]X^ C$U"L+N1(1)=T;TV4'HFY8;/$90@N M2LH\SSF1O0TE.9*+Y1)\LA(XM][*D)U/K#>YK,:U];$*V^#5/5T1VRAH7X8D MK!Q^7$PV*9/92]L_*$UR< @HDG!>^YQ;7V'XP4;- M]\J3=<3?NGKST^F$[,VCZ6F%-ME1,V]O5:2]U8*K>4JE,J',F4') MDKG,0K3-FU/\R,V\>V?.&NKH@3$OD([1>23L^J+HA\'TM_G:BV:R( :P:#5M MN(S6+KR&[%52T=&OL355[L-SL(=3,R7T4$IYC:U6UTU"FM4;QHN)+1VP]70< MW8=K-^=0.RVNI$)9K+8NN\>E,7K6NRU5DH/"ME M4*+US:/X]^#9OG?<3G.W[8Y68M^:;SS/O5[.LYL()1 M9X$AFKP5O_@*TL&:'2U5T4.9_/OQ9"[FV17.)7O6D;EG,E>>I9:1W5WM/^L69+5 M3+\;;$#K**<'R^?E=#8X"S,\+AVPNA1*)+L?LJXCP3R=\ '10R"#+3N=C6P^ MXF,=? ?(I-[4T[A5T(=JTL\WWAA8$C9I4F4A/F>6(4;R&+1P)2,7&DNG0^J! MKD!7#SPX0_CQXFS<,VP.XJI#[,,P&C8(N_'H[7<#>Z3P;ZMO \GU\7)>PM$J M:Z9M@,QUG=(1# 0F#&A35 I2>!<[>;*[5N ]';K:ZF\=@376VS]P\/ETAOGH M*T["Y^M=GA7/I *>#"TJ60:T&@'!N2AH2:%DU4"#2Q^^W29QF0 MM;0EP+-O-=1V,5LN)\WKA!6F7 #%$"%$D2!(S1-G3B?7>C3?@Z .[J3M1QT- M[TT_ /!&8+8+P)Y"30^"V]'0T+9*[4:9#372RX2&AX!*YJTMQD!BM:LVUIX MF=&;PVQ*,7"I0NM2\AU1YJ%1GSMFS#J*:%T'^GXRSN=I]@*_XG#\Y>(*8IY? M&'L[&.)T-A[ALS#%_#Y\.[LQ5DS'("6W!-G6.I$4'7C,%B(O6C%5.%.W!C*L M:NOQJ.=OW^%OK,7Q=E70@RES(_CZ>O3E?';UKDA9S]R4@! (4";0NU+[NTMK ME/=&.,U;6S"KL!RLX=)$^ T[?MR':_%Z=$#6DZ&R&M5N+)0VVNM B0U$WX-% M<@]"521721DHTAM0/D2(A5Z-VLR$%\4S5YM@J1V,;&80>"+W7=)1)U7*W)M.=D;W9V[? MMFBEIG'_,FYH2*R B5/Z^C+?D>A?7H+,F*SS'B$R7D#%Y" PR4 &A]$I4P0O MCR3"\B<>*@T:R+=QM/-YS9GAY$N8S+Y=#4P0&(1THD B!PM4*0:8@7OUQV+3SZ/,&+S@"W(%YROPO(EAFH MKL"VGY_:7(?C;2F@=2*K,]@@#5.("B+F6&]P:@B6!]",F\#H%\6V2)+LF"7W M),%V1))UY-[:GOP[P:)#[GGX,IC5$7.+1D>OSD>+,F.=8S*>&4"M/1V@OJ9\ M"H.<-"99F"G^P49!'9^UY519/QH:]R?>?JNXK[[\CP%.Z"&GW][4N-K\+0A" MUY9J&HRL0P<8*^1*D3V5E)<8ZOJQM9?9#=G!61P]*J:'UH[++D9.[^)=O$<= MP&[QTO-*H#LO[VZF\0[W6-NJ:TMWH5>#1DX>GZ$=FG%=QZ-X!2%S!"&U*3E; MDW/KH5M[P*WNE=_[0:UUM-0GI>:>_70N ;EPY[7-.GA? P8.5";'W@=D4+Q. M)A@7'?9V;^DNG!W6Y[97Y"K*;*B%'LRB1\PD.6'6>>9$KBU&;1W53J<]J^$F M:9(K*D<54V/B/ +F#@FUBRZ'?2MR/[AW.U9YXK)*R=>9A4F25Z%,'>#$%6CE MO.0D4)OD[KEX&_:?W.Q5T3TUD@ M9D&,+MS56X@.7(B^,ETQW_K"U(.@GBQ]6BBI82^;>5#M07075\F>A^%\]NH) M=S[[(&O_=U] B4(P-=/ (TH3^#R\VRF N>:#GPAI>M=)#QT)KAMVO!M7$5S- MC> VI("2@^5(NV-T#&+,M?VDCH)E)Y-L/31R%98G0I^F*FEXF^\NKBOQ')<; M8'%VDH4MLM3[,([<7Z6P@(M%0%(R!^.]R-C:TGD8U9.E3Q,U]7 AI=5DI^?G M9^?#^:(6LVZRQR)* NN5H!?$"#J5I0/Z<=;9V!QLZX!57VMY8J3="TKT4,O< M;JC3G96I4B(6;8#K7(NM.(=0FWHB:AM]-C&JUG-U^UO-GW3?!2T:EF,M5O8+ MR?YX]#$,Z="Y-H5)6L%$;V2NS702*!LX1*,<**WGMV;I/6P=AEL!Y8E1K85" M>DB7OQE/I\M@<:U-[3="2R72*IM4C>))8+1@VK!YM*9US&,%E"?&DQ8*61)6 M97V-5D#9W"N]^;$7U4;9:U4$)\ZF%$ )VN \ M^MKOO##MA56F>>)Z"8QMS4YKH>.[3N1F4EV68-G%!+0WX]'G:DS5]5S=AC*9 MB<0-G7I!RSJ0!\%Y-!"$E!)MTLRU[H2X#,>N"O8VUNV=DV-#&?>0C;N-Z;)& MHPNJGLKNEB/:37W=YAI[@ (;B'M[9"BFV*B4!6FTJ_7&U5,BD\EPFU+VF3G? MNI)WFR1XH!!N6QQ81\K]=#"I.UV:&VSC,%K<5^2E%*/I-,1D:]I%27":3DA6 M O<\!QUD#WU+ED'9OI_10E-W^Y-L+.8>"HBJ,71J6 MX-E1>[H-=76OZC<0=!\&W#)LVL9<3&W@Z9DGGA.VH+6&4I"[9(7$U.F"[EXJ M_Z%& M)>0BC)5USJAH_?+?QG H=MY&LFU8P;P,SV+F10=$/=EX=]'LQL+;3$OWJ'P# M$??\HB^<5U_(FS0,DHP9% 8/(64#7A89E>9%W7;5?QBE/V#9]:WS=23;.CIS M/,*WX]'L],UXE,>CU[6W2 RCWX[IJ)I4B(N!:I8L#T?KM(:QVJB_@&=%0C'! MB1!R2N967GI%G*;;\[9_CF^JEG&_,FW=FN]%& R_/1N.QQ7)YX^GX\GL$T[. MGA',_QK@,+\>9?SC!E:7LRNJ]I?1=9*G4 9"2!I,C$X;7H+@H9/^UWSPCTV$ M/J77;RRVC MFXAN]I/J@*NW:>O+,>UJTOIF.KN7 AL*O/!5ZJ)GBJXYSEV=3B8[+VD/8:EFKD86# M*&C)3/+,4"OMI>YD =SWE%T,1F^AB'$?4FQH\WT_0,V5P)VQ$5**Y+ZP1*:, M4H2$A\2,,]%HT>5=WO=ACJW.[\=+K^%MS]NCT[K .+S9C6L)?\7LO\=(KG7+ MVQMP&-*A(5!#LJZ JGM,,)$.E&"**QA%D(&+ 55D_?U7AX:Q;*7*OO$VN$&O=W'4=?(?!G-XTTK!8[B( _-WBGX^_XBB0+WAY(H;) M;W@QK>7$18,I. ZIA'I#5!F2AN9@F/V% MC,YHC4WJ=OA]/5IT@W&X7.E!#3U$Z=]/Q@DQ3U^1G*HLIHN][R2AB+Y8&GS5:RF?+J^EO!N/ MTOED0I(X\1CIN# *C*E3*'.=?>V+6/J M\PMH=WD:I:I]"S.0<:3J@:?!.3*@ D%/0G,M;*<,P8:[QRI\!\*3OC32L'W4 MW'BZ;'$S^GQ]]^PBEO-RB&F&^=/X^7@X)%=]$H:#_\&3@D$X- CSR4(J![*4 M'&UU1409>#:!J]C):EWSP3\V+7H7=1_=HI90>%[OAM/9O%IR]AXG@W%^.N[ FO ^[&YT[<^MME ZOGQN[^__/#I M];,W+]\=?WKY\6,ZQ7P^Q'%Y/AY]QF89EY"CK0+*H^V-EZ, MH)Q(R<<@/+:.I>QWJ>M:>GVXU'4=^6ZSLK$+KJ=:ZKJ6SKJ6.#Y&X-LDA$@J M\<0J9-R;/%O?=EJ) M3KC%72PMA>:6O&=?4X1.R7J[QT'2B7EF?0BW+<-UM;UXU$%K^U'RW-J[+>PE M.L45SX$+,#R1>8/>@S>.@R\B*)=4\,INJ&W[%+3]&'FV+K%8C4XO^F,Y980E M!\=$3UPTQ8*/U@(JQKSWUMC;AOW:VM9/0=N/D6-[;BNB$[%!>O!SWTT*MLO5G17<#VY ONP8CVAQS$/C2^ MT8SVQZBK!T]R/= "FT>M M=;34)Z5N#)X7B_M+/LL2Z4!G24I0*5L(@?Y'\T3'='0BFM;QB7O@[' <2WM% MKJ+,AEKHX1K#C1?FAACF1?07$9O,+6>T;$R2@#*7ZO5 [>M198-IS;$0XD47\ Y0>S)WUH"Y31@,Z"]EK. WB!$F@SE"D*K15OG5_M M@FO7%DUS_C171@^$>3F=#<["#(]+!Y(7ZY/RE@-*LN:4B04BS&_)Z,2OI%^(PG(M#F+,@BY*Y&M,FUA" % M$F;CO176:-TZ>M@=W:[#S&]Z*"5JIHTMY0Y_F8RGTY.$W&AF,B 3-1NN,SCN M-;&:F80ET59YZ]Q:+[4P?\J/K>ZV0NQ]5_AU%,[JCO8_F.OV57?)]V2Z#<[/ MCD9Y_J?3Z7F]'OA\/)U-W^'L)&M.VZ3+D!,SH+3[_]E[L^XVDB1=\*_<<]^M MV_?EGID'IL2LUEREJ):47=/SPN.+N81;%* &0%6J?_V8 Z1$45PB (] <*G3 MKWW1P]CMK3+_1&6EFP--^,NR?)#QM0A]#;$$M4;CX2I]ZE%+1/ MD&VNF7/-P$<5(?L4N(N"%98:P^D64AX'3%K(>8 PS16R*M+)O*_M>U[^ :)RYMM%>;Y/:[7VU+I MEMT1]WQAJ-:(/HP-W!<1@\> OH"+J1#4-M'^6M2D,.F,(=H\;''XZR'[(K"( MHK*L)1QUP'64$:(@@\REXES)TH?<>N/J!/LB^NBX2U]$'ZE.N"\"-;=%I01. MU8F92; Z_5P"RS&Q0(X\#@S]J26/>NGU_KZ(/O(=LPR^"UU/M2^BE\ZZUL/O M(O!11X [@477>=>%;"XEJL-4)"/_R5B)+GMO6V_UG'I?Q" XZ"/G\6JG+ZL_ M52WOS)%N/^\LU*>16"8W*CH7,_?*62_OLR\?7#5M+Y7TJZ;M(\_Q^B(N*[N= MY:HHH\%7/TMAD! 8>.XN8?4!3. MG>1YVA]$=\[LD227)D<0*NZ%)[> M*G Z96",IR0]BN+%?MJ>8(=;>VWO),\!(HK'?ZUG\X_GL]6GRO))J2+8&"E2 MI&P<>2E!&4DHU!F\4(+\VDAO2\@RN]9VVVVT/!8WKHFL!T@JW$37!_K?7H"_ M"W4#N71W4W88QZZ-%CM 8T\5#%&==3>5C@6KDBJ@2YW1S@,9I=$%<#Q;52-C M#%N7F!\"(/KJ /:0ZYDZ,5 J]@@QK3T/=\U$2>.D,2(%6$KU2F];YQ^GOQ&B7)=A1 MTH,CX,Y2+":#MLQPNOH877U<)""(1CH5*>7H;+2N]630AU@8UPXES;0Q@!5Q M=5CVM83ZJ5'*8BD,N-2;<=F&O& 3P(;$0Q99J>8+(^\@YW$@HY6\!_ \WN&7 M\&V3GC\IUTEC-C&#&D%F[LC30D?FDG7 66)9.(W)M:[)OH.(!#Q M?KU(_ZBU&YA?GB_)IMK.''W_*= ]MJ6UFM\_T?T>$_W5]0Q7IR4HY+%&:!36 MR15,@PL\ PNU3T\JFYI/KM^/XLG.B3I6*=)T&!IZ+.H*7;+*(*D$QTCM5A#4RC /!W1AXU(@<0:<-UW=YV& MAPV&)I)MN)3CQIU4W^%Y_%_G=17$XO.7Q?R*!WB4TI+NPE,;O$9O+#!>Z*FM M-G_DY -RKY/C#*/+K-.UL",!#QL*HXF^X1:.2SG\C82U>KU8K7!U,K\I7GDJ MG#+1U A C&3Z>Y,A&J\@TW5F2U8R^-9K;.\EZF'C91C9-]S%<0.@MU'%;&?.N!.(P\Y2R(Q2D97&1DY$)/R('W@R9JDDF]M4]Q/U<.&R4#2OP$@ M^^7Y*DT_'*B+UZ^B^%(,;Q=K^G46SK;V\-8'.^56!,6+!F.=)Q=?:O":3")(E9.&NKXF[X][H__V'C8VQ!'\#6,1HFWK./W\.RV^7FVPJC[]C6-=>NI:K M>N[_RF"[>GHR.'!3&D/A2W((9%N8:G"0&Q,-O3+DO485'>;0>FK.F,MZ@HXZ MR0Q!J1JP<0H"K_6R=+?ZG(-W5)!UKZ+PH*UVC%YO2KIX=0EME%)OXK$/O(1Y_A-:0HUT[965PMFZW5&C*L8@/G A<]* MY.OU((^@*6T ;>\BS_&;TDR6,=:%UN3U*%")$YTV6##.F>#I/^CV;#B=8%-: M>VWO),\!:L%N3;3]B*"\"R1U?EJX<()[!5'C9I-YANB+JM-()8_$$:9A"XOO M(.[04!DB'-!*%X.7H]](Z-OE+"$_1>-1:<*T*H+1+R& J^70V?&@&>-67P]) MCP&:+7%/!C0[Z**U%?$SE>_PR_DR?0HKW)#V\AP_+%Y\"O./^*H&W=KV9I-AP0K9O?.U6>A1)0@ZQ98"5D@)@M RYR*#JJ$'7S"M+;B'G8 ML&DKZX8FSCX9/1F9$Y0+> M>.:,D#DUOZA'S*%*[03Y\W2R1.5.:0:N" ?D5WIZ(;,.:=C9C9/(H?;1<9<< M:A^I3CB'RDOPI=2BHU V&]DM!"DU1%?GU9CB@AC6XYY:#K677N_/H?:1[Y@I MLRYT/=4<:B^==V4\$)AB7MJ>WI9M0&TO8L\1SO;W[- MRB!9,#X3=34+% V#2#<;(-:%VD@4.O/HLFKMM;V3/$?+H7ZOWM!1.66] Y,# M46=MK&OV!)3"A-"E<)WV'=H[O6J8 <[V+O(<(L!X8_[EPS+,5R&M-]&OVE)" M7/K(R&>QGI5M:"L4QH&\6S3"^3J!=(>DQ1V?/+3V]_/P!Q3OK<_Y"#T8Z1/F M\S-U>._OI =C"T[,.[[QF#]%[V8&WHED _1QY A1UY#R;F^!F3IT6W MZ2U@="FT'G U8N30I:!,2AKHE2/NC$G@.=9E>5Y['E2FP_#X(X=]=-PE\AS M_.Z+S+P7AKQAMJD?EX;0-N[R'/\[HLZE$1&IB%%SFHG$(=8O(1D MT2=&0A&NV\3!AQ0G;J_MG>0Y0/?%T><%D???M:A_?E)^G\W#/,WF'[3^ !M%3_35KFOR\YK M'?7;)7Z>G7\^19831]10O%#DQF[VFM#E9)EFNJX\1]&ZG>)>HAXC+O:5_0 N MWOWC[9!NPJ"L@*#H&E..K-+ R6SAJJ1LC&!,M%XC]I!&"^X!CK:R;V\UG']9 MS*\%W$^E5CEFST$;[LE'H9>3_G?T:"JR99E4@5^O&;K54KCAQS]LO382VP & MP2]IDSH"-[/,C$RU?8;\#ZX]!)L*Z!0=D9717>^XW?M6<1@:^J=TR.EO0+G23Z.<\M***CDL G1 MG@0_1F0-J;-;)]VWKVIX_>K%\9OWQT=O7KXX>?WZZ+>3=T MWRSFZ98_OE(*L_J!62M; M]Q_>2,BA:D4.#8Y%:R4-$'GZ51CA9OXO8NI=R!VH"*4GJ8>I36F@Y.O!RQ$T M- %@,8=2Q1C BRC(44\2O&=D%7N-/&'BSK2^K"8!J'MJ7 Z/ISZ*&0!'KV>I MBFK^\>CC$K=47Z;NDTU&TPV*-?7><@FBP #&&\4CP MEB=^,!7V$5GKFK8_CO[SY/?%^3QO IW?F[&U4L4C&-09E'$:?/V%2R?1&&>* M[#;1[Z:?/M[3NY^@%RVEU/ M72W7-5U:DR)?PG+]K=9F;:+448./-2]?LF0Z2,%F3[)D^6C MI2RVV]R$PQH) VKA7@NBCPC;MZ[<\F"^#V>X^F-&OZP7\RVZ,]E%I<8*HO . M5-"U2ZL8R,XE&Z)+,78=D='YHT_7&&NE!ZL[VQ'ZH.854, MJ\8=L+*'#MJW4_6AV*.*66$&[NEQ5=+4+B!>U^Z@MUXZJ\77Q%E,D";I8R?(R.7!>4L?=['=] M93Q39&C5+(:0:VN[Y ;"/I#N+DFS,3I6B"#-BB5#6RL(L4C@PM@@D:O,NET# M=W_GR2A]5]F.]AAL=U=L[/+\8?$V?/OS"ZDA?9KA5]SV?%2NOC.U.E5."Q.$ M 2.2 .5E@JBE!U-X8L@L\ZY;\+(92>,G&P]>[W5 G1[*4;K8L5+'V4BO0)@: M8I8RD+""!Z\B.J(^,MFUTZ?'9Y\1UEHWK>^W#V3];._OLR6N/KP*5S^P?=8Q+8V??5J?EP*IO5IL)QGD1-(&>EY#D;3_9\0 M$(OQ(9-O:;IM]&Q(U%-%X*'T.L!^IG>X0OJ!GTA^+^DB/EM\^;RE?].+A\GY M&$@ND@1%$F(6G+8(UFBNL @;FM=;WTG0$P1<>T7=FG,Z0)/*_[/X-%_]V^++ M/^A(_#F?;785K;\-V;9R]Q=':V3IP?@46UN,=X7N)PTN5&\DU1DM,2J0PBJI M@F/T[#ZWMO2)%X? V>8=H*O T2\L@G,^5#DD@):UMWM-/?]1)I5[8V#6IU$='ATT/ M=*'TR2:5>JEQ]SS!+CHX+&K(+K:B1 DLTRVO2B K/)1 !K,1EMX"R3OO?C@X M6EHEE48"2Q_1CYI42DDN;!.RT1BG&QAI?I+64L@-$NL%)R3+G;PI\'G%1JJ?1=9=NXJ/'&2KVH M')K,'>@8-CN4&5UO*8(H)MNL Q;6*8[UM*ND=[$^FZBD8=RS7^5?%R*?<)5T M+QWN5 "[BP(.5B6=IK720T1)WRKIX4'2 M1^[-4WR?EG1M'H?EV0R7+W&-%_NPEE\V-^KWJE^=(O.IR)K"II0SEVT= $AKQDRSW& MPD"GM*E(<#4S(J"P&!R*G+-O/<5Z$H#::\]-%!ZTC;V_!M0\J+Q;Q.9J_%G/,? MA9P7.S].KM MK46;"D?E +TG7&O%P26SF<$K>,DBR9B>:VM;H6K<_7^VQ^WOUCH]6:=6-WBF5F7-C "A.0R8>'N@ "(M(UQ9V0R*+1V'SD M_B,O,]-*9.&"@R!#[66W%AS2S:#I4B@&12]C(7'FMI62\\=#$9=M?+6.5!U[/A M76AL4DXVW4*R/936"Q-[2/Q0Z'"V[J>6$8H*Y#*)@!!"8F",9BRJ8K'S"N<# MHF*7@K&10=%'T*,6B65KHF+) JN#>97.Y%75B;HB6&Z3*"YGV0D!#Z!(;"^E M="X/ZR/1YD&KY2*?I_659BIZ,D_6GW#YG=K?PJ:C[]O5.%N.A;Q>P<&C(]=: MA>KSZ@"^1,L,D](FU@D$NWW_L<%C!"V,46 6K)-,H@>K!5E/*1IP@25(F-'* M9)3GG=;"/NT"LUULT"8J.5B!61 M3),R!$ZWGJZ[Z HJ+E)Z^"CI6V V/$CZR+U]@=FUX.WKUR\N2YVT,)$,)9") M"5#.%/!.)RB:":_I^0W8M:;LMF],M8RLET86[<4Y6N48*\22*A[0$SV*!TV/ M(Y? LU!<615TU%V._'/EV%Y61CLE3:!RK NYSY5C>REYWW5..VAH I5CT@>A M2K90FX?(G:>K.6YJ;^EYSLI%ETWK94^3 -1.E6-CXJF/8D:M'"LEB8!:@ AU M1UI("GPN#*R*)M$]')QN/?7B 5>.]5)CY\JQ/CHX;"U0XB0!+PTD(1"4SPZB MDM4(U-8&50)WW5HVGU(MT"YYYX%U,QJ*KH05K],KI,HV^ P88K4"DP,?(P.:3IH>TX!N/WCSX@:1D]3JC'[>UBG3Y_#/W#Y-YPO/L_2:L@BL]N_-EJ5 M64>&IUAF5G=YH3,:8K18B_@9T%/J(?L0DV':L]2ZX^&1EYE)966H$WN3%!J4 M2QEBU@5D76]:A/,V=6J%?2XS&Q++(Y29]0'"HFFM_KI9/% (=+<%GE,G) M88',I:=7,13PS"HPTJ(RC)446_L>CSW!MXNAT4Y) PSI[QLG[D+N!7?7U;#"]"\?%U__E7[T%L/T#S^@>\,''U$$HY?J%VU4 MT- MJ*1LJ;@(YW6AHT- XGY(7/WJN+&%O<6_:"B[(77IE-,)N86@:D%.$!%" MJLL=6"[)"LX#WC7+=@HZO,6='TR%?436.L/PMLS^&Y<_@N VJN*,LU#HNY6A M )XI2ZY#YDP6QP+K-B#EV@\>SX7:3[R+1K(9+4' N1&!HP+B18+RM;4Z10<: M?;#9I>"O%RH^)P@&>%[;*6D""8(NY#XG"/92\IX!W5TT-($$@0V%%46/9/*8 M0&%A=;)_(K)127I+E2BMQ\M- E [)0C&Q%,?Q0R HS_"_)Q\Z_7Y$O/%R(_M MD(\M=2CHW8'K&LRB%26598]C<3='T4P6]%+H83!L-S:!; M2X!$EH6YG("^CJ"4]40*_:O,,90ZRS:Q3MLSGG;YY2Y&3Q.5-.QX[E=$U(7( M)UQ^V4N'.U76[:* @Y5?*N.YM())#T MD?O0P9&B$^?9?)/*_AV1> MD2',#,L0:N:MC/BQQR8V-1:8D&.\VJ._FG__ M2P9VR76UDG9K +S'Y==90B)C,RKP9$ZX7&YX#V=_6RY6*[)QRVR].OF*R_=? M,,W*#'/]J_33L$KOW>);.%O/D%RR[+3)7D$MN '%Z,Z+(EFR?UU 'WGA(78" M33N:GBK0#J3509S?Y3^P+F,Y_NL+O<-X*EDQ+$M=I^<*.BR,KMWD:XD[-XSD MPJ+N-"VRE[O[,PU/$%5-U'%K\+9]6=/[#R_G;Q^>?SN_?&___GJPW^^ M7R_2/UZM5N>8X[>C]%_GL]7F4WL4.O7_2*O2ISW9:U0,=932^>?SL[#&[=39 M%XO/7Y;XJ9K+7Y%NG,5G?$UWS0_D84RA)OT 67&@LC9U!HL!(YE)9$NIH%J' MJOK2N'?0M]OWMF$%S*@BG44(+*@ZB8_79@M+)\@8CCPE55I/\.E#WUB%2(/B MZ)?@[U *.G09T26#OYVOZB.^NG();+S1[#47V9*#$FHSF'$*HLX6IZJ%Z,&[S"!G:WP4W%K1.F=Y(*#U@T4K5NTO#RYB :=MSL5F M8SO.$KSQQS\JQ>XOP/9#T9=D[AR'Y=D,E^0>XB8^\&*Q_'+1RW1!H^)29Z$Y M8)01%&+=@^HU<"NTS#H::7DG)7?\X*-2^Q!";EC[MJ7QZ-W+5^\_8/HT7YPM M/GZ[O&X,\S:51)9N**!B$ 3+$L"QN@8W1ZFN]]#>HD@3N:Y**HZ6WHS HL3#Z?2>+#9V4^=./?50ZW%U@OZI. M#6!Q'],_K;^]JBE(7*U7VQC?R;+^=W54WYQ7ND_*^T^!_GS[IZ>JQETY,R"- M%+4*B5X:I15PR94H.CFA1S#+=Z#\ +5C8P:?#J#> 6KM[^7B.A/_$<[.\6BU MFGV<$_5:E,*-1/!"T9N7%(1=8],Q[!;&J$C-NX>!$LL[D4$Y1NWH_^*!(\?7"T5X*GCX*FDN!Y MOR;>Z@_:WM*5O\5\4PRPF?DH-09N>"T[EZ *\Q S\28S*\EG[[1QC2%W)T$/ M(MG3"P;7IQ/_5^#WUH#+YE Z* MT $4^9?@39U^9AFS=#5J;PY0H'*H(%0#9?:W57;0Q N_Q5"-T6%9]NI9_G_ MG*_6FZ%G%Z,Y;=!!,P&FU@"JI!FXV@?G;4Z9<^V*4L/AY0[*)NG"[Z+:VP'4 M2B_#7CAO9!Y]4#*RU$=N7QB> J/:Z&F)\P\F+5T?K]7(6S]?5EO^P>!N61"41?U(^ MA+_>+<[.?E\L_QF6^91P'Y1($I#[&JK*&1S/"K0I1B6#Q8OF]:?=R9LDHAKZ MY0,I:H#7;E-,_6EQ1C]MM7WT3YF(I6#MZXZ\-FG5.3EH A2FI8V*DP?9?"G3 M+U0< "%#*>T7)WHOB0_P9IVDV6]8%LLZP?4LK%:S,DN;QW6U_6UB_B;!G";& M$(-(0+1N)E5(\HDR92]R8Z#L2.KC1=,8NAO@*;M.[>\DP*-%FKTX M7U;RWN)RMLAW<^"\R5S5#1W2;-IQD X-O?R9+ (LW$7)6V^1WI_JQPO$D37: ML);D^U&ZPR[X3OC;Q7*CKYOH5UK$X)TG?UA84*9D"(D%H#L^ M-#]>/(ZJS0'*8^Z.Y-]%.3^-Q:4B@@7+ZWQ#G\A%"2I!$FC)KDV\A-8^Y1[D M/DT,MM3AK_#3 _@%.3O45GLR%**MDX$X1/*!(?LD3"*GB#7OJKK-+QBWAB)L M5DROEM]?.,P54T?#U59T^.(8-1=]&3]4+89@7#H3)8B<@5"Q\@Q MD/O4;?+78ZG%J"T4L8;"+&*F.XM'<#D(D@?=7"B##/E M2G3KL7H@Z.]:C'Z M*&@JM1C7#?R3:IP?6D+CT M$1'02PG*Q@0QDCMJ?,KD#?@03.L0ZQ1!>D]1RT/%:!_M3@B;%]E0@=P:&3V@ MH-=-N1(A&*W!QT1,29X-;UU'M1_%XP<:QL1'(VCNH-Q!TI)WE:G1P43#I !M MZN9F@QQ"R1&8+I(KC\F+UMM"'W[A[S[F8CMU#)!+NKE6K0M13[WPMY?B.I5[ M[B+UT0I_(V-1*1E!;,H7&2;P&E7=G8M>!RV\;EVR]U *?]LCH8^PIU"'Y[D/ M) (+GM7H-CUS$%A"2$Y&)RQG10]8_SO1.KP&JMVWYJZ/7@Y7#;Q;S!=ERH8Z0/77, M!FU5G7;MR))WFM@G&QY$8,+8J*-K7AIP%ST/H/YRGUA\,U4,<*'4H5?+<'8T MST?Y,XE]M=[.,KZ<,ASIO=6F1@Z6E M0D8(TMQ85W59N'!SJ9^+Q1K/P*!-H)0V$()PX(HG)U_I&&)KLW=OHA\YYL95 MZMC#R'\[>G_\\L7)'V^/W[P_^O#JY,VFC&,SGK]*E42Z8?KM&;WE^Q90[/*M MIJ43>S/;J&AB,S7GE\]>F9#_V[UU MEIR*%]$E;)WC;D;\6"49(Z/TESCF090]E0J.>@=]W]CE(E>EL +%UU5,6#@$ MS Y282PPQND1TXW1>O7[A]^8."H"%HTT,8"!>4G+Y9;T#M0,%#?_F9+#!,QW MU\PM*MY#K,,KFY$%J8NS8)RENU1%!L%G#X7GDIEA1>O6A>)C*/F>4/A0.NXC MS=:CCD\^S\E'6+U>S#_6E6ODL-09VU^QDDB>BO\^KM4D$WE=P%>[6HM"<$%' M$$8(C,QKY]5]=G>/[XWOQNVCDL6P\FP]L/P>$MGESL62K>.<: JE-C"0""++ MA'HX]%-,+5]2V, MC&3%3 !7E[NPD*)FGO$4?"=]=_C8PU5V:TD.,>YA8VO27]Z\4UHGQJ*1(*.E M=TH%0VY/")"=9:[X(IQKW>[Z$P%/VV#?71<# &-W0?Q@8YZOG:0N/ UD]P_! MSV&\ASU@&'RRN+W' M(9HX;/NH=BB+:[M]]O+?5ANSX>3+E?4F4A,M-A;@0M/K$E4D3X 3S<4&E816 MB=M>9M=]7QS?]CJ\SM,:\(>W2BU B6)XU&&45*)Z) M;:DU6'1,Q9R#R.VGE]Q R!-&43L%-;QT5LOUZ;LJB6UOBBK6>Y[!\$@>B!"N MUJK0OWKK*G0MXYTR7><,I--^)N+RU.I#1QQ[O M H'V5\+]IO,>PK^NOCTD-\0)OB 'R99RFA?PM39115\K-60$IC(J[S+WI5.B M[= *O,6&;*^_/@)KK+<_2%*?SS]?$B)R*+44/IG]=O4A\ D"3T*$5!*+ MG>KY[U/>U8\^0.7M++/6CM;.E2$7D^6^_?W3+'W:&OZKO\_.SHY2PK-:](M_ M?KE8H;?=^'12CN?K.M!(1I.UJROTD@J@ M=U8;$'&YGG@JNHKX_POL5E&Y_V M"9KMPU3N/ 1LM$[L[O:Z]Q1Q'1VJP0<4(+%H'^GI8JYUXUXSXI\,K@^K]D/DX.X,8OT' MKFHOTI85?AICMLS[VMY8$\T2R0)S3A)#(M,Q55PTWTC4DOZGB>)#*'^ J Q!IIO8^(9 MTJ/"8(#YR3LS]/,:ZJ.O8796(\N_+Y8;N^HT)1LD4PIL1N)+)PY>JGI\C2!3 M2IBBRU3@?0\OSR@_!"B&F-:\+U]'.6\T'\XN.#Q??UHLZV"&4]3!F\1];6RL M&]B% 5](_#8'SS#:Q+'YL*7AV'F&_(&@\2OJS6&").]P&^W!2P;_;7&^7)$U M]G?$?YR4;2%!_=NG'!6=ZSKPW;EX4=S-Z[K#R%D*+O/L]+ ADLZT/AE83U'W MOT+;3@3:?RSFZT^KGQ@KQ29E+ ,=LZD9.@&NV Q:>:.5,I@-&QG4OU+Y#.># MZ/M7(+O# /D%\;&9>4!__;=OQV>SCS.RMBYKO.B\UM:,4Y$$ABIKYT,"5<<: MTAGU4)C5JCB-!MVP4.Y$YS.8#Z3S7^'L#Q:V_MYBLIPE/"GTO_Z\F&^;3RXX MXYK\!U&GB&B6:MHIDS%E T@F=$XF"=M^[>)@W#P9S$\,&#=D:@Z4B[RH+/B/ M<'9^6=97#:W+\WR:Z+@RPQRX$$G8AM?.22\A&A,=2U8H-_#E?0^%3P;"T]'S M#>C=/]%8C]*KU>H<\\OSY?>X^Y;06[L 5Z=&H>1>&V!.I1J;%R1)CQ"45M); MZ3QKGI/9C=0G ]0Q57H#%"T0@[/N8KC1Z*SOD,'E5WJ$ M;T'WV>8';0HHWF%:?)S7$-@6>2\6J_65R7#<&28$TY!JKPE!BX&/)@#3.0OF MG.#8.D/0F(5V0[7:$+:M[2_.!:Z2)K.?A*N2J291E&"R=(C*A-1\X^\@C(PU M;.N0N+Y]\M:A$#&5*5S;69+?Q[&_ON!S4SX?%/-)J@*,)T^O(B-3GZ."$ *F M'*,1O/7PUSO(.7PWT,&P\LM X38Z&V3L](VD76Z0Z4#<0%W]=Q)VF/;\9FKL M!H\]=# Z4)BRRL;L0$LLH)RHIT-JT,S$Y(3T3K9>&7H @-S3!W\8?/01_0"X MJ%[A#"]7+G"C+9?20T*'H )R\,%R"")&&XV-,K=$("^-LP$&XB^XH'%J+E#+I5N72'4 MB;#'!);VFABB*![/Z(\^$I%_A.4_L%8Y_TR?YV2!"TM^(Z_W7MW.0H]H IF8 M8@1SS*9Y[>0]-#TFD#25_P"UYA>>&N:;';G+C1LY%HM%9F!H2026 .QUR!!D M,2E$S?CU(:7[C[KK1-D!EBE-*(0S@/9NM6T.&V3_4?+X:EX6R\_;\SE.R/W. M;Q\B -]=&-/99%&23XD 36:3=K5ZKX!7DM.=:H0LG@?KFT>*]Z9Z.ILL--,E MA+JG391$9H3B$ 6WP$PV4LFHK'O>9#$N2H?;9-%'V5.)H?\\L-#Y(A(O=9\Q M!C*9@JM6+YF^CKN(1B?3/-_VR$;C]L+ G:-Q^^CBH8P6[<+3\VC<7J-Q>\%D MC!FCN^CXH> W)VNRX ;(>^2@8FW309.AV"2E"#[PZW-NGA!N>XW&G1QL^ZCV M8*-QR<@)R$6 :&H)(*(#Q^OJ0F=*X$(Q*])]+M13'(W;2[D[C<;MHYG64XZN MC5W=R&%%%%_[_3])=:MW[_^\I+B@%=$A%+W9(TW2BK*F*_-92ZRDB&E DS4:\A92G[4"TT,\ R8R;R*K_N,3+8]2%P('\@GN).XR1WT25'>"QOQY&NF=^ M)C1[I5WR LQFH9!-]/ 6YB'R:)(/TK??Q'T@H-QC51\&)WW$W]I8_O!I6;.U M87DVP^5+7&.J!+Y8++\LMF/-+@>YHC46D='U*39CYPN$: QP2S:9T$:;CO9- MQP^.;]$TUM-B8"&W-GO_AO/%YUGZ-PQGZT^OYNG21A(I.YT$Y!S49FP,!&K_YYS\J-3<0X7CUE=N5.BXG%J($%LCN59G3O>;(1O/!611D M,F%Z4G7=AS0W6^EI@/J(NRM#NA#W7,O=6XV]:G5WT<'HM=PR9.:,J6V5B8@T MMHY&50C,1I3"V^!4ZU5H#ZN6>SA\]!']P>HUT;!H!3$MZINK4BED99< TI<2 MHS:EI-;YT@=9K]E+F3O5:_;1Q !UX)VJR]XLYE]QM<9M0''U8;$.9U?_O%:8 MO5FL_Q/7/VK/KD2:5Z4AG8EM/>;OB^7%;]6_QT_)QU&!N0PHZAA^Q%=E-_#;+F9";_LBZZ%L/@7A,;3/6^QQ"D5"XJW5.VI#XL #Z M$$SV1NGSS 8(4/_6:OP+K;0_KHXQ ;?73IKNO#TW"KK%4X6,6QQG9X5/2Z9#+R M?*R[)4-@EK-BG;LVN.>Y5;BWZCF2'+;;. MM5.@%1)J+ON9NCU>K\\S9[4P,]TC4N$"#%8!UFQ1,9P8LJUKMT:@:T)XGG@G,#$ MH#+ [=F4Q7>SU3]^7R*^FJ]QB:OUN[#&BWC-**7D]! M;V9RUBHK KD.K0=IC\7;\^D9__3L@*I#Q-GZ\%G;9^J8F?]8G-&/.9NMOUV] M)PQCMA@4X)2QH$2U9I4DQE,I*I?B"I],_4IO[IY/T* GJ!VRIE1FVH/3R]LB M:Y\GCJM-)*K6=N*ZP *EL%9\DF]STP6I[F)XS0'-&3J^<2,I=E0+!N3#Z5R,Y"FW;@4>CIL'=#0:!LH. M#XQ;/?Q1EX9LDR/7!E^&>>W2W&S)F%^T?JZ&V1O2^_,CK [93R33:8.(,CDM M(YV1X#:&"H*7Y#KKDKR00MI<)A.&>3V]-HABK!>\.)#&)SK+EBR^P@3]JZ)3 M'KU6JKGXGF ;1!^4#M<&T4?9AVZ#N.3^,O.YG07D#5%-IF"(/( BH4)(M8M4 M1F>\S=GFUD;[U>\__(+ 7@A8--+$ %'^:_GP+M0,5,DWA1J\W35SBXKW$.L( MRF92JU G@!9#=ZD6 3PO$M"+6*RS*95.+5$34_(]!6N#Z;B'-(>J--O8GF_/ ME^D3W5J5/L$XNRA-$9@U.=0)Z+?(!\I&0C#TAJ(QC*.),E[?AW)/D=D='QO? M2=Q'&3=5AK62Y !E#3]77&J;#483(;I:F:ZLA\BD !?)(BHN"M,\N/#(:OOW M>WOPM-S;7^OVOY>,!FC2'H7'3^4VG[-@F"9..*LGNXZ6RG(8NEA M4,J7Z%FQHX^5F0QN>]7V3P^V/53;VN+:<2>0JJ/I,(/(7!'%CD,H9'-JIEP) MADM_?2CH\QZG_=3>8(]3#YT-8.W]$D:^($O&&$7@) "5,JBD)$1$#9$G="[H MB*'UV)5;2'G"L&JII(-U'RD74+*@P1@5ZD8*\H$Q12A9!!U4X<7G7H[A$^D^ MVOD>&D0S4ZIAO!C_=7*^7JW#/,_F']\MSLY^7RSK'YX67PP:K2 53UP9(2 * M28?"%9-2-O3?DUE3?R:7YTLB:SM>>VNT M7!U(?_P7+M.,N#K-N@A?IVS[E&N(W&8@BU>"K -H%"8EKN_HVA_,O:E\1NOP MRIV@A4%2*SA;GQ-_K^9;;LEH\L(D+D"@*Z!X$."1&0@I(B-KG'DYF?[4V]EX M!O0$X#&EGH9;7Q1K$[*L$%#'.J\*(WA+;XM4C(6"1:)Q$\/[/<;&^%+]C^U6 MBGG^7I^YJ+_UJ[ %9YB#8R>?+F;N4E=-6MMZ>/19O#^C&F88W M,PAHIM3(^[.U4'.E%PRIXEBL*XK*9D68$Q)\UAFX=IAR=(&509:5M&3B&>ZC MPF""QN.5@_IWG'W\5 _S5UR&CWAI'[]=SA)68Z9<&#.,JUR$R6"TJ>.MBH08 MR:PQH@AKM7723-BQ[\CE\\F8%I"F;87>Q?%I88XC6=O IA#U0MBDZI9N1:+^>ZAWLFMY ZUR1IXD9FU'W_X5E,.G\_5ON?J<(";5$GC[2&@._E-CN4LD-<9%W7[L0S@ MK"^ //F@1,GDK4WM@/7D\?F(#7W$A@3= [8&%9/1*&&@J$ V^F:],?.,3'8I MSXP$X!,PZDWFSK$?7F\QM@[K(JEE_+%8KX9.'0>SNJQKDX M]8$YPEB,!FT1G52>Q6Y[[/J^$^.R.=ZQF3YN6\V4&@ET0P5* M]V#Y_FQ[1TGP4U^B\C98*+*PVO1/5V.=KDW?#M*@"VR8@;F3X/[)/&;3$WTO MX/UZ!.VAC^#M-NWM++N0K8UTUSC!,BB1Z)9TS(,.%GE$P=DP@W7'9?/Y4$T, M2K^>'G=05^D5\3*;KV9I.Q#RTH;0TG.YJ(:&(0X@Q16#BHY_A:T_=.SKRCOW,X.GW'JKLLB@R?@E[B2O4Y0B9"YS8N@-*X>DCL1J6J]D!=Y( M#R&$DD*DYXQ/9C+ZOLP^F:?BX)+N!:L;SE.;?MDVMM_/G/%3J1G=7$: S'7E M54P*(I<6?-09Z?]MRH.4-PW"S=,\$H<'Q@V8/_@C &[=1:%N]DZ&DB?Q+PN '\!V^T^!O] MQ?5ME5";/WQ)K]SW=0FG:-#(: 7Y^%G7I+#Z@ M ](>H8W/SI#HFJ [\DOY[H?%.IQ=,Q%9MB;XZ(#^H78<(M)SR0J4K(6)+#O& MI_:@=.'K^=A,&$<#5'^_72X28E[]3GJY>7Z%-3DI7CA8S^J.W-K(GYF'E$(1 M0J)TS9^*>XEZ1NE0&IQ2[?/Q?YW/UM]>S4E(YYN:\)/U)UQ^^!3F%RR^6F3 N135=[?@F!80HK5%8%(R3F97ZTXG,,^C)V_-!.LA!V@-@ M#\H;NFB)O<)J2%Q(IPWP).KR6QVA3N8#9%P8)G)BOOESY.!SE.^\%L M2JV'O8U9EYC&Y#-P5U.D'"W$A 8DL]K(&J]+#\?(N]-?FJ06[DT\_#0451I= MXUX0..%12880?52 TFKN:^>??H"^;1\1/*#[\<'$B0:#X V^[T.X&#OD ADF MAEQ#L37X[+@#KQ@'%FW!2.(Q8O3E8"/P_8 .WQ30/\&3W NY#SAT=;\@1"H) MM=1 =[.L;?.<-*D\6"N441JS=>'!'.''6T;RI,[QD!A^P.&S^P610@D.-8*. MV8#R"<$Y(4!R)JU3L@C6>B/Y9)A_/LS3/,Q#8O@AAO!J;4B'*XTGG9VEBRPD M#JJ0JQ3)5 'IB'V7;!'IX10Z].'\^1A/\Q@/AMZ'&32\7P8" JS@-7": M& 21,V1=I([!>>0:R)TDD,D.J"4$4GD%Z=[,%S MG55@,D4]F=%S>W'Z@.[7J0<.FP'JA@##SI/I]F:;COJ6OU_Y_V4SCW<3ZOZO?[VF%)+ /S9_ ML/G]*O1W6/Y'_>\_W[WZKJ!__O.?_X)_A;1>I1G.$Z[^)2T^_^M&1>\_G+SX MW[\=O3]^^>+DC[?';]X??7AU\J;N@:S[R!?E8JD]47'\_NW;E[@.L[/5SX2N M9I^_G%V+=/\Z:62W#_WK#^9^9OKB:S_A<%@V\:\UTE_(__- 5],/L)? "#5D M7)68'2AT#H)S 7C*26MF8YQ.XN$[U7M?Z>D3YO,S/"GWTG+KA/4/M3N8'B>6 M4-9N%&\1E/*,[HHZVD[[Y-#*8E7S*?VMB&]X.8>SLT&OY#XH_>5*/HBR;TIU M_(\JO[S^7[6Q!?/__3_IALA$AN+)C%)<,B"!&A"68XDHR"UN[4K]1$!#R'VB'[E,YQ&!?I=T23_E M#@@>!@.+5KJ8U+Z@'VS,\]NS,'\3/N/+C776B:=34GLX/UN/_:KLP$]+\_42 MI'"-_5_!N@=,FNT/::SCAX)?[SR/*22PN2X9*@8A,(&@N?-,QR+=^/,O)H/; M[8]^J+#MH]H!X'I,?LWB&^+&.?@#M^MXM8DFJ+J,7%='DPGPBF<0.8@4N1>E M>:CL!C(FZ*,/KM]%6^7\BI>]9UM=H> ^Q#O!D7*.*I\(, MR@A:%Z***5>G#CO(*OFHN9:QM+9-)F!5#*7C/M)LJ-O-T-6?GINWY\OTB6ZM M2I]@G%T^/PX+DUP!%DDW5M0.G%$< II2Z+KRQE\KS+]E('.'CXUO >RCC,6 MDAS@(=^05H/#F%^>+V?SC]LDU^:U6MU*_^K4B92E=A*2):-&&:%KR N!CH#W M(AHT[6>/[4;J! W(@2.*(ZAT/"1NLJRW4DV.'%?1<[IDC:[=7-F"1ZW!9?KX?F6??.7QPV_;X;X]/)PP<32JA6 MJI!)@DI)@\.HP6!,@EP>1K?T5"ZJ">;A<^%,EFC!B5A U1"@$[5(+$41'7D5 M634O8WB">?@^*!TN#]]'V8?.PV_>0"K;9(!#E%7DZ]LX@L>BU9E):Y2-[.[OK]_IV15X8U4\:] M&MY-D@TC9[>3]N&?BPO2&$KF"UH0.0=0SF:(B=49U8IEG4V6GN^NY._?>;1* MWDV2 Z;;-E>52]+R$A@XDXB6Q!GXXCAP+-[RF*/&UO[$X\JX[V*T[:V)X3/N M7:AY*AGW7IJY.QN[BUB'S[C'B(4;G\$JD8@J7TN*Z-5AV: R+ JO\@-4T,=]Y'F(3+N,F7,PCD@>FI7%?WBM=" /GIC)=UR MEO"4,XXZF )2*TY&M93@+,E))V.-R0Z3=_O=/C=]]LD :6"-W/I>C9;WVYR$ M=[C"Y5?,9;&\;$=MG^^[[TL#Y_EZ,3J=_%[)0FDD&RK&0FB2].#Z: N$HI() MGGN7FC\NCRB_IX-3-G@%UI<,RAL#D9-W&;U0=+?GJ$KS:K@GF-_K@]+A\GM] ME'WH_-Z-7I.)GB7,L@X_%\2 ]/1T1 DQ,*3?3Y8L[^?H42L$W!4]ZJ.)X0,* M7:AY*M&C7IJY.[*PBUB'5S8*E[5D%H(J"E3A#)R4#*0)*;@2T3:OZ)E:]*BA MCOM(<\SHD;^(>23-A(G!0S&2/$U5Z+*J[DD0LAAE/..Z6QJHP\<.'CWJI8RN MT:-=)#F:SWXENF6Y#2XD57L)#2B1!#%?))00-#3V?.()K>19)3JD7_ ML:7X;SC'Y_LQD MX#%$C'SG.76;$707%O[JZ&N8G56+_??%'A#BVT.NV5S#AG@9,OCAY M\^'5F[\=OWGQZOC]^_,O7[;!@ZMB7I078?7I][/%/U_-RV+Y>2.?/8*O;0EH M%9,=4"R-0K6O<;5"?(V$PY>X2LO9EPM6+UX$AS(7(3SXP'R-+&@(6EA(S(6H M;-9)FL;WTSTD[7N5W_SCMW$4*V*B%U""SU@MK&+J^Y?!R)*L$%PI[4;A=M1 M:$L,7+\(6TE[*G'+H_Q_SE?K34B.[N0W^,^CE!;G\W7-L2X7<_K'M W8;1QZ M'JU)-G,H-I [P$N5G":?P'+I E/9-)^/U8O 0T4^FZ'B^L3 P;0S@#]5YS*= ME*.\V#!_X>-UH6F@D.=-]!QHHM]P:EP,I(.Q\%%")DLO(TCN!9!UFJ!VVT+F M63L>G$ZB=:ID/%S<-S'OL+#H(_H!X/"#V?=UO#GY"JL_O^2P1E%M?G%!I$M> ME905F&Q9W4/.B6%'7)-K+V1FRLG66_4Z$3:^<[B_#J\_+LT5,$"@XM)].*'7 M.%1:C])Z]I5$C:OMH_O=O8U:9,_IG95H2UV50X0:8<#H@)Q9:[)IG6_I3-SX M:!G2!AY&)P. YSN!&SE:KSP@1X':)Q'*76K>^1;I0]5K0,H)XDZ"E@93\M#+#Q\E($;Q;S1/_X:K/I MK4IBGK=T_R25'T'2'Y(Q(;' )5A'.%=$<,VV:F(G99T+"M_\ZMF7YL=IV8RB MP0&>N'>UCOVD_+G"(Q+2^B2N2:)UL]KQ7^E33=60G_GSX_SC?O7D0;)L/-#A M)+G)E"&R.OJ:\4 .@/7)E<;@VX/6=BG_$X@%(',.-^/B37&G_>897\Y1]^P.5G M?FJU\MRB IM+HC/#'#TL+@):*6)2Z&5NO0F^+XV/ZPT>5$,#.P8=J.7>%<]8 MKFJW)!HZ!,$F!8P9;476+(?6*=E^%#XN- VHG0$\B#NQ7Z_P&K!]%];X%I>) M7)Y3+,R(D@/=H;5\)DD+(68&+G&EBC'9Q]8>0U\:'Q>>!M70KXC:>X/['?B_ MD5JI;"C%@4&KR8/F$Q5O5LB]7JQ6*3I2/B:C#M._!22MHE41VY M),BOJ_UQP3/07JGD;-$86Z,Z5X M%(;%.FPF@XJ&050;(5F9)?U_")TZP^G'7T$'_=L/9-S\Y8/5FC50Y:*92!L& MC'ZEII8\7#0B=:&I3QU9+W7_H&/<^K$6^KE5U7L*=RS%,XPBUX:%.J\'%$\2 MO-6>W#*AG6*NB&[)^DDI_);"L+'TW4>FK9MI7YZ\?W=^AA?ARBUY%Z5&.DHC M!3KP.O/:,ZP@).,ARKK 17OIM>Z;_??SV8?P^?WY M;'U9-59?(Z0W2 M&D-6:R")/"%2V@4FA& NJDRJO_^2'KL"])#5 =N8'A^]Q MO=Z::L=_U0XO/,U&<"5S'=6MB$FL@[9GWB<1 N>07*V_2?0*.8\)I"]2$EW>F-;YX3O( M>31H:"7R$9LC__[J_8N3-^]?O3FF_SKYX]6+E\?_K#'M&>7C^_5:QG=Z8:17I>+,[H=Q:,O \ERWH6=ZFHK/P(HU2B96>//&OY;TMQL\UX"JBX'F5I$;;3B8 M+!0H5S@XAA:*(=@IZ^D_K1L1VG,Q5A3K8%B^?2C=08!PZ)C9M=Z1'VQM_$K& ML^5*T_.B79VR1F]75-(#BR9QDX)2HG71ZHV$''Y>W6' <7.3UAY*&J)+ZQ=A MA)OYOUSBT8'<@?H]>Y)ZF%;0!DJ^WL8U@H8F "R/'"5YV^1G9_*.R<TL/CJ8]B6@<3CSYO+.^_UUPYR6M^3/^U^#Q++_$K MGBV^;"@.?[U88IZMCSXN<Q QOA<[J'87!U#- %&0W\)9K[6H6HP$N3(=(5 M*8HVMOV @^[4C6_)M-+I]7C\, H98KI!I:N^M#>0INK<4QTDH-=U;J\I$(64 M0'9_3DZQ%$3KUJD[R'DTX&@E\M9^T#LLY_-0,;JU/GC$>T!J2I]>T\) A!DV\FL@Y&B>1+ MZ82=/0EYJM@:4W^M[Z7+Z;^_GY^=?2 3\.UBM='9)=UT/GY#(I3."/UC/3(W MLB"#8^0-"A"%W$2EE8/HT8$IGO&2F+"BVW*\-O0\520>0)L-7?,-"]N]D714 M[CQ5)-4-&\3;#=S>P9J*V62C(OAE\J@"> MD/8;-H_>_TK\L$AF\X^UH>RT6$&G4 OPY+&0ZX(67%0*F)6$PRPS%]T,PG[? M?:K &U [#7M&[R?UC_#7[//YYPO ?Y_FOST3ISDJ4R)=[.0/UX$2)![/) =A M;4E"EY"=V!]4=]+P#+!!M79K4VD[O_4=)IQ]W4[.9F0GI$(7: X.5**;-6)4 M(+4VR+QUX?K.U.Y>ZX_//%7(M)/]KZ@P0Y6>_O9GK=!\__[%R1^_O7JSW0A\ M].;ET?OWQQ^.7OS[GZ_>O]K\WIN:U:SRVZ,,=>=OM2I);<-LH_+4W\Y7A+G5 MZBB1K;^Z9.D"A+FX4C@WD /]HB026KC0D%D4A)=B7&@=FKZ+GG;EHS=\9?7; MMRO_MDUA>B[HF-0F#GJ@ZP@:!3YR,@2]JV.[9<'4.C'3V4LX! ME#*50LT;6-LDOU!FS1U+H+6DZSB73*X%^W8_@#-HW"@R'4?SU? MV$ -0R2.;R K;4(OW_C@(8*23V6FZC%.I MXXF"=^ THW_%*+-,0JDH'P=0[JL[. A.^HB_=7#^Y/,L'2_#95EPC#F;(H$E M@]4-9!"94A#I79;%)F+4=G*V?OJQ!\C\MI7YHHG 6N?T+BAY.0L?YXO5>I:N MLGM!'PJ=C94:E$%+[Y\COY[7:?M,<*VT21BZ==-W^-AC5',SX;8^MV^7^)5, M32*F+ONL]+U^_>*R)$4)R\GP 2D"$2=B@9BLI'\5K$CILO/=XKIW?.11*;N5 M,%LGJHY6GRJ7\W#VK1)U.>,A,R-YJC>-V>R2"V33$FTV*Z;(B>+"A4[JO?'' M/RK%[B_ UBF:#Y^6LZ]X')9G,UR^Q#5N0GDO%LLOFUC?][O%NB)5"+6LS&YV M.A'+*AJP!A,ZNGAX\IV4W/&#CTKM0PBY=8KE[>_OZ;*IS1"7L!0J("\I$R&F M#G8DA]61?PJ),^.0,!L3[W9M7__1CTJY^PFN??)BM3@[K_S]-EM<1&\OR(K1 MQH@I O(ZU 4#AQ@973-)98Q1"'.]_?[6S,5MWWA4BFTDREL3$;M[T*_F:?$9 MWZ_#>A/H^ZDB70:L S_"9CH+N88A0)16@\[!\NBM4:9UU/<..A@@*'24R :"#KQO-R3_Y) M$%U]FGW9)BF28]KJ")80"'7H''@,%NC_:T6UCL9WLD3O&9+[TT0':&L&=*$J93E4>4U#H'2.NA]%G'^$-8+U]?W9>G(75ZJ2\7R_2/S8,YNA] MK*L7BZO[;LEH@.C):E62> O>QFA;6_2W$O.H+^VVJAA@&=/_W]Z;-;>1).FB M[_=7'#OO/AW[:Z:MZNA:E:015=-SGV"Q>(CHI@@- %:7YM=?#P"D2 HD M,X'(! 2IEY*X%/(+]R\CW#U\N8UGP]HNB :*"WR+YC#!@$;JNC_*MXVL!]@I MMB#3Q?'@I0(5:\5X"AJ\4@R24KP8S:5!]9UJ_PE/?S3E]Q%QZQO[+7O>INUS MS>FGK7%]$ KNDZE;7JD37#3YDR%+ RX:)8/T.I9[[3@?N#3H]+B3/@D&DGKK M&Z0G$5Z;JATP;C\D=F7((/Z6%/*.>$"Q$*VLS(N@9.9 M#&B,PHOD7,)N22$'9<4#Y\0QD:*/H$_C&;KVRAU0LB9!WW[C0(H6O28B2HF"/4T7$QZ<*M;7UUT />21LD M0ZMK@,R'1Z!^!?HF?+I^V;K 'AO *^X+FR=IK=8! M1$HKIY#3EFL4H--.T:LHL'FGS*.@V1/^]+&RK(^ZAHBY7"V6LT\X?X\7JSO! M&C>^:=S''0\B&M"LCG"B71U\HG^4('QD&)E*K6>>/P)G_&O3055Y/S#32 \# M6%)DV66LR[S&P\E&]%QG$*J&G71--/%.@WW,9PV&?:2^!"; MQ/5TM^6+VK*>/G3%T>=?ZI"%=4RRE(@B9O#%1U#6(#@A&.0B@R#_,S+?^BKG M25 _A-W<5C7?QB!LKM1ME]M3(>-O.[6FS$0LW M9)ZY5//JN:.34GHQ.8E$;#7-N(WJF2K>RL2<>=(A^64WU M,AM(J*V+O']___+=?):OTO)]K5&]POO@F+'9(6? 65% %I("5U1M.ZX-&I=U MN)\*_(#&GWK22:F\J5A;O^2_O'SV[//G^>S/<+%!(YV1ENQJ$ X-K3.2?YZ< M!>MMB<4G[U6W4K)O/OJDM+J?X%I7;[^@)>+\E]G\=\S3%.;X[#*O_SK-9SC_ M+WLQ>S/TD$'Z^)5\@&)O=' RN>%J]$KE/;%)U=J20?496DN^W@NSS^ MI.@PO ):5X<_NUC]0NVMCP?D<\W6<1&GF"]$Y):3]B?@,+LAZ[4FT M-MDSP[KU>.C\R).BQC"";ETC?@ME;5$QG5TM;A)>7U=NTY%U784@33!>)R![ M1(/*V=-&ET6]D$R).UZD[-:YI_LS3Y40+47=.EGH#F\_U4*DV_T,,'EGZIS& M$CV==B8:",XFH TM&L[H/ZZ;]?_H8TY5[WL*M.'MZ[57<@/G;LV9J!W =?(@ M%7)0K"9%.IZA:)-D"I$.J=S-1'CH$2>EXC:"'"!<^$N8SO\C7%SA\R^_8UA< MK4>X/ ^+Z?IJ+NJ@HB]B8XD40^R3E8QT'GEGO8N^=17?$Y!^B#!S2[5\RQJW M][# V7PE\N4-SIN_O)PN:I]:0GQ]5'6 .E"XN0?, Z5BM%3S_?F! ^MHB-2+ M;P'6=LW//LVN+I>+S1X<@T&IA0,C%)D^+#CP1GE@4HB<(\_MIT]VP768)(L! M^=-<&0,0I@_'G<@F%]J)1/#:B/ M<@9(N7BU6$X_D07^MG3 FLA:R\D*X#J30>Z#AI#(-*]MVU)./,G7 M7M<$%N6199M\IW/MB9KK?3">M.D]J@*_)9[?AW@/X;I^]SH@:]BGX7$TX[=M M&$^KLT%5TGBW>@)AB R-C;1Q6<^A4"GR$9'FD)<0Q MP:T5M$N3X#[2 M;6@>UZ5_F"[KV_#Z,D__G.:K<+%B.CNT?)E>?OR \T_3R_4U6AV7L;A)F$E,Y4PB MB;5DIZA,EE<)D&.,7$?T,:=.YD>_YXYKA0RJO]DXPA\@>/=RNO@\6X2+7^>S MJ\^KLJ!IF=[JTUL80QZ5!XRU.:93 J)3%I!++DTATZJTOL)\ M))6S!#J&7+ M[K+WW<$C^#;O3Q>$ ]U5377:G2][Z&. 2Z>G@2(&9F61())RM"$2 M6J^3 *6X=-%+'UWK&X(#$>:)^\G#\J6/&H;FR?H+S+3U?CD+%_AFMJPW%ZN, MHROZ]N=-LM'UF9H4%J--@D)G:YU@DB%8#+7!,P]6H,BN=2WX/GC'OW1JK/[' MR#6D[@;IQWZG^_CS3S2C/AXNO-&1W]=Q:\H(^XN,ID\FU? MY^K=59QY+E4 M(Z$BI:LRY(SF.B9*T9F%UACAHZSLA_".CM"DFS9@O>>A=,+ M\:V(;A?<8YA^W2$?Q?RJGU4S.TWV.>4B-M'\ZW#=F])K/477_[G9C[BN_EL485\EF9S_'"K M@(5Q)SQ*0*96\T\-.%<%@X9Y9;U@JEO)<-X/C-Y[O]J&XXBTX= M7;\-'6 -9(EM1W080VM_E3W!@3W$/8#5\P"ZZ+@IJ400HN9!!$XX@T,H*I98 M:DN$U'K0Z9@D>,)F&8L#?:3(V0C2& R8,+BJ+1GS"_K6;#VQ\-E\'BX_ MKFSM18VA+6Z:G:Q;IFL75KU-BO*T;B\.LV^OV:#'0$>AW8[0"UUQ2*7H\_P"R*P?2X UGVT$'[1F1]$ ?4T=2)FSS5 M<;U&T]8JZ&_%9N6,3,4P];VPY;$9%4=(ECZB;TV2NX#>5Z"W9B9D98NP"EQ, MJ0YDJL>MB9!%LBEDAM]T7'Z $X\]9>29% .J9C:$7 <(,%R?JR]FG^(F8>FA M#CM\(IP2/@@RD1PG$TFX.H_+>PC2"3F0[#; M(#]!VHVHR@$B(K>QO)M/$[[#^>I[$VF*,=$Z8+)HDHVQ$+76@.3ZN^3JW!_1 MF&,/@CDAVK01>,.&CH]OH]LZ%]T^_=SJT^W9(HL)CY$Q@P@Q&%5#Z?2ZQ"+( M=0DZ\8BL"#\\]UHLY;3Y.;JR&W;0O(G_;W ^,N;F[TA[^)*6LFX-_,<"R]7% M;]-"!HC2R<9(V"4KH)Q7M,.C BU8"3+(7$3K5D;[X#TA-HZFMM:=/*]=FIH% MLG@WG_U)VWJ>%&;>.OT.@.P%F'8?F&C:F>F1!6SW: MFYS;S;LU$=9X;Y(!BX;<#,$2N%I'DYG++CGN$NO63WX/$*=-K/9Z:-EYI"?P M^U-T)CP)$VRPH*449.)+4RO4 T1K0TF9.V9X8_[E9.N4P_T0GP#E#J"Z M(8K/>ASF6R^DZ!B_7MA$1J>UYG8]YD-972 J@V 8)BF-L"RT[GK=$/X)%F1,WII/<>MJX?F7K[^RL0:>_2O,\[N+]F"V6$RZE2\(9"#Q5ZR%Y\&21DL M7_J(MUY]I93PHKZ^F/^#7E0R:MZ6U?H6DU**09ER#=3%M>GK?9T''Q43+I _ MQ;H-/=P5P0G0;#P-;.'-_H'ZZ^%,V]^2S3"?B='2<5$B:*]),%8P"#YQ<$4G M6IS6UC6O3.F$[ 0(-* JMC!FOSA[R^NJ[ZPF0[QBUNH6U.]\GC+2^#L,N)X&QFD$5P09&YG#,$4+2"H)" MFT(2OI1C(7:'Y?SD_J&XL>7U:'Z?TE@$+Y'LYJ_?FL#+&.$R#VT:AY2V[T_I.\-JV+-[/5MZ_QS6P] MPR&O?

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

1Z2E8EH.5.UUJ;CJV+WSR/K9U"QIWP MW'*!I0R(H"FO\RL=LFE?F<%M;OGQKW^L(^1&%X=N]:0&RV3OLM_@(*US\[US MPXZ98_>NO5-1N1AEAF'!6CHF#TVYBZIT)>V49F4')QPH:@"F3S-Z[3)/K>[F M=CV;&:T&%HGSW3Y HSJLWJ?1=] ,5S0IO@U5V=ZS>Q.CI.W>R<_7;&NG=<.Z#28JC3 'OK2.J"0OH"KI MRRV!)\C*H>A$MV_94PF+M4-;Q9[YM(\1! M&^MD59?,J50I45'OCQ];G-0+J*2H _*G0[=3U5(D,0DX,?AC#!H4P*[IGO=, M;=8;;BW'9UK7W,;]7=Z /6,I+]U3]*2N@DODH9]+2JXKK#@+VV\JTD/$8'B% M)P&7,*!)#+2)R]X9F<=N0E7DQW/L7EE&AZ8EZ&W[H/MN#O*@FDF^67PX?4SU MUC#IGJ58U8[ 0)%VE OD%GXIW2\^2=M%GZ\(["[^8QCO6,! M=!-B%9H61N':N]1UYK;DG$[L_^GBU9>STM%J=$?UX V?GP)2R._KB'84N&>9 M\H1X]PI.#=<*5&>GF@EKO7@&3\K1276"_6RLB=@TB34RUL4OV-/?N:/WY"0Q M<*Y Y+=+;L#3^1LD\[1'WTCNSW?]>EN51CBU??RS_>Z/WS+L%GB^TCO('/EV M%HREHIV@+ZHBH"C;"CS9FG,?TF=P:C^TPO0D,'!)/#-X]N'6FX499T8S;.Y2 M[VO%W[M:EF=!Q>_B/B=>S!]59C7U"<&L]S)JE-C8<.#VUMWN7=/F&Y63DT_O M7T>_)SMDQ5Z.M_:B_E]J\W4=83,L$:!VFFMP> V7]IM;=H\,YO*'6[Q MN%!_^F;)X=+.B%"M#V6YFL[NI+'VJY\#^TY(?#?^=22C,_K6/629'UZ=6X^^ MTAN'8CCB1]&P! BS;@Z5;^%(_+L_QLH>E((FMG0OM3[HM#5R82 M*3K'V\W?*R+8U4DO"Q=K48D_D@&)\("S58-7#-2E2)@SXSN_],0_TRC4^?@[ M)@DT@-1Y3AXR0-\J\'T/$[V.T-W.O_Q;EX+DI7_>Y/Q_IW]N64=P7N.)<_"B M C,A4668W33PZMP(_-''4<=MXX@QTU*,T5NL<),J:88\^'[@\&M^3 9?=,@"+I2Z_)!W>4DRE WY6W[*&Y>:Q]F&L$6HO($#<^@RK4F M1RG.=1#_NJLXW*M):4M/Q?260\J*Y6Y#GR;W9OEC2R2_72UYW:*>&16.[P!( M[A#2D9M8OVE@#E92O;0)*CYAN./HXP\K-&4_=E[ K3L_?CK[!/7%XFC,.)HC,*30=-=.=*@W0?GBK@ZGF[_CR3[>A?]]FUM]I<^!O="3*0'*>2[>O M(UCJ_IC?NTLG=/^&+?AOWR#^SVXM8#*C=XK8AA2:Q)J#!,8ZX@C3^G:)FCL7 MV>)VRJ0Z3$?\8(;B@_2VF]^4."L\>S&(YP7VZ[&>8!K1FXWS8Y7&?P77<$R_ M?G9I95_Z],TAZ.5"A>;9+>UN7-C$H+71E P4(ZB8SJOW4,:MU0 _%.$F329U M0/N-L25(\(B>P]+]-5+*IXK#K#K-''OW!&KJ=V!W_M6L?6>]MIS\=0F_O,(K M2A+;_F=N>6O#=<0CDV84I[( &:6[5L7+HDNA ^"."VP;NB7[U#A6D_%U';%G M/BS/(-DFE8+^>"5$YE(F/ZA_(S/MX1K^#C MCP+UB5R%7LB;O!E8Z2'B28@F M$/,L'%Z(8F:F4\L)>>KQKDS!N%C_X/*%H3X%ZH=Z6^=+3TXGZN#5+B$R#EZY M]!)K _,L>ZKW?W7POB'[_]G8J. M_.7Q1'. 4K^.8#AAHLB5KO$-JKA/^4KK"+]E%<[V/DCG\DHG%94 B#W-9_L> M[ N4Z(12=^X^^L7A>A@K_##M^C>]29E[@@A(%\'%]N 5:/*J:SK\P8GX210T^I50QXQ8[.K*B?N>!^,Y&D)?4RW:S@ MG>-C$Q@*-!K2E@!*)1$!:4$3^2KU-ZEBYO4^U"=>MJ"N:LQT,GU?N/SAMRUR M87NOC7U*,B!=T!PXMTM/0Z?MFM*O$+[?'E;8&%@SF'+?6ZA!D_EOCF=3UQ&I M?S0:M* V@LE.#-\6T=PS7S5JOQJMG3;A.X5X<<8[VL5)]G#'U,%S(K]__XEC MS0S^RC'CK^;N?VF@P#]+^SORJE7/P\5D+@\@R7S?!EVXR1P7_*KVG+9YPXS\=/DJ/I KZD???IX MG#+',M\^_N0;.\]3T=^WE-\M?'Y])7:_6L;1EPB4":YY'5&!@K&:3QJXHY?N MSC:!NEYR$QG!;>C-(5O^8#>['%E'^(*^K4JWB;?+Z)G[XB.KT'Y^P\HG D(_ M6B4( Y0A,KH1Q;"S1\5 NZJ5@HB,WFF3)*PI55 M5# OG*G/U/JX0G*_F2>AGA&Q7V_F 4+*]/QY_AD,:!S1>(O%2\O^DUG3YG&\ MQP]>IDGK"%6.X_2R^*-[^-P+VJ.OAPXBO;3NOS-O,[U(M-=%3:TC8-D(<'8P M]J;#!KXF]G4(&CFG%+)723_MQ5A"&:WLZ<'T5B4#D5<%"//2BU$B3+V3'XDU MSVN??*ZU:0<$#OL-O"_\]M_T)>__CM7ROIGZ']?5=2@PHHS+X #> MO9+(MSA-]\4U0/PG&R-BF'K"0V[>:$"Q631&=!-SN4[VU_(Z8F->^P4ACJ3[ M1R?W;6,EL"G6&KQ7KNBK])RS:T&\UP!/0$1>@ TPE?N.PSO:E^6F<;39IT#= M(]DVD9<5 PG+R'-=#8'*IVK2"^LJKT>Y>Y>,G8DU4-:@>XRHSF >$AF7GRY< MQ[5B%$.SQ;@/7N(&/77?,YCHT->?E6[-F :NNCBW7_WZ._2@H(QKXN5\@D&; MN]CQ[TUC+#WFA\&KQYGMUV6[JT?O[^9K11Y>;:B,_M,>?\!-L?7WYL\N-P+&C%11QP@*1,8121L^U M9K!T: M==4ZGSY*6'9TJ W"Q/4?]U/_==G?];*+H#R+!J8QI6VRSS%J:->HHHOAP9<( M&0'FAR;Z?%*K:S-N<#XRK-'2!U$VSI[RZPBQ"\Q** 5H!T#9P'5$J_-?_>(D M5/NO"_]_="%F'YC/FT)3>E[67W[VCE#;Y(:5Z/.$@0OO!O6^+FF)OGO%]Z3[ M]F,I"P+A'^W=_W7A?_^%+IB4=40@.4E5@/%A.9ECQU8 /_6T.][I"@T-BPQ* M;RN@[K2>%K*(B[)(>%HO[<#%0[L7:D,;BGW84N"T;= %NXL9IG477[_F$U!) MB19S_"?XXG]=^%]\XUV\F588GU^EC[4KVX_+!7$X>B]ZXAM:50R&T&$X@@+/V5_QMY]Z;\M_^6HU;5@'7J6,%7\ MKKE(WJ:"S4 L>>48QW0=<5[7D2OUH,X!EE#B^6CC(U8B"3%\!^<0M!V#_XL< MBW^[N<;R\NFN([XE+I!9YHOHWR<")G3$T/8#1@EBU0^*+0.4;7OZQII*BA([ MKR#V:[\L$)[[#VQK,(BD9LC>]R-,WU1GUA']E_ A)?H_/NR!PO6#J^:V90PY ML/H=1"J/C+3-:&*+M[3^FOU>]GO_)34JRZ\XV8\&*E;A] MP( MUU;@+8;>RW;'\@H#5W&NQ5LJK/L),EE#UY+:!O>2)^ZGZE2NK.C7E#@^:M3-R]\8U>VXG09O;?-#$K L;8&M44]/2F#ZW8:U2()+P2E=-&; CXCARIH>A7,G59;\%X7JX_\-E4 M9R/*U>F]%\:)">H]RMVSB4831O_&F7F,S:VO'A0/ZH+RUZU*MOA4\A M;OFV+R.N 1$>8HRTFY/@S>9F=.:.:H5KWNO M7P]]+1.W:2;D3)*-6(F7AMA8\46-W@YW_D'@$@#68PC$-@S)+7ARGJ1'QS=C MA&QOGMR8W4 ]]<1<="$LDX1^V:_Q _^82*E$K=Q+ [77N-FYRUSUNU$667]F M^1F3X&6N7D=<(&[!#6LW]068J"K65,4[#"R]\"N;7%E9$=6]\610ZIYFS:85 MR=4KUJ*KDIYGV?:X?H#@2D--Y<<"RA9;L?Z,Y58]T;9UA%0(S%%[&L#U-LO^3Q!?PU]>FIO702^X3E9,+1K_+F3![2T;UE) M8>1C=J"J1JI/A.5&[YJKR/&%?Z\;X0YN_3HB"( 'YS(\2I>"1ZE-JI(,,XPX MM =5 0(\C6A';GX*^OA; YY(V=$3?S-$GL)@RVO)0X;O98(OO?T MT,.;IX;; <89XB\[(8[T,M3EB5]'O !+?QR-0N\FX,>2(1%>&L,Y[EL<$FL$ MBR'5@[,3S&244O&I>IRM1>%U4PWQH2\FP "/]U>SOG3*]!RY5VD2^=E9,W#! M:U1[/+^:W!8L@]W(S>:X4GOC7\KDZ>>1MJ ^5J\6>.>W**6VW%#ROO)\RZ?@ MH,#FJSB/=@79::*NID+:\TMWP^BPHZ,I0,)N=Q?&_KP0?35:BP MWM.1AE;1EN-F:TJQ_;_MGN^@'U2)Y\CFLYYQ7Q//8T!MQ\1UA!\QZD#8';.S M>!#5_,:^;-%B7X[?L>+/T1/E)WIZM.Z>5>A8N;]ZWDH'L5EL8/3$N4\R(4XFU4(7DGXM0N(PNKEO@/N" M9FW3AK+&ALNP>T&;IUB 5Q%]#L7'<;AI7)U+#;Y=7;NQ\%H07\9V R.?FO1L M=(O<(9MW!<@G'"WV65X"4K1?,*A-)W-DV!3/#Q3NGLE()7:KYV90[Q7H42Y_ M\HM>CHN]^P>K(('2DG/N+=YGMYZ.VZ%YUU"ET,WZ]S/6-NYK: MN O,V^S8Q M !/K["">2(T4,RBH?'^^?_2SXM-WA#_V^<:%SR0F4!YVJBAQ5L =3'Y(A.=O M% >_J3VXS/J#^VH=X:-G>J:O02P<[5[#(+8IHQ+*8Y1>@Z[.Y MX=]@LE)@38+QCL"=71D;?;(4+EU%=#85ZJ6^/[>D;.0DU(%A',D? ZB\$@RL MW;7< L!O0OO@ .>HA=IBCEDM$!?X/*F'I&Q_6\HZSZNN87]7I=1$^-QNHG]D M&"1JS^QMA;9]19]W\)I"-A.%0%?G]P,A*/!LCL/,TDNJ+WY*6.GIBY.S- M.4;+U15;#4,?KXP#E'4$923MES54 8L.W[J.^'W5F)5-UV6RCW*?-"C93Y-! MFZ50+N#TSL.T,4]BX+%HK^3E%5WE" 7#CWJ$1]^",Q2\LOQ%_@=[[QG55/>] MBT90:6+H("U*52F1)@I(1*6)"%::$*7WJ(@$#0F"]!(!A5<4@P*B(D1J%) M 2("(B M*"FH2 GL6.+6%$YXSY?[O_?_X7<_G''N'>,,1L8 QL[>:Z\]YS.? M9Z^YYJ0JOH :Q!0%\]7.MQ'!TZL3@>=!F]P&BQ@+EF' M-J?ZU'N7!FW^&BI_YP'BSMWLO;\^,@^W5/= ::ESKXE]L-P$W.9V8Z'QF+WF M@J]$FITUXUN/)[4&G#P9__+61__$&#V5B8F2UL,NBT>IFK^/OQE2_T!^,;Q, M9XIB)&[9IRX2J<;W";)_%9=4RW<"AU@Y+F_]SBU9AZS&;YN33?W<\TPG][ZB M8"@T"#/ M3C(?9R1=P#&WF7[,_$J*RC"YI,!(#OYX[LDA'7.CR7$*C*UXKG'8BTF;KP>(AGN606[DA]BRI,\OZX M:0T2]0;]@YT-^6O()+%S.!X,*E]I[X!0BL([!5:X<[2&\_@R\&RL(OB=ZJQ^ MI90P73;F.1K+'J=9Q$D3:0K>*;J'>GT./Y[_^XYLAF,\Z7^Z2 NBG![Z2CP M3]!3/YC&N=E_.KY/X\*H7U6HP)]+[P[LUR$?_V\3]/_OGPV:+P\%>?K!=@8E M>TPV8[QX^L*/:Y!F4B\2-/*@0J>NSTW>Y,M7@ E,Z@U+_R!*/?HXZ^N*#PVL M67VPR-0QWW-VNOE"GL,Y_O104@VR;+V*\/.[O%.B0*D$) A3;F_XB6#?FX/. MK/9JF[P -_U;:ZT1.'OC64N^%4H%XPKBP^+B+E3Z]>L5^/E.TSH=VMKO,,O^ M:91DY,MY6[BK$;>N=\<6TNFD3:OL21$P25T0T::= /YF")C'1&RFSL&DT+\[ M][AMO<=REUK1(45H;W,U>]LPF-/I>?1HE7.QMD>;G1>+O 54[/Z+SVN/8LD< M,'0>-0YI'[=R/\2\D#(ZJP?7:["5>Y)=7A]X$6+0<5Z0@Q5;0BB0H^"9.. T M/MM>K774RD,;Q YTX[98FAR??M@^VJX5H7N\Z%P%9,0#=X5]]?T^V2V'9JUE MMM\Y*%&%?4]0X<=5B7B#)'8#WX(C.5:'<7RV&+"=4_:F.3L43['Q?Z(JO3&[ M:POI=^F95Q?2I2RKU,Q3D3NP8SAU'(-AA$JSF6?W\^S#"9N:<)N^M4:W<@N MPSVM5K^HF5:R6_4L0K]_L]'S6I4TU_#.ENR71R4JK?Q-X(:M07)Z>7[\$$'5 M8\%*V:-9&M\*N))Q9T_$]14KU['W'=6)!RK^END@CMX32DMQ9/I(!*E8$3@A MDP/KN7W.8F5\V/1J)_NP@N]*6D']RXMU^T@]ARU72C+@ MU1G7L<\$[6B6WH;Y(LUM>DG?]ZMM*GNQ">,G,K(GHLC;NQX[UR#+EP"8\&[= M-_&?_]DVK9WET#L(1H/("8;9#CP981?6>KVH3"A< @T__<%.OUI_B/]@S^O6 MWO;+YRB0\)CR@Z::B;W"Q$?B YKVR]!( -:[5,_;_8VNW1X3%G<=P3=:2L)Y MD4:-I99Y"_2:Q"8:*2GUJOTIM4F[>+M MQ/778JQ$LE_<2217U<+%&= 9(VZAZ.B;B&#<376B*)+Y +\[DPYW=FS+C!0: M@:K5,P$#3Q=*=YX/>??$Q6?E8>9*\1&Q[2>F%1P]:_\J\PY@XH 2MA;/#C3D M%@*YIWS#L?L!;!GK@(TMW_B67X O]7*.X?FW#9!/#;+H!+Y2WT /HEF"/3L!(I_6^*W!M;'9L>A./])ZZ=\RHY^!WW M_IOXL"6*!A=*JW+(W&M 2PUO]S0Z *7,/S_>3%9$HWH#$&.?KGAL1IO$WH[( MY?CJ#"0F7HJPNEUP9%G&U6K ]L_%37;0Y31>(J[+T5X:UW5TFG1C>1/F*0_!-\!S28+V M%02C^IKPP0CH3-&6*>HBBP4^,"<^I0TCRIZ >(D[V5]2_&AK$"S-@* 1J[M= M',;]9Q+':()I\D-84:M34&_0$5CJ$BI_,+5D*WADK;.(ZCF9F<"3+/=ZO&GW MP+!7BL&.+T5O(SJ\9^U^P@!G*+@3CTBMM8'ZT3XR@X.ZNH$_Y$Q<_;R?P>Y^MN#YC&W@N?98BQ*^BS"K7VY MI*2+K0FI?-W'#0)2CV_3,WK8"Y)$\KLS_[*-0I]*(\WC _-TP!TU]6Z5:RBX M'P+@-$/C'Q]"=QQKH/1J)G MV_E= &2$4FN0,$:M^)D8S$L3W6(,&GNNA_I;V^J6;SO9@$,33R!(>4AW$(J_SV MUS&75/KXZ9-SQGM\_7K2/A<[!RK+GU8Q/@[9^%ZB&P>XTV=X7,9K0:MP.Z[+ M&,&H$FFW7+)\NR%CBA_$A&N#FZ4NC&%<'Q[H.PRV'_6IP M+>5Z^LEW M2O]/,EN*@Z+:(-D20 8#1D'(Y=G,]_C65;&@VS[F>#\.YUM4T6Y<+'=Y+C> M2ZSR*U8[7W3T1.I.JZ_D>E2G?QC+BQW"@0JE"SC.%%5?IZ=S=.@TVH.9GO9T MQM*ZU"NU5B]B-.KV>?5=JRME=32)#0\S_?J8P0I/%LG_L:8OA_Y#CB#G(8"+ MRJ3NLCCN9P'!TB.%ADCYZ;_7_[H+N(/EK_YWKD<]/4-A6V/B%2T%H]\WM\D^ M=]P8G$EJSTY(TN+98D5:4HX<@P,-O5(0T;!I/Z95Y8.=8%;%D2MY$CVM.<[5 M"ZJ/PTBO"E>"Q5Q-8CYG7Q70L@R\QT_KND@OBE#N('TX2^7 /(]+\" MJSE!KNTC&#/-\B9?D_N9.UY/QG+>^DY3]PIQ$^\F -. D+HU"/>TX)Y06TA= M;T&10@Z%I7FZE$K_&5;;FGP#,L\A252^=84Y!9#R3!7P"QIQ#MU1NP$7C=AT\H1RYX]B;:G>S\ M<4Q;-D]=;-"G_?W,Y$ P;MZ)_- #W%\X*936Y>UVK!.1 '7[[6@95E@W(?N! MW&LPZO'A:E#_9]NPF/OEQ[\<6WCWTH<&IG>4QADEUD3K!N.#]7 'KFS@"?Z; MSC?(9,3_HT?.?WU-Z-6'%"-?(-*H3"I?V8V%Y"L9]5[[39EN0F3-*HVV'TA@ MFB \.ZQ]CZGH["FJ&IBY^2JNN?^PYL%5B#E[(.F>(^3?LC([!44X1A6B&=$# MD^KEF6)'"%OL8 R/+><MD*TG_> MZB<-%B1&\/9CAY& CSML3KDZGQQ%GLE@3N;863Q8J[OKZ'E$IN?A8Y**)E$3W:39XU.^N9 -R.Y/9X"O",$G<%F M\U31.*&T(@^V1&^$]:#DW)GW7D<:V0[(QCFAFEIR:GR'M<9?]P0ZXH==YK,N M/U<<=*=\-KGS8PV"AS7 V;:\*WS-$5PH:D:_0W,*/&1RW>4#_])3T/PO=W&I M5_QX>_IW6W1,70S+7]_@P:RNKM3*E//7(Y6J"L3QG_]A6VTE3XF^]1T+'E-( M[B-!C4C&)^-@6%60T'G-'@_ ^A3!%!K%_]7KPGED(C-]_XXX)=L8L6*A!H.OCJ[2#==[E3;\F01^Z$23]X*YQT/7NFU':7_]WS_U#:]5Y^K#L M#KU/9CPC-)3T(68JN+LY)U& MSP_7^@:3!WU=]N14RL2ESWN27V9O;25D=5^K=T(]FQ8_^2'Y&/K'[VSE\G0U_0ZMMS]IXMTOZ%%@SV+$'VXL#_' JPDGUWVPK8( [ NZH M\'O=7AJ67YH+VJ) TC(_^62UG*/ M152*&/7OJG*:5CCG+(U[7N;\]\6?@ST6FV7J7]MD0_@38,QZ7VL<5IYOU@PZ M &-":4, ?G"T]E&! G>8:?E;M2.Z;MAJ9N#R2JQI9<&L5VD,6R__W9<_*%K^?Z-9-=Q#%OUB!N(P=AEA@=018?1<3.6", SS4(K?$T(!C.-\:HV.DS MX#+HLZYUEL,R$7D6'O$[7[W,WV6Z:JH7;3E[;(?."3FG =LD^'^Z=//_?]S& M+5, VQYR8]AR-7,X]6SIZ_Q:5I[NP42K&-^Y:WZ+K3^_K*!0,/%KE;_'/"S. MQXJ=ZHMBX:6PW00 B=_(=^0D]/K+"*7%@6W-]&V+1O8U3Y 8D[:7Q;;HWS)1 MDKZNKMFCFQ+DN]LW%_IH7&D8T!46C1S4=N7!,&:"QT(%_F9_0^Y3D!G!,6*= M80N^")OK:-,B"%AXOO(EAEU[_@PBA)2_,4U2V@UQ;]>6T;T89ZZF(!T1B9RN MYBX)RA&1JYE"?6!K=04?.V&9P_L$ BL[@.XR2[OONT/+CVMN'_7*, MIQ<$;WD&_R_2J#6LB(U(QJ]!MGR+F6M36_[E(8_.CTI7 MQYSXV&6]4IYN,6_Q)_I5A*Y4%V5>_"5XAD&@N3'GEW,>\_>X\I4(ULJ"BME>B(/6 MZ]KF"OJ,@_JM(PGWKCYQ(%1\*X?>1C">$!I^LW^+$"+L$(CD&?#1X'4&4;KV MS2M.,R'7#A'_!)%Y:&_0BSLZ(1[UFN+&SO:XOZ1!)Y M<./6"]*[IZ.$9^I':3".AN-!V(8@K^)] 5#Y>X M^'S<<,E^BL:Z*.X2Y*@1E">/31/<%&[!?OHW'\$K:PV"(M!*#H-Y+-G KQ-: MFR>[[6$V 7I5T8=7[]Z4;5OR36EQTGARJOK%TM,K[[:&92I MQ=CL_RI"Y-^P!A1?J9I;#:8R]Y%#AFD6S(Q4OA0S)[/9EK@5I'9/^MZ+NO8\ MVG=;[+A/4*&DFE[!(0?D_B/$5X5P^'+V3O$YU/3 OUW0WH:O0=1J[>)Y_L*/ MB*WM/LPRJ"OYGAN0D,+7,,W3?EIC)RM+FJFFO(GQ=-6]?4S("8QY[ADTBPN% MW9C5%]Q#A""V8M2;QI?C44H1ZN+]-9&3&J/T,Y/5\+CK:%!CW+"C-/&>^$6% M!Q8!#QTAV&BT&U=I?:T9;,R83SWU,]27 M?MZ'1H\>.WO+Z&6^,L.R\,U,5;$/C!YCOUDD \[8;>.I^X$)W;CFU621%^&+ MP-IF?UQO@!EP?YXR>3;=Z42U'\W/_,!MM]B6I=?B9E?NOJ&;%6"?/4I&&),9 MK?1&'/L ARJ4NL"!LE!L$FL-(MZE2D'*?%PJA:5BU6<"K,J^M@1&N:S6U:V* M D*V1DVJLX(3QO]K]BM\G\^_SLV.?R?S_^7'H#1^D9:+[8S M9X:[7HO* W-64+4&"<5KKD&ZK>90LK@+N, HW'0QB1#*)_[1^)@'/(?C]V&M<0MDR]'E$M'"$T9:2TR^PM[XI6[.W0)8T) M1WO"HD,3/.>UTMTOVY#YRD9"J68F3_?)DDBLX[JC-"YV'?O]X$!]UH8#F[_> MWC+9AP"NFJR45 I[1-3-:B@074ZJ%SQMA]M-6LBIJ$T,G#;NX6YP&&Y.,N'4 M"*5%T[IQ''Q:'D%OQ*Q!-/CZ: M"FY&*ITZ!\I70LJA-;5U,:LQ%>V-9?K9IZ%*]2]V+SHY;(S?F% ]^08!G""" M.X7K92PK ,1-.W<6?KK(B^-,R1DZ1*'\UK9IX%B:'2[WV"%_Y&^AG2,K>4YP M#74NK]+(W.@OCH*GS?7BE'%1'DK887M)T+04G]:^K=I[@ 7+FL :9KM)HF)K M'7NN15]*=/C2>CJ\,OY4_8Z7Z4X71XV/B,]\(^:VKS/6R(FZ)@\\01X1YC&= M@M-"([C1$\VRNBRGFNNLGZ-$4V(3N*FO:NO=R(G1'&+CD>-SEL7=3B?K_]Q7 M7/!=78^"F#%<,"R#T**"CZI=;$WH)2]?1Z5W*# M(4\89)>RT\>>^^GX5>9KP.&A&=N3WP5(CN' -R(,]7M"%&;K6(3) MPAK$*?\B-2*K7H1<^75& ]?+_UFE>6)N;XK"Y MI68>NN437T)TL8.BBR%^LE7[2ME= (KR.(9PQZC= M&162IDVNC,8]V:/['N*7B\S?)EMZQ,D'7MIQ)L$3&CN&B\)/3WH+GOZ"31'< MP;LQ\%Y9PVXI5IYS=T[81;T,U\3"32_-_^$7\:@.7S+,(8N]AVY%C2Q](:<1 M2-0;'3JB$9_"A/ V#_%,E[#JG(RT#E5X9EU[?-W>LC(O=QYFCX,R>3JDU(D4 M^C)1HI33T+!GS]/]U?S3ZVR.?R2U&R$G-! .(!IJ)WMA,ACC#_!ENU,U4-6N MJ@."3\D(FLK?TQY;'O]BWPW.&LR+S;-$:<;H[NJ4^&#IU8U0$V'5&J1Q/GD- M$N1QDTQ"4' I6"L.(5EH I92'>K'HX?N2SVD>UPR-O=#.L\?>%-J0'JIEB)5 M4&HLM1D ?8^HM\ZWU_A&4*4)H6D!!SB;ZZL'6WO' M*W7"TK^^I;GJC]T=N?UH$#/X)IOS<%87PE/)!E":0IK-[%/.[QYRP_QR(Y " MS\1: O9%84_0"\U0A3I\Y3<=CL\RVZ#UNZD6T2!/_4S:CA#OS@AM$\XJ$Q>Z M!@&-#9=7.:O625\%Q9.Z!(: P%5H8V1Q4*]_'"3R:,DR1G3 MJM*HFG#6[H.A=P\G!N_SA#[_1KPE7*_%?-+.E6@PQWM\6(T/?_ZPO73X6&-4HLJ70MO,HBL_ M?&L&7NO"7S1#DN ^'68<0JI0"PS@46%R=EZ/O_F:EL1.JC^H?TZG1D5%*/PJ M] G>7?!D9?"@\CT@BF6,4+.70Y]BC;<4U:B>^?C*0+X;$ M&I&W=;ZSD>8/"A[S8ZSY2DCAUIU "5\QCB5O3984;@ E,0SPR4N":58JFVM:L,_HI?NM(S<])3X*UQM[W<9V:UNU-F8X")[8P3]'GGSN M>_QITI6)8O7<7.SIEK:RDS+%**:\K0J[]!=A _IW%T$)L^TQ_PB8P(HZ$'9H M(D9AZ>CXE3\W;_EW4HSTHO>%Z-YRWGQO;C@#*PY6,/Q/,3-Z4!(+M/F,^%I[ M-RV_(Q_8"E%1;6'^M8I]G36[-(.4?S17Y]DKB)Z.'B($GD9N-#9;G#7Y8!K_ MI%T>*.F^YE$B M +Z)H*Y=@Z'[ MS,\90:N>A1;F-8G#/1Z@B4>6)8QVCT5<#@$H0BDFQZV7+F^OCCXZX]\"L.LJ M'NNU?E:X@[(QR$Y\E/WQR)NNZ<'![WI&L2'G;V_X[:\,) WS5<56W06/VO?S M])?(P/$U2.ZUA!Z4(D8KAVKC<=.TKQ0%URL^G6XK>3/!N/Y.$5O'IXXV=:BE MT*)ZNS9)*/5#A-MQ(XAH DV"2J@G]N&F&WMAF[ 6?/M&=^0>2-%V*QA7D'EQCL0WM;L/]MQ7[ /F M4.CRJTQ2,4RU-_Z25KL*][U1.NF!CT%.\"GSUHK8LAC\VX1E,N.QO3F@RMX/ MH+@Q_RZ.&P"G^-?&B%5@8MVW!^;NH6JK)B:C7_UD'>R'8B<:_YPTV.*$SFD9 MV;'A[D'[1N*^D37(.D+WP)I-B3QED1!5C*D&">7@<;ABY*R2G^T-_8X2O:?2 MY[8=P[K^^9RKM/6T7198_QM_,@?$5,WH0P$G838*DW276D&K7 M4 )J#K69YA@2\1P=ROT ;?:C4^/CU/L"C=/X%4;+!?XG^BYNX#HJ_UF#<%2% M,L3K /'?>J2TL3[Z"R_\,E82_&ZRR8J>;6TS?O-2N)?Z_1,-2B^NJI:\W M+([-O5AY+^&(GE=F_]\-__45M/(?IL@2AD4#8X$HH12<14P-D!C]N92$].+@ M<[=W<(K+7MBU/%!,X[>].H%+3]3J[O;8V&5=E;0&82*40105JSQF=XG!CJ2? M'+4JL]=@&YUHNF7G=79L>^&N$QFS9YW.2KS42;9=][QI<^$'S_ M\(0R&8 ,*X&OM.HT06;,O&-ZTUS['/\(Y,F$*:1O/*)-(_QFA4583 M=TGV%^7G;N,+*);2AK_P@'A18&Y>?WW#J:)REN:T$G5]0( ;! M$=N&+C:)I)NTVFJ//$+BM'"I?05$HX_-<^ G1C.K2NMZ+ M$+/?C=D_PC=\A#GR/CKOXX--I;1#/WR5$9?W5\-M^Z2;'HY7_%!7S4]&N'1L M68_Y*+;J,UD9A@=;G@E3613K9G&3;!TF'KU\U9PN%9@=9.?B-M/@:G?TI&=M M<=^^?9_Y[B)S/KI>*@@-[RVQ%^/@V72@Q'4RNO+[JJ6_![5ECW\G[W ,.L!S M\>JMBP<97U^1IS,49O'\ M[XQ7TVYO0M=M]Z[.*PSQN3JD<&MCI-$7XO2SB6D$8QE.VQU,.LCF68>_&U0* M)MVMJ,.^A"1M@B0) #=NF^ V.<*G+@87AJ,A.^UM2H?< F; P[U(,2SX5LPA@&52 M*QAZ'M=7LK?$7,217'+Z$^)]K"\4H:3TGM$OX-;SZR,UB#.V7%70BW[-KKFT^,@>CL1!V[$'O&8KC8P$=LONSE$.3::8(B%N;(,86E7D9W=Z*? M)4F[1VJ)L\79[M54\X.__6S^!/K(6U_YV'F6C85A)^BJ0A.^C*"I0P[7U>=E M;T0N82(SA0;^_'WCEOGNKTLH3SVF+04N.[?M.M!C_;=Y+ M0?G/-3IWW.(C':_K25QW)@ $XV3KF%CU?._K??,#[84B=OJ MGXF.R_7J)0,QA.1FF#JVJQ[7Y6!OONC<@U3%A4/E(DM_Y_&1V(9%35R?-OGL'$5Y1M\$!SB2#O,QF MW,7J81+!6A$&2X3O>5MO7\MR]S7:MZ6VK,#H:*==7NYN4Q\\1-'_I(U+BLN4 M^8NW+^SDD7=@@/OP-FN^LHQ0YA3/%?N!ONUVY*RFX.ZO-WPIP(-"JAAL'(U5 MO_Z2&!]>@=C9>GMJ15&^7?_=X WU& CO,54H[9L.1YFR$.<6(5U2C YL\_[\,N]T<-/1SN!KN;RD1$/V$$\#HROH0(30580# M(LB\8N17:]MS[72]-](]6J_$M6.*'D9.?G R/'CWHL.VKE-W0B4,Y\+816% MS9QSZAHD&)DAE"FB(E7M_,K/19T5:I$^*/2-'1^MO:MS[\P'4Y]S--K=L@ON M!>YZA2]/YZ9=]81>>M01#(JO]QT;Q>IA1[%6@DRL.5]Y'"/!(70]@"'E'!AT M=M1U'DIQ0;8[8,&:VN]VDYXY'>J]39.9/+/#8P^X7_3E$O .[_@WA(J)B)]X M@ ;S/3@%L(V)Z/$_W'V->C,>+K]@$^$:76#W^P'G:U3PK;>C1V[Y]5]9#IH] M6K&Y'-KZA)C,%XGE36\G[0]@>V\)I^D-AGS%>99UCZSUT=%5E/WV!9+OZ_1< M.\L)=YU/OL])[FTG7I[)JI*G]:U!VG:U4W6?.U<)*A ,$F&3_69L)P**8SS" M:H [YN J((QES;WL?6[:/2BRU&X27Q](C@C[H;MSR3CZ?:]-!GYC\ML>O0;9@#:(6'H$R&168_;K5FZZLN1P$R3!+?$*>H"[S@&+RZ M<*FV[FX5B'.+:/\GI*/]^V/TYP?NW3MUTB/4=-MV;]]Z\,!H]I\:[GHWMG\P M>\'?'%' 618Q$*].&IX"ST9*Z/H18&BC@+;\+Z>.HWOJ(XN]]O!)Q1[;SOX0 MJW@: E6/=9_"2OQ;#_$X> ,88%:S]9F$:9/5#F6^%V=O5C4ZH>>LO76VOYM[ MXSA==+=IF^N/W2;]PR8='D5*M05 M9DKNK*V_<2I E6>-G8618+THT 1&A4_/]] ;5'(>.I)M]!6>#0,\X9D#S-5,K(W@]AHD MY#HA.T ;]'E"CYC=_4%$H>"IKE%+2\J?_%=^.?PL)8R\3T^ M07>TMLKLFGGE<^=.IL2SD?_KZC+R/@Q 0D%X!@4/ZB,I6?9R_!VOQOB.G.$> MW\08Q2.WLLX#RULE_9W^./ #DQEOG8[+*7B VW%\5@;3:X6N^?U+MV?]&+"5-&GJ$+E,4P< M ZDP%65C6A^DO%)4LY 0<:"9W?1$>_^C BD?^=OI6RI3)'7:D4+I>X_"9T51 M+R4,^[XT]'7E#-(/EM*QLV3Y]T7CK*_.5>?Z-=CGG;[$>YWZ8)ZRYR#Q'1XT MS.@C9R.!0PB:LX@PBZ"3]KO/ZQIQF( U7!SZ'J[Z>T-PR>'VHK2\ M8PW)4&FBSD":ZV>Y9&S5M'"2T/"U@G-C#1(V *6)=Y]"KU@JN#*F?KTY_C@3 M>3XN6F-0JNW+1Z_8ZY./"B']5C^.9X5%K$&@F1S[A]QPOBA&A)9)(VS/?VH4 M*LB>8P^?"[M_-H.O5$WM@#>"\B$\6XS!1%4]9[)/%%[%P #N!R'O>/[B?KT/ MS58KL@_NROYZ'QTTF*Z/P'A*-/$MP'O &F0.GMQ$SD9(MR,O$,$$OV95F^/U MC\])G6_-++36W5JQ'1\H^01KC D O0#=3IN,7D0>0MX2*8U&'6%6-=IRT(Y\\%#SWZ%;H>XBI'WB2C>+$$9+.)Z@EF<.:$D@>/G\R#I% .1 M^WAL\12<_(VBP\)7FY@]B^-:HZO5\Y&B1(O7(L$%UPF>B M&*M=;L1L;3D0RG'@>W!4F>/_A!5^GUF>/6>3G&L44FMA892&V_78Y^BR\^X- MO[QN(!B5N!?XGK*K4"FT&[<*R"W]].E7514A@Q@/;8CT,O]T[(7?G[,)&PSO M!#B?V?KD%''?QCQ$GD@#DI;=>);H?+@D=@31C*?0Q1:+'J*-[?Q9 _XV/J$Q9MN_M*_K8^)M.!KKV]?8I0B@0#X%HP=6 HLK2+K/$=RN@?CIS\>X_0 M*>,Q[8>9$\WM:2NL<%?C]T.00A71CQA;0\5$37P0P>@H;AG#TG' \>E0DO,% MGDO?C;L..]S[2EW^:E5\5]K _2WR+I$ARG!PO5>%8J ?+XJ_:_+73(M,V,,% MI)SE M%4:I_V.1FS@N_H/Z=_!/0'P'E7L5VP1AQ?"<$PJ :)1\@J)K3L"O;RDBSFC,9;"5>1H@A2'! MWL6ZEX?KPXG9X>(82WG8[Z'%UWEJ'S2N%CO]J2S8%I9QZ7/EB6+]'(4-?U7G MR%ED:(>:WT("4J[]PH4*:NU22ZGIKY]?.KKKK L_U6;!CR UXF^H\GT+N[/N+KL5CSNFL MD#-=YDLJ[;>D"6TXQGURBV$Z&46>PC.I[ AFA31,%;R\JSG*1<,HY*G3,>L6 M2H?NJ_S@C=_/.*P>U+[!*9DC=Z&F9[KP',4Y:B\*"B(.NXY"V1[RBR.^AWX@ MI*0M3B5H0=/(,N1P.)0./F3G#6JKM98M-QME M2LR6&OG=R?>I4/MZY.R)CS^0XNNUWT43)(KE9B+TF!".D9LF^\Y%EL*7QVL= M&; 4VJ:I'R:6$>JL[QKLXVK#,O%F8S_FY[ #1=J''MWXB>*KXKD71[#[UT\C MU,,<'"MUMZ#"I#"V\>LOSDS'*O4O9$URS!ID:HD;-!'3;LMS$G[0W@CH__IF\':R=]:P96QV?H/K]YZ5-F!; M'&G?QP-1[T3/&(]H@6>14030H+H;22-2C6!\/6U=@'\+G>T2)-D8N=?KE/>Y M07FT@][$\/83W5D03>D_,.'6FY,8*Z:L#->10\JQLG5'>(PBHJ!0_TCULL\Y MFE>+WS3T&^?/IQU\^BJ+L:E_X2 ,C=802F_B2?./<6JK*:B,-4@+@J*%[+F6 MCFALDH%I3KUFSQZ7N ,I&2PIP-]67_BWMS?-ED%:Q@,>2,$CT=]X343,Z M<';_KZ%(O_TKFQKLGDIC5S8FGFLJU-GD&.BVU>B'GW#K)L%+!*.4W.R\+%&' M'<+)"(U ZSF)WE6E@"D' $>!08G,B?A,J\>MF=0X<=^2*/\G>A][BZZMX MG MHK[A<^G-JCUP$8'CRU.ZR2J(6(\;ZJN]M7'=9%E+/WAVL4U\7]G%=#XE!F4T M^_KCP+SN.1?YS]G[I^K#IDG&$/LW0$EV^X$YHO3" VL@OT:+6_1\ :!'E+R8 M#^EM?Z.7[_A&8DMN9=A$DU&WO=EZ L@6X2:^(A@S)_#JMBFN(/*]VD:;B!E8 MR'N:0<=XO-'4QJ?1>;K.2I<>+68<*J)HA>/T3K]1$#Z[R-UF:'(7?C*4B M6E"=Z2"JEN^1$@=0>]7#LB9]WCEGE)QF*.CRD*1NA,D\-UG@3Q'D?L-O/NDG[-)Q+?ATU=QV2UTF?AM/X=5 M_$DYC)'1I=,IRL5S[F,)%+/V5VG^*N["(SI.WXO/%N@=@?P]5-'>WC3&UB>3 M6_,EM^=5ED;Z3Q8!LT'MPYSN!@@.-$Y9+.'%<#2",W0^PXS^=I+"@ MF29\"R9L8U>4W,0OJ(*[Q<%2\YY1R>*D;\O^E?+&+J&FNG^>X;:L=UC_M2J+ M_32[WA\4*_P :[POE.0@>U!; J)PT/@R:$^%W^@ORR:?X-:F4F3CS.OFP4M' MWGD%]3E W(H].[6)O'U"VAJD@&CS>G*3;?:2:J_W]TZ,DB-/-(1/&JFYUP?7&!_'R#Q5>XQ M"7D(1HDZGJ^T!NG&-9;D-[O#*2.+\B"E2^7DE$%%^;EI%\XG$\HY#P5+E[=J M37Z?IW5(=\K>EL,B3B )9'D^#GK_8P_U#;HQ_*<_"?\VQ=7@@ZCA'6"]N( M??= 'HB9S,4:\IVM\4P/2>]9Y^BLB BUPB7/UZ^*C"+"Y'9663T0IU4#=@P?CC#,.1;@O6J&1F9=E:! M\94??A*4%VSO!LR[OY;O'K6+SM=+]PXL.&0!>?O2)- M]A'?/%3:K/#*AJ*#L$P'6Y\'$<9"?6')SFJ6/[2]8@2GP)1E+@&L3] MU>0.3K1Z_&2687U@2?7AEO!@U07-'#V'+X53[GK1]8FI6ZZL\[]V8<]O N"^ M1 !WQQ#RB?H@,J)2H^96RV&>DQ'Q0 RYT9=^567Y8T.G7$OW8"UY0.^\THA>@W#-)X2JWM@QQ M2=BY2[=>^*ZB-,WQ;3D#9L]G>VJ$7E"HZ M%4O#J(RUOI(.?( >Z%O49%A$+(D8Y&F<&GAX/4]QC"O!F5S&U:$O\U@=J::- M3 ^EJ-G=C6Y>)!+)8M:W]:#^&L2#=";D^I6PD[V2M_M8HC%\S^8,*PH_8(U& M<3$Q$EP$\+MKF!W^RV/3,"O/K_<$^H8NWK$A_XM)\H/-.9<*?9#1NY]CNI1Z M;LM;7=?Z;S?38$3,=!.X!KF]%_N>P/7XN@89&?'BI"&G5_FJRL@C-T[B MR5%0<&="*CD,D4:6)S/E.="<=@3KGJQA3]L7Y/(?C_1?>Q6^*FB>WP7;)5$J M+"&O-[O8X?P_FUTHKD&^OWLMSCTG,B+I]=+_Y,#5?)HJ&\ZSQ+[% 7GH&0HR M4M@S(5)V-I,H^R%NCD],J&!H_.>+CF]A=^R#]WTJ2(AX$VZ2,NL05P3 M$*#9) +\A26*3K=C#1((RX,!'O@IV@ W3B2X)X4J\,R8=@<: MM-J<%Q0E"**T3%HH(5O;/A^:TDI'/R>#P6N0Z3!A7@US#2*4;T'P(Y/MKPEJ MA'9\A*".'#PL(QSP(D-_WL5+IH:E3MS>'+RIS&7CK@0*2Y]=BZF;'ON0ZDP!;CQV]J\[LT%9$>44 &S:QSC%3'W^A2S)*,N?NB MO+'5O3P5B;:6T^^Z-'NMR\_=ASB97SK]"YZ,$VLF*!$TEV";VO43:IO?GMM; M'\<<\#'-[<]K2*S=ED2)9#86W!#1IB+M/8(.>WDA#;&W1A9&E$S61CWNU_2M93<_F/D4FOC99TOVS#(S?VHEYW-B5#_& M@3,[V8D$7(=!0R*;";P?F/.0P [9[QF5Z'.#RSYMC='9Q=[4/FQ O^4.T9=6 M?*6]*#=S)'ERQ9_41;]Y-<#J U;?AV\,? [0G3#95$GC]+GS*_N7#FK+ *>$TF6\;<()LD*[!4#G6H,UE?P3XU8NVCQ? B5&E\HL MVWGHW:37NZ UB%/"K<-B?AW3 :X9 RW[?>R]14YQ%!,+N@(4H32*A^*OUP_J MD;4XRJG.(H=K7"=N11]?9,@ZGR(5]]_W0$4C$HV/)K_YOOMVGGW"[O;);R7= M]!3$9OO-"];JT"Z/FP&J0%+>EZZ7;0U RXV8ZEZ[ZN?YMW0VH[B90^%= *_S M;(5.2K',Y#O&A[:4V/"O11_B1L7O]_:]V!&T?;M<)2.H"G*9T$SM98=Q M,8+;'8:8Z\#7,E3B$U"7N=),G/+U3_WB8566.[D3WY3:U'1>4^ZBA]5W,OL M$P[JPODJ15P]V#:L%3C6V8I/JP!^?/)%"W[E1&D%=3T/FEW\T2AEHITWPA)9ZF>)&I4B-4]KTRI ME'/8/BDUAYS6X)X [\RA.PPP3H)_.K2CA'HWQAF&OOQ&IRO<0(X-4?*;D+(H9OX,H+R*\1,&ZL\07M-TE,0=JSMI4H= MQSY8#FIE<+#S9G/^WC7(V63\!T(*'?"!3;EQFU\#B'1$,#*;ANM!J:"[%VGA M&,.JRA3>X7I]=_;*HRKHE,JLN.'?3X]\,"\]&X^^^ONR5_'(^? /#_VKI#GX M8]>\=@$##%@G,86DGD?O(J?,*@"W6]N[_7T]MH"7)[J(P=LH@^?SCN7U?VE( MM-P ("EX1?15#]"F@J6"UWX5'DM=Q@7%QJ1UK_Y()\7LPF][Q]2H82\UI8Z5 M_L$+I6HY/*%4%,\ B?$6I" 8=61IK"K:CT5*QAI&_;Z(+F%EW(@QU#8:647I MMZ6LV/:S/[YUN=M2L=?7X.;CU;NGN/8S7!P(#6,1P>.U]E*@DTET@$;7DIZ);)SLA.=@=XS9^7/\& FI?(^:\.=;\4_! M#,I>$DEEHU8G16^DT7$8L4OSQT%8,0'P)L@+W[5Z\166&-:9]IOYJH"(".(W M1-*;D6FK?-UR[V^>X07G%KH7V9,G>0J.DBVJ\G!:2T.&_-$\@TGCFB42(LLP_\\&O)-J%H+K9RY/GD[JH[M=OS7/J_^8\XK/@XGS1:'=;@ M:X"'.7M79-8@63!IOC5K&SO(;,:]+OSJ;Y2"8N&S$*?=4O-BC5:PZ7MHA _[5H M#&^PX_0-:Q 44<,/A+J _2PM:RIRBUT"R_S]0FG5B^;O(!.AW+_'$$,LP>DBF!>];#,PO*$T&[D M9UM:D><#HT1=P:_,0J=3NKM\SKY+A(1S+82Y&#=0!K"8<[ISH9P?",*9"!7O MAM^Z+9+W>T+%1UNOVQJ9V+PUL?5HRI9!ZW@S4M2Z M*\,K-IP1'0:!7-P$P:+XDH(Z'",9T1Q,AX8*BA"A]%1[ZW^3]?MP6T"= >:9 MF[ZS:?L*M*_/$'[NW2L3G.+Z8,X6=RFSU E-^4-E7^*9H559L!X"'@>H>L*L))N]6U>=K^&&YZH^NJLJ"1N67 )/!Z'S"VS!J_;:OOXNY6IEM%),Y_ M-2RM8!&F/;C^G.'L<@X]CQQ*ARRI?ZD=>=4R$8^4\#GG3]D?TW>FU"6G9D5O M16+_O.6&86PG3,->3S@*JS?L)N,1:EA8=5J[!XLN'O'W >FAHWBO5M/W[N=7 MG?Z$S\5JG<@*\9)VW5[*_RUXQ3_P#-=E@F"T8;>)GG4'>O@0^1X#WXL2A]_H M, 8?=;]UN\$T>O_".2;^ ME/BH.$7'N)A+U"IK(P5&XC%L8KPQN,> XGU$W MB/+UT?,8S(M M&L7HY?2MN"#ZM"[C=PZ2*N)\B!!RAKW*9+#LURBL)N"8EC<3^R9Z:,ON^?W[ MY^^7KL;G:;AP5(KBRL'4HRT=]>TW'K:OXW V>NI"PNWX.;= MZ?C7:9VK.T)N/]H5U.O(VP-2NB_CNH;(3>0,78Y)#G( L.A>T"K]M.-.*5R_ MRO-5_TZ]W!>+XBG7)F?ITM@-?&E0/B3A,1\*FC#AF_WH;_4[2$!UALF5SR^Q MV$256Y\MS'.]Q/!_> M^\,UG^:ZCM]Y7M=Y_G[G>?VO\^].VXPW%=^%\#FB#1IID:DUS;/ZNY"9/TNV M8_ETBA?#?0D5]\LGUE"\?>C\,4$C$]'CR?VXF,*5C1".(%^GD?KPLPRGK+D) MRN9Z7A09*P.VCA!"@JB9?U%I-=L[X8R)_B!CM]?R?I,7%'D?.MG2RN@>8#LM MFBTT7,8>*X:STO3A4DPI'#VZ@$)OJ [(_CX=H?=#W:7PMT_ L9\9C:X\.LQO MFO.X+]TC#_[AI$W*8.]H ENF#8#WC'+Y=2F,:>K1W6&]?]P,(EXM+Z^G25]S M*[[$B>Y(++$#WDSJA260 -O3A-N$.5C?']^8SA"&\1V7Q73:U5ZV>E?6QP?R MCNQO&UKE-G+BW.>-J<$.A48&N6E@,G6P&R>-&<$#?K[]?FQ5_R80S?P++ JB MX@1088[GD2'^S]U1!1<#K"_8Q]70IYY_/R@OH&4M%XCY@1JD![">L%50WT:I MV#YHC+G@--JV,I ]2I-IHKB:5*^Y)VM\'54+4O%JE;O5TAD&E%&0?;0[! FV MPG=E%1D+=I_^@H(0H6ESGN!;6-L4\?FCSM,R,UX(FI-X>>^RVO61,_-L@>M4 M),?E?/'A"(7&U?L77:[^D"$%CR^E_:'RR[##,]AL_KYG9TIB-EYY;'[BQJ,2[E"8U4$)<'> Z'+VC. M=&$&@[.MN2V]+4_4D1HC8,)LQ54/P0)*ZV. <;X56 >&A>=X%"X>\U$+E?"V MC-'.OYYN0+8477KRK6F;% OCW@X2N@!T90,!/?EO?).0%BM)VVM(T7FK_7FA M>JFU9=>$>/!ZZ.]2S,%B/^ZMEU )BQQ B$3?J-E MV+(3,6MEFUB;V/,[SN)S4+GW_).? BI&2A&OS$0PB7=(T$[>^KU125T=Y$R5 M'9>Q_+-E/W;N!UYQOY$L%R)<4T']O3^NR86GLV]RCZF;#3!YF@!D4#W MED]3AX"%EPL"[T_X;%V(WLGA2($F_CMDC,I/+A M%F"G7SL)+W>O%NG0.ETWM?!/I@QC.%_IEN0QY7#1]QKRLH>N/SMA]8@7A4TT ME[.CP$ U$E.JE]X8U9\<:VX ;@T4#O8://E]]T>AI[]G_)68 ]S27\:SQ=GZ MF7(^SC:L6/ IXS1[%*&H[RH2N:3=C=V/>L/@B(.'[BNI3&U_K";>A!"^-3!@ M'O7;^ENK*0*8H(SV*2E 15$[W0I'VBM=AAI=9N[\N69XLN='Q?4\M2LOSS4= M/>B]S^H^A)G&,:(5+.AMQ!(K8-#@6]-!\EIL!:9NTM@4Q?[I<26=IY)\WWS$ MW_V5=<9R]#RBP053ZEE]X^S+U<@&M[DO/8WS;O/OE(V\;@J^>47Y.XY?-4XD M9 +S@=3TX&,!LO0+9G21/V=HW/]P2Q-6T/E1:9*_\I!'L^>-20T^W;;@T=EF1KU4#<0T],#%WE0?]4NISNC7DNS M_-KO5+[GJ&]=EVF^3(5^3DP=!]03[\$/H ;90JK[B\K]YM#3[9ED(D!18 V.A[4I\)F=R%+R.2?^D@!5+V]@3&[ M(*AZX8;^0I.8BZI9>WI!V6PV?&W%=6V_!"-#DM^D]9@$UMQ1.1>O4H@X^$M]DQI#*D?(6*^ MURRP:H$FWZ^/.;'AD]YS/[_Z15Z1W<-'?5,] G$)61;B;S:X3-^]V>QF_=R% MI+AAR8FP;2_X[UPT1[0-&_\#G86R^;$<_49DQ9OK$AEG,._Q34&#"::N^_%F M:3\>@CL>'4ZMC[C4KIR]]^"$[HN>)\8&\M))\M=B]AH$_\^:#?D$+J(CLYCX0B4@)$CX+[\Q7>\<^=OG>3>C>"HXG MG#OK@6JBOP/JDPEW"+.2?=P]\.8VXBRVF2V'JOL\=6324=?[@1"R,GD76F7H Z&=MGYL66@,&8BL#SCJHH6]GY%ISHO+M=0U@B246F M^WWWQ_T!%1/-&W"K"?)X>)%<$"?7W BJK7TF<$"G2K#JY6O!$@CD .0H-WD4 M5+'?L(BJYEAOP/1D.+.G\@T0HO4^8,62'9(J\ORYQYR2Z/*=JV9?@H_\7A(X M&-+0V*L8I5H$?Q6Y/O8",P470F+)I9+LSUA)M'8U$SN)2_<99XI3->1J [>? M.XCB;A,W;B,-1 Q,+N1%WKSD:W*MR7?#+)*"[-66\ILV/T S[*WE.GX? MYI/Q83P.+11-5;K"K=^6\F2HS6"B.>! R'#HV,)#@SH*[[/C7P/+G\&%WW24+@)26H$+JF[/X^92GL4^U_8C)"]4G(UTG M];[:B,_<'?&8KF6/()KPJ?>B\6(H'!D:=T^(\;XP8'B>)#@[?.J7SK!)AZ7S MHV(;]2-UX#P9282GWN?=3,2H,I6!MI13;RV_:NF+&+H"K):%MY/#$A<:;0Y4 M#:VK9IT2[G[8\'+[,H3OJ]/Z"X8B4YV5P;&,RL *<$P]V3(=3\EJ!U[N0AQ8 M)9W2S^X$19:!P=^;ARL'7,-.2-K>5/A-&*@.)VZ"AQ$Q&)V95<'[+BM-B\5!4"'6HT]07TR/B^(/=[G!R#X.O4K$?4: @NKIG#6M\\LA0X MQ#V4,7_VUIF/1N;-7+^L-DPX^<85T!ZHGZGLPS8>(+6,]L=2HDP/G!KAMIC6 M9_"-URB,ZP>9OE>8>?'K9KX<3' H1(9+*6" 0$[#-SMQV)]_5-1]T89*+LI1#HB*JI]XX-JKK##= M"==.^(<$O;&X>G7^M^1J043JX$."A$ M)B1LVUFH>MNR5'OS6R>.O^H]BOITDN>>_+>8O;P;'\E668,W):]/D@ ;PER= M'/HP#4?N:G\Q1RRY$\:/2]EV+9JMVVAQ-\+O^S79_,NBRW3]5P'J"EG9B2WD M10Z @QJD060\%OB+%&-(0R5?!%;Z I *S/LTK=RCA<,]+M>;)><'_4.,?63H M7[7J3*L#?S^^$'']?.>#648@I@?>N,.44B?7;G9CY_"4S,J44]%YFCZ1L4KT M/#CP9W;HAT@JT6A5J_/.SL=.?C.!AV@ +H_$8%93)7]/;T?U"414!+F@G MQXF84.[^XXVO1JM*1!6I?!L/ %FBR_7'8UT'5SW4I_5+FWJ*)8&!:MYO%?67 MK(:5:JQW(;H[447BYV++\Y8RY0>)>'&F:QU[$ :$1B9Q:B_HW*4;X4@N9B0+ M/]&]*$/3_TQBVH:/BKDNGH^85AXM#@Y'@UY:RX&5!0_IL>(WMV%W,XTW%HK7*3M0GIQR7AIIC8\SOP8 M"FI!TTH//_MF7)^EI3CL_"K4T$*WT0"JJL()6C =(+$5M-FB9T!W&HXBO>TT MA^C>A<3^*4=(M-0:GSW<*6N@J%;_QV> QU41^#!Y(D%[4ZPW/>+8PQ%-T<&G8Z\"CX&2OFT# WI9GZ$.@ M/;!$Y*,4](XF*2M]0AMXY>A1-F0OQ$WUE648_Q97&4PZ(-Z6/=6XO3E;20\= M6WJ3;@URD8NN=;483%<'45Q/R8KE.^J)EQ).,*K-$""8 2Q1"NU., MX.0$CF[U8]K>##K!M*&)__QI,1=U5S5J7,/$5U!0]Y7Z2XZ81@_3HON->=N8 M"KR *L*X1M=EM5CO4]?""6W">QU4VO*[/)N[9NGS-SJ/W6[X$FB2>S\%8-BK&A&7G?KQ@#MR9HEJU4^8B9BGWV-"BG@#J\VT(;&^N-NN4C%YFF7SB#YTRUQ'X;& MW:#9CA8\3/(![7BV9@)F491V[(OWB.*V&/!10U/>FYIF&">.I MRI2B\W;55V1V,)<>(>])WHV/>L>#&5OD-B(LALV7OT2-[$7.5O9V[9M&6\CG MND9K"\W<^*&G$YC7GO-)7,-['R:2+[YP$7P*)%,,!T9%8+S,VR""0I+UVSB: MW8R7_/X0,2\+B5F\]OW]0X$5^>5/?"OY>11-D\%="(" 9\):=R$QZZ5373"T M%JL@MT?Y]-M&GV@[1)^$N_[6:K&OSA!M=E \#X,\EG&<++.O$X+6ILDR):UZ M"!S"0T)!5>A&0!6*0);MQZ<4'DZ<7A^CFEVXTQJFY/CUO%59DYY-T#U)'6T9 MT^]S1_S=IXZD$7R8.@"CVT, 2(!#T?+D3)CU)TVRW\%/VV\--*)/4P-_6B3I M\TLM+W/%Y[JM)!!\-F?QWU)%3)M$TYO,QH^ M<47,) %Y_@:G ![83,#OPY*7\'.C9T$BC=L.H)O[.T!/6&9!.88E,[D)\.3[[0TJ='Y@;)<+Y%]:T[[9!JQ=0 MP5.VS_-"6L]K6+J]ZN[U5=W7LFD.0PE=ICVM[ O@<)6_))C4\WDC\-YJ\TPA M?6[_>[^R)W7;YW/S>+AS^R$8+0X1&YN;8XG:6&^\'-J'%<]AJ#J"8)<:^-GV=MBOBT!B89K$;QEJ-;@0Y_ACEC/ M*//]),S'/\@4^&WL[(XU&$06<:3_V.HQ/I).J6KVJP_TN*(ZV=5_0$VV'U23:@E+M.KLN&O;( MN]# +VNO\.N 0.3V_=\!\7LOO1>Q1%VXOS9XK*UGE!N4I0>S7L ICB245Y^L M[)_\TI5%*_KW\AC+!NRS-[E)O[N"-;;BV8<,.2<^WX6,NX^RA>^-LLT0A,G+ M?+\XJH2/B^,0\5W('3BH7MF_GU7Q#TEA#2;!Y%HR22G<&BRH5]MQN5WUCGMV ML$\B5)"3X&? :D-F%B*#5*?/QT@5] MFMY?^ND=-&))O-]/?;A?];?'>M,GD>-4/YQAY M-4?M#0&&+.8C%K@&!=4Q3QEF:(\D$?O>KL- %CZR-.!/F%JN?T'<9[O6,G_U M@]:)C2Q$4=N!WJ*E3B8C3 MY>+!RXN[D+5+[Q54?B\\BGC/F'R(OPNP\\@D\-C*QMH2(;5X'^OY/99B+ZGI MS2ZD1X!21$B^_\\S.X..*"FG^U]['Q]Z%!4 H]\K/.G &([NEHNS>- >1<&+ M_)!M_!')AC44?XN6]#'KFTH9/=R@]L@YY7U&CLWY ?N_^@$G(C2.\V"U..N3 MDA'\:.T2A&WPS?PMBT^:M3ZH= VYX;ZTO_*OFX3]!P?:8(F.G>)[&X:&_N]6 MP@@)<(Q@E9BZ4H,,K],.X$6[-#GP?%_.NWFX^47JF&8/*[@2!;(U/P??-A)A MO*M-.M-=_TE[+H MZ P(T6^ !,#>#BRB:?>V*D/ 09GZ@$IP+F#;X"3)0NG) MU*7ILYWE;7EJQ7"=KBN;T ]E1G22(EH&-*)I7TYW!'% 4:_YP3=MR>_C5EP_ M!?UN"4I89AG^""L#G>C/ MI[LT5^^"7C9@9+0"QSI7X9J->V$A_L$1OT-*M,T6/V<^\Y<(I5IH?,<#=_%] MT'TH$_KVWL2!8>JF_*J+RPW,)Z$7B/=5/\2[6UO]0RKY7F<_C+_#TQ)J MJL!2 %T9)S ?$-SWY@E2:"G6DTX^,LO^\KF"/[C$SD,^E:.AY.W5#4SA^+,.ZG7EG,+/K -H4+*BT*$=; ( M#QDK>4/DV#T[.PG_0S%OGR12X[2/?)9K_Q#Q(D.8:TN=*6Y"Y8O%D@LY8N'* MZ)PBFS^>"DV=F@ Q<#&K)7C_9%(X0(73U4_0P'%>?RQZZ%!/[T% MN9W6U!,Z9Z^;+/\),QMGOV! MU(0N;)@NYVAEL>F1$'K26W.I)MW'D<%;AK^C%CJ>SGZ,*H&.$&9(1&U.\& X MC\&3KR(.2K6H9I M7UOZ;6T^^WY[L"AYD=0)A=I^^.KYUI: M7Y0%&.A\F5OH6;AB7<[K;E\J#[#O?*'Y2$S04?$;3FJ7*+ M'>_2X-22Q

X8C"7GF$\"CW<'^BV+F6],5RIFQ+ M,@R?%RF<7<@Z#PS45ZW-27?55J-<&!:O']L4V$Y6Q*[$)*D*3_T:EG\GK^C^ M6O6T$3=W/Y9C5C=6.2 '+!J$\S!5:WYNU4CN4-,F2_ M/83K#$P82WS0!<<2]3!J' [7,U=#V2Y!^W8AR8N:-.4R2E$51GK5Q;':OVH- M2C7,R#1;]THLOFE!3/_@-V!:2_DX?A8@S6E<8)6QY;%$_)N")'C0TTML&&P0 MH(XK?F=:Z G-E.9ZI*Q.-?U.QA;G!P4HJJ(I#ZO10P'_A/4@N-A\*+YK"J18 MC#!XU>(MHB.R'(R8FW,@PC"G^$K-&)_WAM/H@D$T@RDA6"H,&@X7(P8M+YPDNBS0%O#@59,:6PB"F,, K'%MCKY:ITYMMN)L"%?;,&J:+U MMX6GYO2[6I[[TU_=R5D?_2E^Q>T=ZFJ#U=5#9N)9%%)?-D?E@H->2^.%]7/#QRY!YM!I*& M.4@4V1*841(06CF(8I]BGIE ZVMGF.\'+VGSS_]HVV?4,MNW"IU=+V/LA,GK M5@N?+;]5(WUI B?(2L:8[*TNWX5X[4+F;.DI>XF%7$<29"N D501W !>#%7? M4VP(/B47V:9T.I3L#%1SY[S*87F.* MK095K=],-U=YI]M._0R?*?[YT9"Q*O6A8LGQIU1,]!2\CS"[0U8?R#Q_Z3-; M!RT.)*=K;4>2RA=0!;V.;;^<#<+>R!0;Z#R)"7U= AWBJ$[[M"YYM"3(R]#% M$FT(7O6SQA.],"YS";8_#"O2Q8.&@GJE'B@$)TZ)]8*HJQBBU M-L2MSHB-J-U5JPLM=E;UL8MB"?<@%52"/)'B?3:,PI MX,]I-H_EGS;C+GMAIEL>49^_"_&&RZ,LE]@B+UDM=;5,>T\UH25D"NU$:D1B MY"657U)B(8]-^V99&VL9WPA>>U^[%M&1X\(K-GM=B@!Z461;.P.>>&)B)+5K M.RAEX*O9)'!'GY5/N'VA.9J']83)?S#?(L?:*N%$JTG5S1JKO+@SD1#ZEP=V M$,PU+-&YTXJR2B"/V4-&1-O]UB*!)DJ&3&"!('K5H?D9[3GTPP_5AWD'<)I- M.W;W"S9P2Q&L?"R9 H]!M*[TNP?+F8LP;4'-,(!D3ZN9P*V/J#I'=Z2#,OY- MC8?"NA:\LE.@[;_G)<7_2!KN-5>^^-_UBX0U[<2I-;84V@0%DGKR;Q_U?G@P M^[,PRM'S@&>*O(FL&>\=!!,&VKQ$FV$3"O$]FZ)NX!7KC%#4K0<2"]OTUFY;;ZAGRDZ6=L&Y.Y6H3Z.I^?45 M0VIVNA.76VW==3_ZBVTX^Q9L\'IZO>[_]DZJZDC[Z,SBC]$!$N"! (]6QJ'5 MEUQ=[5RO \B8VO"U1UIG44?LH5$2UJ67;)*4-;81E *>N"),%ZT M;I<0:,AYXA8EQG+.J_B;RX_=?-7J='!?SU'QRQ*0%:7$*\#..@M0[/%02>]G M2X&'*4IZCK$+E,^<:!1QZ0U1/'F\W]NZ=]_YDVK*Y\478^!F!/(\'F?.#TIS MJ(A"8*5A_4;%5C&\8"+#"%6$F,"H?#=7FU1ISA]8=#^WXH"[C#Q995#3=E$F MY)?AW]9J8O8?X2)8G_H$-B^'4_RQ?IOB[)G+8$$O%LI69UZ>,GW 48$LG2Y2 MQ:S;#QDQOU#-CMA6(]_6MD?50?N%:FI1G6EDZD^9D5]N'\M9G1R$%E.E0[1440G9[<J@%^&F+]:PEF:F\I-')VP ?46S(SZ8^;("X:S-Y;0D@Z]]UJ MRNX'XAGFXJK-F<$$/__'<VX7XX%/@BG!O1>2=&WA45;N<-E@@=%ATI&12.S&$L^ M;4RIZ:NTBE&F9#(9MD[PK$#+MP,R3RD@W#_(B6K*=WDB<.3EV0?'_:OE"P-H M^D[G"F/;, MJ3FKQ,!#?J>&;_7&'<[>;!&.CV=5SLO5UU3K$3U$@='>^OVK<&BG=%EOI=^< MS./]^')_^EK*1I!GIE?:8:4\A^M6KVJ-_^N9L=S_U>:+A"82J#W(+&VB)^Q" M&K&&[*PT0L9Q"(O]GV?LU7?#_O,POO_VEIG_/Q__WH+_\>._=PN,.53.\331 M$Z.()2ISM%,)MMFI#Y<*X[LW*D=<4@K=A=BUMG[:I,1N+&JZ1-DV_'TS3O2D MQK8D6S6*0Y7?![L.8BD67FPIAS-\3,LMQHE=R!@.?893%J0-,H_N0E(6L3[X M/SJ;*3#0X<8N)%'J,M7/<.+8G^O]\"KRZ+^ZMCDA4<0&WOLN$;,O5CG%9'EO5 M/?TJ7F1@E3B=(M4D4[;ZTP_ )9.IW F2+'?B[E3;4DD<QC_\-__Z[_]M__XOR#\7V^^ M? 3O>0M[O[HB2@, M/<^#V.$A1$Y (":N"Q%W$/=I$CI>5#]TE69_^Z/Z#\$E!U*]K*Q__,\?[JOJ M\8\___SMV[>?OI-B]5->W/WL.8[_N_^;75[M)DOQ<_W5S:9D> MNE ^UOWY?_WZ\2N]YP\8IEE9X8RJ 2_?!?_PV !HXB7_$O7 #UO[]]^7!TR.1G=<7/&;]3<_N9%VG. MOE:XJ#YBPE=2^OIIU?,C_\\?RO3A<<6[W]T77!Q^[*HH=IZJI$R4E&ZHI/R7 M8X/]?('XEN2M]F6U(%RM[B=;,I["]),U<6\E0_#Q!>X-<['(S0MUG;&IWMW- M4!>+/K[$MEZ+O,*K"5Z+[3 ]D5?J%Q_EO]IAU(-.D&D]3DO=/5'Y]XIGC#=L MN?-HD++__$'^:\F_XW+Y9EVF&2_+*_KW=5JFBKD_XV>U%-X6DMKO^4W&?^4/ MA!=+S+W80[X# QS*%2UR8Q@CWX.(<,[".(I/^ M8(!#=>1[+GB9KPNZ70D?5H>6-[FRJ;4P_CG##[Q\Q.T-4GAE-C3Z_%M9O907KT6=JMQ8>N$!CVI%Z #LQ4<2,G![XWL_^\X^++6TJN-E-? >4> M&>!]%.:<[@BW4H9=7KP$*Z=#P6KX4]TL^='S7:^Q[_[%]'$_[[T<5T4G.B[H MF3EIK_B9YM*0?:S@SF<@BOSA(AVK_*+WJ4%>BO@#R O&"[F5.:#NYEM8E_ . MX\>E,L_9>L5OQ!6EQ5JNBRDFZ4J.R,M;3%;\5BX/;Z1:?UM&H1]SEWF0^<27 M5!XY,*8TAD+$(D X2(0?Z9"Z^=!SX_5.0")((FY"OR>!SX^.-@("V M$II1AQ'P>FPR%IPC$XP26QF(C>"@DWP!6MG!%NJWYZ VYITAF%FB(J.A)V6G M(:"\)*Q!SQC&85]XR>5-]U<9>\>?^"I_5/OIZV;?MG2(8,A+!'0C15I4FHT$ M^1$,0^(*(JV=D!F1ULG1YL92G; 9PRPK;AF7'4:8#URL@;;R&RT@UA/4M"* M:H]ZM!"QQ#6GQYJ47+34?LDF>C<-HX\/&2TX+OD[WOSOA^SFD1>X:@@JE=N0 M*U)6!:;5,HF0A)9AM>=T(<(1AXD3,NB2V(MB/W9"G)APB?[0/T_*,9 QG,D1X=C8/\R-S4"0U^ M[,3^@YJ C>2@%1W\W@EOT9]FCI@E[C(8>%(B,P?D):L->,)@?UJ^SM1SOU;R M.\4%*W][9+CBGN.&CM<>B[G<\Z(H2N3V+D00!1Z"<20(]'W!PB06;A)R0]_: M^5'G1FQ77W\#2C[H>,:^( V,M?U"=I$;WT?4R@LV H-&X@[,\T>Z0WQ&^BC9 M\Q]IC#FU+TD?A@-^)8.;!QY%WN."JR@^]C9_4!9;?>Q]513*A%!VW)OG[27M M:>C5-RF*M._2HKZX"4-:^C%ARM4$0X^)EQ7GO R>< M$I[@&#I4&N2() Z,L?I7Z)$@](,8NYX.69\?:FZ4VTBHP%\ ):4A[6I@>YH\ M[2(VN@O3%"QM(M3'X12=R:?TJ$S^M*4QC0$F(2-]13M*,;ACZ!$LY>F3"@$L M;PO,%/'M5=]3E?I?1YZ0=^2 4C MT'4=#!$+$"3"D79?PKDKV<3U34]L[0DW-_+92 Q$7H!.9M );7K.:W$6=8^% M7V=N1C]%WJBU +5B]?E8K=IF(@=%"#X\X+=0&YD;($>2+E2I6 MK6-@KK_3U5K5%_DES]FW=+5:4B=.$(X1Y$$H(.(!AR0.8YA$?AP%OLN$XQL% M#)F,/C>*VPJO/K]5GMW!5?K$61M!9!@19#0/FD%!8Z$[]J9Z!]BMY* 1'?RX M$1YTTO_!8F#0$-1LQ089C3UM>- 06/8BA 8]9!BSM1[$\C:ODY,+WN4J\_*7 M(B_+I8]B$7MR2^Y&'$$D08$DD-OTA' GQBQ!KJ?EXM,=<&[\]1:7]V8D=192 M/5ZR"=3(5-2)"JH'FY1A=)5_22K:]UU:>4#N M.O.[+/T'9Q^8'# 5*6<-=[4#,[E/[:6TR;^M'SA[D1_O)2B,282@2U7-&4(0 MC&GLPL1W6,@%HL@GP\H36)%O;BRU4\-@57]"TL22GZ,*_EEGC8T<+]29SJQO8*M>9>%?]:>R76&@UG*C4 M@E7\K==CL"/=*Q5ML KM\6=)67 MZZ)'# 1'B4.I UW&/75&)-<##_L0"\=E<4)9Q+7J0.@/.3>>__CA[?6GK]?@ MZM,[\/;FX\>K-S=?KFX_W'P"5[]\N;[^]?K3[5>#\EEZL)_FXW' '-T=V,H+ M-@*#K<22-S48/0.V+M15ZH%-K/-/ELJ9&4%^LI*9WI.F M*V)FI-E._3*S.P?0__LT4Z=3'U4^5/E^7,013!PF!\)03PLM(J9V1!F;DM&JPYH M]%F 1B/0J@0V>W>IE/QCK190>H%.,9W$0OM3JK'H3#A1(R]'_Z1S9+"233A7 M$ZUQ%\^9I07+$K(GE[)+QYAND;.$QL[R9^N9%]?T?,+I2FVYWN?%5[SB7SE5 M \G]F-J_9>H M'[G7[A38I\ZA'L<2>[P64#:ST.4B@ MN2V0.[ZS3B,H\@*64B=0;I0:7 QTV+R9NL'&GXT)_5Y7.Q.AU %;?<"N0E-5 M%+T(7_MU1H>)\UK51R\"[T1-TLN>._#05&YI<MX-V9@?V*#.: V3J8U1]XVB-:8T#V M#FO-GS",R:[K.DWI$_^0T?R!W^+O*G!NESH_Y:J?R%I>)BFT%>EPFMK;O*R6 M@OB(>XX/11@D$'$LI+GI!#"A(G&PE((F1@F\]D6<&S-^K>22!.ML;4#[U0'X MF>IS4TVI'G&^[D2-3+ ;Y4"C'9#J-2'#NPHNP(Z*'2$O#I=VV*9U+E3<,;5: M77F\^;#$WR,(."G/CP?PR_5@Q)$&>.O?<<'E0L2D&/TSX8>\J-)_-+Y P<(H M"50[0U4J&B41@3CT*,0)2XC+:!P'8MGOW77:>WA^1"VJ.-N5S&J27D\Z Y^L M!K@:KG%+@$W#K9VP-:?NA+&,!J&!Y]HNE!,YIR^#U,P!K0_021^SQF.FJ0]P\J@O+Z^_2RDA+Y0SYM*XWQ80Z<1AX+G3"2$!$8P1) M*!(8!)R[(18Q=LR\P[8EG)NUWA-0I8LU(0U,^2RWP0C@QS0#I5*S/)YS,=$$ M:[J17W/:QO8K7UY]K=52E6';Z"E-_5K3":OY#)V$J4KY&,LWKSH^0^$U+N(S M>* +5HWR0UFNY7!%2KG<:]:_6WHX\JBTR6$<4FFG*X]-XN$0,L$\CX5Q$L1& M[NFC(\V-Q1M!05I+N@"/2E9%W@UKU_R]+MGV-T-H_"#B!G1\*8Y3T&H)/K00 MUF(J+T;#HY99\106-MGMX#C3L]0I=0^RS!I2KXH6Q2 MKJ]QD:79G?)$+!WN$]_!JD5T[$$41X$JYZ!,R9"ZW&<1=?0CL\W&GANSM!4& M>",A**2(!GM70]PU7 'CH3DROW1]#;:2@[[HBZZ60RM][8T=#VD#C\%XB$_D M/;"*O)DS81AV)QT+AH^/C=*WXAG0"\O\=)@Z@M0&)F*-Y*= M#Q\XCX0!DUZ R$14>?[5,.._(QJ?)+B7]TS'8$>DW:&H8]<,V\J^D]OBN[M" MG>#(>569BT\\6_./:<8_5/RA7++ "U'H1I UO,1BJ"Q3Z"8H$'X21G%@5$?R MW(!SXZI=>9L4XEIB\+N2&=1"&Q8'/PNZWJ;6)I1C'TE=AJ+Q'E<7&DM;W;/# M3;KCU57^Y<97^[Z!-0U5<0R^:XX M(41"A#".$PX=R=>Q'SB.&YD5-C048&Y4)%^[V+!:H2GD>L0S)I C$U$C^J+7 M[J^6?K$YU'U>J+Q9PL%GG+)%DV&D=+!8O' @>K8J&)H./VT9PX'@[-4R'/J< M@2<"*N3P/E_).\JF1OBGO.*'LM4#/TD"P3%$42Q)#2=RGQ=P 4GH,>0D(D;$ M['Q8=^2YL=G7VYNW_^-/-Q_?77_Y^F_@^G_^]N'VKX:' MJ@:QX2C 'ER'S6 MMJK1*K!@?E)@"HBMDP/M<:<]23"%8^]DP?@!KQ/5\F?5UT"5J%'>+RK_>9NK M7]VLJU+U-ZP+%S1V(O^0546:E2G],UZM^9(0$1!/.)+=A.HV%;F0D"2 /"2! M'U%?A'I>K%?79&YLV2A2IZ'P5A5EIR@WY=&HF6DC98:_- 9'N'-_%:8X(K84 M>=-[HZY[;Y3ZM;QJB\H";' !&V! C--D&M6V@-,DS^9>N!OL5I<6:LR5C(0Z97%]9 MPN1*R_P$8I\ZT!-^@'C,/?E_VD=% X68V_K8B@72KOV ),5,&E>:V:\7S8?& M4=0$*(_MP94:@*T*"]!38@':;;!* EA]/F8+#-AI'DQ35JX M"- SF0S#GCUE>L-%VK_(>;CL64-+,.24WNAR6$=>/3:(J@\' MU"*"6D:;91-.86"M1,+!028NAW!*T?W2!R>O-F]A>_,MDY_@??IX]3TMEP'Q M!>(L@-@E"40)=M49'58$D3 6!T^>&R=LA ._*_$,^M+N G;Z@[X( MAI&_86T$C)K-'M3V@MZRN\^;K)7L037ZG6,/7S"Q?_<]3HMZVUH7'.^28YH= M[[OT*64\8W5T;A1X/$JX"UF$0B@_< IC)PY@1$/A<>I03HV.WD>7>&YT8<%3 MIU1O_&R@I_QBZZWK]#>(U)[N#1K9J3O&>S%_YZVE5V(Z]ZSI-+VV&U9;WG\. M=ZLI_-;%KB=G?1JI0JHNR]:W.I\&R]!KS=+\EYW^ M'+=JCI2L/\8JHL0$\921=9VU$-]!0R./^Y8-(TCN*FF8J127WH+ SMQ'3!E!B?%V75;Y@V3W MVH4<8>8P/W1@)'"=%T-4N1D,A2L7*4)"YF!MG_O^X^>VX'3"&?O=#R!WWOE^ M&1XCL[XN%$8.^.,:7^"%/_#0R5SQQQ7J^^-/7#4PO6U;H+"K*][U=?)]S",_ MD+9C'#*(L,,@Q@Z"D8M]Y@2()KY15:CC0\WOXVV*Y?=Z(O_1,(7M.*QZ>WL[ M8(W\9?>$7&PZ#&CT(#-//CN+AJTTL^,#39M0=E;AO=2Q\W?8V8F^S3.URVVB M?,J4U;EJ.UOE\D-&"Y6Z]F[-VT;SC66Q]#"G;L(CB.LF5((AF+B!!P5%@1?S MQ'>QN&1W>H%L<^.@C2&.>_L@NM%/_7.KX(:ICK>3&WUNAVUB)YJQ5]G8;G4# M.\KU?9BEBFUL]%,] E4N@S7WPR6S>=G^=Z)9?=4]\8BS>_&>V0+^IOOH2X9\ MU;VU!:S.[;=M##&X1UE3B[P.HFL2UV@BA!,X"4R0:LT3J^4X22+H)+'GN3QR M$#4Z+#PPQMP6TXV(3<3K OS?SD^."QYQ 9Z:N(1U=9\7Z3\X^]=_B3W7^_=@ MX3B.^O_MD6!;([9I5[;-KVFOSO+N,ER!=YS6-8[^]5_QW)]D:8NO78,14/ M]!@[>NG 9F)-I<&RJS_[+EVM*\Z6(>..@T2L:(=!1$D"B>-[,'"EAC0,7=<1 MRR=>D%R[)]CAD4S>Z?YXX[W:GW@%5KDT(+:EI2%@C;1UV '+5RM M'G%:*.OG1GS,L[N/Z1-O#B/*/_$5>Y\7OY5\Z45!F#@1@6X011!YKH"8^A2& M@4?!5#R MPEK@YCAS 93(=:?IWTZT6S3F%2.,++&,WIB3V]@";622V>#UI8<7%G*JP-5JE7_#\GL!DF:Z NH? MI6FX.3^QQSLZ:%FBFY-#3M>P8.MLOOE>X%7Z3^DJ2-B&D:A"P7QI*D3!Q$D A&Y89);I#A.7.IH%2T>,OC< M.&G<:)QNC(CXR(0U-[ -#A]&!'VBTP6[X)L= M'0Q$[^39@.DSIW/^#]1VQ[L_]!G#3-+?,FERY7>9,9%NCTLD"M6 MN5ZIHX4Z3YY7U:HY3?A+6MW+ZU4!J,:QK<("EF[HN5$8<.@D@D+$.86QQSWH M1-@C,4M(9-;DTZITO*:V;EVYTS/,'ZUF1AY8>KK53OE\*E_# D5L#5R!%W8$#DX@+&#O8QR$-?8:U*AKI#C@W-MYT M,J\D"9!&S@&]X$]!K&'A6P9N9/+<8-:(6_-G*S#XL17Y#P ");9E+(UJVEG% M="*CO37/4-ZA3#J4\ZPNP55*N7CGQJ>XO =BE7^SL""90GFF M!LO(O+N+R/E>>0.BX8]I M;RT*?F^ B:/?CRFX'_5^],H!EMA-QG_-L^K^8YZQ/*M+51*<_>U&2"91=3_: M=Y2H(/88$2@ML! BYLC/G3HA#)PHB6D4(J2WCS88OB1T,Z:VIB:F"3V<=V(K-L4R98 MU6-0L9C?[E-Z#S"H829Y44AK"XAUUM7TS*555M1_K)W1^U_3 ME7QGY+QW38V3 ,E]-8,L201$(:E>\F>> M,6'S>#UM=KO%:]XS,(JJ#LKZ)&5_D?>,71$AZOC0QRR6K,HP3&@401XXR.&( M^MBC1A%41P::&Z/6889RH(@99DF=NU'*]YV=6485;1[1N'R%;TZ5' M21-.POB67ZN)\O>=.F;ITH652F"KTRA$9PE?2WQXJ323TJ8EZ%ZRJZW'FM?A M^IA6Z5V3@XQ+7E>3HEXL7!IZ,/!0I/+P/(A%C& L$NJ&1)FZ1+<.U_[CYT:1 M6PF!$M&X'-> M/+3/4E-_[<_QJ*X'OL22TY_N\J>?Y3W-ARC_ ML?T&]Y\TR>=W5('NRSM^P1B&4"!5R3+Q,4R2@, PC@3%\H.-A=&N1'?@N7VRO_WT]2=PMQ$=8"7[ M,R@W8AL&SNKBK[?-& /5D3G@MZ]@*S/HA 9UL\RMV"-$%)AB92M$57?8::-/ M#<'8"RPUO7]@G0TA5(?')[[94:C3L4/[B/9/7[@"(%VE3?&AC8\E<"/$20A# MS"E$2+@P"1"%&$<.<[ ?^8Y1.2!+'!?S3MU^ M &!S_)RQ3=#?6GY_SYL_&1;WL#31>K3Y"M,W,JMN-.I[:.I@BUW1%ZJZ"!W+ M_6P95UO52"Q)-6WU$KM0[E4[L?SX@4VBZ#UGZY6*;E,)92178S[Q?LVXJXPI MC_V1/TO3."LQ;04E*[X,2>)XC#F0$Y=!1' "$]\-( V]$'NQ+R)/R_,SGHAS M(_U.PSJNP3T-06_U[IJ.J%&?!_T%H37G>71/?C'9DS- M:?_GFSI2K+K'V8LWX=QLFK>4&@UP6SVE[ LX;5.IT0#>ZRHUWDC#5I7W:996 MO*Z>\R&KY"BI2F"N#W^O'O*B2O]1KV'MV<25JEGR5XZ+]_*&I2\W:]-(MJ]25W)'J0.4/O88V@*HEJCX$DDFY5P+D+TD5QN/O+AR M8?$N+1_S$J_VZI+)W<-JK9S3+X7[G*]2^MS\M]=P#'/?=]T8>CY1C?M\!!.: MA#"@CA]ZON]@IM4>:409Y\:ZNU417Y;S&UX5T=J^H1,_KNE9A-"7?0$W04UZH.(K;LK5-#36M0:2B] M9S'IW'.QNQ*7]W)3J_[G^N_K] FOU#:WWKSVK!TW"7T_]*$?$$>E6 4PB5P& M0]\1@NJ$,KY5/^#;U48["[4F0]C5Z!EE$]*TG;QS#8AAT]AUV.H._EC/. )@3CC:3IPS<_KTP%'XI\K*\_MZ: M$;_D.?N6KE9+%C./Q1&6.[J 0(0C!+'K)S".F/ ]-Q:$A,LJKU0>EM8^06M8 M(V[;##ZZZZ8M5Y^I.CF,B_XOTZVICUM3_TZI9KA_TYL4S2V9=:C'WF7M;Y=J MF<&/&ZE!)_;QWB+FVR4CG&SM@/0&G7938P3$WC[%[.Z!B9D]G]B-4 %)R@I4 M9:P^%_PA73\L$\R(\((8(M]%$+F)"[$C62M&' 5AZ(3,)V8=>LZ.:?()3=.K MIPZV8ZV4 /<4,,S;/ NW'A59A7!D%NK+JDRM&LM.7/!C*[!%_M$&QU9RY]GQ MILWRU%5_+]U3^\:!L8D/CZO\F?.ZJ5@;M8N2Q$UX(#=Z1&WYD",@)K$+O2!R M0@]1' JC#AH'QIC;OJX3L>EH9QCU=P!"/<:X$)B1.6(7DQ%BF4^H;RMH[L ( MTP; '5=Q+YCMQ*7#ONTOO*R*5!VW'MYJ'?YM^P93XF.&0Q^&D>H]&GHU"7C2 MV'"=(&%.S'VCU(E+A)D;6YQP3+S+'W":&4:,7311>E0S%?PC<](%R!O3DPW( M+/'81:),2G@V0'O)C%:>.=!9KLCX/E_).TKU[.IY)F,;I'AYH;_?4EK=LJ1_]>N[^K9\.*.2?0U71S6\%L;#NJ M%FP!KBKY%I-U5;NNJQQ\QJ-5T#F/BRU_]?&!IO5-GU5XSP]]_@Z;V5Z[F0=O M[U78Z(?L.L-U*YKFFJ7C.:Z+'-4RU7$APIX'$^X+R(*0D3!AB#,C2ADNRMPH MYSUGJD]/O?37I=FWR5NT5L#0!WW!)&EN[2:!?FSFTL[':E11A5E;93:7;G*U MQD[0,L%VU)PL+4%FD(9E IA>YI71$R^-7CC2%>9+OEJ]SXMON& O3LY]WW6( M$\:0\%A Y'@8QL(GT(\CAX5A'%,S=ATNRMS8M7_HONXW*21B*&#'PR,&/W%(G>UF!_UK MGO'G7^O2Z5T#A9"*A"O?7RSI$CDQD?\*0TC]2,383TA"M(X"3HXR-SK<.)D> ME*1M+7F3NM#'T#S-;-8PFL(')V4$M9"@D7)0_>QC.)D4SK: UT05L[_P1_FX MVEF99B(O'IK3UX+?R6]9A7W00^\=('BEVI"7MIH9G$/L=#WM8S=/6$C[C/R[ M%;3/73S0"KW'!7^#2\Y4P4B>E4T]@6TVZ)OG[26?\7-=8$91=N-I^)"555&_ M6;QSIU]%.>/?%2FLL]GE]&#F4.\Q+H.%X,$47J+"9BT"$"8^92 M@8C16@.$_.=:48NRY=OWZO>^ MY6[33G^5:;5EVT\K_+3[@5>9F+T]Q.M(,=)26AZ3MI7I^KMJD5'R\D,F.3S- MV5]X>GI: M74JMBC^WI;03CH$?TPPP51JC*,&C),%2Z7P\?G .KX*E)?35)G@&2VAY9@W= MK)(;$-0100/# G1 @!:)S56@QF+"]7*4.9QJO;0K_+S6RU$FQGB]'$>*"_.2 M/V2/ZZK\R)_XRNW:X6$D7)=1Z <.ADAE;<8>"J''D8^2Q,,Q-:I,<6*LN:U$ M_W.=2[S_]5_XK'YB.K1PZ4HC6F61ROB_ZH M=[.U'U>K_)ORL]FCB%.X6.*&@T-,2@JGE'S)!B>O'48#S?JICARWY='?-CWH MEK'O^KZ+8DA]U6=!]8XDG GH.BCT8QRY%!L9'B?&FIOAL15U<#N%4\CJ\8(E MO$:FAQY46S$7H!74'AMHH&&)%$Z--"DW:*C\DB)T;AD02O";JA? _L3QJKI_ M*_=,W9%NZ(>)GQ#(@[JB=1A!XE ,J4LCUQ><8Z'54_;$&'-CAKZ45$II<#)^ M!$2-^('+H1F9!!H!02,A4"(."1TX]I;I!PY<#M3KA@T\\J+"::;B!JH/\L)K:ZR^GSE ML2X6O0EV# ,GQ)S$D$6NW$>)B$),/0YYY"0Q[.;4]YMI]NZ52H*G9 R(J"($97V&0MA$CHNY$F" MD4"2H8A9F;]3H\V-@MI0CUZ3:)/FLWH :YXVVH)M9(HQ1FQ "J,&$M:R&$^- M-7$BHX;:^[F,.C<-+B+!Y4WWK87M4((=YC 8.T2UEH@(C/T@E$8+1PD2)'1% M9%@6HO?XN1%#)YUQ.8<^9'I?_G @1O[4.\%JI^[;@K.T4MNVXEET&2G63WP. M8V&OED+_X5-71SB@V(%Z!X>N&O;]UGUIA/Q6I$WQE1=/*56-T<3[-,,93?&J M%^UU*T(/(_3@ ))3[T L$PYQY'V"B%SJ9P<^.. MC:0[(:3#"L18G40]/GJMJ1F9S0;.BC&%C0&?)0*T*MJD]#D&J"_)=Y0Q)LXR M:0+1;T03AG[UA-.5VO._SXM?Y+W5$B=1D"34A8'*Y4-""!@S-X8AI]R%." ,8HYY0%#H18EC5BIV#K,]3879=KZ5^[U0]:_5=*=EN:Z3A.8W MU9HNAAE,W\B+O(7LG[U 8)/9IS\MJI.^?$G%?0\85@6TO'T1UO MP"G];DF]UE'A4A?'1" 8)B2&*,8.Q(X?0YX(Q%GBB)!S[3/Z0R/,;3WO98+6 MN=<_Z@;\'L?P- =;069\?T\'2IWI/^!T_B R!F?SER(TV^>H_>2%9ES&>+J\SJJT>O[Z@%>K-^LRS7A9+L/$I8R)!/H" MNQ"1A,.8>*I)@O"9(R#0(")F MU65U!Y[;QRQ?E=C8%--OXL [<^.9&?:10R[P &ZD7*K2?;\0^AP:9&].\51O\1M"Z6W0MJAGU',12CV8N16AL2^(% M+B-$Z9U"P!)1'!QB4E(XI>1+ CAY[8!#FMO[0M+%-2Y6*2_>\4I5W,^SMWGQ MF!?U_J,[MV$LCEP_AB$)'(AXZ$(2"Y52Q*CO1XPG3,LG8C+HW,B@$=O@C$(7 M7(T#G1$@&YD=&HE!*S+8R QZ0@\Y^-$%U> L: 1P)SH>T@'9TIF1(4@GCY%T MGS7=R9*A=CN'3:;W#BV1(T?!JLS4IUP]%*^N'E2/WB5').0B9I#Z3-7/3P)( M?%? ./#J M$Q)1PA6M^W277SCE\OEDU54I MB(27Q('O25.-)! QGT'"I>66,.H$0E#J>5JU,,X--#=2Z.0$6T'-R. HHGID M8 .GD3-2O]PC/5!/%= M6M)57JY53+C4@'*$ QS!(@EC:&=R'B2__Q9@?$!='-(F322+Z=:2=&R^= M"O.>*+1;:Y+U6&XV4S<8_2>61>G_ESDI#T>O1%?UY3RLFPW=,.[7H"] 3OLY*:\0W\,T;S(+&F<]B:9MJB3+766::;JZ>?MA4P]]TR:+U#JI\EL+T%=+!0"O'1L;/,ZOU8Y_=M5QE[\ M1M58+NMN3'*UV6U>OT18-V/NE4E:N)MTK,&9-Z"DFQI;#>TQ1I_5W M3P#ZGKM[BC$'N)_>I>5C7N+5+T6^?GR;9U4J/Y:LDO\J4_F(O6:/O^ T^R@- MX25R7.XY-(8X3B)5#R6"21PX$%-&PD0N2#C1.E2]2(JY+3:='J!61%JK&U7 MCBX[;6(70*D#?ORHO[^X;.HT/%A33,C(B\$_QUP8>+NFF).)?%\CSHV94^Q2 M3$^ZR 8_?#J'V:7Z[[C/+G[8L*W7SOFQ6C>KM/'A;0^&-U$BL>\GODLH%$RH MCC(\A 3''(HXCI!(0HICHPKM!F//;:W:R@K>\(R+M-(*ZKAX"O1V+",!.[KG M:A"FQMN& >A8V@68C#RI43\ DIM7M5&B]56S=C MZ6'N43?&T/-)"%6-01@+QX,>1GY,'9^YD5'4HL:80%5.Z>[DQ[ MB.K K4=+ED$@ 5T#)7+?KYJ!W6FQ*1_JSH$M+HV [.CV=@76$[(X!2%EC*OV1)V8L M8TCVF=TT1)Z=#9,D '!$:-O ]L.5NHHA/$G MOLJ;5I@5_@YH([T9O0V<(CVF&Q'VB6JO=@J 1H.ZPJL>BU%*L/KFI% M:M.-6HUJN Q12^0X4(A)>?(RH%Y2YH5/&YAUV_.^R1WN)[FUVOZF;NZ#ZQ( M72QFC)G#,/%A$%$$44@\2*)80.K%+&)1&/DB-$K&-1M_;G9@7_R:+Z4"L*:(P(_,EV_SE1RAKD5_3OZ[2LO4_EF^?>3[WN]"YE MV">12BN6Y$@(A;&D1.@)QX^0AX5/\;"H+'TAYL:0_7[UI-4"X)X:"Y5UVOO% MT% J@WG28\BQT1^9)OO =PJ JY? ]WXQ45B3.9C6PY4,1'BE,"1SD(Z'%PUX MUH"PH1?A3'M)NG7(TLUC/;JD[^O:J\EY_>O/\IV_ES>H4$KE(FC.6\IR_=!< M_S+XE4D+-/0=R D-($I"!'$2AC!)(AZ[L2M%FE#\IYI7XIE!/_J7;BR\_4>54S]0N59 MK=9,CB!-E76E*N.!5?J0JKCL*O\C^!'_ ?"NMXADS(<%^)'T?O64KR1L7>ZD MDH?7?7G^K6P[D]ZECZEC&=,_9[] 11I^3YL>XYU N5<8 M_M)]\97\EEBZ6BN'RE=.)1-4*2^OOZM/EC.5;J6B9]8-<]V(:UQD\@-1A]>U MBEN.IK%#&'?E7CGD#D1())#0R(7$]_P@\(@@Q!^V:[8EXIPMM\>\4JR&5ZOG MI@J76I=I_O"0=_V6:]YLJ%227)K53$BWBJNGU"C)OV9<4FPN-XJ/O&AN!X13 M+,E>W?4,ON7K%0/W^(E++I3_5Z6P QCPVG\]=/MN[74RW=R_QDLRH2G85P]L M]0.=@DTJ[=O=UZ%34ITMM<;D-,X!VY-AW75@38TQYV9*'@OV,:UJCC1&"%<;KZI62>A#E#H)NK,J%^L2'"?(=Z."8B" 6#N+Z;8@,!IX; QT- MYRA!+3S82&]42-1X/C3.%49"^;7B928&V, 7/Q+0$SG3O_!'51Q= :Q<+;7T M9>T E]*#ATYZ:_[A 6B==/":/&\Z#^T +7=3C(\)PE!N/>,@=.0O BU'YYEQYD;P4E)0BPHV MLBZ E-:H4=I14#5HVPY4([/T,92&]94["I=1*SD;L$W6/<[P)3/M&'<.BS-- MXH[>/F5?N',ZO&@%=_;R83OS+A[I;?Y TJPYK=H&(WWA==W-MWE929.!,]<- M.(>!XZ@R=Y(L$Q1&,')XHNQCZIKU@],?>FXDVH_3*QHY 56"FFW4#;#7VZ^/ M@^C(7+L)A^Q)O=@)A6P%!V]/0FR\>3='R](>WF#@2;?RYH"\W-$/>,+ 3!EU M#G\K[ZTW,S[!1/C(@[$?^7+WSF/)3()#[B1N%!!&$[T8Q(-/GQWY*.& DFY0 M+X]=Y/1X93 >(U.'/A3F*22'5+:5(++S[&G3/PZIM9?</;<-4 M/V8X84X$11B'ZHR0P]@+8DB%"%R/^Z'PM5IK6)5J=L30#RYHHTU^3+O $\/2 MZ';F39->IIZ-L6G)3I3'PGHG7:M VR)#*S)-2Z(V8=PC7ZL/'^ SNQ&"JT#B MMK!-QMY)HZWQ&<>A$(1@Z#J*A3T>04(## .!B61B/\%,:P-X>IBYT6HGZ*8J MDSI=5#'5QO[YX\AJ^,VLX#4R\4T!E8'/S ID$[G,/F0B+QZ:U8"H$/D6R<<& M2:X" A22\N<*IUD=Z)\W8?1R?U4]P[ID=1U)NFDFVDO)M7:\<1;3DZZWXW=/ MYWD[J\&.X^W\U1.W5+ZNIUOY 8OZO2SKO/K;>YRU$>F_R$=4Y8>LD7CI,Q8D M+L:0L-B!R,$")IQ*2YIZS.4^0G&D=;(]M>!S6P9JZ>07-MBBGFS&]8SN.<[C MR,N3A:[+C?*@IWV_KD4+P (T$*CP_@:$&?1@'CAMK]V.V53L?X[.S ,GPUJ3 MYJ'C#TE%EY83OQ%_44EZ69EF[=$G\D(/"RZ@+U3/)!:$$+,X@ YR',+"!(6! M0=KXP3'FMH+44JJM_D9.DS3=PS!J;!PN!V=L6M[#9<@Q^Q& 3'*.+P9JHKV" MP8MDF-MZ$H'3>:B';YTP9_2D[+OYG:7GS7[N-K_^CA_2K+[\"Z_6159^R5>K]WFA*'L9.[X7\X3! M./(PE&8[A4F01) Z/!;"C[#G&!URC2WPW.AW5]\N"1VW?4?EC^L> '5YS;:H MN>&I_N@O@IY]/Z?I'7D!V9_9OK)UHOW%VE15G460[E-8VCR&ZS5 MNM' [?2NX-0#)MP;:.BQNT/0N6'8/F%3>;_72*'<_/)/*2]42MQS4Q-W*4A( M?,HPC$-!(2)!!+&?N) E#%%,"/998&+T&XT^-QKN=:'82-K4>;[Z\\!RSF:S MH6=YCX;QR-1]&;S&MN\@F"P9LF9C3VJ5#H+EI8DY["%FA,9XNOQ 17$EC50Y MTU=5)=FR7JG>K_#=$@<>):%/I8GHJT)2#H5QK/*KL* AX;[\?UJUZ4\/,S>* M^O#V_1?0B@IZL@(EK!XUG<'U- ?90VMDLAD&E#;)Z.%P@$U*3G^ZRY]^E@]H MB$3^8\L?9QX["5'HJ=8Q@N;5PVR97^16M<"KJXQ=,;D?357S116WMEMK(G \ MXF*<0!P&GMHV$HB#,()NC-T@BGW&D9$-HS7JW(BA%;I>3_&.V&8&BQ[D>H:* M=2!'YHP^AKL2CUCBPP@D2^:)WIB3FB5&,+PT1\QN'LA%>.+ 9:I&K8-=G54FW M4F5V_[Y.ZP)!OQ1Y62X]#P4XC GT&&<0Q2*&,9&?.(L998A0)XK9\HD7)-?N M@'IR0),7NC_L>.]U)^^BKM#=-%SBGK!I&\9J*;[7(U;OKH'!,>G=?74C?BOY55GRZH:H MDTS./F37W^F]\JZ_SXL;.3Q69?L_>@"@(?)A$ M20(3AR412WCB!L@H[F6X+',CI%H5F NH2H)CI4T)\E8?%7S,6XWJS@@9_P;R M3B^P4HJ!5:M9:EIH]I()U6.UB:9I9,K;S)#4 ]2*@)O>!%WW)VBC#:C5 1M] M+,:;7 ZJK5"2"R29-DKD[=#]^T4?G^5 MDEM_TTWI9#,V'38M>CPZ'LK3,&@C_^(E.RZV]+@ ?35 HX?UW/F+<+1$FL-D MF)0N+X+I)5%>]K!+>^JHG)H\J[-CQ*8+>.NR;(/T7C0X(QQ[+F$N##"-5,M9 M52&-I[L4@\,;!YCK$LJB?&DWJD.?N).7'-]WD3--L9C"PUKO*F$OR2NUC!D-V MO$_,\$<.8]M/4F=3X/HR%&\,8!:Y('!\E9@Z! 3+,C5U/>B:;?MY2[$W?QD><'D])MC9/>M0Z M,OHC4VHKL'SG@9(?=#_W-%B 6H=F]]\V_99:V./0"Q"TQ)U#))B4,R^ Z"57 M7O*HU^[RJ)A[B0B/8L(]Z%.A_*FN4,T="?1<$6#L!^KH['4Z/"KQYL:LXW7O M,SR9M_P6F-J]4\_MA*;P5-/ZBIT8^^C/K@MC+=P_:0?&/K#C=5_<&678(K)U MHN1E^187Q;-HL@7+3;S&$O/0(3CT8! Z$42^H#!!E$.'B@BYKA]X>C4Y#,:< M&]WWO(RJ\>Z.T!>$5>F@K\?(EC$=F68OA].8- T LL2$.B-.2F\&$+SD+)-; M+R6B'6_NVW51R+WJ4N[K'9^XDGXBU8@MB>3FGGD1#.7O?!KX) KQ, XZ--Q\ MZ6?O?'X!:",S>,P+M4X,9:"#L#L)]XGO$,@\YD'DA1'$3D)AC#SN,#=*?.&: M1=/9 WZ::+ICT#]O@+<*N"G;7PKB=$2_=SKW]@Q\%U#\*52LL_O!P5Z)V$\I M?IS33]XU,)TYS;"4O7[TB[[!R\"/6>)S'S(>4HA"Y$),L0-C5W!&W8AXW,C3 M<&*LN1'YIF&UW"U>&&IU"F$]%K&$V\@4TDK9$2^%6..68931['7EWC87E30MU=/E>Z!:WM=^TS:%#2=)@IE(( D/SRN\F?.ZXL^RQ?R7G*@BHLOEPF1IHO#'.BZE*M02%5-G?G0$T(XC,8H M"K#9/FF@)//;0'U:JWFI.RM?V'MHZ.00'%,:8@1=IAP(A*EB.0Y6Q7(\$A&' MB,#(=S#!U$Q3=UA*"-):#[#.6%VMG-<'&CA[_K<2E/4%CZT.=0C!]).G>2 U M_I2,??)4@]VH !H=VB+QB^8<2=6H;!4!S<6=*G7:E,4,J0O!M'60-%"*:4^, M+H-J[VCHPL<-J.S8T/.-N)5V?/FYR)]2QMDR\$)$')] 7]G6B(L()E'L2U,[ M9A'GC&&B%4MU?(BYL>%VF5*54$IE6==R&I0E/ SE:0*S ]#(W-1BA.%DS<7#=TY7;/&DY#M5%D]?.4*&4]L"HWRW MYG_EN+B5./(EX8C[(1.0)(G*:74K%5K, M7SH(NIZU-RJ4(W.I3MY2E0,BK3J<2MM/Z0!J)2;*63J%WQ3Y2@?'GT^NTBEX MC/*43CYH\*%+6LD1GE32Z(YSI/S$JZ7OA7$<<1]2)V(0T4C A/J*UABG09QP M&B?+*J_P2OOY9] ."4'( MPP%D;H(@BMP$$AZX4 (MJ">M:X&,&NQ91'N*FKQ]M#^,C[;VB9GE9,6E MD0(P]0$:N_;2Q]<)O]0'0+L&T_Z= ],M^;M)U%65O5#:-00E%+IR;QS3R$DH$T:YEH8"S(V1OG!:=X/= MZ !VE3#,JC2=#CV*&A/DL3V0_-MQ<"6+U8*#W]O_'24E?2AZMG(I38>?-I%R M(#A[691#GS.,]U3;@Z8W[FJ5?U-Q33?B'1>\*.H>6HU1UX;#Q X)&,$.Y%RE MEWLH@#AR$&0D\5A$DR0QRX(Q&'MN;->)67=#K'=T9OQF KL>M8T$YMAGOM=O M09<-M@!R-762!=BH C:Z+, &<56*8ZP@I0$@6B(WDY$GY;4!D+RDM"&/&'". M>RT$IRJ1<%.>XPNN^&Y/P4]YQN3+)B^3.]8V://Z.Z=U F*_5?C;O*P^\T+9 M-$M!<1RI+E-.&#D0Q=+>BQF-H8,]X7B!+[Q8RX\UJI1S8TBI ]PJ 7@G/J ] M^0V.3T>;78W3Z3G,VO9+F;6U(\@SPX^/JN6XTK,:6]Y152H'@K.YKHAKSK.72_=Q_8"$G MHU0GA8\%5S^W?_IQE9?E'YK2!'*FI!F]5L]M"_SF60EP514I65=U\2YY_V%N MLM4JE?#1)L_;)69FR]H6^ M+7!6-M:4T;Z>2GM'0HBT/'#Z#K!@%$F >01+X/ M>1APEO@)$3'5-FM&$G)N5DVG)NCIN0 [FH*>J@O0*+O)V2J[^%;%DIW""]!7 MV6"1'.O-T#")9C#?(UM$__^8:@-S: 93/I$U])I3;V9SK08 M&;T=RV+LLK-1J/.;>GO2PF4F(:-M\M_*!/<^M_&GKM34;:Q)"&Z1^QU##;K8>HGE%Y?*^7JG6%%^'Q!.O*[-AM[1D[D06E_1;GN- MD0FI)RCH2VHMJO#H=#"Y3:0^@M03JB12%,)8U<5S(A$D'G.(\(FEN,Y+)N.U M8CT/1-;BWE3A*:=*[^QPW D8>4TY%RAJ_)G8C!X] ]_X$:7'!)A+E.D9@ PB M3\\]:8*LJ6_Y,@F"&(54P<&GL';5<;>R]^G=]F+QD#(%S%-7 $]2680!9A#G+@(NDGL(!)Z MD1\9=1FY4)ZY45Z_@'I[)$EJC7IGEXOM$:=R$8I&KZ%E[X=-HQYQ3C@Y8X>: M]>;EP\Z\;",>%N!=?UY:E2;J\W01P-9KUP^3YI6*U5\$W?'J])<]=A@[-^.H M(M--]?LN@.%F$[_P0AY>MF(L$^*(,,$(\M##$/E1!$D4(AA&+G&"D/+0+#YW MN"ASX^3W0PCV@IG0X]9I\!V95EOR_/'C-NIFJPG8JK)/MJJ>T[F),:;3RS&U MQ*07"#(IB5X.V$O^M/#$8=1I<,3F+B/&HL ) AA1AB!"#H5Q(C?J+F&(D82B MP#/*WS(9?&[T>*N*#_3*W!4I/5YKXW+H@P3Y22P8C%#BRG6*AY#$ 9?KE!\[ M 8O2,JCA$&9O 'G?06!W%;-U@/%VV'0N?K[]+ZRV[XRI&9NF' M+$X\Q%7-6 *1QQ*YL8BI_#&,$I]ZG@B8#O,?&V!VW-W*"#HAZ\ N/1H^"N)I M(K4!S=A4:(:*-H6=4_T "96<_G27/_TL;VWX1_YC2SM''S@)<9Q3I_OTSUXW M(*_FS[A(%1-\5GLNY:8H,.TZ?R 2,Q1[B3KC\B$*!88X(0B*.*38\X+ =[4J M3)T;:&X?JRIS;FMD&>0JG0#W]4=N$:N2/>X-2+2;HY#Q?D, ,+X/<#$NX M391?<;MML@#46]4I MX-M]2N]5JJH46!V;U]?*I5\]\['(27NJ#K_Q].Z^C<=;J^M2N8T 14W5ZM*\ M+-/]X=N+?P)_N>=9)WLGT3GA%_WN$IL_E:#D3W66JY!SEA?2(B[74@5<@OM4 M[GCDC,J_T7RU4IF)RC16FA4 M-C:MR@3)5%)I^M0T/V@J BV#R$41YJJ^JK(^(T)@''D<"HD;XW+4%PR-YJ.@7$1']OD/;3C+VI&;8HJCEF;[ +H M;.W;!T@P[>9\.$1[._ +'C7 4M\K%J0BY.1'W7N[RJ7KN#CVB <)]N5NF_DN MC(,XA(E<:'P:QX'@6O2G/>+)^P%2A-#>!R%&TG*CR?J%P0C]$4>+H^T].C30W$N[)"GK"&O#' M25PU*-@66M,X2%\"-<2'VL^;BE,J;.X3KVZ$I.TE99$3NEA 5WA,[NCC M &+F(.B%+"%<4,)OOY$?$> MF9W[4->B@QW9P4[4;]V,1;D]I0[V=O0#P;.TFS<=?=*=_$!H7N[BASYF&/F] MS5?RQURYPI]XSPA]EY94?K'KHA\]17TWCAP/BD"Y,CT<0RP\'_I,MF01PQCL9T6U(W# ML]UH4-]A'DE\:9T1N>5E/)&*8$K$A9&"=?W@9T;;FZLT @, MTK9FH0JOD/.;-3$,X%M:W0.\U<'(0786>1TOF4T\ISA8W=045=*"GKB#/&9G M(31QF]F$IYU D8Q"Z6-IF(B3R<_= M,-0;55:E:B3:]&\HE]SAB! <*#<[EP3!(IAX#$&"$X%=X7@TBDV2DE\.8,00 MDR4>YYNJ8FU[%D-*V(-1UVTT')S1?4.J?GO=#O@<(@.?'XB=TX MAY7;]]4ZM B51BK_5W[8?:J MHC1R(<,AQ:K!(HV,?*=VQ9O;]]^7#12\.:7=]FLS7,(M3Z6> ?!Z$S0R11T, M>U3_WOQATS%Q9QJ5P=&IN ;S[%6EH*Q'3(.^I:L&,O"36H#C0/L2PMJI%$N M/!#CQ5-*^>',@$]YO8WCK,[/+^N]Q\M.>9_RZJ^\4JWV[C(5?+7T!'<%3SP8 M>5%=0L6!V/$9Y%&28#]$B%*M&-+1)9W;^E!K!IH**K0G^T+^I#8W65Z!9U[) MI:/38.#9G?4I-SS[>\V)G,+G?SR9JF[#V^C75551"LG?-E.[U6FAFAZL3_3> M'7[<.!;\MH\KK=8\%]]+ATM '-*ZV\:X^%;N6M2^Y&A- $09S@&"(: M1)"$20BI8#B.. E)H'6P^O+!<^/Q3C:@A-,OJ+*#U6E&O02!L0UI+>6-ZJ8< MTG10O92=!TU6)^60^/WZ* ?_/LRH^R7/V;=TM:I/ZJ15^6Y=I-G=9UZD.5LZ MH4HH=QWH4^Y!Q+ /"7,1)('@Q!'"<[#;=>.ZU3?/3HVI]5[N-M^ZG20@_?R1 ML3F^>D;0Q7!-\QEW8BY )RAH) 6-J/;,$AU +%D6)X>:U#C04?KE^JYUSX"( MJ*LU2ZL/FV?T)M+I#DG_TX S=F+!WRM1Y(]E$^IJHJ4K*NZ2F+^ M65K_6;6,2<)CWXN@XT4,(B3D>N\R!%F 1!*R./8<:K#H#Q!AIC; ATU3'T : M+]O&)5_E(*WX0ZE2HP[EJZD\-0/F,)PQ#=8=80*F.J0_D8Q6]_'I*Z FHE%A M/+0-V'L\U"?B=.OHFU'_,/Q.+@B&CYQNF1BFZ\[B,? 1 Y:4G3C[SVU+ U4" MZ"]MK;TK5>?NKBF7MG212Y'P$DC=D$!$203CT L@]F,1) R[/ ZUP^.-AIZ; MG^,NA@Z^#'- %,I3D6Y_:UFAO. F=%8.4;#>^2%XT5* M3B#V6#)& WNB5:,+[OE.+^=>^%QU=;Q+)LX_6]Y7M59Z'(F>3?-3<> ;7L5*96MDI>#YN3D*F3V MQ.D6H4&:[JQ!PYXP9%>#'],*K[91P_5YN-P]K>7[T09 O2VX_$5Y]8335;/T M7>,B6S+J\#"*!$PB/X9(.!C&*,:0!L1W<8(300/M]6BX''-;G+J8.]I(JZPY M+L4TL:2'SXG.'F82I,?>SS1*@*T6H*_& G2ST&H"-JJ VQQ<3S8?)KN<2>9E MJAW/>/-CN/>Y&-73^Z#ACY]P3W0Q!KO[H\L?-SQM+9-S_?PRFRHF/G>"R(&" M>P(B[B!($L=79?0H(Z&'6>R;9JT=&FAN2\U&3O.TM(,XZAVDV4!GY.5A(^)T M.6FG$+&8DG9PF,DSTDXI>R@A[>3U@WSQA\N7_)JN)"?E&;_ZGI;+4% 2AHD+ M:1T/&2 78B]P(&:("1$APK%^@6.M(>=&$,?K]FS$!K\KP4T.Y/3 U_*F6X9T M="?ZJZ%IY"VWC.KKN#QJN>N3H!)+J_"AD]Y:!PXCG,XXPW6>-*4/W$"S%ZYO MDSN'67'OTTRU7:F+KW]L:Z\_MQ&[Y;LU_ZO<+=]*O/G2I3X*!"90>"Q0)0@" MU7':@X)%0> CACPO-C'KM$>>&XW+5RXT,_'T0=:S^4:!;F2Z;F6N:ZCS!=B( MO5 N&<+!9YRR!5"2@UIT>_:@,5J6#$3]<2>U&(WA>&E"FC]@8+GAK$I9NEHK M]NNJ&O-2MU+T:P>^-T)K6CS;H>@QE$\J1B>E"%,T+ VM"8ZL2\+GAIBW]JZG\ M7JU?W?L&YH-O"FW>B'X:R)2Z!B1,Q M2'S!/9I$3HRU4CHLR3,WHOIZ>_/V?\ W5U^OWX&W-[]^OO[T]4H5 C;,]+YP MDO28:T+H1R:VLPW-1O&^6<+/5C;VA=),FWYM![J]?&M+CQU&K?*A:7DCMJT, M&\?C2V>WZR'$)(E"DD@+#ODB@%B$%/K,"Q*$$X;\Q(1!]8:=&U&^4?UAN6Y8 MK2'$>OQG'[B1::X66'FFMB)/<\Y@AI0E0M,<=%+>,@/B)3T9WCVDUC%6'7 Z MI]D7M0#6^].VH)1#!4*"AI B'LEM9!# A,K_$!^Q!'M!)"*#0LTEIO>03=>Y0 MW:<%J\\IBFO](DW'>@WT1(B)$TB+ JN2Z"3R8>Q0%V('AY2ZA!-NY(]_.<#<>*.3 M#R@!!UD3>Q#J,<0EP(Q,"4:8&%/ ,<4M??-[CY_T(S^FW,NO^NAUPS[C+_R) M9VO^7LHC>:(N$?&7M+KON.-#1E=KIEK EZ4T3.H"HDOA^RB,L0-Y'/@0)5BU M2!$)]%T2H#")/1%K54V_0(:YD4&K@MGW/P1[/8H8&=&16:25'JB/!'3R-_V_ M.@T68*,#Z)2PVTOX @@M\=$0"2:EK L@>LEJESQJ&/$=KE'9.ZM]\[QW0%<7 MKFQ[5[[/"\&;C)\/65N&S?7=1+A(0.$X!"(>.S )XQ@&0H21)XTCXB1=Q1L] M:AQ!2JT/?;09 M'(Q[:(H,MWHN0$_3NL&8Y6)^(TZ$)4(?0\))"7]$B%\N"&,.95Y+N U_>W8] M$P(A&"*.;2!'8%@S[Q<$S"$#E<*W3BT,/G9MO60JG#?M?[ MD?RA"]?4S+@\B-YI9KT4DY$IT10.HWK#Q_0>5'-X[V&3U1T^ID:_]O#1:P8V ME?BNXAC6:7FOJ.!&O..DJITJ081=N2-ED"5,&F5$FF?8(2&,_=!-@CB@5*]H MU+F!YO;9[LJI7E@EZ2!'U5%L]4PD&XB-_%$/ \N\#\(9)&RU,3@VS+1=",XH MN]=$X-SU$V_T5+&A7W.6BI36M\A-:%'?L-^V8.D[+N:NYT(W##A$ B40D\"% MB9\XP@O]1)*0"+ G M35U%KZ]7[=G;O =*G1EL$0> _]I[1A.1_SDVD0,FP=JN]&V[_MYZ0KN2_,O(YYZ#.8;40UC:MWZLEAX$A><&PG$I MB2.CC$Q3 >:WC,#'(J-QUZ4#OU%/KIZARO^'J?%G_%J MS9*G@ M>$QRLZY*^5K5/(&K.OR<\+LTR]0OY"Z\5[+WDHK6."X7P XBX MKPJ8XP3Z/'("Y#!,J=>^8]?9V.>$K_J&=>I-^GYQ:0O\?_3-&GD+^DKOROR/ M.!M@0 \94$,C7S*YN]T<@&[@6>S7C:\A @HCH$ "-4HSV/F.,.>OO3.VJ=(_ MQ\YYA$FTMK,>0[8!^:HW0O!M3SNY,*DGWV1=5J#G"H2]A$.'J$,D-^00BRB M$97\XO"8A$PKY%%CK+GMISMIVX -(.5M>$I*;)!V>0;@TTN79=A&7E%.(38D M8_4,= 89J_8@?-V,56FE53BM-PEMTJI(BU*=V[7(MY:=LO685-%6SJH>?B=S M5L\\8KJ<53U==G)6-6\90K\/*;TNP@I4.;0_4?FR4;N081X@X&)OPW%(N)Z.[T/4U..W=,R$6')-VEGH-7##UB41WM;O'W;96F34M=Y$B.8YS#*$)"!?9% MD!#N0LS)_R'O;9O;QKDTX;^"JJ=JI[O*F.$+2(*SGYS$Z75M$GL2]]QU/_U! MA=>8V[+D(:5T/+]^ 9"4*.L-H$":75N[<[=CB\ Y%\0+!P?G)4@R*HDE]5C, M-34N:KHR*EG!5ECGCL4V(-M>D'B!;O"[D)ZH];CT.(N'M_N-XS.-?)5Q5N7] M6XOSCPQZI[U,G*F1 M3^?=6F"Z\8BRL^WD#I@G.\EAXE%M(G= M7ML_/4;H1VFFU8M)+$ R#,,8*XJB.5;_(T-(47O+MN*.^ MPWOJO'Y%]S_0[PW<5.5?FGJ,I?A,RC_%2A=?VK9#F64D14F64<@E#R$2(8)$ M! G,(Y+1B'*-RK@1X5\J8N_--&9%!M9'9[G^W@MWO7 M_4$Z#@]L_%JK)6@D!EN1.QV3_+&$$T2>&,1NSE'9Q0F&U\SC]K ;*U7E:F:J M1)O$ZPQEG$9"P"BCM+XA)Y1%$/.4"Q;F0N[()WF MAMZJ#^UDU9?,U4H=C^?@L]K*UF7K7/63BWY0[U,OM'J@\S*K?VU?Y-VQ1GE1 M#XK?OHB'_]BWB$QC),H MH!2S%(5.I4Z/3S6U5[*1%!A102MKS[Z')Q"VV];]X#;P^]P7LAZ]<S-QNU#O'V&Z6>('LB*U8V UDS&3/"84ICS4)=5# M BG.4ABB- ZS@*8DL:H^PK:8K]_&'G= MPS>.XVQG0_A";V""Z ]_^7B^X,H MGW0-K&TWR51F+$K4N2,-PUB=.\) &Q,9%%F6!@G#48:=@E,/SC(UROAT]^4W M^'#S]3/X[=DP3F=_)2 M'UR"+%*'% 9QSA4!9:DBH(SG,*6A",.$$QJ%+H$(1^:96EC"%[$"[TE9OIAF M(T^Z8[)C8[@C>-H1B@>4!B:1CH3 B @:&3UV?SL-@J^N;T=F&;?;VVE5][J\ MG?EX/PJXYO]G7:W,9>87)3:I'F]7XJEZ6'X56HU"3296=:J-CG5Z6+Y7'[DO MES\*+OB[E]\K72_L[EGHIG.+[]?:O5+359LY(5@0*ULF@SB+,$0H#6 >1KHT M=X BF>7*G,EMMJ MDA/KN%+]9ZTWN.]^&WYOOPT;]<%6_T$R>L9:+$^;PN#BCKJ[C 7^ZVUJM'E[ MQOJ52[YFJZ:B $)<(H*Q,F]9!!$/D?I))E"D<1;D(4H(=3II[XP^M9WDL^ % MT]76[TFI-I-WX'^0I^?_"=X[1NOM &C'VKUA&9AB&[D&:&)\4&-?P70[8X\; M-'=(K;W@N(,?ZE$KYILH?Q1,W)7-B ]J#!/OE6-.3;+U%[?1DZ@Y7.*E3N-Y>DWV!M" [_)+3C+$K0OM6><'(K/ M^,!KI#HT1W#S5)?F'! G2]0!IF5\7)VIJDQ81-# MHZ6%?VIQ02LOJ 5V#3HZAO!I;O2*V\#\V!^R'H%'9^"X(/+HV,@CAQZ=47 _ M]NC< Y[RENIZ_;>FC.K.X6E&1$Q3G3<@>"P@2C&#A#,"6 M',X[UA)8O0N[:4P/8WC7M+R :.&KHJG>K)UI2UG[TTBMUO'NM9COT61A#T!O+1+V1^X9UZ-,UX\? M;M_?+G12*:]#6699EF/3.C 5VE^ <@$QBU-U!D \QBQ()',**CXXR]1V.G,/ MJKL"&G->*-/E!YG7=ZJZ_&])YD =/$6Y,"\L^6[J]12U1F!>/!6N(4 'H;?C MS8L!'9@*M7Q70$L(&A'/14FYA_^<@L!7\,_!.<8-_3FEYE[@S\D/]XW\>U)? M[;IDXT+1U$+;\.J[K^SW V6<0RDR&0D$DQ2E$,DH@Q2G$J8L)UF,TI0AJR($ MO6:?'*-LA3?$LB.^CX+:;FMC22U#(3XTY7@$NTKQ_;I:+9]$>;^<%^QEFS44!HCP@%'(HT#H MUJ II/I,FDHB,&>IB#*GH@]NTT^-[MKL0QV^\WU1N!\['=&WX[/A,!V8T%HX M]6L%6M'!7TIVT H/_JC%!X,D>O5#SA.K.4X^*JWU ^8UK_4E M.6'J@D+BO;8.RY?W2ZX3R3+)DB"%,@^5W<:" .)$IY3ED6*XF%,96SE"+>>; M&G5M:BUT9+X"1FH=\-!(#K3H[F4J3N%N>V_L#"ZJ8W%J M_-'+65@H>ZBJA*=T0N M..:IKKG=I];VV9FG1CFM=/T*:)\'VLXZ&@2^@3FF%^VA:$<\EV$S,,-T8;DY M TN/7*=CFGO+3MJ;8.1\HF,*[F< '?UDSY 0]BCX>B[NY /IC#',);.A6CZ"A[H*<6X$0.70;47)G#A<.YEQJQ9QWSTZ#;62_>H!R8#KR@Z&R- M6*'CR>8X/=>HEH65VJ_M![N'^I8I+(L?1-=*KEY?T.8DBG",U#&*" )1%"N6 MH0&&28*#E#*!X]S)UWM\JJD1RU92\+%8D 4KU/MQNZA6I4G5=6Q[= )B.R;Q M ]S --(1/.3 MS==<\/I._.EYO6K**-^008HYBQ,< R%2'*(DC15'$-" M2$,4ZW3%+.5.GAM?@DV-D704U7(!*BUD!1;+%2@6M4[J!^/.85N]M+?!@*#^ MNBD>]BS*^G%'#[&OE;;T*[_!^@WMC>ZHU"G,"EJEV@BAG>5K%0-*LSKC9*#L M$M^ ^W*"^Q)K7->Y9S#W'.Z^Q^_'_LHF*E9JM!]B[X[O^FE9KHK_-@(T=P)? MU)[S\)>8_Q"?EXO58S6+0AZF5/OH Q)!E"FZ)VD60BPQCK-8,DZ=[,K+Q)D: MTZM7 ;E1](7+84?,XX$\,!W7BD"CR5[XP96Y+V2K.N%EH]45^*<@);A;>+Q' M] .H)[J]4)A12=8/<*^IU=.H_0AU4P71-#IN,_!G248)D7D.,\ICB+@(("62 M08X"@HC,")-.1'EXFJD1X+9JJF.C()*,RS&E%7S/'F4_W3]O389[JJ&Y,M^INO:H4 M+7$USRP57#"44RAH))4!Q2.8BT! 1@,FXR#,J%N@TZG)IL8.[4%8"WL%EEM! MV[/Q+T5[3/[5/1OO*.01C8*8\Q12EL2ZK%(":8XIY 2%<2@32C&?J2]"L>3? M5J1(Q0_3H5*,GA)Y3^E#^Y]EG>G>U84*G7FG+_&M1_?F^%+Q8Z9]F882XI)&R MG=, 0;59*@(1$D-%(CG+4!"0P*G@]XFYIK=%=D35SL1:5*!E=6YSES.U1/5 MS7^MB]7+W>I1E#.I[ V)P@2&02@@$E@Q2AL%74.Z16<8-NCVM MZEY0[9F/NR=:7Z\5D2S+3WI13.GW*$DPCF.88!TO2V,&B23JIP2C*,Z2*+$K MHW5@[*F9#(UXH)7//DOZ-6BGW^X+H1CZIM86!:<4YR/Z]DIG?CW6:*G+1Y3H MIBD?^TC/DM=B4>E:>@MN7NO[9;4JQ:HHZ[)Z8B%DL>H4D-F&5!&:(I2F&411 MJ-Y5$C+=TE+ 0(:(RERF$7.J"=M7D*F]XC>?[S_=_?/F!KR[^7+S\?8!W'^Z M_N)8[;KOFMAM^6,@/3"#?-W("UJ!!VKC?2E8ONI@]Q5CW*K8%X*U5R/[TO'Z M5_N\V1:V;#IS!3FC/,T)E"G'VC4=PQPA#J,TR7B2_W"/GFCO MUE6Q$%7U?OE$BT7M[J@KL_VWX+=<35+(@FR#%)K^%;L)A>IOZR?!#]X'"U4W^^B\45J-$ [_]&WR*'9GM3_S:-U,AOTM\JMZZ!;[FB M)SL2OHE@XW4[?$O<=SHIOJD@%P=FW9/RKC25^/A_DOE:M&'V,YZA/,IY" .9 MA!")0%E1&6,P3T@B,X9D3+.>\5G'YIR@W=,)TWHF)?BAQ35!+'PYGY.RDY'4 M/Y[EZ!+8WDY[!7;P6^IN=(L26*=GUR(#(_,V66B0.)=S$/D/=SDZXUM%O9R# MX$3PR]E'^_'19U+^*5:=^FV4H4SF80P%%H&^KA80HSB"A&91QB+,(H96V0/6CE(N@6M@_MB(YK\H MWC&M/5'"WO"COO_'E'O]LA_]7.\L.QWW::+*6W/G9=NI)9)AQ(6 (DZ5C9'% M,:1$O?6AQ#C$."^$;9. P%L63F6K3L-K=V+[@VP@=_Z%JLF M+60CZB"-5*Q \9>S=F*NL5/2SJM](./,XJ%^W/%%K+1#^KY<_BBXX.]>?J]T M7MNAOL0!ECD.*84RH 0B=32!.8T8) F.!,_3/)&*2)8K,KVYDU]T>?UE7IL;"K^K_VD[&Y'PGXTM7Q8Z#AL%Z8$+2,)M+JOLN MS+^W, _;,-H=,4]LY3#QJ-3E#LAK'NLQ0C]2JZ/\MG4//O[X4LR8R&*N.Y_$ M*=*A>;JE,,Y"F"5Q2C$F#%,G.^C0)%,S?VH90;41THV&#N)H1SB7HC,PM33 M;.6[ A__$WZYO0+OUV4I?/:O/(6$)\HX.,6HY'!*R=RF>JM2D)79LMO@+0 M[H6^!):!7^==1#Z<0J1'+\3#:GOK=OAJ^)'[&1Y6;K]CX9'/];QY$$0'M^H! M;Q?/Z]6#&J8ID!PQ'D18$ICG,H.(LQ#F@L>0DY@F) C2,';:I8]/-;77NB,I M,*("+6O/*M0G$+:\C/""V]#7$CTA<[^D.(N&K^N*XQ.->W%Q5N&]*XSS3_0, MFS!9NA\)J[V5]#"_@3CQB@<57 O).'X)_N]VIU0 MK%F&1!0'C$">X1 B$F'MC2,PR;(T#$.4J3?>Y3*A,_;4;@L>]!Q@OA70[3WN MHF;W O?$8N W]Y,% ,ZOZP%5/;VGW9%'?4$/J/3ZS3STD9Z[;>WMU"V#G\0# M^=D$)#29:3.6I4B(4,* X1@BJ8[9.(@99#3&+(VC-&'":><].=WD=N%:VK9A M)OB%UG+^^N^.._%ID"UW96_0#;U#-ZC5DIH>=C2Y$FLK8Q1#H(\0T+09)BC88>BD!:36! MA9PD(J&0A%Q[3I,(TCQ4IEDN>8IC'F>Q4S^_P]-,S23;2MG8%VZ$ M=@1+.\JZ'*&!26D/G $R^D^#X(E3CDPR*FN<5O0U+YSY=,^X;F4 F R0CK/U M8]W6C[TT[OU$4(GSA"@&X+G^'W,;2F'.98H#Q%&2.EV@6,PY-4[H7@ML1.UY MD6(#N1U;> 9RQ*L5!PS=P[[M4?$5_&TQX[@AX/80[ 6".SS:LYA:J5MGK%[N MU;=C=;W@.E;K64]SJ%A70AA)LA3#,(T5 >6Z["$- O7/E 0\R!7_.+7DYK(&=F0T%+(#LU(K MM@)5"VZ2]#:B@ZWL0U5.ZX&:KVII+E./6R&M!RA[5='ZC.%&:+K'^D.QFHL[ M>;O@Q8^"K\F\#@Q-XRRE@D&LJ0NE<0YSP0@4DJ6"X0BQS"KM]>@,4Z,F(Z1V M(6W%=+I0/@[E:?+Q M# #-,#&VL:.:O_*:Y0#W=X0OUKRQ''QQV%",ZJU;[M MYS_8U\TL15D*_D!^UM4^;A>*4)BHJJ^B$FJX1T4I'\0/,5\:4IE)S+D@ZF5G MN:ZRD6("RX M)+9.XN& 'MQ!7(MN[K]JX:^TE[Z1'WSMXO[! O<>ON%^X'GS"SM./[)/N!\X M^_[@GN/TJ/-X;[I)?5R6S?N[]3F96SQ>K)3=5*GYWI>BZ>O[<3V?/Q1/HG5% M5P]+W>KWJY#K!=>.:R5W'>93S9A( T9C"E-.L3^VH,?7JMOQ6ZW$RC M*NAXZ+O*FI5_WUGUCYM5WZ@,5DO3ZQULM39[2Z/W=+X"#H4:I_-5&*DDXX-Z MNY_?F"S^U5--QG$6[V3UQ8%%&*_.XCA8[E14'&E*SV[H3F*+D%$>2II!&F;* M7LFB&&*<2"A0&@F9Q9G,W=IWG)]S9(I1I^6B^_0 M]'97FVO=VKT^O0UP%^: S-!>Y;?*.W* P-J'["T3Z4-1J6V4S'\KE^OG^A^" MW\EW+SK4Y\O2.*OKB#OUZ^>F6'O;(H+G,>UNUU9U&2D"QG(<29 MU"5L _43P3ED420I2EG"D5--I^-338U#MY)VPI#[U*T]B*L=[?E!:V!2.PC4 M.'V:S^/CM>KMP8G>H/[M*84/5\(]^43/'LUB/MBC)HJHO]>I"=;<+ M]6J*:G5;56O3443_8!A+%^6O9IR(!.>80R9SKN@D2'0B1J@Y!<6YS!@55M$% M_D6;&OW4>J#5K^D7Y7(_Y?GUM+^.>K,E'>GV M:>RE=;M/&@3]D]='?F<<[[9H$*1V+H>&F6&(K/+WFYSGP\F7GT15/3R211A] M5I]\K&:2TI!DG$%U#! 013B'A.EV&'F>9UDF$X9BU[JP_L2;VI8]7":ZB8N8 MZU"XE=(?K/X2\_2;X?Y32S4UC97&]8WVWN1_ M?]#M=CN/W]B!MZ\N;KNR^G?@6:+B:5,Y-]NHNX2EZJ]IW_:Q'DZ]NZ>"W93D M0T&^+Y;5JF!5Y_S2W.8'&"4!3Q!,<1SK1" $<9IP&(0ABD)"&<^M"LG:3C@U M)F]$!AV9N^X !Q^-#=H63C3/& [,+6?@.Q_^T ]'!P^69SQ'\DOU_5JZ^9<< ML#GI-;(99SQ?D(-6.QX>E^?Z6=5WJT=1ZG[JI7A4Y*Y8OBZ-HPWY!_+S?EGJ MJ:Y7J[*@:W,%_+"\)[HZ83BC640(TK8?BT*(XE";@CF#/$QEB$/,! U[F((7 MB#11,[&I\[0B/T%3G!248FX:?:^6H%B))],C8ZD5-RD &\V--\;-EKQD1>WL MS*$7:*1]PJ"]HT9;D.L7K@&'5 5Q^];+5&_NQ4#ZAZLF$OD614 M^]8#9*]M7Q]#]F/B:\;*M>#WY5**JE*3D/E'(:JF%NQ,ADG.$HYAEJ0KX&&XGGU,U"PE8:M_%*O']VLU MXI,HOPHFBA_:D+Z6BM6OY_/E7T1!HG.>39:RMKQG/) XDY&$L22!VJ+"!!*F M?DK2+(A2)B(61DXM3OI*,K5-JE4$_*4T :TJ^G5LE;D"1*L#-OK4M2[J#EV? MG-T+_=?0SLH>964&WMJ&7!3WWBN7 NJK+4MO.<;MV'(I7'O-7"X><-#3P&^D M6.C9WC^J;["X76RJ%\]R%B'!9 XC%*IC01QQ2% LH) !%EDJ A2BV0]1TJ7G M@\%1D5Q>\:Y@ [[I1D033[<-OQO$,#V^3EX/#%ZPG]C)0>NT\>G6BND%TZJ! M_WR#!1OD2.%EX29ZMNB_@$.=-G0<7R>*9X^SJ+2\QAR?MR>+G>3R]1Z M@<.0BR3% >1II'N)8N]+Z0#.TQ;TJ_^G>/'U+8ES=\9^QQG=^'U-KS=1_\4+\WM>6*3OC# M?;E4YO(3N5U(_1_]JR_+1:G#E4N=C+!;:F*9DKB]OAE\1C"))B'I) M**94O2F(0I*$',I0QH%ZC=)4T&9%;A9\0NO12C/<:J@91ET*M]/F0.!.[)[E MTUENZGV4[ &@Y[.CBP1O0! &!"$N4L 0C3KE3-4B[>:=F%W3%!GS; M674I 5-: *G4 ,56CW]W+!QIN1IVY#< Q@,3W@Z\6F2@9>ZZT< ?K=@>_66. M0/FJ-VDYZ[C%)]V@V*M$Z?AXSVO#K4OLX[+\(OZZ9FRY-CQY7RX7ZD=F9*A, M^]58AHPG>0+C/-3W#HS#G H!PXS'&$36JO07HXZ$TIP'>D$ERG0(I%5=-F6>JX"SW#NY?M1YI"L==_J:_59_*S M>%H_F:",.UE7%+P7YO@THY-;)LQ-W6]*L+[NIJ;;J+%!"-W*"H=+^ZIV+5>%N?E02/Y$01G1%7 MWN(B80KK.;1EJ64#1@'051)TM#3=6SJ?:S0%1E70?AG^L_TRU.H"I2]H%9[" M>CO<;DQAW4=L*?E8?'_417K/OLY,_:-]A<%ZH;C;])!\GNO?JW_4/C5?'2*' M7H63-RV#33[>QL6M!78"@_^&(2F^@'GJ\"IV^3CUCOM!^=-^H_1,B2?5H_X_ MW:-!'0R,$Z?MH[3;<*UC3?$T#4(>09&C#"(6YS!/,@Y3E*1!*CA/H]PI&=Y= MAJF1W>?KK__[YN%:D]VWF_>_?[U]N+WYYIC8WF,E[(AN8'P'9CLM^55]&]91 MX*K3=^U5V\:!6.\"%'UEL/>08-S<]?X0[66M7S!4[^(@3"Q63>&1HOI3V93Z M%^2["&J6:1@Q$3HDO-A#%&>Y!#C5,)<4DS#-);$KG*I#V$F1]E:3EUS MWK58\D4K8GD5,1+.0]]3M&JT_*D$!%H3L*O*%:@70Q^9C3J=S^NJS(T9Y/$B MPP.^OFXY+A%EW"L0#Z#MW8_X&+.G1=SWJKAM%UNM2A,:49F]0'?RNWO60U2_ MJ2%6U>WBWL0A_$,4WQ_5CG']0Y3*D#=__* TVM:[$@RS4"K;.B6)4"PM$IA' M$5,&M@S2$*,HPU8-G2:GV=0HWTBH+#S=G)TOYW-2FL"P.M#$U=J>"LBV=OM4 MY)W0_F04AI919_! U-G5ML/X!I[F_&!:QC8(78$:(WT.K%&Z BU.H &J_@C0 M4'DMW#;9]?=U0IF,7N.>=2:C]K%3T^0$[&\)OMR<.#^K &UBM #0:[$5:7)E>L7>Y M#$E/6T%/(4;E[DVR%X[6\^"T6K(_;ZMJ+?B'M2Z!51.Q(=LV7O9=W<;O M7GU;9V$D$DD1A9D(.$12'6]P+@-(1(:%HD*68R@!0$/[RYZ_@B:S8H^-A MQ7')+(\4PRW$T(:_ ;P6'=2R;PQS(_[5)F<$-!H K8)'<[P?=KZ,9L?9QS5M M^T&S9X#V'*:WF:A?ZD]"F;.;X@^-65M]6-?H15&<>"0YCC!&+A6 Q<0H7.S'7U'C'B JHD154&V%[U'8_@JT= M^WA";&#",5+"6LR="-9S]3_[%8(_C8?/LO!'9AJ_2/QIE0^6C#_S2#^V^")6 M.ISUOES^*+C@[UY^K_29\N[9%+1:?+_6MW1FNAG!#.% YI"B2)$'PQDD89C! M6 9)+&24DSAVZ0-A/[43EXS0)$+G+9JZ4L^-[/JRX)=U92*^?@7+5@- -BJX M\8S#JMC1SC!8#\Q"&F837W_?A?GW%N:-\.#Z/,S.Q.2.F">>=\;)\ MBZ4\<4?S<;U:E^+ 31,(M0,RC M<%/;7KI1_:):%4\FIE\:971JQD8;(&IUKI01N;DX[=/HS>M26VXX;[2 0V\Q MG;4[>;6MMI!:NYV;;=#H-TI^AD_H/2=K>!'M33(W?()Z+(W#ZQQ];] 5*>FM MZ/U<$2Q3!+$ $(I*J8T6*E'R M^D7IBC3@^W*D4=#@#5#<^OX.#/G$VZ$,T%?XPNX\,K[JU9V8:=SB=.=5WJM$9_%(/PXQ(VTNI.JD MT^8D^$6L9CGAG.0R@Q'6&9M!FD+*8@E9$%.6IE$:"NQR3#L]W=3.:O57?GN[ MO5.ZQ(U#SN!L1R/^T!N826K@MO?5;5611MA?K\"7$R3L3")VN'CBD3.3C4HE M=HJ_9A/+IWK&!Z_+16%\2PO^L?BI?VH#QE)$U:F-!9"C1-LD>0BQ.LS!A$E! M@SC,1>A$)L>GFAJ1;"0UE1]D(ZMC5/!Q8.W8PP]< S/'+E*MF /$X9U'PU=L M[_&)QHWF/:OP7OSN^2>\>8'4%,:>N6;_M2YJH].QRZ#;H!/ZRA]R)YAO?QW! MVQ%^D*:#_7 ;SFMP:O*W]A18 &/A'; 9I6_IU*^;(/B0)E1M MM(3K$*Y0YA!':0(ES],DRH( I4Y--P[.,K4M=RLD>-92NM9&/02D'1%=#,_0 M5RM;9(R VRN)R'P5@'UT!PCESX]H>9^S=-3'[YL(^TP275?+C_J/J=?Q0^Q M6(M9$K.$ABF%-)-"WYMP2*,X4N=X*=0_8D2XT]MO,>?4N.!!A\B#LA;.T>RV M@=C-0/$$W%A624?<*QV8#HS H)'8OQUB 8]GX^/4C&]B<5A <,S,L'FT1S_0 M]\O%#U&N=/S(E^5*5!O;/,\#S)DNZ99&RK;@RJP@682AQ#')\URD66+5U/CD M+%/CD_=W7_[SYNN#::GSX>;=@T.[Q:- GN80;_ ,;5L,@(Q#(TD?"(W4"/++ MOUW[:MQX3NN3C1>//CQ>X\1S\N\T/CS[X9##$)(AU/$J4IGTZB>U.,S5^:Z6\ L5&3J O/?HU"WN%J>65 MZ<5(#7U;N@%I*Z)I[NB_O]=A##SW\7HUR9OTZSJLZ+&^7$<^W8\ /@@IRE+P M!_*SOEC5V1&UNV8^7_ZE"QG,L)0REC10)D[,(!*9XH4T"" /A,QD(C*6._7; MLIAS:M30BJSKB=>Q%*:-<>.T;*5VXPD;Z#E*U;:5A.K[BV*(4O4_)(T)S% L M1*1XF :)6_2?+_!'#?/[I$]D$/SG&)#;\;3G[_# I+WY^NH"[6V&Q1;-Z[-H M.G.X SZ>"-UFQE'9W0&"UU3O\NBE_8+.%G*MCE5R-3D3LQ!'>8RH(J8@"-51 MF*601HDR&)$4DJ,\I=AI=_ FV=3VD&[V4YU$2T\FVU;;;%NZGVW;)$&YYE!X M6W8[FGR3Q1R83/?7\732='4R:_KL.E[08<@3YMY[#5TJUQMU'?($Y_'^0[XF MZ.'I/.!(;<9_4+,K"3\LGTBQF'%=S# (!4RHB'1E,09SGF,8H#S*$,D0CZW8 MWF72J1'YD3N"YJUN1 =_U,);$K33(E@X30> ]FUN7L9#U<'A.@"Z(_E?/:'L MYJEUA.NDX]9VK/'\N([:[;AU79]U8_:J7,VV)X<%_X\UF1?RQ91@8J:)Y;:A M^RE,8?#&&-KK'60=K M7KL(SU,&M1JX8TRK?VT-Z7YSCD*$%\'1,N)E@_0P>F\7/Q33+LL773&B>M1% M-Y^*]F?M;J]F*1)"!)Q#(700(4L7PH%):R,L:"4$6MSMOW[SCZ&#%>L7RY$,V&O3 M?1M0(9>*U'_L[ "?;C_> 369*'^(JNF_\3P7ND"4CD%\5)\I*O%OYIMK'MC_ MK6A;ZM05U[<#_%6L'HL%6*H]Y$478%>C;S/DV N;"]T2;@74Z?SU(-5R?N#Y M\O7S5Z"08+Y41_W25XB$_0J?M+DMAAG/W+;7:9)K:CG2Z;AAH MU0*D EHQ_9X>S#3IY3[WL<9VCO.15V[@C7"L1?/:U\P1YA&:G-E*-)F.9XX0 MNK0_U;_6%[2K55G0]JG("8ARC"G3D3>4XZID7>=(*^-JE(\BD6E6\?O5!=H M[;KRM9J.90=Z+IL=-X^P& /S\=W[VZL6ZCTE-G]1>ER!KB;:GJUU\5C$X#(P M?54WZ"G%N&4/+H-JKQ["AF': 3_7E9P?U(BFGB.. M,4]3+B#/F.XHF4J(601V8\3ZI:VPZX.*)O&QF')6H'"!X34HNC_8E MH":XSA3W-.$45=U&4)@&H80(90',488@$7E(,Y'C((S<>.?85-.C MFS9"U/2JO0)%W3NU,C*#7XI%\Z-C_:<38-NRC \(!R:7+7K?:O1J.9L&M#ZI MY1P8WACEZ$0C$\DYA??YX^P3WHJW*+MI^7U1_+[ M/%R:=JLPZ&J\[W725P=;'4&C]E7WEQ<7%/;R9;'CS+=<^[OLH-.1S M-8:K2.1%RK03:HL:1UZGNZ IWJD@XF,QQ!])49K>2$:DNG^2DO6S6#TN M^7*^_/ZRR4TG(>8DC#%,PHPI0UD=T'.>J>T3M:B@E174PH)&6KL-XQRTITG> M(V #$W-/K*PIU!*) [17"?:OWY<__DV-4#.>^F%+=.?&'86<+)5K"<7VX_V, MV-?7_5_$ZN8GFZ^YGJ>I@S$CD7KK21+IJW4.49!E,&!C3W%PC:5NM6' AN[_<:S4ZU'+8V>6^01Z8OP^T 542Z_X)CR"D2>#UFK*42U2%Q!>FY1.SU[0KN6+4J5N(%7/TU0G9CCBD> Q MS/(LAHC%"+8?GFAKYU^%4.F0>G4W/@6M'H7]5X&VP,-G3Y8C,XW?D.6TR@>[L9QYQ%-),V685M6,Y"1- M,Q%#G%-U?HPCILZ/E$+)I P(0USDTL6 .3S-U$R6A[9>674@9<93$:T:7SNR MN!RU@7GB8*DL(^2 Q;%V0!BJ'E8]R=N6P-I1]&S5J]U/O_V]_=;2J689#M(L MD@22* F4V<$%S#,10!ZJ0VD6)VE&49_Z\I[EG)K)\D'\$//EL\Z-$^QQ81R' M;W>WWEW0\>_6>R[3W_-N_4@*T$0OV@\LS00OVKM2_FTOV@] />1%^Z'I^NTL MNBBI$)N&@I\$4>S9MCINKDZJ#VOQ1?Q"Z(EW>XLQ*K%>"M9KYKQXO'[4>*T8 MF1?S]4KM]M^$.N(;!JZ]@H)_5&KK:Z)U72OB3MZ0P&2G M"!K12.89S!A#NAJY-KQ#!&F>1Q(EZO\CJ]8K(\@Z-8+M2@JVHO9*)!IRB>W8 M>2(+-S"!]UPS9YH> 4U/3#ZDI*.2_0B0O]X/QIC26T\_G?NU>E$&NU OU*K. MXK@K]7^UK=\&(Q7?%SIU*Q8!CYF$"0^%LJGC$&(D(_533A!#/$T3IY31R\29 M&O&;<,,?)MQP*>L4KS;#JU@ LM7QXB:!+FOFYG$9?B7&ISM0T4-2H-VGNP![3#M25T$>:M.Q;V ,ZBF6&?47L40OPF5JMY76%\ M%@=I1A)=NH3GBC_C+(B=<#3XT3.Z(Y5.#K(G6:OR[1 M?V FNEQUARJ#/2$8J9R@#11N-?<.Z'NRN%[W\^-5T3L@Y4ZYO$-_O[33C+GR MUW7XJI49^,MR]54094V^?";EGZ*N,B)^KMXI*?^<(8F%C)(0QAF.(:()@CC# M 4RIQ&F2D#SIVU?&28ZIT58=Q]*1'BCQ02,_V"K0MR^,VR+9F7 C0#\P8]JB MWE2H UH'8)08I+%++QB]MW%QD^*-FK;T@NIXBY9^P_5C3G44?UHN3"&#)B / M1YB$+)"0"T8A"E,,\R3E,,(IYRQ)%%T2%T[%,9;F M'*=DOY-FLKM-5MU712]EH4M(FS^8!+RJ+F8RDT$F$!,)Y%G"("*1LHOR,(41 MI2++ LQDG#BTGO*VH%05EKJ.\]BT;'K5MLV4G%+3>*-G\D1E7W MB&?=7E_;7\OUIJ9W=[;QN5-U*=,$=H]9J OZGD@ MZC12OBYUO(0R^,"S*(LE]U65?ZA5.^EF\#[I>+Z*H?#:<7@,-DD_VW^_X6\S MG^EML2G5&<5I0!.20X9#W9H]#2%FNCL29BQ'!-%$!BX' KMII[;+GVD.M=6E MI?ZZ04CO(JJ6BV-WX/ /^=#>X^'0=CZRN('GZ1QC.>FHAQLW(%Z?>!R??M-C MD+GTJF8BY1F-9 19+'2-:$XA(93 '$?=S7].]Y]*GU?,ME?9.CC_OROO'11]0A(\63>L[TRM%'E%?1/?]/'H=V M5W*DXU SZ=_Q.+2+UT#'H5>3]"T*=LVY^AY7]\MJ1>;_?_'\?LG%C(I8K2P6 M,* \ABC,$<2(Q9!'"0]B!2S.K7RAIZ>9VF[>E+EJ1+T"M;! 20NTN*XUP0XB M>WJ#]8?7P#ME7ZAZE 0[A<0%%<$.#CMR0;!3JNW7 SOYZ9ZI=LNJNEM\(_H& MMG/Y.A,)8ID(.8R1%! Q)"&)@A#R'&.=EQVI8X!3)MWA>:9& %I,H"\"E:!Z MR^^(ZI@_=P17.\^%![0&?OW[ .6>X'8:!E_Y:T=F&3<][;2J>]EG9S[>MS:@ M;ACW35G?QC+^M*R[5GU8/I%B,5-;O^ HC&&4I#E$J5L'NI+)1M2NI[/7\=V.19!MQML4M_XC717VFT/]J,GA[B&;/:!. ZD.FP',,4L@0CGNFNYQ)"@+,@8830+ MG;I!V$PZM9VWYZ58OVW9:E5\W#Y.;I,>"F;/%X^#;.164T[HTO'TMN[T;)^4 MMKZ-#AIWYNUB51:+JF!UDEUK"BAV2[GV.**,ZVO'1$+"6 AQFO(H3$@>I%;' MBP%EG!HU7G__7II6<& C;WW5Y))[-LQJ6EPCOOT:#4VI6GI@V,>5O4.QVLP>'G:J?+?O[HMP4C7L@/]^)A9#%JJK/ ME^H7]V)!YJ::Q8*W&=?-U=>,1T%"A:!09C2&*$$9Q'DF8")D$#(L0\UC2#=JK6JTUPAGQV[[.)WFJHNT'YAY M&KD\YA\>U?84)ZB'.GR@_K7E@OWQ1GFSCZK1OJ?'/]#/H+DOE\^B7+W1U&5<4HAQ%D))2493AI(TMWH1;2:;VKO9 MRGH%GK6T9O,3K;P].C*=!#IB-.(ICZ&(I&(\G@4P#S"& 4EHFL<$LRQTZ2OA M#>@1NDN,"K2=>><+OH%9=(O<_0:YFRUR7TX@YVR=V4#BR?PZ.=6H]I6-TJ\- M**MG>O@B/Q35\[(B\]_*Y?I9F6-U;RSU6Z7+JECHFEYUA5YU]'UO?O5=3:I^ MJ@K>_'Z& BQEEN4PSS,*$0X8I!FG$",N8A&'099:G4!]"30USM^*"5A73@(Y;CZCL>&E]CGM!7\=MU,*A8DJ;ON.S@(4YSE@.@TC? MOR540H(#"D7*4XJ9E(@ZA1FX3#ZUW>YUI,Z1OQNDXZ@'&P_Z3J&MPYT1]BTTGGQO=[5+NX\=\E"VK'FVRW/P+QZN,_<,0.S&XV@[%"CG\[H:#5LLI>O M@-9RT)YR'M ?KI7<)<*]=0'QFOJDQ]>YI%.P*W*M,SSG [0C8 M(XRCNF(<$71O8FR'BZ]NQF=F&[>ML9WJ>_V-+1_K66>]S9"YD^])]?AQOOQK MF\&2\H@R*3!D@:Z6HPF&9D$&6Z VW'*;[@&YA0+D#.O;BY!22^*IB?FFK<,N462N_5(K=YIF?;QKI][B;6 M/?&DUWD.\W8=U]M40<'?P<7OX'51LK^W>X4_USG\O=1_7#Z+^[^WB M2'_7&MM@VFO:O!M:_E+H+><=.YW> M#8X#J?6. _3T? @IRM($)==,^$6L-IMF0%,4Y(J?"#7^;,5/E"FFH@F/\C 2 M09P['4U.338U7FIE!2OR$Q C[;\[^CA.06OIX/ $V-#>C18KG=A0"VKBY :Q M5VPP\>79.#75N&X-"Z7W?!HVSUP0'/!%B:Y..6V*#\UB$@09A4P@!)%D":1Q MH P<%C)U'.%YD#CY2 _,,36.J.^?&QG/INY8(^EP9]\?GU&NYFVAZ7?Y?EAY MGW?LKV88_RK]L(H';\R/?-2366"FF&4XEBS6'6=))""B 8:8QA**/$AE@F1& MDO B@\!,,\W7?"6>GIP@HP0@ZX^>^ M,-2V7T_RMAO^CJ)GM_K=3_?C &4N:"_F?;G\47#!W[W\7@E^N_A8+,B"J7/( M-5L5/\Q!?98%A(>A8H,D3U*(HC2 .98<9EDFPB!/A=#Q?_:)-O93.W'%"&DW MVNHU6]YS([NNSR!;N0'9".[&' YK8<!=[#G,[GO*(Y,#D="F([L6-[:#Q5>3XS&SC%CNV4WVOZ+'E M8_U[0A=-B<<%WP2S,45?.G%COJS69:<_NQ!9F&,D(!7J!(4R&D"*H@BF@L9) MBA"+B'/#:/OIIT9![^\^?[Y]^'SSY>$;N/[R ;R_^_)P^^6WFR_O;V\<;WX= MU\&.AX9#=V!:Z@AN,IEW1 =;V<$?6GI@Q/?\(,[50J6GE[GPQ=%\6.[H; >*3J M#8WD0"Y+\$LK/- OX*\[5;2'.B?VA,Y7E0?'V<HQ(()!@,$D3!A$7.B6 )C!E3"2Y[G]#K3I=6LPU M-8.M$577$]P*:\XX5_IW[Y:KQUZ9 :?@MN,N3R .S%,>\.M1"_ L,MYJ_1V? M:>1:?F=5WJ_5=_Z1?E3R5:R(.FSR&U(N%$553<$YH:-U]5U:),,0HB0A$'-. M= I]2L.0ARQPZHMS>)JI$<@U8^NG==T8]8.0!2L<*U(=0=..)"[':&!^: 4$ MK80>J_K9@>")"HY,,BH+G%;T-0&<^73/V[3E8ME&\-5E/YN;^DU(6$*2D,E4 M0"1DIFB Z/9800RC6$0HDSD-&76A@;,S3HT1VB.1J9'[2]/I]E?'B[*S,%O> MC_D$;^AKL8ZL;8GA7QIQ?QTD!L\:'5]78&?G&_?FRU;]O0LOZP?[D4S+6/>B M;(NX%VR&@RA#*%"F!0M,AB&%N< 8ALK*P((CR4DT^R%*NK2EEH/SN+P1W=F& MO2^>ZSZ3"G-0F28)$% M*_BE6 "^G,])V?FK(]<<1MN.7RY&<&!.V5@=2L"Z MO\05,#+Z(Y&3$'@BCL-SC$H6)]5\31"G/]PW^WC)_KPU#>4_F$;Q]Z9'O*F= MR(=K)$<0!YF&>9(DC M:?228WJD8@)02L%$\4-9Y^L%U[&!CP)$01B 5G13.M8U=[G/,MFQS>#0#\Q& M1C90*P!J#4"MPJ:X3*L&J#]KMQ ]4J$O -);CG0?&49.GKX IOVLZDL&ZVE( MM>.*\D?!Q.&F.GJ9?\4JVTC%B-HTTIG%L6< M)#1'D(1266;0'*\5A*^:F&U+/UV!C:Z[OBC3MZS6 AC^HNOM\KEO-#!(-MJ0S&5C#(.DXRF MRJR7&<0AQ3"*<$(B'.!8.$6='9]J:OO$5E+0BMJ[SM )@.W(W0]L S-R3\3< M*Y"2LPGM52LX_T=,Y<&$[R)N?HF1%):K;16V6&Z[;;1(Y MHP@E,5)\(U&"(,I(HBQ>3B#/PC@.\B3AB9.=.X;04Z,O(Z)NX]AT;<["+,E"'HC$*7#OY&Q3VTJ^L4?!UW.S>W EK>D&9_ZA^XNL MVTP!WN9S;]-7M4?%,3[Y]#K8;0S>T!V8T3MR BTH^,.("@;*K+ Q5LBQ:FY M1LZ;L%![/TW"YJ$>[>.V;2HT$9+%2YV0H4[^[\ESH3BM=D&])_.YGG,64R&# M1#"(*-)W:8F >9R8,[C(B(AX@*W*_O69?&HTM)$6L%I<]=]:4H=N8ZX+<)IP MAH9U8/[I=,)I1-?.T1;E1OK6+0K>#X^V0Q^W 5$?J6>;9_3=VK/UA.]D*S;7 M,<=KN]93VYT6:WW'Z%M0B:Z^";8N34K*]0]2F%$_+LMO9"[T'1:9:R_PIV55 MW2^K0G]5-UV.7AE-NJD:27@*\U HXS43.20\"B )4!K@,).$NW6C\"?;U/:8 MKJG[O=2A8.N-.B8T3-2VKM0-PHQ+I=(?+3;?#7.@)HO7CX'G!@?7 E#^O@5V MIO,;K>W &YTQKK=J*5)M%8-R64*MVA78*@>T=J!5K]L.;E +?0#LO56X\B?9 MR&6QO$.Z7TO+_Q2]71C5#49%-C=1T5:7CZ7HW:&G:&Q^_+8L&*YWE-XSLZ.;LMCF-O[;7P M@NCP3HNMF%?U3=\+^*/Y[U"NB[/(^/-<')]J;,?%6:4/^"W./^.UNM^!_.FZ MJL1:_6[;FDN"A"A%M TRM6Z?Q^C#Y55[Q'K8. MH:M04ZA1V!-(R_J%?4=W(W(NBMF'QK/U4))%;8E^%<_+4M%R$.5,MQXF.==^ MYC"'-* ,IDB@'(4I#L+$AI9/33(UDFWE!%M!02VI';.>!/0T3_J":>ACLSM" MUM1E \$!(JH$^]?ORQ__IAZO.4C]L*6>DX..0B0V:K6T8/79?M;:;\LE_ZN8 MS]L4AVT\V#7_/^O&537+44)2@4.H&TBIMY[E$(L@@2)@2[AG[&CC7+^3;3/OZ^W+5KU[Z?S+ M^,5F-!0!#T(!XUQ7N* B@B1F&4S"C BAU\2MGY2K %.CJN[M1*L!Z*IPI8\E MG5\T[FK7KKBNZV3'9$.B/S"I^0?>/8:R)WJ^XB%=IQ\WMK$G.'MQBGW'Z9DU MJD9;O6PO#_Y1K!Z7Z]5707@Q?_D@%*<\%0MSF]!>&'Q8_K70@9'W9<'$EIJO M%XMU>P,]"T.2,]U3 R,:012&")*,"@59I8+3NF#Q7H%;\7)[AF-\5.^I^PZ4?J7S)&RZW M>UKIH*OA*X]T&"''31P=%.B]3-%A9_,2%K^=>5,MO)H%5-* !0%$2""(\H@K M,UVH_29C/.=,LBQS*D1G,>?4+/,^C&X#K?7-L4_ AK] WHEZWXFOZ8@\6.C[ M*7R&"8 _..-;AL&?@N!,,/S)1WN$Q+<>ASMYM#B+R0VJ9F&2Q0FF&(J4I+HX M'='7%;KN;1Z',J-!DC#K8'CK::=&-1NWFCJ+BK:(466*&#VW?WI63]0EZBI3 MN:[^T;).JG*:HX; >F*6Z,)^J%56G6UHF.3E"ZQ ./PC$(P7"?Q7/=5Q6 M90JCB=H6+Y[4QTV:F?[E8JUKZI[[SE>;?YH+>C/:8J5'XW41,/V;9Y-!^*^> M NF=@3\90F\_VGC!\\X:[H3-NS_=SU"]7;"R;M15__=VT;BPJWOR8KR4,HHE M(I1")'$$48022 @B,)*8R30-4T&L[KBM9YS:SM&*!YYK^4P$)&&LU%7RY@6A MQ;Q'0YGSP-L9L5[A''AS:&4%O[32_JKC_C< -Q+[LV"MP?%DOYZ?;U3KU5K] MU[:K_8,]+%=M#=?&<65J-!DS60?T5*O2[)OWRY7>?LB\9KBZ)N%,,B(EPSG$ MC"LSEH@(YH+G4# :F3)^86!U7+Y AJDQD\G/V*IQ!3:*@*TF.M:XT:4QNIH* MGPZV5\\EL[!QAU^(@3EMZFO@8 P/OQ8C6<8#K8F;A7L9FB?-W9Y#CV?[7J;[ MCB%\X5#NP9XWYN1SOZ;S@GV<+\EJE@@I8AI'4,0Z^)Z+%.:<1C!+XQQ'>1X$ M*+2-\MP;?6I[2BT@J"4$1D3[N,Y][$YO 1E&:Q[_4+]#Z\:7>EU5PK1D_;0]AGU6!NNZ%/QN\57?"6G_A?K EZ6N M7US_T^2U?=IT2$]8$.4!BB%),8>(2@0I5_^,*6,)8R)G;BE^7J6;&CU\W&1P M@Z=:E=-1B2.LG]TY^J.0^5170U"G>_ZA ME30-$GVV1!P$?4^'=K^RC7K 'P36U\Z 82;IX3BXDU)L&Q/<+/@'LA(?ED^D M6,PDSTB$&5$D+B.(XAQ!K%N[9:E(8X)CS"2R]@ZYMKIV6+9WT_!(0N::CD-_V^=(-' M;S_:SN^U(W MU5-VO/HZK!3)Z\"K9Q,WY9;E?':<";%%*^N5N;1>&:-I(^\@.MWOK!OI7%RN*'(JL?8NMZ^EI4?YJ.Z;DD0E :02K##**4)I!$ MDD :A"R.0I%S;.4ALIEL:A;(5M:.<[573_J3$-MQBR_@!K\TZ(%9C\)8Y\'P M5NGJQ%0CEZXZK_1^+2J+9_K1ACXXU56[Y_/E7T2I\*&I]_Q ?IH#U?M';?G< M+IK, L23.$JS (I,>Z/"4%%)AG*8ACQB/ I#$CM1B:L 4Z.7;

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´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end XML 135 exas-20231231_htm.xml IDEA: XBRL DOCUMENT 0001124140 2023-01-01 2023-12-31 0001124140 2023-06-30 0001124140 2024-02-21 0001124140 2023-12-31 0001124140 2022-12-31 0001124140 2022-01-01 2022-12-31 0001124140 2021-01-01 2021-12-31 0001124140 us-gaap:CommonStockMember 2020-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001124140 us-gaap:RetainedEarningsMember 2020-12-31 0001124140 2020-12-31 0001124140 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001124140 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001124140 us-gaap:CommonStockMember 2021-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001124140 us-gaap:RetainedEarningsMember 2021-12-31 0001124140 2021-12-31 0001124140 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001124140 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001124140 us-gaap:CommonStockMember 2022-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001124140 us-gaap:RetainedEarningsMember 2022-12-31 0001124140 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001124140 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001124140 us-gaap:CommonStockMember 2023-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001124140 us-gaap:RetainedEarningsMember 2023-12-31 0001124140 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-12-31 0001124140 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-12-31 0001124140 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001124140 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001124140 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001124140 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001124140 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0001124140 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0001124140 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember 2023-01-01 2023-12-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember 2022-01-01 2022-12-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember 2021-01-01 2021-12-31 0001124140 exas:SharesIssuedUponAcquisitionMember 2023-01-01 2023-12-31 0001124140 exas:SharesIssuedUponAcquisitionMember 2022-01-01 2022-12-31 0001124140 exas:SharesIssuedUponAcquisitionMember 2021-01-01 2021-12-31 0001124140 srt:MinimumMember 2023-12-31 0001124140 srt:MaximumMember 2023-12-31 0001124140 exas:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001124140 exas:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001124140 exas:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001124140 exas:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001124140 exas:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001124140 exas:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001124140 exas:UnitedHealthCareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001124140 exas:UnitedHealthCareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001124140 exas:UnitedHealthCareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001124140 exas:UnitedHealthCareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001124140 exas:UnitedHealthCareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001124140 exas:UnitedHealthCareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001124140 exas:StateOfWisconsinMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001124140 exas:StateOfWisconsinMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001124140 exas:StateOfWisconsinMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001124140 exas:StateOfWisconsinMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001124140 exas:StateOfWisconsinMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001124140 exas:StateOfWisconsinMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001124140 us-gaap:ProductMember exas:ScreeningMember 2023-01-01 2023-12-31 0001124140 us-gaap:ProductMember exas:ScreeningMember 2022-01-01 2022-12-31 0001124140 us-gaap:ProductMember exas:ScreeningMember 2021-01-01 2021-12-31 0001124140 us-gaap:ServiceMember exas:ScreeningMember 2023-01-01 2023-12-31 0001124140 us-gaap:ServiceMember exas:ScreeningMember 2022-01-01 2022-12-31 0001124140 us-gaap:ServiceMember exas:ScreeningMember 2021-01-01 2021-12-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:ScreeningMember 2023-01-01 2023-12-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:ScreeningMember 2022-01-01 2022-12-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:ScreeningMember 2021-01-01 2021-12-31 0001124140 exas:ScreeningMember 2023-01-01 2023-12-31 0001124140 exas:ScreeningMember 2022-01-01 2022-12-31 0001124140 exas:ScreeningMember 2021-01-01 2021-12-31 0001124140 us-gaap:ProductMember exas:PrecisionOncologyMember 2023-01-01 2023-12-31 0001124140 us-gaap:ProductMember exas:PrecisionOncologyMember 2022-01-01 2022-12-31 0001124140 us-gaap:ProductMember exas:PrecisionOncologyMember 2021-01-01 2021-12-31 0001124140 us-gaap:ServiceMember exas:PrecisionOncologyMember 2023-01-01 2023-12-31 0001124140 us-gaap:ServiceMember exas:PrecisionOncologyMember 2022-01-01 2022-12-31 0001124140 us-gaap:ServiceMember exas:PrecisionOncologyMember 2021-01-01 2021-12-31 0001124140 exas:InternationalSalesMember exas:PrecisionOncologyMember 2023-01-01 2023-12-31 0001124140 exas:InternationalSalesMember exas:PrecisionOncologyMember 2022-01-01 2022-12-31 0001124140 exas:InternationalSalesMember exas:PrecisionOncologyMember 2021-01-01 2021-12-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:PrecisionOncologyMember 2023-01-01 2023-12-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:PrecisionOncologyMember 2022-01-01 2022-12-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:PrecisionOncologyMember 2021-01-01 2021-12-31 0001124140 exas:PrecisionOncologyMember 2023-01-01 2023-12-31 0001124140 exas:PrecisionOncologyMember 2022-01-01 2022-12-31 0001124140 exas:PrecisionOncologyMember 2021-01-01 2021-12-31 0001124140 exas:COVID19TestingMember 2023-01-01 2023-12-31 0001124140 exas:COVID19TestingMember 2022-01-01 2022-12-31 0001124140 exas:COVID19TestingMember 2021-01-01 2021-12-31 0001124140 exas:VariablePriceContractMember 2023-01-01 2023-12-31 0001124140 exas:VariablePriceContractMember 2022-01-01 2022-12-31 0001124140 exas:VariablePriceContractMember 2021-01-01 2021-12-31 0001124140 exas:CashAndMoneyMarketMember 2023-12-31 0001124140 exas:CashAndMoneyMarketMember 2022-12-31 0001124140 us-gaap:CashEquivalentsMember 2023-12-31 0001124140 us-gaap:CashEquivalentsMember 2022-12-31 0001124140 us-gaap:ShortTermInvestmentsMember 2023-12-31 0001124140 us-gaap:ShortTermInvestmentsMember 2022-12-31 0001124140 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2023-12-31 0001124140 us-gaap:CashEquivalentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2023-12-31 0001124140 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2022-12-31 0001124140 us-gaap:CashEquivalentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 us-gaap:LandMember 2023-12-31 0001124140 us-gaap:LandMember 2022-12-31 0001124140 exas:BuildingsAndLeaseholdImprovementsMember 2023-12-31 0001124140 exas:BuildingsAndLeaseholdImprovementsMember 2022-12-31 0001124140 us-gaap:LandImprovementsMember 2023-12-31 0001124140 us-gaap:LandImprovementsMember 2022-12-31 0001124140 srt:MinimumMember us-gaap:BuildingMember 2023-12-31 0001124140 srt:MaximumMember us-gaap:BuildingMember 2023-12-31 0001124140 us-gaap:BuildingMember 2023-12-31 0001124140 us-gaap:BuildingMember 2022-12-31 0001124140 exas:OfficeEquipmentAndComputerSoftwareMember 2023-12-31 0001124140 exas:OfficeEquipmentAndComputerSoftwareMember 2022-12-31 0001124140 srt:MinimumMember us-gaap:EquipmentMember 2023-12-31 0001124140 srt:MaximumMember us-gaap:EquipmentMember 2023-12-31 0001124140 us-gaap:EquipmentMember 2023-12-31 0001124140 us-gaap:EquipmentMember 2022-12-31 0001124140 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001124140 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001124140 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001124140 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001124140 us-gaap:AssetUnderConstructionMember 2023-12-31 0001124140 us-gaap:AssetUnderConstructionMember 2022-12-31 0001124140 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0001124140 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001124140 us-gaap:BuildingImprovementsMember 2023-12-31 0001124140 us-gaap:TradeNamesMember 2023-12-31 0001124140 us-gaap:CustomerRelationshipsMember 2023-12-31 0001124140 us-gaap:PatentsMember 2023-12-31 0001124140 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001124140 us-gaap:TradeNamesMember 2022-12-31 0001124140 us-gaap:CustomerRelationshipsMember 2022-12-31 0001124140 us-gaap:PatentsMember 2022-12-31 0001124140 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-05 0001124140 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember exas:OncotypeDXGenomicProstateScoreTestMember 2022-08-02 0001124140 us-gaap:ServiceAgreementsMember 2022-07-01 2022-09-30 0001124140 us-gaap:InProcessResearchAndDevelopmentMember 2021-07-01 2021-09-30 0001124140 us-gaap:DevelopedTechnologyRightsMember 2022-04-01 2022-06-30 0001124140 exas:OmicEraMember 2022-01-01 2022-12-31 0001124140 exas:PreventionGeneticsLLCMember 2022-01-01 2022-12-31 0001124140 exas:ResolutionBioscienceMember 2023-01-01 2023-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 exas:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 exas:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 exas:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 exas:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 exas:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 exas:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 exas:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 exas:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 exas:MDxHealthMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 exas:ThriveAshionAndOmicEraMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001124140 exas:ThriveAshionAndOmicEraMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001124140 srt:WeightedAverageMember exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember exas:MeasurementInputProbabilityOfSuccessMember 2023-12-31 0001124140 srt:WeightedAverageMember exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember exas:MeasurementInputProbabilityOfSuccessMember 2022-12-31 0001124140 srt:WeightedAverageMember exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember exas:MeasurementInputPresentValueFactorMember 2023-12-31 0001124140 srt:WeightedAverageMember exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember exas:MeasurementInputPresentValueFactorMember 2022-12-31 0001124140 exas:VentureCapitalInvestmentFundMember 2023-01-01 2023-12-31 0001124140 exas:VentureCapitalInvestmentFundMember 2023-12-31 0001124140 exas:VentureCapitalInvestmentFundMember 2022-12-31 0001124140 us-gaap:ForeignExchangeForwardMember 2023-12-31 0001124140 us-gaap:ForeignExchangeForwardMember 2022-12-31 0001124140 exas:SecuritizedReceivablesMember 2022-06-29 0001124140 srt:MinimumMember exas:SecuritizedReceivablesMember 2022-06-29 0001124140 exas:SecuritizedReceivablesMember 2023-12-31 0001124140 exas:SecuritizedReceivablesMember 2022-12-31 0001124140 us-gaap:RevolvingCreditFacilityMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2021-11-30 0001124140 us-gaap:RevolvingCreditFacilityMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember exas:DailyBloombergShortTermBankYieldIndexRateMember 2021-11-01 2021-11-30 0001124140 us-gaap:LetterOfCreditMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0001124140 us-gaap:LetterOfCreditMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2023-01-01 2023-12-31 0001124140 us-gaap:RevolvingCreditFacilityMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2023-12-31 0001124140 us-gaap:RevolvingCreditFacilityMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2022-12-31 0001124140 us-gaap:ConstructionLoansMember 2019-12-31 0001124140 us-gaap:ConstructionLoansMember exas:OneMonthLondonInterbankOfferRateMember 2022-01-01 2022-12-31 0001124140 exas:ConvertibleNotesPayable2030Member 2023-12-31 0001124140 exas:ConvertibleNotesPayable2030Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001124140 exas:ConvertibleNotesPayable2028Member 2023-12-31 0001124140 exas:ConvertibleNotesPayable2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001124140 exas:ConvertibleNotesPayable2027Member 2023-12-31 0001124140 exas:ConvertibleNotesPayable2027Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001124140 exas:ConvertibleNotesPayable2025Member 2023-12-31 0001124140 exas:ConvertibleNotesPayable2025Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001124140 exas:ConvertibleNotesPayable2028Member 2022-12-31 0001124140 exas:ConvertibleNotesPayable2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001124140 exas:ConvertibleNotesPayable2027Member 2022-12-31 0001124140 exas:ConvertibleNotesPayable2027Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001124140 exas:ConvertibleNotesPayable2025Member 2022-12-31 0001124140 exas:ConvertibleNotesPayable2025Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001124140 exas:ConvertibleNotesPayable2025Member 2018-01-31 0001124140 exas:ConvertibleNotesPayable2025Member 2018-01-01 2018-01-31 0001124140 exas:ConvertibleNotesPayable2025Member 2018-06-30 0001124140 exas:ConvertibleNotesPayable2025Member 2018-06-01 2018-06-30 0001124140 exas:ConvertibleNotesPayable2027Member 2019-03-31 0001124140 exas:ConvertibleNotesPayable2027Member 2019-03-01 2019-03-31 0001124140 exas:ConvertibleNotesPayable2027Member exas:ConvertibleNotesPayable2025Member 2019-03-01 2019-03-31 0001124140 exas:ConvertibleNotesPayable2025Member 2019-03-01 2019-03-31 0001124140 exas:ConvertibleNotesPayable2028Member 2020-02-29 0001124140 exas:ConvertibleNotesPayable2028Member 2020-02-01 2020-02-29 0001124140 exas:ConvertibleNotesPayable2025Member 2020-02-01 2020-02-29 0001124140 2020-02-01 2020-02-29 0001124140 exas:ConvertibleNotesPayable2030Member 2023-03-01 0001124140 exas:ConvertibleNotesPayable2027Member 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2028Member 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2030Member 2023-03-01 2023-03-31 0001124140 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2030Member exas:ConvertibleNotesPayable2025Member 2023-03-06 0001124140 exas:ConvertibleNotesPayable2025Member 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2025Member 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2025Member 2023-01-01 2023-12-31 0001124140 exas:ConvertibleNotesPayable2027Member 2023-01-01 2023-12-31 0001124140 exas:ConvertibleNotesPayable2028Member 2023-01-01 2023-12-31 0001124140 exas:ConvertibleNotesPayable2030Member 2023-01-01 2023-12-31 0001124140 exas:ConvertibleNotesPayable2030Member 2022-01-01 2022-12-31 0001124140 exas:ConvertibleNotesPayable2030Member 2021-01-01 2021-12-31 0001124140 exas:ConvertibleNotesPayable2028Member 2022-01-01 2022-12-31 0001124140 exas:ConvertibleNotesPayable2028Member 2021-01-01 2021-12-31 0001124140 exas:ConvertibleNotesPayable2027Member 2022-01-01 2022-12-31 0001124140 exas:ConvertibleNotesPayable2027Member 2021-01-01 2021-12-31 0001124140 exas:ConvertibleNotesPayable2025Member 2022-01-01 2022-12-31 0001124140 exas:ConvertibleNotesPayable2025Member 2021-01-01 2021-12-31 0001124140 exas:MAYOFoundationMember us-gaap:LicensingAgreementsMember exas:SalesMilestoneRangeThreeMember 2017-10-31 0001124140 exas:MAYOFoundationMember us-gaap:LicensingAgreementsMember 2023-01-01 2023-12-31 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:LicensingAgreementsMember 2021-01-05 0001124140 exas:TARDISTechnologyMember 2021-01-11 2021-01-11 0001124140 exas:TARDISTechnologyMember 2021-01-11 0001124140 exas:TheBroadInstituteLLCMember us-gaap:LicensingAgreementsMember exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember 2023-06-30 0001124140 exas:TheBroadInstituteLLCMember us-gaap:LicensingAgreementsMember exas:SalesMilestoneRangeOneMember 2023-06-30 2023-06-30 0001124140 exas:WatchmakerGenomicsIncMember us-gaap:LicensingAgreementsMember 2023-07-31 0001124140 exas:PfizerIncMember us-gaap:ManufacturedProductOtherMember 2021-11-30 0001124140 us-gaap:ManufacturedProductOtherMember exas:PfizerIncMember 2022-01-01 2022-12-31 0001124140 us-gaap:ManufacturedProductOtherMember exas:PfizerIncMember 2021-01-01 2021-12-31 0001124140 exas:OmicEraMember 2022-05-01 2022-05-31 0001124140 exas:OmicEraMember 2022-05-01 0001124140 exas:PreventionGeneticsLLCMember 2021-12-01 2021-12-31 0001124140 exas:PreventionGeneticsLLCMember 2021-12-31 0001124140 exas:AshionAnalyticsMember 2021-04-01 2021-04-30 0001124140 exas:AshionAnalyticsMember 2021-04-30 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-01 2021-01-31 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-31 0001124140 exas:TARDISTechnologyMember 2021-01-11 2021-01-11 0001124140 exas:TARDISTechnologyMember 2021-01-11 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-12-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-12-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-12-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-12-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-12-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0001124140 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-12-31 0001124140 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-12-31 0001124140 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-12-31 0001124140 exas:OmnibusLongTermIncentivePlan2019Member 2023-01-01 2023-12-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember exas:OmnibusLongTermIncentivePlan2019Member 2023-01-01 2023-12-31 0001124140 srt:MinimumMember exas:OmnibusLongTermIncentivePlan2019Member 2023-01-01 2023-12-31 0001124140 srt:MaximumMember exas:OmnibusLongTermIncentivePlan2019Member 2023-01-01 2023-12-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember exas:OmnibusLongTermIncentivePlan2019Member 2023-12-31 0001124140 us-gaap:RestrictedStockMember exas:OmnibusLongTermIncentivePlan2019Member 2023-12-31 0001124140 exas:OmnibusLongTermIncentivePlan2019Member 2022-06-09 2022-06-09 0001124140 exas:OmnibusLongTermIncentivePlan2019Member 2023-06-08 2023-06-08 0001124140 exas:OmnibusLongTermIncentivePlan2019Member 2023-12-31 0001124140 exas:OmnibusLongTermIncentivePlan2010Member 2023-01-01 2023-12-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember exas:OmnibusLongTermIncentivePlan2010Member 2023-01-01 2023-12-31 0001124140 srt:MinimumMember exas:OmnibusLongTermIncentivePlan2010Member 2023-01-01 2023-12-31 0001124140 srt:MaximumMember exas:OmnibusLongTermIncentivePlan2010Member 2023-01-01 2023-12-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember exas:OmnibusLongTermIncentivePlan2010Member 2023-12-31 0001124140 us-gaap:RestrictedStockMember exas:OmnibusLongTermIncentivePlan2010Member 2023-12-31 0001124140 exas:OmnibusLongTermIncentivePlan2010Member 2023-12-31 0001124140 exas:EmployeeStockPurchasePlan2010Member 2014-07-24 2014-07-24 0001124140 exas:EmployeeStockPurchasePlan2010Member 2016-07-28 2016-07-28 0001124140 exas:EmployeeStockPurchasePlan2010Member 2022-06-09 2022-06-09 0001124140 exas:EmployeeStockPurchasePlan2010Member 2023-12-31 0001124140 srt:MinimumMember exas:EmployeeStockPurchasePlan2010Member 2023-01-01 2023-12-31 0001124140 srt:MaximumMember exas:EmployeeStockPurchasePlan2010Member 2023-01-01 2023-12-31 0001124140 exas:EmployeeStockPurchasePlan2010Member 2023-01-01 2023-12-31 0001124140 exas:EmployeeStockPurchasePlan2010Member 2023-12-31 2023-12-31 0001124140 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001124140 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001124140 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001124140 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001124140 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001124140 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001124140 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001124140 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001124140 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001124140 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001124140 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001124140 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember exas:ThriveEarlierDetectionCorporationMember 2021-01-01 2021-12-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember exas:ThriveEarlierDetectionCorporationMember 2021-01-01 2021-12-31 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-01 2021-12-31 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember 2022-12-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember 2023-12-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001124140 us-gaap:PerformanceSharesMember 2022-12-31 0001124140 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0001124140 us-gaap:PerformanceSharesMember 2023-12-31 0001124140 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0001124140 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001124140 us-gaap:EmployeeStockMember exas:EmployeeStockPurchasePlan2010Member 2023-01-01 2023-12-31 0001124140 us-gaap:EmployeeStockMember exas:EmployeeStockPurchasePlan2010Member 2022-01-01 2022-12-31 0001124140 us-gaap:EmployeeStockMember exas:EmployeeStockPurchasePlan2010Member 2021-01-01 2021-12-31 0001124140 exas:EmployeeStockPurchasePlan2010Member exas:OfferingPeriodEndDateOneMember 2023-04-30 2023-04-30 0001124140 exas:EmployeeStockPurchasePlan2010Member exas:OfferingPeriodEndDateTwoMember 2023-11-01 2023-11-01 0001124140 us-gaap:EmployeeStockMember 2023-01-01 2023-12-31 0001124140 us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001124140 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001124140 srt:MinimumMember us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001124140 srt:MaximumMember us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001124140 srt:MinimumMember us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001124140 srt:MaximumMember us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001124140 exas:EmployeeStockPurchasePlan2019Member 2023-12-31 0001124140 us-gaap:AccountingStandardsUpdate201602Member 2021-01-01 2021-12-31 0001124140 exas:DOSRuleInvestigationMember 2023-09-30 2023-09-30 0001124140 exas:DOSRuleInvestigationMember 2023-01-01 2023-12-31 0001124140 exas:DOSRuleInvestigationMember 2021-01-01 2021-12-31 0001124140 exas:QuiTamSuitMember 2023-10-31 2023-10-31 0001124140 exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2021-12-01 2021-12-31 0001124140 exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2021-12-31 0001124140 exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2023-01-01 2023-12-31 0001124140 exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2023-12-31 0001124140 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2023-12-31 0001124140 us-gaap:OtherNoncurrentAssetsMember exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2023-12-31 0001124140 exas:ResolutionBioscienceMember 2023-09-12 2023-09-12 0001124140 exas:ResolutionBioscienceMember 2023-09-12 0001124140 exas:ResolutionBioscienceMember us-gaap:DevelopedTechnologyRightsMember 2023-09-12 0001124140 exas:OmicEraMember 2022-05-02 2022-05-02 0001124140 exas:OmicEraDiagnosticsAcquisitionMember 2022-05-01 2022-05-31 0001124140 exas:OmicEraMember 2022-05-02 0001124140 exas:PreventionGeneticsLLCMember 2021-12-31 2021-12-31 0001124140 exas:PreventionGeneticsLLCMember exas:BusinessAcquisitionPaymentTrancheOneMember 2021-12-31 2021-12-31 0001124140 exas:PreventionGeneticsLLCMember 2022-12-31 0001124140 exas:AshionAnalyticsMember 2021-04-14 2021-04-14 0001124140 exas:AshionAnalyticsMember 2021-04-14 0001124140 exas:AshionAnalyticsMember exas:CommercialLaunchMilestoneMember 2021-04-14 0001124140 exas:AshionAnalyticsMember exas:MRDProductRevenueMilestoneMember 2021-04-14 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-05 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-05 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember exas:FDAApprovalMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember exas:CenterForMedicareAndMedicaidServicesCMSCoverageMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember exas:AllocatedToConsiderationTransferredMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember exas:AllocatedToPreviousOwnershipInterestMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember exas:AllocatedToCompensationMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember exas:CompensationExpenseMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001124140 us-gaap:EmployeeStockOptionMember exas:ThriveEarlierDetectionCorporationMember 2021-01-05 2021-01-05 0001124140 srt:MinimumMember us-gaap:EmployeeStockOptionMember exas:ThriveEarlierDetectionCorporationMember 2021-01-05 2021-01-05 0001124140 srt:MaximumMember us-gaap:EmployeeStockOptionMember exas:ThriveEarlierDetectionCorporationMember 2021-01-05 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:InvestmentIncomeMember 2021-01-01 2021-03-31 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-06 2021-12-31 0001124140 exas:ThriveEarlierDetectionCorporationMember 2020-01-01 2020-12-31 0001124140 exas:EmployeesWithQualifyingTerminationEventsMember exas:ThriveEarlierDetectionCorporationMember 2021-01-01 2021-03-31 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-01 2021-03-31 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-01 2021-03-31 0001124140 exas:ThriveEarlierDetectionCorporationMember 2021-01-01 2021-12-31 0001124140 exas:PFSGenomicsMember 2021-05-03 0001124140 exas:PFSGenomicsMember 2021-06-23 0001124140 exas:PFSGenomicsMember 2021-06-23 2021-06-23 0001124140 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember exas:OncotypeDXGenomicProstateScoreTestMember 2022-08-02 2022-08-02 0001124140 2022-08-02 0001124140 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember exas:OncotypeDXGenomicProstateScoreTestMember 2022-01-01 2022-12-31 0001124140 2022-08-02 2022-08-02 0001124140 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember exas:OncotypeDXGenomicProstateScoreTestMember 2023-01-01 2023-12-31 0001124140 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember exas:OncotypeDXGenomicProstateScoreTestMember 2023-08-23 0001124140 country:US 2023-01-01 2023-12-31 0001124140 country:US 2022-01-01 2022-12-31 0001124140 country:US 2021-01-01 2021-12-31 0001124140 us-gaap:NonUsMember 2023-01-01 2023-12-31 0001124140 us-gaap:NonUsMember 2022-01-01 2022-12-31 0001124140 us-gaap:NonUsMember 2021-01-01 2021-12-31 0001124140 us-gaap:DomesticCountryMember 2023-12-31 0001124140 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001124140 us-gaap:ForeignCountryMember 2023-12-31 0001124140 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2023-12-31 0001124140 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2023-12-31 0001124140 stpr:CA us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2023-12-31 0001124140 us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0001124140 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0001124140 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001124140 us-gaap:StateAndLocalJurisdictionMember 2023-01-01 2023-12-31 0001124140 us-gaap:StateAndLocalJurisdictionMember 2022-01-01 2022-12-31 0001124140 us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0001124140 us-gaap:ForeignCountryMember 2023-01-01 2023-12-31 0001124140 us-gaap:ForeignCountryMember 2022-01-01 2022-12-31 0001124140 us-gaap:ForeignCountryMember 2021-01-01 2021-12-31 0001124140 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2022-12-31 0001124140 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-12-31 0001124140 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-12-31 0001124140 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2023-01-01 2023-12-31 0001124140 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2022-01-01 2022-12-31 0001124140 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-01-01 2021-12-31 0001124140 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2023-12-31 0001124140 exas:GenomicHealthIncMember us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-01-01 2021-12-31 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2023-01-01 2023-12-31 iso4217:USD shares iso4217:USD shares pure exas:item exas:position exas:test 0001124140 false 2023 FY P3Y P3Y http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherOperatingIncomeExpenseNet 10-K true 2023-12-31 --12-31 false 001-35092 EXACT SCIENCES CORPORATION DE 5505 Endeavor Lane Madison WI 02-0478229 53719 608 284‑5700 Common Stock, $0.01 Par Value EXAS NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 16796351138 181530967 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended December 31, 2023. Portions of such proxy statement are incorporated by reference into Part III of this Form 10‑K.</span> 238 PricewaterhouseCoopers LLP Chicago, Illinois 605378000 242493000 172266000 389564000 203623000 158043000 127475000 118259000 85627000 73898000 1194369000 982257000 698354000 684756000 143708000 167003000 2367120000 2346040000 1890396000 1956240000 177387000 90577000 6471334000 6226873000 78816000 74916000 341683000 299216000 29379000 28366000 50000000 0 14823000 10249000 514701000 412747000 2314276000 2186106000 0 50000000 335982000 352459000 161070000 182399000 3326029000 3183711000 0.01 0.01 5000000 5000000 0 0 0 0 0 0 0.01 0.01 400000000 400000000 181364180 181364180 177925631 177925631 1815000 1780000 6611237000 6311644000 1428000 -5236000 -3469175000 -3265026000 3145305000 3043162000 6471334000 6226873000 2499766000 2084279000 1767087000 654248000 574394000 458757000 425882000 393418000 385646000 727090000 846011000 861889000 893204000 737304000 801262000 92160000 97450000 95001000 621000 15969000 20210000 2793205000 2664546000 2622765000 78427000 -13244000 0 -215012000 -593511000 -855678000 32713000 -19425000 31778000 19447000 19634000 18606000 13266000 -39059000 13172000 -201746000 -632570000 -842506000 2403000 -9064000 -246881000 -204149000 -623506000 -595625000 -1.13 -1.13 -3.54 -3.54 -3.48 -3.48 180144000 180144000 176351000 176351000 171348000 171348000 -204149000 -623506000 -595625000 5343000 -3823000 -2162000 1321000 30000 23000 -197485000 -627299000 -597764000 0 0 -170000 -197485000 -627299000 -597594000 0.01 0.01 159423410 1595000 4279327000 526000 -2045895000 2235553000 580 43000 43000 1295104 13000 14424000 14437000 162606 2000 22932000 22934000 1879169 19000 334004000 334023000 331769 3000 23067000 23070000 10581429 106000 1355064000 1355170000 -595625000 -595625000 -1969000 -1969000 173674067 1738000 6028861000 -1443000 -2641520000 3387636000 706134 6000 6518000 6524000 391129 4000 29198000 29202000 2220510 22000 206801000 206823000 668605 7000 25484000 25491000 265186 3000 14789000 14792000 7000 7000 -623506000 -623506000 -3793000 -3793000 177925631 1780000 6311644000 -5236000 -3265026000 3043162000 194597 2000 3195000 3197000 517550 5000 35095000 35100000 1801954 18000 231294000 231312000 924448 10000 28334000 28344000 0 0 1675000 1675000 -204149000 -204149000 6664000 6664000 181364180 1815000 6611237000 1428000 -3469175000 3145305000 -204149000 -623506000 -595625000 114448000 100108000 85345000 4098000 -21774000 29008000 -955000 -11901000 -253169000 231312000 206823000 253063000 0 0 80960000 10324000 0 0 92160000 97450000 95001000 500000 85337000 0 -13244000 0 621000 15969000 20210000 73300000 0 0 -18044000 -56617000 6360000 27891000 28639000 25825000 399000 10835000 12356000 43416000 -61088000 -25150000 7690000 13231000 9221000 -26701000 -20646000 -16685000 82750000 -52180000 169800000 11618000 84000 24672000 6333000 -1324000 -33263000 156119000 -223559000 -102236000 139854000 131486000 1164050000 363156000 453072000 794322000 124190000 214462000 135766000 0 25000000 0 19794000 0 0 16564000 42823000 18044000 52413000 14686000 499730000 500000 0 58073000 -250000 549000 744000 49679000 74066000 -1082085000 0 50000000 0 3197000 6524000 14437000 28344000 25491000 23070000 0 0 23749000 137976000 0 0 -9751000 -5530000 -5286000 159766000 76485000 8472000 1321000 30000 23000 366885000 -72978000 -1175826000 242790000 315768000 1491594000 609675000 242790000 315768000 18505000 15943000 33177000 0 4600000 350348000 18776000 11519000 10735000 605378000 242493000 315471000 4297000 297000 297000 609675000 242790000 315768000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exact Sciences Corporation (together with its subsidiaries, “Exact” or the “Company”) was incorporated in February 1995. Exact is a leading, global advanced cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Oncotype DX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Exact is currently working to develop additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of Exact Sciences Corporation and those of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company's financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, contingent consideration, and accounting for income taxes.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers cash on hand, demand deposits in a bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value. The unrealized gains and losses, net of tax, on the Company's debt securities are reported in other comprehensive income. Marketable equity securities are measured at fair value and the unrealized gains and losses, net of tax, are recognized in other income (expense) in the consolidated statements of operations. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method. Such amortization is included in investment income, net. Realized gains and losses and declines in value as a result of credit losses on available-for-sale securities are included in the consolidated statements of operations as investment income, net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in the consolidated statements of operations as investment income, net.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates its available-for-sale debt securities in unrealized loss positions to determine whether any impairment is a result of a credit loss or other factors. This evaluation includes, but is not limited to, significant quantitative and qualitative assessments and estimates regarding credit ratings, significance of a security’s loss position, adverse conditions specifically related to the security, and the payment structure of the security. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Doubtful Accounts</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates an allowance for doubtful accounts against accounts receivable using historical collection trends, aging of accounts, current and future implications surrounding the ability to collect such as economic conditions, and regulatory changes. The allowance for doubtful accounts is evaluated on a regular basis and adjusted when trends, significant events, or other substantive evidence such as an adverse change in a payer's ability to pay indicate that expected collections will be less than previously estimated. At December 31, 2023 and 2022, the allowance for doubtful accounts recorded was not significant to the Company's consolidated balance sheets. For the years ended December 31, 2023, 2022 and 2021, there was an insignificant amount of bad debt expense written off against the allowance and charged to operating expense.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method (“FIFO”). The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale, no longer meets quality specifications, or has a cost basis in excess of its estimated realizable value and records a charge to cost of sales for such inventory as appropriate.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct and indirect manufacturing costs incurred during process validation with probable future economic benefit are capitalized. Validation costs incurred for other research and development activities, which are not permitted to be sold, are expensed to research and development in the Company’s consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost and depreciated using the straight-line method over the assets’ estimated useful lives. Land is stated at cost and does not depreciate. Additions and improvements are capitalized, including direct and indirect costs incurred to validate equipment and bring to working conditions. Revalidation costs, including maintenance and repairs are expensed when incurred. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Software Development Costs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal use software, including hosted arrangements, are incurred in three stages: the preliminary project stage, the application development stage, and the post-implementation stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred during the application development stage that meet the criteria for capitalization are capitalized and amortized, when the software is ready for its intended use, using the straight‑line method over the estimated useful life of the software, or the duration of the hosting agreement.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Companies</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether its investments in privately held companies are debt or equity based on their characteristics. The Company also evaluates the investee to determine if the entity is a variable interest entity (“VIE”) and, if so, whether the Company is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required. If consolidation is not required and the Company does not have voting control of the entity, the investment is evaluated to determine if the equity method of accounting should be applied. The equity method applies to investments in common stock or in substance common stock where the Company exercises significant influence over the investee. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in privately held companies determined to be equity securities without readily determinable fair values are accounted for under the measurement alternative method as permitted in Accounting Standards Codification (“ASC”) 321, Investments - Equity Securities. The Company adjusts the carrying value of its non-marketable equity securities for changes from observable transactions for identical or similar investments of the same issuer, less impairment. All gains and losses on non-marketable equity securities, realized and unrealized, are recognized in investment income, net in the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in privately held companies determined to be debt securities are accounted for as available-for-sale or held-to-maturity securities unless the fair value option is elected.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company hedges a portion of its foreign currency exposures related to outstanding monetary assets and liabilities using foreign currency forward contracts. The foreign currency forward contracts are included in prepaid expenses and other current assets or in accrued liabilities in the consolidated balance sheets, depending on the contracts’ net position. These contracts are not designated as hedges, and as a result, changes in their fair value are recorded in other income (expense) in the consolidated statements of operations. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations and Asset Acquisitions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business Combinations are accounted for under the acquisition method in accordance with ASC 805, Business Combinations. The acquisition method requires identifiable assets acquired and liabilities assumed and any non-controlling interest in the business acquired be recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. The amount by which the fair value of consideration transferred as the purchase price exceeds the net fair value of assets acquired and liabilities assumed is recorded as goodwill. Acquisitions that do not meet the definition of a business combination under ASC 805 are accounted for as asset acquisitions. Asset acquisitions are accounted for by allocating the cost of the acquisition to the individual assets acquired and liabilities assumed on a relative fair value basis. Goodwill is not recognized in an asset acquisition with any consideration in excess of net assets acquired allocated to acquired assets on a relative fair value basis. Transaction costs are expensed in a business combination and are considered a component of the cost of the acquisition in an asset acquisition. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased intangible assets are recorded at fair value. The Company uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. The Company’s finite-lived intangible assets are being amortized on a straight-line basis over their estimated useful lives. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent costs are capitalized as incurred, only if the Company determines that there is some probable future economic benefit derived from the transaction. A capitalized patent is amortized over its estimated useful life, beginning when such patent is approved. Capitalized patent costs are expensed upon disapproval, upon a decision by the Company to no longer pursue the patent or when the related intellectual property is either sold or deemed to be no longer of value to the Company. The Company determined that all patent costs incurred during the years ended December 31, 2023, 2022 and 2021 should be expensed and not capitalized as the future economic benefit derived from the patent costs incurred cannot be determined.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-process Research and Development (“IPR&amp;D”)</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The primary basis for determining technological feasibility of these projects is obtaining regulatory approval to market the underlying product. The amounts capitalized are accounted for as indefinite-lived intangible assets and are subject to impairment testing until completion or abandonment of the research and development efforts associated with the projects. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. The value assigned to acquired IPR&amp;D is determined using the multi-period excess earnings method approach, which utilizes significant unobservable inputs (Level 3 inputs) including projected revenues, projected gross margin, projected operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success. There are often major risks and uncertainties associated with IPR&amp;D projects as the Company is required to obtain regulatory approvals in order to market the resulting products. Such approvals require completing clinical trials that demonstrate the product's effectiveness. Consequently, the eventual realized value of the IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized IPR&amp;D projects are tested for impairment annually in the fourth quarter, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, and upon successful completion of the project. The Company considers various factors for potential impairment, including the current legal and regulatory environment, current and future strategic initiatives and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors' products could result in partial or full impairment of the related intangible assets. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain regulatory and product development milestones being achieved. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected probabilities of success, projected payment dates, present value-factors, and projected revenues (for revenue-based considerations). Changes in probabilities of success, present-value factors, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within general and administrative expenses on the Company’s consolidated statements of operations. Cash contingent consideration payments up to the acquisition date fair value of the contingent consideration liability are classified as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are classified as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Asset</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of the Company’s intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test (“GPS test”) resulted in the recognition of variable consideration in accordance with ASC 606. The Company estimates the amount of variable consideration that it is entitled to each quarter using the most likely amount method and considers whether there are any constraints on the consideration. If it is probable that a significant reversal of a gain would not occur, the Company will record a gain. To determine the classification of the consideration, the Company determines if the consideration is conditional on something other than the passage of time. Revenue-based contingent consideration that is conditional on something other than the passage of time, including future revenues from sales related to the GPS test, result in the variable consideration being classified as a contract asset. At the time the amount earned is determined, and passage of time is the only condition remaining, the contract asset is reclassified to a receivable.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collateralized Debt Instruments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt instruments that are collateralized by security interests in financial assets held by the Company are accounted for as a secured borrowing and therefore: (i) the asset balances pledged as collateral are included within the applicable balance sheet line item and the borrowings are included within long-term debt in the consolidated balance sheet; (ii) interest expense is included within the consolidated statements of operations; and (iii) in the case of collateralized accounts receivable, receipts from customers related to the underlying accounts receivable are reflected as operating cash flows, and (iv) borrowings and repayments under the collateralized loans are reflected as financing cash flows within the consolidated statements of cash flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill for possible impairment at the reporting unit level on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting the Company's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the fair value of long-lived assets, which include property, plant and equipment, leases, finite-lived intangible assets, and investments in privately held companies, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,231 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,309 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,309 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of performance share units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable in connection with acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,388 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,050 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,837 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Stock-Based Compensation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company requires all share-based payments to employees, including grants of employee stock options, restricted stock, restricted stock units, shares purchased under an employee stock purchase plan (if certain parameters are not met), and performance share units to be recognized in the financial statements based on their grant date fair values. The estimated fair value of these awards is recognized to expense using the straight-line method over the requisite service period, which is generally the vesting period. The Company will recognize expense on an accelerated basis for restricted stock units upon an employee's death, disability, or upon retirement eligibility, provided certain criteria are met. Forfeitures of any share-based awards are recognized as they occur. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values and recognition of the Company’s share-based payment awards are determined as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each service-based option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of service-based awards for each restricted stock unit award is determined on the date of grant using the closing stock price on that day. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance-based equity awards that do not include a market condition is determined on the date of grant using the closing stock price on that day. The fair value of performance-based equity awards that include a market condition is determined on the date of grant using a Monte Carlo valuation technique. The expense recognized each period is also dependent on the probability of what performance conditions will be met which is determined by management's evaluation of internal and external factors. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the goals and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance targets and operational milestones are not achieved, the award would not vest resulting in no stock-based compensation being recognized and any previously recognized stock-based compensation expense being reversed. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. These expenses include the costs of the Company's proprietary research and development efforts, as well as costs of IPR&amp;D projects acquired as part of an asset acquisition that have no alternative future use. Acquired IPR&amp;D assets that are acquired in an asset acquisition and which have no alternative future use are classified as an investing cash outflow in the consolidated statements of cash flows. Upfront and milestone payments due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred. Milestone payments due to third parties upon, or subsequent to, regulatory approval are capitalized and amortized into research and development costs over the shorter of the remaining license or product patent life, when there are no corresponding revenues related to the license or product. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received, rather than when the payment is made.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the costs of media advertising at the time the advertising takes place. The Company expensed approximately $137.9 million, $170.3 million, and $144.0 million of media advertising during the years ended December 31, 2023, 2022, and 2021, respectively, which is recorded in sales and marketing expenses on the Company’s consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Accounting Standards Board (“FASB”) has issued authoritative guidance that requires fair value to be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under that standard, fair value measurements are separately disclosed by level within the fair value hierarchy. The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles, and certain laboratory and office equipment, and finance leases for certain equipment and vehicles. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (“ROU”) assets and lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit interest rate is not readily determinable in most of the Company’s leases, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the United States (“U.S.”) Treasury rate and an indicative Moody's rating for operating leases or finance leases. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease for up to 10 years, and some of which include options to terminate the lease within 1 year. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest expense on the Company’s consolidated statements of operations. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases acquired in business combinations by measuring the lease liability at the present value of the remaining lease payments as if the acquired lease were a new lease for the Company. This measurement includes recognition of a lease intangible for any below-market terms present in the leases acquired. The below-market lease intangible is included in the ROU asset on the consolidated balance sheets and are amortized over the remaining lease term. The Company has not acquired any leases with above-market terms. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PreventionGenetics, LLC (“PreventionGenetics”), and COVID-19 tests. The services are considered completed when the performance obligation is fulfilled, which is upon release of an approved patient test result to the healthcare provider. The Company follows ASC 606, Revenue from Contracts with Customers, to account for its laboratory service revenues. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laboratory testing services</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with Center for Medicare &amp; Medicaid Services (“CMS”) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, or in the context of certain lab service or reference agreements, the Company requires payment prior to the commencement of the Company's performance obligations. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patient’s test result to the ordering healthcare provider. Or, in the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window. The Company elects the practical expedient to not disclose unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s transaction price is comprised of fixed and variable consideration and is allocated entirely to a single performance obligation defined as the point in time an approved patient test result is released to the ordering healthcare provider. Fixed consideration exists in arrangements where the Company has agreed to provide laboratory testing services to a customer for a specified rate and is expected to be collected in full at that rate. Variable consideration is primarily derived from payer and patient billing and can be impacted by several factors such as the amount of contractual adjustments, any patient co-payments, deductibles or patient adherence incentives, the existence of secondary payers, and claim denials. Estimates of variable consideration are calculated using the expected value method and is the sum of probability-weighted amounts in a range of possible consideration amounts. Several factors are evaluated during this process, such as historical collections experience, current contractual and statutory requirements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> customer mix, patient insurance eligibility and payer reimbursement contracts, and known or anticipated reimbursement trends not yet reflected in the data. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease in the estimate of the transaction price (i.e., an upward or downward revenue adjustment) in the period identified.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon completion of the performance obligations associated with the Company's tests, with recognition, generally occurring at the date of cash receipt. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets. Generally, billing occurs after the release of an approved patient test result to the healthcare provider, resulting in an account receivable. However, the Company sometimes receives advance payment from a patient or a direct bill payer before services are performed, resulting in deferred revenue. The deferred revenue recorded is recognized as revenue at the point in time an approved patient test result is released to the patient's healthcare provider. In the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company’s consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications (e.g. adherence reminder letters). These costs are expensed as incurred and recorded within general and administrative expenses in the Company’s consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales reflects the aggregate costs incurred in delivering the Company's products and services and includes material and service costs, personnel costs, including stock-based compensation expense, equipment and infrastructure expenses associated with laboratory testing services, shipping charges, and allocated overhead such as rent, information technology costs, equipment depreciation and utilities. Costs associated with the shipment of Cologuard test collection kits are recognized upon shipment, and costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company’s international subsidiaries is the U.S. dollar. When the functional currency differs from the local currency, monetary assets and liabilities are remeasured at the current period-end exchange rate, while non-monetary assets and liabilities are remeasured at the historical rate. The gains and losses as a result of exchange rate adjustments of these subsidiaries are recognized in the consolidated statements of operations. Net foreign currency transaction gains or losses were not significant to the consolidated statements of operations for the periods presented. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company’s international subsidiaries where the functional currency is other than the U.S. dollar, the financial statements are translated into the U.S. dollar, and the cumulative adjustments resulting from the translation into the U.S. dollar are included in the Company's consolidated balance sheet as a component of accumulated other comprehensive income (loss) (“AOCI”). </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2023, the Company had cash and cash equivalents deposited in financial institutions in which the balances exceed the federal government agency insured limit of $250,000 by approximately $529.0 million. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2023, the Company’s revenues have been primarily derived from the sale of Cologuard, Oncotype, and COVID-19 tests. The following is a breakdown of revenue and accounts receivable from major payers:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Revenue for the years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Accounts Receivable at December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Major Payer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare and Medicaid Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State of Wisconsin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Positions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income, the Company has determined that a valuation allowance at December 31, 2023 and 2022 is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the Company's effective tax rate.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a directors and officers insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2023 and 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statement (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update amends various Securities and Exchange Commission (“SEC”) paragraphs in the Accounting Standards Codification to reflect the issuance of SEC Staff Accounting Bulletin No. 120, among other things. The Company adopted this conforming guidance upon issuance during the third quarter of fiscal year 2023. There was no significant impact to the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the FASB issued ASU No. 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Update and Simplification</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.</span></div><div style="text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvement to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exact Sciences Corporation (together with its subsidiaries, “Exact” or the “Company”) was incorporated in February 1995. Exact is a leading, global advanced cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Oncotype DX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span>. Exact is currently working to develop additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of Exact Sciences Corporation and those of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company's financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, contingent consideration, and accounting for income taxes.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div>The Company considers cash on hand, demand deposits in a bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value. The unrealized gains and losses, net of tax, on the Company's debt securities are reported in other comprehensive income. Marketable equity securities are measured at fair value and the unrealized gains and losses, net of tax, are recognized in other income (expense) in the consolidated statements of operations. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method. Such amortization is included in investment income, net. Realized gains and losses and declines in value as a result of credit losses on available-for-sale securities are included in the consolidated statements of operations as investment income, net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in the consolidated statements of operations as investment income, net.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current. </span></div>The Company periodically evaluates its available-for-sale debt securities in unrealized loss positions to determine whether any impairment is a result of a credit loss or other factors. This evaluation includes, but is not limited to, significant quantitative and qualitative assessments and estimates regarding credit ratings, significance of a security’s loss position, adverse conditions specifically related to the security, and the payment structure of the security. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Doubtful Accounts</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates an allowance for doubtful accounts against accounts receivable using historical collection trends, aging of accounts, current and future implications surrounding the ability to collect such as economic conditions, and regulatory changes. The allowance for doubtful accounts is evaluated on a regular basis and adjusted when trends, significant events, or other substantive evidence such as an adverse change in a payer's ability to pay indicate that expected collections will be less than previously estimated. At December 31, 2023 and 2022, the allowance for doubtful accounts recorded was not significant to the Company's consolidated balance sheets. For the years ended December 31, 2023, 2022 and 2021, there was an insignificant amount of bad debt expense written off against the allowance and charged to operating expense.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method (“FIFO”). The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale, no longer meets quality specifications, or has a cost basis in excess of its estimated realizable value and records a charge to cost of sales for such inventory as appropriate.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct and indirect manufacturing costs incurred during process validation with probable future economic benefit are capitalized. Validation costs incurred for other research and development activities, which are not permitted to be sold, are expensed to research and development in the Company’s consolidated statements of operations.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div>Property, plant and equipment are stated at cost and depreciated using the straight-line method over the assets’ estimated useful lives. Land is stated at cost and does not depreciate. Additions and improvements are capitalized, including direct and indirect costs incurred to validate equipment and bring to working conditions. Revalidation costs, including maintenance and repairs are expensed when incurred. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Software Development Costs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal use software, including hosted arrangements, are incurred in three stages: the preliminary project stage, the application development stage, and the post-implementation stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred during the application development stage that meet the criteria for capitalization are capitalized and amortized, when the software is ready for its intended use, using the straight‑line method over the estimated useful life of the software, or the duration of the hosting agreement.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Companies</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether its investments in privately held companies are debt or equity based on their characteristics. The Company also evaluates the investee to determine if the entity is a variable interest entity (“VIE”) and, if so, whether the Company is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required. If consolidation is not required and the Company does not have voting control of the entity, the investment is evaluated to determine if the equity method of accounting should be applied. The equity method applies to investments in common stock or in substance common stock where the Company exercises significant influence over the investee. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in privately held companies determined to be equity securities without readily determinable fair values are accounted for under the measurement alternative method as permitted in Accounting Standards Codification (“ASC”) 321, Investments - Equity Securities. The Company adjusts the carrying value of its non-marketable equity securities for changes from observable transactions for identical or similar investments of the same issuer, less impairment. All gains and losses on non-marketable equity securities, realized and unrealized, are recognized in investment income, net in the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in privately held companies determined to be debt securities are accounted for as available-for-sale or held-to-maturity securities unless the fair value option is elected.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div>The Company hedges a portion of its foreign currency exposures related to outstanding monetary assets and liabilities using foreign currency forward contracts. The foreign currency forward contracts are included in prepaid expenses and other current assets or in accrued liabilities in the consolidated balance sheets, depending on the contracts’ net position. These contracts are not designated as hedges, and as a result, changes in their fair value are recorded in other income (expense) in the consolidated statements of operations. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations and Asset Acquisitions</span></div>Business Combinations are accounted for under the acquisition method in accordance with ASC 805, Business Combinations. The acquisition method requires identifiable assets acquired and liabilities assumed and any non-controlling interest in the business acquired be recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. The amount by which the fair value of consideration transferred as the purchase price exceeds the net fair value of assets acquired and liabilities assumed is recorded as goodwill. Acquisitions that do not meet the definition of a business combination under ASC 805 are accounted for as asset acquisitions. Asset acquisitions are accounted for by allocating the cost of the acquisition to the individual assets acquired and liabilities assumed on a relative fair value basis. Goodwill is not recognized in an asset acquisition with any consideration in excess of net assets acquired allocated to acquired assets on a relative fair value basis. Transaction costs are expensed in a business combination and are considered a component of the cost of the acquisition in an asset acquisition. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased intangible assets are recorded at fair value. The Company uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. The Company’s finite-lived intangible assets are being amortized on a straight-line basis over their estimated useful lives. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent costs are capitalized as incurred, only if the Company determines that there is some probable future economic benefit derived from the transaction. A capitalized patent is amortized over its estimated useful life, beginning when such patent is approved. Capitalized patent costs are expensed upon disapproval, upon a decision by the Company to no longer pursue the patent or when the related intellectual property is either sold or deemed to be no longer of value to the Company. The Company determined that all patent costs incurred during the years ended December 31, 2023, 2022 and 2021 should be expensed and not capitalized as the future economic benefit derived from the patent costs incurred cannot be determined.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-process Research and Development (“IPR&amp;D”)</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The primary basis for determining technological feasibility of these projects is obtaining regulatory approval to market the underlying product. The amounts capitalized are accounted for as indefinite-lived intangible assets and are subject to impairment testing until completion or abandonment of the research and development efforts associated with the projects. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. The value assigned to acquired IPR&amp;D is determined using the multi-period excess earnings method approach, which utilizes significant unobservable inputs (Level 3 inputs) including projected revenues, projected gross margin, projected operating expenses, discount rate, tax rate, obsolescence factor, and probability of commercial success. There are often major risks and uncertainties associated with IPR&amp;D projects as the Company is required to obtain regulatory approvals in order to market the resulting products. Such approvals require completing clinical trials that demonstrate the product's effectiveness. Consequently, the eventual realized value of the IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods. </span></div>Capitalized IPR&amp;D projects are tested for impairment annually in the fourth quarter, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, and upon successful completion of the project. The Company considers various factors for potential impairment, including the current legal and regulatory environment, current and future strategic initiatives and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors' products could result in partial or full impairment of the related intangible assets. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain regulatory and product development milestones being achieved. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected probabilities of success, projected payment dates, present value-factors, and projected revenues (for revenue-based considerations). Changes in probabilities of success, present-value factors, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within general and administrative expenses on the Company’s consolidated statements of operations. Cash contingent consideration payments up to the acquisition date fair value of the contingent consideration liability are classified as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are classified as operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Asset</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of the Company’s intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test (“GPS test”) resulted in the recognition of variable consideration in accordance with ASC 606. The Company estimates the amount of variable consideration that it is entitled to each quarter using the most likely amount method and considers whether there are any constraints on the consideration. If it is probable that a significant reversal of a gain would not occur, the Company will record a gain. To determine the classification of the consideration, the Company determines if the consideration is conditional on something other than the passage of time. Revenue-based contingent consideration that is conditional on something other than the passage of time, including future revenues from sales related to the GPS test, result in the variable consideration being classified as a contract asset. At the time the amount earned is determined, and passage of time is the only condition remaining, the contract asset is reclassified to a receivable.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collateralized Debt Instruments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt instruments that are collateralized by security interests in financial assets held by the Company are accounted for as a secured borrowing and therefore: (i) the asset balances pledged as collateral are included within the applicable balance sheet line item and the borrowings are included within long-term debt in the consolidated balance sheet; (ii) interest expense is included within the consolidated statements of operations; and (iii) in the case of collateralized accounts receivable, receipts from customers related to the underlying accounts receivable are reflected as operating cash flows, and (iv) borrowings and repayments under the collateralized loans are reflected as financing cash flows within the consolidated statements of cash flows.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div>The Company evaluates goodwill for possible impairment at the reporting unit level on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting the Company's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>The Company evaluates the fair value of long-lived assets, which include property, plant and equipment, leases, finite-lived intangible assets, and investments in privately held companies, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,231 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,309 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,309 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of performance share units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable in connection with acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,388 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,050 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,837 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 23231000 20309000 20309000 6273000 5255000 4321000 1598000 968000 878000 1286000 1518000 2284000 0 0 45000 32388000 28050000 27837000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Stock-Based Compensation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company requires all share-based payments to employees, including grants of employee stock options, restricted stock, restricted stock units, shares purchased under an employee stock purchase plan (if certain parameters are not met), and performance share units to be recognized in the financial statements based on their grant date fair values. The estimated fair value of these awards is recognized to expense using the straight-line method over the requisite service period, which is generally the vesting period. The Company will recognize expense on an accelerated basis for restricted stock units upon an employee's death, disability, or upon retirement eligibility, provided certain criteria are met. Forfeitures of any share-based awards are recognized as they occur. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values and recognition of the Company’s share-based payment awards are determined as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each service-based option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of service-based awards for each restricted stock unit award is determined on the date of grant using the closing stock price on that day. </span></div>The fair value of performance-based equity awards that do not include a market condition is determined on the date of grant using the closing stock price on that day. The fair value of performance-based equity awards that include a market condition is determined on the date of grant using a Monte Carlo valuation technique. The expense recognized each period is also dependent on the probability of what performance conditions will be met which is determined by management's evaluation of internal and external factors. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the goals and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance targets and operational milestones are not achieved, the award would not vest resulting in no stock-based compensation being recognized and any previously recognized stock-based compensation expense being reversed. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. These expenses include the costs of the Company's proprietary research and development efforts, as well as costs of IPR&amp;D projects acquired as part of an asset acquisition that have no alternative future use. Acquired IPR&amp;D assets that are acquired in an asset acquisition and which have no alternative future use are classified as an investing cash outflow in the consolidated statements of cash flows. Upfront and milestone payments due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred. Milestone payments due to third parties upon, or subsequent to, regulatory approval are capitalized and amortized into research and development costs over the shorter of the remaining license or product patent life, when there are no corresponding revenues related to the license or product. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received, rather than when the payment is made.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the costs of media advertising at the time the advertising takes place. The Company expensed approximately $137.9 million, $170.3 million, and $144.0 million of media advertising during the years ended December 31, 2023, 2022, and 2021, respectively, which is recorded in sales and marketing expenses on the Company’s consolidated statements of operations.</span></div> 137900000 170300000 144000000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Accounting Standards Board (“FASB”) has issued authoritative guidance that requires fair value to be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under that standard, fair value measurements are separately disclosed by level within the fair value hierarchy. The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles, and certain laboratory and office equipment, and finance leases for certain equipment and vehicles. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (“ROU”) assets and lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit interest rate is not readily determinable in most of the Company’s leases, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the United States (“U.S.”) Treasury rate and an indicative Moody's rating for operating leases or finance leases. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease for up to 10 years, and some of which include options to terminate the lease within 1 year. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest expense on the Company’s consolidated statements of operations. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases acquired in business combinations by measuring the lease liability at the present value of the remaining lease payments as if the acquired lease were a new lease for the Company. This measurement includes recognition of a lease intangible for any below-market terms present in the leases acquired. The below-market lease intangible is included in the ROU asset on the consolidated balance sheets and are amortized over the remaining lease term. The Company has not acquired any leases with above-market terms. </span></div>The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract. P1Y P15Y P10Y P1Y <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PreventionGenetics, LLC (“PreventionGenetics”), and COVID-19 tests. The services are considered completed when the performance obligation is fulfilled, which is upon release of an approved patient test result to the healthcare provider. The Company follows ASC 606, Revenue from Contracts with Customers, to account for its laboratory service revenues. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laboratory testing services</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with Center for Medicare &amp; Medicaid Services (“CMS”) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, or in the context of certain lab service or reference agreements, the Company requires payment prior to the commencement of the Company's performance obligations. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patient’s test result to the ordering healthcare provider. Or, in the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window. The Company elects the practical expedient to not disclose unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s transaction price is comprised of fixed and variable consideration and is allocated entirely to a single performance obligation defined as the point in time an approved patient test result is released to the ordering healthcare provider. Fixed consideration exists in arrangements where the Company has agreed to provide laboratory testing services to a customer for a specified rate and is expected to be collected in full at that rate. Variable consideration is primarily derived from payer and patient billing and can be impacted by several factors such as the amount of contractual adjustments, any patient co-payments, deductibles or patient adherence incentives, the existence of secondary payers, and claim denials. Estimates of variable consideration are calculated using the expected value method and is the sum of probability-weighted amounts in a range of possible consideration amounts. Several factors are evaluated during this process, such as historical collections experience, current contractual and statutory requirements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> customer mix, patient insurance eligibility and payer reimbursement contracts, and known or anticipated reimbursement trends not yet reflected in the data. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease in the estimate of the transaction price (i.e., an upward or downward revenue adjustment) in the period identified.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon completion of the performance obligations associated with the Company's tests, with recognition, generally occurring at the date of cash receipt. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets. Generally, billing occurs after the release of an approved patient test result to the healthcare provider, resulting in an account receivable. However, the Company sometimes receives advance payment from a patient or a direct bill payer before services are performed, resulting in deferred revenue. The deferred revenue recorded is recognized as revenue at the point in time an approved patient test result is released to the patient's healthcare provider. In the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company’s consolidated statements of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications (e.g. adherence reminder letters). These costs are expensed as incurred and recorded within general and administrative expenses in the Company’s consolidated statements of operations.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales reflects the aggregate costs incurred in delivering the Company's products and services and includes material and service costs, personnel costs, including stock-based compensation expense, equipment and infrastructure expenses associated with laboratory testing services, shipping charges, and allocated overhead such as rent, information technology costs, equipment depreciation and utilities. Costs associated with the shipment of Cologuard test collection kits are recognized upon shipment, and costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test.</span></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company’s international subsidiaries is the U.S. dollar. When the functional currency differs from the local currency, monetary assets and liabilities are remeasured at the current period-end exchange rate, while non-monetary assets and liabilities are remeasured at the historical rate. The gains and losses as a result of exchange rate adjustments of these subsidiaries are recognized in the consolidated statements of operations. Net foreign currency transaction gains or losses were not significant to the consolidated statements of operations for the periods presented. </span></div>For the Company’s international subsidiaries where the functional currency is other than the U.S. dollar, the financial statements are translated into the U.S. dollar, and the cumulative adjustments resulting from the translation into the U.S. dollar are included in the Company's consolidated balance sheet as a component of accumulated other comprehensive income (loss) (“AOCI”). <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2023, the Company had cash and cash equivalents deposited in financial institutions in which the balances exceed the federal government agency insured limit of $250,000 by approximately $529.0 million. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2023, the Company’s revenues have been primarily derived from the sale of Cologuard, Oncotype, and COVID-19 tests. The following is a breakdown of revenue and accounts receivable from major payers:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Revenue for the years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Accounts Receivable at December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Major Payer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare and Medicaid Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State of Wisconsin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td></tr></table></div> 529000000 0.17 0.14 0.20 0.10 0.14 0.11 0.12 0.12 0.11 0.10 0.09 0.08 0 0.03 0.08 0 0.05 0.09 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Positions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income, the Company has determined that a valuation allowance at December 31, 2023 and 2022 is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the Company's effective tax rate.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a directors and officers insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2023 and 2022.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statement (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update amends various Securities and Exchange Commission (“SEC”) paragraphs in the Accounting Standards Codification to reflect the issuance of SEC Staff Accounting Bulletin No. 120, among other things. The Company adopted this conforming guidance upon issuance during the third quarter of fiscal year 2023. There was no significant impact to the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the FASB issued ASU No. 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Update and Simplification</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.</span></div><div style="text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvement to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.</span></div> REVENUE<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table presents the Company’s revenues disaggregated by revenue source: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Screening</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Parts B &amp; C</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,718 </span></td><td style="background-color:#ffffff;border-right:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Screening</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,864,701 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424,703 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062,308 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Parts B &amp; C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,913 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,905 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Precision Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,110 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601,488 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,676 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Testing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,955 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,088 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,103 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499,766 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,279 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,087 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype DX and therapy selection tests. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $25.2 million and $20.3 million for the years ended December 31, 2023 and 2022, respectively. The Company recorded a downward adjustment to revenue from a change in transaction price of $11.8 million for the year ended December 31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s deferred revenue, which is reported in other current liabilities in the Company’s consolidated balance sheets, was not significant as of December 31, 2023 and 2022.</span></div>Revenue recognized for the year ended December 31, 2023 and 2022, which was included in the deferred revenue balance at the beginning of the year The following table presents the Company’s revenues disaggregated by revenue source: <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Screening</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Parts B &amp; C</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,718 </span></td><td style="background-color:#ffffff;border-right:1pt solid #d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Screening</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,864,701 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424,703 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062,308 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Parts B &amp; C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,913 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,905 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Precision Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,110 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601,488 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,676 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Testing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,955 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,088 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,103 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499,766 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,279 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,087 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 701400000 545458000 438646000 992244000 743238000 569944000 171057000 136007000 53718000 1864701000 1424703000 1062308000 188689000 197327000 197394000 181318000 177518000 180177000 153277000 117738000 109913000 105826000 108905000 74192000 629110000 601488000 561676000 5955000 58088000 143103000 2499766000 2084279000 1767087000 25200000 20300000 11800000 MARKETABLE SECURITIES<div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s cash, cash equivalents, and marketable securities at December 31, 2023 and 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,378 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,493 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,266 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2023, consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in AOCI (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in AOCI (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,649 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     There was no tax impact from the gains and losses in AOCI.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2022, consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in AOCI (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in AOCI (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,704 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     There was no tax impact from the gains and losses in AOCI.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at December 31, 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due after one year through five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,909 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,861 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,462 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,187 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,139 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,462 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,564 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than one year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One year or greater</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,028 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,380 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,408 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2022, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than one year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One year or greater</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,497 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,664)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,501 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of December 31, 2023 and 2022 because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s consolidated statements of operations. The gains and losses recorded were not significant for the years ended December 31, 2023, 2022, and 2021.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s cash, cash equivalents, and marketable securities at December 31, 2023 and 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605,378 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,493 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,266 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 530100000 178168000 75278000 64325000 605378000 242493000 168425000 384415000 3841000 5149000 172266000 389564000 777644000 632057000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2023, consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in AOCI (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in AOCI (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,649 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     There was no tax impact from the gains and losses in AOCI.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2022, consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in AOCI (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in AOCI (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,704 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     There was no tax impact from the gains and losses in AOCI.</span></div> 72243000 0 0 72243000 3035000 0 0 3035000 75278000 0 0 75278000 56594000 166000 44000 56716000 55712000 175000 59000 55828000 35081000 65000 249000 34897000 20984000 0 0 20984000 168371000 406000 352000 168425000 243649000 406000 352000 243703000 63021000 0 0 63021000 1304000 0 0 1304000 64325000 0 0 64325000 228012000 0 2789000 225223000 116318000 20000 1667000 114671000 45374000 2000 855000 44521000 389704000 22000 5311000 384415000 454029000 22000 5311000 448740000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at December 31, 2023:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due after one year through five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,278 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,909 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,861 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,462 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,187 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,139 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,462 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,564 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 72243000 72243000 0 0 3035000 3035000 0 0 75278000 75278000 0 0 33518000 33474000 22194000 22354000 33407000 33403000 23187000 23313000 20984000 20984000 0 0 0 0 35081000 34897000 87909000 87861000 80462000 80564000 163187000 163139000 80462000 80564000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than one year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One year or greater</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,028 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,380 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,408 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2022, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than one year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One year or greater</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,497 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,004 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,664)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,501 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 25895000 41000 2480000 18000 28375000 59000 15756000 35000 3965000 9000 19721000 44000 4377000 5000 10935000 244000 15312000 249000 46028000 81000 17380000 271000 63408000 352000 37458000 337000 187766000 2452000 225224000 2789000 35055000 575000 73702000 1092000 108757000 1667000 27984000 735000 15536000 120000 43520000 855000 100497000 1647000 277004000 3664000 377501000 5311000 INVENTORY<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,593 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,207 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished and finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,882 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,052 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,475 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,593 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,207 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished and finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,882 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,052 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,475 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 58593000 61207000 68882000 57052000 127475000 118259000 PROPERTY, PLANT AND EQUIPMENT<div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and estimated useful lives of property, plant and equipment are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 - 40 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and computer software</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,896 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,756 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,047 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115,557 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,347 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,354 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,756 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     Lesser of remaining lease term, building life, or estimated useful life.</span></div>At December 31, 2023, the Company had $104.6 million of assets under construction, which consisted of $53.2 million in machinery and equipment, $29.1 million of capitalized costs related to software projects, $15.7 million in leasehold and building improvements, and $6.6 million related to buildings. Depreciation will begin on these assets once they are placed into service upon completion. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and estimated useful lives of property, plant and equipment are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 - 40 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and computer software</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,896 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,756 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,047 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115,557 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,347 </span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,354 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,756 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     Lesser of remaining lease term, building life, or estimated useful life.</span></div> 4716000 4716000 214562000 200588000 P15Y 6729000 6417000 P30Y P40Y 290777000 288941000 P3Y 168131000 142896000 P3Y P10Y 290294000 246344000 P3Y P10Y 35756000 34047000 104592000 68398000 1115557000 992347000 417203000 307591000 698354000 684756000 104600000 53200000 29100000 15700000 6600000 INTANGIBLE ASSETS AND GOODWILL<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net-book-value and estimated remaining life of the Company's intangible assets as of December 31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Balance at December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328,543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,331 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366,935)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,396 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366,935)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Balance at December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981,016 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,776)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,240 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,776)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,240 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The gross carrying amount includes an insignificant foreign currency translation adjustment related to the intangible asset     acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,908 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,396 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairment losses recorded on finite-lived intangible assets during the year ended December 31, 2023. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an IPR&amp;D asset of $1.25 billion related to a project associated with the development of a U.S. Food and Drug Administration (“FDA”) approved, blood-based, multi-cancer early detection (“MCED”) test as part of the acquisition of Thrive Earlier Detection Corporation (“Thrive”) in January 2021. The Company performed a quantitative assessment as part of its annual IPR&amp;D impairment analysis in the fourth quarter of 2023 under which it determined that the fair value exceeded the carrying value and no impairment loss was recorded. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2022, the Company completed a sale of the developed technology intangible asset related to the Oncotype DX Genomic Prostate Score test to MDxHealth SA (“MDxHealth”), which was measured using the income approach to determine the fair value. The gross value of the intangible asset was $59.0 million with accumulated amortization of $16.1 million as of the closing date, resulting in a carrying value of $42.9 million, which was derecognized from intangible assets, net in the consolidated balance sheets upon completion of the divestiture. Refer to Note 18 for further information on this sale.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the remaining carrying value of $2.0 million related to the supply agreement intangible asset acquired as part of the combination with Genomic Health, Inc. (“Genomic Health”) was recorded as a non-cash, pre-tax impairment loss due to the termination of the agreement. The Company previously recorded a non-cash, pre-tax impairment loss of $20.2 million during the third quarter of 2021 due to lower than anticipated performance of the underlying product. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the remaining carrying value of $6.6 million related to the developed technology intangible asset acquired as a result of the acquisition of Paradigm Diagnostics, Inc. was recorded as a non-cash, pre-tax impairment loss due to lower than anticipated performance of the underlying product. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized the income approach to measure the fair value of the impaired intangible assets, which involved significant unobservable inputs (Level 3 inputs), including revenue projections, cash flow projections, and discount rates. Impairment losses recorded on intangible assets are included in impairment of long-lived assets in the Company’s consolidated statement of operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill for the years ended December 31, 2023 and 2022 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335,172 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmicEra acquisition</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreventionGenetics acquisition adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of changes in foreign currency exchange rates (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,040 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resolution Bioscience acquisition (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,692 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of changes in foreign currency exchange rates (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367,120 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. </span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)    Refer to Note 18 for further discussion on the Company’s acquisition of Resolution Bioscience, Inc. (“Resolution Bioscience”). </span></div>There were no impairment losses recorded on goodwill for the years ended December 31, 2023, 2022, and 2021. <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net-book-value and estimated remaining life of the Company's intangible assets as of December 31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Balance at December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328,543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,331 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366,935)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,396 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257,331 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366,935)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Balance at December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981,016 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,776)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,240 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,776)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,240 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The gross carrying amount includes an insignificant foreign currency translation adjustment related to the intangible asset     acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.</span></div> P11Y7M6D 104000000 27903000 76097000 P7Y 4000000 889000 3111000 P4Y6M 11542000 9600000 1942000 P7Y3M18D 887789000 328543000 559246000 1007331000 366935000 640396000 1250000000 1250000000 2257331000 366935000 1890396000 P12Y6M 104000000 20653000 83347000 P8Y 4000000 444000 3556000 P4Y2M12D 11542000 8152000 3390000 P7Y9M18D 861474000 245527000 615947000 981016000 274776000 706240000 1250000000 1250000000 2231016000 274776000 1956240000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,908 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,396 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 92908000 91860000 90800000 90800000 90800000 183228000 640396000 1250000000 59000000 16100000 42900000 2000000 20200000 6600000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill for the years ended December 31, 2023 and 2022 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335,172 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmicEra acquisition</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreventionGenetics acquisition adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of changes in foreign currency exchange rates (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,040 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resolution Bioscience acquisition (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,692 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of changes in foreign currency exchange rates (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367,120 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. </span></div>(2)    Refer to Note 18 for further discussion on the Company’s acquisition of Resolution Bioscience, Inc. (“Resolution Bioscience”). 2335172000 10809000 58000 117000 2346040000 20692000 388000 2367120000 0 0 0 FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three levels of the fair value hierarchy established are as follows:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s fair value measurements as of December 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,934 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,238 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281,007)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,614 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,862)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company's credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Inclusive of the American Depository Shares of MDxHealth received as part of the sale of the Company’s GPS test, which are restricted to a holding period of six months after the date of the sale of August 2, 2022. The shares had a fair value of $4.6 million as of December 31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in valuation techniques or transfers between fair value measurement levels during the year ended December 31, 2023. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the fair value option under the income approach to measure certain Level 3 non-marketable securities. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option: </span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of non-marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of non-marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,957 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of non-marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration liabilities was $288.7 million and $306.9 million as of December 31, 2023 and 2022, respectively, which was included in other long-term liabilities in the consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022 (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,021 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,617)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,927 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,044)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    The change in fair value of the contingent consideration liability during the year ended December 31, 2021 was not significant.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)    The increase in contingent consideration liability is due to the contingent consideration associated with the acquisition of OmicEra. Refer to Note 18 for further information. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration liabilities recorded from the Company’s acquisitions of Thrive, Ashion Analytics, LLC (“Ashion”), and OmicEra related to regulatory and product development milestones was $288.7 million and $306.8 million as of December 31, 2023 and 2022, respectively. The Company evaluates the fair value of the expected contingent consideration and the corresponding liabilities related to the regulatory and product development milestones using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the expected contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 89% and 91% as of December 31, 2023 and 2022, respectively, and a weighted average present-value factor of 5.8% and 6.2% as of December 31, 2023 and 2022, respectively. The projected fiscal year of payment range is from 2025 to 2030. Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration liability related to certain revenue milestones associated with the Biomatrica, Inc. acquisition was not significant as of December 31, 2022, and the revenue milestone period ended September 30, 2023. The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Marketable Equity Investments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities without readily determinable fair values, which are classified as a component of other long-term assets, net, had the following aggregate carrying amounts and downward and upward adjustments as of and for the years ended December 31, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upward adjustments (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,314 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Downward adjustments and impairments (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    Cumulative upward adjustments on non-marketable equity securities held as of December 31, 2023 was $5.1 million. The upward adjustments recorded were due to increases in the valuation of the underlying investee as determined by the value of the follow-on rounds of investment by other third-party investors. There were no upward adjustments recorded during the year ended December 31, 2021. </span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)    Cumulative downward adjustments and impairments on non-marketable equity securities held as of December 31, 2023 was $15.1 million. The adjustments recorded were due to adverse changes in the market and the investees’ ability to continue as a going concern. There were no downward adjustments recorded during the year ended December 31, 2021. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a realized gain of $5.4 million, a realized loss of $10.0 million, and a realized gain of $30.5 million on non-marketable securities for the years ended December 31, 2023, 2022, and 2021, respectively. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has committed capital to venture capital investment funds (the “Funds”) of $17.5 million, of which $12.1 million remained callable through 2033 as of December 31, 2023. The aggregate carrying amount of the Funds, which are classified as a component of other long-term assets, net in the Company's consolidated balance sheets, were $5.2 million and $3.9 million as of December 31, 2023 and 2022, respectively. Gains and losses recorded on the Company's investments in the Funds were not significant for the years ended December 31, 2023, 2022, and 2021. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div>The Company enters into foreign currency forward contracts on the last day of each month to mitigate the impact of adverse movements in foreign exchange rates related to the remeasurement of monetary assets and liabilities and hedge the Company’s foreign currency exchange rate exposure. As of December 31, 2023 and 2022, the Company had open foreign currency forward contracts with notional amounts of $39.5 million and $22.3 million, respectively. The Company’s foreign exchange derivative instruments are classified as Level 2 within the fair value hierarchy as they are valued using inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The fair value of the open foreign currency forward contracts was zero at December 31, 2023 and 2022, and there were no gains or losses recorded to adjust the fair value of the open foreign currency contract held as of December 31, 2023. The contracts are closed subsequent to each month-end, and the gains and losses recorded from the contracts were not significant for the years ended December 31, 2023 and 2022. <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s fair value measurements as of December 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,934 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,238 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281,007)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,614 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,862)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company's credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Inclusive of the American Depository Shares of MDxHealth received as part of the sale of the Company’s GPS test, which are restricted to a holding period of six months after the date of the sale of August 2, 2022. The shares had a fair value of $4.6 million as of December 31, 2022.</span></div> 530100000 530100000 0 0 72243000 0 72243000 0 4297000 4297000 0 0 3035000 0 3035000 0 56716000 0 56716000 0 55828000 0 55828000 0 34897000 0 34897000 0 20984000 0 20984000 0 3841000 3841000 0 0 7650000 0 0 7650000 288657000 0 0 288657000 500934000 538238000 243703000 -281007000 178168000 178168000 0 0 63021000 0 63021000 0 1304000 0 1304000 0 297000 297000 0 0 225223000 0 225223000 0 114671000 0 114671000 0 44521000 0 44521000 0 5149000 5149000 0 0 10065000 0 0 10065000 306927000 0 0 306927000 335492000 183614000 448740000 -296862000 4600000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the fair value option under the income approach to measure certain Level 3 non-marketable securities. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option: </span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of non-marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of non-marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,957 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of non-marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3090000 10000000 1038000 -4063000 10065000 6957000 1127000 -10499000 7650000 288700000 306900000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022 (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,021 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price contingent consideration (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,617)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,927 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,044)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,657 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    The change in fair value of the contingent consideration liability during the year ended December 31, 2021 was not significant.</span></div>(2)    The increase in contingent consideration liability is due to the contingent consideration associated with the acquisition of OmicEra. Refer to Note 18 for further information. 359021000 4600000 56617000 77000 306927000 18044000 226000 288657000 288700000 306800000 0.89 0.91 0.058 0.062 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Marketable Equity Investments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities without readily determinable fair values, which are classified as a component of other long-term assets, net, had the following aggregate carrying amounts and downward and upward adjustments as of and for the years ended December 31, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upward adjustments (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,314 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Downward adjustments and impairments (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    Cumulative upward adjustments on non-marketable equity securities held as of December 31, 2023 was $5.1 million. The upward adjustments recorded were due to increases in the valuation of the underlying investee as determined by the value of the follow-on rounds of investment by other third-party investors. There were no upward adjustments recorded during the year ended December 31, 2021. </span></div>(2)    Cumulative downward adjustments and impairments on non-marketable equity securities held as of December 31, 2023 was $15.1 million. The adjustments recorded were due to adverse changes in the market and the investees’ ability to continue as a going concern. There were no downward adjustments recorded during the year ended December 31, 2021. 4314000 779000 4250000 10821000 45968000 39842000 5100000 15100000 5400000 10000000 30500000 17500000 12100000 5200000 3900000 39500000 22300000 0 0 ACCRUED LIABILITIES<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities at December 31, 2023 and 2022 consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,619 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,252 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and trial related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,683 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,216 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities at December 31, 2023 and 2022 consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,619 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,252 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and trial related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,683 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,216 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 247619000 201252000 45405000 43715000 17274000 22329000 14219000 17455000 11210000 10462000 5956000 4003000 341683000 299216000 LONG-TERM DEBT<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable Securitization Facility</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2022, the Company, through a wholly-owned special purpose entity, Exact Receivables LLC (“Exact Receivables”) entered into an accounts receivable securitization program (the “Securitization Facility”) with PNC Bank, National Association (“PNC”), with a scheduled maturity date of June 29, 2024. The Securitization Facility provides Exact Receivables with a revolving line-of-credit of up to $150.0 million of borrowing capacity, subject to certain borrowing base requirements, by collateralizing a security interest in the domestic customer accounts receivable of certain wholly-owned subsidiaries of the Company. The amount available under the Securitization Facility fluctuates over time based on the total amount of eligible customer accounts receivable generated by the Company during the normal course of operations. The Securitization Facility requires the Company to maintain minimum borrowings under the facility of $50.0 million. The debt issuance costs incurred related to the Securitization Facility were not significant and are being amortized over the life of the Securitization Facility through interest expense within the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Securitization Facility, the Company also entered into two Receivables Purchase Agreements (“Receivable Purchase Agreements”) on June 29, 2022. The Receivable Purchase Agreements are among the Company and certain wholly-owned subsidiaries of the Company, and between the Company and Exact Receivables. Under the agreements, the wholly-owned subsidiaries sell all of their right, title and interest in their accounts receivables to Exact Receivables. The receivables are used to collateralize borrowings made under the Securitization Facility. The Company retains the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provides a performance guaranty. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the eligible borrowing base under the Securitization Facility was $108.5 million of which the Company elected to collateralize $50.0 million. As of December 31, 2023 and December 31, 2022, the Company had an outstanding balance of $50.0 million, which is included in debt, current portion and long-term debt, less current portion, respectively, on the Company’s consolidated balance sheets. The outstanding balance accrues interest at a rate equal to a daily secured overnight financing rate (“SOFR”) rate plus a SOFR adjustment and an applicable margin. The interest rate was 6.89% at December 31, 2023. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Loan Agreement</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, the Company entered into a revolving loan agreement (the “Revolving Loan Agreement”) with PNC. The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. In October 2022 the Revolving Loan Agreement was amended to extend the maturity date from November 5, 2023 to November 5, 2025. There were no other amendments to the Revolver. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to various financial covenants under the Revolving Loan Agreement, and as of December 31, 2023, the Company is in compliance with all covenants.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and January 2023, PNC issued letters of credit of $2.9 million and $1.5 million, respectively, which reduced the amount available for cash advances under the line of credit to $145.6 million and $147.1 million as of December 31, 2023 and December 31, 2022, respectively. As of December 31, 2023, the Company has not drawn funds from, nor are any amounts outstanding under, the Revolving Loan Agreement. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan Agreement</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2017, the Company entered into a loan agreement with Fifth Third Bank (the “Construction Loan Agreement”), which provided the Company with a non-revolving construction loan (the “Construction Loan”) of $25.6 million- with a maturity date of December 10, 2022. The Company used the Construction Loan proceeds to finance the construction of an additional clinical laboratory and related facilities in Madison, Wisconsin. The Construction Loan was collateralized by the additional clinical laboratory and related facilities.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan Agreement bore interest at a rate equal to the sum of the 1-month LIBOR rate plus 2.25%. The interest incurred on the Construction Loan was not significant and was capitalized to the construction project. The Company also incurred minimal debt issuance costs which were recorded as a direct deduction from the liability, and amortized over the life of the Construction Loan.</span></div>As part of the Revolving Loan Agreement discussed above, the Company agreed to repay in full all outstanding debt owed to Fifth Third Bank under the Construction Loan Agreement, and as of December 31, 2021, the remaining outstanding balance had been fully repaid in connection with the termination of the Construction Loan Agreement. Any unamortized issuance costs at the time or repayment were recorded as a loss. 150000000 50000000 108500000 50000000 50000000 50000000 0.0689 150000000 150000000 20000000 0.0060 2900000 1500000 145600000 147100000 25600000 0.0225 CONVERTIBLE NOTES<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt Discount and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes - 2.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,993 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,349)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,644 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,475 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes - 1.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt Discount and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,775)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,225 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,500 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes - 1.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances and Settlements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company issued and sold $690.0 million in aggregate principal amount of 1.0% Convertible Notes (the “January 2025 Notes”) with a maturity date of January 15, 2025. The January 2025 Notes accrue interest at a fixed rate of 1.0% per year, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The net proceeds from the issuance of the January 2025 Notes were approximately $671.1 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company issued and sold an additional $218.5 million in aggregate principal amount of 1.0% Convertible Notes (the “June 2025 Notes”). The June 2025 Notes were issued under the same indenture pursuant to which the Company previously issued the January 2025 Notes (the “Indenture”). The January 2025 Notes and the June 2025 Notes (collectively, the “2025 Notes”) have identical terms (including the same January 15, 2025 maturity date) and are treated as a single series of securities. The net proceeds from the issuance of the June 2025 Notes were approximately $225.3 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company issued and sold $747.5 million in aggregate principal amount of 0.375% Convertible Notes (the “2027 Notes”) with a maturity date of March 15, 2027. The 2027 Notes accrue interest at a fixed rate of 0.375% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2019. The net proceeds from the issuance of the 2027 Notes were approximately $729.5 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized a portion of the proceeds from the issuance of the 2027 Notes to settle a portion of the 2025 Notes in privately negotiated transactions. In March 2019, the Company used cash of $494.1 million and an aggregate of 2.2 million shares of the Company’s common stock valued at $182.4 million for total consideration of $676.5 million to settle $493.4 million of the 2025 Notes, of which $0.7 million was used to pay off interest accrued on the 2025 Notes. The transaction resulted in a loss on settlement of convertible notes of $187.7 million, which is reflected in interest expense in the Company’s consolidated statement of operations. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of repurchase.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company issued and sold $1.15 billion in aggregate principal amount of 0.375% Convertible Notes (the “2028 Notes” and, collectively with the 2025 Notes and the 2027 Notes, the “Notes”) with a maturity date of March 1, 2028. The 2028 Notes accrue interest at a fixed rate of 0.375% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2020. The net proceeds from the issuance of the 2028 Notes were approximately $1.13 billion, after deducting underwriting discounts and commissions and the offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company used $150.1 million of the proceeds from the issuance of the 2028 Notes to settle $100.0 million of the 2025 Notes, of which $0.1 million was used to pay off interest accrued on the 2025 Notes. The transaction resulted in a loss on settlement of convertible notes of $50.8 million, which is recorded in interest expense in the Company’s consolidated statement of operations. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of repurchase.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company entered into a privately negotiated exchange and purchase agreement with a single holder of certain of the Company’s 2027 Notes and 2028 Notes. The Company issued the holder $500.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 (the “2030 Notes”) in exchange for $183.7 million of aggregate principal of 2027 Notes, $201.0 million of aggregate principal of 2028 Notes, and $138.0 million of cash. The extinguishment resulted in a gain on settlement of convertible notes of $17.7 million, which is included in interest expense in the consolidated statement of operations for the year ended December 31, 2023. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a privately negotiated exchange agreement with two holders of certain of the 2025 Notes. The Company issued the holder $73.0 million aggregate principal amount of 2030 Notes in exchange for $65.8 million of aggregate principal of 2025 Notes. The extinguishment resulted in a loss on settlement of convertible notes of $7.4 million, which is included in interest expense in the consolidated statement of operations for the year ended December 31, 2023. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from the issuance of the 2030 Notes were approximately $133.0 million, after deducting commissions and offering expenses payable by the Company. The 2030 Notes will mature on March 1, 2030 and bear interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Conversion Features</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the six-months immediately preceding the maturity date of the applicable series of the Company’s convertible notes (the “Notes”), each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert such Notes at any time. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company’s intent and policy to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, 8.21, and 12.37 shares of common stock per $1,000 principal amount for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, $121.84, and $80.83 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively. The 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes are potentially convertible into up to 3.3 million, 5.0 million, 7.8 million, and 7.1 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indentures), will, under certain circumstances, be entitled to an increase in the conversion rate.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a “fundamental change” (as defined in the Indentures), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the closing price of the Company’s common stock of $73.98 on December 31, 2023, the if-converted values on the Notes do not exceed the principal amount.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ranking of Convertible Notes</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company's existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance Costs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,938 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the Notes includes the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,350 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,727 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,727 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on settlement of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,072 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense on convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,204 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,140 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,140 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effective interest rates of the Notes:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 1.04 years, 3.21 years, 4.17 years, and 6.17 years for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively. <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt Discount and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes - 2.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,993 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,349)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,644 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,475 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes - 1.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt Discount and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,775)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,225 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,500 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes - 1.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div>(1)     The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement. 0.02000 572993000 4349000 568644000 684475000 0.00375 949042000 10499000 938543000 887354000 0.00375 563822000 5429000 558393000 549839000 0.01000 249172000 476000 248696000 293300000 0.00375 1150000000 15775000 1134225000 908500000 0.00375 747500000 9445000 738055000 612950000 0.01000 315005000 1179000 313826000 326808000 690000000 0.010 0.010 671100000 218500000 0.010 225300000 747500000 0.00375 0.00375 729500000 494100000 2200000 182400000 676500000 493400000 700000 -187700000 1150000000 0.00375 0.00375 1130000000 150100000 100000000 100000 -50800000 500000000 0.020 183700000 201000000 138000000 -17700000 73000000 65800000 -7400000 133000000 0.020 13.26 8.96 8.21 12.37 75.43 111.66 121.84 80.83 3300000 5000000 7800000 7100000 100 73.98 The following table summarizes the original issuance costs at the time of issuance for each set of Notes:<div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,938 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4938000 24453000 14285000 17646000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the Notes includes the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,350 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,727 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,727 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on settlement of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,072 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense on convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,204 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,140 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,140 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effective interest rates of the Notes:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 5350000 5727000 5727000 106000 147000 147000 10324000 0 0 18072000 10266000 10266000 13204000 16140000 16140000 0.0209 0 0 0.0063 0.0064 0.0064 0.0067 0.0068 0.0068 0.0117 0.0118 0.0118 P1Y14D P3Y2M15D P4Y2M1D P6Y2M1D LICENSE AND COLLABORATION AGREEMENTS <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mayo Foundation for Medical Education Research</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2009, the Company entered into an exclusive, worldwide license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), under which Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition. The Company’s license agreement with Mayo was most recently amended and restated in September 2020. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to pay Mayo up to $3.0 million in sales-based milestone payments upon cumulative net sales of each product using the licensed Mayo intellectual property reaching specified levels. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company has incurred insignificant charges for the years ended December 31, 2023, 2022, and 2021, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company's consolidated statements of operations. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Johns Hopkins University</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with Johns Hopkins University (“JHU”) for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU proprietary data in the development and commercialization of a blood-based, MCED test. The agreement terms would require the Company to pay single-digit sales-based royalties and up to $45.0 million in sales-based milestone payments if net sales of a licensed product using JHU proprietary data reach specified levels. The Company will record the sales-based royalties and sales-based milestones once achievement is deemed probable. The Company has not incurred charges related to the achievement of any sales-based royalties or sales-based milestones as of December 31, 2023.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Targeted Digital Sequencing (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TARDIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> License Agreement </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an exclusive, worldwide license to the proprietary TARDIS technology, which the Company intends to develop and commercialize as a molecular residual disease (“MRD”) test, from The Translational Genomics Research Institute (“TGen”), an affiliate of City of Hope. Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. The Company accounted for this transaction as an asset acquisition. In connection with the asset acquisition, the Company paid upfront fair value consideration of $52.3 million comprised of $25.0 million in cash and issuance of 191,336 shares of common stock valued at $27.3 million based on the average of the high and low market price of the Company’s shares on the acquisition date. In addition, the Company is obligated to make milestone payments to TGen of up to $45.0 million in sales-based milestone payments upon cumulative net sales related to MRD detection and/or treatment reaching specified levels. These payments are contingent upon achievement of these cumulative revenues on or before December 31, 2030. The upfront consideration was recorded to research and development expense in the consolidated statement of operations immediately after acquisition as the asset was deemed to be incomplete and had no alternative future use at the time of acquisition. The Company will record the sales milestones once achievement is deemed probable. No acquisition related costs were incurred in this asset acquisition during the year ended December 31, 2021.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Broad Institute, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company entered into an exclusive license agreement with Broad Institute, Inc. (“Broad Institute”) to utilize the Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (“MAESTRO”) technology in the Company’s MRD testing. Under the license agreement, the Company is obligated to make development milestone payments to Broad Institute of up to $6.5 million upon achievement of certain development milestones related to prospective MRD tests that use the MAESTRO technology. In addition, the Company is obligated to make sales-based milestone payments to Broad Institute that equate up to a mid-single-digit royalty upon the achievement of certain cumulative net sales targets of licensed products using the MAESTRO technology beginning at $500.0 million. The Company will record the development milestones once achieved and the sales milestones once achievement is deemed probable. The Company has not incurred any charges related to the achievement of development milestones or sales milestones as of December 31, 2023. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Watchmaker Genomics, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a co-exclusive development and license agreement with Watchmaker Genomics, Inc. (“Watchmaker”) under which the Company granted Watchmaker a co-exclusive license to the non-bisulfite technology for the detection of methylated DNA and other epigenetic modifications (“TAPS”). TAPS is based on patents obtained by the Company through an exclusive license agreement with the Ludwig Institute for Cancer Research. Under the agreement, both parties have the right to use and develop TAPS for commercial purposes. The Company has the potential to receive up to $82.0 million in sales-based milestone payments and mid-single digit royalties based on future Watchmaker net sales of licensed products including TAPS. Additionally, Watchmaker has the right to sublicense TAPS, and the Company has the potential to receive royalties based on future Watchmaker sublicense receipts.</span></div> 3000000 P5Y 45000000 52300000 25000000 191336 27300000 45000000 6500000 500000000 82000000 PFIZER PROMOTION AGREEMENT<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into a Promotion Agreement (the “Original Promotion Agreement”) with Pfizer, Inc. (“Pfizer”), which was amended and restated in October 2020 (the “Restated Promotion Agreement”). The Restated Promotion Agreement extended the relationship between the Company and Pfizer and restructured the manner in which the Company compensates Pfizer for promotion of the Cologuard test through a service fee, and provision of certain other sales and marketing services related to the Cologuard test. The Restated Promotion Agreement included fixed and performance-related fees, some of which retroactively went into effect on April 1, 2020. In November 2021, the Company and Pfizer entered into an amendment to the Restated Promotion Agreement (the “November 2021 Amendment”), which provided that after November 30, 2021, Pfizer will no longer promote the Cologuard test to healthcare providers. The November 2021 Amendment provided that the Company pay Pfizer a total of $35.9 million in three installments, which occurred during the second, third, and fourth quarters of 2022. The November 2021 Amendment eliminated the Company's obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Cologuard test prior to November 30, 2021. The $35.9 million fee incurred as a result of the November 2021 Amendment was recognized in full during the fourth quarter of 2021. All payments to Pfizer are recorded in sales and marketing expenses in the Company's consolidated statements of operations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Original Promotion Agreement, the service fee was calculated based on incremental gross profits over specified baselines during the term. Under the Restated Promotion Agreement (and prior to giving effect to the November 2021 Amendment), the service fee provided a fee-for-service model that included certain fixed fees and performance-related bonuses. The performance-related bonuses were contingent upon the achievement of certain annual performance criteria with any applicable expense being recognized ratably upon achievement of the payment becoming probable. The Company incurred charges of $7.5 million, and $81.3 million for the service fee during the years ended December 31, 2022 and 2021, respectively. The Company incurred charges of $85.8 million, and $121.0 million for promotion, sales and marketing services performed by Pfizer on behalf of the Company during the years ended December 31, 2022 and 2021, respectively. All services provided by Pfizer under the November 2021 Amendment ended in the third quarter of 2022, and there were no payments made or charges incurred during the year ended December 31, 2023.</span></div> 35900000 35900000 7500000 81300000 85800000 121000000 STOCKHOLDERS' EQUITY<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Issuances</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company completes a business combination or asset acquisition, which are further described in Note 18, the Company may issue shares of the Company's common stock. Stock issuances in relation to acquisitions during the years ended December 31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except for per share data)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period of Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Shares Issued</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmicEra</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,186</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,792 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreventionGenetics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,410</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,444</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thrive</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,323,266</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TARDIS license</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,335</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount recognized in AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Securities (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,162)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,139)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit related to items of other comprehensive loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,466)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,443)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,049)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,019)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,793)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,289)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,236)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,343 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,664 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the amounts recognized in AOCI for the years ended December 31, 2023 and 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about AOCI Components (In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the<br/>Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of available-for-sale investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income (loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Stock issuances in relation to acquisitions during the years ended December 31, 2023, 2022 and 2021 were as follows:<div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except for per share data)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period of Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Shares Issued</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmicEra</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,186</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,792 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreventionGenetics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,410</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,444</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thrive</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,323,266</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TARDIS license</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,335</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,527 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of replaced equity awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,202 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,792 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid related to working capital adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,408 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,129</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,252</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,381</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,775</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,224</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,999</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175,431</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,996</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,348</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of replaced equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,245</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously held equity investment fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,054</span></td></tr></table></div> 265186 14792000 1070410 84252000 125444 16224000 9323266 1191420000 191335 27263000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount recognized in AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Securities (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,162)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,139)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit related to items of other comprehensive loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,466)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,443)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,049)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,019)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,793)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,289)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,236)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,343 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,664 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the amounts recognized in AOCI for the years ended December 31, 2023 and 2022.</span></div> 0 526000 526000 23000 -1648000 -1625000 0 514000 514000 23000 -2162000 -2139000 0 -170000 -170000 23000 -1466000 -1443000 30000 -4049000 -4019000 0 -226000 -226000 30000 -3823000 -3793000 53000 -5289000 -5236000 1321000 1416000 2737000 0 -3927000 -3927000 1321000 5343000 6664000 1374000 54000 1428000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about AOCI Components (In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the<br/>Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of available-for-sale investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income (loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3927000 226000 -514000 -3927000 -226000 514000 STOCK-BASED COMPENSATION<div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Plans</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the following plans for which awards were granted from or had awards outstanding in 2023: the 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan. These plans are collectively referred to as the “Stock Plans.”</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stock Plans are administered by the Human Capital Committee of the Company’s Board of Directors (“Human Capital Committee”). The 2019 Omnibus Long-Term Incentive Plan provides that upon an acquisition of the Company, all equity will accelerate by a period of one year. In addition, upon the termination of an employee without cause or for good reason prior to the first anniversary of the completion of the acquisition, all equity awards then outstanding under the respective plan held by that employee will immediately vest.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Omnibus Long-Term Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company adopted the 2019 Omnibus Long-Term Incentive Plan (the “2019 Stock Plan”) on July 25, 2019 to grant share-based awards to employees, officers, directors, consultants and advisors. Awards granted under the 2019 Stock Plan may include incentive stock options, as defined under the Internal Revenue Code, non-qualified options, restricted stock awards and other stock awards in amounts and with terms and conditions determined by the Human Capital Committee, subject to the provisions of the 2019 Stock Plan. The 2019 Stock Plan will expire on July 25, 2029 and after such date no further awards may be granted under the plan. Options granted under the 2019 Stock Plan expire ten years from the date of grant. Grants made from the 2019 Stock Plan generally vest over a period of <span style="-sec-ix-hidden:f-1238">three</span> to four years. At December 31, 2023, options to purchase 404,833 shares were outstanding under the 2019 Stock Plan and 7,867,224 shares of restricted stock and restricted stock units were outstanding. The Company's stockholders approved amendments to the 2019 Stock Plan to increase the number of shares available for future grant thereunder by 14,000,000 and 4,340,000 shares on June 9, 2022 and June 8, 2023, respectively. At December 31, 2023, there were 16,046,161 shares available for future grant under the 2019 Stock Plan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2010 Omnibus Long-Term Incentive Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company adopted the 2010 Omnibus Long-Term Incentive Plan (the “2010 Stock Plan”) on July 16, 2010 to grant share-based awards to employees, officers, directors, consultants and advisors. Awards granted under the 2010 Stock Plan may include incentive stock options, as defined under the Internal Revenue Code, non-qualified options, restricted stock awards and other stock awards in amounts and with terms and conditions determined by the Human Capital Committee, subject to the provisions of the 2010 Stock Plan. The 2010 Stock Plan expired on July 16, 2020 and after such date no further awards may be granted under the plan. Options granted under the 2010 Stock Plan expire ten years from the date of grant. Grants made from the 2010 Stock Plan generally vest over a period of <span style="-sec-ix-hidden:f-1247">three</span> to four years. At December 31, 2023, options to purchase 881,340 shares were outstanding under the 2010 Stock Plan and 3,340 shares of restricted stock and restricted stock units were outstanding. At December 31, 2023, there were no shares available for future grant under the 2010 Stock Plan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2010 Employee Stock Purchase Plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The 2010 Employee Stock Purchase Plan (the “2010 Purchase Plan”) was adopted by the Company on July 16, 2010 to provide participating employees the right to purchase shares of common stock at a discount through a series of offering periods. The 2010 Purchase Plan will expire on October 31, 2030. The Company’s stockholders approved amendments to the 2010 Employee Stock Purchase Plan to increase the number of shares available for purchase thereunder by 500,000 shares, 2,000,000 shares, and 3,000,000 shares on July 24, 2014, July 28, 2016, and June 9, 2022, respectively. At December 31, 2023, there were 1,834,193 shares of common stock available for purchase by participating employees under the 2010 Purchase Plan.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, all employees whose customary employment is more than 20 hours per week and more than five months in any calendar year are eligible to participate in the 2010 Purchase Plan. Participating employees authorize an amount, between 1% and 15% of the employee’s compensation, to be deducted from the employee’s pay during the offering period. On the last day of the offering period, the employee is deemed to have exercised the employee’s option to purchase shares of Company common stock, at the option exercise price, to the extent of accumulated payroll deductions. Under the terms of the 2010 Purchase Plan, the option exercise price is an amount equal to 85% of the fair market value, as defined under the 2010 Purchase Plan, and no employee can purchase more than $25,000 of Company common stock under the 2010 Purchase Plan in any calendar year. Rights granted under the 2010 Purchase Plan terminate upon an employee’s voluntary withdrawal from the 2010 Purchase Plan at any time or upon termination of employment. At December 31, 2023, there were 3,965,807 cumulative shares issued under the 2010 Purchase Plan.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards (“RSUs”), performance share units (“PSUs”), stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of non-cash stock-based compensation expense by expense category included in the Company's consolidated statements of operations for the years ended December 31, 2023, 2022, and 2021 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,761 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,218 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,835 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there was approximately $354.8 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 2.42 years.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Thrive, the Company accelerated the vesting of shares of previously unvested stock options and restricted stock units for employees with qualifying termination events. During the year ended December 31, 2021, the Company accelerated 139,096 shares of previously unvested stock options and 58,171 shares of previously unvested restricted stock awards and restricted stock units and recorded $19.0 million of non-cash stock-based compensation for the accelerated awards. As further discussed in Note 18, the Company also recorded $86.2 million in stock-based compensation related to accelerated vesting of awards held by Thrive employees in connection with the acquisition.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of each service-based option award on the date of grant using the Black-Scholes option-pricing model, which utilized several key assumptions including risk-free interest rate, expected term, expected volatility, and dividend yield. There were no option awards granted during the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the Stock Plans is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Aggregate intrinsic value in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286,173 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.67 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286,173 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.67 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,878 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,594 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     The total intrinsic value of options exercised during the years ended December 31, 2023, 2022, and 2021 was $11.7 million, $36.4 million, and $155.8 million, respectively, determined as of the date of exercise.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received approximately $3.2 million, $6.5 million, and $14.4 million from stock option exercises during the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock and Restricted Stock Units</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock and restricted stock units is determined on the date of grant using the closing stock price on that day. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock and restricted stock unit activity is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254,709 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.87 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,510,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released (2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,272,763 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.39 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     The weighted average grant date fair value of the restricted stock units granted during the years ended December 31, 2022 and 2021 was $68.18 and $129.16, respectively. </span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)     The fair value of restricted stock units vested and converted to shares of the Company's common stock was $158.2 million, $117.6 million, and $219.4 million for the years ended December 31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of performance share unit activity is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance Share Units (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,846 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.58 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597,801 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.73 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of December 31, 2023 was 772,906.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)     The weighted average grant date fair value of the performance share units granted during the years ended December 31, 2022 and 2021 was $89.43 and $138.09, respectively. </span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)     The fair value of performance share units vested and converted to shares of the Company's common stock was $1.0 million and $27.2 million for the years ended December 31, 2023 and 2022, respectively. There were no performance share units vested and converted to shares of the Company's common stock during the year ended December 31, 2021. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (“ESPP”)</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of ESPP activity is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under the 2010 Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,448 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,605</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,769</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received under the 2010 Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per share of stock purchase rights granted during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 924,448 shares issued during the year ended December 31, 2023 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Offering period ended</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,453 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of ESPP shares is based on the assumptions in the following table:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68% - 4.71%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49% - 4.71%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04% - 0.16%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.13% - 67.30%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.94% - 63.13%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.00% - 68.51%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Issuance</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved shares of its authorized common stock for issuance pursuant to its employee stock purchase and equity plans, including all outstanding stock option grants noted above at December 31, 2023, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares reserved for issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 Stock Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,046,161 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2010 Purchase Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,880,354 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P1Y 0 P10Y P4Y 404833 7867224 14000000 4340000 16046161 0 P10Y P4Y 881340 3340 0 500000 2000000 3000000 1834193 20 P5M 0.01 0.15 0.85 25000 3965807 <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of non-cash stock-based compensation expense by expense category included in the Company's consolidated statements of operations for the years ended December 31, 2023, 2022, and 2021 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,761 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,218 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,835 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 20761000 19218000 16835000 41242000 33825000 49723000 65552000 62568000 55716000 103757000 91212000 216952000 231312000 206823000 339226000 354800000 P2Y5M1D 139096 58171 19000000 86200000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the Stock Plans is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Aggregate intrinsic value in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286,173 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.67 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286,173 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.67 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,878 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,594 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     The total intrinsic value of options exercised during the years ended December 31, 2023, 2022, and 2021 was $11.7 million, $36.4 million, and $155.8 million, respectively, determined as of the date of exercise.</span></div> 1517876 44.82 P4Y8M12D 194629 16.44 37074 95.02 1286173 47.67 P3Y9M18D 42878000 1286173 47.67 P3Y9M18D 42878000 1228594 45.32 P3Y8M12D 42878000 11700000 36400000 155800000 3200000 6500000 14400000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock and restricted stock unit activity is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254,709 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.87 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,510,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released (2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,272,763 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.39 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     The weighted average grant date fair value of the restricted stock units granted during the years ended December 31, 2022 and 2021 was $68.18 and $129.16, respectively. </span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)     The fair value of restricted stock units vested and converted to shares of the Company's common stock was $158.2 million, $117.6 million, and $219.4 million for the years ended December 31, 2023, 2022, and 2021, respectively.</span></div> 5254709 85.87 3510373 62.36 1797915 88.28 694404 73.54 6272763 73.39 68.18 129.16 158200000 117600000 219400000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of performance share unit activity is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance Share Units (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,846 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.58 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597,801 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.73 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of December 31, 2023 was 772,906.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)     The weighted average grant date fair value of the performance share units granted during the years ended December 31, 2022 and 2021 was $89.43 and $138.09, respectively. </span></div>(3)     The fair value of performance share units vested and converted to shares of the Company's common stock was $1.0 million and $27.2 million for the years ended December 31, 2023 and 2022, respectively. There were no performance share units vested and converted to shares of the Company's common stock during the year ended December 31, 2021. 967846 102.58 782966 80.50 12284 78.32 140727 93.73 1597801 92.73 772906 89.43 138.09 1000000 27200000 0 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of ESPP activity is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under the 2010 Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,448 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,605</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,769</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received under the 2010 Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per share of stock purchase rights granted during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 924448 668605 331769 28344000 25491000 23070000 16.32 17.52 34.93 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 924,448 shares issued during the year ended December 31, 2023 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Offering period ended</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,453 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 924448 544453 30.02 379995 31.57 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of ESPP shares is based on the assumptions in the following table:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68% - 4.71%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49% - 4.71%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04% - 0.16%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 - 2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.13% - 67.30%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.94% - 63.13%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.00% - 68.51%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr></table></div> 0.0468 0.0471 0.0149 0.0471 0.0004 0.0016 P1Y3M P0Y6M P2Y P0Y6M P2Y 0.6313 0.6730 0.5094 0.6313 0.4300 0.6851 0 0 0 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved shares of its authorized common stock for issuance pursuant to its employee stock purchase and equity plans, including all outstanding stock option grants noted above at December 31, 2023, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares reserved for issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 Stock Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,046,161 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2010 Purchase Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,880,354 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 16046161 1834193 17880354 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,420 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,172 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,319 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Supplemental disclosure of cash flow information related to the Company's cash and non-cash activities with its leases are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,301</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,448</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,461</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,345</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,290</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,986</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,572</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,369</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,443</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,276</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.33</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    This includes an insignificant amount of right-of-use assets acquired as part of the business combinations described in Note 18 for the years ended December 31, 2023 and 2022, and $39.6 million for the year ended December 31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company’s right-of-use assets from operating leases are $143.7 million and $167.0 million, respectively, which are reported in operating lease right-of-use assets in the Company’s consolidated balance sheets. As of December 31, 2023, the Company has outstanding operating lease obligations of $190.4 million, of which $29.4 million is reported in operating lease liabilities, current portion and $161.1 million is reported in operating lease liabilities, less current portion in the Company’s consolidated balance sheets. As of December 31, 2022, the Company had outstanding operating lease obligations of $210.8 million, of which $28.4 million is reported in operating lease liabilities, current portion and $182.4 million is reported in operating lease liabilities, less current portion in the Company’s consolidated balance sheets. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company’s right-of-use assets from finance leases are $11.3 million and $10.2 million, respectively, which are reported in <span style="-sec-ix-hidden:f-1443"><span style="-sec-ix-hidden:f-1444">other long-term assets</span></span>, net in the Company’s consolidated balance sheets. As of December 31, 2023, the Company has outstanding finance lease obligations of $11.9 million, of which $4.4 million is reported in <span style="-sec-ix-hidden:f-1447"><span style="-sec-ix-hidden:f-1448">other current liabilities</span></span> and $7.5 million is reported in <span style="-sec-ix-hidden:f-1450"><span style="-sec-ix-hidden:f-1451">other long-term liabilities</span></span> in the Company’s consolidated balance sheets. As of December 31, 2022, the Company had outstanding finance lease obligations of $10.6 million, of which $3.2 million is reported in other current liabilities and $7.4 million is reported in other long-term liabilities in the Company’s consolidated balance sheets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities on an annual basis as of December 31, 2023 were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,476 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,748 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,449 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of finance lease liabilities on an annual basis as of December 31, 2023 were as follows (amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,044</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,552</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,220</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,279)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,941</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report on Form 10-K, amounts accrued for legal proceedings and regulatory matters were not significant except for the amounts accrued related to the matters discussed below. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings, including as described below. Except for the proceedings discussed below, the Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DOS Rule Matter</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company’s wholly owned subsidiary Genomic Health, Inc., which was acquired in November 2019, entered into a settlement agreement with the United States of America, acting through the Department of Justice (“DOJ”) and on behalf of the Office of Inspector General of the Department of Health and Human Services, and two qui tam relators to resolve the previously disclosed civil investigation concerning Genomic Health’s compliance with the Medicare Date of Service billing regulations (the “DOS Rule Matter”). Genomic Health entered into the settlement agreement to avoid the delay, uncertainty and expense of protracted litigation. The settlement agreement contains no admission of liability by Genomic Health. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the settlement agreement, the Company made a payment of $32.5 million in September 2023, of which $22.4 million and $10.1 million is included in general and administrative expenses in the Company’s consolidated statements of operations for the years ended December 31, 2023 and 2021, respectively. Following the United States’ receipt of the settlement payment, the Company was released from any civil or administrative monetary claims under the civil False Claims Act and other specified civil statutes and common law theories of liability concerning the conduct identified in the settlement agreement. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2023, the United States District Court for the Eastern District of New York unsealed two qui tam actions filed under the False Claims Act involving the DOS Rule Matter, and on October 2, 2023, those two actions were dismissed with prejudice pursuant to the terms of the settlement agreement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gift Card Matter</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company entered into a settlement agreement to resolve the previously disclosed False Claims Act qui tam suit that alleged a violation of the Federal Anti-Kickback Statute and False Claims Act for offering gift cards to patients in exchange for returning the Cologuard screening test (the “Qui Tam Suit”). In accordance with the settlement agreement, the Company made payment of $13.8 million plus legal fees in October 2023, which is included in general and administrative expenses in the Company's consolidated statement of operations for the year ended December 31, 2023. Following payment of the settlement amount, the Company was released from any civil or administrative monetary claims under the civil False Claims Act and other specified civil statutes and common law theories of liability concerning the conduct identified in the settlement agreement. On November 1, 2023, the court dismissed the qui tam suit with prejudice pursuant to the terms of the settlement agreement.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,420 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,172 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,319 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Supplemental disclosure of cash flow information related to the Company's cash and non-cash activities with its leases are as follows:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,301</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,448</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,461</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,345</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,290</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,986</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,572</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,369</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,443</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,276</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.33</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    This includes an insignificant amount of right-of-use assets acquired as part of the business combinations described in Note 18 for the years ended December 31, 2023 and 2022, and $39.6 million for the year ended December 31, 2021.</span></div> 3845000 4612000 5731000 800000 808000 1018000 36576000 36291000 31730000 750000 476000 628000 8449000 7985000 5212000 50420000 50172000 44319000 39301000 33448000 27461000 783000 699000 938000 3569000 4345000 5290000 4986000 24572000 74369000 5443000 11276000 5460000 P6Y10M13D P7Y5M4D P8Y3M29D P2Y9M18D P3Y3M7D P2Y11M12D 0.0659 0.0637 0.0611 0.0743 0.0660 0.0536 39600000 143700000 167000000 190400000 29400000 161100000 210800000 28400000 182400000 11300000 10200000 11900000 4400000 7500000 10600000 3200000 7400000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities on an annual basis as of December 31, 2023 were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,476 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,748 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,449 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 39476000 36660000 34851000 34226000 27901000 66634000 239748000 49299000 190449000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of finance lease liabilities on an annual basis as of December 31, 2023 were as follows (amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,044</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,552</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,220</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,279)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,941</span></td></tr></table></div> 5044000 4552000 2797000 827000 0 0 13220000 1279000 11941000 32500000 22400000 10100000 13800000 EMPLOYEE BENEFIT PLAN<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a qualified 401(k) retirement savings plan for Exact Sciences employees (the “401(k) Plan”). The Company also maintains additional retirement savings plans that are acquired as a result of business combinations. These plans are maintained for a period of time before being merged into the 401(k) Plan. Under the terms of the 401(k) Plan, participants may elect to defer a portion of their compensation into the 401(k) Plan, subject to certain limitations. Company matching contributions may be made at the discretion of the Company's Human Capital Committee. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Human Capital Committee approved 401(k) Plan matching contributions for the years ended December 31, 2023, 2022, and 2021 in the form of Company common stock equal to 100% of a participant's elective deferrals up to 6% of the participant’s eligible compensation for that year. The Company recorded compensation expense of approximately $40.6 million, $36.5 million, and $30.0 million, respectively, in the statements of operations for the years ended December 31, 2023, 2022, and 2021.</span></div> 1 1 1 0.06 0.06 0.06 40600000 36500000 30000000 WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company entered into an amended agreement (“Amended WEDC Agreement”) with the Wisconsin Economic Development Corporation (“WEDC”) to earn $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the agreement. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned. </span></div>As of December 31, 2023, the Company has earned $11.0 million of the refundable tax credits under the Amended WEDC Agreement. The unpaid portion is $9.3 million, of which $3.8 million is reported in prepaid expenses and other current assets and $5.5 million is reported in other long-term assets, net in the Company's consolidated balance sheets reflecting when collection of the refundable tax credits is expected to occur. During the years ended December 31, 2023, 2022, and 2021, the amounts recorded as an offset to capital expenditures and operating expenses for the tax credits earned were not significant. 18500000 350000000 1300 P5Y 0.10 7000000 11000000 9300000 3800000 5500000 ACQUISITIONS AND DIVESTITURES <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Resolution Bioscience, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2023, the Company completed the acquisition of all of the outstanding capital stock of Resolution Bioscience, Inc. from Agilent Technologies, Inc. Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions through its Clinical Laboratory Improvement Amendments (“CLIA”) certified lab based in Kirkland, Washington. The acquisition provides the Company with a high-quality blood-based therapy selection platform, complementing its comprehensive, tissue-based OncoExTra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> test. The Company has included the financial results of Resolution Bioscience in the consolidated financial statements from the date of the acquisition.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,527 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of replaced equity awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,202 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company replaced unvested RSUs with a combination-date fair value of $4.6 million. Of the total consideration for replaced equity awards, $1.7 million was allocated to the consideration transferred, and $2.9 million was deemed compensatory as it was attributable to post acquisition vesting. The compensatory replaced equity awards will be expensed over the remaining service periods on a straight-line basis.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,663 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,663 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,511 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,202 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a $26.0 million identifiable intangible asset related to the developed technology associated with Resolution Bioscience’s liquid biopsy therapy selection tests. Developed technology represents purchased technology that had reached technological feasibility and for which Resolution Bioscience had substantially completed development as of the acquisition date. The fair value of the developed technology has been determined using the multi-period excess earnings method of the income approach, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected revenues, gross margins, operating expenses, obsolescence, and an estimated discount rate. The developed technology intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the acquired workforce expertise and expected sales force and therapy selection product portfolio synergies. The total goodwill related to this acquisition is deductible for tax purposes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price allocation is preliminary and based upon estimates and assumptions that are subject to change within the measurement period as additional information for the estimates is obtained. The measurement period remains open pending the completion of valuation procedures related to the acquired assets and assumed liabilities, including in connection with the developed technology intangible asset.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Resolution Bioscience, as though the companies were combined as of the beginning of January 1, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507,111 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097,680 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(675,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the results that would have been achieved if the acquisition had taken place at such time. Expected cost savings and other synergistic benefits resulting from the acquisition were not reflected in the unaudited pro forma financial information. The Company did not have any significant, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported unaudited pro forma financial information. Revenue and net loss before tax from Resolution Bioscience included in the Company's consolidated statements of operations for the year ended December 31, 2023 was not significant.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related costs were not significant and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the acquisition.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">OmicEra Diagnostics, GmbH</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2022, the Company completed the acquisition (the “OmicEra Acquisition”) of all of the outstanding equity interests of OmicEra Diagnostics GmbH. The OmicEra Acquisition provided the Company a state-of-the-art proteomics lab based in Planegg, Germany. OmicEra combines its mass spectrometry-based proteome analysis technology with its in-house proteomics scientific expertise to discover more reliable and valuable protein biomarkers, which will expand the Company’s research and development capabilities. The Company has included the financial results of OmicEra in the consolidated financial statements from the date of the acquisition.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,792 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid related to working capital adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,408 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the 265,186 common shares issued as part of the consideration transferred was determined on the basis of the average of the high and low market price of the Company’s shares on the acquisition date, which was $55.78.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase agreement requires the Company to pay a maximum of $6.0 million of additional cash consideration to OmicEra upon the achievement of certain earnout conditions related to the identification of protein biomarkers, as well as the growth of the proteomics research and development team. The fair value of the contingent consideration at the acquisition date was $4.6 million. The fair value of the contingent consideration was estimated using a probability-weighted scenario-based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,586 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,599 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,408 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $10.0 million of identifiable intangible assets related to the developed technology associated with OmicEra’s proteome analysis platform. Developed technology represents purchased technology that had reached technological feasibility and for which OmicEra had substantially completed development as of the date of acquisition. The fair value of the developed technology has been determined using the income approach multi-period excess earnings method, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, margin, obsolescence factor, required rate of return, and tax rate. Cash flows were discounted to their present value as of the closing date. The developed technology intangible asset is amortized on a straight-line basis over its estimated useful life of 16 years.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the excess purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the acquired workforce expertise, the potential to enhance the capabilities of current and future products, and expected research and development synergies. The total goodwill related to this acquisition is deductible for tax purposes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma impact and results of operations disclosures have not been included due to insignificance.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related costs were not significant and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the merger.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">PreventionGenetics, LLC</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company completed the acquisition (the “PreventionGenetics Acquisition”) of all of the outstanding equity interests of PreventionGenetics, LLC. The PreventionGenetics Acquisition provided the Company a CLIA certified and College of American Pathologist (“CAP”) accredited sequencing lab based in Marshfield, Wisconsin. PreventionGenetics provides more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline, whole exome (“PGxome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), and whole genome (“PGnome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) sequencing tests. The Company has included the financial results of PreventionGenetics in the consolidated financial statements from the date of the acquisition. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,129</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,252</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,381</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the 1,070,410 common shares issued as part of consideration transferred was determined on the basis of the average of the high and low market price of the Company's shares on the acquisition date, which was $78.71. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total $101.1 million of consideration settled through the payment of cash, $85.8 million was paid as of December 31, 2021. The remaining $15.3 million represented withheld cash consideration used to cover working capital adjustments or seller claims that arose following the completion of the acquisition. The withheld cash consideration was settled during the year ended December 31, 2022, and there is no remaining liability on the consolidated balance sheet.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related costs were not significant and were recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ashion Analytics, LLC</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2021, the Company completed the acquisition (“Ashion Acquisition”) of all of the outstanding equity interests of Ashion Analytics, LLC from PMed Management, LLC (“PMed”), which is a subsidiary of The Translational Genomics Research Institute. The Ashion Acquisition provided the Company a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona. Ashion developed GEM ExTra®, a comprehensive genomic cancer test, and provides access to whole exome, matched germline, and transcriptome sequencing capabilities. The Company has included the financial results of Ashion in the consolidated financial statements from the date of the acquisition. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,775</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,224</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,999</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the 125,444 common shares issued as part of consideration transferred was determined on the basis of the average of the high and low market price of the Company's shares on the acquisition date, which was $129.33. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration arrangement requires the Company to pay $20.0 million of additional cash consideration to PMed upon the Company’s commercial launch, on or before the tenth anniversary of the Ashion Acquisition, of a test for MRD detection and/or treatment (the “Commercial Launch Milestone”). The fair value of the Commercial Launch Milestone at the acquisition date was $19.0 million. The contingent consideration arrangement also requires the Company to pay $30.0 million of additional cash upon the Company’s achievement, on or before the fifth anniversary of the Ashion Acquisition, of cumulative revenues from MRD products of $500.0 million (the “MRD Product Revenue Milestone”). No value was ascribed to the MRD Product Revenue Milestone based on probability assessments as of the acquisition date. The fair value of the Commercial Launch Milestone and MRD Product Revenue Milestone was estimated using a probability-weighted scenario based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related costs were not significant and were recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Thrive Earlier Detection Corporation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2021, the Company completed the acquisition (“Thrive Merger”) of all of the outstanding capital stock of Thrive Earlier Detection Corporation. Thrive, headquartered in Cambridge, Massachusetts, is a healthcare company dedicated to incorporating earlier cancer detection into routine medical care. The Company expects that combining Thrive’s early-stage MCED test with the Company’s scientific platform, clinical organization, and commercial infrastructure will bring an accurate blood-based, MCED test to patients faster. The Company has included the financial results of Thrive in the consolidated financial statements from the date of the acquisition. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175,431</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,996</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,348</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of replaced equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,245</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously held equity investment fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,054</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued 9,323,266 common shares that had a fair value of $1.19 billion based on the average of the high and low market price of the Company's shares on the acquisition date, which was $127.79. Of the total consideration for common stock issued, $1.18 billion was allocated to the purchase consideration and $16.0 million was recorded as compensation within general and administrative expenses in the consolidated statement of operations on the acquisition date due to accelerated vesting of legacy Thrive restricted stock awards (“RSA”) and RSU awards in connection with the acquisition.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $590.2 million in cash on the acquisition date. Of the total consideration for cash, $585.0 million was allocated to the purchase consideration and $5.2 million was recorded as compensation within general and administrative expenses on the acquisition date due to accelerated vesting of legacy Thrive RSU and RSAs that were cash-settled in connection with the acquisition.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration arrangement requires the Company to pay up to $450.0 million of additional cash consideration to Thrive’s former shareholders upon the achievement of two discrete events, FDA approval and CMS coverage, for $150.0 million and up to $300.0 million, respectively. The fair value of the contingent consideration arrangement at the acquisition date was $352.0 million. The fair value of the contingent consideration was estimated using a probability-weighted scenario based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7. Of the total fair value of the contingent consideration, $331.3 million was allocated to the consideration transferred, $6.4 million was allocated to the Company’s previous ownership interest in Thrive, and $14.3 million was deemed compensatory as participation is dependent on replaced unvested equity awards vesting which requires future service. Compensation expense related to the milestones could be up to $18.2 million undiscounted and will be recognized in the future once probable and payable.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company replaced unvested stock options, RSUs, and RSAs and vested stock options with an acquisition-date fair value of $197.0 million. Of the total consideration for replaced equity awards, $52.2 million was allocated to the consideration transferred and $144.8 million was deemed compensatory as it was attributable to post acquisition vesting. Of the total compensation related to replaced awards, $65.0 million was expensed on the acquisition date due to accelerated vesting of stock options in connection with the acquisition and $79.8 million relates to future services and will be expensed over the remaining service periods of the unvested stock options, RSUs, and RSAs on a straight-line basis. Including expense recognized for accelerated vesting of RSUs and RSAs described above, total expected stock-based compensation expense is $166.0 million, of which $86.2 million was recognized immediately to general and administrative expenses in the consolidated statement of operations due to accelerated vesting. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options assumed by the Company was determined using the Black-Scholes option pricing model. The fair value of the RSA and RSUs assumed by the Company was determined based on the average of the high and low market price of the Company’s shares on the acquisition date. The share conversion ratio of 0.06216 was applied to convert Thrive’s outstanding equity awards for Thrive’s common stock into equity awards for shares of the Company’s common stock.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options assumed were based on the assumptions in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Plan Shares Assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11% - 0.12%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26 - 1.57</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.54% - 71.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per share of options assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$109.74 - $124.89</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously held a preferred stock investment of $12.5 million in Thrive and recognized a gain of approximately $30.5 million on the transaction within investment income (expense), net on the Company’s consolidated statement of operations, which represented the adjustment of the Company’s historical investment to the acquisition date fair value. The fair value of the Company’s previous ownership in Thrive was determined based on the pro-rata share payout applied to the Company’s interest combined with the fair value of the Company’s share of the contingent consideration arrangement, as discussed above.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net loss before tax of Thrive included in the Company’s consolidated statement of operations from the acquisition date of January 5, 2021 to December 31, 2022 was $255.0 million. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Thrive, as though the companies were combined as of the beginning of January 1, 2020.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,279 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,087 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(761,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,014,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information for all periods presented above has been calculated after adjusting the results of Thrive to reflect the business combination accounting effects resulting from this acquisition. The Company incurred $86.2 million of stock-based compensation expense related to accelerated vesting in connection with the acquisition, $13.5 million of stock-based compensation expense related to accelerated vesting for employees with qualifying termination events, and $10.3 million of transaction costs incurred to execute the acquisition during the first quarter of 2021. These expenses are included in general and administrative expenses on the consolidated statement of operations for the year ended December 31, 2021 and are reflected in pro forma earnings for the year ended December 31, 2020 in the table above. The Company recorded a realized gain of $30.5 million during the first quarter of 2021 in investment income (expense), net on the Company’s consolidated statement of operations relating to the Company’s pre-acquisition investment in Thrive. This gain has been reduced to $7.6 million due to the Company’s smaller ownership interest in Thrive on January 1, 2020, and is reflected in pro forma earnings for the year ended December 31, 2020 in the table above. The Company recorded a remeasurement of contingent consideration of $7.2 million related to Thrive in general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2021. This expense is reflected in the year ended December 31, 2020 in the table above. The historical consolidated financial statements have been adjusted in the unaudited pro forma combined financial information to give effect to pro forma events that are directly attributable to the business combination and factually supportable. The unaudited pro forma financial information is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2020.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company incurred $10.3 million of acquisition-related costs recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with acquisition-related severances, the Company recorded $19.0 million of expense related to vesting of previously unvested equity awards and $3.9 million of additional benefit charges for the year ended December 31, 2021. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">PFS Genomics Inc. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2021, the Company acquired 90% of the outstanding capital stock of PFS Genomics Inc. (“PFS”). On June 23, 2021, the Company completed the acquisition of the remaining 10% interest in PFS. The Company paid cash of $33.6 million for 100% of the outstanding capital stock in PFS. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFS is a healthcare company focused on personalizing treatment for breast cancer patients to improve outcomes and reduce unnecessary treatment. The Company expects this acquisition to expand its ability to help guide early-stage breast cancer treatment through individualized radiotherapy treatment decisions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was treated as an asset acquisition under GAAP because substantially all of the fair value of the gross assets acquired were deemed to be associated with the acquired technology.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition related costs were not significant in this asset acquisition.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Oncotype DX Genomic Prostate Score Test</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2022, pursuant to an asset purchase agreement (“Asset Purchase Agreement”) with MDxHealth SA, the Company completed the sale of the intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test, which will allow the Company to focus on the highest impact projects core to the Company’s vision.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing date fair value of the consideration received for the asset was approximately $29.6 million, which consisted of the following: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDxHealth American Depository Shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the 691,171 American Depository Shares received as part of the consideration transferred was determined on the basis of the average of the high and low market price of the MDxHealth’s shares on the date of divestiture, which was $6.70, and is included in marketable securities on the consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Asset Purchase Agreement required MDxHealth to pay the Company up to an additional $70.0 million of contingent consideration that would be earned and receivable in cash and/or equity based on the achievement of certain revenue milestones by MDxHealth between 2023 and 2025. Under the Asset Purchase Agreement, contingent consideration would have been recognized in the consolidated statement of operations when it was probable a significant reversal of a gain would not occur. As of December 31, 2022, no contingent consideration was probable of not resulting in a significant gain reversal due to minimum revenue thresholds in place and therefore it was fully constrained. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the developed technology intangible asset, which was previously included in intangible assets, net on the consolidated balance sheet, was $42.9 million as of the closing date. As a result of the sale, the Company recorded a loss of $13.2 million, which is included in <span style="-sec-ix-hidden:f-1635">other operating income (loss)</span> in the consolidated statement of operations for the year ended December 31, 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Company agreed to provide certain transitional services to MDxHealth through December 31, 2022 and lab testing services for a period of up to 24 months. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2023, the Company and MDxHealth executed the Second Amendment to the Asset Purchase Agreement (“Second Amendment”) related to the sale of the GPS test. Under the Second Amendment, the Company agreed to allow MDxHealth to defer the 2023 contingent consideration payment by three years in exchange for additional consideration and more favorable contingent consideration terms. The Company received additional consideration with a fair value of $3.1 million, which was recorded as a gain for the year ended December 31, 2023, and is included in other operating income (loss) in the consolidated statement of operations.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the Second Amendment, the maximum contingent consideration increased from $70.0 million to $82.5 million and the minimum revenue thresholds previously required to be met under the Asset Purchase Agreement were eliminated. As a result of the elimination of the minimum revenue thresholds, the Company determined that a significant reversal of a gain is not probable and therefore the contingent consideration is no longer constrained. The Company recorded a contingent consideration gain of $73.3 million during the year ended December 31, 2023, which is included in other operating income (loss) in the consolidated statement of operations. The gain was estimated using historical GPS test revenues by MDxHealth under the most likely amount method. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, a portion of the contingent consideration is classified as a contract asset. The contract asset was $41.7 million and zero as of December 31, 2023 and 2022, respectively. The remaining balance of $31.6 million, which represents the amount earned during the 2023 earnout year, is classified as a receivable as of December 31, 2023. The contract asset and receivable are included in other long-term assets, net on the consolidated balance sheet. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction-related costs were not significant and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the divestiture.</span></div> 54200000 52527000 1675000 54202000 4.6 million 1700000 2900000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,663 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,663 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,511 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,202 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,586 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,599 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,408 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14663000 26000000 40663000 7152000 33511000 20691000 54202000 26000000 P17Y <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Resolution Bioscience, as though the companies were combined as of the beginning of January 1, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507,111 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097,680 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(675,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Thrive, as though the companies were combined as of the beginning of January 1, 2020.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,279 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,087 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(761,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,014,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2507111000 2097680000 -237854000 -675091000 19400000 14792000 4600000 16000 19408000 265186 55.78 6000000 4600000 2586000 10000000 12586000 3987000 8599000 10809000 19408000 10000000 P16Y 5000 185400000 101129000 84252000 185381000 1070410 78.71 101100000 85800000 15300000 110000000 74775000 16224000 19000000 109999000 125444 129.33 20000000 19000000 30000000 500000000 2190000000 1175431000 584996000 331348000 52245000 43034000 2187054000 9323266 1190000000 127.79 1180000000 16000000 590200000 585000000 5200000 450000000 150000000 300000000 352000000 331300000 6400000 14300000 18200000 197000000 52200000 144800000 65000000 79800000 166000000 86200000 0.06216 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options assumed were based on the assumptions in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Plan Shares Assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11% - 0.12%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26 - 1.57</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.54% - 71.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per share of options assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$109.74 - $124.89</span></div></td></tr></table></div> 0.0011 0.0012 P1Y3M3D P1Y6M25D 0.6554 0.7100 0 109.74 124.89 12500000 30500000 -255000000 2084279000 1767087000 -761337000 -1014352000 86200000 13500000 10300000 30500000 7600000 7200000 10300000 19000000 3900000 0.90 0.10 33600000 1 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing date fair value of the consideration received for the asset was approximately $29.6 million, which consisted of the following: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDxHealth American Depository Shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing date fair value of the consideration received for the asset was approximately $29.6 million, which consisted of the following: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDxHealth American Depository Shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 29600000 25000000 4631000 0 29631000 691171 6.70 70000000 42900000 13200000 P24M 3100000 70000000 82500000 73300000 41700000 0 31600000 SEGMENT INFORMATION<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the financial information routinely reviewed by the Company’s Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company’s operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,489 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,966,541 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657,174 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499,766 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,279 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,087 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets located in countries outside of the U.S. are not significant.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,489 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,966,541 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657,174 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499,766 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084,279 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,087 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2346489000 1966541000 1657174000 153277000 117738000 109913000 2499766000 2084279000 1767087000 INCOME TAXES<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under financial accounting standards, deferred tax assets or liabilities are computed based on the differences between the financial statement and income tax bases of assets and liabilities using the enacted tax rates. Deferred income tax expense or benefit represents the change in the deferred tax assets or liabilities from period to period. At December 31, 2023, the Company had federal net operating loss, state net operating loss, and foreign net operating loss carryforwards of approximately $402.9 million, $66.0 million, and $10.4 million, respectively, for financial reporting purposes, which may be used to offset future taxable income. The Tax Cuts and Jobs Act (H.R. 1) of 2017 limits the deduction for net operating losses to 80% of current year taxable income and provides for an indefinite carryover period for federal net operating losses. Both provisions are applicable for losses arising in tax years beginning after December 31, 2017. As of December 31, 2023 the Company has $278.5 million of federal net operating loss carryovers incurred after December 31, 2017 with an unlimited carryover period and $124.4 million of federal net operating loss carryovers expiring at various dates through 2037. State and foreign net operating loss carryovers expire at various dates through 2043. All net operating loss carryforwards are subject to review and possible adjustment by federal, state and foreign taxing jurisdictions. The Company also had federal and state research tax credit carryforwards of $70.9 million and $33.0 million, respectively, which may be used to offset future income tax liability. The federal credit carryforwards expire at various dates through 2043 and are subject to review and possible adjustment by the Internal Revenue Service. The state credit carryforwards expire at various dates through 2038 with the exception of $19.7 million of California research and development tax credits that have an indefinite carryforward period. All state tax credits are subject to review and possible adjustment by local tax jurisdictions. In the event of a change of ownership, the federal and state net operating loss and research and development tax credit carryforwards may be subject to annual limitations provided by the Internal Revenue Code and similar state provisions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for taxes consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(801,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,746)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,570)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(842,506)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense (benefit) for income taxes consists of:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,898 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,064)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246,881)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense for the year ended December 31, 2023 of $2.4 million primarily related to current foreign and state tax expense.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the net deferred tax asset with the approximate income tax effect of each type of carryforward, credit and temporary differences are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other temporary differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,868 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,905 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less - Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,036 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,549 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other temporary differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,010)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(467,325)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488,262)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,289)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,713)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income and the realization of deferred tax liabilities, management has determined that a valuation allowance of $465.8 million and $419.4 million at December 31, 2023 and 2022, respectively, is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Given the future limitations on and expiration of certain federal and state deferred tax assets, the recording of a valuation allowance resulted in a deferred tax liability of approximately $17.3 million remaining as of December 31, 2023, which is included in other long-term liabilities on the Company's consolidated balance sheet. The overall change in valuation allowance for December 31, 2023 and 2022 was an increase of $46.5 million and an increase of $157.1 million, respectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity associated with the Company's valuation allowance is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,356)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262,238)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293,397)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances established</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes to existing valuation allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and purchase accounting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465,832)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,356)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262,238)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recorded an increase to the valuation allowance of $44.8 million primarily related to losses from continuing operations. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded an increase to the valuation allowance of $159.9 million primarily related to losses from continuing operations. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded an increase to the valuation allowance of $206.6 million primarily related to losses from continuing operations. Offsetting the increase, the Company recorded a decrease to the valuation allowance of $239.2 million related to the Thrive Merger offset against goodwill.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate differs from the statutory tax rate due to the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state tax rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D asset expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment - convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, the Company recognized a income tax expense, representing an effective tax rate of (1.2)%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of (1.2)% for the year ended December 31, 2023, was primarily attributable to the valuation allowance established against the Company's current period losses.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company recognized an income tax benefit, representing an effective tax rate of 1.3%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 1.3% for the year ended December 31, 2022, was primarily attributable to the valuation allowance established against the Company's current period losses.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, the Company recognized an income tax benefit, representing an effective tax rate of 29.3%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 29.3% for the year ended December 31, 2021, was primarily attributable to an income tax benefit of $239.2 million recorded as a result of a change in the deferred tax asset valuation allowance resulting from the Thrive Merger.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrecognized tax benefits related to federal and state research and development tax credits of $36.4 million, $28.3 million, and $21.8 million as of December 31, 2023, 2022, and 2021, respectively. These amounts have been recorded as a reduction to the Company's deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a tabular reconciliation of the amounts of unrecognized tax benefits:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,270 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,780 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,629 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,861 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to prior year tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to prior year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,399 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,270 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,780 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2000 through 2023, and to state income tax examinations for the tax years 2000 through 2023. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for the years ended December 31, 2023, 2022 and 2021.</span></div> 402900000 66000000 10400000 278500000 124400000 70900000 33000000 19700000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for taxes consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(801,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,746)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,570)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(842,506)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -204128000 -617240000 -801536000 2382000 -15330000 -40970000 -201746000 -632570000 -842506000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense (benefit) for income taxes consists of:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,898 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,064)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246,881)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 2266000 2170000 1388000 2561000 1131000 4898000 2395000 -3292000 -222693000 -1829000 -8926000 -30528000 -2990000 -147000 54000 2403000 -9064000 -246881000 2400000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the net deferred tax asset with the approximate income tax effect of each type of carryforward, credit and temporary differences are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other temporary differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,868 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,905 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less - Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,036 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,549 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other temporary differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,010)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(467,325)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488,262)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,289)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,713)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 477420000 553320000 104580000 87579000 85007000 67976000 47118000 51560000 191468000 108117000 10275000 19353000 915868000 887905000 465832000 419356000 450036000 468549000 415064000 435991000 9465000 4653000 35786000 40674000 7010000 6944000 467325000 488262000 17289000 19713000 465800000 419400000 17300000 46500000 157100000 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity associated with the Company's valuation allowance is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,356)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262,238)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293,397)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances established</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes to existing valuation allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and purchase accounting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465,832)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,356)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262,238)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 419356000 262238000 293397000 44759000 159919000 206574000 1242000 -2780000 1500000 475000 -21000 -239233000 465832000 419356000 262238000 44800000 159900000 206600000 -239200000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate differs from the statutory tax rate due to the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state tax rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D asset expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment - convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.039 0.039 0.036 0.011 -0.002 -0.003 0 -0.001 -0.006 0 0 -0.008 -0.076 -0.023 -0.007 -0.044 -0.020 0.011 -0.035 -0.004 -0.002 0 0 -0.001 -0.007 0 0 -0.025 0.012 0.012 -0.237 -0.244 0.037 -0.012 0.013 0.293 -0.012 -0.012 0.013 0.013 0.293 0.293 -239200000 36400000 28300000 21800000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a tabular reconciliation of the amounts of unrecognized tax benefits:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,270 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,780 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,629 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,861 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to prior year tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease due to prior year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,399 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,270 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,780 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 28270000 21780000 16629000 7447000 5861000 5363000 1108000 629000 0 426000 0 212000 0 0 0 36399000 28270000 21780000 0 0 0 0 0 0

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